{
  "category": "Clinical Pathology",
  "subject": {
    "name": "Hematopathology",
    "url": "https://app.pathprimer.com/curriculum/d83afe59-22bf-4e64-bed8-74697066d46a",
    "lessons": {
      "Acute Lymphoblastic Leukemia": {
        "name": "Acute Lymphoblastic Leukemia",
        "url": "https://app.pathprimer.com/lesson/9744fc63-5115-42ad-9ae9-5725b1419c5b",
        "topics": {
          "B-Lymphoblastic Leukemia": {
            "name": "B-Lymphoblastic Leukemia",
            "url": "https://app.pathprimer.com/document/5f35b841-a17e-4837-a0a3-3390426a7c78/lesson/9744fc63-5115-42ad-9ae9-5725b1419c5b",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "B-ALL is neoplasm of precursors (lymphoblasts) committed to B-cell lineage"
                  },
                  {
                    "text": "When blood and bone marrow are extensively involved, acute lymphoblastic leukemia (B-ALL) is appropriate term"
                  },
                  {
                    "text": "When disease is confined to tissue mass with absent or minimal blood and marrow involvement, term lymphoblastic lymphoma (B-LBL) is used"
                  },
                  {
                    "text": "If patient presents with tissue mass and blood and bone marrow involvement, 25% blasts in marrow defines leukemia (B-ALL)"
                  },
                  {
                    "text": "Blasts express immature markers [CD34 and TdT (terminal deoxynucleotidyl transferase)] and B-cell markers (CD19, CD10, CD79a, subset CD20)"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Causes of ALL remain largely unknown"
                  },
                  {
                    "text": "Many ALLs are thought to be congenital"
                  },
                  {
                    "text": "Genetic abnormalities may result in constitutively activated oncogenes, activated kinase activity, or altered transcriptional regulation"
                  },
                  {
                    "text": "Certain syndromes have increased incidence of B-ALL"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "B-ALL is most common childhood neoplasm"
                  },
                  {
                    "text": "Complex prognostic systems including clinical, biologic, cytogenetic findings, and response to therapy"
                  },
                  {
                    "text": "Overall excellent prognosis"
                  },
                  {
                    "text": "Intensive multiagent chemotherapy is mainstay treatment"
                  },
                  {
                    "text": "Patients at very high risk may benefit from allogeneic SCT"
                  },
                  {
                    "text": "Intrathecal prophylactic therapy routinely done to prevent CNS relapse"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Routine karyotype is required on all new B-ALL cases"
                  },
                  {
                    "text": "Specific FISH panel is required by Children's Oncology Group (COG) protocol"
                  },
                  {
                    "text": "Molecular testings increasingly performed"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "B-cell lymphoblastic leukemia/lymphoma (B-ALL)"
                  },
                  {
                    "text": "B-lymphoblastic leukemia/lymphoma (B-ALL/B-LBL)"
                  },
                  {
                    "text": "Philadelphia-positive lymphoblastic leukemia [Ph(+) ALL]"
                  },
                  {
                    "text": "BCR-ABL1-like (a.k.a. Philadelphia-like) lymphoblastic leukemia ALL (BCR-ABL1-like ALL or Ph-like ALL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "B-cell acute lymphoblastic leukemia/lymphoma (B-ALL/B-LBL)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "B-ALL: Neoplasm of precursors (lymphoblasts) committed to B-cell lineage"
                  },
                  {
                    "text": "When blood and bone marrow are extensively involved, acute lymphoblastic leukemia (B-ALL) is appropriate"
                  },
                  {
                    "text": "When disease is confined to mass with absent or minimal blood and marrow involvement, term lymphoblastic lymphoma (B-LBL) is used"
                  },
                  {
                    "text": "If patient presents with mass lesion and blood and bone marrow involvement, 25% blasts in marrow defines leukemia (B-ALL)"
                  },
                  {
                    "text": "Blasts express immature markers [CD34 and TdT (terminal deoxynucleotidyl transferase)] and B-cell markers (CD19, CD10, CD79a, subset CD20)"
                  }
                ],
                "WHO Classification of B-Lymphoblastic Leukemia/Lymphoma": [
                  {
                    "text": "B-lymphoblastic leukemia/lymphoma, not otherwise specified"
                  },
                  {
                    "text": "B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalitiesB-ALL with t(9;22)(q34.1;q11.2);BCR-ABL1[a.k.a. Philadelphia-positive ALL or Ph(+) ALL]B-ALL with t(v;11q23.3);KMT2ArearrangedB-ALL t(12;21)(p13.2;q22.1);ETV6-RUNX1B-ALL with hyperdiploidyB-ALL with hypodiploidyHaploid (23-29 chromosomes)Low hypodiploid (33-39 chromosomes)Hypodiploid (40-43 chromosomes)Near diploid (44-45)B-ALL with t(5;14)(q31.1;q32.1);IL3-IGHB-ALL with t(1;19)(q23;p13.3);TCF3-PBX1(E2A-PBX1)B-ALL with intrachromosomal amplification of chromosome 21 (iAMP21) (provisional entity)B-ALL with translocations involving tyrosine kinase or cytokine receptors (BCR-ABL1-like ALL) (provisional entity)",
                    "sub_points": [
                      "B-ALL with t(9;22)(q34.1;q11.2);BCR-ABL1[a.k.a. Philadelphia-positive ALL or Ph(+) ALL]",
                      "B-ALL with t(v;11q23.3);KMT2Arearranged",
                      "B-ALL t(12;21)(p13.2;q22.1);ETV6-RUNX1",
                      "B-ALL with hyperdiploidy",
                      "B-ALL with hypodiploidyHaploid (23-29 chromosomes)Low hypodiploid (33-39 chromosomes)Hypodiploid (40-43 chromosomes)Near diploid (44-45)",
                      "Haploid (23-29 chromosomes)",
                      "Low hypodiploid (33-39 chromosomes)",
                      "Hypodiploid (40-43 chromosomes)",
                      "Near diploid (44-45)",
                      "B-ALL with t(5;14)(q31.1;q32.1);IL3-IGH",
                      "B-ALL with t(1;19)(q23;p13.3);TCF3-PBX1(E2A-PBX1)",
                      "B-ALL with intrachromosomal amplification of chromosome 21 (iAMP21) (provisional entity)",
                      "B-ALL with translocations involving tyrosine kinase or cytokine receptors (BCR-ABL1-like ALL) (provisional entity)"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Etiology": [
                  {
                    "text": "Causes of ALL remain largely unknown"
                  },
                  {
                    "text": "B-ALL arises in either hematopoietic stem cell or B-cell progenitor"
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "Genetic factorsEvidence to support that ALLs are congenitalGenetic alterations in preleukemic cells in utero are proposed as initiating eventsMonozygotic twins with concordant leukemia share same genetic abnormalitiesPresence ofETV6-RUNX6(﻿a.k.a.TEL-AML1) gene fusion or hyperdiploidy in neonatal blood spots on Guthrie cards2nd hit may be required for developing overt leukemiaMost cases of ALL withETV6-RUNX1fusion have deletion of nonarrangedETV6allele; latter is subclonal and probably occurs postnatallyLeukemia can develop many years after identification ofETV6-RUNX1fusionGenetic abnormalities may result in constitutively activated oncogenes, activated kinase activity, or altered transcriptional regulationPAX5germline mutation is found to be responsible for familial B-ALL in at least 3 kindreds with incomplete penetranceEVT6germline mutations carry increased risk of developing B-ALL and thrombocytopeniaBCR-ABL1-like B-ALL has gene expression profile similar to Philadelphia(+) ALL but does not haveBCR-ABL1fusionExhibits diverse genetic aberrations that activate tyrosine kinase, may involveABL1,ABL2,PDGFRB,NTRK3,TYK2,CSF1R, andJAK2Alternative translocations involving cytokine receptor-like factor 2 (CRLF2) that are often associated withJAKgene mutationsLess commonly, rearrangements leading to activation of erythropoietin receptor (EPOR)iAMP21 B-ALL has 5 or more copies ofRUNX1geneSyndromes with increased incidence of B-ALLDown syndromeCases withCRLF2translocations are particularly common in Down syndromeRobertsonian translocation, rob(15;21)(q10;q10)c, have 2700x increased risk of developing B-ALL iAMP21All rob(15;21)(q10;q10) patients who developed B-ALL are iAMP21 subtype in one study3.2% of all iAMP21 B-ALL have rob(15;21)(q10;q10)cSyndromes with increased incidence of malignancies including B-ALLLi-Fraumeni syndromeNeurofibromatosis type 1 (NF1)Bloom syndromeAtaxia telangiectasia",
                    "sub_points": [
                      "Evidence to support that ALLs are congenitalGenetic alterations in preleukemic cells in utero are proposed as initiating eventsMonozygotic twins with concordant leukemia share same genetic abnormalitiesPresence ofETV6-RUNX6(﻿a.k.a.TEL-AML1) gene fusion or hyperdiploidy in neonatal blood spots on Guthrie cards2nd hit may be required for developing overt leukemiaMost cases of ALL withETV6-RUNX1fusion have deletion of nonarrangedETV6allele; latter is subclonal and probably occurs postnatallyLeukemia can develop many years after identification ofETV6-RUNX1fusion",
                      "Genetic alterations in preleukemic cells in utero are proposed as initiating events",
                      "Monozygotic twins with concordant leukemia share same genetic abnormalities",
                      "Presence ofETV6-RUNX6(﻿a.k.a.TEL-AML1) gene fusion or hyperdiploidy in neonatal blood spots on Guthrie cards",
                      "2nd hit may be required for developing overt leukemiaMost cases of ALL withETV6-RUNX1fusion have deletion of nonarrangedETV6allele; latter is subclonal and probably occurs postnatallyLeukemia can develop many years after identification ofETV6-RUNX1fusion",
                      "Most cases of ALL withETV6-RUNX1fusion have deletion of nonarrangedETV6allele; latter is subclonal and probably occurs postnatally",
                      "Leukemia can develop many years after identification ofETV6-RUNX1fusion",
                      "Genetic abnormalities may result in constitutively activated oncogenes, activated kinase activity, or altered transcriptional regulationPAX5germline mutation is found to be responsible for familial B-ALL in at least 3 kindreds with incomplete penetranceEVT6germline mutations carry increased risk of developing B-ALL and thrombocytopeniaBCR-ABL1-like B-ALL has gene expression profile similar to Philadelphia(+) ALL but does not haveBCR-ABL1fusionExhibits diverse genetic aberrations that activate tyrosine kinase, may involveABL1,ABL2,PDGFRB,NTRK3,TYK2,CSF1R, andJAK2Alternative translocations involving cytokine receptor-like factor 2 (CRLF2) that are often associated withJAKgene mutationsLess commonly, rearrangements leading to activation of erythropoietin receptor (EPOR)iAMP21 B-ALL has 5 or more copies ofRUNX1gene",
                      "PAX5germline mutation is found to be responsible for familial B-ALL in at least 3 kindreds with incomplete penetrance",
                      "EVT6germline mutations carry increased risk of developing B-ALL and thrombocytopenia",
                      "BCR-ABL1-like B-ALL has gene expression profile similar to Philadelphia(+) ALL but does not haveBCR-ABL1fusionExhibits diverse genetic aberrations that activate tyrosine kinase, may involveABL1,ABL2,PDGFRB,NTRK3,TYK2,CSF1R, andJAK2Alternative translocations involving cytokine receptor-like factor 2 (CRLF2) that are often associated withJAKgene mutationsLess commonly, rearrangements leading to activation of erythropoietin receptor (EPOR)",
                      "Exhibits diverse genetic aberrations that activate tyrosine kinase, may involveABL1,ABL2,PDGFRB,NTRK3,TYK2,CSF1R, andJAK2",
                      "Alternative translocations involving cytokine receptor-like factor 2 (CRLF2) that are often associated withJAKgene mutations",
                      "Less commonly, rearrangements leading to activation of erythropoietin receptor (EPOR)",
                      "iAMP21 B-ALL has 5 or more copies ofRUNX1gene",
                      "Syndromes with increased incidence of B-ALLDown syndromeCases withCRLF2translocations are particularly common in Down syndromeRobertsonian translocation, rob(15;21)(q10;q10)c, have 2700x increased risk of developing B-ALL iAMP21All rob(15;21)(q10;q10) patients who developed B-ALL are iAMP21 subtype in one study3.2% of all iAMP21 B-ALL have rob(15;21)(q10;q10)c",
                      "Down syndromeCases withCRLF2translocations are particularly common in Down syndrome",
                      "Cases withCRLF2translocations are particularly common in Down syndrome",
                      "Robertsonian translocation, rob(15;21)(q10;q10)c, have 2700x increased risk of developing B-ALL iAMP21All rob(15;21)(q10;q10) patients who developed B-ALL are iAMP21 subtype in one study3.2% of all iAMP21 B-ALL have rob(15;21)(q10;q10)c",
                      "All rob(15;21)(q10;q10) patients who developed B-ALL are iAMP21 subtype in one study",
                      "3.2% of all iAMP21 B-ALL have rob(15;21)(q10;q10)c",
                      "Syndromes with increased incidence of malignancies including B-ALLLi-Fraumeni syndromeNeurofibromatosis type 1 (NF1)Bloom syndromeAtaxia telangiectasia",
                      "Li-Fraumeni syndrome",
                      "Neurofibromatosis type 1 (NF1)",
                      "Bloom syndrome",
                      "Ataxia telangiectasia"
                    ]
                  },
                  {
                    "text": "Environmental factors linked to increased incidenceExposure to intrauterine ionizing radiationExposure to ionizing radiationExposure to pesticidesPost chemotherapy",
                    "sub_points": [
                      "Exposure to intrauterine ionizing radiation",
                      "Exposure to ionizing radiation",
                      "Exposure to pesticides",
                      "Post chemotherapy"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "B-ALL is most common childhood neoplasm"
                  },
                  {
                    "text": "Incidence is estimated at 1-4.75/100,000 persons per year"
                  },
                  {
                    "text": "80-85% of ALL is of B-cell origin"
                  },
                  {
                    "text": "75% of cases present before age 6"
                  },
                  {
                    "text": "Slight male predominance"
                  }
                ],
                "Site": [
                  {
                    "text": "Bone marrow is primary site"
                  },
                  {
                    "text": "Blood is typically involved"
                  },
                  {
                    "text": "CNS, lymph nodes, liver, spleen, and testis in males are often involved"
                  },
                  {
                    "text": "Skin, soft tissue, bone, and lymph nodes are primary sites of involvement in B-LBL"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Constitutional symptomsFeverNight sweatsWeight loss",
                    "sub_points": [
                      "Fever",
                      "Night sweats",
                      "Weight loss"
                    ]
                  },
                  {
                    "text": "Symptoms related to anemia, thrombocytopenia, or neutropeniaFatigueBleeding tendencyNeutropenic fever",
                    "sub_points": [
                      "Fatigue",
                      "Bleeding tendency",
                      "Neutropenic fever"
                    ]
                  },
                  {
                    "text": "Signs and symptoms related to leukemic infiltrateBone painArthralgiasCNS symptomsFrequent hepatosplenomegalyLymphadenopathy may be present",
                    "sub_points": [
                      "Bone pain",
                      "Arthralgias",
                      "CNS symptoms",
                      "Frequent hepatosplenomegaly",
                      "Lymphadenopathy may be present"
                    ]
                  },
                  {
                    "text": "Unique featuresB-ALL with t(12;21)(p13.2;q22.1);ETV6-RUNX1is common in children, accounting for ~ 25% of B-ALL but rare in infants or adultst(9;22) is seen in ~ 25% of adult patients but only 2-5% in childhood ALLKMT2A (a.k.a.MLL)rearrangement is most common in infants, who often present with very high white blood cell count and higher rate of CNS involvementiAMP21 B-ALL occurs in ~ 2% of children with ALL, especially older children with median age of 9 years and low WBC counts",
                    "sub_points": [
                      "B-ALL with t(12;21)(p13.2;q22.1);ETV6-RUNX1is common in children, accounting for ~ 25% of B-ALL but rare in infants or adults",
                      "t(9;22) is seen in ~ 25% of adult patients but only 2-5% in childhood ALL",
                      "KMT2A (a.k.a.MLL)rearrangement is most common in infants, who often present with very high white blood cell count and higher rate of CNS involvement",
                      "iAMP21 B-ALL occurs in ~ 2% of children with ALL, especially older children with median age of 9 years and low WBC counts"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Variable white blood cell (WBC) count50% of patients have WBC < 10 x 10⁹/L (low)30% of patients have WBC between 10-50 x 10⁹/L20% of patients have WBC > 50 x 10⁹/L20% of patients may have preleukemic state with cytopenia 2-9 months before overt leukemia",
                    "sub_points": [
                      "50% of patients have WBC < 10 x 10⁹/L (low)",
                      "30% of patients have WBC between 10-50 x 10⁹/L",
                      "20% of patients have WBC > 50 x 10⁹/L",
                      "20% of patients may have preleukemic state with cytopenia 2-9 months before overt leukemia"
                    ]
                  },
                  {
                    "text": "Anemia and thrombocytopenia almost always present"
                  },
                  {
                    "text": "Rarely patients present with asymptomatic eosinophilia"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Multiagent chemotherapy is mainstay of treatmentPatients are stratified as standard risk or high risk based on clinical, biologic prognostic factors, and cytogenetic findingsPatients are further stratified at end of induction based on response to therapy and minimal residual disease (MRD) assessment",
                    "sub_points": [
                      "Patients are stratified as standard risk or high risk based on clinical, biologic prognostic factors, and cytogenetic findings",
                      "Patients are further stratified at end of induction based on response to therapy and minimal residual disease (MRD) assessment"
                    ]
                  },
                  {
                    "text": "Intrathecal prophylactic therapy routinely done to prevent CNS relapse"
                  },
                  {
                    "text": "Cranial radiation can be limited to small subset of patients or abandoned to reduce neuropsychological sequelae"
                  },
                  {
                    "text": "Stem cell/bone marrow transplantationAutologous stem cell transplant (SCT) not effectivePatients with the following very high-risk findings may benefit from allogeneic SCTFailure to achieve complete remission after 5 weeks of therapyt(9;22) or t(4;11) positiveWBC count > 100 x 10⁹/L",
                    "sub_points": [
                      "Autologous stem cell transplant (SCT) not effective",
                      "Patients with the following very high-risk findings may benefit from allogeneic SCTFailure to achieve complete remission after 5 weeks of therapyt(9;22) or t(4;11) positiveWBC count > 100 x 10⁹/L",
                      "Failure to achieve complete remission after 5 weeks of therapy",
                      "t(9;22) or t(4;11) positive",
                      "WBC count > 100 x 10⁹/L"
                    ]
                  },
                  {
                    "text": "Supportive therapy for cytopenia(s)"
                  },
                  {
                    "text": "Novel therapiesTargeted therapy: Ph-like ALL may be targeted with tyrosine kinase inhibitors &/or JAK inhibitorsImmunotherapy: Bispecific T-cell engager antibodies and CART cells may offer greater promise in relapsed patients",
                    "sub_points": [
                      "Targeted therapy: Ph-like ALL may be targeted with tyrosine kinase inhibitors &/or JAK inhibitors",
                      "Immunotherapy: Bispecific T-cell engager antibodies and CART cells may offer greater promise in relapsed patients"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Overall prognosisExcellent; complete remission rate > 95% in children and 60-85% in adultsCure rate is ~ 80% in children and < 50% in adultsInfants withKMT2Agene rearrangement generally have poor prognosisAdolescents and young adults have better outcome when treated with pediatric protocols than with adult protocolsCNS and testis are sanctuary for leukemic cells and are common relapse sites",
                    "sub_points": [
                      "Excellent; complete remission rate > 95% in children and 60-85% in adults",
                      "Cure rate is ~ 80% in children and < 50% in adults",
                      "Infants withKMT2Agene rearrangement generally have poor prognosis",
                      "Adolescents and young adults have better outcome when treated with pediatric protocols than with adult protocols",
                      "CNS and testis are sanctuary for leukemic cells and are common relapse sites"
                    ]
                  },
                  {
                    "text": "Clinical and biologic prognostic factorsFavorable factorsAge 1-10 yearsFemaleWBC < 50 x 10⁹/LCommon type of ALL by immunophenotypeNo CNS diseaseUnfavorable factors< 1 or > 10 yearsMaleWBC > 50 x 10⁹/LLack of CD10 expression by immunophenotypingPresence of CNS disease",
                    "sub_points": [
                      "Favorable factorsAge 1-10 yearsFemaleWBC < 50 x 10⁹/LCommon type of ALL by immunophenotypeNo CNS disease",
                      "Age 1-10 years",
                      "Female",
                      "WBC < 50 x 10⁹/L",
                      "Common type of ALL by immunophenotype",
                      "No CNS disease",
                      "Unfavorable factors< 1 or > 10 yearsMaleWBC > 50 x 10⁹/LLack of CD10 expression by immunophenotypingPresence of CNS disease",
                      "< 1 or > 10 years",
                      "Male",
                      "WBC > 50 x 10⁹/L",
                      "Lack of CD10 expression by immunophenotyping",
                      "Presence of CNS disease"
                    ]
                  },
                  {
                    "text": "Cytogenetic abnormalities as prognostic predicatorsFavorableHyperdiploidy (> 50 chromosomes, especially with trisomy 4, 10, 17)t(12;21) orETV6-RUNX6fusionUnfavorableHypodiploidy (< 45 chromosomes)t(9;22) orBCR-ABL-1fusionKMT2Arearrangement; t(4;11) orKMT2A/AF4fusionB-ALL with iAMP21Complex abnormalitiesBCR-ABL1-like B-ALLIntermediatet(5;14) orIL3-IGHfusiont(1;19) orTCF3-PBX1(a.k.a.E2A-PBX1) fusionNormal karyotypeAny other abnormalities not in favorable or unfavorable categories",
                    "sub_points": [
                      "FavorableHyperdiploidy (> 50 chromosomes, especially with trisomy 4, 10, 17)t(12;21) orETV6-RUNX6fusion",
                      "Hyperdiploidy (> 50 chromosomes, especially with trisomy 4, 10, 17)",
                      "t(12;21) orETV6-RUNX6fusion",
                      "UnfavorableHypodiploidy (< 45 chromosomes)t(9;22) orBCR-ABL-1fusionKMT2Arearrangement; t(4;11) orKMT2A/AF4fusionB-ALL with iAMP21Complex abnormalitiesBCR-ABL1-like B-ALL",
                      "Hypodiploidy (< 45 chromosomes)",
                      "t(9;22) orBCR-ABL-1fusion",
                      "KMT2Arearrangement; t(4;11) orKMT2A/AF4fusion",
                      "B-ALL with iAMP21",
                      "Complex abnormalities",
                      "BCR-ABL1-like B-ALL",
                      "Intermediatet(5;14) orIL3-IGHfusiont(1;19) orTCF3-PBX1(a.k.a.E2A-PBX1) fusionNormal karyotypeAny other abnormalities not in favorable or unfavorable categories",
                      "t(5;14) orIL3-IGHfusion",
                      "t(1;19) orTCF3-PBX1(a.k.a.E2A-PBX1) fusion",
                      "Normal karyotype",
                      "Any other abnormalities not in favorable or unfavorable categories"
                    ]
                  },
                  {
                    "text": "Response to therapy as prognostic predicatorFavorableNo blasts in marrow at day 7 or 14Morphologic remission at end of inductionGood peripheral blood response to week of systemic steroid prior to multiagent chemotherapyUnfavorableMorphological blasts in marrow at day 7 or 14Requirement for 2 or more cycles of induction chemotherapy to achieve complete morphologic remissionPoor peripheral blood response to week of systemic steroid therapy",
                    "sub_points": [
                      "FavorableNo blasts in marrow at day 7 or 14Morphologic remission at end of inductionGood peripheral blood response to week of systemic steroid prior to multiagent chemotherapy",
                      "No blasts in marrow at day 7 or 14",
                      "Morphologic remission at end of induction",
                      "Good peripheral blood response to week of systemic steroid prior to multiagent chemotherapy",
                      "UnfavorableMorphological blasts in marrow at day 7 or 14Requirement for 2 or more cycles of induction chemotherapy to achieve complete morphologic remissionPoor peripheral blood response to week of systemic steroid therapy",
                      "Morphological blasts in marrow at day 7 or 14",
                      "Requirement for 2 or more cycles of induction chemotherapy to achieve complete morphologic remission",
                      "Poor peripheral blood response to week of systemic steroid therapy"
                    ]
                  },
                  {
                    "text": "MRD assessmentLow risk for relapseLow MRD (< 10⁻³) at day 8 or 15Low MRD (< 10⁻³) at end of inductionHigh risk for relapseHigh MRD (> 10⁻³) at day 8 or 15High MRD (> 10⁻³) at end of induction",
                    "sub_points": [
                      "Low risk for relapseLow MRD (< 10⁻³) at day 8 or 15Low MRD (< 10⁻³) at end of induction",
                      "Low MRD (< 10⁻³) at day 8 or 15",
                      "Low MRD (< 10⁻³) at end of induction",
                      "High risk for relapseHigh MRD (> 10⁻³) at day 8 or 15High MRD (> 10⁻³) at end of induction",
                      "High MRD (> 10⁻³) at day 8 or 15",
                      "High MRD (> 10⁻³) at end of induction"
                    ]
                  },
                  {
                    "text": "Gene expression analysisDefines distinctive ALL subsetsHelps to separate patients who may be resistant to certain chemotherapy agentsHelps to predict early response and MRD",
                    "sub_points": [
                      "Defines distinctive ALL subsets",
                      "Helps to separate patients who may be resistant to certain chemotherapy agents",
                      "Helps to predict early response and MRD"
                    ]
                  },
                  {
                    "text": "PharmacogenomicsCan predict how rapidly & effectively individual patients metabolize certain chemotherapeutic agents",
                    "sub_points": [
                      "Can predict how rapidly & effectively individual patients metabolize certain chemotherapeutic agents"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "BloodBlasts are usually present in peripheral bloodBlasts vary in size from small to largeL1 blasts: Small blasts with scant cytoplasm, condensed chromatin, and indistinctive nucleoliL2 blasts: Large blasts with moderate cytoplasm, dispersed chromatin, and variable nucleoliMay have coarse azurophilic cytoplasmic granulesEosinophilia often seen in B-ALL with t(5;14)",
                    "sub_points": [
                      "Blasts are usually present in peripheral blood",
                      "Blasts vary in size from small to large",
                      "L1 blasts: Small blasts with scant cytoplasm, condensed chromatin, and indistinctive nucleoli",
                      "L2 blasts: Large blasts with moderate cytoplasm, dispersed chromatin, and variable nucleoli",
                      "May have coarse azurophilic cytoplasmic granules",
                      "Eosinophilia often seen in B-ALL with t(5;14)"
                    ]
                  },
                  {
                    "text": "Bone marrowHypercellular marrow, usually extensively replaced by lymphoblastsBlasts are fairly uniform in bone marrowCore biopsy shows extensive replacement by lymphoblastsCore biopsy may show starry-sky pattern due to high number of mitotic figuresPatchy or diffuse preserved hematopoietic cellsRarely marrow necrosis; ALL is most common neoplasm to present as diffuse necrosis in BM",
                    "sub_points": [
                      "Hypercellular marrow, usually extensively replaced by lymphoblasts",
                      "Blasts are fairly uniform in bone marrow",
                      "Core biopsy shows extensive replacement by lymphoblasts",
                      "Core biopsy may show starry-sky pattern due to high number of mitotic figures",
                      "Patchy or diffuse preserved hematopoietic cells",
                      "Rarely marrow necrosis; ALL is most common neoplasm to present as diffuse necrosis in BM"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Often used when flow cytometric analysis is not availableCD34, TdT to confirm immaturity of blastsCD19, CD79a, and CD20 to identify B-cell lineage",
                    "sub_points": [
                      "CD34, TdT to confirm immaturity of blasts",
                      "CD19, CD79a, and CD20 to identify B-cell lineage"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Degree of differentiation determines immunophenotypeEarliest stage blasts express CD19, cytoplasmic CD79a, cytoplasmic CD22, and TdT; such ALLs occur in infancyIntermediate stage blasts express CD10, CD19, surface CD79a, surface CD22, and TdTMost mature stage blasts express cytoplasmic μ chains (c-μ), CD34 often negative",
                    "sub_points": [
                      "Earliest stage blasts express CD19, cytoplasmic CD79a, cytoplasmic CD22, and TdT; such ALLs occur in infancy",
                      "Intermediate stage blasts express CD10, CD19, surface CD79a, surface CD22, and TdT",
                      "Most mature stage blasts express cytoplasmic μ chains (c-μ), CD34 often negative"
                    ]
                  },
                  {
                    "text": "CD34 and CD20 expression variable"
                  },
                  {
                    "text": "CD45 can be negative but is typically weak"
                  },
                  {
                    "text": "Approximately 20-30% of cases also express myeloid associated antigen markers CD15, CD13, and CD33"
                  },
                  {
                    "text": "CD13 expression is often seen in B-ALL with t(12;21)"
                  },
                  {
                    "text": "CD13 and CD33 often expressed in B-ALL with t(9;22)"
                  },
                  {
                    "text": "Switch in immunophenotype during therapy is very common, usually gain or loss of myeloid markers"
                  }
                ],
                "PCR": [
                  {
                    "text": "Almost all cases have clonal rearrangement ofIGHgene"
                  },
                  {
                    "text": "Majority of cases also have clonal rearrangement of T-cell receptor gene"
                  },
                  {
                    "text": "RT-PCR is performed if fusion is detected, such asBCR-ABL1, to establish baseline and to follow-up minimal residual disease"
                  },
                  {
                    "text": "Cancer gene panels are performed in selected institutions &/or selected patients"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Cytogenetic studyRoutine karyotype is required on all new B-ALL casesAbnormalities are found in majority of B-ALL/B-LBL casest(12;21)(p13;q22)TV6-RUNX1(a.k.a.ETV6-RUNX1); most common fusion in pediatric ALLt(1;19)(q23;p13.3)TCF3-PBX1(E2A-PBX1)t(9;22)(q34.1;q11.2)BCR-ABL1t(v;11q23.3)KMT2Arearranged; especially ALL in neonates/infantst(5;14)(q31;q32)IL3-IgH, associated with eosinophiliaHyperdiploidyHypodiploidy",
                    "sub_points": [
                      "Routine karyotype is required on all new B-ALL cases",
                      "Abnormalities are found in majority of B-ALL/B-LBL cases",
                      "t(12;21)(p13;q22)TV6-RUNX1(a.k.a.ETV6-RUNX1); most common fusion in pediatric ALL",
                      "t(1;19)(q23;p13.3)TCF3-PBX1(E2A-PBX1)",
                      "t(9;22)(q34.1;q11.2)BCR-ABL1",
                      "t(v;11q23.3)KMT2Arearranged; especially ALL in neonates/infants",
                      "t(5;14)(q31;q32)IL3-IgH, associated with eosinophilia",
                      "Hyperdiploidy",
                      "Hypodiploidy"
                    ]
                  },
                  {
                    "text": "Fluorescence in situ hybridization (FISH) studiesRequired by Children's Oncology Group (COG) protocolt(9;22)Aneuploidy for chromosomes 4, 10, 17KMT2Agene rearrangementt(12;21) to detect fusion gene as well as detect copy number ofRUNX1gene to exclude iAMP21",
                    "sub_points": [
                      "Required by Children's Oncology Group (COG) protocolt(9;22)Aneuploidy for chromosomes 4, 10, 17KMT2Agene rearrangementt(12;21) to detect fusion gene as well as detect copy number ofRUNX1gene to exclude iAMP21",
                      "t(9;22)",
                      "Aneuploidy for chromosomes 4, 10, 17",
                      "KMT2Agene rearrangement",
                      "t(12;21) to detect fusion gene as well as detect copy number ofRUNX1gene to exclude iAMP21"
                    ]
                  },
                  {
                    "text": "Next generation sequencing and gene expression profiling becoming more routine"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Hematogones": [
                  {
                    "text": "Can be numerous in children, especially during recovery after BM insults"
                  },
                  {
                    "text": "Immunophenotypic spectrum of hematogonesDemonstrates gradual gain of CD20 expressionGradual loss of CD10, TdT, and CD34Lack of aberrant antigen expression",
                    "sub_points": [
                      "Demonstrates gradual gain of CD20 expression",
                      "Gradual loss of CD10, TdT, and CD34",
                      "Lack of aberrant antigen expression"
                    ]
                  }
                ],
                "Burkitt Lymphoma": [
                  {
                    "text": "Burkitt lymphoma (BL) is mature, high-grade B-cell lymphoma"
                  },
                  {
                    "text": "Lymphoma cells are large with unique punctate cytoplasmic vacuoles"
                  },
                  {
                    "text": "BL expresses surface immunoglobulin and lacks immature markers CD34 or TdT"
                  }
                ],
                "Other Leukemias": [
                  {
                    "text": "Immunophenotyping is helpful to distinguish B-ALL from other leukemias"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "T-Cell Lymphoblastic Leukemia/Lymphoma": {
            "name": "T-Cell Lymphoblastic Leukemia/Lymphoma",
            "url": "https://app.pathprimer.com/document/0624e684-79b3-4ef0-9eaa-a5857911f565/lesson/9744fc63-5115-42ad-9ae9-5725b1419c5b",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Clonal proliferation of hematopoietic stem cell with immature T-cell immunophenotype"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "T-cell acute lymphoblastic leukemia (T-ALL)Approximately 15% of all childhood ALLApproximately 25% of adult ALLAge at diagnosis < 10 years in ~ 1/2 of childhood T-ALL",
                    "sub_points": [
                      "Approximately 15% of all childhood ALL",
                      "Approximately 25% of adult ALL",
                      "Age at diagnosis < 10 years in ~ 1/2 of childhood T-ALL"
                    ]
                  },
                  {
                    "text": "T-cell lymphoblastic lymphoma (T-LBL)Approximately 85% of all lymphoblastic lymphomasAge at diagnosis < 10 years in ~ 1/2 of childhood T-LBL",
                    "sub_points": [
                      "Approximately 85% of all lymphoblastic lymphomas",
                      "Age at diagnosis < 10 years in ~ 1/2 of childhood T-LBL"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Flow cytometry/immunohistochemistryT lymphoblasts usually express TdTT lymphoblasts variably express CD1a, CD2, CD4, CD5, CD7, CD8 and CD3 (surface or cytoplasmic)T lymphoblasts may also coexpress CD10 &/or CD34",
                    "sub_points": [
                      "T lymphoblasts usually express TdT",
                      "T lymphoblasts variably express CD1a, CD2, CD4, CD5, CD7, CD8 and CD3 (surface or cytoplasmic)",
                      "T lymphoblasts may also coexpress CD10 &/or CD34"
                    ]
                  },
                  {
                    "text": "CytogeneticsStructural chromosomal abnormalities detected in approximately 50% of T-ALL/T-LBL",
                    "sub_points": [
                      "Structural chromosomal abnormalities detected in approximately 50% of T-ALL/T-LBL"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "T-acute lymphoblastic leukemia (T-ALL)/T-lymphoblastic lymphoma (T-LBL)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Clonal proliferation of hematopoietic stem cells with immature T-cell immunophenotype"
                  },
                  {
                    "text": "T-ALL and T-LBL were historically separated based on numbers of lymphoblasts in bone marrow"
                  },
                  {
                    "text": "Current 2008 WHO combines T-ALL and T-LBL as a single biologic entity"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "T-cell acute lymphoblastic leukemia (T-ALL)Approximately 15% of all childhood ALLApproximately 25% of adult ALLAge at diagnosis: < 10 years in ~ 1/2 of childhood T-ALLMore common in adolescent males",
                    "sub_points": [
                      "Approximately 15% of all childhood ALL",
                      "Approximately 25% of adult ALL",
                      "Age at diagnosis: < 10 years in ~ 1/2 of childhood T-ALL",
                      "More common in adolescent males"
                    ]
                  },
                  {
                    "text": "T-cell lymphoblastic lymphoma (T-LBL)Approximately 85% of all lymphoblastic lymphomasAge at diagnosis: < 10 years in ~ 1/2 of childhood T-LBLMore common in adolescent males",
                    "sub_points": [
                      "Approximately 85% of all lymphoblastic lymphomas",
                      "Age at diagnosis: < 10 years in ~ 1/2 of childhood T-LBL",
                      "More common in adolescent males"
                    ]
                  },
                  {
                    "text": "Early T-cell precursor ALL/LL (ETP-ALL)Newly recognized subtype of T-ALLSignificant overlap with mixed phenotype acute leukemia (MPAL)Early stage of T-cell maturation; myeloid antigen coexpressionLeukemic and lymphomatous manifestations",
                    "sub_points": [
                      "Newly recognized subtype of T-ALL",
                      "Significant overlap with mixed phenotype acute leukemia (MPAL)",
                      "Early stage of T-cell maturation; myeloid antigen coexpression",
                      "Leukemic and lymphomatous manifestations"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "T-acute lymphoblastic leukemiaCommonly manifests with high leukocyte count with circulating blastsOften concurrent mediastinal or other tissue massLymphadenopathy and hepatosplenomegaly commonRelative sparing of trilineage hematopoiesis in bone marrow compared to B-ALLCNS involvement more common than in T-lymphoblastic lymphoma",
                    "sub_points": [
                      "Commonly manifests with high leukocyte count with circulating blasts",
                      "Often concurrent mediastinal or other tissue mass",
                      "Lymphadenopathy and hepatosplenomegaly common",
                      "Relative sparing of trilineage hematopoiesis in bone marrow compared to B-ALL",
                      "CNS involvement more common than in T-lymphoblastic lymphoma"
                    ]
                  },
                  {
                    "text": "T-cell lymphoblastic lymphomaFrequently manifests with rapidly growing anterior mediastinal massPleural &/or pericardial effusions often presentRespiratory symptoms and superior vena cava syndrome may be seenBone marrow involvement at diagnosis in about 20% of cases",
                    "sub_points": [
                      "Frequently manifests with rapidly growing anterior mediastinal mass",
                      "Pleural &/or pericardial effusions often present",
                      "Respiratory symptoms and superior vena cava syndrome may be seen",
                      "Bone marrow involvement at diagnosis in about 20% of cases"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Pediatric T-acute lymphoblastic leukemia/lymphomaHigher risk compared to B-ALLIncreased risk of isolated CNS relapse",
                    "sub_points": [
                      "Higher risk compared to B-ALL",
                      "Increased risk of isolated CNS relapse"
                    ]
                  },
                  {
                    "text": "Adult T-acute lymphoblastic leukemiaBetter prognosis than B-ALL likely due to low rate of adverse cytogenetic abnormalities in T-ALLAdult T-lymphoblastic lymphomaShort survival with failure to achieve CRAge > 40 yearsLDH level > 2x upper limits of normalHemoglobin level < 10 g/dL",
                    "sub_points": [
                      "Better prognosis than B-ALL likely due to low rate of adverse cytogenetic abnormalities in T-ALL",
                      "Adult T-lymphoblastic lymphomaShort survival with failure to achieve CRAge > 40 yearsLDH level > 2x upper limits of normalHemoglobin level < 10 g/dL",
                      "Short survival with failure to achieve CRAge > 40 yearsLDH level > 2x upper limits of normalHemoglobin level < 10 g/dL",
                      "Age > 40 years",
                      "LDH level > 2x upper limits of normal",
                      "Hemoglobin level < 10 g/dL"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Blood and Bone Marrow Findings": [
                  {
                    "text": "Peripheral blood findings in T-ALLLeukocytosis with circulating lymphoblastsLymphoblasts are small to medium-sized with high N:C ratio in most casesLymphoblasts can show significant size variation ranging from small to largeCases with small lymphoblasts may be confused with circulating mature T-cell lymphomaLarge lymphoblasts typically contain immature nuclear chromatin and distinct nucleoliCytoplasmic vacuoles may be seen in some casesT lymphoblasts are morphologically indistinguishable from B lymphoblastsCytopenias may be present",
                    "sub_points": [
                      "Leukocytosis with circulating lymphoblastsLymphoblasts are small to medium-sized with high N:C ratio in most casesLymphoblasts can show significant size variation ranging from small to largeCases with small lymphoblasts may be confused with circulating mature T-cell lymphomaLarge lymphoblasts typically contain immature nuclear chromatin and distinct nucleoliCytoplasmic vacuoles may be seen in some casesT lymphoblasts are morphologically indistinguishable from B lymphoblasts",
                      "Lymphoblasts are small to medium-sized with high N:C ratio in most cases",
                      "Lymphoblasts can show significant size variation ranging from small to large",
                      "Cases with small lymphoblasts may be confused with circulating mature T-cell lymphoma",
                      "Large lymphoblasts typically contain immature nuclear chromatin and distinct nucleoli",
                      "Cytoplasmic vacuoles may be seen in some cases",
                      "T lymphoblasts are morphologically indistinguishable from B lymphoblasts",
                      "Cytopenias may be present"
                    ]
                  },
                  {
                    "text": "Bone marrow findings in T-ALLLymphoblasts in marrow aspirate show morphologic features similar to those found in bloodExtensive marrow involvement on core biopsy and clot sectionsSheets of blasts with immature nuclear chromatin and numerous mitoses typically seenIn contrast to B-lineage ALL, normal trilineage hematopoiesis relatively preserved",
                    "sub_points": [
                      "Lymphoblasts in marrow aspirate show morphologic features similar to those found in blood",
                      "Extensive marrow involvement on core biopsy and clot sections",
                      "Sheets of blasts with immature nuclear chromatin and numerous mitoses typically seen",
                      "In contrast to B-lineage ALL, normal trilineage hematopoiesis relatively preserved"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Flow Cytometry": [
                  {
                    "text": "T lymphoblasts usually express TdT"
                  },
                  {
                    "text": "T lymphoblasts variably express CD1a, CD2, CD5, CD7, and CD3 (surface or cytoplasmic)"
                  },
                  {
                    "text": "T lymphoblasts frequently coexpress CD4 and CD8 but could express only former/latter or neither"
                  },
                  {
                    "text": "T lymphoblasts may also coexpress CD10"
                  },
                  {
                    "text": "Subset of T-ALL cases also express CD34"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Antigen receptor gene rearrangementsClonal rearrangements of T-cell receptor genes detected in virtually all casesConcomitant clonal rearrangements of immunoglobulin heavy chain in 20% of cases",
                    "sub_points": [
                      "Clonal rearrangements of T-cell receptor genes detected in virtually all cases",
                      "Concomitant clonal rearrangements of immunoglobulin heavy chain in 20% of cases"
                    ]
                  },
                  {
                    "text": "Recurrent cytogenetic abnormalitiesStructural chromosomal abnormalities detected in approximately 50% of T-ALLTranslocations involving T-cell receptor (TRG@) gene lociFound in about 40% of T-ALL casesTCRαandTCRδat 14q11,TCRβat 7q34, andTCRγat 14p14-15 are involvedThese translocations occur due to errors duringTRG@gene rearrangements",
                    "sub_points": [
                      "Structural chromosomal abnormalities detected in approximately 50% of T-ALL",
                      "Translocations involving T-cell receptor (TRG@) gene lociFound in about 40% of T-ALL casesTCRαandTCRδat 14q11,TCRβat 7q34, andTCRγat 14p14-15 are involvedThese translocations occur due to errors duringTRG@gene rearrangements",
                      "Found in about 40% of T-ALL cases",
                      "TCRαandTCRδat 14q11,TCRβat 7q34, andTCRγat 14p14-15 are involved",
                      "These translocations occur due to errors duringTRG@gene rearrangements"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Precursor B-Lymphoblastic Leukemia/Lymphoma": [
                  {
                    "text": "B lymphoblasts are cytomorphologically similar to T lymphoblasts"
                  },
                  {
                    "text": "Flow cytometry or immunohistochemistry can easily separate T lymphoblasts from B lymphoblasts"
                  }
                ],
                "Mature T-Cell Lymphoma": [
                  {
                    "text": "Subset of T lymphoblasts with mature-appearing morphology may mimic a mature T-cell lymphoma"
                  },
                  {
                    "text": "Angioimmunoblastic T-cell lymphoma may have overlapping immunophenotype including expression of CD3 and CD10"
                  },
                  {
                    "text": "Expression of immature markers in T lymphoblasts are useful to separate T lymphoblasts from mature T-cell lymphoma"
                  }
                ],
                "8p11Myeloproliferative Syndrome": [
                  {
                    "text": "Myeloid and lymphoid neoplasm withFGFR1abnormalities (WHO classification)"
                  },
                  {
                    "text": "Aggressive neoplasms with eosinophilia, circulating blasts, leukemoid reaction, and myeloproliferative features"
                  },
                  {
                    "text": "> 20% blasts of either myeloid, mixed lineage, or T-lineage in some cases"
                  },
                  {
                    "text": "Myeloproliferative features and rearrangements ofFGFR1gene at 8p11 separates this neoplasm from T-ALL"
                  }
                ],
                "Indolent T-Lymphoblastic Proliferation": [
                  {
                    "text": "Isolated case reports of indolent T-lymphoblastic proliferation in upper airway"
                  },
                  {
                    "text": "Nonclonal by T-cell receptor gene rearrangement studies"
                  },
                  {
                    "text": "Ectopic thymic tissue needs to be excluded"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Mixed Phenotype Acute Leukemia": {
            "name": "Mixed Phenotype Acute Leukemia",
            "url": "https://app.pathprimer.com/document/14e351f6-03af-44b2-ba21-af2ae5f742a2/lesson/9744fc63-5115-42ad-9ae9-5725b1419c5b",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Mixed phenotype acute leukemia (MPAL)"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Aggressive disease"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Blasts ≥ 20%"
                  },
                  {
                    "text": "Blast population(s)Single populationDimorphic populationOr, may have 2 separate populations",
                    "sub_points": [
                      "Single population",
                      "Dimorphic population",
                      "Or, may have 2 separate populations"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Expression of 2 or more lineage-associated antigens by flow cytometry, cytochemistry, &/or immunohistochemistryMyeloid: Myeloperoxidaseormonocytic: NSE, CD11c, CD14, CD64, lysozymeB-lymphoid: CD19 and CD79a, CD22, or CD10T-lymphoid: Cytoplasmic or surface CD3",
                    "sub_points": [
                      "Myeloid: Myeloperoxidaseormonocytic: NSE, CD11c, CD14, CD64, lysozyme",
                      "B-lymphoid: CD19 and CD79a, CD22, or CD10",
                      "T-lymphoid: Cytoplasmic or surface CD3"
                    ]
                  },
                  {
                    "text": "GeneticsEvaluate for t(9;22) and 11q23 (MLL) rearrangementExclude recurring genetic abnormality that warrants alternative diagnosis [e.g., AML with t(8;21), AML with t(9;11)]",
                    "sub_points": [
                      "Evaluate for t(9;22) and 11q23 (MLL) rearrangement",
                      "Exclude recurring genetic abnormality that warrants alternative diagnosis [e.g., AML with t(8;21), AML with t(9;11)]"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Mixed phenotype acute leukemia (MPAL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Acute biphenotypic leukemias"
                  },
                  {
                    "text": "Acute leukemias of ambiguous lineage"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Clonal stem cell disorder with ≥ 20% blasts"
                  },
                  {
                    "text": "Evidence of expression of 2 or more cell lineages: Myeloid, T cell, B cell"
                  },
                  {
                    "text": "Two definitionsTwo or more leukemic blast populations (1 myeloid, 1 lymphoid); \"biphenotypic\"Single blast population coexpressing lymphoid and myeloid (e.g., myeloperoxidase) or monocytic markers",
                    "sub_points": [
                      "Two or more leukemic blast populations (1 myeloid, 1 lymphoid); \"biphenotypic\"",
                      "Single blast population coexpressing lymphoid and myeloid (e.g., myeloperoxidase) or monocytic markers"
                    ]
                  },
                  {
                    "text": "Five diagnostic categoriesMPAL with t(9;22)(q34;q11.2),BCR-ABL1MPAL with t(v;11q23),MLLrearrangedMPAL, B/myeloid, not otherwise specifiedMPAL, T/myeloid, not otherwise specifiedMPAL, other",
                    "sub_points": [
                      "MPAL with t(9;22)(q34;q11.2),BCR-ABL1",
                      "MPAL with t(v;11q23),MLLrearranged",
                      "MPAL, B/myeloid, not otherwise specified",
                      "MPAL, T/myeloid, not otherwise specified",
                      "MPAL, other"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Molecular Pathogenesis": [
                  {
                    "text": "Variety of genetic lesions"
                  },
                  {
                    "text": "Rearrangements ofMLL(mixed lineage leukemia) gene commont(4;11)(q21;q23) most commonMLLgene on 11q23Molecular consequenceDisruption of normal MLL functionFusion partners take control of targets normally controlled by MLL",
                    "sub_points": [
                      "t(4;11)(q21;q23) most common",
                      "MLLgene on 11q23",
                      "Molecular consequenceDisruption of normal MLL functionFusion partners take control of targets normally controlled by MLL",
                      "Disruption of normal MLL function",
                      "Fusion partners take control of targets normally controlled by MLL"
                    ]
                  },
                  {
                    "text": "t(9;22)(q34;q11.2),BCR-ABL1fusion"
                  },
                  {
                    "text": "Deletions of 6q, 5q, and 12p"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "~ 2-5% of adult acute leukemias are mixed phenotype/biphenotypic"
                  }
                ],
                "Age": [
                  {
                    "text": "Frequency appears similar across all age groups"
                  },
                  {
                    "text": "MLL-rearranged MPAL more common in pediatric population; typically infants"
                  }
                ],
                "Site": [
                  {
                    "text": "Peripheral blood"
                  },
                  {
                    "text": "Bone marrow"
                  },
                  {
                    "text": "Occasional extramedullary presentation"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Abnormal complete blood cell count (CBC); increased blasts and cytopenias"
                  },
                  {
                    "text": "Fatigue"
                  },
                  {
                    "text": "Bleeding"
                  },
                  {
                    "text": "Infection"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "CBC with differential"
                  },
                  {
                    "text": "Peripheral blood smear"
                  },
                  {
                    "text": "Bone marrow biopsy"
                  },
                  {
                    "text": "Flow cytometry"
                  },
                  {
                    "text": "Conventional cytogenetics"
                  },
                  {
                    "text": "Molecular genetics as needed"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Not standardized"
                  },
                  {
                    "text": "Variable use of AML or ALL therapies"
                  },
                  {
                    "text": "Possible stem cell transplantation"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Poor compared to age-matched controls with AML or ALL"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Peripheral Blood": [
                  {
                    "text": "Anemia"
                  },
                  {
                    "text": "Thrombocytopenia"
                  },
                  {
                    "text": "Neutropenia"
                  },
                  {
                    "text": "Circulating blastsBlast population(s)May see 1 blast populationorTwo distinct populationsorDimorphic populationVariable blast cytologyLymphoid-like blast appearanceIntermediate sizeSmooth chromatinInconspicuous nucleoliScant cytoplasmMyeloid-like blast appearanceLarge sizeFine chromatinNucleoliModerate cytoplasmPossible cytoplasmic granules or Auer rods",
                    "sub_points": [
                      "Blast population(s)May see 1 blast populationorTwo distinct populationsorDimorphic population",
                      "May see 1 blast populationor",
                      "Two distinct populationsor",
                      "Dimorphic population",
                      "Variable blast cytology",
                      "Lymphoid-like blast appearanceIntermediate sizeSmooth chromatinInconspicuous nucleoliScant cytoplasm",
                      "Intermediate size",
                      "Smooth chromatin",
                      "Inconspicuous nucleoli",
                      "Scant cytoplasm",
                      "Myeloid-like blast appearanceLarge sizeFine chromatinNucleoliModerate cytoplasmPossible cytoplasmic granules or Auer rods",
                      "Large size",
                      "Fine chromatin",
                      "Nucleoli",
                      "Moderate cytoplasm",
                      "Possible cytoplasmic granules or Auer rods"
                    ]
                  },
                  {
                    "text": "Often markedly elevated white blood cell countParticularly those withMLLrearrangement",
                    "sub_points": [
                      "Particularly those withMLLrearrangement"
                    ]
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "Hypercellular"
                  },
                  {
                    "text": "Effacement by blast population(s)"
                  },
                  {
                    "text": "No significant background dysplasia"
                  },
                  {
                    "text": "No specific bony changes"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Determine Myeloid Expression": [
                  {
                    "text": "MyeloperoxidaseUtilize flow cytometry, cytochemistry, and immunohistochemistry",
                    "sub_points": [
                      "Utilize flow cytometry, cytochemistry, and immunohistochemistry"
                    ]
                  },
                  {
                    "text": "Monocytic differentiationNSE, CD11c, CD14, CD64, lysozymeCytochemistry: NSEImmunohistochemistry: LysozymeFlow cytometry: CD11c, CD14, CD64",
                    "sub_points": [
                      "NSE, CD11c, CD14, CD64, lysozymeCytochemistry: NSEImmunohistochemistry: LysozymeFlow cytometry: CD11c, CD14, CD64",
                      "Cytochemistry: NSE",
                      "Immunohistochemistry: Lysozyme",
                      "Flow cytometry: CD11c, CD14, CD64"
                    ]
                  }
                ],
                "Determine B-Lymphoid Expression": [
                  {
                    "text": "Strong CD19 and 1 additional B-cell marker CD79a, cytoplasmic CD22, or CD10Or weak CD19 and 2 additional B-cell lineage markers",
                    "sub_points": [
                      "Or weak CD19 and 2 additional B-cell lineage markers"
                    ]
                  },
                  {
                    "text": "Flow cytometry preferred"
                  }
                ],
                "Determine T-Lymphoid Expression": [
                  {
                    "text": "CD3 (cytoplasmicorsurface)Flow cytometry is preferredUse antibody to CD3 epsilon chainImmunohistochemistryExercise caution in interpreting positive results given that CD3 zeta chain (present in natural killer cells) may cross-react",
                    "sub_points": [
                      "Flow cytometry is preferredUse antibody to CD3 epsilon chain",
                      "Use antibody to CD3 epsilon chain",
                      "ImmunohistochemistryExercise caution in interpreting positive results given that CD3 zeta chain (present in natural killer cells) may cross-react",
                      "Exercise caution in interpreting positive results given that CD3 zeta chain (present in natural killer cells) may cross-react"
                    ]
                  }
                ],
                "Genetics": [
                  {
                    "text": "May utilize cytogenetics, FISH, or molecular genetics methods"
                  },
                  {
                    "text": "t(9;22)(q34;q11.2),BCR-ABL1fusionDiagnose as MPAL with t(9;22)(q34;q11.2),BCR-ABL1Cases with history of CML or presenting as CML in blasts phase are excluded",
                    "sub_points": [
                      "Diagnose as MPAL with t(9;22)(q34;q11.2),BCR-ABL1",
                      "Cases with history of CML or presenting as CML in blasts phase are excluded"
                    ]
                  },
                  {
                    "text": "t(v;11q23),MLLrearrangedDiagnose as MPAL with t(v;11q23),MLLrearrangedMust meet specific criteria for MPAL",
                    "sub_points": [
                      "Diagnose as MPAL with t(v;11q23),MLLrearranged",
                      "Must meet specific criteria for MPAL"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Acute Myeloid Leukemias (AML) With Aberrant B-Lineage Expression": [
                  {
                    "text": "Not common"
                  },
                  {
                    "text": "AML with t(8;21) shows characteristic expression of the B-lineage-associated markers, CD19 and Pax-5"
                  }
                ],
                "Acute Lymphoblastic Leukemias (ALL) With Aberrant Myeloid Expression": [
                  {
                    "text": "Common with both B- and T-cell ALL"
                  },
                  {
                    "text": "CD13 and CD33 typical myeloid markers"
                  },
                  {
                    "text": "Exclude recurring genetic abnormality warranting alternative diagnosis: t(9;22), t(12;21), etc."
                  }
                ],
                "ALL With t(v;11q23),MLLRearranged": [
                  {
                    "text": "B-ALL phenotype most common"
                  },
                  {
                    "text": "Most common type of infant ALL"
                  },
                  {
                    "text": "Most common translocation is t(4;11)"
                  },
                  {
                    "text": "Dismal prognosis"
                  }
                ],
                "AML With t(v;11q23),MLLRearranged": [
                  {
                    "text": "If t(9;11)(p22;q23;MLLT3-MLLdetected, diagnose as AML with recurring genetic abnormality"
                  },
                  {
                    "text": "Often appear monocytic or have a monocytic component"
                  }
                ],
                "AML With t(9;22)(q34;q11.2),BCR-ABL1Fusion": [
                  {
                    "text": "Must distinguish from CML presenting in blast phase"
                  }
                ],
                "Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2),BCR-ABL1Fusion": [
                  {
                    "text": "~ 5% of pediatric ALL and 25% of adult ALL"
                  },
                  {
                    "text": "Vast majority are B lineage"
                  },
                  {
                    "text": "High-risk disease with poor prognosis"
                  },
                  {
                    "text": "Aberrant expression of CD13 and CD33 quite common; myeloperoxidase negative"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Poor prognosis"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Acute leukemia expressing 2 or more different lineage-associated antigens"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Acute Myeloid Leukemia and Myeloid Neoplasms": {
        "name": "Acute Myeloid Leukemia and Myeloid Neoplasms",
        "url": "https://app.pathprimer.com/lesson/e328b112-0403-4322-9b2b-5e6e7ecbe471",
        "topics": {
          "Overview of Acute Myeloid Leukemia": {
            "name": "Overview of Acute Myeloid Leukemia",
            "url": "https://app.pathprimer.com/document/3710f0c6-f7fe-4599-af8e-801597babc62/lesson/e328b112-0403-4322-9b2b-5e6e7ecbe471",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Acute myeloid leukemia (AML)"
                  },
                  {
                    "text": "International Consensus Classification (ICC)"
                  },
                  {
                    "text": "WHO 5th edition (WHO-HAEM5)"
                  },
                  {
                    "text": "Myelodysplasia-related gene mutations (MRG) (ICC designation only)"
                  },
                  {
                    "text": "Myelodysplasia-related cytogenetic abnormalities (i.e., karyotype) (MRC) (ICC designation only)"
                  },
                  {
                    "text": "Myelodysplastic syndrome (MDS) (ICC); myelodysplastic neoplasm (MDN) (WHO-HAEM5)"
                  },
                  {
                    "text": "Myeloproliferative neoplasm (MPN)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Acute myelogenous leukemia"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Clonal hematopoietic stem/progenitor cell neoplasm"
                  },
                  {
                    "text": "Heterogeneous group of genetically distinct neoplasms"
                  }
                ]
              },
              "Classification": {
                "Classification Systems Overview: ICC and WHO-HAEM5 Comparisons": [
                  {
                    "text": "2 major AML categories in both classificationsAML with recurrent (defining) genetic abnormalities (ICC and WHO-HAEM5)ICCrequires≥ 10% blastsfor 20 of 21 subtypes of AML with recurrent genetic abnormalitiesException is that AML withBCR::ABL1has ≥ 20% blast percentage requirementAML with mutated bZIPCEBPA: Specific requirement for this type of mutation in ICCAML with defining genetic abnormalities (WHO-HAEM5)WHO-HAEM5 hasnoblast percentage requirement for 12 of 15 subtypes of AML with defining genetic abnormality subtypes≥ 20% blast requirementfor all other AML subtypes (ICC and WHO-HAEM5)ICCsubtypes includeAML with t(9;22)(q34.1;q11.2)/BCR::ABL1AML with mutatedTP53(ICC entity only)AML, myelodysplasia-related gene mutations (MRG) (ICC designation only)AML, myelodysplasia-related cytogenetic abnormalities (MRC) (ICC designation only)AML, not otherwise specified (NOS)ICC doesnotinclude either therapy-related or germline disorder-associated AML cases as entities\"Therapy-related\" and \"germline disorder-associated\" are listed as qualifiers to primary ICC diagnosisWHO-HAEM5subtypes include3 genetically defined subtypes: AML withCEBPA, AML withBCR::ABL1mutation, and AML, myelodysplasia-related (AML-MR) subtypesAML with biallelicCEBPAmutation, per WHO, has ≥ 20% blast requirement8 other subtypes defined by differentiation (no genetic requirements)Includes AML with minimal differentiation, ± maturation, and AML with monocytic, erythroid, basophilic, or megakaryoblastic differentiationIncludes postcytotoxic therapy and germline predisposition-related secondary AML entitiesKey ICC vs. WHO-HAEM5 differences≥ 10% blast threshold for AML with recurrent genetic abnormalities (ICC); no blast percentage requirement (WHO-HAEM5)ICC requiresin-frame bZIPCEBPAmutation (onlyCEBPAmutation linked to favorable outcome as per recent studies) and ≥ 10% blasts: WHO-HAEM5 requires biallelicCEBPAmutation and ≥ 20% blastsAML with mutatedTP53is entity in ICC; included with complex karyotype in AML-MR in WHO-HAEM5Therapy-related AML is not regarded as diagnostic entity in ICC but is retained in WHO-HAEM5AML entities in ICC are defined largely by genetic profile with therapy-relatedness reported as qualifierWHO-HAEM5 includes therapy-related (postcytotoxic) and germline predisposition-related in secondary AMLAML defined by differentiation (WHO-HAEM5) designated as AML, NOS in ICCMost cases in this category in WHO-HAEM4 have genetic abnormalities that allow them to be moved to 1 of new ICC genetic entitiesRetained in WHO-HAEM5 with largely French American British (FAB) designations and definitionsAML-MR in WHO-HAEM5 corresponds to WHO-HAEM4 AML-MRC definitions",
                    "sub_points": [
                      "AML with recurrent (defining) genetic abnormalities (ICC and WHO-HAEM5)ICCrequires≥ 10% blastsfor 20 of 21 subtypes of AML with recurrent genetic abnormalitiesException is that AML withBCR::ABL1has ≥ 20% blast percentage requirementAML with mutated bZIPCEBPA: Specific requirement for this type of mutation in ICCAML with defining genetic abnormalities (WHO-HAEM5)WHO-HAEM5 hasnoblast percentage requirement for 12 of 15 subtypes of AML with defining genetic abnormality subtypes",
                      "ICCrequires≥ 10% blastsfor 20 of 21 subtypes of AML with recurrent genetic abnormalitiesException is that AML withBCR::ABL1has ≥ 20% blast percentage requirementAML with mutated bZIPCEBPA: Specific requirement for this type of mutation in ICC",
                      "Exception is that AML withBCR::ABL1has ≥ 20% blast percentage requirement",
                      "AML with mutated bZIPCEBPA: Specific requirement for this type of mutation in ICC",
                      "AML with defining genetic abnormalities (WHO-HAEM5)WHO-HAEM5 hasnoblast percentage requirement for 12 of 15 subtypes of AML with defining genetic abnormality subtypes",
                      "WHO-HAEM5 hasnoblast percentage requirement for 12 of 15 subtypes of AML with defining genetic abnormality subtypes",
                      "≥ 20% blast requirementfor all other AML subtypes (ICC and WHO-HAEM5)ICCsubtypes includeAML with t(9;22)(q34.1;q11.2)/BCR::ABL1AML with mutatedTP53(ICC entity only)AML, myelodysplasia-related gene mutations (MRG) (ICC designation only)AML, myelodysplasia-related cytogenetic abnormalities (MRC) (ICC designation only)AML, not otherwise specified (NOS)ICC doesnotinclude either therapy-related or germline disorder-associated AML cases as entities\"Therapy-related\" and \"germline disorder-associated\" are listed as qualifiers to primary ICC diagnosisWHO-HAEM5subtypes include3 genetically defined subtypes: AML withCEBPA, AML withBCR::ABL1mutation, and AML, myelodysplasia-related (AML-MR) subtypesAML with biallelicCEBPAmutation, per WHO, has ≥ 20% blast requirement8 other subtypes defined by differentiation (no genetic requirements)Includes AML with minimal differentiation, ± maturation, and AML with monocytic, erythroid, basophilic, or megakaryoblastic differentiationIncludes postcytotoxic therapy and germline predisposition-related secondary AML entities",
                      "ICCsubtypes includeAML with t(9;22)(q34.1;q11.2)/BCR::ABL1AML with mutatedTP53(ICC entity only)AML, myelodysplasia-related gene mutations (MRG) (ICC designation only)AML, myelodysplasia-related cytogenetic abnormalities (MRC) (ICC designation only)AML, not otherwise specified (NOS)",
                      "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
                      "AML with mutatedTP53(ICC entity only)",
                      "AML, myelodysplasia-related gene mutations (MRG) (ICC designation only)",
                      "AML, myelodysplasia-related cytogenetic abnormalities (MRC) (ICC designation only)",
                      "AML, not otherwise specified (NOS)",
                      "ICC doesnotinclude either therapy-related or germline disorder-associated AML cases as entities\"Therapy-related\" and \"germline disorder-associated\" are listed as qualifiers to primary ICC diagnosis",
                      "\"Therapy-related\" and \"germline disorder-associated\" are listed as qualifiers to primary ICC diagnosis",
                      "WHO-HAEM5subtypes include3 genetically defined subtypes: AML withCEBPA, AML withBCR::ABL1mutation, and AML, myelodysplasia-related (AML-MR) subtypesAML with biallelicCEBPAmutation, per WHO, has ≥ 20% blast requirement8 other subtypes defined by differentiation (no genetic requirements)Includes AML with minimal differentiation, ± maturation, and AML with monocytic, erythroid, basophilic, or megakaryoblastic differentiationIncludes postcytotoxic therapy and germline predisposition-related secondary AML entities",
                      "3 genetically defined subtypes: AML withCEBPA, AML withBCR::ABL1mutation, and AML, myelodysplasia-related (AML-MR) subtypes",
                      "AML with biallelicCEBPAmutation, per WHO, has ≥ 20% blast requirement",
                      "8 other subtypes defined by differentiation (no genetic requirements)",
                      "Includes AML with minimal differentiation, ± maturation, and AML with monocytic, erythroid, basophilic, or megakaryoblastic differentiation",
                      "Includes postcytotoxic therapy and germline predisposition-related secondary AML entities",
                      "Key ICC vs. WHO-HAEM5 differences≥ 10% blast threshold for AML with recurrent genetic abnormalities (ICC); no blast percentage requirement (WHO-HAEM5)ICC requiresin-frame bZIPCEBPAmutation (onlyCEBPAmutation linked to favorable outcome as per recent studies) and ≥ 10% blasts: WHO-HAEM5 requires biallelicCEBPAmutation and ≥ 20% blastsAML with mutatedTP53is entity in ICC; included with complex karyotype in AML-MR in WHO-HAEM5Therapy-related AML is not regarded as diagnostic entity in ICC but is retained in WHO-HAEM5AML entities in ICC are defined largely by genetic profile with therapy-relatedness reported as qualifierWHO-HAEM5 includes therapy-related (postcytotoxic) and germline predisposition-related in secondary AMLAML defined by differentiation (WHO-HAEM5) designated as AML, NOS in ICCMost cases in this category in WHO-HAEM4 have genetic abnormalities that allow them to be moved to 1 of new ICC genetic entitiesRetained in WHO-HAEM5 with largely French American British (FAB) designations and definitionsAML-MR in WHO-HAEM5 corresponds to WHO-HAEM4 AML-MRC definitions",
                      "≥ 10% blast threshold for AML with recurrent genetic abnormalities (ICC); no blast percentage requirement (WHO-HAEM5)ICC requiresin-frame bZIPCEBPAmutation (onlyCEBPAmutation linked to favorable outcome as per recent studies) and ≥ 10% blasts: WHO-HAEM5 requires biallelicCEBPAmutation and ≥ 20% blasts",
                      "ICC requiresin-frame bZIPCEBPAmutation (onlyCEBPAmutation linked to favorable outcome as per recent studies) and ≥ 10% blasts: WHO-HAEM5 requires biallelicCEBPAmutation and ≥ 20% blasts",
                      "AML with mutatedTP53is entity in ICC; included with complex karyotype in AML-MR in WHO-HAEM5",
                      "Therapy-related AML is not regarded as diagnostic entity in ICC but is retained in WHO-HAEM5AML entities in ICC are defined largely by genetic profile with therapy-relatedness reported as qualifierWHO-HAEM5 includes therapy-related (postcytotoxic) and germline predisposition-related in secondary AML",
                      "AML entities in ICC are defined largely by genetic profile with therapy-relatedness reported as qualifier",
                      "WHO-HAEM5 includes therapy-related (postcytotoxic) and germline predisposition-related in secondary AML",
                      "AML defined by differentiation (WHO-HAEM5) designated as AML, NOS in ICCMost cases in this category in WHO-HAEM4 have genetic abnormalities that allow them to be moved to 1 of new ICC genetic entitiesRetained in WHO-HAEM5 with largely French American British (FAB) designations and definitions",
                      "Most cases in this category in WHO-HAEM4 have genetic abnormalities that allow them to be moved to 1 of new ICC genetic entities",
                      "Retained in WHO-HAEM5 with largely French American British (FAB) designations and definitions",
                      "AML-MR in WHO-HAEM5 corresponds to WHO-HAEM4 AML-MRC definitions"
                    ]
                  }
                ],
                "ICC": [
                  {
                    "text": "AML with recurrent genetic abnormalities (21 subtypes)"
                  },
                  {
                    "text": "AML, MRG or MRCGene mutations [variant allele frequency (VAF ≥ 2%]:ASXL1,BCOR,EZH2,RUNX1,SF3B1,SRSF2,STAG2,U2AF1,ZRSR2Complexcytogenetic abnormalities (≥ 3 unrelated abnormalities, excluding -Y): del(5q/t(5q)/add(5q), -7/del(7q), +8, del(12p)/t(12p)/add(12p), i(17q), -17/add(17p) or del(17p), del(20q), &/or idic(X)(q13)",
                    "sub_points": [
                      "Gene mutations [variant allele frequency (VAF ≥ 2%]:ASXL1,BCOR,EZH2,RUNX1,SF3B1,SRSF2,STAG2,U2AF1,ZRSR2",
                      "Complexcytogenetic abnormalities (≥ 3 unrelated abnormalities, excluding -Y): del(5q/t(5q)/add(5q), -7/del(7q), +8, del(12p)/t(12p)/add(12p), i(17q), -17/add(17p) or del(17p), del(20q), &/or idic(X)(q13)"
                    ]
                  },
                  {
                    "text": "AML with mutatedTP53(VAF ≥ 10%)"
                  },
                  {
                    "text": "AML, NOS"
                  }
                ],
                "WHO-HAEM5": [
                  {
                    "text": "AML with defining genetic abnormalities"
                  },
                  {
                    "text": "AML-MR"
                  },
                  {
                    "text": "AML defined by differentiation"
                  },
                  {
                    "text": "Secondary AMLCytotoxic therapy relatedGermline predisposition related",
                    "sub_points": [
                      "Cytotoxic therapy related",
                      "Germline predisposition related"
                    ]
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Age Range": [
                  {
                    "text": "All ages affected but predominates in older patients; median: ~ 70 years> 50% of patients ≥ 65 at diagnosis",
                    "sub_points": [
                      "> 50% of patients ≥ 65 at diagnosis"
                    ]
                  },
                  {
                    "text": "Overall, proportion of acute leukemias that are AML increases with age~ 80% of acute leukemias in adults are myeloid",
                    "sub_points": [
                      "~ 80% of acute leukemias in adults are myeloid"
                    ]
                  },
                  {
                    "text": "Some disease types are more prevalent in older adultse.g., AML, MRG or AML, MRC",
                    "sub_points": [
                      "e.g., AML, MRG or AML, MRC"
                    ]
                  },
                  {
                    "text": "Some AML types are more prevalent in younger patientsAML with recurring genetic abnormality [e.g., t(15;17), t(8;21), inv(16)/t(16;16), t(9;11)]AML with t(1;22) occurs in infants and children < 3 yearsCongenital AML enriched for cases with 11q23 mutations",
                    "sub_points": [
                      "AML with recurring genetic abnormality [e.g., t(15;17), t(8;21), inv(16)/t(16;16), t(9;11)]",
                      "AML with t(1;22) occurs in infants and children < 3 years",
                      "Congenital AML enriched for cases with 11q23 mutations"
                    ]
                  }
                ],
                "Incidence": [
                  {
                    "text": "4.3 cases per 100,000 population; SEER dataIncidence increases dramatically with ageMale predominance in adults",
                    "sub_points": [
                      "Incidence increases dramatically with age",
                      "Male predominance in adults"
                    ]
                  },
                  {
                    "text": "~ 20,000 new cases in USA each year~ 11,000 AML patients die each year",
                    "sub_points": [
                      "~ 11,000 AML patients die each year"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "Variable clinical courseClinically aggressive in most casesAcute promyelocytic leukemia (APL) can be cured without conventional chemotherapyAll-trans retinoic acid (ATRA) and arsenic trioxide highly effective in low-stage APL (lower WBC)Very rare cases spontaneously regressNeonatal AML with t(8;16) (p11.2;p13.3)/KAT6A::CREBBPreported rarely to spontaneously regress",
                    "sub_points": [
                      "Clinically aggressive in most cases",
                      "Acute promyelocytic leukemia (APL) can be cured without conventional chemotherapyAll-trans retinoic acid (ATRA) and arsenic trioxide highly effective in low-stage APL (lower WBC)",
                      "All-trans retinoic acid (ATRA) and arsenic trioxide highly effective in low-stage APL (lower WBC)",
                      "Very rare cases spontaneously regressNeonatal AML with t(8;16) (p11.2;p13.3)/KAT6A::CREBBPreported rarely to spontaneously regress",
                      "Neonatal AML with t(8;16) (p11.2;p13.3)/KAT6A::CREBBPreported rarely to spontaneously regress"
                    ]
                  },
                  {
                    "text": "Despite advances in classification and treatment, prognosis remains unfavorable for older patients with adverse AML subtypes and patients who are not eligible for allogeneic stem cell transplantation"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Development of AML": [
                  {
                    "text": "Somatic mutations drive development of AMLSerial acquisition of somatic mutations in hematopoietic stem cells and progenitor cellsComplex series of genetic events that varies by AML subtype",
                    "sub_points": [
                      "Serial acquisition of somatic mutations in hematopoietic stem cells and progenitor cells",
                      "Complex series of genetic events that varies by AML subtype"
                    ]
                  },
                  {
                    "text": "Germline mutations play role in some casesGermline predisposition disorders (familial)Family history and biallelic mutation are clues to familial inheritanceDistinct germline mutations described that are unique to each syndrome/conditionRisk of developing myeloid neoplasm, including AML, variesGermline mutations inCEBPA,GATA2,TP53,RUNX1, and othersRelatively more common germline predisposition syndromes include Fanconi anemia, severe congenital neutropenia, and Shwachman-Diamond syndromeIncreased recognition of germline disorder-associated AML due to increased genetic testingMore often recognized in adults than previouslyDown syndrome (not familial; sporadic)10-20x increased risk for AML> 500x increased risk for acute megakaryoblastic leukemia",
                    "sub_points": [
                      "Germline predisposition disorders (familial)Family history and biallelic mutation are clues to familial inheritanceDistinct germline mutations described that are unique to each syndrome/conditionRisk of developing myeloid neoplasm, including AML, variesGermline mutations inCEBPA,GATA2,TP53,RUNX1, and othersRelatively more common germline predisposition syndromes include Fanconi anemia, severe congenital neutropenia, and Shwachman-Diamond syndrome",
                      "Family history and biallelic mutation are clues to familial inheritanceDistinct germline mutations described that are unique to each syndrome/conditionRisk of developing myeloid neoplasm, including AML, varies",
                      "Distinct germline mutations described that are unique to each syndrome/condition",
                      "Risk of developing myeloid neoplasm, including AML, varies",
                      "Germline mutations inCEBPA,GATA2,TP53,RUNX1, and others",
                      "Relatively more common germline predisposition syndromes include Fanconi anemia, severe congenital neutropenia, and Shwachman-Diamond syndrome",
                      "Increased recognition of germline disorder-associated AML due to increased genetic testingMore often recognized in adults than previously",
                      "More often recognized in adults than previously",
                      "Down syndrome (not familial; sporadic)10-20x increased risk for AML> 500x increased risk for acute megakaryoblastic leukemia",
                      "10-20x increased risk for AML",
                      "> 500x increased risk for acute megakaryoblastic leukemia"
                    ]
                  },
                  {
                    "text": "Environmental exposures and antecedent cytotoxic therapyCases of AML following cytotoxic therapy are increasing likely due to improved survival for primary neoplasmTherapy-related is qualifier in ICC classification but is retained as secondary AML entity in WHO-HAEM5",
                    "sub_points": [
                      "Cases of AML following cytotoxic therapy are increasing likely due to improved survival for primary neoplasm",
                      "Therapy-related is qualifier in ICC classification but is retained as secondary AML entity in WHO-HAEM5"
                    ]
                  }
                ],
                "Progression of Underlying Myeloid Neoplasm": [
                  {
                    "text": "Variable risk of progression of myelodysplastic syndrome (MDS), MDS/myeloproliferative neoplasm (MPN), or MPN to AMLLinked to acquisition of additional mutations associated with increased cell proliferation and reduced cell maturation",
                    "sub_points": [
                      "Linked to acquisition of additional mutations associated with increased cell proliferation and reduced cell maturation"
                    ]
                  },
                  {
                    "text": "Qualifier in ICC; e.g., AML progressed from MDS"
                  },
                  {
                    "text": "Secondary AML in WHO-HAEM5"
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Clinical Presentation": [
                  {
                    "text": "Symptoms related to bone marrow failureFatigue (anemia)Bleeding (thrombocytopenia)Infection (neutropenia)",
                    "sub_points": [
                      "Fatigue (anemia)",
                      "Bleeding (thrombocytopenia)",
                      "Infection (neutropenia)"
                    ]
                  },
                  {
                    "text": "Extramedullary involvementSkin lesionsGingival hyperplasiaMyeloid sarcomas in other sites",
                    "sub_points": [
                      "Skin lesions",
                      "Gingival hyperplasia",
                      "Myeloid sarcomas in other sites"
                    ]
                  }
                ],
                "Clinical Risk Factors": [],
                "Risk stratification and other prognostic factors": [
                  {
                    "text": "Risk stratification; European Leukemia Network (ELN) and National Comprehensive Cancer Network (NCCN)Favorable riskCytogenetics: t(8;21), inv(16)Mutations:NPM1withoutFLT3,CEBPA(bZIP)Intermediate riskCytogenetic/molecular abnormalities not classified as favorable or adverset(9:11) and several distinct combinations ofNPM1andFLT3mutations [e.g., (-/+)]Adverse riskCytogenetics: t(6;9), t(v;11q23), t(9;22), t(8;16), inv(3), -5/del(5q), -7, -17/abnl(17p), complex karyotypeMutations:ASXL1,BCOR,EZH2,RUNX1,SF3B1,SRSF2,STAG2,U2AF1, &/orZRSR2MutatedTP53",
                    "sub_points": [
                      "Favorable riskCytogenetics: t(8;21), inv(16)Mutations:NPM1withoutFLT3,CEBPA(bZIP)",
                      "Cytogenetics: t(8;21), inv(16)",
                      "Mutations:NPM1withoutFLT3,CEBPA(bZIP)",
                      "Intermediate riskCytogenetic/molecular abnormalities not classified as favorable or adverset(9:11) and several distinct combinations ofNPM1andFLT3mutations [e.g., (-/+)]",
                      "Cytogenetic/molecular abnormalities not classified as favorable or adverse",
                      "t(9:11) and several distinct combinations ofNPM1andFLT3mutations [e.g., (-/+)]",
                      "Adverse riskCytogenetics: t(6;9), t(v;11q23), t(9;22), t(8;16), inv(3), -5/del(5q), -7, -17/abnl(17p), complex karyotypeMutations:ASXL1,BCOR,EZH2,RUNX1,SF3B1,SRSF2,STAG2,U2AF1, &/orZRSR2MutatedTP53",
                      "Cytogenetics: t(6;9), t(v;11q23), t(9;22), t(8;16), inv(3), -5/del(5q), -7, -17/abnl(17p), complex karyotype",
                      "Mutations:ASXL1,BCOR,EZH2,RUNX1,SF3B1,SRSF2,STAG2,U2AF1, &/orZRSR2",
                      "MutatedTP53"
                    ]
                  },
                  {
                    "text": "Prior chemotherapy &/or radiation adverse"
                  },
                  {
                    "text": "Progression from underlying myeloid neoplasm, e.g., MDS, adverse"
                  },
                  {
                    "text": "Reduced performance status at diagnosis, adverse"
                  }
                ],
                "Therapy": [
                  {
                    "text": "Generally consists of induction, consolidation, and maintenance chemotherapy therapy for non-APL subtypesGoal: No measurable residual disease< 5% residual blastsMeasurable residual disease assessment essentialMeasurable (minimal) residual disease detected by either flow cytometric immunophenotyping or molecular genetic assessment is more predictive of outcome than morphologic assessment",
                    "sub_points": [
                      "Goal: No measurable residual disease< 5% residual blastsMeasurable residual disease assessment essentialMeasurable (minimal) residual disease detected by either flow cytometric immunophenotyping or molecular genetic assessment is more predictive of outcome than morphologic assessment",
                      "< 5% residual blasts",
                      "Measurable residual disease assessment essentialMeasurable (minimal) residual disease detected by either flow cytometric immunophenotyping or molecular genetic assessment is more predictive of outcome than morphologic assessment",
                      "Measurable (minimal) residual disease detected by either flow cytometric immunophenotyping or molecular genetic assessment is more predictive of outcome than morphologic assessment"
                    ]
                  },
                  {
                    "text": "Induction therapy for APLUtilization of ATRA ± arsenic trioxideEarly use of ATRA decreases risk of APL-induced DIC and fibrinolysis and greatly reduces early mortality from hemorrhage or, much less often, thrombosis",
                    "sub_points": [
                      "Utilization of ATRA ± arsenic trioxide",
                      "Early use of ATRA decreases risk of APL-induced DIC and fibrinolysis and greatly reduces early mortality from hemorrhage or, much less often, thrombosis"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Myeloid sarcomasSoft, variable color on fresh sectioningMay be greenish or white/yellowVariable foci of necrosis",
                    "sub_points": [
                      "Soft, variable color on fresh sectioningMay be greenish or white/yellow",
                      "May be greenish or white/yellow",
                      "Variable foci of necrosis"
                    ]
                  }
                ],
                "Specimen Handling": [
                  {
                    "text": "Required for work-up of all cases of AMLCBC and blood &/or bone marrow microscopic examinationFlow cytometric immunophenotyping to determine blast lineageChromosomal study: Conventional karyotypingFISH testing can be included to rapidly assess for specific mutations, such asPML::RARAin APLKey assessment if karyotyping is unsuccessful or cryptic mutation is suspectedMolecular genetic assessmentMyeloid gene panel assessment by next-generation sequencing on all casesOther genetic tests usefulIndividual gene mutation assessment is rapid and useful forNPM1,FLT3, other mutationsComplete clinical historyPrior therapy informationPrior hematologic disorder/neoplasmPrior CBC results",
                    "sub_points": [
                      "CBC and blood &/or bone marrow microscopic examination",
                      "Flow cytometric immunophenotyping to determine blast lineage",
                      "Chromosomal study: Conventional karyotypingFISH testing can be included to rapidly assess for specific mutations, such asPML::RARAin APLKey assessment if karyotyping is unsuccessful or cryptic mutation is suspected",
                      "FISH testing can be included to rapidly assess for specific mutations, such asPML::RARAin APLKey assessment if karyotyping is unsuccessful or cryptic mutation is suspected",
                      "Key assessment if karyotyping is unsuccessful or cryptic mutation is suspected",
                      "Molecular genetic assessmentMyeloid gene panel assessment by next-generation sequencing on all casesOther genetic tests usefulIndividual gene mutation assessment is rapid and useful forNPM1,FLT3, other mutations",
                      "Myeloid gene panel assessment by next-generation sequencing on all cases",
                      "Other genetic tests usefulIndividual gene mutation assessment is rapid and useful forNPM1,FLT3, other mutations",
                      "Individual gene mutation assessment is rapid and useful forNPM1,FLT3, other mutations",
                      "Complete clinical historyPrior therapy informationPrior hematologic disorder/neoplasmPrior CBC results",
                      "Prior therapy information",
                      "Prior hematologic disorder/neoplasm",
                      "Prior CBC results"
                    ]
                  },
                  {
                    "text": "Additional studies to be consideredMPO cytochemical stainUseful for rapid diagnosis of APLUseful in distinction of AML from acute leukemia of ambiguous lineage",
                    "sub_points": [
                      "MPO cytochemical stainUseful for rapid diagnosis of APLUseful in distinction of AML from acute leukemia of ambiguous lineage",
                      "Useful for rapid diagnosis of APL",
                      "Useful in distinction of AML from acute leukemia of ambiguous lineage"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Blasts and Blast Equivalents: General Features": [
                  {
                    "text": "Blasts/blast equivalentsMyeloblastsDispersed, fine, blastic chromatinUsually sparse cytoplasmic azurophilic granules, Auer rods in some casesMonoblastsDispersed, fine, blastic chromatinAbundant blue-gray cytoplasm with variable fine granulesPromonocytesDispersed fine chromatin, minimal nuclear indentationsAbundant blue-gray cytoplasmMegakaryoblastsHighly variable nuclear chromatin, may be fine, blastic, or more condensedMay see cytoplasmic blebbing/shedding but not specificPromyelocytes (abnormal)Counted as blasts/blast equivalents in APL onlySingle or bilobed nuclei, hypo- or hypergranular cytoplasm, may see cytoplasm packed with Auer rodsPronormoblasts enumerated in WHO-HAEM5 category of acute erythroid leukemiaIn ICC, pure erythroid leukemia is included in AML with mutatedTP53categoryRound nuclei with variable nuclear chromatinDeeply basophilic cytoplasm",
                    "sub_points": [
                      "MyeloblastsDispersed, fine, blastic chromatinUsually sparse cytoplasmic azurophilic granules, Auer rods in some cases",
                      "Dispersed, fine, blastic chromatin",
                      "Usually sparse cytoplasmic azurophilic granules, Auer rods in some cases",
                      "MonoblastsDispersed, fine, blastic chromatinAbundant blue-gray cytoplasm with variable fine granules",
                      "Dispersed, fine, blastic chromatin",
                      "Abundant blue-gray cytoplasm with variable fine granules",
                      "PromonocytesDispersed fine chromatin, minimal nuclear indentationsAbundant blue-gray cytoplasm",
                      "Dispersed fine chromatin, minimal nuclear indentations",
                      "Abundant blue-gray cytoplasm",
                      "MegakaryoblastsHighly variable nuclear chromatin, may be fine, blastic, or more condensedMay see cytoplasmic blebbing/shedding but not specific",
                      "Highly variable nuclear chromatin, may be fine, blastic, or more condensed",
                      "May see cytoplasmic blebbing/shedding but not specific",
                      "Promyelocytes (abnormal)Counted as blasts/blast equivalents in APL onlySingle or bilobed nuclei, hypo- or hypergranular cytoplasm, may see cytoplasm packed with Auer rods",
                      "Counted as blasts/blast equivalents in APL only",
                      "Single or bilobed nuclei, hypo- or hypergranular cytoplasm, may see cytoplasm packed with Auer rods",
                      "Pronormoblasts enumerated in WHO-HAEM5 category of acute erythroid leukemiaIn ICC, pure erythroid leukemia is included in AML with mutatedTP53categoryRound nuclei with variable nuclear chromatinDeeply basophilic cytoplasm",
                      "In ICC, pure erythroid leukemia is included in AML with mutatedTP53category",
                      "Round nuclei with variable nuclear chromatin",
                      "Deeply basophilic cytoplasm"
                    ]
                  },
                  {
                    "text": "Enumeration of blast percentageIn bloodPercentage of circulating WBCsIn uncomplicated bone marrowPercentage of all nucleated cells, excluding histiocytes, megakaryocytes, mast cellsIn bone marrow, complicated by 2nd hematologic neoplasmPercentage of all nucleated cells, excluding coexisting tumor cells (e.g., plasma cells in myeloma, lymphoid cells in chronic lymphocytic leukemia)",
                    "sub_points": [
                      "In bloodPercentage of circulating WBCs",
                      "Percentage of circulating WBCs",
                      "In uncomplicated bone marrowPercentage of all nucleated cells, excluding histiocytes, megakaryocytes, mast cells",
                      "Percentage of all nucleated cells, excluding histiocytes, megakaryocytes, mast cells",
                      "In bone marrow, complicated by 2nd hematologic neoplasmPercentage of all nucleated cells, excluding coexisting tumor cells (e.g., plasma cells in myeloma, lymphoid cells in chronic lymphocytic leukemia)",
                      "Percentage of all nucleated cells, excluding coexisting tumor cells (e.g., plasma cells in myeloma, lymphoid cells in chronic lymphocytic leukemia)"
                    ]
                  },
                  {
                    "text": "Key blast count thresholds≥ 10% in blood or bone marrow for ICC category of AML with recurrent genetic abnormalityRequisite ≥ 20% blasts in blood &/or bone marrow for AML withBCR::ABL1, AML with mutatedTP53, AML, MRG, AML, MRC, and AML, NOS per ICC criteria",
                    "sub_points": [
                      "≥ 10% in blood or bone marrow for ICC category of AML with recurrent genetic abnormality",
                      "Requisite ≥ 20% blasts in blood &/or bone marrow for AML withBCR::ABL1, AML with mutatedTP53, AML, MRG, AML, MRC, and AML, NOS per ICC criteria"
                    ]
                  }
                ],
                "Blood": [
                  {
                    "text": "Abnormal CBC"
                  },
                  {
                    "text": "Cytopenias (usually profound hematopoietic failure due to extensive bone marrow effacement by AML)AnemiaThrombocytopeniaNeutropenia",
                    "sub_points": [
                      "Anemia",
                      "Thrombocytopenia",
                      "Neutropenia"
                    ]
                  },
                  {
                    "text": "Circulating blasts/blast equivalents"
                  },
                  {
                    "text": "Assess for dysplasia, which may be present, but is not required for genetically-defined AML subtypes by ICC"
                  },
                  {
                    "text": "Assess erythrocytes for evidence of DIC; most relevant in APL"
                  }
                ],
                "Bone Marrow Aspirate": [
                  {
                    "text": "RequirementsAdequate specimen, well stainedCellularRepresentativeIf fibrotic or dry tap, assess touch preparation",
                    "sub_points": [
                      "Adequate specimen, well stainedCellularRepresentativeIf fibrotic or dry tap, assess touch preparation",
                      "Cellular",
                      "Representative",
                      "If fibrotic or dry tap, assess touch preparation"
                    ]
                  },
                  {
                    "text": "Enumerate blasts"
                  },
                  {
                    "text": "Assess for increased/abnormal-appearing mast cellsMastocytosis may be concurrent",
                    "sub_points": [
                      "Mastocytosis may be concurrent"
                    ]
                  }
                ],
                "Bone Marrow Core Biopsy": [
                  {
                    "text": "RequirementsAdequate, technically optimal specimen",
                    "sub_points": [
                      "Adequate, technically optimal specimen"
                    ]
                  },
                  {
                    "text": "Identify blastsUtilize IHC if neededCaveatsNot all blasts are CD34(+), particularly APL, megakaryocytic, monocytic, and erythroid lineage blastsIHC not as sensitive as flow cytometry",
                    "sub_points": [
                      "Utilize IHC if needed",
                      "CaveatsNot all blasts are CD34(+), particularly APL, megakaryocytic, monocytic, and erythroid lineage blastsIHC not as sensitive as flow cytometry",
                      "Not all blasts are CD34(+), particularly APL, megakaryocytic, monocytic, and erythroid lineage blasts",
                      "IHC not as sensitive as flow cytometry"
                    ]
                  },
                  {
                    "text": "Evaluate for associated concurrent neoplasmMastocytosis, other",
                    "sub_points": [
                      "Mastocytosis, other"
                    ]
                  }
                ],
                "Specialized Testing": [
                  {
                    "text": "Cytochemical stainsMPOUseful for rapid diagnosis of APLStrong uniform positivity in virtually all APL cellsIf positive, confirms myeloid lineageIf negative, does not exclude myeloid lineage~ 5% of acute monoblastic leukemias may show scattered MPO(+) granulesNSEIf positive, confirms monocytic lineageIf negative, does not exclude monocytic lineage",
                    "sub_points": [
                      "MPOUseful for rapid diagnosis of APLStrong uniform positivity in virtually all APL cellsIf positive, confirms myeloid lineageIf negative, does not exclude myeloid lineage~ 5% of acute monoblastic leukemias may show scattered MPO(+) granules",
                      "Useful for rapid diagnosis of APLStrong uniform positivity in virtually all APL cells",
                      "Strong uniform positivity in virtually all APL cells",
                      "If positive, confirms myeloid lineage",
                      "If negative, does not exclude myeloid lineage",
                      "~ 5% of acute monoblastic leukemias may show scattered MPO(+) granules",
                      "NSEIf positive, confirms monocytic lineageIf negative, does not exclude monocytic lineage",
                      "If positive, confirms monocytic lineage",
                      "If negative, does not exclude monocytic lineage"
                    ]
                  },
                  {
                    "text": "Flow cytometric immunophenotyping (FCI)Required for all new cases of AMLEstablishes lineage of blastsEstablishes phenotype \"fingerprint\" for future monitoringBlast markersCD34: Not all blasts are CD34(+)CD117: Also stains pronormoblasts, mast cellsTdT: Stains subset of AMLsMyeloid markersMPO, CD13, CD33Monocytic lineage markersCD14, CD36/CD64 coexpression, CD163, CD4 (weak), CD33 (bright)Megakaryocytic lineage markersCD41b, CD42b, CD61; CD31 also positive but not lineage specificErythroid lineage markersCD235a, hemoglobin A, CD71, E-cadherinE-cadherin most specific and stains most immature erythroid lineage cells",
                    "sub_points": [
                      "Required for all new cases of AML",
                      "Establishes lineage of blasts",
                      "Establishes phenotype \"fingerprint\" for future monitoring",
                      "Blast markersCD34: Not all blasts are CD34(+)CD117: Also stains pronormoblasts, mast cellsTdT: Stains subset of AMLs",
                      "CD34: Not all blasts are CD34(+)",
                      "CD117: Also stains pronormoblasts, mast cells",
                      "TdT: Stains subset of AMLs",
                      "Myeloid markersMPO, CD13, CD33",
                      "MPO, CD13, CD33",
                      "Monocytic lineage markersCD14, CD36/CD64 coexpression, CD163, CD4 (weak), CD33 (bright)",
                      "CD14, CD36/CD64 coexpression, CD163, CD4 (weak), CD33 (bright)",
                      "Megakaryocytic lineage markersCD41b, CD42b, CD61; CD31 also positive but not lineage specific",
                      "CD41b, CD42b, CD61; CD31 also positive but not lineage specific",
                      "Erythroid lineage markersCD235a, hemoglobin A, CD71, E-cadherinE-cadherin most specific and stains most immature erythroid lineage cells",
                      "CD235a, hemoglobin A, CD71, E-cadherinE-cadherin most specific and stains most immature erythroid lineage cells",
                      "E-cadherin most specific and stains most immature erythroid lineage cells"
                    ]
                  },
                  {
                    "text": "IHC stainsUseful if flow cytometry inadequate or not performedIn general, fewer antibodies are available compared with flow cytometrySome are unique to IHC, howeverCD68: Myeloid and monocyticLysozyme: Monocytic",
                    "sub_points": [
                      "Useful if flow cytometry inadequate or not performed",
                      "In general, fewer antibodies are available compared with flow cytometrySome are unique to IHC, howeverCD68: Myeloid and monocyticLysozyme: Monocytic",
                      "Some are unique to IHC, however",
                      "CD68: Myeloid and monocytic",
                      "Lysozyme: Monocytic"
                    ]
                  },
                  {
                    "text": "CytogeneticsShould be performed on all cases of AMLDiagnostic: e.g., AML with recurring genetic abnormalityPrognostic: Favorable, intermediate, and unfavorable risk groups",
                    "sub_points": [
                      "Should be performed on all cases of AML",
                      "Diagnostic: e.g., AML with recurring genetic abnormality",
                      "Prognostic: Favorable, intermediate, and unfavorable risk groups"
                    ]
                  },
                  {
                    "text": "FISHRapid diagnosis of APLPerform as needed; essential if conventional karyotype failsDepending on morphologic suspicionMonocytic differentiation: InvestigateCBFB::MYH11andKMT2AtranslocationsConfirmation of cytogenetic findings as needed",
                    "sub_points": [
                      "Rapid diagnosis of APL",
                      "Perform as needed; essential if conventional karyotype failsDepending on morphologic suspicionMonocytic differentiation: InvestigateCBFB::MYH11andKMT2AtranslocationsConfirmation of cytogenetic findings as needed",
                      "Depending on morphologic suspicionMonocytic differentiation: InvestigateCBFB::MYH11andKMT2Atranslocations",
                      "Monocytic differentiation: InvestigateCBFB::MYH11andKMT2Atranslocations",
                      "Confirmation of cytogenetic findings as needed"
                    ]
                  },
                  {
                    "text": "Molecular geneticsMyeloid gene panel required for all cases; additional genetic tests often neededMust include all AML, MRG genes as well as othersFLT3should be assessed in all AMLsNPM1andFLT3can be assessed by PCR",
                    "sub_points": [
                      "Myeloid gene panel required for all cases; additional genetic tests often neededMust include all AML, MRG genes as well as others",
                      "Must include all AML, MRG genes as well as others",
                      "FLT3should be assessed in all AMLsNPM1andFLT3can be assessed by PCR",
                      "NPM1andFLT3can be assessed by PCR"
                    ]
                  }
                ]
              },
              "Reporting Criteria": {
                "Minimum Requirements": [
                  {
                    "text": "Use ICC &/or WHO-HAEM5 classification"
                  },
                  {
                    "text": "If feasible, issue integrated report to incorporate all genetic testing resultsPathologist must insure that all specialized testing results are available to treating physician",
                    "sub_points": [
                      "Pathologist must insure that all specialized testing results are available to treating physician"
                    ]
                  }
                ],
                "Communication of Results": [
                  {
                    "text": "New diagnosis, unsuspected relapse, suspected APL, associated DIC"
                  },
                  {
                    "text": "Prompt notification of clinician(s)"
                  }
                ]
              },
              "Differential Diagnosis": {
                "Recombinant G-CSF Therapy": [
                  {
                    "text": "Blast count may transiently exceed 20% in hypocellular specimen"
                  },
                  {
                    "text": "Transient phenomenon, nonclonal, no Auer rods"
                  }
                ],
                "Blast Phase or Transformation of Preexisting Myeloid Neoplasm": [
                  {
                    "text": "Clinical history required"
                  }
                ],
                "Other Subtype of Acute Leukemia": [
                  {
                    "text": "Acute lymphoblastic leukemia (ALL)"
                  },
                  {
                    "text": "Acute leukemia of ambiguous lineage (ALAL)"
                  },
                  {
                    "text": "Blastic plasmacytoid dendritic cell neoplasm (BPDCN)"
                  }
                ]
              },
              "Diagnostic Challenges": {
                "AML With Recurrent Genetic Abnormalities (ICC Criteria)": [
                  {
                    "text": "ICC ≥ 10% blast threshold overlaps with ICC MDS/AML cases, MPN in accelerated-phase cases, and chronic myelomonocytic leukemia-2 (CMML-2) cases"
                  },
                  {
                    "text": "Genetic assessment and clinical history are key in making these distinctions"
                  }
                ],
                "Hypocellular AML": [
                  {
                    "text": "Document ≥ 20% blasts by IHC if specimen inadequate for morphologic count or FCI"
                  }
                ],
                "Marked Increase in Erythroid Precursors (> 50% of Total Cells)": [
                  {
                    "text": "High-grade MDS vs. pure (acute) erythroid leukemiaPure erythroid leukemia (AML with mutatedTP53subtype in ICC), (acute erythroid leukemia in WHO-HAEM5)> 80% erythroid precursors> 30% of erythroid precursors are pronormoblastsMDS with abundant erythroid precursors (blasts < 20%)Myeloid blast count determined as percent of all nucleated elementsMDS often shows admixture of all stages of erythroid differentiation",
                    "sub_points": [
                      "Pure erythroid leukemia (AML with mutatedTP53subtype in ICC), (acute erythroid leukemia in WHO-HAEM5)> 80% erythroid precursors> 30% of erythroid precursors are pronormoblasts",
                      "> 80% erythroid precursors",
                      "> 30% of erythroid precursors are pronormoblasts",
                      "MDS with abundant erythroid precursors (blasts < 20%)Myeloid blast count determined as percent of all nucleated elementsMDS often shows admixture of all stages of erythroid differentiation",
                      "Myeloid blast count determined as percent of all nucleated elements",
                      "MDS often shows admixture of all stages of erythroid differentiation"
                    ]
                  },
                  {
                    "text": "Exclude nonneoplastic disordersNutritional deficiency (especially vitamin B12 or folate deficiency)Erythropoietin therapy",
                    "sub_points": [
                      "Nutritional deficiency (especially vitamin B12 or folate deficiency)",
                      "Erythropoietin therapy"
                    ]
                  }
                ],
                "Fibrosis": [
                  {
                    "text": "Often inaspirable"
                  },
                  {
                    "text": "More accurate blast count may require IHC: CD34, CD117"
                  },
                  {
                    "text": "Underlying hematologic malignancy may be masked"
                  }
                ],
                "CMML vs. AML With Monocytic Component": [
                  {
                    "text": "Bone marrow often shows higher proportion of immature cells than blood"
                  },
                  {
                    "text": "Bone marrow examination required for CMML cases by ICC criteria to avoid misdiagnosing blood as CMML when bone marrow shows AML"
                  }
                ],
                "AML vs. ALAL vs. ALL": [
                  {
                    "text": "AML cases commonly show aberrant antigen expression, such as CD19 or TdT, but these cases of otherwise straightforward AML donotquality as ALAL"
                  },
                  {
                    "text": "Aberrant expression of CD13, CD33 may occur in otherwise straightforward B-ALL"
                  },
                  {
                    "text": "Note that cases of B-ALL may show MPO positivity by either FCI or IHC staining"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Acute Myeloid Leukemia With t(8;21)(q22;q22), RUNX1-RUNX1T1": {
            "name": "Acute Myeloid Leukemia With t(8;21)(q22;q22), RUNX1-RUNX1T1",
            "url": "https://app.pathprimer.com/document/58e0f9e0-623e-4d5e-a95b-f85d133aa1bd/lesson/e328b112-0403-4322-9b2b-5e6e7ecbe471",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Diagnostic genetic abnormality:RUNX1-RUNX1T1fusion"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Normally core binding factor (CBF) alpha subunit (a.k.a. RUNX1) interacts with CBF beta subunitCBF alpha and beta form transcription factor complexCBF alpha subunit binds to DNA promoter sequences involved in hematopoiesis",
                    "sub_points": [
                      "CBF alpha and beta form transcription factor complex",
                      "CBF alpha subunit binds to DNA promoter sequences involved in hematopoiesis"
                    ]
                  },
                  {
                    "text": "t(8;21) results in chimeric fusion protein RUNX1-RUNX1T1"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Favorable risk"
                  },
                  {
                    "text": "~ 70% of patients harbor an additional chromosomal abnormalityKITmutations found in 12-47% of patientsOccur mostly in exon 17May confer adverse prognosis",
                    "sub_points": [
                      "KITmutations found in 12-47% of patientsOccur mostly in exon 17May confer adverse prognosis",
                      "Occur mostly in exon 17",
                      "May confer adverse prognosis"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Increased myeloblastsSome cases < the required 20% (low blast count AML)",
                    "sub_points": [
                      "Some cases < the required 20% (low blast count AML)"
                    ]
                  },
                  {
                    "text": "Characteristic Auer rodsSingle, thin, tapered ends",
                    "sub_points": [
                      "Single, thin, tapered ends"
                    ]
                  },
                  {
                    "text": "Abnormal neutrophilic precursorsSalmon-colored granules and dysplastic nuclear features",
                    "sub_points": [
                      "Salmon-colored granules and dysplastic nuclear features"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "ImmunophenotypingIncreased myeloblasts; CD34(+), CD13(+), CD33(+)May show expression of B-associated antigens; CD19, CD79a, Pax-5May show expression of TdT or CD56",
                    "sub_points": [
                      "Increased myeloblasts; CD34(+), CD13(+), CD33(+)May show expression of B-associated antigens; CD19, CD79a, Pax-5May show expression of TdT or CD56",
                      "May show expression of B-associated antigens; CD19, CD79a, Pax-5",
                      "May show expression of TdT or CD56"
                    ]
                  },
                  {
                    "text": "Cytogenetics/FISH/molecularDemonstrate t(8;21) orRUNX1-RUNX1T1fusion",
                    "sub_points": [
                      "Demonstrate t(8;21) orRUNX1-RUNX1T1fusion"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "AML with t(8;21)(q22;q22),RUNX1-RUNX1T1"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "AML withAML1-ETOfusion"
                  },
                  {
                    "text": "Core binding factor AML"
                  }
                ],
                "Definitions": [
                  {
                    "text": "AML with specific genetic findingt(8;21)(q22;q22) or variant orRUNX1-RUNX1T1(a.k.a.AML1-ETO) gene fusion",
                    "sub_points": [
                      "t(8;21)(q22;q22) or variant orRUNX1-RUNX1T1(a.k.a.AML1-ETO) gene fusion"
                    ]
                  },
                  {
                    "text": "Blast count may not meet typical requirement of ≥ 20%So-called low blast count AML or oligoblastic AMLAML is defined by presence of genetic abnormality, regardless of blast count",
                    "sub_points": [
                      "So-called low blast count AML or oligoblastic AML",
                      "AML is defined by presence of genetic abnormality, regardless of blast count"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Environmental Exposure": [
                  {
                    "text": "None identified for de novo AML with t(8;21)"
                  },
                  {
                    "text": "Therapy-related AML with t(8;21)Prior exposure to cytotoxic agents &/or radiotherapy",
                    "sub_points": [
                      "Prior exposure to cytotoxic agents &/or radiotherapy"
                    ]
                  }
                ],
                "Molecular Pathogenesis": [
                  {
                    "text": "NormalCore binding factor (CBF) alpha subunit (a.k.a. RUNX1) interacts with CBF beta subunitCBF alpha and beta form transcription factor complexCBF alpha subunit binds to DNA promoter sequences involved in hematopoiesis",
                    "sub_points": [
                      "Core binding factor (CBF) alpha subunit (a.k.a. RUNX1) interacts with CBF beta subunit",
                      "CBF alpha and beta form transcription factor complex",
                      "CBF alpha subunit binds to DNA promoter sequences involved in hematopoiesis"
                    ]
                  },
                  {
                    "text": "Abnormalt(8;21) results in chimeric fusion protein RUNX1-RUNX1T1Downregulates normal transcriptional activity",
                    "sub_points": [
                      "t(8;21) results in chimeric fusion protein RUNX1-RUNX1T1",
                      "Downregulates normal transcriptional activity"
                    ]
                  },
                  {
                    "text": "\"Multi-hit\" model of AMLClass 1 and class 2 mutationsRUNX1-RUNX1T1fusion is considered a class 2 mutationInsufficient alone for leukemia formationDevelopment of overt leukemia requires concurrent class 1 mutation (e.g.,KIT,FLT3, orRASmutation)",
                    "sub_points": [
                      "Class 1 and class 2 mutations",
                      "RUNX1-RUNX1T1fusion is considered a class 2 mutationInsufficient alone for leukemia formation",
                      "Insufficient alone for leukemia formation",
                      "Development of overt leukemia requires concurrent class 1 mutation (e.g.,KIT,FLT3, orRASmutation)"
                    ]
                  }
                ],
                "Discovery of t(8;21)": [
                  {
                    "text": "1st AML reciprocal translocation identified with common banding techniques (1975)"
                  }
                ],
                "Association with Systemic Mastocytosis": [
                  {
                    "text": "AML with t(8;21) is the most common AML associated with mastocytosis"
                  },
                  {
                    "text": "WHO 2008 terminologySystemic mastocytosis with associated hematological non-mast cell lineage disease (SM-AHNMD)",
                    "sub_points": [
                      "Systemic mastocytosis with associated hematological non-mast cell lineage disease (SM-AHNMD)"
                    ]
                  },
                  {
                    "text": "KITD816V mutation in blasts and mast cells may indicate common progenitor"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "10-15% of pediatric AML cases"
                  },
                  {
                    "text": "7% of adult AML cases"
                  }
                ],
                "Age": [
                  {
                    "text": "Predominates in younger patients (20-40 years)"
                  }
                ],
                "Sex": [
                  {
                    "text": "Equal M:F ratio"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Abnormal CBC, or symtpoms due to cytopeniasAnemia → fatigueThrombocytopenia → easy bruising, petechiaeNeutropenia common → infectionVariable white blood cell countVariable percent blast count",
                    "sub_points": [
                      "Anemia → fatigue",
                      "Thrombocytopenia → easy bruising, petechiae",
                      "Neutropenia common → infection",
                      "Variable white blood cell count",
                      "Variable percent blast count"
                    ]
                  },
                  {
                    "text": "Myeloid sarcomas commonGingival hyperplasiaCutaneous involvementSplenomegaly, rare",
                    "sub_points": [
                      "Gingival hyperplasia",
                      "Cutaneous involvement",
                      "Splenomegaly, rare"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Chemotherapy"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Favorable risk"
                  },
                  {
                    "text": "Complete remission commonEspecially with intensive postremission treatmentMultiple cycles of high-dose cytarabine50-60% cured with contemporary treatment",
                    "sub_points": [
                      "Especially with intensive postremission treatmentMultiple cycles of high-dose cytarabine",
                      "Multiple cycles of high-dose cytarabine",
                      "50-60% cured with contemporary treatment"
                    ]
                  },
                  {
                    "text": "Prognostic genetic factors~ 70% of patients harbor an additional chromosomal abnormality-Y; worse overall survival-X; no obvious impactdel(9q); better overall survival in non-white individuals+8; no impactKITmutationsFound in 12-47% of patientsOccur mostly in exon 17May confer adverse prognosisFLT3mutationsInfrequent; 4-12%Internal tandem duplication and point mutations in the tyrosine kinase domainPrognostic significance unknown",
                    "sub_points": [
                      "~ 70% of patients harbor an additional chromosomal abnormality-Y; worse overall survival-X; no obvious impactdel(9q); better overall survival in non-white individuals+8; no impact",
                      "-Y; worse overall survival",
                      "-X; no obvious impact",
                      "del(9q); better overall survival in non-white individuals",
                      "+8; no impact",
                      "KITmutationsFound in 12-47% of patientsOccur mostly in exon 17May confer adverse prognosis",
                      "Found in 12-47% of patients",
                      "Occur mostly in exon 17",
                      "May confer adverse prognosis",
                      "FLT3mutationsInfrequent; 4-12%Internal tandem duplication and point mutations in the tyrosine kinase domainPrognostic significance unknown",
                      "Infrequent; 4-12%",
                      "Internal tandem duplication and point mutations in the tyrosine kinase domain",
                      "Prognostic significance unknown"
                    ]
                  },
                  {
                    "text": "Minimal residual disease monitoringQuantitative RT-PCR studiesGoal: Identify molecular remission while on therapyMolecular remission predictive of durable complete remissionAbsence ofRUNX1-RUNX1T1fusion may not be necessary for long-term remission> 1 log increase in transcript levels associated with increased relapse risk",
                    "sub_points": [
                      "Quantitative RT-PCR studiesGoal: Identify molecular remission while on therapyMolecular remission predictive of durable complete remissionAbsence ofRUNX1-RUNX1T1fusion may not be necessary for long-term remission> 1 log increase in transcript levels associated with increased relapse risk",
                      "Goal: Identify molecular remission while on therapy",
                      "Molecular remission predictive of durable complete remission",
                      "Absence ofRUNX1-RUNX1T1fusion may not be necessary for long-term remission",
                      "> 1 log increase in transcript levels associated with increased relapse risk"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Peripheral bloodAnemiaThrombocytopeniaCirculating blasts; possibly with Auer rodsGenerally leukocytosis dominated by blastsEvidence of neutrophilic maturationOccasionally monocytic componentWBC count rarely exceeds 100 x 10⁹/L",
                    "sub_points": [
                      "Anemia",
                      "Thrombocytopenia",
                      "Circulating blasts; possibly with Auer rods",
                      "Generally leukocytosis dominated by blasts",
                      "Evidence of neutrophilic maturation",
                      "Occasionally monocytic component",
                      "WBC count rarely exceeds 100 x 10⁹/L"
                    ]
                  },
                  {
                    "text": "Bone marrow aspirateIncreased myeloid blastsVariable blast countSome cases less than the required 20% (low blast count AML)Characteristic Auer rodsThin with tapered, \"cigar-shaped\" endsUsually single within a cellSeen in cytoplasm of blasts and maturing/mature granulocytesAbnormal neutrophilic precursorsNumerous pink/salmon-colored granulesGranules may abnormally aggregate in discrete region of cytoplasmDysplastic nuclei with megaloblastoid change and abnormal nuclear segmentationIn < 20% of cases, monocytic componentErythroid and megakaryocytic lineages often decreased due to marrow replacement by AMLIncreased and atypical, spindled mast cells if concurrent systemic mastocytosis",
                    "sub_points": [
                      "Increased myeloid blasts",
                      "Variable blast countSome cases less than the required 20% (low blast count AML)",
                      "Some cases less than the required 20% (low blast count AML)",
                      "Characteristic Auer rodsThin with tapered, \"cigar-shaped\" endsUsually single within a cellSeen in cytoplasm of blasts and maturing/mature granulocytes",
                      "Thin with tapered, \"cigar-shaped\" ends",
                      "Usually single within a cell",
                      "Seen in cytoplasm of blasts and maturing/mature granulocytes",
                      "Abnormal neutrophilic precursorsNumerous pink/salmon-colored granulesGranules may abnormally aggregate in discrete region of cytoplasmDysplastic nuclei with megaloblastoid change and abnormal nuclear segmentation",
                      "Numerous pink/salmon-colored granules",
                      "Granules may abnormally aggregate in discrete region of cytoplasm",
                      "Dysplastic nuclei with megaloblastoid change and abnormal nuclear segmentation",
                      "In < 20% of cases, monocytic component",
                      "Erythroid and megakaryocytic lineages often decreased due to marrow replacement by AML",
                      "Increased and atypical, spindled mast cells if concurrent systemic mastocytosis"
                    ]
                  },
                  {
                    "text": "Bone marrow core biopsy100% cellularWith an increasing proportion of neutrophilic maturation, sheets of blasts may not be conspicuousMegakaryocytic lineage is decreased but morphologically unremarkableMay see associated mast cell diseaseFocal, compact, dense aggregates of mast cellsMast cell aggregates may be overshadowed by the AML (so-called occult mastocytosis)Mastocytosis is often revealed after treatment of AMLOsteosclerotic bone",
                    "sub_points": [
                      "100% cellular",
                      "With an increasing proportion of neutrophilic maturation, sheets of blasts may not be conspicuous",
                      "Megakaryocytic lineage is decreased but morphologically unremarkable",
                      "May see associated mast cell diseaseFocal, compact, dense aggregates of mast cellsMast cell aggregates may be overshadowed by the AML (so-called occult mastocytosis)Mastocytosis is often revealed after treatment of AMLOsteosclerotic bone",
                      "Focal, compact, dense aggregates of mast cells",
                      "Mast cell aggregates may be overshadowed by the AML (so-called occult mastocytosis)",
                      "Mastocytosis is often revealed after treatment of AML",
                      "Osteosclerotic bone"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Cytology": [
                  {
                    "text": "Myeloperoxidase (MPO): Myeloblasts positive"
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "Increased blasts: CD34, CD117 positiveMay show Pax-5 positivity",
                    "sub_points": [
                      "May show Pax-5 positivity"
                    ]
                  },
                  {
                    "text": "Associated mast cell disease: Mast cells positive for tryptase &/or CD117, CD25 &/or CD2"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Myeloblasts: CD34, CD33, CD13, weak CD45"
                  },
                  {
                    "text": "Aberrant antigen expression commonB-associated antigens: CD79a, CD19TdTCD56",
                    "sub_points": [
                      "B-associated antigens: CD79a, CD19",
                      "TdT",
                      "CD56"
                    ]
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "FISH forRUNX1-RUNX1T1Confirmatory of recurring genetic abnormalityPerform if morphology suggestive, but cytogenetics are inconclusive",
                    "sub_points": [
                      "Confirmatory of recurring genetic abnormality",
                      "Perform if morphology suggestive, but cytogenetics are inconclusive"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Molecular forRUNX1-RUNX1T1Diagnosis if other techniques suboptimal or unavailableResidual disease monitoring",
                    "sub_points": [
                      "Diagnosis if other techniques suboptimal or unavailable",
                      "Residual disease monitoring"
                    ]
                  },
                  {
                    "text": "Translocation t(8;21)(q22;q22) or variant readily detected on conventional cytogenetic analysis"
                  },
                  {
                    "text": "Rare submicroscopic events resulting in crypticRUNX1-RUNX1T1fusion; need FISH/molecular for confirmation"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Acute Myeloid Leukemia with Monocytic Component": [
                  {
                    "text": "AML with inversion 16Abnormal eosinophils with mixed eosinophil/basophil granules",
                    "sub_points": [
                      "Abnormal eosinophils with mixed eosinophil/basophil granules"
                    ]
                  },
                  {
                    "text": "AML with t(9;11)(p22;q23);MLLT3-MLLMonoblasts and promonocytes predominateNo Auer rods",
                    "sub_points": [
                      "Monoblasts and promonocytes predominate",
                      "No Auer rods"
                    ]
                  },
                  {
                    "text": "Acute myelomonocytic leukemiaTranslocation t(8;21) &/orRUNX1-RUNX1T1fusion absent",
                    "sub_points": [
                      "Translocation t(8;21) &/orRUNX1-RUNX1T1fusion absent"
                    ]
                  }
                ],
                "Chronic Myelogenous Leukemia with Prominent Neutrophilia": [
                  {
                    "text": "Basophilia often present but may be remarkably inconspicuous"
                  },
                  {
                    "text": "Translocation t(9;22)(q34;q11.2) orBCR-ABL1fusion present"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Blast count may be < 20% (so-called low blast count AML)"
                  },
                  {
                    "text": "Morphologic cluesBlasts with distinctive, thin, tapered, Auer rodsSalmon-colored granules in granulocytesNeutrophilic maturation",
                    "sub_points": [
                      "Blasts with distinctive, thin, tapered, Auer rods",
                      "Salmon-colored granules in granulocytes",
                      "Neutrophilic maturation"
                    ]
                  },
                  {
                    "text": "May be associated with systemic mastocytosis"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Acute Myeloid Leukemia With inv(16)(p13.1q22) or t(16;16)(p13.1;q22),CBFB-MYH11": {
            "name": "Acute Myeloid Leukemia With inv(16)(p13.1q22) or t(16;16)(p13.1;q22),CBFB-MYH11",
            "url": "https://app.pathprimer.com/document/32971456-a3b4-4293-b392-6690db307651/lesson/e328b112-0403-4322-9b2b-5e6e7ecbe471",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "AML with inv(16)(p13.1q22)"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Extramedullary involvement common, including skin (especially scalp), and CNS"
                  },
                  {
                    "text": "Absolute monocytosis common"
                  },
                  {
                    "text": "Favorable risk"
                  },
                  {
                    "text": "KITmutations may be found in 22-27% of cases"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Abnormal immature eosinophils in bone marrowContain dark purple-gray granules in addition to typical eosinophilic granules",
                    "sub_points": [
                      "Contain dark purple-gray granules in addition to typical eosinophilic granules"
                    ]
                  },
                  {
                    "text": "May not see abnormal eosinophil component in peripheral blood"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Inversion 16 abnormality is subtle and may be overlooked"
                  },
                  {
                    "text": "If cytogenetics normal but morphology suggests AML with inv 16, pursue FISH, molecular studies"
                  },
                  {
                    "text": "Molecular testing forCBFB-MYH11for diagnosis and residual disease monitoring"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Acute myeloid leukemia (AML) with inv(16)(p13.1q22)"
                  },
                  {
                    "text": "Core binding factor (CBF)"
                  },
                  {
                    "text": "Central nervous system (CNS)"
                  },
                  {
                    "text": "White blood cell (WBC)"
                  },
                  {
                    "text": "Myeloperoxidase (MPO)"
                  },
                  {
                    "text": "Neuron-specific enolase (NSE)"
                  },
                  {
                    "text": "Fluorescence in situ hybridization (FISH)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "AML with abnormal eosinophils"
                  },
                  {
                    "text": "AML M4 in French-American-British classification"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Acute myeloid leukemia with recurring genetic abnormality (WHO, 2008)inv(16)(p.13.1q22)t(16;16)(p13.1;q22)CBFB-MYH11genetic fusionCore binding factor beta (CBFB)Myosin heavy chain gene (MYH11)",
                    "sub_points": [
                      "inv(16)(p.13.1q22)",
                      "t(16;16)(p13.1;q22)",
                      "CBFB-MYH11genetic fusionCore binding factor beta (CBFB)Myosin heavy chain gene (MYH11)",
                      "Core binding factor beta (CBFB)",
                      "Myosin heavy chain gene (MYH11)"
                    ]
                  },
                  {
                    "text": "Presence of genetic abnormality is sufficient to warrant diagnosis of AMLDoes not require requisite 20% blasts",
                    "sub_points": [
                      "Does not require requisite 20% blasts"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Molecular Pathogenesis": [
                  {
                    "text": "In normal cells: CBF beta protein interacts with CBF alpha subunit (a.k.a.RUNX1) to form CBF transcription factor complex"
                  },
                  {
                    "text": "In cells with inv(16) or variant: Genetic rearrangement results inCBFB-MYH11molecular fusionPersistent transcriptional activation and leukemogenesis",
                    "sub_points": [
                      "Persistent transcriptional activation and leukemogenesis"
                    ]
                  },
                  {
                    "text": "Abnormal CBFB-MYH11 chimeric protein acts by preventing normal proteolysis of CBF complex"
                  },
                  {
                    "text": "\"Multihit\" model of AMLClass 1 and class 2 mutations are needed for leukemogenesisCBFB-MYH11fusion is considered class 2 mutationDevelopment of overt leukemia requires class 1 mutation (e.g.,KIT,FLT3, orRASmutation)",
                    "sub_points": [
                      "Class 1 and class 2 mutations are needed for leukemogenesis",
                      "CBFB-MYH11fusion is considered class 2 mutation",
                      "Development of overt leukemia requires class 1 mutation (e.g.,KIT,FLT3, orRASmutation)"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Approximately 6-12% of pediatric AML"
                  },
                  {
                    "text": "Approximately 8% of adult AML"
                  }
                ],
                "Age": [
                  {
                    "text": "Median: 40-45 yr"
                  }
                ],
                "Sex": [
                  {
                    "text": "No predilection"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Cytopenias"
                  },
                  {
                    "text": "Absolute monocytosis common"
                  },
                  {
                    "text": "Extramedullary involvement commonMore common than AML with t(8;21)Skin, especially scalpCNSSplenomegaly in 30% of patients",
                    "sub_points": [
                      "More common than AML with t(8;21)",
                      "Skin, especially scalp",
                      "CNS",
                      "Splenomegaly in 30% of patients"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Favorable risk"
                  },
                  {
                    "text": "Complete remission commonRates reach approximately 90% after standard induction therapy",
                    "sub_points": [
                      "Rates reach approximately 90% after standard induction therapy"
                    ]
                  },
                  {
                    "text": "Prognostic genetic factors1 or more secondary chromosome abnormalitiesTrisomy 8 linked to adverse outcomeAssociated withKITmutationsMay be found in 22-27% of casesPrognostic impact not well definedFLT3-ITDmutations in 20%Linked to adverse outcome",
                    "sub_points": [
                      "1 or more secondary chromosome abnormalitiesTrisomy 8 linked to adverse outcome",
                      "Trisomy 8 linked to adverse outcome",
                      "Associated withKITmutationsMay be found in 22-27% of casesPrognostic impact not well defined",
                      "May be found in 22-27% of cases",
                      "Prognostic impact not well defined",
                      "FLT3-ITDmutations in 20%Linked to adverse outcome",
                      "Linked to adverse outcome"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Peripheral bloodPancytopeniaLeukocytosis with increased myeloid blasts and immature-appearing monocytic cellsWBCs may exceed 100 x 10⁹/L in 20% of patientsEosinophils may be mildly increased",
                    "sub_points": [
                      "Pancytopenia",
                      "Leukocytosis with increased myeloid blasts and immature-appearing monocytic cellsWBCs may exceed 100 x 10⁹/L in 20% of patients",
                      "WBCs may exceed 100 x 10⁹/L in 20% of patients",
                      "Eosinophils may be mildly increased"
                    ]
                  },
                  {
                    "text": "Bone marrowIncreased myeloid blasts and immature monocytic cellsBlasts and promonocytes typically comprise > 20% of nucleated cellsMay be less (low blast count AML)Abnormal immature eosinophilsContain dark purple-gray granules in addition to typical eosinophilic granulesMainly at myelocyte stage of development",
                    "sub_points": [
                      "Increased myeloid blasts and immature monocytic cells",
                      "Blasts and promonocytes typically comprise > 20% of nucleated cellsMay be less (low blast count AML)",
                      "May be less (low blast count AML)",
                      "Abnormal immature eosinophilsContain dark purple-gray granules in addition to typical eosinophilic granulesMainly at myelocyte stage of development",
                      "Contain dark purple-gray granules in addition to typical eosinophilic granules",
                      "Mainly at myelocyte stage of development"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Cytology": [
                  {
                    "text": "Myeloblasts positive for cytochemical MPO and monocytic cells positive for NSE"
                  },
                  {
                    "text": "Abnormal basophilic granules in eosinophils; MPO and toluidine blue negative (distinct from basophils)"
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "Increased myeloblasts: CD34, CD117 positive"
                  },
                  {
                    "text": "Monocytic component: CD68, CD163, lysozyme positive"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Myeloblasts positive for CD34, CD33, weak CD45"
                  },
                  {
                    "text": "Monocytic cells: CD36, CD64, CD33, HLA-DR, moderate CD45, weak CD4, variable CD14"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Cytogenetic/FISH studiesAdditional chromosomal abnormalities seen in 30-40% of cases+22, +8, +21 commonInversion 16 abnormality is subtle and may be overlookedIf cytogenetics normal but morphology suggests AML with inv 16, pursue FISH, molecular studies",
                    "sub_points": [
                      "Additional chromosomal abnormalities seen in 30-40% of cases+22, +8, +21 common",
                      "+22, +8, +21 common",
                      "Inversion 16 abnormality is subtle and may be overlooked",
                      "If cytogenetics normal but morphology suggests AML with inv 16, pursue FISH, molecular studies"
                    ]
                  },
                  {
                    "text": "Molecular assessment forCBFB-MYH11For diagnosis and residual disease monitoring",
                    "sub_points": [
                      "For diagnosis and residual disease monitoring"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Acute Myeloid Leukemia With t(8;21)(q22;q22),RUNX1-RUNX1T1": [
                  {
                    "text": "Blasts show characteristic, single, thin, tapered Auer rods and salmon-colored granules"
                  }
                ],
                "Acute Myeloid Leukemia With t(9;11)(p22;q23),MLLT3-MLL": [
                  {
                    "text": "Associated with extramedullary and CNS involvement"
                  },
                  {
                    "text": "Abnormal eosinophil precursors with basophilic granules ﻿not﻿seen"
                  }
                ],
                "Acute Myeloid Leukemia, Not Otherwise Categorized (Myelomonocytic Type)": [
                  {
                    "text": "Lack of cytogenetic inv(16) or t(16;16) or molecularCBFB-MYH11fusion"
                  }
                ],
                "Therapy-Related Myeloid Neoplasm With Inversion 16": [
                  {
                    "text": "Requires clinical history of prior therapy"
                  },
                  {
                    "text": "Prognosis worse than for de novo AML with inv 16"
                  }
                ],
                "Colony Stimulating Factor Therapy": []
              },
              "Selected References": {}
            }
          },
          "Acute Promyelocytic Leukemia With t(15;17)(q22;q21), PML-RARA and Variants": {
            "name": "Acute Promyelocytic Leukemia With t(15;17)(q22;q21), PML-RARA and Variants",
            "url": "https://app.pathprimer.com/document/0de7aaea-a974-4ff7-a580-cf8c13bab44f/lesson/e328b112-0403-4322-9b2b-5e6e7ecbe471",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "AML with increased abnormal promyelocytes and blasts"
                  },
                  {
                    "text": "Defined by detection ofPML-RARAor t(15;17)(q22;q21)"
                  },
                  {
                    "text": "Typical or hypergranular variantAbnormal promyelocytes with irregular and often bilobed nucleiNumerous large cytoplasmic granulesAbnormal cells with numerous Auer rods (faggot cells) can be identified in majority of cases",
                    "sub_points": [
                      "Abnormal promyelocytes with irregular and often bilobed nuclei",
                      "Numerous large cytoplasmic granules",
                      "Abnormal cells with numerous Auer rods (faggot cells) can be identified in majority of cases"
                    ]
                  },
                  {
                    "text": "Hypogranular (microgranular) variantFrequent marked leukocytosisAbsent or scant cytoplasmic granules by light microscopyPresence of abundant submicroscopic granules highlighted by strong MPO reactivityFrequent bilobed nuclei (sliding plates)",
                    "sub_points": [
                      "Frequent marked leukocytosis",
                      "Absent or scant cytoplasmic granules by light microscopy",
                      "Presence of abundant submicroscopic granules highlighted by strong MPO reactivity",
                      "Frequent bilobed nuclei (sliding plates)"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Chief clinical feature is bleeding diathesis due toPlasmin-dependent primary fibrinolysisDisseminated intravascular coagulation (DIC)",
                    "sub_points": [
                      "Plasmin-dependent primary fibrinolysis",
                      "Disseminated intravascular coagulation (DIC)"
                    ]
                  },
                  {
                    "text": "All-trans-retinoic acid (ATRA)Can induce complete response in APL withPML-RARAfusionAML with t(5;17) variant translocation also ATRA responsiveAML with t(11;17) variant translocation is resistant to ATRA",
                    "sub_points": [
                      "Can induce complete response in APL withPML-RARAfusion",
                      "AML with t(5;17) variant translocation also ATRA responsive",
                      "AML with t(11;17) variant translocation is resistant to ATRA"
                    ]
                  },
                  {
                    "text": "Induction therapy typically includes anthracyclines and ATRA"
                  },
                  {
                    "text": "Maintenance ATRA and chemotherapy after achievement of complete remission"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Flow cytometryBright expression of CD33, variable expression of CD13, expression of CD117 in most casesLow to absent CD34 and HLA-DR in most cases",
                    "sub_points": [
                      "Bright expression of CD33, variable expression of CD13, expression of CD117 in most cases",
                      "Low to absent CD34 and HLA-DR in most cases"
                    ]
                  },
                  {
                    "text": "Cytochemical stainsMyeloperoxidase (MPO)Reactivity: Always strong reactivity in all leukemic cells of both hypergranular and microgranular formsStaining pattern: Dark blue MPO granular staining covering entire cytoplasm and often nuclei of leukemic cells",
                    "sub_points": [
                      "Myeloperoxidase (MPO)",
                      "Reactivity: Always strong reactivity in all leukemic cells of both hypergranular and microgranular forms",
                      "Staining pattern: Dark blue MPO granular staining covering entire cytoplasm and often nuclei of leukemic cells"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Acute promyelocytic leukemia (APL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "APL with t(15;17)(q22;q21),PML-RARA(current 2008 WHO classification)"
                  },
                  {
                    "text": "Acute myeloid leukemia (AML), M3 subtype, FAB classification (AML-M3)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Acute promyelocytic leukemia with t(15;17)(q22;q21),PML-RARADistinct subtype of AML with increased abnormal promyelocytes and blastsBlockage of maturation of granulocytic lineages at promyelocyte stage15;17 balanced reciprocal translocation represents karyotypic hallmark of disease",
                    "sub_points": [
                      "Distinct subtype of AML with increased abnormal promyelocytes and blasts",
                      "Blockage of maturation of granulocytic lineages at promyelocyte stage",
                      "15;17 balanced reciprocal translocation represents karyotypic hallmark of disease"
                    ]
                  },
                  {
                    "text": "Morphologic and genetic variantsTypical APL or hypergranular variantAbnormal promyelocytes with irregular and often bilobed nucleiNumerous large cytoplasmic granulesAbnormal cells with numerous Auer rods (faggot cells) can be identified in majority of casesHypogranular (microgranular) APL variantFrequent marked leukocytosisAbsent or scant cytoplasmic granules by light microscopyPresence of abundant submicroscopic granules highlighted by strong myeloperoxidase reactivityFrequent bilobed nuclei (sliding plates, butterfly-shaped)Rare \"faggot cells\" present in most casesAPL variants with non-PMLgene rearranged withRARAgene (APL with alternateRARAfusion)AML with t(5;17)(q35;q21),NPM1-RARAAML with t(11;17)(q23;q21),ZBTB16-RARAAML with t(11;17)(q13;q21),NUMA1-RARAAML with t(17;17)(q11.2;q21),STAT5B-RARA",
                    "sub_points": [
                      "Typical APL or hypergranular variantAbnormal promyelocytes with irregular and often bilobed nucleiNumerous large cytoplasmic granulesAbnormal cells with numerous Auer rods (faggot cells) can be identified in majority of cases",
                      "Abnormal promyelocytes with irregular and often bilobed nuclei",
                      "Numerous large cytoplasmic granules",
                      "Abnormal cells with numerous Auer rods (faggot cells) can be identified in majority of cases",
                      "Hypogranular (microgranular) APL variantFrequent marked leukocytosisAbsent or scant cytoplasmic granules by light microscopyPresence of abundant submicroscopic granules highlighted by strong myeloperoxidase reactivityFrequent bilobed nuclei (sliding plates, butterfly-shaped)Rare \"faggot cells\" present in most cases",
                      "Frequent marked leukocytosis",
                      "Absent or scant cytoplasmic granules by light microscopy",
                      "Presence of abundant submicroscopic granules highlighted by strong myeloperoxidase reactivity",
                      "Frequent bilobed nuclei (sliding plates, butterfly-shaped)",
                      "Rare \"faggot cells\" present in most cases",
                      "APL variants with non-PMLgene rearranged withRARAgene (APL with alternateRARAfusion)AML with t(5;17)(q35;q21),NPM1-RARAAML with t(11;17)(q23;q21),ZBTB16-RARAAML with t(11;17)(q13;q21),NUMA1-RARAAML with t(17;17)(q11.2;q21),STAT5B-RARA",
                      "AML with t(5;17)(q35;q21),NPM1-RARA",
                      "AML with t(11;17)(q23;q21),ZBTB16-RARA",
                      "AML with t(11;17)(q13;q21),NUMA1-RARA",
                      "AML with t(17;17)(q11.2;q21),STAT5B-RARA"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Molecular Pathogenesis": [
                  {
                    "text": "Classic APL is caused by t(15:17)(q22;q21) chromosomal translocationt(15;17)(q22;q21) occurs exclusively in APLRetinoic acid receptor alpha (RARA) gene on 17q21 fused with promyelocytic leukemia (PML) gene on 15q22Wild-typePMLgene acts as tumor suppressor geneRARAgene promotes cell differentiation and suppresses cell growthBreakpoint inRARAgene consistently occurs in intron 2Breakpoints inPMLgene occur in 3 different sitesIntron 6 (bcr1), resulting in long form transcriptExon 6 (bcr2), resulting in variable form transcriptIntron 3 (bcr3), resulting in short form transcriptNovelPML-PARAfusion gene generated on chromosome 15PML-RARAfusion gene encodes PML-RARA fusion protein",
                    "sub_points": [
                      "t(15;17)(q22;q21) occurs exclusively in APL",
                      "Retinoic acid receptor alpha (RARA) gene on 17q21 fused with promyelocytic leukemia (PML) gene on 15q22",
                      "Wild-typePMLgene acts as tumor suppressor gene",
                      "RARAgene promotes cell differentiation and suppresses cell growth",
                      "Breakpoint inRARAgene consistently occurs in intron 2",
                      "Breakpoints inPMLgene occur in 3 different sitesIntron 6 (bcr1), resulting in long form transcriptExon 6 (bcr2), resulting in variable form transcriptIntron 3 (bcr3), resulting in short form transcript",
                      "Intron 6 (bcr1), resulting in long form transcript",
                      "Exon 6 (bcr2), resulting in variable form transcript",
                      "Intron 3 (bcr3), resulting in short form transcript",
                      "NovelPML-PARAfusion gene generated on chromosome 15",
                      "PML-RARAfusion gene encodes PML-RARA fusion protein"
                    ]
                  },
                  {
                    "text": "Functions of novel PML-RARA fusion proteinKey role in molecular pathogenesis of APLDisrupts endogenous signaling pathways of both PML and RARABlocks myeloid differentiationMyeloid differentiation block appears necessary but not sufficient for development of APLMutations in oncogenes such asFLT3may cooperate withPML-RARAto induce leukemia",
                    "sub_points": [
                      "Key role in molecular pathogenesis of APL",
                      "Disrupts endogenous signaling pathways of both PML and RARA",
                      "Blocks myeloid differentiation",
                      "Myeloid differentiation block appears necessary but not sufficient for development of APL",
                      "Mutations in oncogenes such asFLT3may cooperate withPML-RARAto induce leukemia"
                    ]
                  },
                  {
                    "text": "APL with crypticPML-RARArearrangementCrypticPML-RARArearrangements not detectable by conventional cytogeneticsFISH using targeted probes usually detects crypticPML-RARArearrangementsFISH using targeted probes may fail to detect crypticPML-RARAin rare casesRT-PCR successfully detects and subtypes all 3 forms ofPML-RARAtranscriptsNo major biologic differences compared to classic APL with t(15;17)(q22;q21)",
                    "sub_points": [
                      "CrypticPML-RARArearrangements not detectable by conventional cytogenetics",
                      "FISH using targeted probes usually detects crypticPML-RARArearrangements",
                      "FISH using targeted probes may fail to detect crypticPML-RARAin rare cases",
                      "RT-PCR successfully detects and subtypes all 3 forms ofPML-RARAtranscripts",
                      "No major biologic differences compared to classic APL with t(15;17)(q22;q21)"
                    ]
                  },
                  {
                    "text": "APL with variantRARAtranslocationsClassified as AML with variantRARAtranslocations or APL with alternateRARAfusionAML with t(5;17)(q35;q21),NPM1-RARANucleophosmin (NPM1) gene on 5q35 fused withRARAgene on 17q21AML with t(11;17)(q23;q21),ZBTB16-RARAZBTB16(previouslyPLZF) gene on 11q23 fused withRARAgene on 17q21AML with t(11;17)(q13;q21),NUMA1-RARANUMA1(nuclear mitotic apparatus) gene on 11q13 fused withRARAgene on 17q21AML with t(17;17)(q11.2;q21),STAT5B-RARASignal transducer & activator of transcriptionSTAT5Bgene fused withRARAgene",
                    "sub_points": [
                      "Classified as AML with variantRARAtranslocations or APL with alternateRARAfusion",
                      "AML with t(5;17)(q35;q21),NPM1-RARANucleophosmin (NPM1) gene on 5q35 fused withRARAgene on 17q21",
                      "Nucleophosmin (NPM1) gene on 5q35 fused withRARAgene on 17q21",
                      "AML with t(11;17)(q23;q21),ZBTB16-RARAZBTB16(previouslyPLZF) gene on 11q23 fused withRARAgene on 17q21",
                      "ZBTB16(previouslyPLZF) gene on 11q23 fused withRARAgene on 17q21",
                      "AML with t(11;17)(q13;q21),NUMA1-RARANUMA1(nuclear mitotic apparatus) gene on 11q13 fused withRARAgene on 17q21",
                      "NUMA1(nuclear mitotic apparatus) gene on 11q13 fused withRARAgene on 17q21",
                      "AML with t(17;17)(q11.2;q21),STAT5B-RARASignal transducer & activator of transcriptionSTAT5Bgene fused withRARAgene",
                      "Signal transducer & activator of transcriptionSTAT5Bgene fused withRARAgene"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Accounts for 5-8% of AML cases"
                  },
                  {
                    "text": "Independent risk factors of APL diagnosis among patients with AML are young age, Hispanic background, and obesity"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Acute promyelocytic leukemia with t(15;17)(q22;q21),PML-RARA"
                  },
                  {
                    "text": "Chief clinical feature in APL is life-threatening coagulopathy and bleeding diathesis due toPlasmin-dependent primary fibrinolysisDisseminated intravascular coagulation (DIC)Profound thrombocytopenia due to combined production and survival defect",
                    "sub_points": [
                      "Plasmin-dependent primary fibrinolysis",
                      "Disseminated intravascular coagulation (DIC)",
                      "Profound thrombocytopenia due to combined production and survival defect"
                    ]
                  },
                  {
                    "text": "Marked leukocytosis in hypogranular variant"
                  },
                  {
                    "text": "(15;17)(q22;q21) chromosomal translocation is the hallmark of disease"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Rapid and accurate diagnosis of APL is crucial due toPotential life-threatening coagulopathyAggressive management of coagulopathy essential until ATRA therapy becomes effective (about 5 days)Unique response to all-trans-retinoic acid alpha (ATRA) and arsenic trioxide",
                    "sub_points": [
                      "Potential life-threatening coagulopathy",
                      "Aggressive management of coagulopathy essential until ATRA therapy becomes effective (about 5 days)",
                      "Unique response to all-trans-retinoic acid alpha (ATRA) and arsenic trioxide"
                    ]
                  },
                  {
                    "text": "All-trans-retinoic acid (ATRA)Coagulopathy resolves (after about 5 days of therapy)Allows re-expression of genes regulating promyelocyte differentiationDifferentiation to neutrophils occursCan induce complete response in APL withPML-RARAfusion",
                    "sub_points": [
                      "Coagulopathy resolves (after about 5 days of therapy)",
                      "Allows re-expression of genes regulating promyelocyte differentiation",
                      "Differentiation to neutrophils occurs",
                      "Can induce complete response in APL withPML-RARAfusion"
                    ]
                  },
                  {
                    "text": "Optimal therapy typically includes anthracyclines in addition to ATRA"
                  },
                  {
                    "text": "ATRA-based maintenance after achievement of complete remission"
                  },
                  {
                    "text": "Arsenic trioxide (ATO) currently regarded as best treatment option in setting of relapsed APL"
                  },
                  {
                    "text": "Recent studies suggest that ATRA and arsenic trioxide may be curativeMay become front line therapy in favorable risk patients",
                    "sub_points": [
                      "May become front line therapy in favorable risk patients"
                    ]
                  },
                  {
                    "text": "Response to ATRA in AML with variantRARAtranslocationsAML with t(5;17)(q35;q21),NPM1-RARAisATRA responsiveAML with t(11;17)(q23;q21),ZBTB16-RARAis resistant to ATRAAML with t(11;17)(q13;q21),NUMA1-RARAis responsive to ATRA per isolated case reportAML with t(17;17)(q11.2;q21),STA5B-RARAis resistant to ATRA per isolated case report",
                    "sub_points": [
                      "AML with t(5;17)(q35;q21),NPM1-RARAisATRA responsive",
                      "AML with t(11;17)(q23;q21),ZBTB16-RARAis resistant to ATRA",
                      "AML with t(11;17)(q13;q21),NUMA1-RARAis responsive to ATRA per isolated case report",
                      "AML with t(17;17)(q11.2;q21),STA5B-RARAis resistant to ATRA per isolated case report"
                    ]
                  },
                  {
                    "text": "Minimal residual disease (MRD) monitoring by quantitative real time (QR)-PCRPost-induction log reduction inPML-RARAtranscripts is not predictive of relapse riskSequential MRD assessment from the end of consolidation more reliable in detecting MRD and early relapseAdvantages of MRD monitoring to deliver preemptive therapy while the patient still in subclinical diseaseReduced treatment-related toxicityReduced hospitalization & improved outcomeReduced risk of death from potential coagulopathy that accompanies clinical relapse",
                    "sub_points": [
                      "Post-induction log reduction inPML-RARAtranscripts is not predictive of relapse risk",
                      "Sequential MRD assessment from the end of consolidation more reliable in detecting MRD and early relapse",
                      "Advantages of MRD monitoring to deliver preemptive therapy while the patient still in subclinical diseaseReduced treatment-related toxicityReduced hospitalization & improved outcomeReduced risk of death from potential coagulopathy that accompanies clinical relapse",
                      "Reduced treatment-related toxicity",
                      "Reduced hospitalization & improved outcome",
                      "Reduced risk of death from potential coagulopathy that accompanies clinical relapse"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "APL with t(15;17)(q22;q21),PML-RARAis curable in most patientsMore favorable than other AML with recurrent cytogenetic abnormalitiesEarly death from coagulopathy in 10% of patients < 50 years and in 35% of patients > 50 yearsSensitive to treatment with differentiating agent ATRARisk factors include age and WBCNo significant adverse impact in cases with additional cytogenetic abnormalitiesUncertain significance of presence ofFLT3ITD mutation in APLOverall good response to arsenic trioxide in relapsed or refractory APL casesATRA plus arsenic trioxide may be curativewithoutchemotherapy in good risk patients",
                    "sub_points": [
                      "More favorable than other AML with recurrent cytogenetic abnormalities",
                      "Early death from coagulopathy in 10% of patients < 50 years and in 35% of patients > 50 years",
                      "Sensitive to treatment with differentiating agent ATRA",
                      "Risk factors include age and WBC",
                      "No significant adverse impact in cases with additional cytogenetic abnormalities",
                      "Uncertain significance of presence ofFLT3ITD mutation in APL",
                      "Overall good response to arsenic trioxide in relapsed or refractory APL cases",
                      "ATRA plus arsenic trioxide may be curativewithoutchemotherapy in good risk patients"
                    ]
                  },
                  {
                    "text": "APL with crypticPML-RARArearrangementsSimilar biologic behavior to classic APL with t(15;17)(q22;q21)Responds to ATRA",
                    "sub_points": [
                      "Similar biologic behavior to classic APL with t(15;17)(q22;q21)",
                      "Responds to ATRA"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Blood": [
                  {
                    "text": "Typical hypergranular APLHigh level of suspicion required in this subtype of APL due toTypically very low white blood cell countMarked thrombocytopenia prototypicIncreased blasts with variably irregular, often kidney-shaped or bilobed or convoluted nucleiIncreased abnormal promyelocytes with densely packed large granulesMust search for hypergranular promyelocytes that may be concentrated at feather edge of smearLarge or abundant granules may obscure nuclear cytoplasmic borderDust-like cytoplasmic granules in some cellsNumerous intracytoplasmic Auer rods in some cells (faggot cells)",
                    "sub_points": [
                      "High level of suspicion required in this subtype of APL due toTypically very low white blood cell countMarked thrombocytopenia prototypic",
                      "Typically very low white blood cell count",
                      "Marked thrombocytopenia prototypic",
                      "Increased blasts with variably irregular, often kidney-shaped or bilobed or convoluted nuclei",
                      "Increased abnormal promyelocytes with densely packed large granulesMust search for hypergranular promyelocytes that may be concentrated at feather edge of smear",
                      "Must search for hypergranular promyelocytes that may be concentrated at feather edge of smear",
                      "Large or abundant granules may obscure nuclear cytoplasmic border",
                      "Dust-like cytoplasmic granules in some cells",
                      "Numerous intracytoplasmic Auer rods in some cells (faggot cells)"
                    ]
                  },
                  {
                    "text": "Typical hypogranular (microgranular) APLTypically high white blood cell countResembles acute monocytic leukemiaBlasts with sparse to absent microscopic granulesBlasts with frequent bilobed nuclei (sliding plates)Rare faggot cells detected in most cases",
                    "sub_points": [
                      "Typically high white blood cell count",
                      "Resembles acute monocytic leukemia",
                      "Blasts with sparse to absent microscopic granules",
                      "Blasts with frequent bilobed nuclei (sliding plates)",
                      "Rare faggot cells detected in most cases"
                    ]
                  },
                  {
                    "text": "APL with crypticPML-RARArearrangementsLack cytogenetically detectable classic t(15;17)(q22;q21)No major morphologic differences compared to classic APL with t(15;17)(q22;q21)Similar biologic behavior to classic APL with t(15;17)(q22;q21)Respond to ATRA, similar to classic APL with cytogenetically detected t(15;17)(q22;q21)",
                    "sub_points": [
                      "Lack cytogenetically detectable classic t(15;17)(q22;q21)",
                      "No major morphologic differences compared to classic APL with t(15;17)(q22;q21)",
                      "Similar biologic behavior to classic APL with t(15;17)(q22;q21)",
                      "Respond to ATRA, similar to classic APL with cytogenetically detected t(15;17)(q22;q21)"
                    ]
                  },
                  {
                    "text": "APL with variant RARA translocationsAML with t(5;17)(q35;q21),NPM1-RARAMorphologic overlap with APL with t(15;17)Hypergranular promyelocytes and subset of hypogranular promyelocytesAuer rods are not usually detectedAML with t(11;17)(q23;q21),ZBTB16-RARABlasts with regular nuclei, abundant cytoplasm with coarse or fine granulesAuer rods are usually absentIncreased number of pelgeroid neutrophilsAML with t(17;17)(q11.2;q21),STAT5B-RARAMorphologically has been classified as AML-M1 in FAB classification with subset of blasts resembling M3 variant",
                    "sub_points": [
                      "AML with t(5;17)(q35;q21),NPM1-RARAMorphologic overlap with APL with t(15;17)Hypergranular promyelocytes and subset of hypogranular promyelocytesAuer rods are not usually detected",
                      "Morphologic overlap with APL with t(15;17)",
                      "Hypergranular promyelocytes and subset of hypogranular promyelocytes",
                      "Auer rods are not usually detected",
                      "AML with t(11;17)(q23;q21),ZBTB16-RARABlasts with regular nuclei, abundant cytoplasm with coarse or fine granulesAuer rods are usually absentIncreased number of pelgeroid neutrophils",
                      "Blasts with regular nuclei, abundant cytoplasm with coarse or fine granules",
                      "Auer rods are usually absent",
                      "Increased number of pelgeroid neutrophils",
                      "AML with t(17;17)(q11.2;q21),STAT5B-RARAMorphologically has been classified as AML-M1 in FAB classification with subset of blasts resembling M3 variant",
                      "Morphologically has been classified as AML-M1 in FAB classification with subset of blasts resembling M3 variant"
                    ]
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "Bone marrow aspirate findingsIncreased blasts and abnormal promyelocytesMore reliable than peripheral blood for accurate blasts and promyelocytes count",
                    "sub_points": [
                      "Increased blasts and abnormal promyelocytes",
                      "More reliable than peripheral blood for accurate blasts and promyelocytes count"
                    ]
                  },
                  {
                    "text": "Bone marrow trephine biopsy findingsUsually hypercellular for ageSheets of leukemic promyelocytes with abundant, pink, granular cytoplasm and irregular nuclei",
                    "sub_points": [
                      "Usually hypercellular for age",
                      "Sheets of leukemic promyelocytes with abundant, pink, granular cytoplasm and irregular nuclei"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Histochemistry": [
                  {
                    "text": "Myeloperoxidase (MPO)Cytochemical stain requiring enzyme functionReactivity: Always strong reactivity in all leukemic cells of both hypergranular and microgranular formsStaining pattern: Dark blue MPO granular staining covering entire cytoplasm and often nuclei of leukemic cells",
                    "sub_points": [
                      "Cytochemical stain requiring enzyme function",
                      "Reactivity: Always strong reactivity in all leukemic cells of both hypergranular and microgranular forms",
                      "Staining pattern: Dark blue MPO granular staining covering entire cytoplasm and often nuclei of leukemic cells"
                    ]
                  },
                  {
                    "text": "Nonspecific esterase (NSE)Cytochemical stain requiring enzyme functionWeakly positive in about 25% of cases",
                    "sub_points": [
                      "Cytochemical stain requiring enzyme function",
                      "Weakly positive in about 25% of cases"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "High side scatter due to granularity of cytoplasm"
                  },
                  {
                    "text": "Bright expression of CD33, variable expression of CD13, expression of CD117 in most cases"
                  },
                  {
                    "text": "Low to absent CD34 and HLA-DR in most cases"
                  },
                  {
                    "text": "Frequent variable expression of CD34 and CD2 inMicrogranular variantAPL with bcr3 transcript (short form)",
                    "sub_points": [
                      "Microgranular variant",
                      "APL with bcr3 transcript (short form)"
                    ]
                  },
                  {
                    "text": "CD56 expression in about 20% of cases"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Demonstration ofPML-RARAfusion gene is considered diagnostic hallmark of APLFISH analysis is preferred as an initial test in all suspected casesRapid turn-around timeSuccessful detection of most so-called crypticPML-RARArearrangements typically missed by conventional cytogeneticsFISH may fail in rare cases of APL with molecularly detectablePML-RARArearrangementConventional cytogenetics recommended in all casesDetects additional chromosomal aberrations if any existDetection of alternativeRARApartners",
                    "sub_points": [
                      "FISH analysis is preferred as an initial test in all suspected casesRapid turn-around timeSuccessful detection of most so-called crypticPML-RARArearrangements typically missed by conventional cytogeneticsFISH may fail in rare cases of APL with molecularly detectablePML-RARArearrangement",
                      "Rapid turn-around time",
                      "Successful detection of most so-called crypticPML-RARArearrangements typically missed by conventional cytogenetics",
                      "FISH may fail in rare cases of APL with molecularly detectablePML-RARArearrangement",
                      "Conventional cytogenetics recommended in all casesDetects additional chromosomal aberrations if any existDetection of alternativeRARApartners",
                      "Detects additional chromosomal aberrations if any exist",
                      "Detection of alternativeRARApartners"
                    ]
                  },
                  {
                    "text": "Conventional cytogeneticsProvides most complete information including complex translocations and other abnormalities in addition to t(15;17)Detects t(15;17)(q22;q12) in 80-90% of casesReasons for false-negative cytogeneticsCryptic translocationsMicro-insertionsFluorescence in situ hybridization (FISH) for t(15:17)Can be performed in both interphase nuclei and in dividing cellsDetects most cryptic 15;17 translocations that are missed by conventional cytogeneticsUseful in assessing minimal residual disease but less sensitive than RT-PCRFISH does not detect all possible rearrangedPML-RARAcasesFISH can potentially missPML-RARAgenerated by small insertions, particularly when large probes are usedReverse transcriptase PCR (RT-PCR)Identifies the specificPML-RARAtranscript typeHighly sensitive compare to FISH for minimal residual disease (MRD) detectionGenerally considered qualitative or semi-quantitative testHigh-quality RNA requiredQuantitative real-time PCR (QR-PCR)Identifies the specific type ofPML-RARAtranscriptAccurately measures & quantifies fusion transcriptMost sensitive method for detection of minimal residual diseaseMost sensitive method for detection of early molecular relapse following molecular remissionHigh-quality RNA requiredMRD detection rate significantly higher in bone marrow aspirate specimen compared to peripheral blood sample",
                    "sub_points": [
                      "Provides most complete information including complex translocations and other abnormalities in addition to t(15;17)",
                      "Detects t(15;17)(q22;q12) in 80-90% of cases",
                      "Reasons for false-negative cytogeneticsCryptic translocationsMicro-insertions",
                      "Cryptic translocations",
                      "Micro-insertions",
                      "Fluorescence in situ hybridization (FISH) for t(15:17)Can be performed in both interphase nuclei and in dividing cellsDetects most cryptic 15;17 translocations that are missed by conventional cytogeneticsUseful in assessing minimal residual disease but less sensitive than RT-PCRFISH does not detect all possible rearrangedPML-RARAcasesFISH can potentially missPML-RARAgenerated by small insertions, particularly when large probes are used",
                      "Can be performed in both interphase nuclei and in dividing cells",
                      "Detects most cryptic 15;17 translocations that are missed by conventional cytogenetics",
                      "Useful in assessing minimal residual disease but less sensitive than RT-PCR",
                      "FISH does not detect all possible rearrangedPML-RARAcases",
                      "FISH can potentially missPML-RARAgenerated by small insertions, particularly when large probes are used",
                      "Reverse transcriptase PCR (RT-PCR)Identifies the specificPML-RARAtranscript typeHighly sensitive compare to FISH for minimal residual disease (MRD) detectionGenerally considered qualitative or semi-quantitative testHigh-quality RNA required",
                      "Identifies the specificPML-RARAtranscript type",
                      "Highly sensitive compare to FISH for minimal residual disease (MRD) detection",
                      "Generally considered qualitative or semi-quantitative test",
                      "High-quality RNA required",
                      "Quantitative real-time PCR (QR-PCR)Identifies the specific type ofPML-RARAtranscriptAccurately measures & quantifies fusion transcriptMost sensitive method for detection of minimal residual diseaseMost sensitive method for detection of early molecular relapse following molecular remissionHigh-quality RNA requiredMRD detection rate significantly higher in bone marrow aspirate specimen compared to peripheral blood sample",
                      "Identifies the specific type ofPML-RARAtranscript",
                      "Accurately measures & quantifies fusion transcript",
                      "Most sensitive method for detection of minimal residual disease",
                      "Most sensitive method for detection of early molecular relapse following molecular remission",
                      "High-quality RNA required",
                      "MRD detection rate significantly higher in bone marrow aspirate specimen compared to peripheral blood sample"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Acute Monocytic Leukemia": [
                  {
                    "text": "Hypogranular APL can mimic acute monocytic leukemia cytologically"
                  },
                  {
                    "text": "MPO reaction weak to negative in acute monocytic leukemia but strongly positive in APL"
                  },
                  {
                    "text": "NSE reaction positive in acute monocytic leukemia but weak to negative in APL"
                  },
                  {
                    "text": "Expression of HLA-DR and CD15 usually low to negative in APL"
                  },
                  {
                    "text": "Acute monocytic leukemia lacksPML-RARArearrangement"
                  }
                ],
                "Reactive Promyelocytic Regeneration": [
                  {
                    "text": "Early marrow recovery post chemotherapy or other insults"
                  },
                  {
                    "text": "Growth factor (i.e., G-CSF) administration"
                  },
                  {
                    "text": "Drug-induced maturation arrest (i.e., cocaine contaminated with levamisole)"
                  },
                  {
                    "text": "Bone marrow typically markedly hypocellular"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3),KMT2A-MLLT3": {
            "name": "Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3),KMT2A-MLLT3",
            "url": "https://app.pathprimer.com/document/1ac63c4c-d5f3-4aa2-b131-9d473fcc6349/lesson/e328b112-0403-4322-9b2b-5e6e7ecbe471",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Specific subtype of acute myeloid leukemia (AML) with recurrent genetic abnormality (ICC)/with defining genetic abnormality (WHO-HAEM5)"
                  },
                  {
                    "text": "7 subentities of AML withKMT2Arearrangement in ICCAML with t(9;11)(p21.3;q23.3)/MLLT3::KMT2A(ICC)6 other ICC subentities included in category of AML with otherKMT2Arearrangements (ICC)",
                    "sub_points": [
                      "AML with t(9;11)(p21.3;q23.3)/MLLT3::KMT2A(ICC)",
                      "6 other ICC subentities included in category of AML with otherKMT2Arearrangements (ICC)"
                    ]
                  },
                  {
                    "text": "WHO-HAEM5 has only 1 category (AML withKMT2Arearrangement) and does not specify entities or blast threshold"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Extramedullary disease/myeloid sarcoma commonSites: Skin, CNS",
                    "sub_points": [
                      "Sites: Skin, CNS"
                    ]
                  },
                  {
                    "text": "DIC"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "≥ 10% blasts in peripheral blood &/or bone marrow (ICC)"
                  },
                  {
                    "text": "No blast threshold in WHO-HAEM5"
                  },
                  {
                    "text": "Usually monoblasts and promonocytes predominate"
                  },
                  {
                    "text": "Hypercellular bone marrow"
                  },
                  {
                    "text": "No significant eosinophilia"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Cytochemistry: NSE(+)"
                  },
                  {
                    "text": "ImmunophenotypingMonocytic differentiation: CD4(+), CD33 (bright +), CD36/CD64 coexpression, CD14(+), CD163 (variable)Blast markers often (-): CD34, CD117",
                    "sub_points": [
                      "Monocytic differentiation: CD4(+), CD33 (bright +), CD36/CD64 coexpression, CD14(+), CD163 (variable)",
                      "Blast markers often (-): CD34, CD117"
                    ]
                  },
                  {
                    "text": "GeneticsCytogenetics typically reveals classic translocationFISH forKMT2Ashould be considered in any case of AML with monocytic differentiationGene expression profile and RNA-seq may identify cryptic cases",
                    "sub_points": [
                      "Cytogenetics typically reveals classic translocationFISH forKMT2Ashould be considered in any case of AML with monocytic differentiation",
                      "FISH forKMT2Ashould be considered in any case of AML with monocytic differentiation",
                      "Gene expression profile and RNA-seq may identify cryptic cases"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Chronic myelomonocytic leukemia (CMML), especially CMML-210-19% blasts/blast equivalents in bone marrow in CMML-2Delineation of monoblasts and promonocytes essential",
                    "sub_points": [
                      "10-19% blasts/blast equivalents in bone marrow in CMML-2",
                      "Delineation of monoblasts and promonocytes essential"
                    ]
                  },
                  {
                    "text": "Acute myelomonocytic leukemia, not otherwise specified (WHO-HAEM5)"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Acute myeloid leukemia (AML)"
                  },
                  {
                    "text": "International Consensus Classification (ICC)"
                  },
                  {
                    "text": "WHO 5th edition (WHO-HAEM5)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "AML withKMT2Arearrangement (WHO-HAEM5)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "AML with t(9;11) and other specificKMT2Arearrangements≥ 10% blasts in blood or bone marrow required by ICC; no blast threshold in WHO-HAEM5Blast types include myeloblasts and monocytic blast equivalents",
                    "sub_points": [
                      "≥ 10% blasts in blood or bone marrow required by ICC; no blast threshold in WHO-HAEM5",
                      "Blast types include myeloblasts and monocytic blast equivalents"
                    ]
                  },
                  {
                    "text": "t(9;11) translocation involvesMLLT3andKMT2AgenesKMT2Agene: Chromosomal location 11q23.3Human homologue of trithorax gene inDrosophilaMLLT3gene: Chromosomal location 9p21.3",
                    "sub_points": [
                      "KMT2Agene: Chromosomal location 11q23.3Human homologue of trithorax gene inDrosophila",
                      "Human homologue of trithorax gene inDrosophila",
                      "MLLT3gene: Chromosomal location 9p21.3"
                    ]
                  },
                  {
                    "text": "Morphology and immunophenotype indicate monocytic differentiationStrong association with AML M5 and M4 subtypes in French-American-British (FAB) classificationMegakaryocytic differentiation may be seen in pediatric patients withKMT2A::MLLT3orKMT2A::MLLT10",
                    "sub_points": [
                      "Strong association with AML M5 and M4 subtypes in French-American-British (FAB) classification",
                      "Megakaryocytic differentiation may be seen in pediatric patients withKMT2A::MLLT3orKMT2A::MLLT10"
                    ]
                  }
                ]
              },
              "CLASSIFICATION": {
                "ICC and WHO-HAEM5 Comparisons": [
                  {
                    "text": "AML with recurrent genetic abnormalities (ICC)/AML with defining genetic abnormalities (WHO-HAEM5)AML with t(9;11)(p21.3;q23.3)/MLLT3::KMT2A(ICC)≥ 10% blast threshold (ICC only)AML with otherKMT2Arearrangements (ICC)≥ 10% blast threshold (ICC)Includes 6 subentities with otherKMT2Arearrangementst(4;11), t(6;11), 2 types with t(10;11), and 2 types with t(11;19)Partner genes includeAFF1,AFDN,MLLT10,TET1,ELL, andMLLT1Only 1 category in WHO-HAEM5: AML withKMT2ArearrangementDiagnosed irrespective of blast percentage",
                    "sub_points": [
                      "AML with t(9;11)(p21.3;q23.3)/MLLT3::KMT2A(ICC)≥ 10% blast threshold (ICC only)",
                      "≥ 10% blast threshold (ICC only)",
                      "AML with otherKMT2Arearrangements (ICC)≥ 10% blast threshold (ICC)Includes 6 subentities with otherKMT2Arearrangementst(4;11), t(6;11), 2 types with t(10;11), and 2 types with t(11;19)Partner genes includeAFF1,AFDN,MLLT10,TET1,ELL, andMLLT1",
                      "≥ 10% blast threshold (ICC)",
                      "Includes 6 subentities with otherKMT2Arearrangementst(4;11), t(6;11), 2 types with t(10;11), and 2 types with t(11;19)Partner genes includeAFF1,AFDN,MLLT10,TET1,ELL, andMLLT1",
                      "t(4;11), t(6;11), 2 types with t(10;11), and 2 types with t(11;19)",
                      "Partner genes includeAFF1,AFDN,MLLT10,TET1,ELL, andMLLT1",
                      "Only 1 category in WHO-HAEM5: AML withKMT2ArearrangementDiagnosed irrespective of blast percentage",
                      "Diagnosed irrespective of blast percentage"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Epidemiology": [
                  {
                    "text": "May occur at any age~ 9-12% of pediatric AML~ 1-2% of adult AML",
                    "sub_points": [
                      "~ 9-12% of pediatric AML",
                      "~ 1-2% of adult AML"
                    ]
                  }
                ],
                "Normal Function ofKMT2A": [
                  {
                    "text": "Encodes DNA-binding proteinTranscription regulatory factor important in hematopoiesis (e.g.,HOXgenes)Methylates histone H3 lysine 4Chromatin remodelingDirectly binds to promoter sequences",
                    "sub_points": [
                      "Transcription regulatory factor important in hematopoiesis (e.g.,HOXgenes)",
                      "Methylates histone H3 lysine 4",
                      "Chromatin remodeling",
                      "Directly binds to promoter sequences"
                    ]
                  }
                ],
                "Normal Function ofMLLT3": [
                  {
                    "text": "Involved in regulation of transcription"
                  }
                ],
                "Function of Chimeric t(v;11)(v;q23.3);KMT2AGene Fusions": [
                  {
                    "text": "KMT2Ais frequent target for rearrangementAlterations implicated in leukemogenesis include deletions, duplications, inversions, translocations> 70 gene translocation partners reportedMLLT3is most common, t(9;11)(p22;q23)ICC specifies 7KMT2A-rearranged subtypes as distinct entitiesIn addition toMLLT3, includesAFF1,AFDN,MLLT10,TET1,ELL, andMLLT1",
                    "sub_points": [
                      "Alterations implicated in leukemogenesis include deletions, duplications, inversions, translocations> 70 gene translocation partners reportedMLLT3is most common, t(9;11)(p22;q23)ICC specifies 7KMT2A-rearranged subtypes as distinct entitiesIn addition toMLLT3, includesAFF1,AFDN,MLLT10,TET1,ELL, andMLLT1",
                      "> 70 gene translocation partners reportedMLLT3is most common, t(9;11)(p22;q23)",
                      "MLLT3is most common, t(9;11)(p22;q23)",
                      "ICC specifies 7KMT2A-rearranged subtypes as distinct entitiesIn addition toMLLT3, includesAFF1,AFDN,MLLT10,TET1,ELL, andMLLT1",
                      "In addition toMLLT3, includesAFF1,AFDN,MLLT10,TET1,ELL, andMLLT1"
                    ]
                  },
                  {
                    "text": "Chimeric transcripts encode abnormal proteinsAlterations involve 5' portion and promoter regions ofKMT2Aand 3' portion of partner geneLeukemia withKMT2Arearrangement has distinct gene expression profileSimilar to early hematopoietic stem cellsOverexpression ofHOXgenes",
                    "sub_points": [
                      "Alterations involve 5' portion and promoter regions ofKMT2Aand 3' portion of partner gene",
                      "Leukemia withKMT2Arearrangement has distinct gene expression profileSimilar to early hematopoietic stem cellsOverexpression ofHOXgenes",
                      "Similar to early hematopoietic stem cells",
                      "Overexpression ofHOXgenes"
                    ]
                  },
                  {
                    "text": "Variety of acute leukemias associated withKMT2AtranslocationsAMLB-acute lymphoblastic leukemiaAcute leukemia of ambiguous lineageAML may develop following cytotoxic therapy: Therapy-related is diagnosis qualifier in ICCT-acute lymphoblastic leukemia (rare)",
                    "sub_points": [
                      "AML",
                      "B-acute lymphoblastic leukemia",
                      "Acute leukemia of ambiguous lineage",
                      "AML may develop following cytotoxic therapy: Therapy-related is diagnosis qualifier in ICC",
                      "T-acute lymphoblastic leukemia (rare)"
                    ]
                  }
                ],
                "Multihit Model of Acute Myeloid Leukemia Pathogenesis": [
                  {
                    "text": "Both class 1 and class 2 mutations are needed for leukemogenesisClass 1 mutations increase cellular proliferationClass 2 mutations impair cellular differentiation or maturation",
                    "sub_points": [
                      "Class 1 mutations increase cellular proliferation",
                      "Class 2 mutations impair cellular differentiation or maturation"
                    ]
                  },
                  {
                    "text": "KMT2Agene fusions are considered class 2 mutationsChimeric proteins result in abrogation of normal differentiation signals",
                    "sub_points": [
                      "Chimeric proteins result in abrogation of normal differentiation signals"
                    ]
                  },
                  {
                    "text": "Other common molecular alterations inKMT2A-rearranged cases include RAS pathway mutations,FLT3tyrosine kinase domain mutations, and mutations inRUNX1,TET2,PLCG2, andZRSR2"
                  },
                  {
                    "text": "Mutation profiles ofKMT2A-rearranged AML tend to show fewer mutations compared to other cases"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Age": [
                  {
                    "text": "All ages affected; more common in children"
                  }
                ],
                "Sex": [
                  {
                    "text": "M = F"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Leukocytosis, monocytosis, increased blasts"
                  },
                  {
                    "text": "Anemia and thrombocytopenia"
                  },
                  {
                    "text": "Extramedullary disease (cutaneous, gingival hyperplasia, CNS)"
                  },
                  {
                    "text": "Organomegaly"
                  },
                  {
                    "text": "DIC"
                  }
                ],
                "Treatment": [
                  {
                    "text": "ChemotherapyInduction and consolidation therapyNovel therapies, including menin inhibitors, being studied",
                    "sub_points": [
                      "Induction and consolidation therapy",
                      "Novel therapies, including menin inhibitors, being studied"
                    ]
                  },
                  {
                    "text": "Allogeneic stem cell transplantation"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "AML with t(9;11)/KMT2A::MLLT3corresponds to intermediate-risk group"
                  },
                  {
                    "text": "AMLs with otherKMT2Arearrangements stratified to adverse-risk group"
                  },
                  {
                    "text": "Measurable residual disease monitoringEarly achievement of molecular negativity forKMT2A::MLLT3fusion transcriptMay portend longer remission statusIncreasingKMT2A::MLLT3transcript levelsMay herald early disease relapse",
                    "sub_points": [
                      "Early achievement of molecular negativity forKMT2A::MLLT3fusion transcriptMay portend longer remission status",
                      "May portend longer remission status",
                      "IncreasingKMT2A::MLLT3transcript levelsMay herald early disease relapse",
                      "May herald early disease relapse"
                    ]
                  },
                  {
                    "text": "Presence of other mutations may influence prognosisRAS pathway mutations associated with worse prognosis",
                    "sub_points": [
                      "RAS pathway mutations associated with worse prognosis"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Morphology": [
                  {
                    "text": "Peripheral bloodVariable WBC count, often leukocytosisAnemia and thrombocytopeniaCirculating monoblasts and promonocytes, usually > 20%Smaller subset of myeloid blastsMonoblastsLarge with round nuclear contoursNuclei with fine chromatin and prominent nucleolusAbundant variably basophilic cytoplasm with possible vacuolesFine cytoplasmic azurophilic granulesTypically no Auer rodsPromonocytesIntermediate to largeSmaller, variably prominent nucleoliAbundant, lightly basophilic cytoplasmGently lobulated nuclei with delicate nuclear foldingMore even/dispersed chromatin pattern than typical monocyteTypically no significant granulocytic or platelet dysplasia",
                    "sub_points": [
                      "Variable WBC count, often leukocytosis",
                      "Anemia and thrombocytopenia",
                      "Circulating monoblasts and promonocytes, usually > 20%",
                      "Smaller subset of myeloid blasts",
                      "MonoblastsLarge with round nuclear contoursNuclei with fine chromatin and prominent nucleolusAbundant variably basophilic cytoplasm with possible vacuolesFine cytoplasmic azurophilic granulesTypically no Auer rods",
                      "Large with round nuclear contours",
                      "Nuclei with fine chromatin and prominent nucleolus",
                      "Abundant variably basophilic cytoplasm with possible vacuoles",
                      "Fine cytoplasmic azurophilic granules",
                      "Typically no Auer rods",
                      "PromonocytesIntermediate to largeSmaller, variably prominent nucleoliAbundant, lightly basophilic cytoplasmGently lobulated nuclei with delicate nuclear foldingMore even/dispersed chromatin pattern than typical monocyte",
                      "Intermediate to large",
                      "Smaller, variably prominent nucleoli",
                      "Abundant, lightly basophilic cytoplasm",
                      "Gently lobulated nuclei with delicate nuclear folding",
                      "More even/dispersed chromatin pattern than typical monocyte",
                      "Typically no significant granulocytic or platelet dysplasia"
                    ]
                  },
                  {
                    "text": "Bone marrow aspirate smearsHypercellularUsually markedly increased monoblasts and promonocytesConstitute > 80% of marrow nucleated cellsMarkedly decreased background normal hematopoiesisTypically no significant background dysplasiaNo significant basophilia or eosinophilia",
                    "sub_points": [
                      "Hypercellular",
                      "Usually markedly increased monoblasts and promonocytesConstitute > 80% of marrow nucleated cells",
                      "Constitute > 80% of marrow nucleated cells",
                      "Markedly decreased background normal hematopoiesis",
                      "Typically no significant background dysplasia",
                      "No significant basophilia or eosinophilia"
                    ]
                  },
                  {
                    "text": "Bone marrow core biopsyHypercellularEffacement of normal bone marrow hematopoiesisPredominant population of blasts/promonocytesMay see scattered admixed residual hematopoietic elementsMorphologic features of blasts/blast equivalentsLarge with abundant pink cytoplasmVariably irregular/twisted nuclear appearanceSmall nucleoliNo significant disease-related bony changesNo associated eosinophilia",
                    "sub_points": [
                      "Hypercellular",
                      "Effacement of normal bone marrow hematopoiesisPredominant population of blasts/promonocytesMay see scattered admixed residual hematopoietic elements",
                      "Predominant population of blasts/promonocytes",
                      "May see scattered admixed residual hematopoietic elements",
                      "Morphologic features of blasts/blast equivalentsLarge with abundant pink cytoplasmVariably irregular/twisted nuclear appearanceSmall nucleoli",
                      "Large with abundant pink cytoplasm",
                      "Variably irregular/twisted nuclear appearance",
                      "Small nucleoli",
                      "No significant disease-related bony changes",
                      "No associated eosinophilia"
                    ]
                  }
                ],
                "Extramedullary Disease": [
                  {
                    "text": "Myeloid sarcomaEffacement of normal tissue architecture by uniform blastic-appearing population",
                    "sub_points": [
                      "Effacement of normal tissue architecture by uniform blastic-appearing population"
                    ]
                  },
                  {
                    "text": "Sites most affected: Skin, gingiva, CNS"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Cytochemistry": [
                  {
                    "text": "MPOHighlights cells of neutrophilic lineageTypically negative in monoblasts and promonocytesOccasional cases may show scattered MPO(+) granules in monocytic cells",
                    "sub_points": [
                      "Highlights cells of neutrophilic lineage",
                      "Typically negative in monoblasts and promonocytes",
                      "Occasional cases may show scattered MPO(+) granules in monocytic cells"
                    ]
                  },
                  {
                    "text": "Nonspecific esterase (NSE) (α-naphthyl butyrate esterase)/butyrate esterase (BE)Highlights cells of monocytic lineageTypically positive in monoblasts and promonocytesGenerally variable staining intensityTechnically challenging stain to perform",
                    "sub_points": [
                      "Highlights cells of monocytic lineage",
                      "Typically positive in monoblasts and promonocytes",
                      "Generally variable staining intensity",
                      "Technically challenging stain to perform"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Monoblasts and promonocytesCD64, CD36, CD4, and CD33 (+); HLA-DR (variable); CD14 (diminished/lost); CD13 (variable)Other: CD56 (variable +), CD123(+), CD45(+)",
                    "sub_points": [
                      "CD64, CD36, CD4, and CD33 (+); HLA-DR (variable); CD14 (diminished/lost); CD13 (variable)",
                      "Other: CD56 (variable +), CD123(+), CD45(+)"
                    ]
                  },
                  {
                    "text": "Myeloid blasts (usually minor component)Typically CD34, CD117, CD13, and CD33 (+)",
                    "sub_points": [
                      "Typically CD34, CD117, CD13, and CD33 (+)"
                    ]
                  },
                  {
                    "text": "Various phenotypes observed in following patternsImmature monocytic: CD64 (bright +) and CD4(+) with diminished CD14, CD13, and CD36 with increased CD117 and CD15Mature monocytic: CD64, CD36, CD14, and CD4 (+); dim CD15; CD117 and CD34 (-)Acute promyelocytic leukemia (APL)-like: CD117, CD13, and CD33 (+); CD34 and HLA-DR (-)Myelomonocytic: Comprises myeloblast and monocytic components (≥ 20% each)Myeloblastic: CD34, CD117, CD13, CD33, and HLA-DR (+)",
                    "sub_points": [
                      "Immature monocytic: CD64 (bright +) and CD4(+) with diminished CD14, CD13, and CD36 with increased CD117 and CD15",
                      "Mature monocytic: CD64, CD36, CD14, and CD4 (+); dim CD15; CD117 and CD34 (-)",
                      "Acute promyelocytic leukemia (APL)-like: CD117, CD13, and CD33 (+); CD34 and HLA-DR (-)",
                      "Myelomonocytic: Comprises myeloblast and monocytic components (≥ 20% each)",
                      "Myeloblastic: CD34, CD117, CD13, CD33, and HLA-DR (+)"
                    ]
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "CD34 most often (-)"
                  },
                  {
                    "text": "Markers supporting monocytic differentiationCD68(+), CD4(+), lysozyme (+), CD163(+) (~ 50% of cases), CD14(+)",
                    "sub_points": [
                      "CD68(+), CD4(+), lysozyme (+), CD163(+) (~ 50% of cases), CD14(+)"
                    ]
                  },
                  {
                    "text": "Myeloid-associated antigensCD33(+), MPO(-), CD13 (variable)",
                    "sub_points": [
                      "CD33(+), MPO(-), CD13 (variable)"
                    ]
                  }
                ],
                "FISH forKMT2ARearrangement": [
                  {
                    "text": "ConfirmsKMT2Agene rearrangement using break-apart probe"
                  },
                  {
                    "text": "DetectsKMT2Agene rearrangement otherwise masked in complex karyotype or cryptic alteration"
                  },
                  {
                    "text": "RareKMT2Arearrangements (likeKMT2A::USP2) are not detected by FISH testing"
                  },
                  {
                    "text": "Partner gene isnotrevealed using break-apart probe strategy"
                  },
                  {
                    "text": "KMT2Agene rearrangements arenotspecific for AMLSeen in some acute leukemias of B-cell, T-cell, or ambiguous lineageMore common gene partners in AML:MLLT1(ENL),MLLT10(AF10),MLLT4(AF6)",
                    "sub_points": [
                      "Seen in some acute leukemias of B-cell, T-cell, or ambiguous lineage",
                      "More common gene partners in AML:MLLT1(ENL),MLLT10(AF10),MLLT4(AF6)"
                    ]
                  }
                ],
                "Cytogenetics": [
                  {
                    "text": "Rearrangements involving 11q23 are typically readily evidentSecondary cytogenetic abnormalities common",
                    "sub_points": [
                      "Secondary cytogenetic abnormalities common"
                    ]
                  },
                  {
                    "text": "Rarely, complex, unusual, or cryptic rearrangements make detection difficult or impossibleFISH forKMT2Arearrangement should be performed",
                    "sub_points": [
                      "FISH forKMT2Arearrangement should be performed"
                    ]
                  }
                ],
                "Molecular Detection of Fusion Transcripts": [
                  {
                    "text": "RNA-seq may determine exact nature of rearrangement or identify partner gene in translocationsKMT2Apartial tandem duplication is seen in myelodysplastic syndrome and AML and does not meet criteria for AML withKMT2Arearrangement",
                    "sub_points": [
                      "KMT2Apartial tandem duplication is seen in myelodysplastic syndrome and AML and does not meet criteria for AML withKMT2Arearrangement"
                    ]
                  },
                  {
                    "text": "rt-PCR may be used for measurable residual disease testingNot available for all rearrangementsAssessment of transcript levels while on therapy may aid in disease monitoringDetection of transcript after attaining remission negativity may predict early relapse prior to clinical &/or morphologic relapse",
                    "sub_points": [
                      "Not available for all rearrangements",
                      "Assessment of transcript levels while on therapy may aid in disease monitoring",
                      "Detection of transcript after attaining remission negativity may predict early relapse prior to clinical &/or morphologic relapse"
                    ]
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "Not routinely used in clinical care"
                  },
                  {
                    "text": "Can identify cases with crypticKMT2Arearrangements"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Acute Myelomonocytic Leukemia, Not Otherwise Specified (WHO-HAEM5 Only)": [
                  {
                    "text": "AbsenceofKMT2Arearrangement or any other AML-type recurrent cytogenetic abnormality"
                  },
                  {
                    "text": "Presence of ≥ 20% blasts/equivalentsand≥ 20% maturing granulocytes and ≥ 20% monocytic lineage cells"
                  }
                ],
                "Chronic Myelomonocytic Leukemia (Especially Chronic Myelomonocytic Leukemia-2)": [
                  {
                    "text": "10-19% blasts/blast equivalents in chronic myelomonocytic leukemia (CMML)-2"
                  },
                  {
                    "text": "Lack of t(9;11) or otherKMT2Atranslocation"
                  },
                  {
                    "text": "Often background granulocytic and megakaryocytic dysplasia"
                  },
                  {
                    "text": "Clonal; no recurrent cytogenetic abnormalities"
                  }
                ],
                "Blastic Plasmacytoid Dendritic Cell Neoplasm": [
                  {
                    "text": "CD4, CD56, and CD123 (+); lysozyme and MPO (-)"
                  },
                  {
                    "text": "KMT2Arearrangements very rare"
                  }
                ],
                "Myeloid Neoplasm Post Cytotoxic Therapy (WHO-HAEM5 Only)": [
                  {
                    "text": "Also enriched inKMT2Arearrangements"
                  },
                  {
                    "text": "History of cytotoxic therapy"
                  }
                ],
                "G-CSF": [
                  {
                    "text": "History of G-CSF administration"
                  },
                  {
                    "text": "Neutrophilia and monocytosis with left shift and blasts"
                  },
                  {
                    "text": "Hypercellular bone marrow"
                  },
                  {
                    "text": "Nonclonal and transient"
                  }
                ],
                "Juvenile Myelomonocytic Leukemia": [
                  {
                    "text": "≤ 20% blasts/blast equivalents"
                  },
                  {
                    "text": "Lack of t(9;11) or otherKMT2Atranslocation"
                  },
                  {
                    "text": "Monosomy 7 in ~ 30% of cases"
                  },
                  {
                    "text": "5 mutations involving primarily RAS pathway genes define specific juvenile myelomonocytic leukemia subtypes"
                  }
                ],
                "AML With Inv(16)(p13.1q22)/t(16;16)(p13.1;q22)/CBFB::MYH11": [
                  {
                    "text": "Often has conspicuous monocytic component; ≥ 10% blast threshold"
                  },
                  {
                    "text": "Has abnormal eosinophils with coarse basophilic granules"
                  },
                  {
                    "text": "Presence of inv(16), t(16;16), orCBFB::MYH11abnormality"
                  }
                ],
                "Chronic Myeloid Leukemia": [
                  {
                    "text": "Monocytes typically comprise < 5% of WBCs"
                  },
                  {
                    "text": "Diagnosis confirmed by detectingBCR::ABL1fusion or t(9;22)"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Extramedullary disease predilectionSkin, gingiva, CNS",
                    "sub_points": [
                      "Skin, gingiva, CNS"
                    ]
                  },
                  {
                    "text": "DIC"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Abnormal CBC and blood smear morphologyVariable WBC count with immature monocytesAnemia, thrombocytopenia, and neutropenia",
                    "sub_points": [
                      "Variable WBC count with immature monocytes",
                      "Anemia, thrombocytopenia, and neutropenia"
                    ]
                  },
                  {
                    "text": "Abnormal bone marrow morphologySheets of blasts &/or monocytic blast equivalents",
                    "sub_points": [
                      "Sheets of blasts &/or monocytic blast equivalents"
                    ]
                  },
                  {
                    "text": "Cytogenetics11q23 rearrangements, including t(9;11), seen on karyotypeFISH to detect/confirmKMT2Agene rearrangement",
                    "sub_points": [
                      "11q23 rearrangements, including t(9;11), seen on karyotype",
                      "FISH to detect/confirmKMT2Agene rearrangement"
                    ]
                  },
                  {
                    "text": "Molecular studiesDetection ofKMT2A::MLLT3transcript levels may be useful for measurable residual disease monitoringMyeloid gene molecular profile may influence treatment and prognosis",
                    "sub_points": [
                      "Detection ofKMT2A::MLLT3transcript levels may be useful for measurable residual disease monitoring",
                      "Myeloid gene molecular profile may influence treatment and prognosis"
                    ]
                  },
                  {
                    "text": "Other ancillary testsPhenotype: Establish monocytic/myeloid lineageCytochemistry: Confirm monocytic component if NSE(+)",
                    "sub_points": [
                      "Phenotype: Establish monocytic/myeloid lineage",
                      "Cytochemistry: Confirm monocytic component if NSE(+)"
                    ]
                  }
                ]
              },
              "REPORTING": {
                "Diagnostic Tips": [
                  {
                    "text": "Diagnose AML with t(9;11)(p21.3;q23.3);MLLT3::KMT2A(ICC only)≥ 10% blasts/blast equivalents",
                    "sub_points": [
                      "≥ 10% blasts/blast equivalents"
                    ]
                  },
                  {
                    "text": "Diagnose AML withKMT2Arearrangement (ICC and WHO-HAEM5)≥ 10% blasts/blast equivalents (ICC only); no blast threshold for WHO-HAEM5",
                    "sub_points": [
                      "≥ 10% blasts/blast equivalents (ICC only); no blast threshold for WHO-HAEM5"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Acute Myeloid Leukemia With t(6;9)(p22;q34); DEK-NUP214": {
            "name": "Acute Myeloid Leukemia With t(6;9)(p22;q34); DEK-NUP214",
            "url": "https://app.pathprimer.com/document/4e171990-e7ee-4778-88ae-fb5cb36d88e4/lesson/e328b112-0403-4322-9b2b-5e6e7ecbe471",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Acute myeloid leukemia (AML) with fusion ofDEKandNUP214genes via t(6;9)(p23;q34)"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Median white blood cell (WBC) count at presentation ~12 x 10⁹/LTypically lower than other AMLs",
                    "sub_points": [
                      "Typically lower than other AMLs"
                    ]
                  },
                  {
                    "text": "Basophilia common"
                  },
                  {
                    "text": "Poor prognosis (median survival ~ 1 year)"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Bone marrowIncreased basophils (> 2%) in ~ 50% of patientsMultilineage dysplasia present in most casesErythroid hyperplasia commonBlasts ≥ 20%; nonspecific blast morphology",
                    "sub_points": [
                      "Increased basophils (> 2%) in ~ 50% of patients",
                      "Multilineage dysplasia present in most cases",
                      "Erythroid hyperplasia common",
                      "Blasts ≥ 20%; nonspecific blast morphology"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "FLT3ITD mutations are common (~ 70% of cases)"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Acute myeloid leukemia (AML) with translocation t(6;9)(23;q34) leading to fusion ofDEKandNUP214genes"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "1% of AML in both pediatric and adult populations"
                  },
                  {
                    "text": "Median age at presentationChildren: 13 yearsAdults: 35 years",
                    "sub_points": [
                      "Children: 13 years",
                      "Adults: 35 years"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Cytopenias"
                  },
                  {
                    "text": "Basophilia is common"
                  },
                  {
                    "text": "Median WBC count at presentation ~12 x 10⁹/LTypically lower than other AMLs",
                    "sub_points": [
                      "Typically lower than other AMLs"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Allogeneic transplant usually recommended due to poor prognosis"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "PoorMedian survival ~ 1 year",
                    "sub_points": [
                      "Median survival ~ 1 year"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Bone marrowIncreased basophils (> 2%) in ~ 50% of patientsMultilineage dysplasia present in most casesErythroid hyperplasia is commonBlasts ≥ 20%; nonspecific blast morphologyMay present with a low blast count (< 20%)",
                    "sub_points": [
                      "Increased basophils (> 2%) in ~ 50% of patients",
                      "Multilineage dysplasia present in most cases",
                      "Erythroid hyperplasia is common",
                      "Blasts ≥ 20%; nonspecific blast morphologyMay present with a low blast count (< 20%)",
                      "May present with a low blast count (< 20%)"
                    ]
                  },
                  {
                    "text": "Peripheral bloodAnisopoikilocytosisHypogranular neutrophilsNucleated red blood cellsHypogranular platelets",
                    "sub_points": [
                      "Anisopoikilocytosis",
                      "Hypogranular neutrophils",
                      "Nucleated red blood cells",
                      "Hypogranular platelets"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Flow Cytometry": [
                  {
                    "text": "Nonspecific myeloid blast immunophenotype with coexpression of CD45, CD13, CD33, HLA-DR, MPO"
                  },
                  {
                    "text": "Variable expression of CD34, CD15, CD11c"
                  },
                  {
                    "text": "~ 50-60% of cases are TdT positive"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "t(6;9)(23;q34) leads to fusion ofDEKgene on chromosome 6 andNUP214gene on chromosome 9"
                  },
                  {
                    "text": "Fusion product is chimeric protein containing full-length DEK protein and C-terminal two-thirds of NUP214 proteinNucleoporin fusion proteinEnhances protein translocationActivates mTOR pathway and downstream proliferation",
                    "sub_points": [
                      "Nucleoporin fusion proteinEnhances protein translocationActivates mTOR pathway and downstream proliferation",
                      "Enhances protein translocation",
                      "Activates mTOR pathway and downstream proliferation"
                    ]
                  },
                  {
                    "text": "DEKgene:Locus =6p22.3, although chromosome 6 breakpoint in t(6;9) has been historically designated as 6p23Gene product functions as a chromatin-remodeling proteinBinds DNA proximal to promoters to repress/activate transcriptionInduces DNA-positive supercoiling",
                    "sub_points": [
                      "Gene product functions as a chromatin-remodeling proteinBinds DNA proximal to promoters to repress/activate transcriptionInduces DNA-positive supercoiling",
                      "Binds DNA proximal to promoters to repress/activate transcription",
                      "Induces DNA-positive supercoiling"
                    ]
                  },
                  {
                    "text": "NUP214gene:Locus =9q34.1Gene product is a nucleoporinGene product functions as part of nuclear membrane pore involved in molecular transport between nucleus and cytoplasm",
                    "sub_points": [
                      "Gene product is a nucleoporin",
                      "Gene product functions as part of nuclear membrane pore involved in molecular transport between nucleus and cytoplasm"
                    ]
                  }
                ],
                "Molecular Genetics": [
                  {
                    "text": "FLT3ITD mutations are common (~ 70% of cases)"
                  },
                  {
                    "text": "RT-PCRLimited breakpoints for detection of fusion transcriptUseful to detect molecular relapse",
                    "sub_points": [
                      "Limited breakpoints for detection of fusion transcript",
                      "Useful to detect molecular relapse"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Acute Myeloid Leukemia, Not Otherwise Specified": [
                  {
                    "text": "Basophilia less frequent"
                  },
                  {
                    "text": "No t(6;9)(p23;q34) translocation"
                  }
                ],
                "Chronic Myelogenous Leukemia With Blast Transformation": [
                  {
                    "text": "Chronic myelogenous leukemia (CML) will have a BCR-ABL1 translocation"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Acute Myeloid Leukemia With inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1": {
            "name": "Acute Myeloid Leukemia With inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1",
            "url": "https://app.pathprimer.com/document/554f49ca-cfdb-4313-b2ef-cc2b93ec0bcc/lesson/e328b112-0403-4322-9b2b-5e6e7ecbe471",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "AML with fusion ofRPN1andMECOM(EVI1) genes"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) placesMECOMunder strong promoter of housekeeping geneRibophorin 1(RPN1)"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Poor prognosis"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Multilineage dysplasia"
                  },
                  {
                    "text": "Atypical megakaryocytes (small and hypolobated) most common"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "50% of cases have concurrent monosomy 7"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Acute myeloid leukemia (AML)"
                  },
                  {
                    "text": "Myelodysplastic syndrome (MDS)"
                  },
                  {
                    "text": "Myeloperoxidase (MPO)"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Function ofRPN1Gene Product": [
                  {
                    "text": "Housekeeping membrane protein found only in rough endoplasmic reticulumComponent of N-oligosaccharyltransferase complexTransfers high mannose oligosaccharides to asparagine residues in nascent polypeptide chains",
                    "sub_points": [
                      "Component of N-oligosaccharyltransferase complexTransfers high mannose oligosaccharides to asparagine residues in nascent polypeptide chains",
                      "Transfers high mannose oligosaccharides to asparagine residues in nascent polypeptide chains"
                    ]
                  }
                ],
                "Function ofMECOMLocus": [
                  {
                    "text": "Encodes 2 proteins via alternative splicing and distinct transcription sitesEVI1 proteinTranscription factor with zinc finger DNA binding motifsInteracts with other coactivators and corepressorsExpression upregulated at promyelocyte stageMDS1-EVI1 proteinContains 188 additional amino acids at N-terminus of EVI1 proteinIncludes PRDI-BF1-RIZ1 (PR) domain with methyltransferase activity",
                    "sub_points": [
                      "EVI1 proteinTranscription factor with zinc finger DNA binding motifsInteracts with other coactivators and corepressorsExpression upregulated at promyelocyte stage",
                      "Transcription factor with zinc finger DNA binding motifs",
                      "Interacts with other coactivators and corepressors",
                      "Expression upregulated at promyelocyte stage",
                      "MDS1-EVI1 proteinContains 188 additional amino acids at N-terminus of EVI1 proteinIncludes PRDI-BF1-RIZ1 (PR) domain with methyltransferase activity",
                      "Contains 188 additional amino acids at N-terminus of EVI1 protein",
                      "Includes PRDI-BF1-RIZ1 (PR) domain with methyltransferase activity"
                    ]
                  }
                ],
                "Function ofRPN1-MECOMFusion": [
                  {
                    "text": "inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) placesMECOMunder strong promoter of housekeeping gene ﻿Ribophorin 1 (RPN1)Increases protein expression ofEVI1Enhances cellular differentiation and proliferation, contributing to leukemogenesis",
                    "sub_points": [
                      "Increases protein expression ofEVI1",
                      "Enhances cellular differentiation and proliferation, contributing to leukemogenesis"
                    ]
                  },
                  {
                    "text": "inv(3)(q21.3q26.2) breaks 3' ofEVI1region"
                  },
                  {
                    "text": "t(3;3)(q21.3;q26.2) breaks 5' ofEVI1region"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Incidence1-2% of AML",
                    "sub_points": [
                      "1-2% of AML"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Occurs most commonly in adults"
                  },
                  {
                    "text": "Median age: 56 years"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Typically presents with anemia and normal or elevated platelet count"
                  },
                  {
                    "text": "De novo or arising from MDS"
                  },
                  {
                    "text": "Hepatosplenomegaly in some patients"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Allogeneic hematopoietic stem cell transplantation"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Poor prognosis"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Peripheral Blood": [
                  {
                    "text": "Dysplastic neutrophilsHypogranular, pseudo–Pelger-Huët anomaly",
                    "sub_points": [
                      "Hypogranular, pseudo–Pelger-Huët anomaly"
                    ]
                  },
                  {
                    "text": "Naked nuclei of megakaryocytes and giant platelets (often hypogranular) are common"
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "Multilineage dysplasiaAtypical megakaryocytes (small and hypolobated) most common",
                    "sub_points": [
                      "Atypical megakaryocytes (small and hypolobated) most common"
                    ]
                  },
                  {
                    "text": "Increased blasts (> 20%) with different morphologiesUndifferentiated, myelocytic, monocytic, or megakaryoblastic",
                    "sub_points": [
                      "Undifferentiated, myelocytic, monocytic, or megakaryoblastic"
                    ]
                  },
                  {
                    "text": "Low MPO activity"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Flow Cytometry": [
                  {
                    "text": "Positive expression of CD34, CD13, CD33, HLA-DR, and CD38"
                  },
                  {
                    "text": "Expression of CD7, or megakaryocytic antigens CD41 and CD61 in subset of cases"
                  }
                ],
                "Molecular Genetics": [
                  {
                    "text": "MECOMgene; MDS1 and EVI1 complex locusGene locus: 3q26.2Size: 580 kb; 22 exons",
                    "sub_points": [
                      "Gene locus: 3q26.2",
                      "Size: 580 kb; 22 exons"
                    ]
                  },
                  {
                    "text": "RPN1gene, Ribophorin IGene locus: 3q21.3Size: 30.9 kb; 10 exons",
                    "sub_points": [
                      "Gene locus: 3q21.3",
                      "Size: 30.9 kb; 10 exons"
                    ]
                  }
                ],
                "Cytogenetics": [
                  {
                    "text": "Karyotype; inv(3) or t(3;3)Secondary abnormalities common50% of cases have concurrent monosomy 7",
                    "sub_points": [
                      "Secondary abnormalities common",
                      "50% of cases have concurrent monosomy 7"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Blast Phase of Chronic Myelogenous Leukemia,BCR-ABL1Positive": [
                  {
                    "text": "RPN1-MECOMfusion may be acquired in progression of CML"
                  },
                  {
                    "text": "BCR-ABL1in addition toRPN1-MECOMsuggests progression of CML"
                  }
                ],
                "MDS WithRPN1-EVI1Fusion": [
                  {
                    "text": "< 20% blasts"
                  }
                ],
                "AML With MDS-Related Changes": [
                  {
                    "text": "Presence of abnormal karyotype in AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) takes precedence over AML with MDS-related changes"
                  }
                ],
                "Acute Megakaryoblastic Leukemia": [
                  {
                    "text": "﻿Presence of abnormal karyotype in AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) takes precedence over acute megakaryoblastic leukemia"
                  }
                ],
                "AML With t(1;22)(p13;q13)": [
                  {
                    "text": "AML with t(1;22)(p13;q13) occurs in very young children vs. AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) seen primarily in adults"
                  },
                  {
                    "text": "Different karyotypic abnormalities"
                  }
                ],
                "Myeloid Proliferations Related to Down Syndrome": [
                  {
                    "text": "AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) is not associated with Down syndrome"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Acute Myeloid Leukemia (Megakaryoblastic) With t(1;22)(p13;q13); RBM15-MKL1": {
            "name": "Acute Myeloid Leukemia (Megakaryoblastic) With t(1;22)(p13;q13); RBM15-MKL1",
            "url": "https://app.pathprimer.com/document/050bf85b-d834-4d3c-9583-d5bc66179901/lesson/e328b112-0403-4322-9b2b-5e6e7ecbe471",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Acute myeloid leukemia with translocation t(1;22)(p13;q13); fusion ofRBM15andMKL1genes"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Affects infants and young children almost exclusively (< 3 years)Median age: 4 monthsOccurs most commonly in infants with Down syndrome",
                    "sub_points": [
                      "Median age: 4 months",
                      "Occurs most commonly in infants with Down syndrome"
                    ]
                  },
                  {
                    "text": "Hepatosplenomegaly or skeletal lesions"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Bone marrow typically has associated reticulin and collagen fibrosis"
                  },
                  {
                    "text": "Blasts show morphological and immunophenotypical features of megakaryoblasts"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13)"
                  },
                  {
                    "text": "Acute myeloid leukemia (AML)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Acute myeloid leukemia with translocation t(1;22)(p13;q13); fusion ofRBM15andMKL1genesMegakaryocytic differentiationOccurs almost exclusively in infants",
                    "sub_points": [
                      "Megakaryocytic differentiation",
                      "Occurs almost exclusively in infants"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "RBM15-MKL1﻿ gene fusion": [
                  {
                    "text": "Translocation t(1;22)(p13;q13)"
                  }
                ],
                "RBM15gene": [
                  {
                    "text": "Gene locus: 1p13"
                  },
                  {
                    "text": "Exons: 5"
                  }
                ],
                "MKL1gene": [
                  {
                    "text": "Gene locus: 22q13"
                  },
                  {
                    "text": "Exons: 19"
                  }
                ],
                "Normal Function ofRBM15Gene Product": [
                  {
                    "text": "RBM15 (RNA binding motif protein 15), also known as OTT (\"one twenty-two\")"
                  },
                  {
                    "text": "RNA-binding motifsInteract with spliceosome components",
                    "sub_points": [
                      "Interact with spliceosome components"
                    ]
                  },
                  {
                    "text": "Spen paralog and ortholog C-terminal (SPOC) domainTranscriptional repression or activation",
                    "sub_points": [
                      "Transcriptional repression or activation"
                    ]
                  },
                  {
                    "text": "Chromatin and RNA binding and histone modification"
                  },
                  {
                    "text": "Suppression of myeloid differentiation"
                  }
                ],
                "Normal Function ofMKL1Gene Product": [
                  {
                    "text": "MKL1 (megakaryocyte leukemia-1), a.k.a. MAL (megakaryocytic acute leukemia)"
                  },
                  {
                    "text": "Encodes a DNA-binding motif involved in chromatin organization"
                  },
                  {
                    "text": "Coactivator of serum response factor (SRF)"
                  }
                ],
                "Abnormal Function of RBM15-MKL1 Fusion Protein": [
                  {
                    "text": "Constitutive and deregulated serum response factor (SRF) activation of target genes by MKL1 activity"
                  },
                  {
                    "text": "Chromatin remodeling, HOX-induced differentiation, and extracellular signaling"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "< 1% of all AML"
                  },
                  {
                    "text": "Females > males"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Affects infants and young children almost exclusively (< 3 years)Median age: 4 monthsOccurs most commonly in infants with Down syndrome",
                    "sub_points": [
                      "Median age: 4 months",
                      "Occurs most commonly in infants with Down syndrome"
                    ]
                  },
                  {
                    "text": "Hepatosplenomegaly more common than skeletal lesions"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Anemia"
                  },
                  {
                    "text": "Thrombocytopenia"
                  },
                  {
                    "text": "Moderate leukocytosis"
                  }
                ],
                "Treatment": [
                  {
                    "text": "May have good response with intensive AML chemotherapy and long disease-free survival"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Intermediate"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Bone marrow typically has associated reticulin and collagen fibrosisBone marrow aspirate may be hemodilute or aparticulate due to fibrosisFibrosis may create infiltrative pattern of small round blue cells that mimics metastatic tumor",
                    "sub_points": [
                      "Bone marrow aspirate may be hemodilute or aparticulate due to fibrosis",
                      "Fibrosis may create infiltrative pattern of small round blue cells that mimics metastatic tumor"
                    ]
                  },
                  {
                    "text": "Blasts show morphological and immunophenotypical features of megakaryoblastsMedium-to-large sizeFine nuclear chromatinAgranular basophilic cytoplasm with blebbing or pseudopod formation",
                    "sub_points": [
                      "Medium-to-large size",
                      "Fine nuclear chromatin",
                      "Agranular basophilic cytoplasm with blebbing or pseudopod formation"
                    ]
                  },
                  {
                    "text": "Micromegakaryocytes are common"
                  },
                  {
                    "text": "Granulocytic and erythroid dysplasia are NOT present"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Flow Cytometry": [
                  {
                    "text": "Positive for 1 or more platelet glycoproteins: CD41 (glycoprotein IIb/IIIa), CD61 (glycoprotein IIIa), &/or CD42 (glycoprotein Ib)"
                  },
                  {
                    "text": "CD36 typically positive"
                  },
                  {
                    "text": "Variably positive for CD13, CD33 expression (myeloid marker), CD4, CD7, &/or CD56"
                  },
                  {
                    "text": "CD34, CD45, and HLA-DR often negative"
                  }
                ],
                "Cytogenetics": [
                  {
                    "text": "Translocation t(1;22)(p13;q13)"
                  }
                ],
                "Molecular Genetics": [
                  {
                    "text": "RBM15-MKL1fusion transcript detected by RT-PCR"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Acute megakaryoblastic leukemia": [
                  {
                    "text": "Megakaryoblastic differentiation, but no t(1;22) translocation"
                  }
                ],
                "Acute myeloid leukemia with inv(3)(q21q26) or t(3;3)(q21;q26.2)": [
                  {
                    "text": "Megakaryoblastic differentiation, but different genetic abnormalities"
                  }
                ],
                "Myeloid leukemia associated with Down Syndrome": [
                  {
                    "text": "Megakaryoblastic differentiation, but withGATA1mutation and no t(1;22) translocation"
                  }
                ],
                "Acute panmyelosis with myelofibrosis": [
                  {
                    "text": "Fibrosis and increased blasts, but blasts do not have megakaryocytic differentiation"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Acute Myeloid Leukemia, FAB Classification": {
            "name": "Acute Myeloid Leukemia, FAB Classification",
            "url": "https://app.pathprimer.com/document/14a503b3-80ec-43dd-957a-0c436192b2bf/lesson/e328b112-0403-4322-9b2b-5e6e7ecbe471",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "A morphology-based classification system of AML developed by group of French, American, and British leukemia experts without emphasis on prognostic factors that were addressed by newer WHO classification system"
                  }
                ]
              },
              "OVERVIEW": {
                "Acute Myeloid Leukemia, FAB Classification": [
                  {
                    "text": "Morphology-based classification system"
                  },
                  {
                    "text": "Developed by group of FAB leukemia experts in 1970s to define morphologic subtypes of AML"
                  },
                  {
                    "text": "Prognostic factors not emphasizedAddressed by newer WHO classification system",
                    "sub_points": [
                      "Addressed by newer WHO classification system"
                    ]
                  }
                ],
                "Subtype M0: Acute Myeloid Leukemia With Minimal Differentiation": [
                  {
                    "text": "Blasts are in ≥ 30% peripheral blood or bone marrow"
                  },
                  {
                    "text": "﻿Epidemiology﻿Rare (< 5% of AML cases)Usually present with symptoms of bone marrow failure with anemia, neutropenia, and thrombocytopeniaMost common in infants and older adultsPoor prognosis",
                    "sub_points": [
                      "Rare (< 5% of AML cases)",
                      "Usually present with symptoms of bone marrow failure with anemia, neutropenia, and thrombocytopenia",
                      "Most common in infants and older adults",
                      "Poor prognosis"
                    ]
                  },
                  {
                    "text": "﻿Morphology﻿Blasts are poorly differentiated and may resemble lymphoblastsAgranular cytoplasmNo Auer rods",
                    "sub_points": [
                      "Blasts are poorly differentiated and may resemble lymphoblastsAgranular cytoplasmNo Auer rods",
                      "Agranular cytoplasm",
                      "No Auer rods"
                    ]
                  },
                  {
                    "text": "﻿Immunophenotype﻿Blasts are negative for MPO, CAE, and Sudan Black B by cytochemistry (distinguishes M0 from M1)Express early hematopoietic-associated antigens (CD34, CD38, HLA-DR) and CD13, CD33, and CD117~ 50% coexpress TdT~ 40% coexpress CD7Blasts are negative for myeloid-specific and monocyte-specific antigens (CD11b, CD15, CD14, CD64)Negative for B- and T-cell lymphoid markers (except CD7)",
                    "sub_points": [
                      "Blasts are negative for MPO, CAE, and Sudan Black B by cytochemistry (distinguishes M0 from M1)",
                      "Express early hematopoietic-associated antigens (CD34, CD38, HLA-DR) and CD13, CD33, and CD117~ 50% coexpress TdT~ 40% coexpress CD7",
                      "~ 50% coexpress TdT",
                      "~ 40% coexpress CD7",
                      "Blasts are negative for myeloid-specific and monocyte-specific antigens (CD11b, CD15, CD14, CD64)",
                      "Negative for B- and T-cell lymphoid markers (except CD7)"
                    ]
                  },
                  {
                    "text": "No unique genetic abnormalities"
                  }
                ],
                "Subtype M1: Acute Myeloid Leukemia Without Maturation": [
                  {
                    "text": "Blasts are ≥ 30% in peripheral blood or bone marrow and comprise ≥ 90% of nonerythroid cells in marrow"
                  },
                  {
                    "text": "﻿Epidemiology﻿5-10% of AML casesOccurs in all age groups; majority in adultsUsually present with symptoms of bone marrow failure with anemia, neutropenia, and thrombocytopenia",
                    "sub_points": [
                      "5-10% of AML cases",
                      "Occurs in all age groups; majority in adults",
                      "Usually present with symptoms of bone marrow failure with anemia, neutropenia, and thrombocytopenia"
                    ]
                  },
                  {
                    "text": "﻿Morphology﻿Blasts are variably differentiated; range from myeloid blasts with granules/Auer rods to blasts that resemble lymphoblasts",
                    "sub_points": [
                      "Blasts are variably differentiated; range from myeloid blasts with granules/Auer rods to blasts that resemble lymphoblasts"
                    ]
                  },
                  {
                    "text": "ImmunophenotypeBlasts are positive for MPO or Sudan Black B by cytochemistry (distinguishes M1 from M0)Express 1 or more myeloid-associated antigens (CD13, CD33, and CD117) and often coexpress CD34 &/or HLA-DRTypically negative for granulocyte-specific and monocyte-specific antigens (CD65, CD15, CD14, CD64)CD7 is expressed in ~ 30% of cases",
                    "sub_points": [
                      "Blasts are positive for MPO or Sudan Black B by cytochemistry (distinguishes M1 from M0)",
                      "Express 1 or more myeloid-associated antigens (CD13, CD33, and CD117) and often coexpress CD34 &/or HLA-DR",
                      "Typically negative for granulocyte-specific and monocyte-specific antigens (CD65, CD15, CD14, CD64)",
                      "CD7 is expressed in ~ 30% of cases"
                    ]
                  }
                ],
                "Subtype M2: Acute Myeloid Leukemia With Maturation": [
                  {
                    "text": "Blasts are ≥ 30%, with ≥ 10% of granulocytic cells showing maturation at promyelocyte stage or later"
                  },
                  {
                    "text": "Monocytic cells < 20% of marrow cells"
                  },
                  {
                    "text": "﻿Epidemiology﻿10% of AML casesOccurs in all age groups; majority in adultsPatients present with anemia, neutropenia, and thrombocytopeniaVariable white blood cell count and blast number",
                    "sub_points": [
                      "10% of AML cases",
                      "Occurs in all age groups; majority in adults",
                      "Patients present with anemia, neutropenia, and thrombocytopenia",
                      "Variable white blood cell count and blast number"
                    ]
                  },
                  {
                    "text": "﻿Morphology﻿Variable degrees of dysplasia are often presentBlasts may have granules and commonly have Auer rodsEosinophils, basophils, and mast cells may be increased",
                    "sub_points": [
                      "Variable degrees of dysplasia are often present",
                      "Blasts may have granules and commonly have Auer rods",
                      "Eosinophils, basophils, and mast cells may be increased"
                    ]
                  },
                  {
                    "text": "﻿Immunophenotype﻿Positive for MPO by cytochemistryExpresses myeloid antigens (CD11b, CD13, CD15, CD33, CD65)Express CD34, HLA-DR, &/or CD117 in subset of blastsTypically negative for monocytic markers (CD14 and CD64)CD7 is expressed in ~ 20-30% of cases",
                    "sub_points": [
                      "Positive for MPO by cytochemistry",
                      "Expresses myeloid antigens (CD11b, CD13, CD15, CD33, CD65)",
                      "Express CD34, HLA-DR, &/or CD117 in subset of blasts",
                      "Typically negative for monocytic markers (CD14 and CD64)",
                      "CD7 is expressed in ~ 20-30% of cases"
                    ]
                  }
                ],
                "Subtype M3: Acute Promyelocytic Leukemia": [
                  {
                    "text": "AML with abnormal promyelocytes"
                  },
                  {
                    "text": "Classic APL has PML-RARA fusion or t(15;17)(q22;q21)"
                  },
                  {
                    "text": "Now separately defined category by WHO classification"
                  },
                  {
                    "text": "ATRA can induce complete response in APL with t(15;17)(q22;q21)"
                  },
                  {
                    "text": "﻿Epidemiology﻿5-8% of AML casesBleeding diathesis due to plasmin-dependent primary fibrinolysis and DIC are common",
                    "sub_points": [
                      "5-8% of AML cases",
                      "Bleeding diathesis due to plasmin-dependent primary fibrinolysis and DIC are common"
                    ]
                  },
                  {
                    "text": "﻿Morphology﻿AML with increased abnormal promyelocytes and blasts in bone marrow",
                    "sub_points": [
                      "AML with increased abnormal promyelocytes and blasts in bone marrow"
                    ]
                  },
                  {
                    "text": "2 typesTypical or hypergranular variantAbnormal promyelocytes with irregular and often kidney-shaped or bilobed nucleiNumerous large cytoplasmic granulesNumerous cytoplasmic bundles of Auer rods (“faggot cells”) in most casesHypogranular variantFrequent marked leukocytosisPredominantly bilobed nucleiAbsence or paucity of large cytoplasmic granulesAbundant submicroscopic granules highlighted by strong MPO reactivity",
                    "sub_points": [
                      "Typical or hypergranular variantAbnormal promyelocytes with irregular and often kidney-shaped or bilobed nucleiNumerous large cytoplasmic granulesNumerous cytoplasmic bundles of Auer rods (“faggot cells”) in most cases",
                      "Abnormal promyelocytes with irregular and often kidney-shaped or bilobed nuclei",
                      "Numerous large cytoplasmic granules",
                      "Numerous cytoplasmic bundles of Auer rods (“faggot cells”) in most cases",
                      "Hypogranular variantFrequent marked leukocytosisPredominantly bilobed nucleiAbsence or paucity of large cytoplasmic granulesAbundant submicroscopic granules highlighted by strong MPO reactivity",
                      "Frequent marked leukocytosis",
                      "Predominantly bilobed nuclei",
                      "Absence or paucity of large cytoplasmic granulesAbundant submicroscopic granules highlighted by strong MPO reactivity",
                      "Abundant submicroscopic granules highlighted by strong MPO reactivity"
                    ]
                  },
                  {
                    "text": "﻿Immunophenotype﻿Strongly MPO positive by cytochemistryFlow cytometryHigh side-scatter due to granularity of cytoplasmBright expression of CD33 and CD117, variable expression of CD13, and low to absent expression of CD34 and HLA-DRMay be useful in distinguishing APL from other AML typesNegative to weak CD15, CD65, CD11a, and CD18~ 20% show expression of CD56",
                    "sub_points": [
                      "Strongly MPO positive by cytochemistry",
                      "Flow cytometryHigh side-scatter due to granularity of cytoplasmBright expression of CD33 and CD117, variable expression of CD13, and low to absent expression of CD34 and HLA-DRMay be useful in distinguishing APL from other AML typesNegative to weak CD15, CD65, CD11a, and CD18~ 20% show expression of CD56",
                      "High side-scatter due to granularity of cytoplasm",
                      "Bright expression of CD33 and CD117, variable expression of CD13, and low to absent expression of CD34 and HLA-DRMay be useful in distinguishing APL from other AML types",
                      "May be useful in distinguishing APL from other AML types",
                      "Negative to weak CD15, CD65, CD11a, and CD18",
                      "~ 20% show expression of CD56"
                    ]
                  }
                ],
                "Subtype M4: Acute Myelomonocytic Leukemia": [
                  {
                    "text": "Acute leukemia with both myeloid and monocytic differentiation≥ 30% blasts (including promonocytes) in peripheral blood or bone marrow≥ 20% neutrophils and their precursors in bone marrow≥ 20% monocytes and their precursors in bone marrow",
                    "sub_points": [
                      "≥ 30% blasts (including promonocytes) in peripheral blood or bone marrow",
                      "≥ 20% neutrophils and their precursors in bone marrow",
                      "≥ 20% monocytes and their precursors in bone marrow"
                    ]
                  },
                  {
                    "text": "﻿Epidemiology﻿5-10% of AML casesOccurs in all age groups; more common in adultsPatients present with cytopenias, fever, fatigue",
                    "sub_points": [
                      "5-10% of AML cases",
                      "Occurs in all age groups; more common in adults",
                      "Patients present with cytopenias, fever, fatigue"
                    ]
                  },
                  {
                    "text": "Trisomy 8 present in most cases"
                  },
                  {
                    "text": "﻿Morphology﻿Myeloblasts (medium size)Round to slightly irregular nuclei with fine chromatinScant cytoplasmMonoblasts/promonocytes (large size)Round indented nuclei with delicate lacy chromatin and prominent nucleoliAbundant basophilic cytoplasm with scattered fine azurophilic cytoplasmic granules and vacuoles",
                    "sub_points": [
                      "Myeloblasts (medium size)Round to slightly irregular nuclei with fine chromatinScant cytoplasm",
                      "Round to slightly irregular nuclei with fine chromatin",
                      "Scant cytoplasm",
                      "Monoblasts/promonocytes (large size)Round indented nuclei with delicate lacy chromatin and prominent nucleoliAbundant basophilic cytoplasm with scattered fine azurophilic cytoplasmic granules and vacuoles",
                      "Round indented nuclei with delicate lacy chromatin and prominent nucleoli",
                      "Abundant basophilic cytoplasm with scattered fine azurophilic cytoplasmic granules and vacuoles"
                    ]
                  },
                  {
                    "text": "Peripheral blood typically has increased monocytes"
                  },
                  {
                    "text": "﻿Immunophenotype﻿MPO is positive in at least 3% of blasts, and NSE is positive in monoblasts/promonocytesVariably express myeloid antigens (CD13, CD33, CD15, and CD65) and monocytic antigens (CD4, CD14, CD11b, CD11c, CD64, CD68, CD163, lysozyme)Often subset express CD34, CD117, &/or HLA-DR",
                    "sub_points": [
                      "MPO is positive in at least 3% of blasts, and NSE is positive in monoblasts/promonocytes",
                      "Variably express myeloid antigens (CD13, CD33, CD15, and CD65) and monocytic antigens (CD4, CD14, CD11b, CD11c, CD64, CD68, CD163, lysozyme)",
                      "Often subset express CD34, CD117, &/or HLA-DR"
                    ]
                  }
                ],
                "Subtype M5: Acute Monoblastic and Monocytic Leukemia": [
                  {
                    "text": "≥ 80% of leukemic cells are of monocytic lineage"
                  },
                  {
                    "text": "≥ 30% of blasts or blast equivalents (promonocytes)"
                  },
                  {
                    "text": "﻿Epidemiology﻿~ 10% of AML casesMost common in adults (mean age: 49 years)﻿Bleeding diathesis and extramedullary and CNS lesions common﻿Generally poor prognosis",
                    "sub_points": [
                      "~ 10% of AML cases",
                      "Most common in adults (mean age: 49 years)",
                      "﻿Bleeding diathesis and extramedullary and CNS lesions common﻿",
                      "Generally poor prognosis"
                    ]
                  },
                  {
                    "text": "﻿Morphology﻿Monoblasts are large with round nuclei and abundant basophilic cytoplasmCan exhibitPseudopod formationFine azurophilic granulesCytoplasmic vacuolesFine chromatin with prominent nucleoliPromonocytes can have more convoluted nuclei and are considered blast equivalents﻿Hemophagocytosis observed in cases associated with t(8;16)(p11.2;p13.3)﻿",
                    "sub_points": [
                      "Monoblasts are large with round nuclei and abundant basophilic cytoplasmCan exhibitPseudopod formationFine azurophilic granulesCytoplasmic vacuolesFine chromatin with prominent nucleoli",
                      "Can exhibitPseudopod formationFine azurophilic granulesCytoplasmic vacuolesFine chromatin with prominent nucleoli",
                      "Pseudopod formation",
                      "Fine azurophilic granules",
                      "Cytoplasmic vacuoles",
                      "Fine chromatin with prominent nucleoli",
                      "Promonocytes can have more convoluted nuclei and are considered blast equivalents",
                      "﻿Hemophagocytosis observed in cases associated with t(8;16)(p11.2;p13.3)﻿"
                    ]
                  },
                  {
                    "text": "﻿Immunophenotype﻿NSE is usually positive and MPO negative by cytochemistryLysozyme, CD68, and CD163 (markers of monocytic differentiation) are positive with stainingPositive for immature markers: CD117 > CD34Flow cytometry≥ 2 monocytic markers (CD14, CD4, CD11b, CD11c, CD64, CD68, CD36, lysozyme)Typically coexpress myeloid antigens CD13, CD33, CD15, and CD65Aberrant expression of CD7 ± CD56 in subset of cases (25-40%)",
                    "sub_points": [
                      "NSE is usually positive and MPO negative by cytochemistry",
                      "Lysozyme, CD68, and CD163 (markers of monocytic differentiation) are positive with staining",
                      "Positive for immature markers: CD117 > CD34",
                      "Flow cytometry≥ 2 monocytic markers (CD14, CD4, CD11b, CD11c, CD64, CD68, CD36, lysozyme)Typically coexpress myeloid antigens CD13, CD33, CD15, and CD65Aberrant expression of CD7 ± CD56 in subset of cases (25-40%)",
                      "≥ 2 monocytic markers (CD14, CD4, CD11b, CD11c, CD64, CD68, CD36, lysozyme)",
                      "Typically coexpress myeloid antigens CD13, CD33, CD15, and CD65",
                      "Aberrant expression of CD7 ± CD56 in subset of cases (25-40%)"
                    ]
                  }
                ],
                "Subtype M6: Acute Erythroid Leukemia (Pure Erythroid Leukemia)": [
                  {
                    "text": "﻿Epidemiology﻿Pure cases (Di Guglielmo disease) are extremely rare (< 5% of AML cases)Can occur at any age, including in childhoodSevere anemia ± erythroblasts in circulation are commonRapid clinical progression",
                    "sub_points": [
                      "Pure cases (Di Guglielmo disease) are extremely rare (< 5% of AML cases)",
                      "Can occur at any age, including in childhood",
                      "Severe anemia ± erythroblasts in circulation are common",
                      "Rapid clinical progression"
                    ]
                  },
                  {
                    "text": "﻿Morphology﻿Immature erythroid cells (undifferentiated or proerythroblasts) ≥ 80% of bone marrow cellsErythroblastsMedium to large in size, with round nuclei, fine chromatin, prominent nucleoli﻿Deeply basophilic cytoplasm﻿﻿PAS-positive vacuoles﻿May be smaller and resemble lymphoblasts",
                    "sub_points": [
                      "Immature erythroid cells (undifferentiated or proerythroblasts) ≥ 80% of bone marrow cells",
                      "ErythroblastsMedium to large in size, with round nuclei, fine chromatin, prominent nucleoli﻿Deeply basophilic cytoplasm﻿﻿PAS-positive vacuoles﻿May be smaller and resemble lymphoblasts",
                      "Medium to large in size, with round nuclei, fine chromatin, prominent nucleoli",
                      "﻿Deeply basophilic cytoplasm﻿",
                      "﻿PAS-positive vacuoles﻿",
                      "May be smaller and resemble lymphoblasts"
                    ]
                  },
                  {
                    "text": "﻿Immunophenotype﻿Immunophenotype may be nonspecificMore differentiated cases show expression of glycophorin, hemoglobin A, but are negative for myeloid markersOften negative for CD34, HLA-DRMay be positive for CD36 &/or CD117Negative for MPO and Sudan Black B by cytochemistryPositive for PAS and α-naphthyl esterase",
                    "sub_points": [
                      "Immunophenotype may be nonspecificMore differentiated cases show expression of glycophorin, hemoglobin A, but are negative for myeloid markers",
                      "More differentiated cases show expression of glycophorin, hemoglobin A, but are negative for myeloid markers",
                      "Often negative for CD34, HLA-DR",
                      "May be positive for CD36 &/or CD117",
                      "Negative for MPO and Sudan Black B by cytochemistry",
                      "Positive for PAS and α-naphthyl esterase"
                    ]
                  }
                ],
                "Subtype M7: Acute Megakaryoblastic Leukemia": [
                  {
                    "text": "≥ 30% blasts, with 50% of blasts demonstrating megakaryocytic differentiation"
                  },
                  {
                    "text": "﻿Epidemiology﻿Rare (< 5% of AML cases)Occurs in both adults and childrenTypically present with cytopenias, but thrombocytosis can occur﻿Concurrent primary mediastinal germ cell tumors may occur﻿Poor prognosis; Median survival < 1 year in adults",
                    "sub_points": [
                      "Rare (< 5% of AML cases)",
                      "Occurs in both adults and children",
                      "Typically present with cytopenias, but thrombocytosis can occur",
                      "﻿Concurrent primary mediastinal germ cell tumors may occur﻿",
                      "Poor prognosis; Median survival < 1 year in adults"
                    ]
                  },
                  {
                    "text": "﻿Morphology﻿Peripheral blood can show heterogeneity in platelet size; often with giant formsBone marrowIncreased megakaryoblasts or undifferentiated blastsAggregates of megakaryocytes with dysplastic and monolobated formsMegakaryoblasts are medium-to-large size cellsOval to slightly irregular nuclei with ≥ 1 nucleoliBasophilic, agranular cytoplasm﻿Frequent cytoplasmic blebbing and pseudopod formation﻿Associated marrow fibrosis may occur (results in dry tap)",
                    "sub_points": [
                      "Peripheral blood can show heterogeneity in platelet size; often with giant forms",
                      "Bone marrowIncreased megakaryoblasts or undifferentiated blastsAggregates of megakaryocytes with dysplastic and monolobated forms",
                      "Increased megakaryoblasts or undifferentiated blasts",
                      "Aggregates of megakaryocytes with dysplastic and monolobated forms",
                      "Megakaryoblasts are medium-to-large size cellsOval to slightly irregular nuclei with ≥ 1 nucleoliBasophilic, agranular cytoplasm﻿Frequent cytoplasmic blebbing and pseudopod formation﻿",
                      "Oval to slightly irregular nuclei with ≥ 1 nucleoli",
                      "Basophilic, agranular cytoplasm",
                      "﻿Frequent cytoplasmic blebbing and pseudopod formation﻿",
                      "Associated marrow fibrosis may occur (results in dry tap)"
                    ]
                  },
                  {
                    "text": "﻿Immunophenotype﻿Negative for Sudan Black B, MPO, and CAE by cytochemistryMegakaryoblasts typically positive for ≥ 1 megakaryocytic marker (CD41, CD42b, CD61)Typically negative for CD34, CD45, HLA-DR, TdT, and lymphoid-specific antigens negative on flow cytometryMyeloid antigens CD13 and CD33 may be positive; but negative for MPO and granulocytic antigens",
                    "sub_points": [
                      "Negative for Sudan Black B, MPO, and CAE by cytochemistry",
                      "Megakaryoblasts typically positive for ≥ 1 megakaryocytic marker (CD41, CD42b, CD61)",
                      "Typically negative for CD34, CD45, HLA-DR, TdT, and lymphoid-specific antigens negative on flow cytometry",
                      "Myeloid antigens CD13 and CD33 may be positive; but negative for MPO and granulocytic antigens"
                    ]
                  },
                  {
                    "text": "Exclusion of AML with myelodysplasia-related changes, AML with t(1;22), inv(3), t(3;3), therapy-related AML, and Down syndrome-related cases is required for diagnosis"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "GCSF effect"
                  },
                  {
                    "text": "Blast phase of preexisting myeloproliferative neoplasm or myeloproliferative/myelodysplastic neoplasm"
                  },
                  {
                    "text": "Refractory anemia with excess blasts (RAEB-2)"
                  },
                  {
                    "text": "Acute lymphoblastic leukemia"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Acute myeloid leukemia (AML)"
                  },
                  {
                    "text": "Acute promyelocytic leukemia (APL)"
                  },
                  {
                    "text": "All-trans retinoic acid (ATRA)"
                  },
                  {
                    "text": "Chloroacetate esterase (CAE)"
                  },
                  {
                    "text": "Disseminated intravascular coagulation (DIC)"
                  },
                  {
                    "text": "French-American-British (FAB)"
                  },
                  {
                    "text": "Granulocyte colony-stimulating factor (GCSF)"
                  },
                  {
                    "text": "Myeloperoxidase (MPO)"
                  },
                  {
                    "text": "Not otherwise specified (NOS)"
                  },
                  {
                    "text": "Nonspecific esterase (NSE)"
                  },
                  {
                    "text": "Periodic acid-Schiff (PAS)"
                  },
                  {
                    "text": "World Health Organization (WHO)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Acute myelogenous leukemia"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Myeloid blasts or blast equivalents ≥ 30% of cells in peripheral blood or bone marrow"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Acute Myeloid Leukemia With Myelodysplasia-Related Changes": {
            "name": "Acute Myeloid Leukemia With Myelodysplasia-Related Changes",
            "url": "https://app.pathprimer.com/document/256a0c49-9e8d-4368-a768-9656e0583735/lesson/e328b112-0403-4322-9b2b-5e6e7ecbe471",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Acute myeloid leukemia derived from hematopoietic stem cell, which meets at least 1 of 3 criteriaAntecedent myelodysplasia or myelodysplastic/myeloproliferative neoplasmDysplasia of > 50% of erythroid, megakaryocytic, &/or granulocytic lineage cellsMDS-associated cytogenetic abnormality",
                    "sub_points": [
                      "Antecedent myelodysplasia or myelodysplastic/myeloproliferative neoplasm",
                      "Dysplasia of > 50% of erythroid, megakaryocytic, &/or granulocytic lineage cells",
                      "MDS-associated cytogenetic abnormality"
                    ]
                  },
                  {
                    "text": "Other requirementsMust fulfill blast criteria for AMLAbsence of history of chemotherapy (alkylating agents, topoisomerase II inhibitor therapy) &/or radiotherapyAbsence of AML-defining cytogenetic abnormalities",
                    "sub_points": [
                      "Must fulfill blast criteria for AML",
                      "Absence of history of chemotherapy (alkylating agents, topoisomerase II inhibitor therapy) &/or radiotherapy",
                      "Absence of AML-defining cytogenetic abnormalities"
                    ]
                  },
                  {
                    "text": "Generally similar pathogenetic mechanisms as myelodysplasia (MDS)"
                  },
                  {
                    "text": "Common type of AML in elderly patients"
                  },
                  {
                    "text": "Can occur at any age"
                  },
                  {
                    "text": "Generally aggressive and poorly responsive to therapy"
                  },
                  {
                    "text": "Median survival times generally lower than seen in other AML subtypes"
                  },
                  {
                    "text": "Dysplastic features similar to those described in myelodysplasia"
                  },
                  {
                    "text": "Cytogenetic features may be most predictive of outcome"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Acute myeloid leukemia with myelodysplasia-related changes (AML with MDS-related changes)"
                  },
                  {
                    "text": "Complete blood count (CBC)"
                  },
                  {
                    "text": "Red blood cell (RBC)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Acute myeloid leukemia with multilineage dysplasia"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Acute myeloid leukemia derived from hematopoietic stem cell that meetsat least1 of 3 criteriaAntecedent myelodysplasia (MDS) or myelodysplastic/myeloproliferative neoplasm (MDS/MPN)Multilineage dysplasiaAt least 50% of cells dysplastic in at least 2 lineagesMDS-associated cytogenetic abnormality",
                    "sub_points": [
                      "Antecedent myelodysplasia (MDS) or myelodysplastic/myeloproliferative neoplasm (MDS/MPN)",
                      "Multilineage dysplasiaAt least 50% of cells dysplastic in at least 2 lineages",
                      "At least 50% of cells dysplastic in at least 2 lineages",
                      "MDS-associated cytogenetic abnormality"
                    ]
                  },
                  {
                    "text": "Other requirements includeMust fulfill blast criteria for AML (> 20% blasts in blood or bone marrow)﻿Absence﻿of history of chemotherapy (alkylating agents, topoisomerase II inhibitor therapy) &/or radiotherapyMust ﻿lack﻿AML-defining cytogenetic abnormalities",
                    "sub_points": [
                      "Must fulfill blast criteria for AML (> 20% blasts in blood or bone marrow)",
                      "﻿Absence﻿of history of chemotherapy (alkylating agents, topoisomerase II inhibitor therapy) &/or radiotherapy",
                      "Must ﻿lack﻿AML-defining cytogenetic abnormalities"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Mechanisms of Leukemogenesis": [
                  {
                    "text": "Not well-delineated"
                  },
                  {
                    "text": "Generally thought to be similar pathogenetic mechanisms as myelodysplasia"
                  },
                  {
                    "text": "Often associated with unbalanced cytogenetic abnormalities similar to those seen in MDS"
                  },
                  {
                    "text": "Rarely associated with balanced abnormalities, usually reciprocal translocations"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Age": [
                  {
                    "text": "Can occur at any age, predominates in elderly"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Symptoms or consequences of cytopenias are commonFatigue from anemiaFever from neutropenic infectionBleeding from thrombocytopeniaSymptoms due to hematopoietic failure may be severe",
                    "sub_points": [
                      "Fatigue from anemia",
                      "Fever from neutropenic infection",
                      "Bleeding from thrombocytopenia",
                      "Symptoms due to hematopoietic failure may be severe"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "CBC with differential and morphologic reviewOften multiple numerical and qualitative blood abnormalities presentMay see significant numbers of circulating blasts",
                    "sub_points": [
                      "Often multiple numerical and qualitative blood abnormalities present",
                      "May see significant numbers of circulating blasts"
                    ]
                  },
                  {
                    "text": "Wide variety of other laboratory tests may be utilized to exclude other causes of cytopenias"
                  }
                ],
                "Natural History": [
                  {
                    "text": "Generally aggressive and poorly responsive to therapyException: AML occurring in children with antecedent MDS may be associated with less aggressive disease course",
                    "sub_points": [
                      "Exception: AML occurring in children with antecedent MDS may be associated with less aggressive disease course"
                    ]
                  },
                  {
                    "text": "Cytogenetic features may be most predictive of outcome"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Multiagent AML-specific chemotherapy may be utilized in patients meeting appropriate treatment criteria"
                  },
                  {
                    "text": "Chemotherapy plus allogeneic stem cell transplant optimal for younger, chemotherapy-responsive patients"
                  },
                  {
                    "text": "Palliative therapy for elderly patients or those with significant comorbidities"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Median survival times generally lower than seen in other AML subtypes"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Blood": [
                  {
                    "text": "RBC dysplasia consisting ofAnisopoikilocytosisBasophilic stipplingNucleated RBCs with aberrant nuclear featuresCabot rings",
                    "sub_points": [
                      "Anisopoikilocytosis",
                      "Basophilic stippling",
                      "Nucleated RBCs with aberrant nuclear features",
                      "Cabot rings"
                    ]
                  },
                  {
                    "text": "Granulocytic dysplasia consisting ofHypogranular cytoplasmNuclear hyposegmentation (pseudo-Pelger-Huët) &/or hypersegmentation",
                    "sub_points": [
                      "Hypogranular cytoplasm",
                      "Nuclear hyposegmentation (pseudo-Pelger-Huët) &/or hypersegmentation"
                    ]
                  },
                  {
                    "text": "Myeloblast percentage may exceed 20% in bloodBlasts may contain Auer rods or granulesMay see significant monocytic component with variable immaturityMonoblasts and promonocytes (blast equivalents) are included in blast percentage",
                    "sub_points": [
                      "Blasts may contain Auer rods or granules",
                      "May see significant monocytic component with variable immaturityMonoblasts and promonocytes (blast equivalents) are included in blast percentage",
                      "Monoblasts and promonocytes (blast equivalents) are included in blast percentage"
                    ]
                  },
                  {
                    "text": "Platelet dysplasia consisting ofEnlarged, hypogranular formsCirculating megakaryocyte fragments",
                    "sub_points": [
                      "Enlarged, hypogranular forms",
                      "Circulating megakaryocyte fragments"
                    ]
                  }
                ],
                "Bone Marrow Examination": [
                  {
                    "text": "AspirateAt least 50% of cells in 2 hematopoietic lineages must show dysplastic changesErythroid lineage dysplasia consists ofNuclear irregularities (budding, bridging, abnormal lobation)Megaloblastic changeKaryorrhexisMultinucleationRing sideroblastsGranulocytic dysplasia consists ofHypogranular cytoplasmNuclear hyposegmentation (pseudo-Pelger-Huët) &/or hypersegmentationBizarre nuclear segmentationNuclear to cytoplasmic dyssynchronyPseudo-Chediak-Higashi granulesMegakaryocytic dysplasia on aspirate smear or clot/core biopsy sectionsClusteringSignificant component of megakaryoblasts may be presentSmall megakaryocytes with hypolobated nuclei (micro megs)Megakaryocytes with multiple, separate (pawn ball) nuclear lobesMegakaryocytic component may be inconspicuous by morphologic reviewBlast percentage > 20% (erythroblasts ﻿not﻿included)May contain Auer rods, which are formed of fused lysosomes/primary neutrophilic granules",
                    "sub_points": [
                      "At least 50% of cells in 2 hematopoietic lineages must show dysplastic changes",
                      "Erythroid lineage dysplasia consists ofNuclear irregularities (budding, bridging, abnormal lobation)Megaloblastic changeKaryorrhexisMultinucleationRing sideroblasts",
                      "Nuclear irregularities (budding, bridging, abnormal lobation)",
                      "Megaloblastic change",
                      "Karyorrhexis",
                      "Multinucleation",
                      "Ring sideroblasts",
                      "Granulocytic dysplasia consists ofHypogranular cytoplasmNuclear hyposegmentation (pseudo-Pelger-Huët) &/or hypersegmentationBizarre nuclear segmentationNuclear to cytoplasmic dyssynchronyPseudo-Chediak-Higashi granules",
                      "Hypogranular cytoplasm",
                      "Nuclear hyposegmentation (pseudo-Pelger-Huët) &/or hypersegmentation",
                      "Bizarre nuclear segmentation",
                      "Nuclear to cytoplasmic dyssynchrony",
                      "Pseudo-Chediak-Higashi granules",
                      "Megakaryocytic dysplasia on aspirate smear or clot/core biopsy sectionsClusteringSignificant component of megakaryoblasts may be presentSmall megakaryocytes with hypolobated nuclei (micro megs)Megakaryocytes with multiple, separate (pawn ball) nuclear lobesMegakaryocytic component may be inconspicuous by morphologic review",
                      "Clustering",
                      "Significant component of megakaryoblasts may be present",
                      "Small megakaryocytes with hypolobated nuclei (micro megs)",
                      "Megakaryocytes with multiple, separate (pawn ball) nuclear lobes",
                      "Megakaryocytic component may be inconspicuous by morphologic review",
                      "Blast percentage > 20% (erythroblasts ﻿not﻿included)May contain Auer rods, which are formed of fused lysosomes/primary neutrophilic granules",
                      "May contain Auer rods, which are formed of fused lysosomes/primary neutrophilic granules"
                    ]
                  },
                  {
                    "text": "Bone marrow clot/core biopsyUsually hypercellularIncreased, dysplastic megakaryocytesImmunohistochemistry may be required to detect very small dysplastic megakaryocytesLeft-shifted granulopoiesis with abnormal localization of immature precursorsVariable predominance of erythroid lineage cells with poor colony formation and variable left shift",
                    "sub_points": [
                      "Usually hypercellular",
                      "Increased, dysplastic megakaryocytesImmunohistochemistry may be required to detect very small dysplastic megakaryocytes",
                      "Immunohistochemistry may be required to detect very small dysplastic megakaryocytes",
                      "Left-shifted granulopoiesis with abnormal localization of immature precursors",
                      "Variable predominance of erythroid lineage cells with poor colony formation and variable left shift"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "CD34Highlights blast percentage and abnormal clustering of blastsMay be crucial in inaspirable or poor-quality aspirate specimens",
                    "sub_points": [
                      "Highlights blast percentage and abnormal clustering of blasts",
                      "May be crucial in inaspirable or poor-quality aspirate specimens"
                    ]
                  },
                  {
                    "text": "Myeloperoxidase (MPO)Highlights abnormal localization of immature precursors (ALIP)Clusters of strongly MPO positive cells away from bony trabeculae",
                    "sub_points": [
                      "Highlights abnormal localization of immature precursors (ALIP)Clusters of strongly MPO positive cells away from bony trabeculae",
                      "Clusters of strongly MPO positive cells away from bony trabeculae"
                    ]
                  },
                  {
                    "text": "Hemoglobin A/glycophorin AHighlights erythroid lineage cellsMay show disrupted colony formation with individually dispersed erythroid cells",
                    "sub_points": [
                      "Highlights erythroid lineage cells",
                      "May show disrupted colony formation with individually dispersed erythroid cells"
                    ]
                  },
                  {
                    "text": "CD61/CD42bHighlights number of megakaryocytes and distribution (clustering)Highlights small, inconspicuous megakaryocytes",
                    "sub_points": [
                      "Highlights number of megakaryocytes and distribution (clustering)",
                      "Highlights small, inconspicuous megakaryocytes"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Blast enumeration (does ﻿not﻿replace morphologic count)"
                  },
                  {
                    "text": "Major value in delineation of myeloblasts, monoblasts, and megakaryoblasts"
                  },
                  {
                    "text": "Demonstrates aberrant patterns of antigen expression"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Assess selected cases forNPM1,FLT3, andCEBPAmutations"
                  },
                  {
                    "text": "Detection of balanced and unbalanced abnormalities"
                  },
                  {
                    "text": "MDS-related unbalanced cytogenetic abnormalities include-7/del(7q)-5/del (5q)i(17q)/t(17p)-13/del(13q)del(11q)del(12p)/t(12p)del(9q)idic(X)(q13)",
                    "sub_points": [
                      "-7/del(7q)",
                      "-5/del (5q)",
                      "i(17q)/t(17p)",
                      "-13/del(13q)",
                      "del(11q)",
                      "del(12p)/t(12p)",
                      "del(9q)",
                      "idic(X)(q13)"
                    ]
                  },
                  {
                    "text": "MDS-related balanced abnormalities includet(11;16)(q23;p13.3)t(3;21)(q26.2;q22.1)t(1;3)(p36.3;q21.1)t(2;11)(p21;q23)t(5;12)(q33;p12)t(5;7)(q33;q11.2)t(5;17)(q33;p13)t(5;10)(q33;q21)t(3;5)(q25;q34)",
                    "sub_points": [
                      "t(11;16)(q23;p13.3)",
                      "t(3;21)(q26.2;q22.1)",
                      "t(1;3)(p36.3;q21.1)",
                      "t(2;11)(p21;q23)",
                      "t(5;12)(q33;p12)",
                      "t(5;7)(q33;q11.2)",
                      "t(5;17)(q33;p13)",
                      "t(5;10)(q33;q21)",
                      "t(3;5)(q25;q34)"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Other Myeloid Neoplasms": [
                  {
                    "text": "High-grade MDSBlast percent < 20%Multilineage dysplasia commonCan see Auer rods in refractory anemia with excess blasts (RAEB) 2",
                    "sub_points": [
                      "Blast percent < 20%",
                      "Multilineage dysplasia common",
                      "Can see Auer rods in refractory anemia with excess blasts (RAEB) 2"
                    ]
                  },
                  {
                    "text": "Myelodysplastic/myeloproliferative neoplasmsBlast percent < 20%May see multilineage dysplasiaCan see Auer rods in chronic myelomonocytic leukemia (CMML) 2",
                    "sub_points": [
                      "Blast percent < 20%",
                      "May see multilineage dysplasia",
                      "Can see Auer rods in chronic myelomonocytic leukemia (CMML) 2"
                    ]
                  },
                  {
                    "text": "Other AML subtypesMultilineage dysplasia common in acute erythroid leukemia and other subtypes of AML, not otherwise specified (NOS)AML with MDS-related changes ispreferreddiagnostic label if definitional criteria are metTherapy-related myeloid neoplasms commonly show multilineage dysplasiaPrior therapyexcludesdiagnosis of AML with MDS-related changesClinical information is essential in identifying these patients",
                    "sub_points": [
                      "Multilineage dysplasia common in acute erythroid leukemia and other subtypes of AML, not otherwise specified (NOS)",
                      "AML with MDS-related changes ispreferreddiagnostic label if definitional criteria are met",
                      "Therapy-related myeloid neoplasms commonly show multilineage dysplasiaPrior therapyexcludesdiagnosis of AML with MDS-related changesClinical information is essential in identifying these patients",
                      "Prior therapyexcludesdiagnosis of AML with MDS-related changes",
                      "Clinical information is essential in identifying these patients"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Key Interpretation Issues": [
                  {
                    "text": "Meet AML criteria in blood/bone marrow, > 20% blasts (excluding erythroblasts)"
                  },
                  {
                    "text": "Meet at least 1 of 3 major criteria for AML with MDS-related changesFull cytogenetic karyotyping required to assess for MDS-related cytogenetic abnormalitiesExclude patients with antecedent chemotherapy or those in whom cytogenetics reveals AML-defining karyotypeQuantify extent of dysplasia (must be present in at least 50% of cells in 2 lineages)",
                    "sub_points": [
                      "Full cytogenetic karyotyping required to assess for MDS-related cytogenetic abnormalities",
                      "Exclude patients with antecedent chemotherapy or those in whom cytogenetics reveals AML-defining karyotype",
                      "Quantify extent of dysplasia (must be present in at least 50% of cells in 2 lineages)"
                    ]
                  },
                  {
                    "text": "Recognize that AML with MDS-related changes is biologic subtype of AML and that this diagnostic label \"trumps\" an AML, NOS subtype when criteria are met"
                  },
                  {
                    "text": "Recognize that dysplasia itself may not be prognostically significant"
                  },
                  {
                    "text": "Cytogenetic features may be most predictive of outcome"
                  },
                  {
                    "text": "Integrate molecular genetic results forNPM1,FLT3,andCEBPAinto interpretation"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Therapy-related Myeloid Neoplasms": {
            "name": "Therapy-related Myeloid Neoplasms",
            "url": "https://app.pathprimer.com/document/b389f980-82dc-438f-ba36-02b24e85abc2/lesson/e328b112-0403-4322-9b2b-5e6e7ecbe471",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Clonal myeloid neoplasm arising in setting of antecedent therapy for underlying, unrelated neoplastic or nonneoplastic disorderAlkylating agent therapyWide-field radiation therapy with BM exposureTopoisomerase II inhibitor therapyHigh-dose chemotherapy with autologous stem cell transplant",
                    "sub_points": [
                      "Alkylating agent therapy",
                      "Wide-field radiation therapy with BM exposure",
                      "Topoisomerase II inhibitor therapy",
                      "High-dose chemotherapy with autologous stem cell transplant"
                    ]
                  },
                  {
                    "text": "Therapy-related myeloid neoplasms exhibit spectrum of features fulfilling criteria for various subtypes of myeloid malignancies"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Acquired clonal molecular genetic abnormalities thought to induce t-MNLoss of part or all of chromosomes 5 and 7 following alkylating agent therapyAcquisition of 11q23 (MLL) translocation following topoisomerase II inhibitor therapyAlthough 2 genetic subtypes described, most patients developing t-MN have received both alkylating agents and topoisomerase II inhibitors",
                    "sub_points": [
                      "Loss of part or all of chromosomes 5 and 7 following alkylating agent therapy",
                      "Acquisition of 11q23 (MLL) translocation following topoisomerase II inhibitor therapy",
                      "Although 2 genetic subtypes described, most patients developing t-MN have received both alkylating agents and topoisomerase II inhibitors"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Increasing incidence of t-MN due to improved survival times for antecedent disorders"
                  },
                  {
                    "text": "Patients with alkylating agent-related MN typically present with symptoms of progressive cytopenias"
                  },
                  {
                    "text": "Patients with topoisomerase II inhibitor therapy-related MN typically show abrupt onset of severe symptoms (acute leukemia-like presentation)"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Therapy-related myeloid neoplasm (t-MN)"
                  },
                  {
                    "text": "Therapy-related acute myeloid leukemia (t-AML)"
                  },
                  {
                    "text": "Therapy-related myelodysplasia (t-MDS)"
                  },
                  {
                    "text": "Therapy-related myelodysplastic/myeloproliferative neoplasm (t-MDS/MPN)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Clonal myeloid neoplasm arising in clinical setting of antecedent therapy for underlying, unrelated neoplastic or nonneoplastic disorderAlkylating agent therapyWide field radiation therapy with exposure to bone marrow sitesTopoisomerase II inhibitor therapyHigh-dose chemotherapy with autologous stem cell transplantOther chemotherapeutic agents",
                    "sub_points": [
                      "Alkylating agent therapy",
                      "Wide field radiation therapy with exposure to bone marrow sites",
                      "Topoisomerase II inhibitor therapy",
                      "High-dose chemotherapy with autologous stem cell transplant",
                      "Other chemotherapeutic agents"
                    ]
                  },
                  {
                    "text": "Therapy-related myeloid neoplasms can exhibit spectrum of hematologic and morphologic featuresFulfill criteria for various subtypes of myeloid malignanciest-AMLt-MDSt-MDS/MPNt-MN can occur from 1 to > 10 years following therapy",
                    "sub_points": [
                      "Fulfill criteria for various subtypes of myeloid malignanciest-AMLt-MDSt-MDS/MPNt-MN can occur from 1 to > 10 years following therapy",
                      "t-AML",
                      "t-MDS",
                      "t-MDS/MPN",
                      "t-MN can occur from 1 to > 10 years following therapy"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Genetic Features": [
                  {
                    "text": "Acquired clonal molecular genetic abnormalities thought to induce t-MNLoss of part or all of chromosomes 5 and 7 following alkylating agent therapyMay be associated with other chromosomal losses/gainsAcquisition of 11q23 (MLL) translocation following topoisomerase II inhibitor therapyMLLis topoisomerase II cleavage siteAlthough 2 genetic subtypes described, most patients developing t-MN have received both alkylating agents and topoisomerase II inhibitorsSome occupational exposures may induce t-MN-like disordersSome patients who develop t-MN may have underlying predispositionGenetic variants (polymorphisms) in genes that metabolize drugsPolymorphisms in DNA repair genes",
                    "sub_points": [
                      "Loss of part or all of chromosomes 5 and 7 following alkylating agent therapyMay be associated with other chromosomal losses/gains",
                      "May be associated with other chromosomal losses/gains",
                      "Acquisition of 11q23 (MLL) translocation following topoisomerase II inhibitor therapyMLLis topoisomerase II cleavage site",
                      "MLLis topoisomerase II cleavage site",
                      "Although 2 genetic subtypes described, most patients developing t-MN have received both alkylating agents and topoisomerase II inhibitors",
                      "Some occupational exposures may induce t-MN-like disorders",
                      "Some patients who develop t-MN may have underlying predispositionGenetic variants (polymorphisms) in genes that metabolize drugsPolymorphisms in DNA repair genes",
                      "Genetic variants (polymorphisms) in genes that metabolize drugs",
                      "Polymorphisms in DNA repair genes"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Increasing incidence of t-MN due to improved survival times for antecedent disorders"
                  },
                  {
                    "text": "Up to 20% of older patients with AML have history of antecedent chemotherapy or toxic occupational exposure"
                  }
                ],
                "Age": [
                  {
                    "text": "Can occur over wide age range"
                  },
                  {
                    "text": "Occurs in children and adolescents treated for pediatric tumors such as sarcomas"
                  },
                  {
                    "text": "Occurs in adults treated for wide variety of hematopoietic and nonhematopoietic neoplasms"
                  },
                  {
                    "text": "Occurs in adults treated with chemotherapy for diverse nonneoplastic conditions"
                  },
                  {
                    "text": "Highest incidence of t-MN in older patients with antecedent substantial alkylating agent therapyOften multiple courses of therapy",
                    "sub_points": [
                      "Often multiple courses of therapy"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "No distinctive gender predilection"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "No distinctive ethnic associations"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Patients with alkylating agent-related MN typically present with symptoms of progressive cytopeniasGenerally manifest 5-10 years following alkylating agent therapyMyelodysplasia (MDS)-like presentationGradual worsening of symptomatology over monthsSingle-lineage or multilineage cytopenias that may become severeProgressive dysplasias",
                    "sub_points": [
                      "Generally manifest 5-10 years following alkylating agent therapy",
                      "Myelodysplasia (MDS)-like presentation",
                      "Gradual worsening of symptomatology over months",
                      "Single-lineage or multilineage cytopenias that may become severe",
                      "Progressive dysplasias"
                    ]
                  },
                  {
                    "text": "Patients with topoisomerase II inhibitor therapy-related myeloid neoplasm (MN) typically exhibit abrupt onset of symptomatologyGenerally manifest 1-5 years following topoisomerase II inhibitor therapyAcute presentation, AML-like pictureSevere hematopoietic failure-induced cytopenias",
                    "sub_points": [
                      "Generally manifest 1-5 years following topoisomerase II inhibitor therapy",
                      "Acute presentation, AML-like picture",
                      "Severe hematopoietic failure-induced cytopenias"
                    ]
                  },
                  {
                    "text": "High incidence of t-MDS in patients undergoing high-dose chemotherapy followed by autologous stem cell transplant for underlying neoplasmsStandard treatment for various neoplasms including myeloma",
                    "sub_points": [
                      "Standard treatment for various neoplasms including myeloma"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Complete blood count (CBC) with differential and morphologic reviewAssess for features of t-AML, t-MDS, or t-MDS/MPN",
                    "sub_points": [
                      "Assess for features of t-AML, t-MDS, or t-MDS/MPN"
                    ]
                  },
                  {
                    "text": "Numerous other tests to exclude other causes of cytopenias or other CBC abnormalities"
                  }
                ],
                "Natural History": [
                  {
                    "text": "t-MN of any subtype is generally clinically aggressive and poorly responsive to therapy"
                  }
                ],
                "Treatment": [
                  {
                    "text": "TherapyTraditional antileukemic therapy not curative in most patients with t-MNAllogeneic stem cell transplant in selected patients",
                    "sub_points": [
                      "Traditional antileukemic therapy not curative in most patients with t-MN",
                      "Allogeneic stem cell transplant in selected patients"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Cytogenetic features of t-MN key prognostic factor"
                  },
                  {
                    "text": "Median survival times < 1 year for alkylating agent-related MN with complex unbalanced chromosomal abnormalities & loss of genetic material"
                  },
                  {
                    "text": "Somewhat longer median survival time for patients with t-MN associated with balanced translocations"
                  },
                  {
                    "text": "Outcome may not be linked to blast percentage or other morphologic criteria for subclassification as AML vs. MDS vs. MDS/MPN"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Blood": [
                  {
                    "text": "Prototypic alkylating agent-related subtypeVariably severe, progressive cytopeniasPancytopenia may be presentProminent dysplasia, often multilineageLeft shift, variable percent blasts, may be low",
                    "sub_points": [
                      "Variably severe, progressive cytopenias",
                      "Pancytopenia may be present",
                      "Prominent dysplasia, often multilineage",
                      "Left shift, variable percent blasts, may be low"
                    ]
                  },
                  {
                    "text": "Prototypic topoisomerase II inhibitor therapy-related subtypeSevere anemia, thrombocytopenia, and neutropeniaVariable WBC, often elevatedBlasts often > 20%Often monoblastic, acute monocytic, or acute myelomonocytic leukemiasOther AML subtypes include APL and AML with maturation &/or eosinophiliaEach of these subtypes linked to balanced translocation",
                    "sub_points": [
                      "Severe anemia, thrombocytopenia, and neutropenia",
                      "Variable WBC, often elevated",
                      "Blasts often > 20%",
                      "Often monoblastic, acute monocytic, or acute myelomonocytic leukemias",
                      "Other AML subtypes include APL and AML with maturation &/or eosinophiliaEach of these subtypes linked to balanced translocation",
                      "Each of these subtypes linked to balanced translocation"
                    ]
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "Prototypic alkylating agent-related subtypeVariable cellularity, often hypercellularMultilineage dysplasia, may be strikingIncreased small hypolobated megakaryocytesVariable blast percentage (< 5% up to > 20%)Variable fibrosis, but common",
                    "sub_points": [
                      "Variable cellularity, often hypercellular",
                      "Multilineage dysplasia, may be striking",
                      "Increased small hypolobated megakaryocytes",
                      "Variable blast percentage (< 5% up to > 20%)",
                      "Variable fibrosis, but common"
                    ]
                  },
                  {
                    "text": "Prototypic topoisomerase II inhibitor-related subtypeHypercellular bone marrowMorphologic features of acute monoblastic/monocytic/myelomonocytic leukemiaLinked to 11q23 translocationsOther subtypes linked to different balanced translocationsAcute promyelocytic leukemia with t(15;17)(q22;q12)Acute myeloid leukemia with t(8;21)(q22;q22)Acute myeloid leukemia with eosinophilia with inv 16(p13q22)Blasts/blast equivalents usually (not always) exceed 20%",
                    "sub_points": [
                      "Hypercellular bone marrow",
                      "Morphologic features of acute monoblastic/monocytic/myelomonocytic leukemiaLinked to 11q23 translocations",
                      "Linked to 11q23 translocations",
                      "Other subtypes linked to different balanced translocationsAcute promyelocytic leukemia with t(15;17)(q22;q12)Acute myeloid leukemia with t(8;21)(q22;q22)Acute myeloid leukemia with eosinophilia with inv 16(p13q22)",
                      "Acute promyelocytic leukemia with t(15;17)(q22;q12)",
                      "Acute myeloid leukemia with t(8;21)(q22;q22)",
                      "Acute myeloid leukemia with eosinophilia with inv 16(p13q22)",
                      "Blasts/blast equivalents usually (not always) exceed 20%"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "CD34Blast percentage and clusteringException: Not all myeloid blasts are CD34(+)",
                    "sub_points": [
                      "Blast percentage and clustering",
                      "Exception: Not all myeloid blasts are CD34(+)"
                    ]
                  },
                  {
                    "text": "Bone marrow immunoarchitectureMyeloperoxidase highlights abnormal localization of immature myeloid precursorsHemoglobin A/glycophorin A to assess erythroid lineage colony formation",
                    "sub_points": [
                      "Myeloperoxidase highlights abnormal localization of immature myeloid precursors",
                      "Hemoglobin A/glycophorin A to assess erythroid lineage colony formation"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Assess lineage of immature cell populations"
                  },
                  {
                    "text": "Assess for aberrant antigen expression profile"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Assess for balanced vs. unbalanced chromosomal abnormalitiesBalanced AML-type translocationsLoss of genetic material in unbalanced (numerical) abnormalities common; some cases also show gains",
                    "sub_points": [
                      "Balanced AML-type translocations",
                      "Loss of genetic material in unbalanced (numerical) abnormalities common; some cases also show gains"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Other Myeloid Neoplasms": [
                  {
                    "text": "Not linked to antecedent chemotherapy"
                  },
                  {
                    "text": "De novo presentation"
                  },
                  {
                    "text": "May be morphologically and genetically identical to t-MN"
                  },
                  {
                    "text": "Subclassified based on WHO 2008 morphologic and genetic criteria"
                  }
                ],
                "Chemotherapy-Induced Dysplasia and Bone Marrow Suppression": [
                  {
                    "text": "Proximate torecentnot remote chemotherapy"
                  },
                  {
                    "text": "Usually resolves after chemotherapy discontinued"
                  },
                  {
                    "text": "Long-term bone marrow suppression in some patients"
                  }
                ],
                "Coincidental Myeloid Neoplasm in Patients with History of Chemotherapy": [
                  {
                    "text": "Lacks prototypic morphologic or genetic features of the 2 t-MN subtypes"
                  },
                  {
                    "text": "Appears to be unrelated to antecedent chemotherapy"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Key Strategies": [
                  {
                    "text": "Comprehensive morphologic, immunophenotypic, and genetic assessment of all myeloid neoplasms"
                  },
                  {
                    "text": "Suspect possible t-MN ifMorphologic and genetic features suggest distinctive t-MN subtypesPatient has compelling history of chemotherapy &/or radiation exposure",
                    "sub_points": [
                      "Morphologic and genetic features suggest distinctive t-MN subtypes",
                      "Patient has compelling history of chemotherapy &/or radiation exposure"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Myeloid Proliferations Related to Down Syndrome": {
            "name": "Myeloid Proliferations Related to Down Syndrome",
            "url": "https://app.pathprimer.com/document/9984963c-4cef-40a2-9a9e-499ba9007d1f/lesson/e328b112-0403-4322-9b2b-5e6e7ecbe471",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Myeloid proliferations related to Down syndrome (MPRDS) encompasses transient abnormal myelopoiesis (TAM) and myeloid leukemia associated with Down syndrome (MLADS)"
                  },
                  {
                    "text": "Transient abnormal myelopoiesisUnusual myeloid proliferation resembling acute myeloid leukemia (AML)Resolves spontaneously",
                    "sub_points": [
                      "Unusual myeloid proliferation resembling acute myeloid leukemia (AML)",
                      "Resolves spontaneously"
                    ]
                  },
                  {
                    "text": "Myeloid leukemia associated with Down syndromeIncludes both early, MDS-like phase, and subsequent frank leukemic state",
                    "sub_points": [
                      "Includes both early, MDS-like phase, and subsequent frank leukemic state"
                    ]
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "AcquiredGATA1mutations are present in TAM and MLADS"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "20-30% of patients who develop TAM later develop MLADS"
                  },
                  {
                    "text": "MLADS is associated with chemosensitivity and a good prognosis"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "\"Conventional\" AML in setting of Down syndromePatients with Down syndrome may also develop \"conventional\" AMLThese patients are usually older than age 5 at diagnosisGATA1mutations are absent",
                    "sub_points": [
                      "Patients with Down syndrome may also develop \"conventional\" AML",
                      "These patients are usually older than age 5 at diagnosis",
                      "GATA1mutations are absent"
                    ]
                  },
                  {
                    "text": "Reactive leukocytosis due to neonatal infection"
                  },
                  {
                    "text": "AML with t(1;22)(p13;q13)"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Down syndromeConstitutional trisomy 21Characterized by a number of congenital and developmental abnormalities, including (in neonate)HypotoniaSlanted palpebral fissuresEpicanthal foldsSingle transverse palmar creaseFrequent cardiac anomaliesRare individuals may be mosaics for trisomy 21In these patients, a subset of cells carry normal chromosome complementPhenotypic effects may be mild, depending on prominence of trisomic cellsVery rarely, phenotypically normal mosaic individuals can be affected by myeloid proliferations described in this chapter",
                    "sub_points": [
                      "Constitutional trisomy 21",
                      "Characterized by a number of congenital and developmental abnormalities, including (in neonate)HypotoniaSlanted palpebral fissuresEpicanthal foldsSingle transverse palmar creaseFrequent cardiac anomalies",
                      "Hypotonia",
                      "Slanted palpebral fissures",
                      "Epicanthal folds",
                      "Single transverse palmar crease",
                      "Frequent cardiac anomalies",
                      "Rare individuals may be mosaics for trisomy 21In these patients, a subset of cells carry normal chromosome complementPhenotypic effects may be mild, depending on prominence of trisomic cellsVery rarely, phenotypically normal mosaic individuals can be affected by myeloid proliferations described in this chapter",
                      "In these patients, a subset of cells carry normal chromosome complement",
                      "Phenotypic effects may be mild, depending on prominence of trisomic cells",
                      "Very rarely, phenotypically normal mosaic individuals can be affected by myeloid proliferations described in this chapter"
                    ]
                  },
                  {
                    "text": "Myeloid proliferations related to Down syndrome (MPRDS)Major category of myeloid neoplasia in 2008 WHO classificationIncludes 2 distinct entitiesTransient abnormal myelopoiesis (TAM)Unusual myeloid proliferation resembling acute myeloid leukemia (AML)Resolves spontaneouslyMyeloid leukemia associated with Down syndrome (MLADS)In patients with Down syndrome, there is no prognostic or therapeutic distinction between states resembling myelodysplastic syndrome (MDS) and AMLThus, MLADS incorporates both of these disease states without regard to blast percentage",
                    "sub_points": [
                      "Major category of myeloid neoplasia in 2008 WHO classification",
                      "Includes 2 distinct entities",
                      "Transient abnormal myelopoiesis (TAM)Unusual myeloid proliferation resembling acute myeloid leukemia (AML)Resolves spontaneously",
                      "Unusual myeloid proliferation resembling acute myeloid leukemia (AML)",
                      "Resolves spontaneously",
                      "Myeloid leukemia associated with Down syndrome (MLADS)In patients with Down syndrome, there is no prognostic or therapeutic distinction between states resembling myelodysplastic syndrome (MDS) and AMLThus, MLADS incorporates both of these disease states without regard to blast percentage",
                      "In patients with Down syndrome, there is no prognostic or therapeutic distinction between states resembling myelodysplastic syndrome (MDS) and AML",
                      "Thus, MLADS incorporates both of these disease states without regard to blast percentage"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Normal Function ofGATA1": [
                  {
                    "text": "GATA1is located at Xp11.23"
                  },
                  {
                    "text": "Encodes transcription factor that binds to specific DNA sequencesNameGATA1derives from protein's recognition of sequences that contain the motif G-A-T-A",
                    "sub_points": [
                      "NameGATA1derives from protein's recognition of sequences that contain the motif G-A-T-A"
                    ]
                  },
                  {
                    "text": "Binding of GATA1 protein modulates transcription of associated genes"
                  },
                  {
                    "text": "Regulation by GATA1 is important in normal erythropoiesis and megakaryopoiesis"
                  },
                  {
                    "text": "GATA1encompasses 6 exonsUse of translation start site in exon 2 results in production of full-length GATA1 proteinThis form of the protein predominates in normal cell",
                    "sub_points": [
                      "Use of translation start site in exon 2 results in production of full-length GATA1 proteinThis form of the protein predominates in normal cell",
                      "This form of the protein predominates in normal cell"
                    ]
                  }
                ],
                "Role ofGATA1Mutation in MPRDS": [
                  {
                    "text": "AcquiredGATA1mutations are present in TAM and MLADSConversely,GATA1mutations are not observed in myeloid neoplasia outside clinical setting of Down syndrome",
                    "sub_points": [
                      "Conversely,GATA1mutations are not observed in myeloid neoplasia outside clinical setting of Down syndrome"
                    ]
                  },
                  {
                    "text": "TheseGATA1mutations result in decreased production of normal full-length GATA1 proteinPremature arrest of translationProtein synthesis can instead proceed from an alternative start site (methionine at position 83)However, use of this alternative exon 3 start site leads to abbreviated (\"short form\") GATA1 proteinThis form lacks amino terminal portion of protein essential for transcriptional activation of some genes",
                    "sub_points": [
                      "Premature arrest of translation",
                      "Protein synthesis can instead proceed from an alternative start site (methionine at position 83)However, use of this alternative exon 3 start site leads to abbreviated (\"short form\") GATA1 proteinThis form lacks amino terminal portion of protein essential for transcriptional activation of some genes",
                      "However, use of this alternative exon 3 start site leads to abbreviated (\"short form\") GATA1 protein",
                      "This form lacks amino terminal portion of protein essential for transcriptional activation of some genes"
                    ]
                  },
                  {
                    "text": "Association between trisomy 21 and acquiredGATA1mutations remains unexplained"
                  }
                ],
                "Etiologic Relationship Between TAM and MLADS": [
                  {
                    "text": "Some studies have detected differences in gene expression profiles between TAM and MLADS blasts"
                  },
                  {
                    "text": "Blasts in MLADS often show clonal cytogenetic abnormalities in addition to constitutional trisomy 21Trisomy 8 is commonly identifiedIn contrast, these additional clonal abnormalities are not characteristic of TAM",
                    "sub_points": [
                      "Trisomy 8 is commonly identified",
                      "In contrast, these additional clonal abnormalities are not characteristic of TAM"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Down syndrome affects approximately 1 in 800 newborns"
                  },
                  {
                    "text": "TAM develops in at least 10% of newborns with Down syndromeTrue incidence may be higher since routine CBCs may not be performed in all cases",
                    "sub_points": [
                      "True incidence may be higher since routine CBCs may not be performed in all cases"
                    ]
                  },
                  {
                    "text": "MLADS develops in 1-2% of patients with Down syndromeUsually occurs by age 4 or 5",
                    "sub_points": [
                      "Usually occurs by age 4 or 5"
                    ]
                  },
                  {
                    "text": "20-30% of patients who develop TAM later develop MLADS"
                  }
                ],
                "Presentation": [
                  {
                    "text": "TAMAcute blastemiaHepatosplenomegalyAverage age at diagnosis is 3-7 daysOnly exceptional cases present after 2 months of ageTAM has also been documented during fetal developmentCan cause hydrops fetalis",
                    "sub_points": [
                      "Acute blastemia",
                      "Hepatosplenomegaly",
                      "Average age at diagnosis is 3-7 daysOnly exceptional cases present after 2 months of age",
                      "Only exceptional cases present after 2 months of age",
                      "TAM has also been documented during fetal developmentCan cause hydrops fetalis",
                      "Can cause hydrops fetalis"
                    ]
                  },
                  {
                    "text": "MLADSMay initially manifest as months-long state with many features similar to refractory cytopenia of childhood",
                    "sub_points": [
                      "May initially manifest as months-long state with many features similar to refractory cytopenia of childhood"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Conventional cytogeneticsConfirms constitutional trisomy 21",
                    "sub_points": [
                      "Confirms constitutional trisomy 21"
                    ]
                  },
                  {
                    "text": "Flow cytometrySimilar findings in TAM and MLADSBlasts express CD13, CD33, CD7, CD117, CD36, CD42, CD61Blasts in TAM are more likely to also express CD34, CD56, and CD41 than are blasts in MLADS",
                    "sub_points": [
                      "Similar findings in TAM and MLADS",
                      "Blasts express CD13, CD33, CD7, CD117, CD36, CD42, CD61Blasts in TAM are more likely to also express CD34, CD56, and CD41 than are blasts in MLADS",
                      "Blasts in TAM are more likely to also express CD34, CD56, and CD41 than are blasts in MLADS"
                    ]
                  },
                  {
                    "text": "Molecular analysisIndicated to detectGATA1mutation if diagnosis as TAM or MLADS is not certain, &/or to determine eligibility for treatment protocol",
                    "sub_points": [
                      "Indicated to detectGATA1mutation if diagnosis as TAM or MLADS is not certain, &/or to determine eligibility for treatment protocol"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "TAMMinority of patients die during TAM episodeHepatic fibrosis significantly contributes to this mortalityIf patients survive acute period of TAM, spontaneous remission is expectedHowever, 20-30% of these patients will later develop MLADSRemaining patients experience durable remission",
                    "sub_points": [
                      "Minority of patients die during TAM episodeHepatic fibrosis significantly contributes to this mortality",
                      "Hepatic fibrosis significantly contributes to this mortality",
                      "If patients survive acute period of TAM, spontaneous remission is expectedHowever, 20-30% of these patients will later develop MLADSRemaining patients experience durable remission",
                      "However, 20-30% of these patients will later develop MLADS",
                      "Remaining patients experience durable remission"
                    ]
                  },
                  {
                    "text": "MLADSGood prognosis in young Down syndrome patients withGATA1mutationsSpecific treatment protocols are indicated for this population",
                    "sub_points": [
                      "Good prognosis in young Down syndrome patients withGATA1mutationsSpecific treatment protocols are indicated for this population",
                      "Specific treatment protocols are indicated for this population"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Morphologic Features of Blasts in TAM and MLADS": [
                  {
                    "text": "Usually megakaryoblastsBasophilic cytoplasmScant basophilic (MPO negative) granulesCytoplasmic blebbing",
                    "sub_points": [
                      "Basophilic cytoplasm",
                      "Scant basophilic (MPO negative) granules",
                      "Cytoplasmic blebbing"
                    ]
                  }
                ],
                "Other Features of TAM": [
                  {
                    "text": "Peripheral bloodThrombocytopeniaGenerally impressive leukocytosis, though some cases have normal white blood cell countBlastemia",
                    "sub_points": [
                      "Thrombocytopenia",
                      "Generally impressive leukocytosis, though some cases have normal white blood cell count",
                      "Blastemia"
                    ]
                  },
                  {
                    "text": "Bone marrowErythroid and megakaryocytic dysplasia",
                    "sub_points": [
                      "Erythroid and megakaryocytic dysplasia"
                    ]
                  }
                ],
                "Other Features of MLADS": [
                  {
                    "text": "Peripheral bloodPronounced dysplasia and macrocytosis are present in early stage of disease, even in absence of blasts",
                    "sub_points": [
                      "Pronounced dysplasia and macrocytosis are present in early stage of disease, even in absence of blasts"
                    ]
                  },
                  {
                    "text": "Bone marrowTrilineage dysplasia",
                    "sub_points": [
                      "Trilineage dysplasia"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "\"Conventional\" AML in Setting of Down Syndrome": [
                  {
                    "text": "Patients with Down syndrome may also develop \"conventional\" AMLThese patients are usually older than age 5 at diagnosisGATA1mutations are absent",
                    "sub_points": [
                      "These patients are usually older than age 5 at diagnosis",
                      "GATA1mutations are absent"
                    ]
                  }
                ],
                "Acute Lymphoblastic Leukemia (ALL) in Setting of Down Syndrome": [
                  {
                    "text": "Patients with Down syndrome also have greatly increased risk of developing ALL"
                  },
                  {
                    "text": "Routine immunophenotyping permits distinction between ALL and MPRDS"
                  }
                ],
                "Reactive Leukocytosis Due to Neonatal Infection": [
                  {
                    "text": "Acute blastemia of TAM is generally in excess of left shift associated with infection or inflammation, though overlap may occurIn uncertain cases, documentation of megakaryoblastic immunophenotype &/orGATA1mutation support a diagnosis of TAMClinical features of infection typically present",
                    "sub_points": [
                      "In uncertain cases, documentation of megakaryoblastic immunophenotype &/orGATA1mutation support a diagnosis of TAM",
                      "Clinical features of infection typically present"
                    ]
                  }
                ],
                "AML With t(1;22)(p13;q13)": [
                  {
                    "text": "Megakaryoblastic leukemia that presents in infants and young childrenThese features overlap significantly with TAM and MLADS",
                    "sub_points": [
                      "These features overlap significantly with TAM and MLADS"
                    ]
                  },
                  {
                    "text": "Though TAM and MLADS are restricted to children with Down syndrome, in rare cases (especially involving trisomy 21 mosaicism), diagnosis of Down syndrome will not yet be established when myeloid proliferation is recognizedThus, conventional cytogenetic analysis, which will detect both trisomy 21 and t(1;22), is essential",
                    "sub_points": [
                      "Thus, conventional cytogenetic analysis, which will detect both trisomy 21 and t(1;22), is essential"
                    ]
                  }
                ],
                "GATA1-Related X-Linked Cytopenia": [
                  {
                    "text": "Familial disorder characterized by inheritedGATA1mutations and cytopenias of variable lineage"
                  },
                  {
                    "text": "Completely unrelated in all respects to Down syndrome and MPRDS"
                  },
                  {
                    "text": "Thus,GATA1-related X-linked cytopenia only enters the differential diagnosis ifGATA1analysis is considered in isolation from clinical findings"
                  },
                  {
                    "text": "However, inheritedGATA1mutations are most often missense mutations and are therefore distinct from those seen in MPRDS"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Myelodysplastic Syndromes": {
        "name": "Myelodysplastic Syndromes",
        "url": "https://app.pathprimer.com/lesson/b91f9007-5151-4611-a335-6c428b56c3e0",
        "topics": {
          "Overview and Classification of Myelodysplastic Syndromes": {
            "name": "Overview and Classification of Myelodysplastic Syndromes",
            "url": "https://app.pathprimer.com/document/c019fb61-fd1a-46db-94c3-ca2d5f8a0cce/lesson/b91f9007-5151-4611-a335-6c428b56c3e0",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Myelodysplastic syndrome (MDS)Refractory cytopenia with unilineage dysplasia (RCUD)Refractory anemia with ring sideroblasts (RARS)Refractory cytopenia with multilineage dysplasia (RCMD)Refractory anemia with excess blasts (RAEB)Myelodysplastic syndrome, unclassifiable (MDS-U)MDS associated with isolated del(5q) (MDS/del5q)Refractory cytopenia of childhood (RCC)",
                    "sub_points": [
                      "Refractory cytopenia with unilineage dysplasia (RCUD)",
                      "Refractory anemia with ring sideroblasts (RARS)",
                      "Refractory cytopenia with multilineage dysplasia (RCMD)",
                      "Refractory anemia with excess blasts (RAEB)",
                      "Myelodysplastic syndrome, unclassifiable (MDS-U)",
                      "MDS associated with isolated del(5q) (MDS/del5q)",
                      "Refractory cytopenia of childhood (RCC)"
                    ]
                  }
                ],
                "Definitions": [
                  {
                    "text": "Myelodysplastic syndromes are a heterogeneous group of molecularly distinct entities that haveVariable degrees of ineffective hematopoiesisSimultaneous proliferation and apoptosis of hematopoietic cells< 20% blasts in marrowPeripheral blood with unexplained and persistent cytopenia(s)< 20% blasts< 1.0 x 10⁹/L monocytesDysplasia in 1 or more myeloid lineagesNeutrophilic myeloidErythroidMegakaryocyticIncreased risk for development of acute myeloid leukemia (AML)",
                    "sub_points": [
                      "Variable degrees of ineffective hematopoiesisSimultaneous proliferation and apoptosis of hematopoietic cells< 20% blasts in marrow",
                      "Simultaneous proliferation and apoptosis of hematopoietic cells",
                      "< 20% blasts in marrow",
                      "Peripheral blood with unexplained and persistent cytopenia(s)< 20% blasts< 1.0 x 10⁹/L monocytes",
                      "< 20% blasts",
                      "< 1.0 x 10⁹/L monocytes",
                      "Dysplasia in 1 or more myeloid lineagesNeutrophilic myeloidErythroidMegakaryocytic",
                      "Neutrophilic myeloid",
                      "Erythroid",
                      "Megakaryocytic",
                      "Increased risk for development of acute myeloid leukemia (AML)"
                    ]
                  },
                  {
                    "text": "2008 WHO classification system for hematologic cancersMDS is 1 of 5 major categories of myeloid neoplasmsOthers include myeloproliferative neoplasms (MPN), MPN/MDS, AML, and myeloid/lymphoid neoplasms with eosinophilia and abnormalities ofPDGFRA,PDGFRB, orFGFR1Criteria apply to diagnostic peripheral blood and bone marrow specimens prior to any definitive therapy",
                    "sub_points": [
                      "MDS is 1 of 5 major categories of myeloid neoplasmsOthers include myeloproliferative neoplasms (MPN), MPN/MDS, AML, and myeloid/lymphoid neoplasms with eosinophilia and abnormalities ofPDGFRA,PDGFRB, orFGFR1",
                      "Others include myeloproliferative neoplasms (MPN), MPN/MDS, AML, and myeloid/lymphoid neoplasms with eosinophilia and abnormalities ofPDGFRA,PDGFRB, orFGFR1",
                      "Criteria apply to diagnostic peripheral blood and bone marrow specimens prior to any definitive therapy"
                    ]
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Age Range": [
                  {
                    "text": "Primarily a disease of elderlyMedian age is 70 years in western countriesAnnual incidence of > 30/100,000 among those aged > 70 yearsPrecedes or related to majority of AML in elderlyMedian age is ~ 10 years younger in Asian countries",
                    "sub_points": [
                      "Median age is 70 years in western countriesAnnual incidence of > 30/100,000 among those aged > 70 yearsPrecedes or related to majority of AML in elderly",
                      "Annual incidence of > 30/100,000 among those aged > 70 years",
                      "Precedes or related to majority of AML in elderly",
                      "Median age is ~ 10 years younger in Asian countries"
                    ]
                  },
                  {
                    "text": "Only ~ 10% of MDS patients are < 50 years of ageRare among childrenIncidence is < 0.01/100,000 individuals per yearOften associated with a genetic disorder or is therapy-related instead of de novo disease",
                    "sub_points": [
                      "Rare among childrenIncidence is < 0.01/100,000 individuals per yearOften associated with a genetic disorder or is therapy-related instead of de novo disease",
                      "Incidence is < 0.01/100,000 individuals per year",
                      "Often associated with a genetic disorder or is therapy-related instead of de novo disease"
                    ]
                  }
                ],
                "Gender": [
                  {
                    "text": "Increased incidence in menMale:Female = 1.8:1",
                    "sub_points": [
                      "Male:Female = 1.8:1"
                    ]
                  },
                  {
                    "text": "Exception is MDS/del(5q), which has a female predominance"
                  }
                ],
                "Incidence": [
                  {
                    "text": "Individuals diagnosed per year~ 12,000 in USA~ 20,000 in Europe",
                    "sub_points": [
                      "~ 12,000 in USA",
                      "~ 20,000 in Europe"
                    ]
                  }
                ],
                "Classification of Adult MDS": [
                  {
                    "text": "Peripheral blood ≥ 2% blasts or bone marrow > 5% blasts or Auer rodsRAEB"
                  },
                  {
                    "text": "Dysplasia in ≥ 10% of cells in lineageMultilineage dysplasiaRCMDSingle-lineage dysplasia with uni- or bicytopeniaRing sideroblasts≥ 15%:RARSIsolated del(5q) on cytogenetic analysis:MDS/del5qNeither of the above:RCUDSingle-lineage dysplasia with pancytopenia or 1% peripheral blood blastsMDS-U",
                    "sub_points": [
                      "Multilineage dysplasiaRCMD",
                      "RCMD",
                      "Single-lineage dysplasia with uni- or bicytopeniaRing sideroblasts≥ 15%:RARSIsolated del(5q) on cytogenetic analysis:MDS/del5qNeither of the above:RCUD",
                      "Ring sideroblasts≥ 15%:RARS",
                      "Isolated del(5q) on cytogenetic analysis:MDS/del5q",
                      "Neither of the above:RCUD",
                      "Single-lineage dysplasia with pancytopenia or 1% peripheral blood blastsMDS-U",
                      "MDS-U"
                    ]
                  },
                  {
                    "text": "Persistent cytopenia(s) but insufficient dysplasia or blastsRecurrent cytogenetic abnormality indicative of MDS:MDS-U",
                    "sub_points": [
                      "Recurrent cytogenetic abnormality indicative of MDS:MDS-U"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Histogenesis": [
                  {
                    "text": "Probably originates from primitive hematopoietic stem cellInitiating mutation or transforming event is unknownGeneral lack of understanding about pathogenesisReason specific MDS entities may be difficult to diagnose and classify",
                    "sub_points": [
                      "Initiating mutation or transforming event is unknown",
                      "General lack of understanding about pathogenesisReason specific MDS entities may be difficult to diagnose and classify",
                      "Reason specific MDS entities may be difficult to diagnose and classify"
                    ]
                  },
                  {
                    "text": "Putative pathogenic mechanismsAbnormal stem cell gives rise to clonal myelopoiesisInfluenced by haploinsufficiency and epigenetic changesIneffective hematopoiesis and apoptosisClonal myelopoiesis causes abnormal stromal response with altered immune and cytokine responsesCytokines and immune system (particularly cytotoxic T cells) suppress proliferation and support apoptosisClonal evolution develops with additional mutationsTransformation to high-grade MDS and AMLLoss of tumor suppressor genesChromosome deletionsInactivation by hypermethylation",
                    "sub_points": [
                      "Abnormal stem cell gives rise to clonal myelopoiesisInfluenced by haploinsufficiency and epigenetic changes",
                      "Influenced by haploinsufficiency and epigenetic changes",
                      "Ineffective hematopoiesis and apoptosisClonal myelopoiesis causes abnormal stromal response with altered immune and cytokine responsesCytokines and immune system (particularly cytotoxic T cells) suppress proliferation and support apoptosis",
                      "Clonal myelopoiesis causes abnormal stromal response with altered immune and cytokine responses",
                      "Cytokines and immune system (particularly cytotoxic T cells) suppress proliferation and support apoptosis",
                      "Clonal evolution develops with additional mutationsTransformation to high-grade MDS and AMLLoss of tumor suppressor genesChromosome deletionsInactivation by hypermethylation",
                      "Transformation to high-grade MDS and AML",
                      "Loss of tumor suppressor genes",
                      "Chromosome deletions",
                      "Inactivation by hypermethylation"
                    ]
                  },
                  {
                    "text": "Subsets of MDS have different \"phenotypes\"Mutator phenotypeGenetic instability: Stepwise progression of genetic events that often leads to AMLNonmutator phenotypeRelatively stable disease with little progression over timeTransformation to leukemia is unusualLow-grade subsets of MDS",
                    "sub_points": [
                      "Mutator phenotypeGenetic instability: Stepwise progression of genetic events that often leads to AML",
                      "Genetic instability: Stepwise progression of genetic events that often leads to AML",
                      "Nonmutator phenotypeRelatively stable disease with little progression over timeTransformation to leukemia is unusualLow-grade subsets of MDS",
                      "Relatively stable disease with little progression over time",
                      "Transformation to leukemia is unusual",
                      "Low-grade subsets of MDS"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Clinical Presentation": [
                  {
                    "text": "Individuals typically present with symptoms or signs relating to cytopenia(s)Anemia is most common finding at presentation in adultsPallor, weaknessNeutropeniaRecurrent infectionsThrombocytopeniaBleeding, petechiae",
                    "sub_points": [
                      "Anemia is most common finding at presentation in adultsPallor, weakness",
                      "Pallor, weakness",
                      "NeutropeniaRecurrent infections",
                      "Recurrent infections",
                      "ThrombocytopeniaBleeding, petechiae",
                      "Bleeding, petechiae"
                    ]
                  },
                  {
                    "text": "Childhood MDSMore likely to present with neutropenia or thrombocytopenia than isolated anemia",
                    "sub_points": [
                      "More likely to present with neutropenia or thrombocytopenia than isolated anemia"
                    ]
                  }
                ],
                "Clinical Risk Factors": [],
                "Prognostic factors and risk": [
                  {
                    "text": "Major risk factor for survival is age at time of diagnosisComorbidities increase with ageDecreased effectiveness of treatment in elderly or patients with significant comorbidities",
                    "sub_points": [
                      "Comorbidities increase with age",
                      "Decreased effectiveness of treatment in elderly or patients with significant comorbidities"
                    ]
                  },
                  {
                    "text": "Highly variable clinical courseRanges from indolent subtypes to forms approaching AMLRequires risk-adapted treatment strategy",
                    "sub_points": [
                      "Ranges from indolent subtypes to forms approaching AML",
                      "Requires risk-adapted treatment strategy"
                    ]
                  },
                  {
                    "text": "International Prognostic Scoring system (IPSS)Developed by Greenberg and coworkers in 1997Based on number of cytopenias, % bone marrow blasts, and cytogenetic abnormalitiesUseful for predicting survival and risk of leukemic transformation for adults",
                    "sub_points": [
                      "Developed by Greenberg and coworkers in 1997",
                      "Based on number of cytopenias, % bone marrow blasts, and cytogenetic abnormalities",
                      "Useful for predicting survival and risk of leukemic transformation for adults"
                    ]
                  },
                  {
                    "text": "Bone marrow fibrosis (grade 2 or 3)Present in ~ 10% of casesAlters IPSS categoryShifts patient to more advanced risk group (1 step)",
                    "sub_points": [
                      "Present in ~ 10% of cases",
                      "Alters IPSS category",
                      "Shifts patient to more advanced risk group (1 step)"
                    ]
                  },
                  {
                    "text": "Median survival times drop whenBlast percentage increasesSeverity of dysplasia increasesHemoglobin is < 8 g/dLLymphopenia is < 1.2 x 10⁹/L (suggested in some studies)",
                    "sub_points": [
                      "Blast percentage increases",
                      "Severity of dysplasia increases",
                      "Hemoglobin is < 8 g/dL",
                      "Lymphopenia is < 1.2 x 10⁹/L (suggested in some studies)"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Conventional cytogenetic analysisRequires adequate bone marrow aspirate specimenMay need to disaggregate trephine biopsy if fibrotic or packed marrowEssential during initial evaluation to establish baseline karyotype40-60% of patients have a clonal abnormalityMost common are gains or losses of a large chromosome segment (i.e., -5, 5q-, -7, +8)Helpful for diagnosis when persistent cytopenias but insufficient dysplasia or blastsMDS-UEssential for risk assessmentKaryotypes associated with adverse prognosis are seen more frequently in high-grade MDS",
                    "sub_points": [
                      "Requires adequate bone marrow aspirate specimenMay need to disaggregate trephine biopsy if fibrotic or packed marrow",
                      "May need to disaggregate trephine biopsy if fibrotic or packed marrow",
                      "Essential during initial evaluation to establish baseline karyotype40-60% of patients have a clonal abnormalityMost common are gains or losses of a large chromosome segment (i.e., -5, 5q-, -7, +8)",
                      "40-60% of patients have a clonal abnormality",
                      "Most common are gains or losses of a large chromosome segment (i.e., -5, 5q-, -7, +8)",
                      "Helpful for diagnosis when persistent cytopenias but insufficient dysplasia or blastsMDS-U",
                      "MDS-U",
                      "Essential for risk assessmentKaryotypes associated with adverse prognosis are seen more frequently in high-grade MDS",
                      "Karyotypes associated with adverse prognosis are seen more frequently in high-grade MDS"
                    ]
                  },
                  {
                    "text": "Fluorescence in situ hybridization (FISH)Helpful if insufficient conventional cytogenetic study (i.e., < 20 metaphases)Can perform on bone marrow touch preparations, aspirate smears, or remaining cytogenetic cell pellet",
                    "sub_points": [
                      "Helpful if insufficient conventional cytogenetic study (i.e., < 20 metaphases)Can perform on bone marrow touch preparations, aspirate smears, or remaining cytogenetic cell pellet",
                      "Can perform on bone marrow touch preparations, aspirate smears, or remaining cytogenetic cell pellet"
                    ]
                  },
                  {
                    "text": "Flow cytometric analysisHelpful to screen for increased CD34 or CD117 positive blasts and abnormal immunophenotypeCoexpression of CD7, CD56, CD10, CD11b, or CD15 on blast populationAbnormal intensity of antigen expression, i.e., increased CD117 and CD13 on CD34(+) blast populationAbsence of CD33, CD13, or HLA-DR on blast populationAbsence of hematogone population",
                    "sub_points": [
                      "Helpful to screen for increased CD34 or CD117 positive blasts and abnormal immunophenotypeCoexpression of CD7, CD56, CD10, CD11b, or CD15 on blast populationAbnormal intensity of antigen expression, i.e., increased CD117 and CD13 on CD34(+) blast populationAbsence of CD33, CD13, or HLA-DR on blast populationAbsence of hematogone population",
                      "Coexpression of CD7, CD56, CD10, CD11b, or CD15 on blast population",
                      "Abnormal intensity of antigen expression, i.e., increased CD117 and CD13 on CD34(+) blast population",
                      "Absence of CD33, CD13, or HLA-DR on blast population",
                      "Absence of hematogone population"
                    ]
                  },
                  {
                    "text": "Immunohistochemistryon bone marrow core biopsy (or clot) sectionsCD34 for blasts; CD117 if blasts are CD34 negativeQuantify blasts; evaluate for aggregation or clusteringParticularly helpful for hypoplastic marrowsCD34 also useful to evaluate for neovascularizationMyeloperoxidaseQuantify myeloid lineageAbnormal localization of immature precursors (ALIP)Hemoglobin A, glycophorin, or CD71Quantify erythroid lineageDisruption of normal erythroid colony formationCD61 or CD42bQuantify megakaryocytesAbnormal megakaryocytic clustering or paratrabecular localization",
                    "sub_points": [
                      "CD34 for blasts; CD117 if blasts are CD34 negativeQuantify blasts; evaluate for aggregation or clusteringParticularly helpful for hypoplastic marrowsCD34 also useful to evaluate for neovascularization",
                      "Quantify blasts; evaluate for aggregation or clustering",
                      "Particularly helpful for hypoplastic marrows",
                      "CD34 also useful to evaluate for neovascularization",
                      "MyeloperoxidaseQuantify myeloid lineageAbnormal localization of immature precursors (ALIP)",
                      "Quantify myeloid lineage",
                      "Abnormal localization of immature precursors (ALIP)",
                      "Hemoglobin A, glycophorin, or CD71Quantify erythroid lineageDisruption of normal erythroid colony formation",
                      "Quantify erythroid lineage",
                      "Disruption of normal erythroid colony formation",
                      "CD61 or CD42bQuantify megakaryocytesAbnormal megakaryocytic clustering or paratrabecular localization",
                      "Quantify megakaryocytes",
                      "Abnormal megakaryocytic clustering or paratrabecular localization"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "DrugsAzacytidine and its derivative decitabineLenalidomide (analogue of thalidomide)Most effective if patient has 5q-",
                    "sub_points": [
                      "Azacytidine and its derivative decitabine",
                      "Lenalidomide (analogue of thalidomide)Most effective if patient has 5q-",
                      "Most effective if patient has 5q-"
                    ]
                  },
                  {
                    "text": "Risk-adapted treatment strategyVery low riskMonitor only if disease remains stableLow riskMonitor frequently but no treatment if multilineage dysplasia or intermediate-risk cytogenetics without symptomsRecombinant human erythropoietin if transfusion dependent and no 5q-Lenalidomide if transfusion dependent & has 5q-Intermediate, high, and very high riskAllogeneic stem cell transplantation if < 65 years oldAzacytidine or decitabine if transplant ineligible",
                    "sub_points": [
                      "Very low riskMonitor only if disease remains stable",
                      "Monitor only if disease remains stable",
                      "Low riskMonitor frequently but no treatment if multilineage dysplasia or intermediate-risk cytogenetics without symptomsRecombinant human erythropoietin if transfusion dependent and no 5q-Lenalidomide if transfusion dependent & has 5q-",
                      "Monitor frequently but no treatment if multilineage dysplasia or intermediate-risk cytogenetics without symptoms",
                      "Recombinant human erythropoietin if transfusion dependent and no 5q-",
                      "Lenalidomide if transfusion dependent & has 5q-",
                      "Intermediate, high, and very high riskAllogeneic stem cell transplantation if < 65 years oldAzacytidine or decitabine if transplant ineligible",
                      "Allogeneic stem cell transplantation if < 65 years old",
                      "Azacytidine or decitabine if transplant ineligible"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Cumulative probability of transformation to AML at 5 yearsVery low-risk MDS: 0.03High-risk MDS: 0.84",
                    "sub_points": [
                      "Very low-risk MDS: 0.03",
                      "High-risk MDS: 0.84"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Peripheral Blood": [
                  {
                    "text": "Cytopenias (% of cases)Anemia (85%)< 10 g/dL (60%)Neutropenia (40%)Thrombocytopenia (30%)Pancytopenia (15%)",
                    "sub_points": [
                      "Anemia (85%)< 10 g/dL (60%)",
                      "< 10 g/dL (60%)",
                      "Neutropenia (40%)",
                      "Thrombocytopenia (30%)",
                      "Pancytopenia (15%)"
                    ]
                  },
                  {
                    "text": "Evaluate blast percentageBased on 200-cell leukocyte differential countBlast morphology defined by International Working Group on Morphology of Myelodysplastic Syndrome DeterminationBlasts common in higher grade MDS",
                    "sub_points": [
                      "Based on 200-cell leukocyte differential countBlast morphology defined by International Working Group on Morphology of Myelodysplastic Syndrome Determination",
                      "Blast morphology defined by International Working Group on Morphology of Myelodysplastic Syndrome Determination",
                      "Blasts common in higher grade MDS"
                    ]
                  },
                  {
                    "text": "Evaluate for dysplasiaRed blood cells, myeloid lineage, plateletsdel(17p)Associated with pseudo-Pelger-Huët nuclei and neutrophils with small cytoplasmic vacuolesDeletion ofTP53High risk of leukemia transformation",
                    "sub_points": [
                      "Red blood cells, myeloid lineage, platelets",
                      "del(17p)Associated with pseudo-Pelger-Huët nuclei and neutrophils with small cytoplasmic vacuolesDeletion ofTP53High risk of leukemia transformation",
                      "Associated with pseudo-Pelger-Huët nuclei and neutrophils with small cytoplasmic vacuoles",
                      "Deletion ofTP53",
                      "High risk of leukemia transformation"
                    ]
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "Aspirate or touch preparationsPerform 500-cell leukocyte differential countBlast percentage based on visual inspection and not flow cytometric analysisDysplasia in ≥ 10% of cell lineageRequires high-quality smears/preparationsDo not perform on specimens exposed to anticoagulants for > 2 hours before smear preparation",
                    "sub_points": [
                      "Perform 500-cell leukocyte differential countBlast percentage based on visual inspection and not flow cytometric analysis",
                      "Blast percentage based on visual inspection and not flow cytometric analysis",
                      "Dysplasia in ≥ 10% of cell lineageRequires high-quality smears/preparationsDo not perform on specimens exposed to anticoagulants for > 2 hours before smear preparation",
                      "Requires high-quality smears/preparations",
                      "Do not perform on specimens exposed to anticoagulants for > 2 hours before smear preparation"
                    ]
                  },
                  {
                    "text": "Bone marrow trephine biopsy and clot sectionsBiopsy adequate if 1.5 cm in length and at right angles to cortical boneCellularityUsually hypercellular or normocellular with ineffective hematopoiesisErythroid hyperplasia is most commonHypocellular in ~ 10% of adults, ~ 70% of childrenHypocellular if < 30% or < 20% cellular at diagnosis and < 60 or ≥ 60 years old, respectivelyBlasts in aggregates (3-5 cells) or clusters (> 5 cells)Associated with aggressive MDS if localized away from vascular structures or bony trabeculaeBlasts may be myeloblasts, monoblasts, megakaryoblasts, or combinationMegakaryocyte dysplasia may be better appreciated in biopsy sections than aspirate smearsEvaluation of ≥ 30 megakaryocytes is required (includes aspirate smears and touch preparations)",
                    "sub_points": [
                      "Biopsy adequate if 1.5 cm in length and at right angles to cortical bone",
                      "CellularityUsually hypercellular or normocellular with ineffective hematopoiesisErythroid hyperplasia is most commonHypocellular in ~ 10% of adults, ~ 70% of childrenHypocellular if < 30% or < 20% cellular at diagnosis and < 60 or ≥ 60 years old, respectively",
                      "Usually hypercellular or normocellular with ineffective hematopoiesis",
                      "Erythroid hyperplasia is most common",
                      "Hypocellular in ~ 10% of adults, ~ 70% of children",
                      "Hypocellular if < 30% or < 20% cellular at diagnosis and < 60 or ≥ 60 years old, respectively",
                      "Blasts in aggregates (3-5 cells) or clusters (> 5 cells)Associated with aggressive MDS if localized away from vascular structures or bony trabeculaeBlasts may be myeloblasts, monoblasts, megakaryoblasts, or combination",
                      "Associated with aggressive MDS if localized away from vascular structures or bony trabeculae",
                      "Blasts may be myeloblasts, monoblasts, megakaryoblasts, or combination",
                      "Megakaryocyte dysplasia may be better appreciated in biopsy sections than aspirate smearsEvaluation of ≥ 30 megakaryocytes is required (includes aspirate smears and touch preparations)",
                      "Evaluation of ≥ 30 megakaryocytes is required (includes aspirate smears and touch preparations)"
                    ]
                  }
                ]
              },
              "Differential Diagnosis": {
                "Idiopathic Cytopenia of Uncertain Significance": [
                  {
                    "text": "Proposed diagnosis for rare cases of persistent cytopenia(s) (> 6 months)Cytopenia may be of 1 or more lineages (red blood cells, neutrophils, platelets)Does not fulfill criteria for MDSDiagnosis of exclusion after careful evaluation60% of patients develop MDS in 1-10 years",
                    "sub_points": [
                      "Cytopenia may be of 1 or more lineages (red blood cells, neutrophils, platelets)Does not fulfill criteria for MDSDiagnosis of exclusion after careful evaluation",
                      "Does not fulfill criteria for MDS",
                      "Diagnosis of exclusion after careful evaluation",
                      "60% of patients develop MDS in 1-10 years"
                    ]
                  }
                ],
                "Nutritional Deficiency": [
                  {
                    "text": "Vitamin B12, folate, and copper deficiencies"
                  }
                ],
                "Medications": [
                  {
                    "text": "Chemotherapy, multiple medications including clotrimazole and valproic acid"
                  }
                ],
                "Toxin Exposure": [
                  {
                    "text": "Heavy metal poisoning (particularly arsenic), alcohol"
                  }
                ],
                "Infectious and Autoimmune Disorders": [
                  {
                    "text": "HIV, EBV, parvovirus, CMV, SLE, collagen vascular disorders, etc.May induce myelofibrosis",
                    "sub_points": [
                      "May induce myelofibrosis"
                    ]
                  }
                ],
                "Congenital Disorders": [
                  {
                    "text": "Congenital dyserythropoietic anemia, myelokathexis, congenital sideroblastic anemias"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Myelodysplastic Syndromes With Ring Sideroblasts": {
            "name": "Myelodysplastic Syndromes With Ring Sideroblasts",
            "url": "https://app.pathprimer.com/document/ef77bd93-d7af-4ca4-8195-57412158649e/lesson/b91f9007-5151-4611-a335-6c428b56c3e0",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "SF3B1mutation is myelodysplastic syndrome (MDS)-defining genetic abnormality in cytopenic patientTypically heterozygousSF3B1mutationVariant allele frequency (VAF) ≥ 10% (ICC); VAF ≥ 5% (WHO-HAEM5)Cytopenia involving ≥ 1 lineage based on IPSS values",
                    "sub_points": [
                      "Typically heterozygousSF3B1mutationVariant allele frequency (VAF) ≥ 10% (ICC); VAF ≥ 5% (WHO-HAEM5)",
                      "Variant allele frequency (VAF) ≥ 10% (ICC); VAF ≥ 5% (WHO-HAEM5)",
                      "Cytopenia involving ≥ 1 lineage based on IPSS values"
                    ]
                  },
                  {
                    "text": "Low-grade MDSBlasts < 2% in blood, < 5% in BM≥ 10% dysplasia in 1 lineagenotrequired per ICC; required by WHO-HAEM5",
                    "sub_points": [
                      "Blasts < 2% in blood, < 5% in BM",
                      "≥ 10% dysplasia in 1 lineagenotrequired per ICC; required by WHO-HAEM5"
                    ]
                  },
                  {
                    "text": "Includes cases previously classified as MDS with RS and single or multilineage dysplasia"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Clonal hematopoietic stem cell disorderSF3B1mutation is early event in MDS pathogenesis",
                    "sub_points": [
                      "SF3B1mutation is early event in MDS pathogenesis"
                    ]
                  },
                  {
                    "text": "Critical component of splicing machinery~ 100 genes involved in erythroid differentiation are missplicedContributes to ineffective hematopoiesis",
                    "sub_points": [
                      "~ 100 genes involved in erythroid differentiation are misspliced",
                      "Contributes to ineffective hematopoiesis"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "SF3B1is only currently known gene mutation to confer favorable prognosis in MDSIndolent clinical course",
                    "sub_points": [
                      "Indolent clinical course"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Peripheral bloodMacrocytic or normochromic normocytic anemia",
                    "sub_points": [
                      "Macrocytic or normochromic normocytic anemia"
                    ]
                  },
                  {
                    "text": "Bone marrowIncrease in erythroid precursors usually with dysplasia (not required by ICC)Iron stain often shows increased iron stores and ring sideroblasts (RS) (not required by ICC)",
                    "sub_points": [
                      "Increase in erythroid precursors usually with dysplasia (not required by ICC)",
                      "Iron stain often shows increased iron stores and ring sideroblasts (RS) (not required by ICC)"
                    ]
                  }
                ],
                "Diagnostic Checklist": [
                  {
                    "text": "Test forSF3B1mutation after excluding nonclonal sideroblastic anemias"
                  },
                  {
                    "text": "RS are not required for diagnosis of MDS-SF3B1by ICC"
                  },
                  {
                    "text": "Classify asotherMDS type if concurrent del(5q), -7/del(7q), complex karyotype, multihitTP53(VAF ≥ 10%)ICC: inv(3), abnormal 3q26, orRUNX1mutations also exclusionary",
                    "sub_points": [
                      "ICC: inv(3), abnormal 3q26, orRUNX1mutations also exclusionary"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Myelodysplastic syndrome with mutatedSF3B1(MDS-SF3B1) [International Consensus Classification (ICC)]"
                  },
                  {
                    "text": "Myelodysplastic neoplasm with low blasts andSF3B1mutation (MDN-SF3B1) [WHO 5th edition (WHO-HAEM5)]"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "MDS with ring sideroblasts (RS) and single lineage or multilineage dysplasia (WHO revised 4th edition)"
                  },
                  {
                    "text": "Refractory cytopenia with multilineage dysplasia with RS (WHO 3rd edition)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Low-grade MDS with defining genetic abnormalitySF3B1Blasts < 2% in peripheral blood, < 5% in bone marrowSplicing factor 3b subunit 1 (SF3B1) mutationVariant allele frequency (VAF) ≥ 10% (ICC); VAF ≥ 5% (WHO-HAEM5)WHO-HAEM5 only: ≥ 15% RS fulfills criteria if mutation analysis not availableCytopenia involving ≥ 1 lineage based on International Prognosis Scoring System (IPSS) valuesHgb < 13 g, males; < 12 g, femalesAbsolute neutrophil count < 1.8 x 10⁹/LPlatelet count < 150 x 10⁹/LAlternatively, use local laboratory reference ranges but less optimalRS are not required to make diagnosis per ICCDoes not meet criteria for other myeloid neoplasmNo del(5q), -7/del(7q), complex karyotype, multihitTP53(VAF ≥ 10%)ICC: No inv(3), abnormal 3q26, orRUNX1mutationsNo cytoses, includingWBC ≥ 13 × 10⁹/L, monocytosis (≥ 0.5 × 10⁹/L and ≥ 10% of leukocytes), or platelets ≥ 450 × 10⁹/LDysplasia (> 10%) involving ≥ 1 lineage (WHO-HAEM5)Not required to make diagnosis per ICC",
                    "sub_points": [
                      "Blasts < 2% in peripheral blood, < 5% in bone marrow",
                      "Splicing factor 3b subunit 1 (SF3B1) mutationVariant allele frequency (VAF) ≥ 10% (ICC); VAF ≥ 5% (WHO-HAEM5)WHO-HAEM5 only: ≥ 15% RS fulfills criteria if mutation analysis not available",
                      "Variant allele frequency (VAF) ≥ 10% (ICC); VAF ≥ 5% (WHO-HAEM5)",
                      "WHO-HAEM5 only: ≥ 15% RS fulfills criteria if mutation analysis not available",
                      "Cytopenia involving ≥ 1 lineage based on International Prognosis Scoring System (IPSS) valuesHgb < 13 g, males; < 12 g, femalesAbsolute neutrophil count < 1.8 x 10⁹/LPlatelet count < 150 x 10⁹/LAlternatively, use local laboratory reference ranges but less optimal",
                      "Hgb < 13 g, males; < 12 g, females",
                      "Absolute neutrophil count < 1.8 x 10⁹/L",
                      "Platelet count < 150 x 10⁹/L",
                      "Alternatively, use local laboratory reference ranges but less optimal",
                      "RS are not required to make diagnosis per ICC",
                      "Does not meet criteria for other myeloid neoplasmNo del(5q), -7/del(7q), complex karyotype, multihitTP53(VAF ≥ 10%)ICC: No inv(3), abnormal 3q26, orRUNX1mutationsNo cytoses, includingWBC ≥ 13 × 10⁹/L, monocytosis (≥ 0.5 × 10⁹/L and ≥ 10% of leukocytes), or platelets ≥ 450 × 10⁹/L",
                      "No del(5q), -7/del(7q), complex karyotype, multihitTP53(VAF ≥ 10%)",
                      "ICC: No inv(3), abnormal 3q26, orRUNX1mutations",
                      "No cytoses, includingWBC ≥ 13 × 10⁹/L, monocytosis (≥ 0.5 × 10⁹/L and ≥ 10% of leukocytes), or platelets ≥ 450 × 10⁹/L",
                      "WBC ≥ 13 × 10⁹/L, monocytosis (≥ 0.5 × 10⁹/L and ≥ 10% of leukocytes), or platelets ≥ 450 × 10⁹/L",
                      "Dysplasia (> 10%) involving ≥ 1 lineage (WHO-HAEM5)Not required to make diagnosis per ICC",
                      "Not required to make diagnosis per ICC"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Developmental Anomaly": [
                  {
                    "text": "Clonal hematopoietic stem cell disorderSF3B1mutation is early event in MDS pathogenesis",
                    "sub_points": [
                      "SF3B1mutation is early event in MDS pathogenesis"
                    ]
                  },
                  {
                    "text": "Primary defect of mitochondrial iron metabolismAbnormal iron starting in early erythroid precursorsIron accumulates within mitochondria in ferritin form",
                    "sub_points": [
                      "Abnormal iron starting in early erythroid precursorsIron accumulates within mitochondria in ferritin form",
                      "Iron accumulates within mitochondria in ferritin form"
                    ]
                  }
                ],
                "Molecular Pathogenesis": [
                  {
                    "text": "SF3B1 gene is on chromosome 2q33.1Encodes subunit 1 of SF3b component in small nuclear ribonucleoproteins complexCritical component of splicing machineryCatalyzes removal of introns from precursor mRNA",
                    "sub_points": [
                      "Encodes subunit 1 of SF3b component in small nuclear ribonucleoproteins complexCritical component of splicing machineryCatalyzes removal of introns from precursor mRNA",
                      "Critical component of splicing machinery",
                      "Catalyzes removal of introns from precursor mRNA"
                    ]
                  },
                  {
                    "text": "SF3B1somatic mutationMutations are heterozygous substitutionsAssociated with aberrant 3' splice-site selectionMisspliced transcripts are degraded or form mutant proteinsResults in abnormal cell differentiation and maturation~ 100 genes involved in erythroid differentiation are missplicedIncludeABCB7,PPOX,TMEM14CImportant for heme biosynthesis, mitochondrial iron metabolismCoordinated missplicing ofABCB7andTMEM14Ccauses RS formationContributes to ineffective hematopoiesisApoptosis of polychromatic and orthochromatic erythroblastsInappropriately decreased hepcidin levelsGene expression profiles and sequencing dataHigher number of differentially expressed genes compared to other MDS-associated mutationsPositive predictive value for myeloid neoplasm with RS is 98%SF3B1mutation may be seen in other MDS subtype, MDS/myeloproliferative neoplasms (MPN), or MPN",
                    "sub_points": [
                      "Mutations are heterozygous substitutionsAssociated with aberrant 3' splice-site selectionMisspliced transcripts are degraded or form mutant proteinsResults in abnormal cell differentiation and maturation",
                      "Associated with aberrant 3' splice-site selection",
                      "Misspliced transcripts are degraded or form mutant proteinsResults in abnormal cell differentiation and maturation",
                      "Results in abnormal cell differentiation and maturation",
                      "~ 100 genes involved in erythroid differentiation are missplicedIncludeABCB7,PPOX,TMEM14CImportant for heme biosynthesis, mitochondrial iron metabolismCoordinated missplicing ofABCB7andTMEM14Ccauses RS formation",
                      "IncludeABCB7,PPOX,TMEM14CImportant for heme biosynthesis, mitochondrial iron metabolism",
                      "Important for heme biosynthesis, mitochondrial iron metabolism",
                      "Coordinated missplicing ofABCB7andTMEM14Ccauses RS formation",
                      "Contributes to ineffective hematopoiesisApoptosis of polychromatic and orthochromatic erythroblastsInappropriately decreased hepcidin levels",
                      "Apoptosis of polychromatic and orthochromatic erythroblasts",
                      "Inappropriately decreased hepcidin levels",
                      "Gene expression profiles and sequencing dataHigher number of differentially expressed genes compared to other MDS-associated mutations",
                      "Higher number of differentially expressed genes compared to other MDS-associated mutations",
                      "Positive predictive value for myeloid neoplasm with RS is 98%SF3B1mutation may be seen in other MDS subtype, MDS/myeloproliferative neoplasms (MPN), or MPN",
                      "SF3B1mutation may be seen in other MDS subtype, MDS/myeloproliferative neoplasms (MPN), or MPN"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "MDS-SF3B1comprises 17% of MDS"
                  },
                  {
                    "text": "Includes > 90% of MDS cases with ≥ 5% RS"
                  }
                ],
                "Age": [
                  {
                    "text": "Older individuals; median: 70-75 years"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Often present with anemia (> 50%)Clinical symptoms relate to anemia",
                    "sub_points": [
                      "Clinical symptoms relate to anemia"
                    ]
                  },
                  {
                    "text": "Thrombocytopenia (13%), neutropenia (8%)"
                  },
                  {
                    "text": "Liver and spleen may show iron overload"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Blood counts and smear review"
                  },
                  {
                    "text": "Bone marrow evaluation, includingIron-stained aspirate smearCount ≥ 100 nucleated erythroid precursors for RS percentageCytogenetic analysisClonal chromosomal abnormalities identified in 20-30% of casesUsually involves single chromosomeFlow cytometric analysisAberrant erythroid maturation pattern or phenotypeLower mean expression of CD71Increased coefficient of variationImmunohistochemistryCD71, CD235a stain erythroid lineageErythroid left shift highlighted by E-cadherin, CD117Molecular geneticsSF3B1somatic mutations cluster in exons 12-16Median VAF is ~ 40%SF3B1K700E accounts for > 50% of mutationsOther hotspots at codons 666, 662, 622, 625",
                    "sub_points": [
                      "Iron-stained aspirate smearCount ≥ 100 nucleated erythroid precursors for RS percentage",
                      "Count ≥ 100 nucleated erythroid precursors for RS percentage",
                      "Cytogenetic analysisClonal chromosomal abnormalities identified in 20-30% of casesUsually involves single chromosome",
                      "Clonal chromosomal abnormalities identified in 20-30% of casesUsually involves single chromosome",
                      "Usually involves single chromosome",
                      "Flow cytometric analysisAberrant erythroid maturation pattern or phenotypeLower mean expression of CD71Increased coefficient of variation",
                      "Aberrant erythroid maturation pattern or phenotypeLower mean expression of CD71Increased coefficient of variation",
                      "Lower mean expression of CD71",
                      "Increased coefficient of variation",
                      "ImmunohistochemistryCD71, CD235a stain erythroid lineageErythroid left shift highlighted by E-cadherin, CD117",
                      "CD71, CD235a stain erythroid lineage",
                      "Erythroid left shift highlighted by E-cadherin, CD117",
                      "Molecular geneticsSF3B1somatic mutations cluster in exons 12-16Median VAF is ~ 40%SF3B1K700E accounts for > 50% of mutationsOther hotspots at codons 666, 662, 622, 625",
                      "SF3B1somatic mutations cluster in exons 12-16Median VAF is ~ 40%SF3B1K700E accounts for > 50% of mutationsOther hotspots at codons 666, 662, 622, 625",
                      "Median VAF is ~ 40%",
                      "SF3B1K700E accounts for > 50% of mutations",
                      "Other hotspots at codons 666, 662, 622, 625"
                    ]
                  },
                  {
                    "text": "Serologic iron studiesIncreased serum iron, transferrin saturation, ferritin",
                    "sub_points": [
                      "Increased serum iron, transferrin saturation, ferritin"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "RBC transfusions, if symptomaticContributes to iron overload",
                    "sub_points": [
                      "Contributes to iron overload"
                    ]
                  },
                  {
                    "text": "Erythropoiesis-stimulating agents, i.e., erythropoietin, darbepoietin"
                  },
                  {
                    "text": "Drugs modulating TGF-β superfamily ligandsLuspatercept abolishes transfusion requirement for many patients; sotatercept",
                    "sub_points": [
                      "Luspatercept abolishes transfusion requirement for many patients; sotatercept"
                    ]
                  },
                  {
                    "text": "Lenalidomide; other medications in clinical trials"
                  },
                  {
                    "text": "Iron chelation therapy for systemic iron overload"
                  },
                  {
                    "text": "Bone marrow transplant in severe cases for eligible patients"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "SF3B1mutation is independent predictor of favorable prognosisIndolent clinical course~ 9-year average survival with isolatedSF3B1mutationWorse outcome associated with some gene comutationsActive area of researchVery low risk of leukemic evolutionNot affected by mutation type, VAF percentage, concurrent mutations in epigenetic regulators",
                    "sub_points": [
                      "Indolent clinical course~ 9-year average survival with isolatedSF3B1mutationWorse outcome associated with some gene comutationsActive area of research",
                      "~ 9-year average survival with isolatedSF3B1mutation",
                      "Worse outcome associated with some gene comutationsActive area of research",
                      "Active area of research",
                      "Very low risk of leukemic evolution",
                      "Not affected by mutation type, VAF percentage, concurrent mutations in epigenetic regulators"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Cytologic Features": [
                  {
                    "text": "Peripheral blood< 2% circulating blastsMacrocytic or normochromic normocytic anemiaPossibly dimorphic with minor population of hypochromic microcytic cellsBasophilic stippling, Pappenheimer bodiesMay have additional cytopenia(s)",
                    "sub_points": [
                      "< 2% circulating blasts",
                      "Macrocytic or normochromic normocytic anemiaPossibly dimorphic with minor population of hypochromic microcytic cellsBasophilic stippling, Pappenheimer bodies",
                      "Possibly dimorphic with minor population of hypochromic microcytic cells",
                      "Basophilic stippling, Pappenheimer bodies",
                      "May have additional cytopenia(s)"
                    ]
                  },
                  {
                    "text": "Bone marrow< 5% blasts, no Auer rodsIncrease in erythroid precursors with left shiftOften dysplastic, i.e., megaloblastic, abnormal nuclear segmentation, binucleationNonerythroid lineagesNo significant dysplasia or only mild myeloid dysplasia",
                    "sub_points": [
                      "< 5% blasts, no Auer rods",
                      "Increase in erythroid precursors with left shiftOften dysplastic, i.e., megaloblastic, abnormal nuclear segmentation, binucleation",
                      "Often dysplastic, i.e., megaloblastic, abnormal nuclear segmentation, binucleation",
                      "Nonerythroid lineagesNo significant dysplasia or only mild myeloid dysplasia",
                      "No significant dysplasia or only mild myeloid dysplasia"
                    ]
                  },
                  {
                    "text": "Iron-stained bone marrow aspirate smearsIncreased iron stores, erythroid iron, RSSideroblasts: International Working Group definitionsType 1: < 5 siderotic granules in cytoplasmType 2: ≥ 5 siderotic granules not in perinuclear distributionType 3: ≥ 5 siderotic granules in perinuclear distribution surrounding ≥ 1/3 of nuclear circumferenceOnly type 3 qualifies asRS",
                    "sub_points": [
                      "Increased iron stores, erythroid iron, RS",
                      "Sideroblasts: International Working Group definitionsType 1: < 5 siderotic granules in cytoplasmType 2: ≥ 5 siderotic granules not in perinuclear distributionType 3: ≥ 5 siderotic granules in perinuclear distribution surrounding ≥ 1/3 of nuclear circumferenceOnly type 3 qualifies asRS",
                      "Type 1: < 5 siderotic granules in cytoplasm",
                      "Type 2: ≥ 5 siderotic granules not in perinuclear distribution",
                      "Type 3: ≥ 5 siderotic granules in perinuclear distribution surrounding ≥ 1/3 of nuclear circumferenceOnly type 3 qualifies asRS",
                      "Only type 3 qualifies asRS"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Nonclonal Acquired Sideroblastic Anemias": [
                  {
                    "text": "Caused by medications (i.e., isoniazide), toxins (i.e., lead, excess alcohol)"
                  },
                  {
                    "text": "Deficiencies of copper (often zinc induced), pyridoxine, or folate"
                  },
                  {
                    "text": "Chronic inflammation, renal disease"
                  }
                ],
                "Congenital Sideroblastic Anemias": [
                  {
                    "text": "Germline genetic mutations in mitochondrial pathwaysRare, and present at young ageUsually hypochromic microcytic anemia with RSX-linked, autosomal recessive, or component of congenital syndrome",
                    "sub_points": [
                      "Rare, and present at young ageUsually hypochromic microcytic anemia with RS",
                      "Usually hypochromic microcytic anemia with RS",
                      "X-linked, autosomal recessive, or component of congenital syndrome"
                    ]
                  }
                ],
                "Other Myeloid Neoplasms": [
                  {
                    "text": "Clonal cytopenia of undetermined significanceSF3B1mutation VAF ≥ 2% (ICC) and ≤ 5% (WHO)High risk for progression to MDS-SF3B1",
                    "sub_points": [
                      "SF3B1mutation VAF ≥ 2% (ICC) and ≤ 5% (WHO)High risk for progression to MDS-SF3B1",
                      "High risk for progression to MDS-SF3B1"
                    ]
                  },
                  {
                    "text": "Genetic abnormalities that supersedeSF3B1mutation in MDS classificationMDS with del(5q)~ 20% haveSF3B1mutationMDS with mutatedTP53ICC and WHO have different criteria forTP53mutationMDS, not otherwise specifiedMDS with RS and wildtypeSF3B1(ICC)SF3B1mutation with concurrentRUNX1mutation, -7, del(7q), or complex karyotype",
                    "sub_points": [
                      "MDS with del(5q)~ 20% haveSF3B1mutation",
                      "~ 20% haveSF3B1mutation",
                      "MDS with mutatedTP53ICC and WHO have different criteria forTP53mutation",
                      "ICC and WHO have different criteria forTP53mutation",
                      "MDS, not otherwise specifiedMDS with RS and wildtypeSF3B1(ICC)SF3B1mutation with concurrentRUNX1mutation, -7, del(7q), or complex karyotype",
                      "MDS with RS and wildtypeSF3B1(ICC)",
                      "SF3B1mutation with concurrentRUNX1mutation, -7, del(7q), or complex karyotype"
                    ]
                  },
                  {
                    "text": "SF3B1mutation case with elevated blast percentageBlast percentage determines classification as MDS with excess blasts, MDS/acute myeloid leukemia (AML), or AML",
                    "sub_points": [
                      "Blast percentage determines classification as MDS with excess blasts, MDS/acute myeloid leukemia (AML), or AML"
                    ]
                  },
                  {
                    "text": "MDS/MPN with mutatedSF3B1and thrombocytosis (ICC)80-90%SF3B1, 50-60%JAK2V617F mutations",
                    "sub_points": [
                      "80-90%SF3B1, 50-60%JAK2V617F mutations"
                    ]
                  },
                  {
                    "text": "Chronic myelomonocytic leukemia with mutatedSF3B1(MDS/MPN subtype)"
                  },
                  {
                    "text": "MPN withSF3B1mutation (in conjunction withJAK2,MPL, orCALRmutation)Essential thrombocytosis, primary myelofibrosis",
                    "sub_points": [
                      "Essential thrombocytosis, primary myelofibrosis"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "RS represent dysplastic erythroid cells if nonclonal sideroblastic anemia is excludedClinical and laboratory correlation is essentialExclude nutritional deficiencies, toxins, drugs associated with RSEvaluate forSF3B1mutation",
                    "sub_points": [
                      "Clinical and laboratory correlation is essentialExclude nutritional deficiencies, toxins, drugs associated with RS",
                      "Exclude nutritional deficiencies, toxins, drugs associated with RS",
                      "Evaluate forSF3B1mutation"
                    ]
                  },
                  {
                    "text": "SF3B1mutation is currently only gene mutation that confers favorable prognosis in MDSRS do not have independent prognostic value",
                    "sub_points": [
                      "RS do not have independent prognostic value"
                    ]
                  },
                  {
                    "text": "RS are not required for diagnosis of MDS-SF3B1by ICC"
                  },
                  {
                    "text": "Dysplasia is not required for diagnosis by ICC"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Refractory Anemia With Unilineage Dysplasia": {
            "name": "Refractory Anemia With Unilineage Dysplasia",
            "url": "https://app.pathprimer.com/document/24d70a8a-fd23-4897-bfb2-d72cd098fddf/lesson/b91f9007-5151-4611-a335-6c428b56c3e0",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "MDS disorders characterized by unicytopenia or bicytopenia plus dysplasia"
                  },
                  {
                    "text": "Can further specify based on lineageRefractory anemia is most commonRefractory neutropeniaRefractory thrombocytopenia",
                    "sub_points": [
                      "Refractory anemia is most common",
                      "Refractory neutropenia",
                      "Refractory thrombocytopenia"
                    ]
                  },
                  {
                    "text": "Dysplasia isolated to a single lineageInvolves ≥ 10% of cells in affected cell lineageUsually of same lineage as cytopenia",
                    "sub_points": [
                      "Involves ≥ 10% of cells in affected cell lineage",
                      "Usually of same lineage as cytopenia"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Older adults; median age: 65-70 years"
                  },
                  {
                    "text": "Low-grade MDSProlonged and indolent courseMay require transfusions or erythropoietin therapyOnly rare cases progress to acute myeloid leukemia",
                    "sub_points": [
                      "Prolonged and indolent course",
                      "May require transfusions or erythropoietin therapy",
                      "Only rare cases progress to acute myeloid leukemia"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Peripheral blood< 1% blasts",
                    "sub_points": [
                      "< 1% blasts"
                    ]
                  },
                  {
                    "text": "Bone marrow< 5% blastsUnilineage dysplasia",
                    "sub_points": [
                      "< 5% blasts",
                      "Unilineage dysplasia"
                    ]
                  }
                ],
                "Diagnostic Checklist": [
                  {
                    "text": "May be difficult to diagnose based on morphology aloneHelpful if clonal cytogenetic abnormality (found in ~ 50% of cases)",
                    "sub_points": [
                      "Helpful if clonal cytogenetic abnormality (found in ~ 50% of cases)"
                    ]
                  },
                  {
                    "text": "If normal karyotype, need to exclude nonclonal causes for cytopenia and dysplasiaEvaluate for at least 6 months before establishing diagnosis",
                    "sub_points": [
                      "Evaluate for at least 6 months before establishing diagnosis"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Refractory cytopenia with unilineage dysplasia (RCUD)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Group of myelodysplastic syndromes (MDS) that present with RCUDRefractory anemia (RA) is most common in adultsRefractory neutropenia is rareRefractory thrombocytopenia is rareBicytopenia may be present but not pancytopenia",
                    "sub_points": [
                      "Refractory anemia (RA) is most common in adults",
                      "Refractory neutropenia is rare",
                      "Refractory thrombocytopenia is rare",
                      "Bicytopenia may be present but not pancytopenia"
                    ]
                  },
                  {
                    "text": "Unilineage dysplasia involves ≥ 10% of cells in affected cell lineageDysplasia is usually of same lineage as cytopenia",
                    "sub_points": [
                      "Dysplasia is usually of same lineage as cytopenia"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Environmental Exposure": [
                  {
                    "text": "Chemicals or solvents such as benzene"
                  },
                  {
                    "text": "Toxins such as cigarette smoke"
                  }
                ],
                "Acquired Disorder": [
                  {
                    "text": "Clonal hematopoietic stem cell diseaseIncreased apoptosis with ineffective hematopoiesisImmune dysregulation plays a roleAllows growth of dysplastic clone",
                    "sub_points": [
                      "Increased apoptosis with ineffective hematopoiesis",
                      "Immune dysregulation plays a roleAllows growth of dysplastic clone",
                      "Allows growth of dysplastic clone"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "10-20% of MDS"
                  }
                ],
                "Age": [
                  {
                    "text": "Older adults, median age 65-70 years"
                  }
                ],
                "Sex": [
                  {
                    "text": "Similar incidence for males and females"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Most common presentation is macrocytic or normochromic normocytic anemia"
                  },
                  {
                    "text": "Symptoms relate to type of cytopeniaAnemiaFatigue, dizziness, headaches, palpitationsNeutropeniaIncreased infectionsThrombocytopeniaHemorrhagic complications",
                    "sub_points": [
                      "AnemiaFatigue, dizziness, headaches, palpitations",
                      "Fatigue, dizziness, headaches, palpitations",
                      "NeutropeniaIncreased infections",
                      "Increased infections",
                      "ThrombocytopeniaHemorrhagic complications",
                      "Hemorrhagic complications"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "CBC and peripheral blood smear reviewCytopenias includeAnemiaNeutropeniaThrombocytopenia",
                    "sub_points": [
                      "Cytopenias includeAnemiaNeutropeniaThrombocytopenia",
                      "Anemia",
                      "Neutropenia",
                      "Thrombocytopenia"
                    ]
                  },
                  {
                    "text": "Reticulocyte count: Not elevated"
                  },
                  {
                    "text": "Assess each lineage for dysplasia"
                  },
                  {
                    "text": "Bone marrow evaluationIron-stained aspirate smear or touch preparationCytogenetic evaluation",
                    "sub_points": [
                      "Iron-stained aspirate smear or touch preparation",
                      "Cytogenetic evaluation"
                    ]
                  },
                  {
                    "text": "Vitamin B12, folate, and iron levels are normal"
                  },
                  {
                    "text": "Erythropoietin level if transfusion dependent"
                  }
                ],
                "Treatment": [],
                "Adjuvant therapy": [
                  {
                    "text": "Very low-risk MDSNo treatment if stableFollow regularly",
                    "sub_points": [
                      "No treatment if stable",
                      "Follow regularly"
                    ]
                  },
                  {
                    "text": "Intermediate-risk cytogeneticsMonitor every 3 months if no symptoms",
                    "sub_points": [
                      "Monitor every 3 months if no symptoms"
                    ]
                  },
                  {
                    "text": "If symptomaticRed blood cell transfusions for significant anemiaPlatelet transfusions for marked thrombocytopenia (rare)",
                    "sub_points": [
                      "Red blood cell transfusions for significant anemia",
                      "Platelet transfusions for marked thrombocytopenia (rare)"
                    ]
                  }
                ],
                "Drugs": [
                  {
                    "text": "Recombinant erythropoietin therapy if inadequate endogenous production"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Low-grade MDSProlonged and indolent courseMedian survival is ~ 6 yearsSome cases have survivals similar to peersRare cases behave more like RCMDLow incidence of progression to AML< 1% per year~ 2-10% at 5 yearsRefractory anemiaUsually low or intermediate risk scoresRefractory thrombocytopeniaLow risk scores90% alive at > 2 years",
                    "sub_points": [
                      "Prolonged and indolent courseMedian survival is ~ 6 yearsSome cases have survivals similar to peersRare cases behave more like RCMD",
                      "Median survival is ~ 6 years",
                      "Some cases have survivals similar to peers",
                      "Rare cases behave more like RCMD",
                      "Low incidence of progression to AML< 1% per year~ 2-10% at 5 years",
                      "< 1% per year",
                      "~ 2-10% at 5 years",
                      "Refractory anemiaUsually low or intermediate risk scores",
                      "Usually low or intermediate risk scores",
                      "Refractory thrombocytopeniaLow risk scores90% alive at > 2 years",
                      "Low risk scores",
                      "90% alive at > 2 years"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Peripheral Blood": [
                  {
                    "text": "< 1% blasts"
                  },
                  {
                    "text": "Evaluate for dysplasiaRed blood cells, myeloid lineage, or platelets",
                    "sub_points": [
                      "Red blood cells, myeloid lineage, or platelets"
                    ]
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "< 5% blastsNo aggregates or clusters of blasts (CD34[+]) in biopsy sections",
                    "sub_points": [
                      "No aggregates or clusters of blasts (CD34[+]) in biopsy sections"
                    ]
                  },
                  {
                    "text": "Dysplasia in ≥ 10% of cells in single lineageDyserythropoiesis needs to be significant",
                    "sub_points": [
                      "Dyserythropoiesis needs to be significant"
                    ]
                  },
                  {
                    "text": "Adequate or increased precursors in lineage with cytopenia"
                  },
                  {
                    "text": "Prussian blue stained aspirate smearIron stores may be increasedRing sideroblasts: < 15% of erythroid precursors",
                    "sub_points": [
                      "Iron stores may be increased",
                      "Ring sideroblasts: < 15% of erythroid precursors"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Refractory Anemia with Ring Sideroblasts": [
                  {
                    "text": "Similar to RCUD except that erythroid lineage has ≥ 15% ring sideroblasts"
                  }
                ],
                "Myelodysplastic Syndrome, Unclassifiable": [
                  {
                    "text": "Similar to RCUD except 1% blasts in peripheral blood or presence of pancytopenia"
                  }
                ],
                "Idiopathic Cytopenia of Undetermined Lineage": [
                  {
                    "text": "Proposed term for persistent cytopeniaInvolving 1 or more myeloid lineages> 6 months duration",
                    "sub_points": [
                      "Involving 1 or more myeloid lineages",
                      "> 6 months duration"
                    ]
                  },
                  {
                    "text": "No cytogenetic abnormality that would be presumptive evidence of MDS"
                  }
                ],
                "Erythroid Dysplasia Secondary to Nonneoplastic Process": [
                  {
                    "text": "Nutrient deficiency: Vitamin B12, folate, or copper"
                  },
                  {
                    "text": "Infection: HIV"
                  },
                  {
                    "text": "Chemotherapy or other drug"
                  },
                  {
                    "text": "Toxins: Alcohol, lead, or arsenic poisoning"
                  },
                  {
                    "text": "Inherited disorder: Congenital dyserythropoietic anemia"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Refractory Anemia With Multilineage Dysplasia": {
            "name": "Refractory Anemia With Multilineage Dysplasia",
            "url": "https://app.pathprimer.com/document/19b47134-50e9-410e-bf96-e023c28a0136/lesson/b91f9007-5151-4611-a335-6c428b56c3e0",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "MDS with cytopenia(s) and dysplasiaCytopenia in 1 or more lineagesDysplasia in 2 or more lineages",
                    "sub_points": [
                      "Cytopenia in 1 or more lineages",
                      "Dysplasia in 2 or more lineages"
                    ]
                  },
                  {
                    "text": "Blasts< 1% in peripheral blood, < 5% in bone marrow",
                    "sub_points": [
                      "< 1% in peripheral blood, < 5% in bone marrow"
                    ]
                  },
                  {
                    "text": "Account for 30-40% of MDS"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Clonal expansion of a neoplastic hematopoietic stem/progenitor cell"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Patients commonly seek medical attention for symptoms of anemia"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Dysplasia"
                  },
                  {
                    "text": "Bone marrowTypically hypercellularAbnormal architecture in biopsy sections",
                    "sub_points": [
                      "Typically hypercellular",
                      "Abnormal architecture in biopsy sections"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Perform CD34 immunostains on biopsy sectionsIf aggregates (3-5 cells) or clusters (> 5 cells) of CD34 positive blasts, consider RAEB instead",
                    "sub_points": [
                      "If aggregates (3-5 cells) or clusters (> 5 cells) of CD34 positive blasts, consider RAEB instead"
                    ]
                  },
                  {
                    "text": "Cytogenetic analysis50% have abnormal karyotypes~ 20% have unfavorable karyotypes",
                    "sub_points": [
                      "50% have abnormal karyotypes",
                      "~ 20% have unfavorable karyotypes"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Myelodysplastic syndrome (MDS)"
                  },
                  {
                    "text": "Refractory cytopenia with multilineage dysplasia (RCMD)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "MDS with cytopenia(s) and dysplasia1 or more cytopeniasAnemia, neutropenia, &/or thrombocytopeniaDysplasia in 2 or more myeloid lineagesErythroid, granulocytic, and megakaryocyticBlasts: < 1% in peripheral blood, < 5% in bone marrow",
                    "sub_points": [
                      "1 or more cytopeniasAnemia, neutropenia, &/or thrombocytopenia",
                      "Anemia, neutropenia, &/or thrombocytopenia",
                      "Dysplasia in 2 or more myeloid lineagesErythroid, granulocytic, and megakaryocytic",
                      "Erythroid, granulocytic, and megakaryocytic",
                      "Blasts: < 1% in peripheral blood, < 5% in bone marrow"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Environmental Exposure": [
                  {
                    "text": "Benzene and other industrial solvents"
                  },
                  {
                    "text": "Insecticides, pesticides"
                  },
                  {
                    "text": "Cigarette smoking"
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "Clonal expansion of a neoplastic hematopoietic stem/progenitor cellGene mutationsMaintain proliferation of early progenitor cellsAbnormal cell maturationProportional loss of mature cellsProgressive decrease in normal hematopoietic stem/progenitor cellsRole for tumor suppressor genes in disease onsetAbnormal T-cell mediated immune dysregulationSecondary B-cell immune dysregulationAbnormal marrow microenvironmentIneffective hematopoiesisPeripheral cytopeniasIncreased apoptosis of late marrow precursors",
                    "sub_points": [
                      "Gene mutationsMaintain proliferation of early progenitor cellsAbnormal cell maturationProportional loss of mature cells",
                      "Maintain proliferation of early progenitor cells",
                      "Abnormal cell maturation",
                      "Proportional loss of mature cells",
                      "Progressive decrease in normal hematopoietic stem/progenitor cellsRole for tumor suppressor genes in disease onsetAbnormal T-cell mediated immune dysregulationSecondary B-cell immune dysregulationAbnormal marrow microenvironment",
                      "Role for tumor suppressor genes in disease onset",
                      "Abnormal T-cell mediated immune dysregulation",
                      "Secondary B-cell immune dysregulation",
                      "Abnormal marrow microenvironment",
                      "Ineffective hematopoiesisPeripheral cytopeniasIncreased apoptosis of late marrow precursors",
                      "Peripheral cytopenias",
                      "Increased apoptosis of late marrow precursors"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Accounts for 30-40% of MDS"
                  }
                ],
                "Age": [
                  {
                    "text": "Disease of older individualsPeak incidence for men is 70-74 yearsPeak incidence for women is 75-79 years",
                    "sub_points": [
                      "Peak incidence for men is 70-74 years",
                      "Peak incidence for women is 75-79 years"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "Incidence is slightly higher in men"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Symptoms relate to cytopeniasCommonly seek medical attention for symptoms of anemiaFatigue, dyspnea, palpitations, headache, dizzinessExaggerated bleedingThrombocytopenia and platelet dysfunctionInfectionNeutropenia and neutrophil dysfunction",
                    "sub_points": [
                      "Commonly seek medical attention for symptoms of anemiaFatigue, dyspnea, palpitations, headache, dizziness",
                      "Fatigue, dyspnea, palpitations, headache, dizziness",
                      "Exaggerated bleedingThrombocytopenia and platelet dysfunction",
                      "Thrombocytopenia and platelet dysfunction",
                      "InfectionNeutropenia and neutrophil dysfunction",
                      "Neutropenia and neutrophil dysfunction"
                    ]
                  },
                  {
                    "text": "Occasional mild hepatomegaly or splenomegaly"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Complete blood count and differential cell countDegree of cytopenia required unless definitive morphologic or cytogenetic abnormalitiesHemoglobin < 10g/dLNeutrophil count < 1.8 x 10⁹/LPlatelet count < 100 x 10⁹/L",
                    "sub_points": [
                      "Degree of cytopenia required unless definitive morphologic or cytogenetic abnormalitiesHemoglobin < 10g/dLNeutrophil count < 1.8 x 10⁹/LPlatelet count < 100 x 10⁹/L",
                      "Hemoglobin < 10g/dL",
                      "Neutrophil count < 1.8 x 10⁹/L",
                      "Platelet count < 100 x 10⁹/L"
                    ]
                  },
                  {
                    "text": "Bone marrow evaluationCytogenetic evaluation is essential",
                    "sub_points": [
                      "Cytogenetic evaluation is essential"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Allogeneic hematopoietic stem cell transplantationOnly curative treatmentReduced intensity conditioning regimens reduce morbidity",
                    "sub_points": [
                      "Only curative treatment",
                      "Reduced intensity conditioning regimens reduce morbidity"
                    ]
                  }
                ],
                "Options, risks, complications": [
                  {
                    "text": "Therapeutic considerations are based on the following factorsAge and comorbidities, risk category",
                    "sub_points": [
                      "Age and comorbidities, risk category"
                    ]
                  },
                  {
                    "text": "Higher risk disease in patients who cannot tolerate high-intensity therapySupportive care alone, new therapeutic agents",
                    "sub_points": [
                      "Supportive care alone, new therapeutic agents"
                    ]
                  }
                ],
                "Drugs": [
                  {
                    "text": "Immunomodulatory drugs"
                  },
                  {
                    "text": "Methyltransferase inhibitors"
                  },
                  {
                    "text": "Azacytidine and decitabineProlongs survival in intermediate- to high-risk patients",
                    "sub_points": [
                      "Prolongs survival in intermediate- to high-risk patients"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Majority of patients have intermediate IPSS risk score"
                  },
                  {
                    "text": "Pathologic determinants of prognosis includeType of karyotypic abnormalitiesComplex karyotype or -7 are poor prognostic markersDegree of cytopenias or dysplasiaPresence of circulating blasts and blast % in bone marrow",
                    "sub_points": [
                      "Type of karyotypic abnormalitiesComplex karyotype or -7 are poor prognostic markers",
                      "Complex karyotype or -7 are poor prognostic markers",
                      "Degree of cytopenias or dysplasia",
                      "Presence of circulating blasts and blast % in bone marrow"
                    ]
                  },
                  {
                    "text": "Overall median survival is 30-60 months~ 10% develop AML at 2 years after diagnosisPatients with complex karyotypes have similar survivals to patients with refractory anemia with excess blasts (RAEB)",
                    "sub_points": [
                      "~ 10% develop AML at 2 years after diagnosis",
                      "Patients with complex karyotypes have similar survivals to patients with refractory anemia with excess blasts (RAEB)"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Peripheral Blood": [
                  {
                    "text": "Unicytopenia or bicytopeniaAnemia is often macrocyticReduced polychromasiaDysplasiaMay need buffy coat if markedly leukopenic",
                    "sub_points": [
                      "Anemia is often macrocyticReduced polychromasia",
                      "Reduced polychromasia",
                      "DysplasiaMay need buffy coat if markedly leukopenic",
                      "May need buffy coat if markedly leukopenic"
                    ]
                  },
                  {
                    "text": "< 1% circulating blasts"
                  },
                  {
                    "text": "No monocytosis or pancytopenia"
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "Typically hypercellular≥ 10% dysplasia in 2 or 3 lineagesMegakaryocyte dysplasia is based on assessment of ≥ 30 megakaryocytes in biopsy sectionsSome studies suggest > 40% megakaryocytic dysplasia is better criterion than ≥ 10%< 5% blastsAbnormal architecture in biopsy sectionsAbnormal localization of immature precursors (ALIP)Abnormal paratrabecular location of megakaryocytes or erythroid precursorsIncreased megakaryocytes with clusteringDisruption of erythroid colonies",
                    "sub_points": [
                      "≥ 10% dysplasia in 2 or 3 lineagesMegakaryocyte dysplasia is based on assessment of ≥ 30 megakaryocytes in biopsy sectionsSome studies suggest > 40% megakaryocytic dysplasia is better criterion than ≥ 10%",
                      "Megakaryocyte dysplasia is based on assessment of ≥ 30 megakaryocytes in biopsy sections",
                      "Some studies suggest > 40% megakaryocytic dysplasia is better criterion than ≥ 10%",
                      "< 5% blasts",
                      "Abnormal architecture in biopsy sectionsAbnormal localization of immature precursors (ALIP)Abnormal paratrabecular location of megakaryocytes or erythroid precursorsIncreased megakaryocytes with clusteringDisruption of erythroid colonies",
                      "Abnormal localization of immature precursors (ALIP)",
                      "Abnormal paratrabecular location of megakaryocytes or erythroid precursors",
                      "Increased megakaryocytes with clustering",
                      "Disruption of erythroid colonies"
                    ]
                  },
                  {
                    "text": "Subset of cases may be hypocellular or fibroticHistiocytes often increased",
                    "sub_points": [
                      "Histiocytes often increased"
                    ]
                  },
                  {
                    "text": "Prussian blue iron stainEvaluate aspirate smear or touch preparationIncreased stores &/or erythroid iron incorporationIncreased erythroid iron incorporationRing sideroblasts may comprise ≥ 15% of erythroid precursors",
                    "sub_points": [
                      "Evaluate aspirate smear or touch preparation",
                      "Increased stores &/or erythroid iron incorporationIncreased erythroid iron incorporationRing sideroblasts may comprise ≥ 15% of erythroid precursors",
                      "Increased erythroid iron incorporation",
                      "Ring sideroblasts may comprise ≥ 15% of erythroid precursors"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Perform CD34 immunostains on biopsy sectionsIf aggregates (3-5 cells) or clusters (> 5 cells) of CD34 positive blasts, consider RAEB instead",
                    "sub_points": [
                      "If aggregates (3-5 cells) or clusters (> 5 cells) of CD34 positive blasts, consider RAEB instead"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Karyotypic abnormalities present in ~ 50% of patientsCommonly +8, -7, del(7q), -5, del(5q), and del(20q), complex karyotypes~ 20% have unfavorable karyotypes",
                    "sub_points": [
                      "Commonly +8, -7, del(7q), -5, del(5q), and del(20q), complex karyotypes",
                      "~ 20% have unfavorable karyotypes"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Nutritional Deficiencies": [
                  {
                    "text": "Vitamin B12, folic acid, and copper deficiency"
                  }
                ],
                "Exposure to Heavy Metals or Toxins": [
                  {
                    "text": "Particularly arsenic"
                  }
                ],
                "Chemotherapy or Drug Effect": [
                  {
                    "text": "Associated cytopenias or dysplasiaAntibiotics (i.e., cotrimoxazole) may cause nuclear hypolobation of neutrophils",
                    "sub_points": [
                      "Antibiotics (i.e., cotrimoxazole) may cause nuclear hypolobation of neutrophils"
                    ]
                  }
                ],
                "Congenital Hematologic Disorders": [
                  {
                    "text": "Development of secondary MDS associated withFanconi anemiaDyskeratosis congenitaShwachman-Diamond syndromeSevere congenital neutropenia",
                    "sub_points": [
                      "Fanconi anemia",
                      "Dyskeratosis congenita",
                      "Shwachman-Diamond syndrome",
                      "Severe congenital neutropenia"
                    ]
                  }
                ],
                "Therapy-related Myeloid Neoplasms": [
                  {
                    "text": "Patients who have received cytotoxic chemotherapy, radiation therapy, or allogeneic stem cell transplantsSimilar morphologic findings as RCMD",
                    "sub_points": [
                      "Similar morphologic findings as RCMD"
                    ]
                  }
                ],
                "Other Myelodysplastic Syndromes": [
                  {
                    "text": "Refractory anemia with excess blasts (1, 2)Multilineage dysplasia and2-19% blasts in peripheral blood5-19% blasts in bone marrowAuer rods advance MDS case to RAEB-2",
                    "sub_points": [
                      "Multilineage dysplasia and2-19% blasts in peripheral blood5-19% blasts in bone marrowAuer rods advance MDS case to RAEB-2",
                      "2-19% blasts in peripheral blood",
                      "5-19% blasts in bone marrow",
                      "Auer rods advance MDS case to RAEB-2"
                    ]
                  },
                  {
                    "text": "Myelodysplastic syndrome, unclassifiableCase does not fulfill criteria for other MDS subtype",
                    "sub_points": [
                      "Case does not fulfill criteria for other MDS subtype"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Refractory Anemia With Excess Blasts": {
            "name": "Refractory Anemia With Excess Blasts",
            "url": "https://app.pathprimer.com/document/2445db33-1947-484e-9860-32e06497bef6/lesson/b91f9007-5151-4611-a335-6c428b56c3e0",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "MDS with increased blasts or Auer rods"
                  },
                  {
                    "text": "RAEB-12-4% blasts in peripheral bloodor5-9% blasts in bone marrow",
                    "sub_points": [
                      "2-4% blasts in peripheral bloodor",
                      "5-9% blasts in bone marrow"
                    ]
                  },
                  {
                    "text": "RAEB-25-19% blasts in peripheral bloodor10-19% blasts in bone marroworAuer rods",
                    "sub_points": [
                      "5-19% blasts in peripheral bloodor",
                      "10-19% blasts in bone marrowor",
                      "Auer rods"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "35-40% of MDSMost MDS with reticulin fibrosis is RAEB-F25% 5-year survival rate",
                    "sub_points": [
                      "Most MDS with reticulin fibrosis is RAEB-F",
                      "25% 5-year survival rate"
                    ]
                  },
                  {
                    "text": "Progress to AML at 5 years25% of RAEB-1 cases35% (to 50%) of RAEB-2 cases",
                    "sub_points": [
                      "25% of RAEB-1 cases",
                      "35% (to 50%) of RAEB-2 cases"
                    ]
                  },
                  {
                    "text": "High-risk MDSMay be treated similarly to AML",
                    "sub_points": [
                      "May be treated similarly to AML"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Dysplasia is often more pronounced than for other types of MDS"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Cytogenetic analysis is essential"
                  },
                  {
                    "text": "ImmunohistochemistryArchitectural abnormalities are common",
                    "sub_points": [
                      "Architectural abnormalities are common"
                    ]
                  },
                  {
                    "text": "Flow cytometryAbnormal maturation patterns common",
                    "sub_points": [
                      "Abnormal maturation patterns common"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Refractory anemia with excess blasts (RAEB)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Myelodysplastic syndrome (MDS) with increased blasts or Auer rods"
                  },
                  {
                    "text": "2 categories based on prognosisRAEB-12-4% blasts in peripheral bloodor5-9% blasts in bone marrowRAEB-25-19% blasts in peripheral bloodor10-19% blasts in bone marrowAuer rods, if present, advance MDS case to RAEB-2",
                    "sub_points": [
                      "RAEB-12-4% blasts in peripheral bloodor5-9% blasts in bone marrow",
                      "2-4% blasts in peripheral bloodor",
                      "5-9% blasts in bone marrow",
                      "RAEB-25-19% blasts in peripheral bloodor10-19% blasts in bone marrowAuer rods, if present, advance MDS case to RAEB-2",
                      "5-19% blasts in peripheral bloodor",
                      "10-19% blasts in bone marrow",
                      "Auer rods, if present, advance MDS case to RAEB-2"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Hematopoietic Stem Cell Disorder": [
                  {
                    "text": "Clonal hematopoietic stem cell disorder"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "35-40% of MDS15-20% RAEB-120% RAEB-2Associated reticulin fibrosis seen in ~ 10% of MDS; most are RAEB-F (fibrosis)",
                    "sub_points": [
                      "15-20% RAEB-1",
                      "20% RAEB-2",
                      "Associated reticulin fibrosis seen in ~ 10% of MDS; most are RAEB-F (fibrosis)"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Older individuals, primarily > 50 years of age"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Often seek medical attention for symptoms of anemiaFatigue, dyspnea, palpitations, headache, dizziness",
                    "sub_points": [
                      "Fatigue, dyspnea, palpitations, headache, dizziness"
                    ]
                  },
                  {
                    "text": "Other symptoms related to cytopeniasExaggerated bleeding from thrombocytopenia with platelet dysfunctionInfection secondary to decreased neutrophils and neutrophil dysfunction",
                    "sub_points": [
                      "Exaggerated bleeding from thrombocytopenia with platelet dysfunction",
                      "Infection secondary to decreased neutrophils and neutrophil dysfunction"
                    ]
                  },
                  {
                    "text": "Occasional mild hepatomegaly or splenomegaly"
                  }
                ],
                "Treatment": [
                  {
                    "text": "High-risk MDSMay be treated similarly to acute myeloid leukemia (AML)Depends partly on tempo of disease progressionIntensive chemotherapy with variety of regimensRAEB-2 patients who are candidates for stem cell transplantationTopotecan-cytarabine or idarubicin-cytarabine-based regimens",
                    "sub_points": [
                      "May be treated similarly to acute myeloid leukemia (AML)Depends partly on tempo of disease progression",
                      "Depends partly on tempo of disease progression",
                      "Intensive chemotherapy with variety of regimens",
                      "RAEB-2 patients who are candidates for stem cell transplantationTopotecan-cytarabine or idarubicin-cytarabine-based regimens",
                      "Topotecan-cytarabine or idarubicin-cytarabine-based regimens"
                    ]
                  },
                  {
                    "text": "Hematopoietic stem cell transplantationPatient must have low comorbidity scoresHigh upfront treatment-related mortalityMay want to delay for low-risk or intermediate-risk patientsRisk of relapse increases if cytogenetics classified as poor risk",
                    "sub_points": [
                      "Patient must have low comorbidity scores",
                      "High upfront treatment-related mortalityMay want to delay for low-risk or intermediate-risk patients",
                      "May want to delay for low-risk or intermediate-risk patients",
                      "Risk of relapse increases if cytogenetics classified as poor risk"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "25% 5-year survival ratePatients have progressive bone marrow failure with increasing cytopeniasDie from complications such as bleeding and infectionsSubset progresses to AML25% of RAEB-1 cases at 5 years35% (to 50%) of RAEB-2 cases at 5 years",
                    "sub_points": [
                      "Patients have progressive bone marrow failure with increasing cytopeniasDie from complications such as bleeding and infections",
                      "Die from complications such as bleeding and infections",
                      "Subset progresses to AML25% of RAEB-1 cases at 5 years35% (to 50%) of RAEB-2 cases at 5 years",
                      "25% of RAEB-1 cases at 5 years",
                      "35% (to 50%) of RAEB-2 cases at 5 years"
                    ]
                  },
                  {
                    "text": "Predicted survival based on blast percentage, cytogenetic abnormalities, cytopeniasRAEB-1Intermediate-risk prognostic groupMedian survival is ~ 16-40 monthsRAEB-2High-risk groupMedian survival is ~ 9-20 months",
                    "sub_points": [
                      "RAEB-1Intermediate-risk prognostic groupMedian survival is ~ 16-40 months",
                      "Intermediate-risk prognostic group",
                      "Median survival is ~ 16-40 months",
                      "RAEB-2High-risk groupMedian survival is ~ 9-20 months",
                      "High-risk group",
                      "Median survival is ~ 9-20 months"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Cytologic Features": [
                  {
                    "text": "Peripheral bloodAnemia with anisopoikilocytosisNeutropenia with dysplastic featuresBlasts increased but < 20%ThrombocytopeniaGiant or hypogranular platelets",
                    "sub_points": [
                      "Anemia with anisopoikilocytosis",
                      "Neutropenia with dysplastic features",
                      "Blasts increased but < 20%",
                      "ThrombocytopeniaGiant or hypogranular platelets",
                      "Giant or hypogranular platelets"
                    ]
                  },
                  {
                    "text": "Bone marrowUsually hypercellular, often multilineage dysplasiaDysplasia is often (but not always) more pronounced than for other types of MDSIncreased blasts in clusters or aggregatesErythropoiesis may be increased, variably dysplasticColony formation disrupted or abnormally located near paratrabecular areasGranulopoiesis may be increased, variably dysplasticAbnormal localization of immature precursors (ALIP) in nonparatrabecular areasMegakaryocytes may be increased, variably dysplastic",
                    "sub_points": [
                      "Usually hypercellular, often multilineage dysplasiaDysplasia is often (but not always) more pronounced than for other types of MDS",
                      "Dysplasia is often (but not always) more pronounced than for other types of MDS",
                      "Increased blasts in clusters or aggregates",
                      "Erythropoiesis may be increased, variably dysplasticColony formation disrupted or abnormally located near paratrabecular areas",
                      "Colony formation disrupted or abnormally located near paratrabecular areas",
                      "Granulopoiesis may be increased, variably dysplasticAbnormal localization of immature precursors (ALIP) in nonparatrabecular areas",
                      "Abnormal localization of immature precursors (ALIP) in nonparatrabecular areas",
                      "Megakaryocytes may be increased, variably dysplastic"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Biopsy sectionsCD34 for blasts; CD117 if blasts are CD34(-)Myeloperoxidase or CD33 for myeloid evaluationHemoglobin A, glycophorin, or CD71 for erythroid evaluation",
                    "sub_points": [
                      "CD34 for blasts; CD117 if blasts are CD34(-)",
                      "Myeloperoxidase or CD33 for myeloid evaluation",
                      "Hemoglobin A, glycophorin, or CD71 for erythroid evaluation"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Increased blasts by flow cytometric analysisUsually positive for CD34 &/or CD117Commonly positive for CD38, HLA-DR, CD33, CD13Aberrant expression of CD7 (20%) and CD56 (10%)",
                    "sub_points": [
                      "Usually positive for CD34 &/or CD117",
                      "Commonly positive for CD38, HLA-DR, CD33, CD13",
                      "Aberrant expression of CD7 (20%) and CD56 (10%)"
                    ]
                  },
                  {
                    "text": "Abnormal maturation patterns common"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Provides prognostic informationExcludes low blast count AML",
                    "sub_points": [
                      "Excludes low blast count AML"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Recovery from Bone Marrow Aplasia": [
                  {
                    "text": "Transient increase in blasts> 5% regenerative blastsGrowth factor effect (if given) with increased blasts",
                    "sub_points": [
                      "> 5% regenerative blasts",
                      "Growth factor effect (if given) with increased blasts"
                    ]
                  }
                ],
                "De Novo AML with Low Blast Count": [
                  {
                    "text": "Consider if Auer rods presentAuer rods are rare in MDS",
                    "sub_points": [
                      "Auer rods are rare in MDS"
                    ]
                  },
                  {
                    "text": "Cytogenetic evidence for specific translocation regardless of blast countt(15;17), t(8;21), inv16, t(16;16), t(9:11), t(11;19), t(11;17), t(8;16), t(1;22)",
                    "sub_points": [
                      "t(15;17), t(8;21), inv16, t(16;16), t(9:11), t(11;19), t(11;17), t(8;16), t(1;22)"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Blast percentage is based on visual inspection, not flow cytometry result"
                  },
                  {
                    "text": "Blasts may be difficult to differentiate from dysplastic promyelocytes and myelocytesIf blasts are CD34(+), immunostains help to quantify in biopsy sections",
                    "sub_points": [
                      "If blasts are CD34(+), immunostains help to quantify in biopsy sections"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Myelodysplastic Syndrome with Isolated del(5q)": {
            "name": "Myelodysplastic Syndrome with Isolated del(5q)",
            "url": "https://app.pathprimer.com/document/b9c5ef9e-9c14-41c9-9432-3624979e3760/lesson/b91f9007-5151-4611-a335-6c428b56c3e0",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Clonal hematopoietic neoplasm with an isolated del(5q) involving 5q31-5q33 region"
                  },
                  {
                    "text": "Blasts < 1% in peripheral blood (PB) and < 5% in bone marrow (BM)"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "PBThrombocytosisAnemiaBlasts < 1%",
                    "sub_points": [
                      "Thrombocytosis",
                      "Anemia",
                      "Blasts < 1%"
                    ]
                  },
                  {
                    "text": "BMNormocellular to hypercellularMegakaryocytic proliferationAbnormal megakaryocytic morphology: Small, hypo-/monolobatedBlasts < 5%",
                    "sub_points": [
                      "Normocellular to hypercellular",
                      "Megakaryocytic proliferation",
                      "Abnormal megakaryocytic morphology: Small, hypo-/monolobated",
                      "Blasts < 5%"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "CytogeneticsIdentifyisolateddel(5q)Deleted 5q region is variable but includes 5q31-5q33",
                    "sub_points": [
                      "Identifyisolateddel(5q)",
                      "Deleted 5q region is variable but includes 5q31-5q33"
                    ]
                  },
                  {
                    "text": "FISHUseful to demonstrate del(5q) if cytogenetics suboptimalIncapableof excluding presence of additional cytogenetic abnormalities",
                    "sub_points": [
                      "Useful to demonstrate del(5q) if cytogenetics suboptimal",
                      "Incapableof excluding presence of additional cytogenetic abnormalities"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Myelodysplastic syndrome (MDS)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "5q minus syndrome"
                  },
                  {
                    "text": "MDS with deletion 5q"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Clonal hematopoietic neoplasm with an isolated del(5q) involving 5q31-5q33 region"
                  },
                  {
                    "text": "Blasts < 1% in PB and < 5% in BM)"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Commonly Deleted Region (CDR) at 5q": [
                  {
                    "text": "RPS14deficiencyRPS14 is a component of the ribosomal subunit 40SPoor erythroid developmentIncreased erythroid apoptosisDoes not explain thrombocytosis or stem cell expansion",
                    "sub_points": [
                      "RPS14 is a component of the ribosomal subunit 40S",
                      "Poor erythroid development",
                      "Increased erythroid apoptosis",
                      "Does not explain thrombocytosis or stem cell expansion"
                    ]
                  },
                  {
                    "text": "Decreased microRNA expression; miR-145 and miR-146aInduces 5q minus phenotype in miceHypolobated megakaryocytes and thrombocytosis",
                    "sub_points": [
                      "Induces 5q minus phenotype in miceHypolobated megakaryocytes and thrombocytosis",
                      "Hypolobated megakaryocytes and thrombocytosis"
                    ]
                  },
                  {
                    "text": "SPARC,EGR1, andCTNNA1haploinsufficiencyThese genes may also play a role",
                    "sub_points": [
                      "These genes may also play a role"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Age": [
                  {
                    "text": "Adults; median age: 75 years"
                  }
                ],
                "Sex": [
                  {
                    "text": "Female predominance"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Abnormal complete blood cell count (CBC)"
                  },
                  {
                    "text": "Anemia"
                  },
                  {
                    "text": "Thrombocytosis (usually)"
                  },
                  {
                    "text": "Variable other cytopenias"
                  },
                  {
                    "text": "Blasts < 1% in peripheral blood"
                  }
                ],
                "Treatment": [],
                "Drugs": [
                  {
                    "text": "LenalidomideCategorized as an immunomodulatory agentAchieves durable transfusion independence in 2/3 of patientsReturn of BM cellularity close to normal",
                    "sub_points": [
                      "Categorized as an immunomodulatory agent",
                      "Achieves durable transfusion independence in 2/3 of patients",
                      "Return of BM cellularity close to normal"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Good"
                  },
                  {
                    "text": "Median overall survival: > 12 years"
                  },
                  {
                    "text": "Low risk of transformation to acute myeloid leukemia"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Peripheral Blood": [
                  {
                    "text": "Macrocytic anemia"
                  },
                  {
                    "text": "Variable other cytopenias"
                  },
                  {
                    "text": "Thrombocytopenia is distinctly unusualPatients typically have thrombocytosis",
                    "sub_points": [
                      "Patients typically have thrombocytosis"
                    ]
                  },
                  {
                    "text": "Blasts < 1%"
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "Normocellular to hypercellular"
                  },
                  {
                    "text": "Megakaryocytic proliferation"
                  },
                  {
                    "text": "Abnormal megakaryocytic morphologySmall hypo-/monolobated or \"micromegakaryocytes\"May have distinctly separate nuclei",
                    "sub_points": [
                      "Small hypo-/monolobated or \"micromegakaryocytes\"",
                      "May have distinctly separate nuclei"
                    ]
                  },
                  {
                    "text": "Blasts < 5% of nucleated cellsNo Auer rods",
                    "sub_points": [
                      "No Auer rods"
                    ]
                  },
                  {
                    "text": "No significant erythroid or granulocytic dysplasia"
                  },
                  {
                    "text": "Erythroid elements may be decreased"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Flow Cytometry": [
                  {
                    "text": "Myeloblast population may be identifiedCD34(+), CD117(+), CD13(+), CD33(+), myeloperoxidase(+)Aberrant immunophenotype may be present",
                    "sub_points": [
                      "CD34(+), CD117(+), CD13(+), CD33(+), myeloperoxidase(+)",
                      "Aberrant immunophenotype may be present"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Deletion 5qPresent as sole abnormalityMay variably extend along long arm of chromosome 5q but always involves deletion of 5q31-5q33 region",
                    "sub_points": [
                      "Present as sole abnormality",
                      "May variably extend along long arm of chromosome 5q but always involves deletion of 5q31-5q33 region"
                    ]
                  },
                  {
                    "text": "No other cytogenetic abnormalities identified"
                  }
                ],
                "Fluorescence In Situ Hybridization": [
                  {
                    "text": "Detection of 5q deletion in setting of suboptimal cytogenetic study"
                  },
                  {
                    "text": "Incapableof determining whether deletion of 5q is isolated"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Other Subtypes of MDS": [
                  {
                    "text": "Refractory cytopenias with multilineage dysplasiaMultilineage dysplasia uncommon in MDS with del(5q)",
                    "sub_points": [
                      "Multilineage dysplasia uncommon in MDS with del(5q)"
                    ]
                  },
                  {
                    "text": "Refractory anemia with excess blastsBlasts ≥ 5% in BMMay see Auer rods",
                    "sub_points": [
                      "Blasts ≥ 5% in BM",
                      "May see Auer rods"
                    ]
                  }
                ],
                "Caveats": [
                  {
                    "text": "Strict WHO criteria must be utilized"
                  },
                  {
                    "text": "Cases with > 5% blasts or additional cytogenetic abnormalitiesAdverse outcomeBelong in another WHO category",
                    "sub_points": [
                      "Adverse outcome",
                      "Belong in another WHO category"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms": {
        "name": "Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms",
        "url": "https://app.pathprimer.com/lesson/74c9ecc8-b842-4e36-acf8-277b06dc00d9",
        "topics": {
          "Overview of Myeloproliferative Neoplasms": {
            "name": "Overview of Myeloproliferative Neoplasms",
            "url": "https://app.pathprimer.com/document/48e2882a-1979-4645-880b-11a9aca79678/lesson/74c9ecc8-b842-4e36-acf8-277b06dc00d9",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Myeloproliferative neoplasms (MPNs)"
                  },
                  {
                    "text": "International Consensus Classification (ICC)"
                  },
                  {
                    "text": "WHO 5th edition (WHO-HAEM5)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Chronic myeloproliferative disorders (CMPD)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Clonal hematopoietic (HP) neoplasm characterized by bone marrow hypercellularity and intact maturation with effective hematopoieses, resulting in elevations of ≥ 1 HP lineages in bloodMyeloblasts not substantially increased, and dysplasia is not significant in chronic phase of MPNMolecular genetic abnormalities are present in MPN and define several subtypesMutation status also predictive of outcomeMutations in tyrosine kinase genes in most MPNs~ 5-8% of classic (JAK2-predominant) MPN cases are unclassifiable",
                    "sub_points": [
                      "Myeloblasts not substantially increased, and dysplasia is not significant in chronic phase of MPN",
                      "Molecular genetic abnormalities are present in MPN and define several subtypesMutation status also predictive of outcome",
                      "Mutation status also predictive of outcome",
                      "Mutations in tyrosine kinase genes in most MPNs",
                      "~ 5-8% of classic (JAK2-predominant) MPN cases are unclassifiable"
                    ]
                  }
                ]
              },
              "Classification": {
                "ICC/WHO-HAEM5 Classification of MPN Into 4 Broad Categories": [
                  {
                    "text": "1 MPN defined byBCR::ABL1fusion:Chronic myeloid leukemia (CML)"
                  },
                  {
                    "text": "4JAK2mutation-predominant (classic) MPNs:Polycythemia vera(PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), andMPN, unclassifiable(MPN-U)"
                  },
                  {
                    "text": "1CSF3Rmutation-associated MPN:Chronic neutrophilic leukemia (CNL)"
                  },
                  {
                    "text": "1 eosinophilia-related MPN:Chronic eosinophilic leukemia, not otherwise specified (CEL, NOS)"
                  },
                  {
                    "text": "MPN-UCases do not fulfill criteria for other MPN but have many features or overlapping features of MPNsUsually has features ofJAK2mutation-predominant (classic) MPN",
                    "sub_points": [
                      "Cases do not fulfill criteria for other MPN but have many features or overlapping features of MPNsUsually has features ofJAK2mutation-predominant (classic) MPN",
                      "Usually has features ofJAK2mutation-predominant (classic) MPN"
                    ]
                  }
                ],
                "ICC and WHO-HAEM5 Classification Comparisons": [
                  {
                    "text": "Many similarities between ICC and WHO-HAEM5 MPN entities and diagnostic criteria"
                  },
                  {
                    "text": "ICC includes accelerated phase (AP) for CML, while WHO-HAEM5 does not include APWHO-HAEM5 considers CML biphasic disease (chronic and blast phase) in era of tyrosine kinase inhibitor (TKI) therapy",
                    "sub_points": [
                      "WHO-HAEM5 considers CML biphasic disease (chronic and blast phase) in era of tyrosine kinase inhibitor (TKI) therapy"
                    ]
                  },
                  {
                    "text": "WHO-HAEM5 includes juvenile myelomonocytic leukemia (JMML) in MPN category, while ICC includes JMML in new pediatric &/or germline mutation-associated disorders category"
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Age Range": [
                  {
                    "text": "MPNs predominate in middle-aged to older adults"
                  },
                  {
                    "text": "Rare presentations in children (CML most common)"
                  }
                ],
                "Sex": [
                  {
                    "text": "No striking predilection"
                  }
                ],
                "Ethnicity Relationship": [
                  {
                    "text": "No striking ethnic predilection"
                  }
                ],
                "Incidence": [
                  {
                    "text": "Rates for MPN subtypes range from rare case reports of CNL to 1-2 cases per 100,000 for CML and ET"
                  }
                ],
                "Natural History/Disease Course": [
                  {
                    "text": "Disease course best delineated for CML, PV, PMF, and ET"
                  },
                  {
                    "text": "ET often very indolent, requiring minimal antithrombotic therapy; prolonged survival times (> 25 years)Low rate of either fibrotic progression (< 10%) or progression to myelodysplasia or acute myeloid leukemia (< 5%)",
                    "sub_points": [
                      "Low rate of either fibrotic progression (< 10%) or progression to myelodysplasia or acute myeloid leukemia (< 5%)"
                    ]
                  },
                  {
                    "text": "PV characterized by long stable phase usually with eventual progression to myelofibrosis (> 10-year survival); substantial risk of thrombosis; antithrombotic therapy needed"
                  },
                  {
                    "text": "PMF shows variable survival times: Range of ~ 6-15 yearsJAK2vs.CALRvs.MPLvs. triple-negative mutation status linked to outcome and thrombosis riskMutation-enhanced International Prognostic Scoring System/others integrate cytogenetics and molecular findings",
                    "sub_points": [
                      "JAK2vs.CALRvs.MPLvs. triple-negative mutation status linked to outcome and thrombosis risk",
                      "Mutation-enhanced International Prognostic Scoring System/others integrate cytogenetics and molecular findings"
                    ]
                  },
                  {
                    "text": "CML patients experience overall 10-year survival rate of 80-90% due to effective TKI therapy"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Mutations in Tyrosine Kinase Genes Resulting in Constitutive Activation": [
                  {
                    "text": "Present in almost all types of common MPN"
                  },
                  {
                    "text": "BCR::ABL1fusion geneDefines CML; required for diagnosisResponsible for dysregulated overproduction of neutrophils, basophils, and variable other HP cells",
                    "sub_points": [
                      "Defines CML; required for diagnosis",
                      "Responsible for dysregulated overproduction of neutrophils, basophils, and variable other HP cells"
                    ]
                  },
                  {
                    "text": "JAK2V617F mutationDetected in virtually all cases of PV (alternateJAK2mutation in remainder)Detected in ~ 60% of ET and PMF casesOccasionally detected in other myeloid neoplasms",
                    "sub_points": [
                      "Detected in virtually all cases of PV (alternateJAK2mutation in remainder)",
                      "Detected in ~ 60% of ET and PMF cases",
                      "Occasionally detected in other myeloid neoplasms"
                    ]
                  },
                  {
                    "text": "CALRmutations in PMF and ET that lackJAK2mutationLinked to outcomeMany differentCALRmutations described with common feature of constitutive tyrosine kinase activity",
                    "sub_points": [
                      "Linked to outcome",
                      "Many differentCALRmutations described with common feature of constitutive tyrosine kinase activity"
                    ]
                  },
                  {
                    "text": "MPLW515 L/K mutationDetected in some PMF and ET cases",
                    "sub_points": [
                      "Detected in some PMF and ET cases"
                    ]
                  },
                  {
                    "text": "CSF3Rmutation characteristic in CNLPredominates in CNL but seen in other myeloid neoplasms, including atypical CML (aCML)",
                    "sub_points": [
                      "Predominates in CNL but seen in other myeloid neoplasms, including atypical CML (aCML)"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Presentation": [
                  {
                    "text": "Most MPNs exhibit indolent type of presentation with gradual onset of symptomatology"
                  },
                  {
                    "text": "Splenomegaly is hallmark of many MPNsCML, PV, PMF",
                    "sub_points": [
                      "CML, PV, PMF"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "CBC with differential provides many clues to MPN and specific MPN subtypesMarked nontoxic neutrophilia, left shift to blasts, and basophilia in CMLErythrocytosis in PVPV is only MPN in which erythrocytosis is featureLeukocytosis, leukoerythroblastic picture, and teardrop-shaped RBCs in PMF, fibrotic phaseThrombocytosis in ET; also common in CML, early, prefibrotic PMF, and prepolycythemic PVMarked mature neutrophilia with toxic changes and minimal left shift in CNLMarked eosinophilia in CEL, NOS",
                    "sub_points": [
                      "Marked nontoxic neutrophilia, left shift to blasts, and basophilia in CML",
                      "Erythrocytosis in PVPV is only MPN in which erythrocytosis is feature",
                      "PV is only MPN in which erythrocytosis is feature",
                      "Leukocytosis, leukoerythroblastic picture, and teardrop-shaped RBCs in PMF, fibrotic phase",
                      "Thrombocytosis in ET; also common in CML, early, prefibrotic PMF, and prepolycythemic PV",
                      "Marked mature neutrophilia with toxic changes and minimal left shift in CNL",
                      "Marked eosinophilia in CEL, NOS"
                    ]
                  },
                  {
                    "text": "Many other laboratory tests utilized to exclude differential diagnostic considerations and assess cell turnover, iron stores, and erythropoietin levels"
                  }
                ],
                "Treatment": [
                  {
                    "text": "TKI therapy has resulted in markedly prolonged survival in CMLDramatic reduction in incidence of blast phase",
                    "sub_points": [
                      "Dramatic reduction in incidence of blast phase"
                    ]
                  },
                  {
                    "text": "Prevention of thrombotic complications is key goal in classic MPN therapy"
                  },
                  {
                    "text": "TKIs inJAK2mutation-mediated neoplasms in clinical useMany novel inhibitors of other pathways under development, especially for PMF",
                    "sub_points": [
                      "Many novel inhibitors of other pathways under development, especially for PMF"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Blood": [
                  {
                    "text": "Key general features during stable phase of disease include cytosis(es), lack of dysplasia, blasts < 2%"
                  },
                  {
                    "text": "Other specific features of individual MPNsErythrocytosis in PVNeutrophilia in CML and CNLLeft shift with low blast percentage and basophilia in CMLMinimal, more limited, left shift with toxic changes in CNLTeardrop-shaped erythrocytes in PMF, fibrotic phaseMarked eosinophilia in CEL",
                    "sub_points": [
                      "Erythrocytosis in PV",
                      "Neutrophilia in CML and CNLLeft shift with low blast percentage and basophilia in CMLMinimal, more limited, left shift with toxic changes in CNL",
                      "Left shift with low blast percentage and basophilia in CML",
                      "Minimal, more limited, left shift with toxic changes in CNL",
                      "Teardrop-shaped erythrocytes in PMF, fibrotic phase",
                      "Marked eosinophilia in CEL"
                    ]
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "General featuresHypercellularityPanmyelosis in PVPredominance of granulocytic lineage in CML, PMF, and CNLIncreased megakaryocytes, often with distinctive features that support subclassificationDistinctive abnormal megakaryocytes in CML and classic MPNsIntact maturation, blasts not increased in chronic (stable) phaseLack of dysplasia in stable phase",
                    "sub_points": [
                      "HypercellularityPanmyelosis in PVPredominance of granulocytic lineage in CML, PMF, and CNL",
                      "Panmyelosis in PV",
                      "Predominance of granulocytic lineage in CML, PMF, and CNL",
                      "Increased megakaryocytes, often with distinctive features that support subclassificationDistinctive abnormal megakaryocytes in CML and classic MPNs",
                      "Distinctive abnormal megakaryocytes in CML and classic MPNs",
                      "Intact maturation, blasts not increased in chronic (stable) phase",
                      "Lack of dysplasia in stable phase"
                    ]
                  },
                  {
                    "text": "Distinctive MPN subtype-specific featuresSmall, hypolobated (dwarf) megakaryocytes in CMLMarkedly hyperlobated (staghorn) megakaryocytes in ETProminent intrasinusoidal megakaryocytes in PMFPleomorphic megakaryocytes in PMF with prominent clusteringOsteosclerosis in PMFFibrosis in PMFProgresses over timeNormocellularity in some ETMarked eosinophilia in CEL",
                    "sub_points": [
                      "Small, hypolobated (dwarf) megakaryocytes in CML",
                      "Markedly hyperlobated (staghorn) megakaryocytes in ET",
                      "Prominent intrasinusoidal megakaryocytes in PMFPleomorphic megakaryocytes in PMF with prominent clustering",
                      "Pleomorphic megakaryocytes in PMF with prominent clustering",
                      "Osteosclerosis in PMF",
                      "Fibrosis in PMFProgresses over time",
                      "Progresses over time",
                      "Normocellularity in some ET",
                      "Marked eosinophilia in CEL"
                    ]
                  }
                ]
              },
              "Ancillary Tests": {
                "Flow Cytometric Immunophenotyping": [
                  {
                    "text": "Relatively limited utility in chronic-phase MPNValuable for blast lineage assessment and enumeration in progressive MPNs",
                    "sub_points": [
                      "Valuable for blast lineage assessment and enumeration in progressive MPNs"
                    ]
                  }
                ],
                "Cytogenetics/FISH/Molecular Genetic Testing": [
                  {
                    "text": "Essential in diagnosis of all MPN subtypesInitial diagnostic step is to identify asBCR::ABL1(+) or (-)JAK2,CALR, orMPLmutation status essential in classic MPNsMany additional gene mutations may be identified that impact prognosisConfirmation of clonality in CNL, CEL, NOS",
                    "sub_points": [
                      "Initial diagnostic step is to identify asBCR::ABL1(+) or (-)",
                      "JAK2,CALR, orMPLmutation status essential in classic MPNs",
                      "Many additional gene mutations may be identified that impact prognosis",
                      "Confirmation of clonality in CNL, CEL, NOS"
                    ]
                  },
                  {
                    "text": "Essential forexclusionaryreasons in many MPNs"
                  }
                ]
              },
              "Differential Diagnosis": {
                "MPN vs. Disorders That Mimic MPN": [
                  {
                    "text": "Collagen vascular diseases"
                  },
                  {
                    "text": "Chronic infections"
                  },
                  {
                    "text": "Myeloma-associated with paraneoplastic neutrophilia that mimics CNL"
                  }
                ],
                "MPN vs. Other Myeloid Neoplasms": [
                  {
                    "text": "Apply ICC/WHO-HAEM5 criteria"
                  }
                ],
                "MPN in Stable (Chronic) Phase vs. MPN in Progression to More Aggressive Process": [
                  {
                    "text": "Blast percentage, additional genetic findings, fibrosis, and clinical changes define disease progression"
                  }
                ]
              },
              "Diagnostic Checklist": {
                "Clinical and Pathologic Tips": [
                  {
                    "text": "Review of CBC data and blood smear for clues to MPN and likely specific MPN subtype"
                  },
                  {
                    "text": "Generous use of molecular/genetic testing and conventional karyotyping/FISH as appropriateMolecular genetic tests can be performed on bloodBone marrow specimens optimal for conventional cytogenetics",
                    "sub_points": [
                      "Molecular genetic tests can be performed on blood",
                      "Bone marrow specimens optimal for conventional cytogenetics"
                    ]
                  },
                  {
                    "text": "Appropriate testing to exclude neoplastic and nonneoplastic differential diagnostic considerations"
                  },
                  {
                    "text": "Integrate clinical, hematologic, morphologic, and genetic findings into final diagnosis"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Polycythemia Vera": {
            "name": "Polycythemia Vera",
            "url": "https://app.pathprimer.com/document/e70798f1-2e4d-455f-be96-61f2dad29305/lesson/74c9ecc8-b842-4e36-acf8-277b06dc00d9",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Subtype of classic chronic myeloproliferative neoplasm characterized in 2008 WHO byIncreased red blood cellsJAK2gene gain-of-function somatic mutation",
                    "sub_points": [
                      "Increased red blood cells",
                      "JAK2gene gain-of-function somatic mutation"
                    ]
                  },
                  {
                    "text": "Three polycythemia vera phasesPrepolycythemic phase with mild erythrocytosisOvert polycythemic phase with significant increased red blood cell massSpent phase and postpolycythemic myelofibrosis",
                    "sub_points": [
                      "Prepolycythemic phase with mild erythrocytosis",
                      "Overt polycythemic phase with significant increased red blood cell mass",
                      "Spent phase and postpolycythemic myelofibrosis"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "﻿Laboratory tests useful in work-up of suspected PV﻿Serum erythropoietin (EPO) valueEndogenous erythroid colony formationTests forJAK2V617F orJAK2exon 12 mutations",
                    "sub_points": [
                      "Serum erythropoietin (EPO) value",
                      "Endogenous erythroid colony formation",
                      "Tests forJAK2V617F orJAK2exon 12 mutations"
                    ]
                  },
                  {
                    "text": "PrognosisMedian survival > 10 years with treatmentHigh risk with history of thrombosis and age > 60Progression to MDS or AML in 2-10% of cases",
                    "sub_points": [
                      "Median survival > 10 years with treatment",
                      "High risk with history of thrombosis and age > 60",
                      "Progression to MDS or AML in 2-10% of cases"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Common recurring cytogenetic abnormalitiesTrisomy 8, trisomy 9, del(20q), del(13q), and del(9p)",
                    "sub_points": [
                      "Trisomy 8, trisomy 9, del(20q), del(13q), and del(9p)"
                    ]
                  },
                  {
                    "text": "JAK2V617F mutationPresent in 96% of patients with PV",
                    "sub_points": [
                      "Present in 96% of patients with PV"
                    ]
                  },
                  {
                    "text": "JAK2exon 12 mutations3% frequency among all patients with PV",
                    "sub_points": [
                      "3% frequency among all patients with PV"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Polycythemia vera (PV)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Classic chronic myeloproliferative neoplasm (MPN) characterized in 2008 WHO byIncreased red blood cellsJanus kinase 2 (JAK2) gene gain-of-function somatic mutation",
                    "sub_points": [
                      "Increased red blood cells",
                      "Janus kinase 2 (JAK2) gene gain-of-function somatic mutation"
                    ]
                  },
                  {
                    "text": "3 phases of polycythemia veraPrepolycythemic phase with mild erythrocytosisOvert polycythemic phase with significantly increased red blood cell (RBC) massSpent phase and postpolycythemic myelofibrosisNormalization followed by decrease in RBC massFurther enlargement of spleenMarked reticulin and collagen fibrosis of marrowExtramedullary hematopoiesis (EMH)",
                    "sub_points": [
                      "Prepolycythemic phase with mild erythrocytosis",
                      "Overt polycythemic phase with significantly increased red blood cell (RBC) mass",
                      "Spent phase and postpolycythemic myelofibrosisNormalization followed by decrease in RBC massFurther enlargement of spleenMarked reticulin and collagen fibrosis of marrowExtramedullary hematopoiesis (EMH)",
                      "Normalization followed by decrease in RBC mass",
                      "Further enlargement of spleen",
                      "Marked reticulin and collagen fibrosis of marrow",
                      "Extramedullary hematopoiesis (EMH)"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Underlying Etiology of PV": [
                  {
                    "text": "Genetic disposition reported in some families"
                  },
                  {
                    "text": "Ionizing radiation and occupational toxin exposure suggested as possible cause"
                  },
                  {
                    "text": "Underlying cause is uncertain in most patients"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Estimated 2-3 per 100,000 persons affected each year"
                  },
                  {
                    "text": "Higher incidence among Ashkenazi Jews"
                  },
                  {
                    "text": "Slight male predominance"
                  },
                  {
                    "text": "Average age at diagnosis is 60 years"
                  },
                  {
                    "text": "Rare in patients < 30 years"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Patients frequently present with thrombotic events"
                  },
                  {
                    "text": "Nonspecific symptoms such as headaches, dizziness, pruritus, and visual disturbances may exist"
                  },
                  {
                    "text": "Weight loss and arthropathies due to gout may be seen"
                  },
                  {
                    "text": "Hepatosplenomegaly, ruddy cyanosis, conjunctival plethora, and hypertension can be detected on exam"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "﻿Laboratory tests useful in work-up of suspected PV﻿Serum erythropoietin (EPO) valueEndogenous erythroid colony formationTests forJAK2V617F orJAK2exon 12 mutations",
                    "sub_points": [
                      "Serum erythropoietin (EPO) value",
                      "Endogenous erythroid colony formation",
                      "Tests forJAK2V617F orJAK2exon 12 mutations"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "PV is not curative by current drug therapyLow-dose aspirin plus phlebotomy for management of low-risk PV patientsLow-dose aspirin plus phlebotomy plus hydroxyurea in high-risk PV patients",
                    "sub_points": [
                      "Low-dose aspirin plus phlebotomy for management of low-risk PV patients",
                      "Low-dose aspirin plus phlebotomy plus hydroxyurea in high-risk PV patients"
                    ]
                  },
                  {
                    "text": "Allogeneic stem cell transplantation (SCT) can be potentially curative in post-PV myelofibrosisAllogeneic SCT has limited usage due to high incidence of mortality and morbidity",
                    "sub_points": [
                      "Allogeneic SCT has limited usage due to high incidence of mortality and morbidity"
                    ]
                  },
                  {
                    "text": "Investigational drug therapies in post-PV myelofibrosisJAK1 & JAK2 inhibitors in clinical trials",
                    "sub_points": [
                      "JAK1 & JAK2 inhibitors in clinical trials"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Median survival: > 10 years with treatment"
                  },
                  {
                    "text": "High risk with history of thrombosis and age > 60"
                  },
                  {
                    "text": "Low risk without history of thrombosis and age < 60"
                  },
                  {
                    "text": "Most patients die of thrombosis or hemorrhage"
                  },
                  {
                    "text": "Progression to myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)2-3% incidence in patients who were not treated with cytotoxic agents10% or more incidence in patients who were treated with cytotoxic agents",
                    "sub_points": [
                      "2-3% incidence in patients who were not treated with cytotoxic agents",
                      "10% or more incidence in patients who were treated with cytotoxic agents"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Blood and Bone Marrow Findings": [
                  {
                    "text": "﻿Prepolycythemic and polycythemic phases﻿Peripheral blood findingsMild to significantly increased normochromic/normocytic red blood cellsNeutrophilia and, rarely, basophilia may be presentOccasional immature granulocytic cells may be seen in polycythemic phaseProminent thrombocytosis in about 15% of casesBone marrow findingsBone marrow typically hypercellular for ageIncreased subcortical bone marrow cellularityPanmyelosis but more prominent erythroid and megakaryocytic lineagesPanmyelosis prominent in polycythemic phaseMorphologically normal erythropoiesis and granulopoiesisIncreased megakaryocytes with hyperlobated forms commonly present",
                    "sub_points": [
                      "Peripheral blood findingsMild to significantly increased normochromic/normocytic red blood cellsNeutrophilia and, rarely, basophilia may be presentOccasional immature granulocytic cells may be seen in polycythemic phaseProminent thrombocytosis in about 15% of cases",
                      "Mild to significantly increased normochromic/normocytic red blood cells",
                      "Neutrophilia and, rarely, basophilia may be present",
                      "Occasional immature granulocytic cells may be seen in polycythemic phase",
                      "Prominent thrombocytosis in about 15% of cases",
                      "Bone marrow findingsBone marrow typically hypercellular for ageIncreased subcortical bone marrow cellularityPanmyelosis but more prominent erythroid and megakaryocytic lineagesPanmyelosis prominent in polycythemic phaseMorphologically normal erythropoiesis and granulopoiesisIncreased megakaryocytes with hyperlobated forms commonly present",
                      "Bone marrow typically hypercellular for age",
                      "Increased subcortical bone marrow cellularity",
                      "Panmyelosis but more prominent erythroid and megakaryocytic lineages",
                      "Panmyelosis prominent in polycythemic phase",
                      "Morphologically normal erythropoiesis and granulopoiesis",
                      "Increased megakaryocytes with hyperlobated forms commonly present"
                    ]
                  },
                  {
                    "text": "﻿\"Spent phase\" and postpolycythemic myelofibrosis﻿Peripheral blood with leukoerythroblastic pictureProminent anisopoikilocytosis including teardrop forms and occasional nucleated red blood cellsOccasional immature granulocytic cells but no significant dyspoietic cellsBone marrow findingsProminent reticulin and collagen fibrosisVariable bone marrow cellularity but often hypocellular for ageMegakaryocytic clusters with hyperchromatic and dysmorphic nucleiDecreased erythropoiesis and granulopoiesisDilated marrow sinuses may be seen with intrasinusoidal trilineage hematopoiesisOsteosclerosis may be seen in late-stage disease",
                    "sub_points": [
                      "Peripheral blood with leukoerythroblastic pictureProminent anisopoikilocytosis including teardrop forms and occasional nucleated red blood cellsOccasional immature granulocytic cells but no significant dyspoietic cells",
                      "Prominent anisopoikilocytosis including teardrop forms and occasional nucleated red blood cells",
                      "Occasional immature granulocytic cells but no significant dyspoietic cells",
                      "Bone marrow findingsProminent reticulin and collagen fibrosisVariable bone marrow cellularity but often hypocellular for ageMegakaryocytic clusters with hyperchromatic and dysmorphic nucleiDecreased erythropoiesis and granulopoiesisDilated marrow sinuses may be seen with intrasinusoidal trilineage hematopoiesisOsteosclerosis may be seen in late-stage disease",
                      "Prominent reticulin and collagen fibrosis",
                      "Variable bone marrow cellularity but often hypocellular for age",
                      "Megakaryocytic clusters with hyperchromatic and dysmorphic nuclei",
                      "Decreased erythropoiesis and granulopoiesis",
                      "Dilated marrow sinuses may be seen with intrasinusoidal trilineage hematopoiesis",
                      "Osteosclerosis may be seen in late-stage disease"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Flow Cytometry": [
                  {
                    "text": "No consistent immunophenotypic abnormality described in the absence of leukemic transformation"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "JAK2V617F mutationGain-of-function mutation in pseudokinase domainMutation occurs in all myeloid lineagesPresent in 96% of patients with PVAlso detected in > 50% of essential thrombocythemia (ET) and primary myelofibrosis (PMF)JAK2V617F mutation homozygous in most PV cases",
                    "sub_points": [
                      "Gain-of-function mutation in pseudokinase domain",
                      "Mutation occurs in all myeloid lineages",
                      "Present in 96% of patients with PV",
                      "Also detected in > 50% of essential thrombocythemia (ET) and primary myelofibrosis (PMF)",
                      "JAK2V617F mutation homozygous in most PV cases"
                    ]
                  },
                  {
                    "text": "JAK2exon 12 mutationsRelatively specific forJAK2V617F-negative PV3% frequency among all patients with PVJAK2exon 12 mutations are often heterozygousAssociated with predominantly erythroid myelopoiesis and younger age at diagnosis",
                    "sub_points": [
                      "Relatively specific forJAK2V617F-negative PV",
                      "3% frequency among all patients with PV",
                      "JAK2exon 12 mutations are often heterozygous",
                      "Associated with predominantly erythroid myelopoiesis and younger age at diagnosis"
                    ]
                  },
                  {
                    "text": "Common recurring cytogenetic abnormalities includeTrisomy 8, trisomy 9, del(20q), del(13q), and del(9p)",
                    "sub_points": [
                      "Trisomy 8, trisomy 9, del(20q), del(13q), and del(9p)"
                    ]
                  },
                  {
                    "text": "Cytogenetic abnormalities in PV patients with transformation to MDS or AMLDetected in virtually all patients with transformation to MDS/AMLCytogenetic abnormalities include those commonly seen in therapy-related MDS/AML",
                    "sub_points": [
                      "Detected in virtually all patients with transformation to MDS/AML",
                      "Cytogenetic abnormalities include those commonly seen in therapy-related MDS/AML"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Chronic Myeloid Leukemia (CML)": [
                  {
                    "text": "Absence of t(9;22) and presence ofJAK2mutation useful in separating PV from CML"
                  }
                ],
                "Essential Thrombocythemia (ET)": [
                  {
                    "text": "Prepolycythemic phase in patients with thrombocytosis may clinically mimic ET"
                  },
                  {
                    "text": "Bone marrow panmyelosis in PV helps in distinguishing PV from ET"
                  }
                ],
                "Primary Myelofibrosis (PMF)": [
                  {
                    "text": "Postpolycythemic myelofibrosis may show bone marrow morphologic findings similar to PMF"
                  },
                  {
                    "text": "Prior documented diagnosis of PV distinguishes post-PV myelofibrosis from PMF"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "2008 WHO Diagnostic Criteria for PV": [
                  {
                    "text": "﻿Major criteria﻿Hgb > 18.5 g/dL in men and > 16.5 g/dL in women or other evidence of increased RBC volumePresence ofJAK2V617F or other functionally similar mutation such asJAK2exon 12 mutation",
                    "sub_points": [
                      "Hgb > 18.5 g/dL in men and > 16.5 g/dL in women or other evidence of increased RBC volume",
                      "Presence ofJAK2V617F or other functionally similar mutation such asJAK2exon 12 mutation"
                    ]
                  },
                  {
                    "text": "﻿Minor criteria﻿Hypercellular for age bone marrow biopsy with prominent panmyelosisLow-serum erythropoietin (EPO) levelEndogenous erythroid colony formation in vitro",
                    "sub_points": [
                      "Hypercellular for age bone marrow biopsy with prominent panmyelosis",
                      "Low-serum erythropoietin (EPO) level",
                      "Endogenous erythroid colony formation in vitro"
                    ]
                  },
                  {
                    "text": "Requirements for diagnosis of polycythemia veraPresence of both major and 1 minor criteriaorPresence of 1st major criterion and 2 minor criteria",
                    "sub_points": [
                      "Presence of both major and 1 minor criteriaor",
                      "Presence of 1st major criterion and 2 minor criteria"
                    ]
                  }
                ],
                "Diagnostic Criteria for Post-PV Myelofibrosis": [
                  {
                    "text": "﻿Required criteria﻿Documentation of a prior diagnosis of WHO-defined PVBone marrow fibrosis grade 2-3 (0-3 scale) or grade 3-4 (0-4 scale)",
                    "sub_points": [
                      "Documentation of a prior diagnosis of WHO-defined PV",
                      "Bone marrow fibrosis grade 2-3 (0-3 scale) or grade 3-4 (0-4 scale)"
                    ]
                  },
                  {
                    "text": "﻿Additional criteria (2 are required)﻿Anemia or sustained loss of need for either phlebotomy or cytoreductive therapy for erythrocytosisLeukoerythroblastic peripheral blood pictureIncreasing splenomegaly (an increase in palpable splenomegaly of > 5 cm from the left costal margin or appearance of newly palpable splenomegaly)Development of > 1 of 3 constitutional symptoms: > 10% weight loss in 6 months, night sweats, unexplained fever",
                    "sub_points": [
                      "Anemia or sustained loss of need for either phlebotomy or cytoreductive therapy for erythrocytosis",
                      "Leukoerythroblastic peripheral blood picture",
                      "Increasing splenomegaly (an increase in palpable splenomegaly of > 5 cm from the left costal margin or appearance of newly palpable splenomegaly)",
                      "Development of > 1 of 3 constitutional symptoms: > 10% weight loss in 6 months, night sweats, unexplained fever"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Primary Myelofibrosis": {
            "name": "Primary Myelofibrosis",
            "url": "https://app.pathprimer.com/document/fe9b4a0b-59dc-45fe-8248-685d52d609fd/lesson/74c9ecc8-b842-4e36-acf8-277b06dc00d9",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Myeloproliferative neoplasm (MPN)"
                  },
                  {
                    "text": "Manifests initially as megakaryocytic and granulocytic proliferation and results in fibrosis"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Extramedullary hematopoiesis"
                  },
                  {
                    "text": "Microvascular complications"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Early phaseVariable anemia, thrombocytosis, and granulocytic leukocytosisBM absent/minimal fibrosisBM pleomorphic megakaryocytes",
                    "sub_points": [
                      "Variable anemia, thrombocytosis, and granulocytic leukocytosis",
                      "BM absent/minimal fibrosis",
                      "BM pleomorphic megakaryocytes"
                    ]
                  },
                  {
                    "text": "Late/fibrotic phasePB leukoerythroblastosisBM marked fibrosis/osteosclerosisMegakaryocytic atypiaMay form large sheets and tight clustersCloud shape/hyperlobated nuclei",
                    "sub_points": [
                      "PB leukoerythroblastosis",
                      "BM marked fibrosis/osteosclerosis",
                      "Megakaryocytic atypiaMay form large sheets and tight clustersCloud shape/hyperlobated nuclei",
                      "May form large sheets and tight clusters",
                      "Cloud shape/hyperlobated nuclei"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "GeneticsJAK2V617F mutation present in ~ 60% of patientsCALRmutations in 25% of casesMPLmutation in 5% of cases",
                    "sub_points": [
                      "JAK2V617F mutation present in ~ 60% of patients",
                      "CALRmutations in 25% of cases",
                      "MPLmutation in 5% of cases"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "OtherBCR-ABL1negative MPNs"
                  },
                  {
                    "text": "Chronic myelogenous leukemia,BCR-ABL1positive"
                  },
                  {
                    "text": "Secondary causes of leukoerythroblastosis and bone marrow fibrosis"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Primary myelofibrosis (PMF)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Myeloproliferative neoplasm (MPN)"
                  },
                  {
                    "text": "Manifests initially as megakaryocytic and granulocytic proliferation and results in fibrosis"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Molecular Pathogenesis": [
                  {
                    "text": "JAK2V617F mutation present in ~ 60%"
                  },
                  {
                    "text": "CALRmutations in 25% of cases"
                  },
                  {
                    "text": "MPLmutations at codon 515 present in ~ 5%"
                  },
                  {
                    "text": "9% triple negative cases"
                  },
                  {
                    "text": "BCR-ABL1fusion absent"
                  }
                ],
                "Fibrosis Hypothesis": [
                  {
                    "text": "Secondary proliferation of polyclonal fibroblasts"
                  },
                  {
                    "text": "Fibroblasts are stimulated by clonally expanding megakaryocytes"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "~ 0.2/100,000 in United States"
                  }
                ],
                "Age": [
                  {
                    "text": "Median at diagnosis: 67 years"
                  },
                  {
                    "text": "Predominantly adults"
                  }
                ],
                "Sex": [
                  {
                    "text": "No significant predilection"
                  }
                ],
                "Site": [
                  {
                    "text": "Peripheral blood (PB) and bone marrow (BM)"
                  },
                  {
                    "text": "Spleen"
                  },
                  {
                    "text": "Liver"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Abdominal fullness"
                  },
                  {
                    "text": "Fatigue"
                  },
                  {
                    "text": "Splenomegaly"
                  },
                  {
                    "text": "Early satiety"
                  },
                  {
                    "text": "Left upper quadrant pain"
                  },
                  {
                    "text": "Fever"
                  },
                  {
                    "text": "Night sweats"
                  },
                  {
                    "text": "Weight loss"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Complete blood cell count (CBC)"
                  },
                  {
                    "text": "Peripheral blood smear review"
                  },
                  {
                    "text": "Bone marrow examination"
                  },
                  {
                    "text": "Molecular genetics (JAK2, CALR, MPL)"
                  },
                  {
                    "text": "Cytogenetics; exclude CMLBCR-ABL1"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Risk-adapted therapy"
                  },
                  {
                    "text": "Allogeneic stem cell transplantOnly curative therapy",
                    "sub_points": [
                      "Only curative therapy"
                    ]
                  },
                  {
                    "text": "Drug therapyHydroxyureaFor leukocytosis, thrombocytosis, and splenomegalyThalidomide/lenalidomide and steroidsFor cytopenias, splenomegalyTargeted therapy againstJAK2, CALR, MPL",
                    "sub_points": [
                      "HydroxyureaFor leukocytosis, thrombocytosis, and splenomegaly",
                      "For leukocytosis, thrombocytosis, and splenomegaly",
                      "Thalidomide/lenalidomide and steroidsFor cytopenias, splenomegaly",
                      "For cytopenias, splenomegaly",
                      "Targeted therapy againstJAK2, CALR, MPL"
                    ]
                  },
                  {
                    "text": "SplenectomyHigh-risk procedureNear 10% mortality",
                    "sub_points": [
                      "High-risk procedure",
                      "Near 10% mortality"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "SurvivalBetter overall survival inCALRpositive casesWide range in survival",
                    "sub_points": [
                      "Better overall survival inCALRpositive cases",
                      "Wide range in survival"
                    ]
                  },
                  {
                    "text": "Prognostic factorsBiologic subletsJAK2+ PMF: Overall survival 9.2 yearsCALR+ PMF: Overall survival 18 yearsMPL+ PMF: Overall survival 9 yearsTriple negative PMF: Overall survival 3 yearsSeveral prognostic scoring systemsVariables assessedAge > 65 yearsHemoglobin < 10 g/dLLeukocyte count > 25 x 10⁹/LCirculating blasts ≥ 1%Constitutional symptomsMutation statusLeukemic transformationPoor prognosis~ 4-20% of patientsMore common in triple negative patientsMicrovascular eventsThrombosisHemorrhage",
                    "sub_points": [
                      "Biologic subletsJAK2+ PMF: Overall survival 9.2 yearsCALR+ PMF: Overall survival 18 yearsMPL+ PMF: Overall survival 9 yearsTriple negative PMF: Overall survival 3 years",
                      "JAK2+ PMF: Overall survival 9.2 years",
                      "CALR+ PMF: Overall survival 18 years",
                      "MPL+ PMF: Overall survival 9 years",
                      "Triple negative PMF: Overall survival 3 years",
                      "Several prognostic scoring systems",
                      "Variables assessedAge > 65 yearsHemoglobin < 10 g/dLLeukocyte count > 25 x 10⁹/LCirculating blasts ≥ 1%Constitutional symptomsMutation status",
                      "Age > 65 years",
                      "Hemoglobin < 10 g/dL",
                      "Leukocyte count > 25 x 10⁹/L",
                      "Circulating blasts ≥ 1%",
                      "Constitutional symptoms",
                      "Mutation status",
                      "Leukemic transformationPoor prognosis~ 4-20% of patientsMore common in triple negative patients",
                      "Poor prognosis",
                      "~ 4-20% of patients",
                      "More common in triple negative patients",
                      "Microvascular eventsThrombosisHemorrhage",
                      "Thrombosis",
                      "Hemorrhage"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Peripheral Blood": [
                  {
                    "text": "Early/prefibrotic phaseAnemiaVariable thrombocytosisPlatelets may show dysplastic featuresVariable granulocytic leukocytosisUsually mildNo dysplasiaNo erythrocytosis",
                    "sub_points": [
                      "Anemia",
                      "Variable thrombocytosisPlatelets may show dysplastic features",
                      "Platelets may show dysplastic features",
                      "Variable granulocytic leukocytosisUsually mildNo dysplasia",
                      "Usually mild",
                      "No dysplasia",
                      "No erythrocytosis"
                    ]
                  },
                  {
                    "text": "Fibrotic phaseLeukoerythroblastosisMarked erythroid anisopoikilocytosis including dacryocytes (teardrop forms)Circulating micromegakaryocytes and megakaryocytic nucleiVariable circulating blasts",
                    "sub_points": [
                      "Leukoerythroblastosis",
                      "Marked erythroid anisopoikilocytosis including dacryocytes (teardrop forms)",
                      "Circulating micromegakaryocytes and megakaryocytic nuclei",
                      "Variable circulating blasts"
                    ]
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "Early/prefibrotic phaseFibrosis may be absent/minimalHypercellularMegakaryocytic atypiaCluster formationPleomorphicRange in size from small to largeBare nucleiGranulocytic predominanceNo significant dysplasiaBlasts < 5%Dilated sinusesIntrasinusoidal hematopoiesisLymphoid aggregates",
                    "sub_points": [
                      "Fibrosis may be absent/minimal",
                      "Hypercellular",
                      "Megakaryocytic atypiaCluster formationPleomorphicRange in size from small to largeBare nuclei",
                      "Cluster formation",
                      "Pleomorphic",
                      "Range in size from small to large",
                      "Bare nuclei",
                      "Granulocytic predominanceNo significant dysplasia",
                      "No significant dysplasia",
                      "Blasts < 5%",
                      "Dilated sinuses",
                      "Intrasinusoidal hematopoiesis",
                      "Lymphoid aggregates"
                    ]
                  },
                  {
                    "text": "Fibrotic phaseMarked reticulin/collagen fibrosisOsteosclerosisFocal hypocellularity admixed with foci of intact hematopoiesisMegakaryocytic atypiaMay form large sheets and tight clustersCloud shape/hyperlobated nucleiIncreased blasts10-19%: Accelerated disease phase≥ 20%: Transformation to acute leukemia",
                    "sub_points": [
                      "Marked reticulin/collagen fibrosis",
                      "Osteosclerosis",
                      "Focal hypocellularity admixed with foci of intact hematopoiesis",
                      "Megakaryocytic atypiaMay form large sheets and tight clustersCloud shape/hyperlobated nuclei",
                      "May form large sheets and tight clusters",
                      "Cloud shape/hyperlobated nuclei",
                      "Increased blasts10-19%: Accelerated disease phase≥ 20%: Transformation to acute leukemia",
                      "10-19%: Accelerated disease phase",
                      "≥ 20%: Transformation to acute leukemia"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Histochemistry": [
                  {
                    "text": "ReticulinGrading scheme (Thiele et al, 2005)Grades 0-3: Normal to marked, respectively",
                    "sub_points": [
                      "Grading scheme (Thiele et al, 2005)Grades 0-3: Normal to marked, respectively",
                      "Grades 0-3: Normal to marked, respectively"
                    ]
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "Valuable particularly in fibrotic/\"dry tap\" cases"
                  },
                  {
                    "text": "CD34 to enumerate blastsCaveat: Not all blasts are CD34(+)",
                    "sub_points": [
                      "Caveat: Not all blasts are CD34(+)"
                    ]
                  },
                  {
                    "text": "CD42b to highlight megakaryocytic atypiaMay reveal morphologically occult, small atypical megakaryocytes",
                    "sub_points": [
                      "May reveal morphologically occult, small atypical megakaryocytes"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Identify blasts; semiquantitative"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "JAK2V617F mutationsPresent in ~ 60% of cases",
                    "sub_points": [
                      "Present in ~ 60% of cases"
                    ]
                  },
                  {
                    "text": "CALRmutations in 90% ofJAK2negative cases; 25% of total cases"
                  },
                  {
                    "text": "MPLmutationsPresent in 5% of cases",
                    "sub_points": [
                      "Present in 5% of cases"
                    ]
                  },
                  {
                    "text": "Detect clonal abnormalities"
                  },
                  {
                    "text": "Most common cytogenetic abnormalities: +8, +9, 13q-, 20q-"
                  },
                  {
                    "text": "Cytogenetic risk stratificationFavorable: Normal karyotype, isolated 20q-, isolated 13q-, isolated +9Unfavorable: Isolated +8, -7/7q, inv(3), complex karyotype",
                    "sub_points": [
                      "Favorable: Normal karyotype, isolated 20q-, isolated 13q-, isolated +9",
                      "Unfavorable: Isolated +8, -7/7q, inv(3), complex karyotype"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Prefibrotic PMF": [
                  {
                    "text": "Essential thrombocythemic (ET)"
                  },
                  {
                    "text": "Masked polycythemia vera (PV)"
                  },
                  {
                    "text": "Chronic myelogenous leukemiaBCR-ABL1positive (CML)"
                  },
                  {
                    "text": "Reactive thrombocytosis"
                  }
                ],
                "Fibrotic Phase (PMF)": [
                  {
                    "text": "Spent phase of PV"
                  },
                  {
                    "text": "CML with fibrosis"
                  },
                  {
                    "text": "Myelodysplasia (MDS) with fibrosis"
                  },
                  {
                    "text": "Systemic mastocytosis"
                  },
                  {
                    "text": "Other neoplasms and nonneoplastic disorders with BM fibrosis"
                  }
                ],
                "Other Causes of Leukoerythroblastosis": [
                  {
                    "text": "Secondary reaction"
                  },
                  {
                    "text": "ExamplesMetastatic tumorOsteopetrosisSevere infection &/or blood loss",
                    "sub_points": [
                      "Metastatic tumor",
                      "Osteopetrosis",
                      "Severe infection &/or blood loss"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Essential Thrombocythemia": {
            "name": "Essential Thrombocythemia",
            "url": "https://app.pathprimer.com/document/b8605003-19d3-4672-97d2-1ec785756966/lesson/74c9ecc8-b842-4e36-acf8-277b06dc00d9",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Clonal mature hematopoietic myeloproliferative neoplasm with sustained thrombocytosis ≥ 450 x 10⁹/L"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Vascular disturbances in 50% of individuals"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Peripheral bloodVariable thrombocytosis but ≥ 450 x 10⁹/LNo significant left shift in granulocytic series, circulating blasts unusual",
                    "sub_points": [
                      "Variable thrombocytosis but ≥ 450 x 10⁹/L",
                      "No significant left shift in granulocytic series, circulating blasts unusual"
                    ]
                  },
                  {
                    "text": "Bone marrowNormal cellularity to mildly hypercellularBlasts < 5%Striking megakaryocytic proliferationAbsent/minimal reticulin fibrosis",
                    "sub_points": [
                      "Normal cellularity to mildly hypercellular",
                      "Blasts < 5%",
                      "Striking megakaryocytic proliferation",
                      "Absent/minimal reticulin fibrosis"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "JAK2andCALRmutations define 2 biologic subtypes"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Essential thrombocythemia (ET)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Essential thrombocytosis"
                  },
                  {
                    "text": "Primary thrombocytosis"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Clonal mature hematopoietic myeloproliferative neoplasm (MPN)"
                  },
                  {
                    "text": "Sustained thrombocytosis ≥ 450 x 10⁹/L"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Molecular Pathogenesis": [
                  {
                    "text": "~ 60% of cases harborJAK2V617F activating mutation (JAK2+ ET)"
                  },
                  {
                    "text": "~ 25% of ET cases harborCALRmutation (CALR+ ET)"
                  },
                  {
                    "text": "JAK2andCALRmutations are mutually exclusive; define distinct biologic subtypes"
                  }
                ],
                "Familial ET": [
                  {
                    "text": "Rare"
                  },
                  {
                    "text": "Incidence ofJAK2mutation lower than in sporadic ET"
                  },
                  {
                    "text": "Incidence of thrombosis lower than in sporadic ET"
                  },
                  {
                    "text": "ActivatingMPLmutation thought to be main cause"
                  },
                  {
                    "text": "Reported 100% 10-year survival"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "0.6-2.5/100,000 people per year"
                  }
                ],
                "Age": [
                  {
                    "text": "Typically adults"
                  },
                  {
                    "text": "6th and 7th decades of life"
                  },
                  {
                    "text": "May present in children; exclude familial"
                  }
                ],
                "Sex": [
                  {
                    "text": "Female predominance inJAK2+ ET"
                  },
                  {
                    "text": "Male predominance inCALR+ ET"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Thrombocytosis on CBC"
                  },
                  {
                    "text": "Vascular disturbances in 50% of individualsThrombosisHemorrhageIncreased risk of miscarriage",
                    "sub_points": [
                      "Thrombosis",
                      "Hemorrhage",
                      "Increased risk of miscarriage"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "CBC with differential"
                  },
                  {
                    "text": "PB and BM examination"
                  },
                  {
                    "text": "Conventional cytogenetics"
                  },
                  {
                    "text": "Molecular studies as neededJAK2V617F seen in 60% of casesCALRmutation in 25%MPLmutations in < 5%",
                    "sub_points": [
                      "JAK2V617F seen in 60% of cases",
                      "CALRmutation in 25%",
                      "MPLmutations in < 5%"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Low-dose aspirin, unless contraindicated"
                  },
                  {
                    "text": "Cytoreductive therapyAim is to reduce thrombotic complicationsHydroxyureaAnagrelide",
                    "sub_points": [
                      "Aim is to reduce thrombotic complications",
                      "Hydroxyurea",
                      "Anagrelide"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "JAK2+ ET vs.CALR+ ETHigher risk of thrombosis",
                    "sub_points": [
                      "Higher risk of thrombosis"
                    ]
                  },
                  {
                    "text": "Predictors of thrombosisAge > 60 yearsJAK2mutation detectedPrior history of thrombosis",
                    "sub_points": [
                      "Age > 60 years",
                      "JAK2mutation detected",
                      "Prior history of thrombosis"
                    ]
                  },
                  {
                    "text": "Acute leukemia transformationRare eventPoor prognosis",
                    "sub_points": [
                      "Rare event",
                      "Poor prognosis"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Peripheral Blood": [
                  {
                    "text": "Variable thrombocytosis but ≥ 450 x 10⁹/L"
                  },
                  {
                    "text": "Striking platelet anisocytosisSmall and large plateletsHypogranular forms may be seen",
                    "sub_points": [
                      "Small and large platelets",
                      "Hypogranular forms may be seen"
                    ]
                  },
                  {
                    "text": "Circulating megakaryocytic nuclei"
                  },
                  {
                    "text": "Neutrophilia may occasionally be observed"
                  },
                  {
                    "text": "No significant left shift in granulocytic series"
                  },
                  {
                    "text": "No significant basophilia"
                  },
                  {
                    "text": "Circulating blasts unusual"
                  },
                  {
                    "text": "Red blood cell morphology unremarkable"
                  },
                  {
                    "text": "White blood cell morphology unremarkable"
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "Normal cellularity to mildly hypercellular"
                  },
                  {
                    "text": "Generally no significant granulocytic or erythroid proliferationOccasionally may encounter mild granulocytic hyperplasiaConsider early phase of primary myelofibrosis",
                    "sub_points": [
                      "Occasionally may encounter mild granulocytic hyperplasiaConsider early phase of primary myelofibrosis",
                      "Consider early phase of primary myelofibrosis"
                    ]
                  },
                  {
                    "text": "Blasts < 5%"
                  },
                  {
                    "text": "Striking megakaryocytic proliferationIncreased numbersLoosely clusteredMarkedly enlarged, hyperlobatedET megakaryocytes are largest of all BM disordersMay see intrasinusoidal/perisinusoidal distribution",
                    "sub_points": [
                      "Increased numbers",
                      "Loosely clustered",
                      "Markedly enlarged, hyperlobatedET megakaryocytes are largest of all BM disorders",
                      "ET megakaryocytes are largest of all BM disorders",
                      "May see intrasinusoidal/perisinusoidal distribution"
                    ]
                  },
                  {
                    "text": "Absent/minimal reticulin fibrosis"
                  },
                  {
                    "text": "Rare lymphoid nodules"
                  },
                  {
                    "text": "Normal iron storesUnless concurrent iron deficiencyExclude iron-deficient polycythemia vera",
                    "sub_points": [
                      "Unless concurrent iron deficiencyExclude iron-deficient polycythemia vera",
                      "Exclude iron-deficient polycythemia vera"
                    ]
                  },
                  {
                    "text": "Normal bone"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Histochemistry": [
                  {
                    "text": "ReticulinAbsent to minimal fibrosisProgressive fibrosis in rare cases",
                    "sub_points": [
                      "Absent to minimal fibrosis",
                      "Progressive fibrosis in rare cases"
                    ]
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "Highlight abnormal megakaryocytic proliferationCD41, CD42b, CD61",
                    "sub_points": [
                      "CD41, CD42b, CD61"
                    ]
                  },
                  {
                    "text": "Evaluate blasts if BM aspirate is suboptimalCD34; not all blasts are CD34(+)CD117; will also highlight mast cells and pronormoblasts",
                    "sub_points": [
                      "CD34; not all blasts are CD34(+)",
                      "CD117; will also highlight mast cells and pronormoblasts"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Blasts < 5% in typical ET"
                  },
                  {
                    "text": "Rare cases of leukemic transformation of ETBlasts > 20%; usually myeloid phenotype",
                    "sub_points": [
                      "Blasts > 20%; usually myeloid phenotype"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "~ 60% of cases harborJAK2V617F mutation (exon 14)"
                  },
                  {
                    "text": "JAK2exon 12 mutations reportedly absent"
                  },
                  {
                    "text": "CALRmutations in ~ 25%"
                  },
                  {
                    "text": "MPLmutations seen in < 5%"
                  },
                  {
                    "text": "TET2and mutations of possible prognostic significance also observed"
                  },
                  {
                    "text": "Karyotype usually normal"
                  },
                  {
                    "text": "~ 10% of cases of typical ET show a clonal abnormality at presentation"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Reactive Thrombocytosis": [
                  {
                    "text": "Numerous causesIron deficiency anemiaPlatelet count usually < 550 x 10⁹/LTraumaSurgeryAcute stressAcute infectionThrombocytopenia often seen in sepsisChronic inflammatory/infectious conditionsPostsplenectomyOccult malignancy",
                    "sub_points": [
                      "Iron deficiency anemiaPlatelet count usually < 550 x 10⁹/L",
                      "Platelet count usually < 550 x 10⁹/L",
                      "Trauma",
                      "Surgery",
                      "Acute stress",
                      "Acute infectionThrombocytopenia often seen in sepsis",
                      "Thrombocytopenia often seen in sepsis",
                      "Chronic inflammatory/infectious conditions",
                      "Postsplenectomy",
                      "Occult malignancy"
                    ]
                  },
                  {
                    "text": "Cause is usually clinically apparent"
                  },
                  {
                    "text": "BM examination is not required"
                  }
                ],
                "BCR-ABL1Negative MPNs": [
                  {
                    "text": "Polycythemia veraProdromal phase (masked PV)Erythrocytosis may not yet be evidentMay closely mimic ETEarly phaseErythrocytosisSubnormal erythropoietin levelMay be iron deficientPanmyelosis in BMLoose collections of variably hyperlobulated megakaryocytes",
                    "sub_points": [
                      "Prodromal phase (masked PV)Erythrocytosis may not yet be evidentMay closely mimic ET",
                      "Erythrocytosis may not yet be evident",
                      "May closely mimic ET",
                      "Early phaseErythrocytosisSubnormal erythropoietin levelMay be iron deficientPanmyelosis in BMLoose collections of variably hyperlobulated megakaryocytes",
                      "Erythrocytosis",
                      "Subnormal erythropoietin level",
                      "May be iron deficient",
                      "Panmyelosis in BM",
                      "Loose collections of variably hyperlobulated megakaryocytes"
                    ]
                  },
                  {
                    "text": "Primary myelofibrosis (PMF)pEarly phaseMay show remarkable overlap with ETGranulocytic proliferationPleomorphic megakaryocytes; small to giant, hyperchromaticFibrosisPossible osteosclerosis changes",
                    "sub_points": [
                      "Early phaseMay show remarkable overlap with ETGranulocytic proliferationPleomorphic megakaryocytes; small to giant, hyperchromaticFibrosisPossible osteosclerosis changes",
                      "May show remarkable overlap with ET",
                      "Granulocytic proliferation",
                      "Pleomorphic megakaryocytes; small to giant, hyperchromatic",
                      "Fibrosis",
                      "Possible osteosclerosis changes"
                    ]
                  }
                ],
                "CML With Thrombocytosis": [
                  {
                    "text": "Peripheral absolute basophilia"
                  },
                  {
                    "text": "Abnormal megakaryocytesSmall and hypolobated",
                    "sub_points": [
                      "Small and hypolobated"
                    ]
                  },
                  {
                    "text": "t(9;22)(q34;q11.2);BCR-ABL1positive"
                  }
                ],
                "Myelodysplasia With Thrombocytosis": [
                  {
                    "text": "MDS with isolated del(5q)Macrocytic anemiaCharacteristic small, hypolobated megakaryocytes",
                    "sub_points": [
                      "Macrocytic anemia",
                      "Characteristic small, hypolobated megakaryocytes"
                    ]
                  },
                  {
                    "text": "Other subtypes of MDSMorphologic dysplasia",
                    "sub_points": [
                      "Morphologic dysplasia"
                    ]
                  }
                ],
                "Refractory Anemia With Ring Sideroblasts and Thrombocytosis": [
                  {
                    "text": "Anemia and ring sideroblasts"
                  },
                  {
                    "text": "Provisional entity in MDS/MPN category"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Chronic Neutrophilic Leukemia": {
            "name": "Chronic Neutrophilic Leukemia",
            "url": "https://app.pathprimer.com/document/487d0d80-f4d8-411f-a2a5-e81af4930e53/lesson/74c9ecc8-b842-4e36-acf8-277b06dc00d9",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Chronic neutrophilic leukemia (CNL)"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Unknown"
                  },
                  {
                    "text": "Extremely rare disease"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Hepatosplenomegaly"
                  },
                  {
                    "text": "Bleeding, gout, pruritus"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "PB neutrophilia; blasts < 1%, WBC ≥ 25 x 10⁹/L, immature granulocytes < 10% of WBC"
                  },
                  {
                    "text": "BM hypercellular with granulocytic predominance; blasts < 5%, occasional erythroid and megakaryocytic proliferation"
                  },
                  {
                    "text": "No dysplasia, no basophilia, and no monocytosis"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "GeneticsAbsence ofBCR-ABL1fusionNo rearrangement ofPDGFRA,PDGFRB, andFGFR1Cytogenetics most often normalJAK2V617F mutation has been reported",
                    "sub_points": [
                      "Absence ofBCR-ABL1fusion",
                      "No rearrangement ofPDGFRA,PDGFRB, andFGFR1",
                      "Cytogenetics most often normal",
                      "JAK2V617F mutation has been reported"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Chronic neutrophilic leukemia (CNL)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Clonal hematopoietic neoplasm manifesting predominantly in granulocytic lineage"
                  },
                  {
                    "text": "Persistent peripheral blood (PB) neutrophilia"
                  },
                  {
                    "text": "Persistent bone marrow (BM) granulocytic proliferation"
                  },
                  {
                    "text": "Reactive neutrophilia and other myeloproliferative neoplasms (MPNs) must be completely excluded"
                  },
                  {
                    "text": "BCR-ABL1negative"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Unknown": [
                  {
                    "text": "Rare disease< 500 cases reported in the literature",
                    "sub_points": [
                      "< 500 cases reported in the literature"
                    ]
                  },
                  {
                    "text": "CNL neutrophils may be dysfunctionalDecreased stimulation with granulocyte colony stimulating factor (G-CSF)Insufficiency of some inflammatory cytokine-specific signaling",
                    "sub_points": [
                      "Decreased stimulation with granulocyte colony stimulating factor (G-CSF)",
                      "Insufficiency of some inflammatory cytokine-specific signaling"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Age": [
                  {
                    "text": "Median: 6th decade"
                  }
                ],
                "Sex": [
                  {
                    "text": "Slight male predominance"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Abnormal complete blood cell count (CBC)"
                  },
                  {
                    "text": "Hepatomegaly"
                  },
                  {
                    "text": "Splenomegaly"
                  },
                  {
                    "text": "Neutrophilia"
                  },
                  {
                    "text": "Majority of patients are asymptomatic"
                  },
                  {
                    "text": "Gout"
                  },
                  {
                    "text": "Pruritus"
                  },
                  {
                    "text": "Mucocutaneous bleeding"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "CBC"
                  },
                  {
                    "text": "PB and BM examination"
                  },
                  {
                    "text": "Cytogenetics"
                  }
                ],
                "Treatment": [
                  {
                    "text": "VariableDepends on symptomatologyWatchful waitingIf indolentCytoreductive agents (e.g., hydroxyurea)Toxic chemotherapyIf progressive or symptomatic diseaseAllogeneic stem cell transplant in rare cases",
                    "sub_points": [
                      "Depends on symptomatology",
                      "Watchful waitingIf indolent",
                      "If indolent",
                      "Cytoreductive agents (e.g., hydroxyurea)",
                      "Toxic chemotherapyIf progressive or symptomatic disease",
                      "If progressive or symptomatic disease",
                      "Allogeneic stem cell transplant in rare cases"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Heterogeneous; indolent to aggressive"
                  },
                  {
                    "text": "Survival ranges from < 1 year to > 20 years"
                  },
                  {
                    "text": "Median survival < 2 years"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Peripheral Blood": [
                  {
                    "text": "Neutrophilia and increased band forms"
                  },
                  {
                    "text": "WBC ≥ 25 x 10⁹/L"
                  },
                  {
                    "text": "Toxic changes with prominent granules may be seenMust exclude reactive condition",
                    "sub_points": [
                      "Must exclude reactive condition"
                    ]
                  },
                  {
                    "text": "Absence of dysplasia"
                  },
                  {
                    "text": "No significant basophilia"
                  },
                  {
                    "text": "No significant monocytosis"
                  },
                  {
                    "text": "Immature granulocytes (metamyelocytes, myelocytes, and promyelocytes) constitute < 10% of WBC"
                  },
                  {
                    "text": "Blasts comprise < 1% of WBC"
                  },
                  {
                    "text": "Variable anemia and thrombocytopenia"
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "Hypercellular; granulocytic predominance; blasts < 5%"
                  },
                  {
                    "text": "May see megakaryocytic &/or erythroid proliferation"
                  },
                  {
                    "text": "May see histiocytic neutrophilic phagocytosis"
                  },
                  {
                    "text": "No dysplasia"
                  },
                  {
                    "text": "No significant reticulin fibrosis"
                  },
                  {
                    "text": "Normal bony trabeculae"
                  }
                ],
                "Ancillary Studies": [
                  {
                    "text": "Conventional cytogenetics90% of cases are cytogenetically normalReported abnormalities include +8, +9, +21, and del(20q)Clonal evolution with disease progressionAbsence of recurrent genetic abnormality defining another myeloid disordert(9;22)(q34;q11.2) in chronic myelogenous leukemiaRearrangements ofPDGFRA,PDGFRB, andFGFR1",
                    "sub_points": [
                      "90% of cases are cytogenetically normal",
                      "Reported abnormalities include +8, +9, +21, and del(20q)",
                      "Clonal evolution with disease progression",
                      "Absence of recurrent genetic abnormality defining another myeloid disordert(9;22)(q34;q11.2) in chronic myelogenous leukemiaRearrangements ofPDGFRA,PDGFRB, andFGFR1",
                      "t(9;22)(q34;q11.2) in chronic myelogenous leukemia",
                      "Rearrangements ofPDGFRA,PDGFRB, andFGFR1"
                    ]
                  },
                  {
                    "text": "Fluorescence in situ hybridizationBCR-ABL1fusion absent",
                    "sub_points": [
                      "BCR-ABL1fusion absent"
                    ]
                  },
                  {
                    "text": "Molecular studiesJAK2V617F mutation has been reported",
                    "sub_points": [
                      "JAK2V617F mutation has been reported"
                    ]
                  },
                  {
                    "text": "Demonstrating clonality can be challengingIf cytogenetics normalProgenitor cell assaysX-inactivation studies",
                    "sub_points": [
                      "If cytogenetics normalProgenitor cell assaysX-inactivation studies",
                      "Progenitor cell assays",
                      "X-inactivation studies"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Reactive Neutrophilia/Leukemoid Reaction": [
                  {
                    "text": "Exclude acute bacterial, viral, or other infections"
                  },
                  {
                    "text": "Exclude inflammatory disorder/collagen vascular disease"
                  },
                  {
                    "text": "Exclude drug effect (e.g., steroids)"
                  }
                ],
                "Underlying Neoplasm": [
                  {
                    "text": "Neutrophilia can be seen in setting of underlying hematopoietic or nonhematopoietic disorders"
                  },
                  {
                    "text": "Result of chemokines &/or other molecules secreted by tumor cells"
                  },
                  {
                    "text": "Hematopoietic neoplasms; most commonly myeloma"
                  },
                  {
                    "text": "Nonhematopoietic neoplasms; transitional cell carcinoma, hepatocellular carcinoma"
                  }
                ],
                "Granulocyte Colony Stimulating Factor (G-CSF) Effect": [
                  {
                    "text": "Exogenous administration &/or endogenous"
                  },
                  {
                    "text": "Neutrophilia with left shift, including occasional myeloblasts, in PB"
                  },
                  {
                    "text": "Monocytosis may be seen"
                  },
                  {
                    "text": "Clinical history is necessary"
                  }
                ],
                "Chronic Myelogenous Leukemia,BCR-ABL1Positive (CML)": [
                  {
                    "text": "PB neutrophilia with left shift and basophilia"
                  },
                  {
                    "text": "Hypercellular BM with granulocytic predominance and small, hypolobated megakaryocytes"
                  },
                  {
                    "text": "Genetics reveal t(9;22)q34;q11.2) or variant;BCR-ABL1genetic fusion"
                  }
                ],
                "BCR-ABL1Negative MPNs": [
                  {
                    "text": "Primary myelofibrosis (PMF), prefibrotic phaseMegakaryocytes abnormal and clustered in PMF",
                    "sub_points": [
                      "Megakaryocytes abnormal and clustered in PMF"
                    ]
                  },
                  {
                    "text": "Polycythemia vera (PV)Erythrocytosis and low serum erythropoietin level in PV",
                    "sub_points": [
                      "Erythrocytosis and low serum erythropoietin level in PV"
                    ]
                  },
                  {
                    "text": "Essential thrombocythemia (ET)Thrombocytosis in ET",
                    "sub_points": [
                      "Thrombocytosis in ET"
                    ]
                  }
                ],
                "Chronic Myelomonocytic Leukemia (CMML)": [
                  {
                    "text": "CNL shows no significant monocytosis"
                  },
                  {
                    "text": "CMML shows dysplastic features in at least 50% of cases"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Myeloid neoplasm"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Diagnosis of exclusionMust exclude reactive neutrophilia, including G-CSF effectMust exclude paraneoplastic phenomenon due to underlying neoplasmMust exclude other clonal myeloid neoplasms",
                    "sub_points": [
                      "Must exclude reactive neutrophilia, including G-CSF effect",
                      "Must exclude paraneoplastic phenomenon due to underlying neoplasm",
                      "Must exclude other clonal myeloid neoplasms"
                    ]
                  },
                  {
                    "text": "Sustained, unexplained neutrophilia"
                  },
                  {
                    "text": "No significant blasts in PB or BM"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Chronic Eosinophilic Leukemia, Not Otherwise Specified": {
            "name": "Chronic Eosinophilic Leukemia, Not Otherwise Specified",
            "url": "https://app.pathprimer.com/document/2f566024-90b8-4a26-a544-12c1ea23d7a3/lesson/74c9ecc8-b842-4e36-acf8-277b06dc00d9",
            "content": {
              "KEY FACTS": {
                "Clinical Issues": [
                  {
                    "text": "IncidenceRare",
                    "sub_points": [
                      "Rare"
                    ]
                  },
                  {
                    "text": "End-organ damageTissue eosinophil infiltration",
                    "sub_points": [
                      "Tissue eosinophil infiltration"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "PB and BMEosinophiliaBlasts < 20%Blasts > 2% in PB and > 5% in BM in absence of clonal genetic abnormality",
                    "sub_points": [
                      "Eosinophilia",
                      "Blasts < 20%",
                      "Blasts > 2% in PB and > 5% in BM in absence of clonal genetic abnormality"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "May detect clonal genetic abnormality"
                  },
                  {
                    "text": "ExcludeBCR-ABL1and rearrangements ofPDGFRA,PDGFRB, andFGFR1"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Reactive eosinophiliaNumerous causes",
                    "sub_points": [
                      "Numerous causes"
                    ]
                  },
                  {
                    "text": "Myeloid and lymphoid neoplasms with eosinophilia and abnormalities ofPDGFRA,PDGFRB, andFGFR1"
                  },
                  {
                    "text": "Other myeloid neoplasmsAcute myeloid leukemia with inv(16) and abnormal eosinophilsChronic myelogenous leukemia;BCR-ABL1positiveBCR-ABL1negative myeloproliferative neoplasms",
                    "sub_points": [
                      "Acute myeloid leukemia with inv(16) and abnormal eosinophils",
                      "Chronic myelogenous leukemia;BCR-ABL1positive",
                      "BCR-ABL1negative myeloproliferative neoplasms"
                    ]
                  },
                  {
                    "text": "Underlying malignancyHodgkin/non-Hodgkin lymphoma, mastocytosis, lymphoblastic leukemia",
                    "sub_points": [
                      "Hodgkin/non-Hodgkin lymphoma, mastocytosis, lymphoblastic leukemia"
                    ]
                  }
                ],
                "Diagnostic Checklist": [
                  {
                    "text": "Diagnosis of exclusion"
                  },
                  {
                    "text": "Sustained clonal eosinophilia"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Chronic eosinophilic leukemia, not otherwise specified (CEL, NOS)"
                  },
                  {
                    "text": "Peripheral blood (PB)"
                  },
                  {
                    "text": "Bone marrow (BM)"
                  },
                  {
                    "text": "Central nervous system (CNS)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Clonal hematopoietic myeloproliferative neoplasm"
                  },
                  {
                    "text": "Manifests as sustained proliferation of eosinophils and precursors"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Rare; difficult to determine accuratelySignificant degree of diagnostic overlap with hypereosinophilic syndromeDiscovery of recurring genetic abnormalities warranting alternate diagnosis",
                    "sub_points": [
                      "Significant degree of diagnostic overlap with hypereosinophilic syndrome",
                      "Discovery of recurring genetic abnormalities warranting alternate diagnosis"
                    ]
                  }
                ],
                "Site": [
                  {
                    "text": "PB"
                  },
                  {
                    "text": "BM"
                  },
                  {
                    "text": "Peripheral tissues with end-organ damageCNSHeartGastrointestinal tractOthers",
                    "sub_points": [
                      "CNS",
                      "Heart",
                      "Gastrointestinal tract",
                      "Others"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "AsymptomaticIncidental identification of eosinophilia on complete blood cell count",
                    "sub_points": [
                      "Incidental identification of eosinophilia on complete blood cell count"
                    ]
                  },
                  {
                    "text": "SymptomaticFeverFatiguePruritusGastrointestinal disturbanceEndomyocardial fibrosisCNS symptoms",
                    "sub_points": [
                      "Fever",
                      "Fatigue",
                      "Pruritus",
                      "Gastrointestinal disturbance",
                      "Endomyocardial fibrosis",
                      "CNS symptoms"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Aim is to reduce eosinophilia"
                  },
                  {
                    "text": "Hydroxyurea, empiric trial of imatinib, interferon-α, other chemotherapeutic agents"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Varies: Depends on associated tissue damage, increasing blasts, clonal evolution"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Peripheral Blood": [
                  {
                    "text": "EosinophiliaMostly mature eosinophilsOccasional eosinophil precursorsEosinophil count ≥ 1.5 x 10⁹/L",
                    "sub_points": [
                      "Mostly mature eosinophils",
                      "Occasional eosinophil precursors",
                      "Eosinophil count ≥ 1.5 x 10⁹/L"
                    ]
                  },
                  {
                    "text": "Abnormal eosinophil cytologyNot specific for neoplasiaHypogranulationAggregation of granules into 1 location in the cytoplasmNuclear lobation abnormalitiesCytoplasmic vacuoles",
                    "sub_points": [
                      "Not specific for neoplasia",
                      "Hypogranulation",
                      "Aggregation of granules into 1 location in the cytoplasm",
                      "Nuclear lobation abnormalities",
                      "Cytoplasmic vacuoles"
                    ]
                  },
                  {
                    "text": "Neutrophilia common"
                  },
                  {
                    "text": "Blasts < 20%"
                  },
                  {
                    "text": "No significant population of mast cells"
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "Usually hypercellular due to eosinophilia"
                  },
                  {
                    "text": "Intact erythropoiesis, granulopoiesis, and megakaryopoiesis"
                  },
                  {
                    "text": "Blasts < 20%"
                  },
                  {
                    "text": "Dysplasia may be seenExclude myelodysplasia with associated eosinophilia",
                    "sub_points": [
                      "Exclude myelodysplasia with associated eosinophilia"
                    ]
                  },
                  {
                    "text": "Charcot-Leyden crystals may be observed"
                  },
                  {
                    "text": "Fibrosis due to release of eosinophil granules"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Tryptase: Exclude mast cell disease"
                  },
                  {
                    "text": "T-cell markers: Exclude T-cell neoplasm"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Exclude acute leukemiaDetect lymphoblasts or myeloblasts (≥ 20%)",
                    "sub_points": [
                      "Detect lymphoblasts or myeloblasts (≥ 20%)"
                    ]
                  },
                  {
                    "text": "Exclude aberrant T-cell clone"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "T-cell receptor gamma gene rearrangement for occult T-cell clone"
                  },
                  {
                    "text": "Document clonality"
                  },
                  {
                    "text": "Exclude recurring genetic abnormalities that would render an alternative diagnosise.g., t(9;22)(q34;q11.2);BCR-ABL1fusion in CMLRearrangement ofPDGFRA(4q),PDGFRB(5q), andFGFR1(8p)",
                    "sub_points": [
                      "e.g., t(9;22)(q34;q11.2);BCR-ABL1fusion in CML",
                      "Rearrangement ofPDGFRA(4q),PDGFRB(5q), andFGFR1(8p)"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Reactive (Secondary) Eosinophilia": [
                  {
                    "text": "Parasitic infection"
                  },
                  {
                    "text": "Drug/medication or other hypersensitivity reaction"
                  },
                  {
                    "text": "Allergic conditions"
                  },
                  {
                    "text": "Skin diseases (e.g., eczema)"
                  },
                  {
                    "text": "Pulmonary disorders"
                  },
                  {
                    "text": "Collagen vascular disease"
                  }
                ],
                "Reactive (Secondary) Eosinophilia Due to Underlying Clonal, Nonmyeloid Neoplasm": [
                  {
                    "text": "Due to secretion of cytokine(s), which drive eosinophil proliferationIL-2, IL-3, IL-5",
                    "sub_points": [
                      "IL-2, IL-3, IL-5"
                    ]
                  },
                  {
                    "text": "T-cell lymphomaBM neoplastic T-cells may be morphologically occult",
                    "sub_points": [
                      "BM neoplastic T-cells may be morphologically occult"
                    ]
                  },
                  {
                    "text": "Acute lymphoblastic leukemia≥ 20% lymphoblasts",
                    "sub_points": [
                      "≥ 20% lymphoblasts"
                    ]
                  },
                  {
                    "text": "Hodgkin lymphoma"
                  }
                ],
                "Myeloid and Lymphoid Neoplasms With Eosinophilia": [
                  {
                    "text": "Genetic rearrangementsPDGFRA,PDGFRB, andFGFR1",
                    "sub_points": [
                      "PDGFRA,PDGFRB, andFGFR1"
                    ]
                  }
                ],
                "Other Myeloid Neoplasms With Eosinophilia": [
                  {
                    "text": "BCR-ABL1negative myeloproliferative neoplasms"
                  },
                  {
                    "text": "Myelodysplastic syndrome"
                  },
                  {
                    "text": "Acute myeloid leukemiaFor example, inv(16) with abnormal eosinophils",
                    "sub_points": [
                      "For example, inv(16) with abnormal eosinophils"
                    ]
                  },
                  {
                    "text": "Systemic mastocytosis"
                  }
                ],
                "Chronic Myelogenous Leukemia": [
                  {
                    "text": "t(9;22)(q34;q11.2);BCR-ABL1positive"
                  }
                ],
                "Hypereosinophilic Syndrome": [
                  {
                    "text": "PB blasts < 2% and BM blasts < 5% ﻿and﻿no clonal genetic abnormality"
                  },
                  {
                    "text": "End-organ tissue damage"
                  }
                ],
                "Hypereosinophilia": [
                  {
                    "text": "Nonclonal eosinophilia"
                  },
                  {
                    "text": "No end-organ tissue damage"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "End-organ damage from tissue eosinophilia"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "There should be evidence of clonality or increased myeloblasts in PB or BMOtherwise will be classified as hypereosinophilic syndrome",
                    "sub_points": [
                      "Otherwise will be classified as hypereosinophilic syndrome"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Chronic Myelomonocytic Leukemia": {
            "name": "Chronic Myelomonocytic Leukemia",
            "url": "https://app.pathprimer.com/document/51a55fde-9734-4269-8060-32645de3da19/lesson/74c9ecc8-b842-4e36-acf8-277b06dc00d9",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Chronic myelomonocytic leukemia (CMML) is myelodysplastic/myeloproliferative neoplasmLike other entities in this \"overlap\" category, combines features of both myelodysplastic syndrome and myeloproliferative neoplasm",
                    "sub_points": [
                      "Like other entities in this \"overlap\" category, combines features of both myelodysplastic syndrome and myeloproliferative neoplasm"
                    ]
                  },
                  {
                    "text": "Blasts and blast equivalents include myeloblasts, monoblasts, and promonocytes"
                  },
                  {
                    "text": "Clonal monocytosis of undetermined significance (CMUS) and clonal cytopenia and monocytosis of undetermined significance (CCMUS) are precursor states, under International Consensus Classification (ICC)"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Cases range from those with predominant myelodysplastic features to those with more myeloproliferative findings"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Careful attention to updated diagnostic criteria is essentialICC and WHO 5th edition (WHO-HAEM5) are similar but not identical with increased emphasis on clonality as detected by molecular and cytogenetic methodsBoth allow diagnosis of CMML with absolute (≥ 0.5 x 10⁹/L) and relative (≥ 10%) monocytosis, depending on fulfillment of additional criteria",
                    "sub_points": [
                      "ICC and WHO 5th edition (WHO-HAEM5) are similar but not identical with increased emphasis on clonality as detected by molecular and cytogenetic methods",
                      "Both allow diagnosis of CMML with absolute (≥ 0.5 x 10⁹/L) and relative (≥ 10%) monocytosis, depending on fulfillment of additional criteria"
                    ]
                  },
                  {
                    "text": "Gene mutations in > 90% of CMML casesTET2,SRSF2, andASXL1mutations are common",
                    "sub_points": [
                      "TET2,SRSF2, andASXL1mutations are common"
                    ]
                  },
                  {
                    "text": "~ 15-30% of cases progress to acute myeloid leukemia"
                  },
                  {
                    "text": "Integrated risk stratification tools include cytogenetic and molecular data, as well as morphologic and clinical findings"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Reactive monocytosis"
                  },
                  {
                    "text": "Chronic myeloid leukemia"
                  },
                  {
                    "text": "Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions"
                  },
                  {
                    "text": "Acute myeloid leukemia"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Chronic myelomonocytic leukemia (CMML)"
                  },
                  {
                    "text": "International Consensus Classification (ICC)"
                  },
                  {
                    "text": "WHO 5th edition (WHO-HAEM5)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "CMML is myelodysplastic/myeloproliferative neoplasm (MDS/MPN)Like other entities in this \"overlap\" category, combines features of both MDS and MPN",
                    "sub_points": [
                      "Like other entities in this \"overlap\" category, combines features of both MDS and MPN"
                    ]
                  }
                ]
              },
              "CLASSIFICATION": {
                "ICC vs. WHO-HAEM5 Comparisons": [
                  {
                    "text": "Overall, many similarities in criteria, blast percentage ranges, absolute monocyte count and percent of WBC, genetic features, and exclusionary criteria, including bone marrow examination to exclude other myeloid neoplasms"
                  },
                  {
                    "text": "Both include CMML-1 and CMML-2 subtypes with similar criteria"
                  },
                  {
                    "text": "Both classifications include myelodysplastic and myeloproliferative subtypes based on WBC count"
                  },
                  {
                    "text": "Both have similar comprehensive exclusion criteria and generally similar criteria for cases lacking genetic findings"
                  },
                  {
                    "text": "Both cite newly proposed monocyte partitioning by flow cytometric immunophenotyping to support diagnosis"
                  }
                ],
                "ICC Diagnostic Criteria": [
                  {
                    "text": "Monocytosis defined as monocytes ≥ 0.5 x 10⁹/L and ≥ 10% of WBC for clonality-confirmed cases"
                  },
                  {
                    "text": "Cytopenia (using same thresholds as MDS)Small proportion of cases may show only borderline or no cytopenia, usually in early-phase disease",
                    "sub_points": [
                      "Small proportion of cases may show only borderline or no cytopenia, usually in early-phase disease"
                    ]
                  },
                  {
                    "text": "Blasts (including promonocytes) < 20% of cells in blood and bone marrow"
                  },
                  {
                    "text": "Presence of clonalityAbnormal cytogenetics &/or presence of at least 1 myeloid neoplasm-associated mutation of at least 10% variant allele frequencySRSF2,TET2, &/orASXL1mutations occur in up to 80% of casesCooccurrence ofSRSF2andTET2mutations highly characteristic of CMMLMany other myeloid neoplasm-associated mutations can be identified",
                    "sub_points": [
                      "Abnormal cytogenetics &/or presence of at least 1 myeloid neoplasm-associated mutation of at least 10% variant allele frequencySRSF2,TET2, &/orASXL1mutations occur in up to 80% of casesCooccurrence ofSRSF2andTET2mutations highly characteristic of CMMLMany other myeloid neoplasm-associated mutations can be identified",
                      "SRSF2,TET2, &/orASXL1mutations occur in up to 80% of cases",
                      "Cooccurrence ofSRSF2andTET2mutations highly characteristic of CMML",
                      "Many other myeloid neoplasm-associated mutations can be identified"
                    ]
                  },
                  {
                    "text": "However, in caseswithoutevidence of clonalityMonocytes must be ≥ 1 x 10⁹/L and ≥ 10% of WBC with 1 of followingIncreased blasts and equivalents (including promonocytes) ≥ 5% in bone marrow &/or ≥ 2% in peripheral bloodorMorphologic dysplasiaorAbnormal immunophenotype consistent with CMMLIn cases lacking clonality, documentation of persistent monocytosis and rigorous exclusion of secondary causes of monocytosis, such as infection, are often necessary",
                    "sub_points": [
                      "Monocytes must be ≥ 1 x 10⁹/L and ≥ 10% of WBC with 1 of followingIncreased blasts and equivalents (including promonocytes) ≥ 5% in bone marrow &/or ≥ 2% in peripheral bloodorMorphologic dysplasiaorAbnormal immunophenotype consistent with CMML",
                      "Increased blasts and equivalents (including promonocytes) ≥ 5% in bone marrow &/or ≥ 2% in peripheral bloodor",
                      "Morphologic dysplasiaor",
                      "Abnormal immunophenotype consistent with CMML",
                      "In cases lacking clonality, documentation of persistent monocytosis and rigorous exclusion of secondary causes of monocytosis, such as infection, are often necessary"
                    ]
                  },
                  {
                    "text": "Bone marrow with morphologic findings consistent with CMML and lacking diagnostic features of acute myeloid leukemia (AML), MPN, or other conditions associated with monocytosisHypercellularity due to myeloid proliferation often with increased monocytes",
                    "sub_points": [
                      "Hypercellularity due to myeloid proliferation often with increased monocytes"
                    ]
                  },
                  {
                    "text": "NoBCR::ABL1or genetic abnormalities of myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions"
                  },
                  {
                    "text": "ICC, subtyping and subgrouping of CMML (i.e., myeloproliferative CMML, CMML-1, CMML-2) are similar to scheme presented in WHO-HAEM5"
                  }
                ],
                "WHO-HAEM5 Diagnostic Criteria": [
                  {
                    "text": "Prerequisite criteriaPeripheral blood with persistent absolute (≥ 0.5 x 10⁹/L) and relative (≥ 10%) monocytosis< 20% blasts in blood and bone marrowBlasts and equivalents include myeloblasts, monoblasts, and promonocytesAbsence of diagnostic criteria for chronic myeloid leukemia (CML) or other MPNMPNs can be associated with monocytosis at presentation or during course of disease and can mimic CMMLDocumented history of MPN excludes CMMLPresence of MPN features in bone marrow &/or high burden of MPN-associated mutations (JAK2,CALR, orMPL) tends to support MPN with monocytosis rather than CMMLAbsence of diagnostic criteria for myeloid/lymphoid neoplasms with eosinophilia and defining gene rearrangements (e.g.,PDGFRA,PDGFRB,FGFR1, orJAK2)These should be specifically excluded in cases with eosinophilia",
                    "sub_points": [
                      "Peripheral blood with persistent absolute (≥ 0.5 x 10⁹/L) and relative (≥ 10%) monocytosis",
                      "< 20% blasts in blood and bone marrowBlasts and equivalents include myeloblasts, monoblasts, and promonocytes",
                      "Blasts and equivalents include myeloblasts, monoblasts, and promonocytes",
                      "Absence of diagnostic criteria for chronic myeloid leukemia (CML) or other MPNMPNs can be associated with monocytosis at presentation or during course of disease and can mimic CMMLDocumented history of MPN excludes CMMLPresence of MPN features in bone marrow &/or high burden of MPN-associated mutations (JAK2,CALR, orMPL) tends to support MPN with monocytosis rather than CMML",
                      "MPNs can be associated with monocytosis at presentation or during course of disease and can mimic CMML",
                      "Documented history of MPN excludes CMML",
                      "Presence of MPN features in bone marrow &/or high burden of MPN-associated mutations (JAK2,CALR, orMPL) tends to support MPN with monocytosis rather than CMML",
                      "Absence of diagnostic criteria for myeloid/lymphoid neoplasms with eosinophilia and defining gene rearrangements (e.g.,PDGFRA,PDGFRB,FGFR1, orJAK2)These should be specifically excluded in cases with eosinophilia",
                      "These should be specifically excluded in cases with eosinophilia"
                    ]
                  },
                  {
                    "text": "Supporting criteriaDysplasia involving ≥ 1 myeloid lineagesMorphologic dysplasia should be present in ≥ 10% of cells of hematopoietic lineage in bone marrowAcquired clonal cytogenetic or molecular abnormalityKey genes, per WHO, areASXL1,EZH2,BCOR,SRSF2,U2AF1,SF3B1,ZRSR2, and othersAbnormal partitioning of peripheral blood monocyte subsetsIncreased classic monocytes (> 94%) in absence of known active autoimmune diseases &/or systemic inflammatory syndromes",
                    "sub_points": [
                      "Dysplasia involving ≥ 1 myeloid lineagesMorphologic dysplasia should be present in ≥ 10% of cells of hematopoietic lineage in bone marrow",
                      "Morphologic dysplasia should be present in ≥ 10% of cells of hematopoietic lineage in bone marrow",
                      "Acquired clonal cytogenetic or molecular abnormalityKey genes, per WHO, areASXL1,EZH2,BCOR,SRSF2,U2AF1,SF3B1,ZRSR2, and others",
                      "Key genes, per WHO, areASXL1,EZH2,BCOR,SRSF2,U2AF1,SF3B1,ZRSR2, and others",
                      "ASXL1,EZH2,BCOR,SRSF2,U2AF1,SF3B1,ZRSR2, and others",
                      "Abnormal partitioning of peripheral blood monocyte subsetsIncreased classic monocytes (> 94%) in absence of known active autoimmune diseases &/or systemic inflammatory syndromes",
                      "Increased classic monocytes (> 94%) in absence of known active autoimmune diseases &/or systemic inflammatory syndromes"
                    ]
                  },
                  {
                    "text": "Prerequisite criteria must be present in all casesIf absolute monocyte count is ≥ 1 x 10⁹/L, ≥ 1 supporting criteria must be presentIf absolute monocyte count is < 1 x 10⁹/L (i.e., ≥ 0.5 x 10⁹/L but < 1 x 10⁹/L), both dysplasia and acquired clonal cytogenetic/molecular abnormality must be present",
                    "sub_points": [
                      "If absolute monocyte count is ≥ 1 x 10⁹/L, ≥ 1 supporting criteria must be present",
                      "If absolute monocyte count is < 1 x 10⁹/L (i.e., ≥ 0.5 x 10⁹/L but < 1 x 10⁹/L), both dysplasia and acquired clonal cytogenetic/molecular abnormality must be present"
                    ]
                  },
                  {
                    "text": "PerICC and WHO-HAEM5, cases may be subtyped as either myelodysplastic CMML (MD-CMML) or myeloproliferative CMML (MP-CMML)MD-CMML is diagnosed when WBC count < 13 x 10⁹/LMP-CMML is diagnosed when WBC count ≥ 13 x 10⁹/L",
                    "sub_points": [
                      "MD-CMML is diagnosed when WBC count < 13 x 10⁹/L",
                      "MP-CMML is diagnosed when WBC count ≥ 13 x 10⁹/L"
                    ]
                  },
                  {
                    "text": "PerICC and WHO-HAEM5, CMML is further subgrouped based on blast percentage (including equivalents)CMML-1< 5% in peripheral blood and < 10% in bone marrowCMML-25-19% in peripheral blood or 10-19% in bone marrowCMML-2 is also diagnosed when Auer rods are identified, though thorough exclusion of AML must be carried out in this rare circumstance",
                    "sub_points": [
                      "CMML-1< 5% in peripheral blood and < 10% in bone marrow",
                      "< 5% in peripheral blood and < 10% in bone marrow",
                      "CMML-25-19% in peripheral blood or 10-19% in bone marrowCMML-2 is also diagnosed when Auer rods are identified, though thorough exclusion of AML must be carried out in this rare circumstance",
                      "5-19% in peripheral blood or 10-19% in bone marrow",
                      "CMML-2 is also diagnosed when Auer rods are identified, though thorough exclusion of AML must be carried out in this rare circumstance"
                    ]
                  },
                  {
                    "text": "ICCalso definesprecursor statesof clonal monocytosis that fall short of overt CMMLClonal monocytosis of undetermined significance (CMUS)Persistent monocytosis, defined as monocytes ≥ 0.5 x 10⁹/L and ≥ 10% of WBCPresence of at least 1 myeloid neoplasm-associated mutation of appropriate variant allele frequency (i.e., ≥ 2%)No significant dysplasia, increased blasts (including promonocytes), or morphologic findings of CMML on bone marrow examinationBone marrow findings of CMML include hypercellularity with myeloid predominance, often with increased monocytes, and in proportion of cases monoblasts &/or blast equivalents (i.e., promonocytes) &/or dysplasia in at least 1 lineageNo criteria for another myeloid or other hematopoietic neoplasm are fulfilledNo reactive condition that would explain monocytosis is detectedClonal cytopenia and monocytosis of undetermined significance (CCMUS)Same as CMUS but with presence of cytopenia (thresholds same as for MDS)",
                    "sub_points": [
                      "Clonal monocytosis of undetermined significance (CMUS)Persistent monocytosis, defined as monocytes ≥ 0.5 x 10⁹/L and ≥ 10% of WBCPresence of at least 1 myeloid neoplasm-associated mutation of appropriate variant allele frequency (i.e., ≥ 2%)No significant dysplasia, increased blasts (including promonocytes), or morphologic findings of CMML on bone marrow examinationBone marrow findings of CMML include hypercellularity with myeloid predominance, often with increased monocytes, and in proportion of cases monoblasts &/or blast equivalents (i.e., promonocytes) &/or dysplasia in at least 1 lineageNo criteria for another myeloid or other hematopoietic neoplasm are fulfilledNo reactive condition that would explain monocytosis is detected",
                      "Persistent monocytosis, defined as monocytes ≥ 0.5 x 10⁹/L and ≥ 10% of WBC",
                      "Presence of at least 1 myeloid neoplasm-associated mutation of appropriate variant allele frequency (i.e., ≥ 2%)",
                      "No significant dysplasia, increased blasts (including promonocytes), or morphologic findings of CMML on bone marrow examinationBone marrow findings of CMML include hypercellularity with myeloid predominance, often with increased monocytes, and in proportion of cases monoblasts &/or blast equivalents (i.e., promonocytes) &/or dysplasia in at least 1 lineage",
                      "Bone marrow findings of CMML include hypercellularity with myeloid predominance, often with increased monocytes, and in proportion of cases monoblasts &/or blast equivalents (i.e., promonocytes) &/or dysplasia in at least 1 lineage",
                      "No criteria for another myeloid or other hematopoietic neoplasm are fulfilled",
                      "No reactive condition that would explain monocytosis is detected",
                      "Clonal cytopenia and monocytosis of undetermined significance (CCMUS)Same as CMUS but with presence of cytopenia (thresholds same as for MDS)",
                      "Same as CMUS but with presence of cytopenia (thresholds same as for MDS)"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Site": [
                  {
                    "text": "In addition to peripheral blood and bone marrow involvement, tissue-based leukemic infiltrates may occur"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Cases range from those with predominant myelodysplastic features to those with more myeloproliferative findings"
                  },
                  {
                    "text": "Leukocytosis in majority of casesHepatosplenomegaly more common in those with leukocytosis",
                    "sub_points": [
                      "Hepatosplenomegaly more common in those with leukocytosis"
                    ]
                  },
                  {
                    "text": "Symptoms of cytopenia(s)"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Conventional cytogenetic analysisCytogenetic abnormalities are detected in up to 40% of cases but none specific for CMMLTrisomy 8, monosomy 7/del(7q), del(20q), trisomy 21Can usefully document clonalityAssists in excluding abnormalities diagnostic of some alternative hematologic malignanciest(9;22)(q34.1;q11.2)Rearrangement of specific tyrosine kinase genes",
                    "sub_points": [
                      "Cytogenetic abnormalities are detected in up to 40% of cases but none specific for CMMLTrisomy 8, monosomy 7/del(7q), del(20q), trisomy 21",
                      "Trisomy 8, monosomy 7/del(7q), del(20q), trisomy 21",
                      "Can usefully document clonality",
                      "Assists in excluding abnormalities diagnostic of some alternative hematologic malignanciest(9;22)(q34.1;q11.2)Rearrangement of specific tyrosine kinase genes",
                      "t(9;22)(q34.1;q11.2)",
                      "Rearrangement of specific tyrosine kinase genes"
                    ]
                  },
                  {
                    "text": "FISH forPDGFRArearrangementSincePDGFRArearrangement is routinely cryptic on karyotype, FISH is necessary in cases of possible CMML with eosinophilia, if positive CMML is excluded",
                    "sub_points": [
                      "SincePDGFRArearrangement is routinely cryptic on karyotype, FISH is necessary in cases of possible CMML with eosinophilia, if positive CMML is excluded"
                    ]
                  },
                  {
                    "text": "Assessment forBCR::ABL1fusionCML withBCR::ABL1fusion must be excluded in cases of possible CMMLCrucial distinction given sustained response to tyrosine kinase inhibitor therapy in CMLCases of CML with p190 form of chimeric protein may show significant monocytosis, mimicking CMMLRare cases ofBCR::ABL1fusion are cryptic on karyotypeThus, WHO-HAEM5 specifies that RT-PCR &/or FISH analysis forBCR::ABL1fusion gene must be performed alongside conventional karyotyping",
                    "sub_points": [
                      "CML withBCR::ABL1fusion must be excluded in cases of possible CMMLCrucial distinction given sustained response to tyrosine kinase inhibitor therapy in CML",
                      "Crucial distinction given sustained response to tyrosine kinase inhibitor therapy in CML",
                      "Cases of CML with p190 form of chimeric protein may show significant monocytosis, mimicking CMML",
                      "Rare cases ofBCR::ABL1fusion are cryptic on karyotypeThus, WHO-HAEM5 specifies that RT-PCR &/or FISH analysis forBCR::ABL1fusion gene must be performed alongside conventional karyotyping",
                      "Thus, WHO-HAEM5 specifies that RT-PCR &/or FISH analysis forBCR::ABL1fusion gene must be performed alongside conventional karyotyping"
                    ]
                  },
                  {
                    "text": "Molecular assessmentMyeloid next-generation sequencing panels identify mutations in > 90% of CMML casesMolecular data is now considered critical for complete diagnosis of possible CMMLThese mutations affect diverse cellular functions with epigenetic regulation and spliceosomal function most often implicatedThese mutations are not specific for CMML, as they are seen in wide variety of other myeloid neoplasmsMost common areTET2,SRSF2, andASXL1mutationsFollowed byCBL,KRAS,NRAS,RUNX1, andSETBP1mutationsCoexistence ofSRSF2andTET2mutations is highly suggestive of CMML, per ICCASXL1mutation is linked to adverse prognosisTET2mutation (especially multipleTET2mutations and truncating mutations) linked to better prognosisMutations inNRAS,RUNX1, andSETBP1also linked to outcome",
                    "sub_points": [
                      "Myeloid next-generation sequencing panels identify mutations in > 90% of CMML casesMolecular data is now considered critical for complete diagnosis of possible CMML",
                      "Molecular data is now considered critical for complete diagnosis of possible CMML",
                      "These mutations affect diverse cellular functions with epigenetic regulation and spliceosomal function most often implicated",
                      "These mutations are not specific for CMML, as they are seen in wide variety of other myeloid neoplasms",
                      "Most common areTET2,SRSF2, andASXL1mutationsFollowed byCBL,KRAS,NRAS,RUNX1, andSETBP1mutations",
                      "Followed byCBL,KRAS,NRAS,RUNX1, andSETBP1mutations",
                      "Coexistence ofSRSF2andTET2mutations is highly suggestive of CMML, per ICC",
                      "ASXL1mutation is linked to adverse prognosis",
                      "TET2mutation (especially multipleTET2mutations and truncating mutations) linked to better prognosis",
                      "Mutations inNRAS,RUNX1, andSETBP1also linked to outcome"
                    ]
                  },
                  {
                    "text": "Flow cytometry criteriaMonocytes may show number of abnormal (though individually nonspecific) patterns of antigen expressionDecreased expression of CD14, CD36, CD64, CD15, and HLA-DRAberrant coexpression of CD2 and CD56Combination of decreased CD14 expression in 20% of bone marrow monocytes with at least 2 immunophenotypic aberrancies has been reported to be relatively specific for CMML (vs. reactive monocytosis)Abnormal partitioning of peripheral blood monocyte subsets is recognized as supporting criterion for CMML in cases with absolute monocyte count ≥ 1 x 10⁹/L, per ICC and WHO-HAEM5Classic (MO1) monocytes express CD14 but not CD16Intermediate (MO2) monocytes express both CD14 and CD16Nonclassic (MO3) monocytes express CD16 with absent/low CD14CMML supporting criterion is increased classic monocytes (> 94%) in absence of known active autoimmune diseases &/or systemic inflammatory syndromesCD34(+) blasts may also be increasedOften show immunophenotypic aberrancy",
                    "sub_points": [
                      "Monocytes may show number of abnormal (though individually nonspecific) patterns of antigen expressionDecreased expression of CD14, CD36, CD64, CD15, and HLA-DRAberrant coexpression of CD2 and CD56Combination of decreased CD14 expression in 20% of bone marrow monocytes with at least 2 immunophenotypic aberrancies has been reported to be relatively specific for CMML (vs. reactive monocytosis)",
                      "Decreased expression of CD14, CD36, CD64, CD15, and HLA-DR",
                      "Aberrant coexpression of CD2 and CD56",
                      "Combination of decreased CD14 expression in 20% of bone marrow monocytes with at least 2 immunophenotypic aberrancies has been reported to be relatively specific for CMML (vs. reactive monocytosis)",
                      "Abnormal partitioning of peripheral blood monocyte subsets is recognized as supporting criterion for CMML in cases with absolute monocyte count ≥ 1 x 10⁹/L, per ICC and WHO-HAEM5Classic (MO1) monocytes express CD14 but not CD16Intermediate (MO2) monocytes express both CD14 and CD16Nonclassic (MO3) monocytes express CD16 with absent/low CD14CMML supporting criterion is increased classic monocytes (> 94%) in absence of known active autoimmune diseases &/or systemic inflammatory syndromes",
                      "Classic (MO1) monocytes express CD14 but not CD16",
                      "Intermediate (MO2) monocytes express both CD14 and CD16",
                      "Nonclassic (MO3) monocytes express CD16 with absent/low CD14",
                      "CMML supporting criterion is increased classic monocytes (> 94%) in absence of known active autoimmune diseases &/or systemic inflammatory syndromes",
                      "CD34(+) blasts may also be increasedOften show immunophenotypic aberrancy",
                      "Often show immunophenotypic aberrancy"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "CMML prognosis is generally poor but somewhat heterogeneousIncreased blast percentage is associated with relatively inferior prognosisMedian overall survival: 38 months for CMML-1 vs. 24 months for CMML-2",
                    "sub_points": [
                      "Increased blast percentage is associated with relatively inferior prognosisMedian overall survival: 38 months for CMML-1 vs. 24 months for CMML-2",
                      "Median overall survival: 38 months for CMML-1 vs. 24 months for CMML-2"
                    ]
                  },
                  {
                    "text": "MP-CMML associated with adverse prognosis"
                  },
                  {
                    "text": "Integrated risk stratification tools include cytogenetic and molecular data, as well as morphologic and clinical findings"
                  },
                  {
                    "text": "~ 15-30% of cases progress to AML"
                  },
                  {
                    "text": "NPM1mutation uncommon in CMML but does not exclude diagnosisGenerally correlates with high risk of progression to AMLIf present, alternative diagnosis of AML or imminent progression should be considered",
                    "sub_points": [
                      "Generally correlates with high risk of progression to AML",
                      "If present, alternative diagnosis of AML or imminent progression should be considered"
                    ]
                  },
                  {
                    "text": "CMUS and CCMUS may be followed similarly to cases of CCUSHowever, risk of progression is generally to CMML rather than MDS",
                    "sub_points": [
                      "However, risk of progression is generally to CMML rather than MDS"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Features of Blast Equivalents": [
                  {
                    "text": "MonoblastNuclear chromatin is quite open and consistent with blast stage of differentiationProminent nucleoli usually presentNuclear contours are round with only minimal irregularity or foldingCytoplasm may be relatively abundant",
                    "sub_points": [
                      "Nuclear chromatin is quite open and consistent with blast stage of differentiationProminent nucleoli usually present",
                      "Prominent nucleoli usually present",
                      "Nuclear contours are round with only minimal irregularity or folding",
                      "Cytoplasm may be relatively abundant"
                    ]
                  },
                  {
                    "text": "Promonocyte (blast equivalent)Intermediate form of maturation between monoblast and monocyteNuclear chromatin is finely dispersed/open, more dispersed than that of monocyteNuclear contours are lightly folded and creased; nucleoli often presentCytoplasm is usually lightly basophilic and variably vacuolated",
                    "sub_points": [
                      "Intermediate form of maturation between monoblast and monocyte",
                      "Nuclear chromatin is finely dispersed/open, more dispersed than that of monocyte",
                      "Nuclear contours are lightly folded and creased; nucleoli often present",
                      "Cytoplasm is usually lightly basophilic and variably vacuolated"
                    ]
                  }
                ],
                "Peripheral Blood": [
                  {
                    "text": "Monocytic cells are increased, but status of other lineages varies by case; cytopenia must be present"
                  },
                  {
                    "text": "Total WBC count may be increased or normal, and anemia &/or thrombocytopenia may be present"
                  },
                  {
                    "text": "Some cases also show mild basophilia or eosinophilia"
                  },
                  {
                    "text": "Dysplasia, especially involving granulocytic lineage, typically present"
                  }
                ],
                "Bone Marrow Aspirate": [
                  {
                    "text": "Granulocytic, erythroid, &/or megakaryocytic dysplasia are often present"
                  },
                  {
                    "text": "Cytochemical NSE stain helps to highlight monocytic lineage cells"
                  }
                ],
                "Bone Marrow Biopsy or Clot Section": [
                  {
                    "text": "ImmunohistochemistryCD163, CD68, lysozyme, and CD14 (+)IRF8 identifies immature monocytic cells but due to only modest concordance with morphologic blast count in CMML specifically; ICC recommends further study of this marker in CMML",
                    "sub_points": [
                      "CD163, CD68, lysozyme, and CD14 (+)",
                      "IRF8 identifies immature monocytic cells but due to only modest concordance with morphologic blast count in CMML specifically; ICC recommends further study of this marker in CMML"
                    ]
                  },
                  {
                    "text": "Minority of cases show nodular collections of plasmacytoid dendritic cellsHighlighted by CD123Clonally related to CMML",
                    "sub_points": [
                      "Highlighted by CD123",
                      "Clonally related to CMML"
                    ]
                  },
                  {
                    "text": "Variable mild to moderate reticulin fibrosis"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Reactive Monocytosis": [
                  {
                    "text": "In cases without significant dysplasia or clonal genetic abnormality, causes of reactive monocytosis must be excludedChronic infection, other causes of inflammationAutoimmune syndromeUnrelated neoplasm",
                    "sub_points": [
                      "Chronic infection, other causes of inflammation",
                      "Autoimmune syndrome",
                      "Unrelated neoplasm"
                    ]
                  }
                ],
                "Chronic Myeloid Leukemia": [
                  {
                    "text": "In particular, CML with p190 form of chimeric protein may show significant monocytosis, mimicking CMML"
                  }
                ],
                "Myeloid/Lymphoid Neoplasms With Eosinophilia and Tyrosine Kinase Gene Fusions": [
                  {
                    "text": "Cases withPDGFRBrearrangement are especially associated with CMML-like presentation"
                  },
                  {
                    "text": "Should be formally excluded when eosinophilia also present"
                  }
                ],
                "Acute Myeloid Leukemia": [
                  {
                    "text": "Distinction from CMML-2 depends on careful morphologic assessment of degree of monocytic immaturity"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Not uncommon for blasts and equivalents to be more prominent in bone marrow than peripheral bloodBone marrow biopsy is indicated to best distinguish CMML from AML",
                    "sub_points": [
                      "Bone marrow biopsy is indicated to best distinguish CMML from AML"
                    ]
                  },
                  {
                    "text": "Distinction of blast equivalent promonocytes from more mature &/or dysplastic monocytes is a uniquely challenging morphologic task in hematopathology"
                  },
                  {
                    "text": "Cytochemical NSE stain is rapid and efficient means of documenting monocytic proliferation"
                  },
                  {
                    "text": "Presence of MPN driver mutation (e.g.,CALRorMPL) mutation would tend to support diagnosis of MPNHowever, careful assessment of bone marrow morphology is also essential in making this distinction (especially in cases withJAK2V617F)",
                    "sub_points": [
                      "However, careful assessment of bone marrow morphology is also essential in making this distinction (especially in cases withJAK2V617F)"
                    ]
                  },
                  {
                    "text": "Special care must be taken when absolute monocyte count is ≥ 0.5 x 10⁹/L but < 1 x 10⁹/LDiagnosis of CMML in these cases represents novel innovation on part of WHO-HAEM5 and ICC, whereas previously diagnostic threshold was 1 x 10⁹/LIncreased emphasis on molecular genetic findings allows enhanced interpretation of these so-called oligomonocytic casesBoth WHO-HAEM5 and ICC require detection of adequate clonal molecular genetic finding in these casesWHO-HAEM5 would also require evidence of morphologic dysplasia in this groupICC would also require evidence of overall bone marrow picture compatible with CMML",
                    "sub_points": [
                      "Diagnosis of CMML in these cases represents novel innovation on part of WHO-HAEM5 and ICC, whereas previously diagnostic threshold was 1 x 10⁹/LIncreased emphasis on molecular genetic findings allows enhanced interpretation of these so-called oligomonocytic cases",
                      "Increased emphasis on molecular genetic findings allows enhanced interpretation of these so-called oligomonocytic cases",
                      "Both WHO-HAEM5 and ICC require detection of adequate clonal molecular genetic finding in these casesWHO-HAEM5 would also require evidence of morphologic dysplasia in this groupICC would also require evidence of overall bone marrow picture compatible with CMML",
                      "WHO-HAEM5 would also require evidence of morphologic dysplasia in this group",
                      "ICC would also require evidence of overall bone marrow picture compatible with CMML"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Juvenile Myelomonocytic Leukemia": {
            "name": "Juvenile Myelomonocytic Leukemia",
            "url": "https://app.pathprimer.com/document/0de5d5fc-1d13-44eb-bf2d-29e2b7172e84/lesson/74c9ecc8-b842-4e36-acf8-277b06dc00d9",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Clonal hematopoietic disorder of childhood characterized by proliferation of myelomonocytic cells"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Mutations in various genes lead to constitutive activation of RAS pathway and cell proliferation"
                  },
                  {
                    "text": "Inactivation of tumor suppressor genesNF1andBCL"
                  },
                  {
                    "text": "Mutations in oncogenesNRAS,KRAS2, orPTPN11"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Symptoms may mimic viral infections"
                  },
                  {
                    "text": "Hepatosplenomegaly and lymphadenopathy"
                  },
                  {
                    "text": "In vitro GM-CSF hypersensitivity of myeloid precursors"
                  },
                  {
                    "text": "Monosomy 7 in 25% of JMML cases"
                  },
                  {
                    "text": "JMML is resistant to essentially all chemotherapy"
                  },
                  {
                    "text": "75% occur in children < 3 years of age"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "PB is most important specimen for diagnosis"
                  },
                  {
                    "text": "Predominantly neutrophils with some immature forms; monocytes with immatures forms"
                  },
                  {
                    "text": "Dysplasia in granulocytes and monocytes"
                  },
                  {
                    "text": "Blasts < 20%; usually < 5%"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Juvenile myelomonocytic leukemia (JMML)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Clonal hematopoietic disorder of childhood characterized by proliferation of myelomonocytic cells"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Etiology": [
                  {
                    "text": "Derived from hematopoietic stem cell"
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "Mutations in various genes of RAS/MAPK signaling pathway are characteristic and lead to constitutive activation of RAS pathway and cell proliferation"
                  },
                  {
                    "text": "Inactivation of tumor suppressor genesNF1andCBLPatients with neurofibromatosis type 1 (NF1) have 200-500x increased risk for JMML",
                    "sub_points": [
                      "Patients with neurofibromatosis type 1 (NF1) have 200-500x increased risk for JMML"
                    ]
                  },
                  {
                    "text": "Mutations in oncogenesNRAS,KRAS2, orPTPN11"
                  },
                  {
                    "text": "Patients with Noonan syndrome are at increased risk for JMML"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "1.3 per million children 0-14 years of age per year"
                  },
                  {
                    "text": "75% occur in children < 3 years of age; median age at diagnosis is 2 years diagnosis is 2 years"
                  },
                  {
                    "text": "M:F = 2:1"
                  }
                ],
                "Site": [
                  {
                    "text": "Bone marrow & peripheral blood (PB) are primary sites"
                  },
                  {
                    "text": "Liver and spleen are involved in almost all cases"
                  },
                  {
                    "text": "Skin, lymph nodes, and respiratory tract may also be involved"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Constitutional symptoms may mimic viral infections"
                  },
                  {
                    "text": "Symptoms related to anemia and thrombocytopenia"
                  },
                  {
                    "text": "Hepatosplenomegaly and lymphadenopathy"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Leukocytosis, thrombocytopenia, and anemia"
                  },
                  {
                    "text": "In vitro granulocyte-macrophage colony-stimulating factor (GM-CSF) hypersensitivity of myeloid progenitors"
                  },
                  {
                    "text": "Increased fetal hemoglobin (HbF)"
                  }
                ],
                "Treatment": [
                  {
                    "text": "JMML is resistant to chemotherapy"
                  },
                  {
                    "text": "Stem cell transplantation (SCT) is curative option"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "5-year event-free survival after SCT is about 50%"
                  },
                  {
                    "text": "Leading cause of death is leukemic relapse"
                  },
                  {
                    "text": "Median survival without SCT is 1 year"
                  },
                  {
                    "text": "Age > 2 years at diagnosis, high fetal hemoglobin, and low platelet count correlate with worse prognosis"
                  },
                  {
                    "text": "JMML developing in Noonan syndrome patients tend to regress spontaneously"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "BloodPB is most important specimen for diagnosisLeukocytosis with median WBC count of 25,000-30,000/μLMonocytosisNeutrophils with some immature forms; monocytes with immature formsDysplasia in granulocytes and monocytesBlasts < 20%; usually < 5%",
                    "sub_points": [
                      "PB is most important specimen for diagnosis",
                      "Leukocytosis with median WBC count of 25,000-30,000/μL",
                      "Monocytosis",
                      "Neutrophils with some immature forms; monocytes with immature forms",
                      "Dysplasia in granulocytes and monocytes",
                      "Blasts < 20%; usually < 5%"
                    ]
                  },
                  {
                    "text": "Bone marrowHypercellular with myeloid hyperplasiaMinimal dysmyelopoiesis including pseudo-Pelger-Huët forms or hypogranularityMonocytic lineage accounts for 5-10% of all cellsBlasts < 20%",
                    "sub_points": [
                      "Hypercellular with myeloid hyperplasia",
                      "Minimal dysmyelopoiesis including pseudo-Pelger-Huët forms or hypogranularity",
                      "Monocytic lineage accounts for 5-10% of all cells",
                      "Blasts < 20%"
                    ]
                  }
                ],
                "Diagnostic Criteria": [
                  {
                    "text": "Absolute monocyte count > 1,000/μL"
                  },
                  {
                    "text": "< 20% blasts in blood and bone marrow"
                  },
                  {
                    "text": "Absence ofBCR-ABL-1fusion"
                  },
                  {
                    "text": "Plus 2 of the 5 following criteriaCirculating myeloid precursorsWBC > 10,000/μLIncreased HbF for ageIn vitro GM-CSF hypersensitivity of myeloid progenitorsClonal cytogenetic abnormalitySomatic mutation inRASorPTPN11NF1gene mutationMonosomy 7Other",
                    "sub_points": [
                      "Circulating myeloid precursors",
                      "WBC > 10,000/μL",
                      "Increased HbF for age",
                      "In vitro GM-CSF hypersensitivity of myeloid progenitors",
                      "Clonal cytogenetic abnormalitySomatic mutation inRASorPTPN11NF1gene mutationMonosomy 7Other",
                      "Somatic mutation inRASorPTPN11",
                      "NF1gene mutation",
                      "Monosomy 7",
                      "Other"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "PCR": [
                  {
                    "text": "RAS,NF1,PTNT11, orCBLmutations"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "65% of cases, normal karyotype; 25%, monosomy 7"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Viral Infections": [
                  {
                    "text": "CMV, EBV, human herpesvirus 6 (HHV6), parvovirus infections may cause transient myeloproliferation, mimicking JMML"
                  },
                  {
                    "text": "Negative forRAS,NF1,PTNT11, orCBLmutations"
                  },
                  {
                    "text": "No clonal cytogenetic abnormality"
                  },
                  {
                    "text": "Serology tests helpful in differential diagnosis"
                  }
                ],
                "Congenital Acute Myeloid Leukemia (AML)": [
                  {
                    "text": "> 20% blasts in PB or BM"
                  },
                  {
                    "text": "Cytogenetic study may show AML-associated specific abnormality, helpful to distinguish JMML from AML"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Mastocytosis": {
            "name": "Mastocytosis",
            "url": "https://app.pathprimer.com/document/9dc848e4-4560-4316-a2d7-62ae3115e405/lesson/74c9ecc8-b842-4e36-acf8-277b06dc00d9",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "D816VKITactivating mutation most common"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Urticaria pigmentosa"
                  },
                  {
                    "text": "Mast cell mediator release symptoms: Pruritus, flushing, diarrhea, abdominal pain"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Focal, compact aggregates of mast cells in BM"
                  },
                  {
                    "text": "Atypical mast cell morphologySpindled, hypogranular, immature, nucleoli",
                    "sub_points": [
                      "Spindled, hypogranular, immature, nucleoli"
                    ]
                  },
                  {
                    "text": "Bony changesOsteosclerosis, osteopenia",
                    "sub_points": [
                      "Osteosclerosis, osteopenia"
                    ]
                  },
                  {
                    "text": "Fibrosis common"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "ImmunophenotypingIdentify mast cells by CD117 and tryptase coexpressionIdentify aberrant mast cell expression of CD25 &/or CD2",
                    "sub_points": [
                      "Identify mast cells by CD117 and tryptase coexpression",
                      "Identify aberrant mast cell expression of CD25 &/or CD2"
                    ]
                  },
                  {
                    "text": "Molecular geneticsIdentify D816VKITmutation",
                    "sub_points": [
                      "Identify D816VKITmutation"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Systemic mastocytosis (SM)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Clonal hematopoietic myeloproliferative neoplasm"
                  },
                  {
                    "text": "Manifests as neoplastic proliferation of mast cells"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "D816VKITMutation": [
                  {
                    "text": "≥ 90% of cases"
                  },
                  {
                    "text": "Stabilizes KIT in active form"
                  },
                  {
                    "text": "Constitutive activation"
                  },
                  {
                    "text": "Not predictive ofDisease activityDisease severityDisease progression",
                    "sub_points": [
                      "Disease activity",
                      "Disease severity",
                      "Disease progression"
                    ]
                  },
                  {
                    "text": "Might be sufficient by itself to induce SMTransgenic mice expressing D816VKITin their mast cells develop SM",
                    "sub_points": [
                      "Transgenic mice expressing D816VKITin their mast cells develop SM"
                    ]
                  }
                ],
                "TET2Mutations": [
                  {
                    "text": "Seen in approximately 30% of cases"
                  },
                  {
                    "text": "Putative tumor suppressor gene"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Age": [
                  {
                    "text": "Typically adults"
                  },
                  {
                    "text": "Rare in children"
                  }
                ],
                "Site": [
                  {
                    "text": "Bone marrow"
                  },
                  {
                    "text": "Spleen"
                  },
                  {
                    "text": "Other tissues include skin, liver, gastrointestinal tract"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Vary from asymptomatic to symptomatic"
                  },
                  {
                    "text": "Symptoms due to release of mediators from mast cells:PruritusFlushingDiarrheaAbdominal pain",
                    "sub_points": [
                      "Pruritus",
                      "Flushing",
                      "Diarrhea",
                      "Abdominal pain"
                    ]
                  },
                  {
                    "text": "Symptoms due to mast cell infiltration of organs:Urticaria pigmentosaSevere cytopeniasBone marrow failureOrganomegalyOrgan failureWeight loss",
                    "sub_points": [
                      "Urticaria pigmentosa",
                      "Severe cytopenias",
                      "Bone marrow failure",
                      "Organomegaly",
                      "Organ failure",
                      "Weight loss"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Complete blood cell count"
                  },
                  {
                    "text": "Serum tryptase level"
                  },
                  {
                    "text": "Bone marrow (BM) examinationTrephine biopsy ≥ 2 cmAdequate BM aspirate, as possibleImmunohistochemistryCD117TryptaseCD25Molecular studiesD816VKITmutation analysis as needed",
                    "sub_points": [
                      "Trephine biopsy ≥ 2 cm",
                      "Adequate BM aspirate, as possible",
                      "ImmunohistochemistryCD117TryptaseCD25",
                      "CD117",
                      "Tryptase",
                      "CD25",
                      "Molecular studiesD816VKITmutation analysis as needed",
                      "D816VKITmutation analysis as needed"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "End-organ damage/failureCytoreductive therapyHematopoietic stem cell transplantationOnly chance for remission",
                    "sub_points": [
                      "Cytoreductive therapy",
                      "Hematopoietic stem cell transplantationOnly chance for remission",
                      "Only chance for remission"
                    ]
                  },
                  {
                    "text": "D816VKITinhibitorsPKC412 (midostaurin)Dasatinib",
                    "sub_points": [
                      "PKC412 (midostaurin)",
                      "Dasatinib"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Indolent or stable diseaseYears to decadesMay not differ significantly from age-matched controls",
                    "sub_points": [
                      "Years to decades",
                      "May not differ significantly from age-matched controls"
                    ]
                  },
                  {
                    "text": "Smoldering diseaseDefined as indolent SM but with 2 or more \"B\" findings> 30% BM involvement &/or serum tryptase > 20 ng/mLSigns of abnormal myelopoiesis but not diagnostic for AHNMDHepatomegaly, splenomegaly, or lymphadenopathy without dysfunctionIn 1 study, outcome inferior to indolent disease",
                    "sub_points": [
                      "Defined as indolent SM but with 2 or more \"B\" findings> 30% BM involvement &/or serum tryptase > 20 ng/mLSigns of abnormal myelopoiesis but not diagnostic for AHNMDHepatomegaly, splenomegaly, or lymphadenopathy without dysfunction",
                      "> 30% BM involvement &/or serum tryptase > 20 ng/mL",
                      "Signs of abnormal myelopoiesis but not diagnostic for AHNMD",
                      "Hepatomegaly, splenomegaly, or lymphadenopathy without dysfunction",
                      "In 1 study, outcome inferior to indolent disease"
                    ]
                  },
                  {
                    "text": "Aggressive diseaseDefined as SM but with 1 or more \"C\" findingsBM dysfunctionLiver dysfunctionSkeletal osteolytic lesions &/or pathologic fractureSymptoms of hypersplenismGastrointestinal dysfunction resulting in weight lossIntermediate to poor outcome",
                    "sub_points": [
                      "Defined as SM but with 1 or more \"C\" findingsBM dysfunctionLiver dysfunctionSkeletal osteolytic lesions &/or pathologic fractureSymptoms of hypersplenismGastrointestinal dysfunction resulting in weight loss",
                      "BM dysfunction",
                      "Liver dysfunction",
                      "Skeletal osteolytic lesions &/or pathologic fracture",
                      "Symptoms of hypersplenism",
                      "Gastrointestinal dysfunction resulting in weight loss",
                      "Intermediate to poor outcome"
                    ]
                  },
                  {
                    "text": "Rapidly progressive disease/mast cell leukemiaPoor outcome in generalHowever, may be more favorableIf successful HSC transplantation",
                    "sub_points": [
                      "Poor outcome in general",
                      "However, may be more favorableIf successful HSC transplantation",
                      "If successful HSC transplantation"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Bone Marrow Findings": [
                  {
                    "text": "Increased mast cellsIf ≥ 20% of nucleated BM aspirate: Mast cell leukemiaMast cells commonly within BM particlesMast cell enumeration occurs away from BM particles",
                    "sub_points": [
                      "If ≥ 20% of nucleated BM aspirate: Mast cell leukemia",
                      "Mast cells commonly within BM particles",
                      "Mast cell enumeration occurs away from BM particles"
                    ]
                  },
                  {
                    "text": "Atypical morphologySpindledTypically ≥ 25% of mast cells (minor criterion)Hypogranular, clear cytoplasmNucleoliImmature nuclear features",
                    "sub_points": [
                      "SpindledTypically ≥ 25% of mast cells (minor criterion)",
                      "Typically ≥ 25% of mast cells (minor criterion)",
                      "Hypogranular, clear cytoplasm",
                      "Nucleoli",
                      "Immature nuclear features"
                    ]
                  },
                  {
                    "text": "Abnormal architecture on core biopsyFocal, compact, dense aggregates of mast cells≥ 15 mast cellsParatrabecularMay see predominantly spindled streaming along bony trabeculaeMay mimic fibrohistiocytic lesionParafollicular\"Target\" lesionCore of mast cells or lymphocytesCore surrounded by lymphocytes &/or eosinophils or mast cellsDiffuse",
                    "sub_points": [
                      "Focal, compact, dense aggregates of mast cells≥ 15 mast cells",
                      "≥ 15 mast cells",
                      "ParatrabecularMay see predominantly spindled streaming along bony trabeculaeMay mimic fibrohistiocytic lesion",
                      "May see predominantly spindled streaming along bony trabeculae",
                      "May mimic fibrohistiocytic lesion",
                      "Parafollicular\"Target\" lesionCore of mast cells or lymphocytesCore surrounded by lymphocytes &/or eosinophils or mast cells",
                      "\"Target\" lesion",
                      "Core of mast cells or lymphocytes",
                      "Core surrounded by lymphocytes &/or eosinophils or mast cells",
                      "Diffuse"
                    ]
                  },
                  {
                    "text": "Fibrosis associated with mast cell lesionsMay contribute to \"dry tap\"May explain discordance between apparent degree of involvement of aspirate and core biopsy",
                    "sub_points": [
                      "May contribute to \"dry tap\"",
                      "May explain discordance between apparent degree of involvement of aspirate and core biopsy"
                    ]
                  },
                  {
                    "text": "Bony changesOsteosclerosisOsteopeniaFracture site",
                    "sub_points": [
                      "Osteosclerosis",
                      "Osteopenia",
                      "Fracture site"
                    ]
                  },
                  {
                    "text": "Careful inspection of mast cell component in overt myeloid or lymphoid neoplasmAHNMD may obscure underlying SM at initial presentationSo-called occult SMSM evident after treatment of AHNMD",
                    "sub_points": [
                      "AHNMD may obscure underlying SM at initial presentation",
                      "So-called occult SM",
                      "SM evident after treatment of AHNMD"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Identify mast cell aggregatesCoexpression of CD117 and tryptaseTryptase expression aloneNot specific for mast cellsCD117 expression aloneNot specific for mast cells",
                    "sub_points": [
                      "Coexpression of CD117 and tryptase",
                      "Tryptase expression aloneNot specific for mast cells",
                      "Not specific for mast cells",
                      "CD117 expression aloneNot specific for mast cells",
                      "Not specific for mast cells"
                    ]
                  },
                  {
                    "text": "Aberrant antigen expression on mast cellsCD25CD2",
                    "sub_points": [
                      "CD25",
                      "CD2"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Identify mast cell populationCD117 bright (+)Moderate CD45 expressionMast cell percentage often lowCell loss during processingHemodilutionDifficult to aspirate",
                    "sub_points": [
                      "CD117 bright (+)",
                      "Moderate CD45 expression",
                      "Mast cell percentage often lowCell loss during processingHemodilutionDifficult to aspirate",
                      "Cell loss during processing",
                      "Hemodilution",
                      "Difficult to aspirate"
                    ]
                  },
                  {
                    "text": "Assess antigen aberrancy on mast cellsCD2CD25",
                    "sub_points": [
                      "CD2",
                      "CD25"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "D816VKITactivating mutationPresent in ≥ 90% of casesRenders tumor cells insensitive to imatinib",
                    "sub_points": [
                      "Present in ≥ 90% of cases",
                      "Renders tumor cells insensitive to imatinib"
                    ]
                  },
                  {
                    "text": "KITgene sequencing if D816Vnegative"
                  },
                  {
                    "text": "No known recurring cytogenetic abnormality in SM"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Mast Cell Hyperplasia": [
                  {
                    "text": "Reactive"
                  },
                  {
                    "text": "No formation of compact aggregates"
                  },
                  {
                    "text": "No atypical morphology"
                  },
                  {
                    "text": "No aberrant antigen expression"
                  }
                ],
                "SM With Associated Hematologic Non-Mast Cell Disorder (SM-AHNMD)": [
                  {
                    "text": "Myeloid neoplasms"
                  },
                  {
                    "text": "Lymphoid and plasmacytic neoplasms"
                  },
                  {
                    "text": "Occult SMProminent AHNMD may initially obscure underlying SM",
                    "sub_points": [
                      "Prominent AHNMD may initially obscure underlying SM"
                    ]
                  },
                  {
                    "text": "D816VKIT mutations may reside in both mast cells and AHNMDSuggests common stem/progenitor cell origin",
                    "sub_points": [
                      "Suggests common stem/progenitor cell origin"
                    ]
                  },
                  {
                    "text": "May detectJAK2V617F mutation in AHNMDRare cases of SM and PMF harborJAK2andKITmutations in both disease components",
                    "sub_points": [
                      "Rare cases of SM and PMF harborJAK2andKITmutations in both disease components"
                    ]
                  }
                ],
                "Mast Cell Leukemia": [
                  {
                    "text": "≥ 20% neoplastic mast cells in BM aspirate with immaturity"
                  },
                  {
                    "text": "Typical round morphology not spindled"
                  },
                  {
                    "text": "Usually ≥ 10% circulating mast cells"
                  }
                ],
                "FIP1L1-PDGFRAPositive Myeloid Neoplasm": [
                  {
                    "text": "Increased mast cells"
                  },
                  {
                    "text": "Eosinophilia"
                  },
                  {
                    "text": "Mast cells individually distributed"
                  },
                  {
                    "text": "Defined by genetics"
                  }
                ],
                "Disorders Displaying Fibrotic or Clear Cell Appearance": [
                  {
                    "text": "Hairy cell leukemiaB-cell neoplasmTryptase negative",
                    "sub_points": [
                      "B-cell neoplasm",
                      "Tryptase negative"
                    ]
                  },
                  {
                    "text": "Splenic marginal zone lymphomaB-cell neoplasmTryptase negative",
                    "sub_points": [
                      "B-cell neoplasm",
                      "Tryptase negative"
                    ]
                  },
                  {
                    "text": "Renal osteodystrophyNonclonalNo mast cell aggregatesOsteitis fibrosis cystica changes",
                    "sub_points": [
                      "Nonclonal",
                      "No mast cell aggregates",
                      "Osteitis fibrosis cystica changes"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Urticaria pigmentosa"
                  },
                  {
                    "text": "Mast cell mediator release symptoms"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Focal, compact aggregates of abnormal mast cells"
                  },
                  {
                    "text": "Mast cell phenotype: CD117(+), tryptase(+)"
                  },
                  {
                    "text": "Aberrant mast cell phenotype: CD2 &/or CD25(+)"
                  },
                  {
                    "text": "Assess mast cell as % of nucleated cells in BM aspirates"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "B-Cell Lymphoproliferative Disorders": {
        "name": "B-Cell Lymphoproliferative Disorders",
        "url": "https://app.pathprimer.com/lesson/5fa09a8a-53fc-4bfc-9404-09d15374a7a2",
        "topics": {
          "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma": {
            "name": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
            "url": "https://app.pathprimer.com/document/c624f757-cb09-4648-a416-af2eac3a3ac9/lesson/5fa09a8a-53fc-4bfc-9404-09d15374a7a2",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Monoclonal B-cell population of ≥ 5 X 10⁹/L in blood for 3 months with CLL IPWeak monotypic SIg, weak CD20, weak CD22CD5 coexpression, absent FMC7",
                    "sub_points": [
                      "Weak monotypic SIg, weak CD20, weak CD22",
                      "CD5 coexpression, absent FMC7"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Most common leukemia in western countries"
                  },
                  {
                    "text": "CBC with differential to establish absolute lymphocyte count"
                  },
                  {
                    "text": "Blood: Monotonous, mature lymphocytosis"
                  },
                  {
                    "text": "Bone marrowLymphoid infiltrates in bone marrow nodular, nonparatrabecularLymphocytes have round nuclei, condensed chromatin, inconspicuous nucleoli, and scant cytoplasm",
                    "sub_points": [
                      "Lymphoid infiltrates in bone marrow nodular, nonparatrabecular",
                      "Lymphocytes have round nuclei, condensed chromatin, inconspicuous nucleoli, and scant cytoplasm"
                    ]
                  },
                  {
                    "text": "Outcome linked to risk stratification"
                  },
                  {
                    "text": "Aggressive biologic typeCD38(+) in > 30% of leukemia cellsZAP70(+) in > 30% of leukemia cellsUnmutated/germlineIGHV@( > 98% homology with known cell line sequence)Unfavorable cytogenetics: Especially del(11q), del(17p), complex abnormalities",
                    "sub_points": [
                      "CD38(+) in > 30% of leukemia cells",
                      "ZAP70(+) in > 30% of leukemia cells",
                      "Unmutated/germlineIGHV@( > 98% homology with known cell line sequence)",
                      "Unfavorable cytogenetics: Especially del(11q), del(17p), complex abnormalities"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Chronic lymphocytic leukemia (CLL)"
                  },
                  {
                    "text": "Small lymphocytic lymphoma (SLL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "B-chronic lymphocytic leukemia"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Sustained (3 months) monoclonal B-cell population of ≥ 5 x 10⁹/L in blood with CLL immunophenotype (IP)Weak monotypic surface immunoglobulinWeak CD20, weak CD22CD5 coexpression, absent FMC7",
                    "sub_points": [
                      "Weak monotypic surface immunoglobulin",
                      "Weak CD20, weak CD22",
                      "CD5 coexpression, absent FMC7"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Pathogenesis": [
                  {
                    "text": "Deletions in microRNA genesNormally function as tumor suppressor genesWhen downregulated, this results in increased expression of antiapoptotic proteinsDysregulated expression of antiapoptotic proteins is key oncogenic factorBcl-2 expression upregulated in CLL",
                    "sub_points": [
                      "Normally function as tumor suppressor genes",
                      "When downregulated, this results in increased expression of antiapoptotic proteins",
                      "Dysregulated expression of antiapoptotic proteins is key oncogenic factor",
                      "Bcl-2 expression upregulated in CLL"
                    ]
                  },
                  {
                    "text": "Linked to chronic antigenic stimulationPossibly due to infectious agent",
                    "sub_points": [
                      "Possibly due to infectious agent"
                    ]
                  },
                  {
                    "text": "Environmental exposurePossible association with radiation/chemical exposures",
                    "sub_points": [
                      "Possible association with radiation/chemical exposures"
                    ]
                  }
                ],
                "Precursor Lesion for CLL": [
                  {
                    "text": "Monoclonal B lymphocytosis (MBL)Found in normal subjectsIncidence increases with ageVariable absolute lymphocyte count (< 5 x 10⁹/L)Detected in banked samples in almost all patients who developed overt CLL in long-term screening programDistinction from low stage CLL based on absolute lymphocyte count can be problematic",
                    "sub_points": [
                      "Found in normal subjects",
                      "Incidence increases with age",
                      "Variable absolute lymphocyte count (< 5 x 10⁹/L)",
                      "Detected in banked samples in almost all patients who developed overt CLL in long-term screening program",
                      "Distinction from low stage CLL based on absolute lymphocyte count can be problematic"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Most common leukemia in Western countries"
                  },
                  {
                    "text": "Incidence increases with age; 50/100,000 in > 80-year-old males"
                  }
                ],
                "Age": [
                  {
                    "text": "Middle age to elderly (median: 70 years)"
                  }
                ],
                "Sex": [
                  {
                    "text": "Male predominance"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "Predominates in western countries"
                  },
                  {
                    "text": "Rare in Asian populations"
                  }
                ],
                "Site": [
                  {
                    "text": "Predominantly involves bone marrow and blood; may manifest in extramedullary sites as SLLLymph nodesSpleenOther extramedullary sites less common",
                    "sub_points": [
                      "Lymph nodes",
                      "Spleen",
                      "Other extramedullary sites less common"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "> 80% of patients are asymptomatic (detected by routine CBC)"
                  },
                  {
                    "text": "Remainder typically present with symptoms of anemia, lymphadenopathy"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "CBC with differential to establish absolute lymphocyte count"
                  },
                  {
                    "text": "CBC to assess for cytopeniasAnemiaNeutropeniaThrombocytopenia",
                    "sub_points": [
                      "Anemia",
                      "Neutropenia",
                      "Thrombocytopenia"
                    ]
                  },
                  {
                    "text": "Blood smear review to assess lymphocyte morphology"
                  },
                  {
                    "text": "Flow cytometry to confirm clonality and demonstrate prototypic CLL profile"
                  },
                  {
                    "text": "Serum measurement of lactate dehydrogenase, β2-microglobulin, thymidine kinase"
                  }
                ],
                "Natural History": [
                  {
                    "text": "~ 1/3 of patients never require therapy"
                  },
                  {
                    "text": "~ 1/3 show eventual disease progression requiring therapy"
                  },
                  {
                    "text": "~ 1/3 require therapy at or soon after diagnosis"
                  },
                  {
                    "text": "Natural history linked to risk stratification"
                  },
                  {
                    "text": "Risk stratificationAggressive biologic typeCD38(+) in > 30% of leukemia cellsZAP70(+) in > 30% of leukemia cellsUnmutated/germlineIGHV﻿@﻿( > 98% homology with known cell line sequence)Unfavorable cytogenetics: Especially del(11q), del(17p), complex abnormalitiesMedian survival < 10 yearsIndolent biologic typeCD38(-)ZAP70(-)MutatedIGHV@(somatic hypermutation)Favorable cytogenetics: iso del(13q), normalMedian survival > 25 yearsIntermediate typeDiscordance between key biologic parameters: (CD38[-], ZAP70[+]); (CD38[+], ZAP70[-]); (ZAP70[+], mutatedIGHV﻿@﻿); (ZAP70[-], germlineIGHV@)Cytogenetic discordance with other parametersIntermediate survival time: > 10 but < 25 years",
                    "sub_points": [
                      "Aggressive biologic typeCD38(+) in > 30% of leukemia cellsZAP70(+) in > 30% of leukemia cellsUnmutated/germlineIGHV﻿@﻿( > 98% homology with known cell line sequence)Unfavorable cytogenetics: Especially del(11q), del(17p), complex abnormalitiesMedian survival < 10 years",
                      "CD38(+) in > 30% of leukemia cells",
                      "ZAP70(+) in > 30% of leukemia cells",
                      "Unmutated/germlineIGHV﻿@﻿( > 98% homology with known cell line sequence)",
                      "Unfavorable cytogenetics: Especially del(11q), del(17p), complex abnormalities",
                      "Median survival < 10 years",
                      "Indolent biologic typeCD38(-)ZAP70(-)MutatedIGHV@(somatic hypermutation)Favorable cytogenetics: iso del(13q), normalMedian survival > 25 years",
                      "CD38(-)",
                      "ZAP70(-)",
                      "MutatedIGHV@(somatic hypermutation)",
                      "Favorable cytogenetics: iso del(13q), normal",
                      "Median survival > 25 years",
                      "Intermediate typeDiscordance between key biologic parameters: (CD38[-], ZAP70[+]); (CD38[+], ZAP70[-]); (ZAP70[+], mutatedIGHV﻿@﻿); (ZAP70[-], germlineIGHV@)Cytogenetic discordance with other parametersIntermediate survival time: > 10 but < 25 years",
                      "Discordance between key biologic parameters: (CD38[-], ZAP70[+]); (CD38[+], ZAP70[-]); (ZAP70[+], mutatedIGHV﻿@﻿); (ZAP70[-], germlineIGHV@)",
                      "Cytogenetic discordance with other parameters",
                      "Intermediate survival time: > 10 but < 25 years"
                    ]
                  },
                  {
                    "text": "Newer risk stratification parametersGeneticTP53,NOTCH1,SF3B1,ATMmutations linked to prognosisMicroRNA signature linked to outcomeEpigenetic gene mutation analysis may provide additional prognostic information",
                    "sub_points": [
                      "GeneticTP53,NOTCH1,SF3B1,ATMmutations linked to prognosisMicroRNA signature linked to outcomeEpigenetic gene mutation analysis may provide additional prognostic information",
                      "TP53,NOTCH1,SF3B1,ATMmutations linked to prognosis",
                      "MicroRNA signature linked to outcome",
                      "Epigenetic gene mutation analysis may provide additional prognostic information"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "If required, fludarabine ± cyclophosphamide ± rituximab most common front-line therapy"
                  },
                  {
                    "text": "Many other therapeutic optionsTargeted therapiesCART therapy (chimeric antigen receptor T cell)Allogeneic stem cell transplant",
                    "sub_points": [
                      "Targeted therapies",
                      "CART therapy (chimeric antigen receptor T cell)",
                      "Allogeneic stem cell transplant"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Many prognostic factors ranging from Rai or Binet stage to molecular features"
                  },
                  {
                    "text": "Independent prognostic significance for stage, gender, CD38, ZAP70, cytogenetics, and somatic hypermutation status"
                  },
                  {
                    "text": "Linked to biologic subtypes and age at diagnosis"
                  },
                  {
                    "text": "Overall 10-year median survival (35%)Median survival for favorable subtype > 25 yearsMedian survival for unfavorable subtype < 10 years",
                    "sub_points": [
                      "Median survival for favorable subtype > 25 years",
                      "Median survival for unfavorable subtype < 10 years"
                    ]
                  },
                  {
                    "text": "Transformations linked to adverse outcomesOccur in 5-10% of casesProlymphocytoid transformationOvert large cell lymphoma (Richter)Hodgkin-like transformation",
                    "sub_points": [
                      "Occur in 5-10% of cases",
                      "Prolymphocytoid transformation",
                      "Overt large cell lymphoma (Richter)",
                      "Hodgkin-like transformation"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Blood": [
                  {
                    "text": "Absolute lymphocytosis"
                  },
                  {
                    "text": "Lymphocytes have round nuclei, condensed chromatin, inconspicuous nucleoli, and scant cytoplasm"
                  },
                  {
                    "text": "Atypical cases show greater heterogeneity of lymphocytesProlymphocytesLymphocytes with clefted nucleiOther variant morphology",
                    "sub_points": [
                      "Prolymphocytes",
                      "Lymphocytes with clefted nuclei",
                      "Other variant morphology"
                    ]
                  },
                  {
                    "text": "Variable cytopenias"
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "Lymphocytes often account for > 30% of cells"
                  },
                  {
                    "text": "Lymphocyte morphology similar to blood"
                  },
                  {
                    "text": "Nodular or diffuse infiltration on core biopsyUsually nonparatrabecular",
                    "sub_points": [
                      "Usually nonparatrabecular"
                    ]
                  }
                ],
                "Transformations of CLL": [
                  {
                    "text": "Multiple morphologic subtypes"
                  },
                  {
                    "text": "Prolymphocytoid transformationIncreasing numbers of lymphocytes with distinct nucleoliMay be associated with immunophenotypic variations",
                    "sub_points": [
                      "Increasing numbers of lymphocytes with distinct nucleoli",
                      "May be associated with immunophenotypic variations"
                    ]
                  },
                  {
                    "text": "Overt diffuse large B-cell lymphomaTermed Richter transformationUsually extramedullary transformationBone marrow involved in minority of casesMay represent true clonal transformation of underlying CLLMay be secondary, often EBV-associated, neoplasm",
                    "sub_points": [
                      "Termed Richter transformationUsually extramedullary transformation",
                      "Usually extramedullary transformation",
                      "Bone marrow involved in minority of cases",
                      "May represent true clonal transformation of underlying CLL",
                      "May be secondary, often EBV-associated, neoplasm"
                    ]
                  },
                  {
                    "text": "Hodgkin-like transformationMorphologic and immunophenotypic Reed-Sternberg-like cells presentDiscrete area of effacement distinct from CLL/SLL infiltrates",
                    "sub_points": [
                      "Morphologic and immunophenotypic Reed-Sternberg-like cells present",
                      "Discrete area of effacement distinct from CLL/SLL infiltrates"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Paraffin immunohistochemistry for CD20, LEF1, CD79a, CD43, CD5, CD23, Cyclin-D1, and Ki-67 may be helpful in cases in which fresh cells for flow cytometry are not available"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Multicolor immunophenotyping"
                  },
                  {
                    "text": "Essential in defining immunophenotypic profile of CLLWeak monotypic surface Ig, weak CD20, CD23, CD5 ( absence of FMC7)",
                    "sub_points": [
                      "Weak monotypic surface Ig, weak CD20, CD23, CD5 ( absence of FMC7)"
                    ]
                  },
                  {
                    "text": "Aid in providing prognostic information (CD38 and ZAP70)"
                  }
                ],
                "PCR": [
                  {
                    "text": "IGHV﻿@﻿mutation status can be assessed to compare patient cells to normal cell lines> 2% variation from normal cell line designated as mutatedSomatic hypermutation linked to favorable prognosis",
                    "sub_points": [
                      "> 2% variation from normal cell line designated as mutated",
                      "Somatic hypermutation linked to favorable prognosis"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Essential in defining prognostic groups"
                  },
                  {
                    "text": "FISH preferable due to low proliferation rate of CLL cells"
                  },
                  {
                    "text": "Molecular testing may provide additional prognostic information"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Reactive Lymphocytosis": [
                  {
                    "text": "Morphologic heterogeneity, activated features"
                  },
                  {
                    "text": "Usually, T cells predominate by flow cytometry"
                  },
                  {
                    "text": "Predominates in young patients"
                  },
                  {
                    "text": "Linked to viral infections"
                  }
                ],
                "Polyclonal B-Lymphocytosis": [
                  {
                    "text": "Rare disorder affecting young women, usually heavy smokers"
                  },
                  {
                    "text": "May be familial, HLA association"
                  },
                  {
                    "text": "Lymphocytes may be binucleated"
                  },
                  {
                    "text": "Mature polyclonal B cells by flow cytometry"
                  }
                ],
                "Monoclonal B-Lymphocytosis (MBL)": [
                  {
                    "text": "Detected in 5% of subjects"
                  },
                  {
                    "text": "Detected at higher rate in elderly controls and family members of CLL kindred"
                  },
                  {
                    "text": "Distinction between CLL and MBL based onAbsolute monoclonal lymphocyte count < 5 X 10⁹/L in patientswithoutclinical evidence of SLLAll CBC parameters, including absolute lymphocyte count, often normal in MBL",
                    "sub_points": [
                      "Absolute monoclonal lymphocyte count < 5 X 10⁹/L in patientswithoutclinical evidence of SLL",
                      "All CBC parameters, including absolute lymphocyte count, often normal in MBL"
                    ]
                  }
                ],
                "Other B-Chronic Lymphoproliferative Disorders": [
                  {
                    "text": "MCLdistinguished from CLL by documentation of t(11;14)(q13;q32)Morphology may closely mimic CLLCCND1/IGH﻿@﻿by cytogenetics/FISHCyclin-D1 expression by immunohistochemistry",
                    "sub_points": [
                      "Morphology may closely mimic CLL",
                      "CCND1/IGH﻿@﻿by cytogenetics/FISH",
                      "Cyclin-D1 expression by immunohistochemistry"
                    ]
                  },
                  {
                    "text": "B-PLLdistinguished from CLL byPredominance of prolymphocytes in bloodMay exhibit dramatic lymphocytosisProminent splenomegalyMust exclude MCL by genetic testingAbsence of CLL by history",
                    "sub_points": [
                      "Predominance of prolymphocytes in blood",
                      "May exhibit dramatic lymphocytosis",
                      "Prominent splenomegaly",
                      "Must exclude MCL by genetic testing",
                      "Absence of CLL by history"
                    ]
                  },
                  {
                    "text": "Other B-cell neoplasms (e.g., follicular and splenic lymphomas) can usually be distinguished from CLL byClinical featuresMorphologyMulticolor flow cytometric immunophenotypingCytogenetics/FISH",
                    "sub_points": [
                      "Clinical features",
                      "Morphology",
                      "Multicolor flow cytometric immunophenotyping",
                      "Cytogenetics/FISH"
                    ]
                  }
                ]
              },
              "STAGING": {
                "Rai and Binet Staging Systems": [
                  {
                    "text": "Stage determined by extent of nodal disease and hematopoietic compromise as reflected by cytopenias"
                  }
                ]
              },
              "REPORTING": {
                "Key Elements to Report": [
                  {
                    "text": "CBC data with absolute lymphocyte count"
                  },
                  {
                    "text": "Morphologic and immunophenotypic features of leukemic cells (best clues to CLL)"
                  },
                  {
                    "text": "Discussion of significance of prognostic features assessed including CD38, ZAP70, FISH, andIGHV@"
                  },
                  {
                    "text": "Recommendations for additional tests to provide either diagnostic information (for inconclusive cases) or prognostic information (in cases of clear-cut CLL)"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Follicular Lymphoma": {
            "name": "Follicular Lymphoma",
            "url": "https://app.pathprimer.com/document/b1897811-8b49-4873-969f-ce3ab1fcba66/lesson/5fa09a8a-53fc-4bfc-9404-09d15374a7a2",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "B-cell neoplasm composed of germinal center B cells (centrocytes and centroblasts) with at least partially follicular pattern"
                  },
                  {
                    "text": "Associated with t(14;18) gene rearrangement ofIGH(chromosome 14) andBCL2(﻿chromosome 18)﻿"
                  },
                  {
                    "text": "t(14;18) translocation leads to overexpression of BCL-2 protein, and subsequent survival advantage for mutated cellst(14;18)(q32;q21) placesBCL2gene under influence ofIGHpromoterBCL-2 protein is antiapoptotic protein",
                    "sub_points": [
                      "t(14;18)(q32;q21) placesBCL2gene under influence ofIGHpromoter",
                      "BCL-2 protein is antiapoptotic protein"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "FL transformation to more clinically aggressive B-cell lymphomas occurs in ~ 30% of FL patientsMost typically transforms into DLBCL",
                    "sub_points": [
                      "Most typically transforms into DLBCL"
                    ]
                  },
                  {
                    "text": "Pediatric follicular lymphomaLocalized disease, usually involves head and neck lymph nodes, tonsilsUsually Bcl-2(-) and lacks t(14;18)(q32;q21) orIgH-BCL2High histological grade; 3A, but most patients have good prognosis",
                    "sub_points": [
                      "Localized disease, usually involves head and neck lymph nodes, tonsils",
                      "Usually Bcl-2(-) and lacks t(14;18)(q32;q21) orIgH-BCL2",
                      "High histological grade; 3A, but most patients have good prognosis"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Bone marrow: Paratrabecular pattern of involvement of centrocytes and, less frequently, centroblasts"
                  },
                  {
                    "text": "Peripheral blood: Neoplastic cells have highly indented or cleaved nuclei"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Positive for pan B-cell antigens; CD19, CD20, CD22, CD79a, and PAX-5"
                  },
                  {
                    "text": "Positive for BCL-2 and germinal center markers CD10, BCL-6, and GCET-1"
                  },
                  {
                    "text": "Typically negative for CD5, CD43, and MUM1/IRF4"
                  },
                  {
                    "text": "Follicular dendritic cells outline neoplastic follicles (CD21 and CD23 positive)"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Diffuse large B-cell lymphoma (DLBCL)"
                  },
                  {
                    "text": "Follicular lymphoma (FL)"
                  },
                  {
                    "text": "Follicular Lymphoma International Prognostic Index 2 (FLIPI 2)"
                  },
                  {
                    "text": "High-power field (HPF)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "B-cell neoplasm composed of germinal center B cells (centrocytes and centroblasts) with at least partially follicular pattern"
                  },
                  {
                    "text": "Associated with t(14;18) gene rearrangement ofIGH(chromosome 14) andBCL2 (﻿chromosome 18)﻿"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Molecular Pathogenesis": [
                  {
                    "text": "Almost 100% of FL have cytogenetic abnormalitiesSeventy-five to 90% have translocation t(14;18)(q32;q21)t(14;18)(q32;q21) placesBCL2gene under influence ofIGHpromoterBCL2 protein is expressed in normal resting B cells and T cells, but not in normal germinal center cellsGerminal center cells undergo negative selection, and apoptosis is important mechanism of immune system developmentBCL-2 protein is antiapoptotic proteint(14;18) translocation leads to overexpression of BCL-2 protein and subsequent survival advantage for mutated cells",
                    "sub_points": [
                      "Seventy-five to 90% have translocation t(14;18)(q32;q21)",
                      "t(14;18)(q32;q21) placesBCL2gene under influence ofIGHpromoterBCL2 protein is expressed in normal resting B cells and T cells, but not in normal germinal center cellsGerminal center cells undergo negative selection, and apoptosis is important mechanism of immune system developmentBCL-2 protein is antiapoptotic protein",
                      "BCL2 protein is expressed in normal resting B cells and T cells, but not in normal germinal center cellsGerminal center cells undergo negative selection, and apoptosis is important mechanism of immune system development",
                      "Germinal center cells undergo negative selection, and apoptosis is important mechanism of immune system development",
                      "BCL-2 protein is antiapoptotic protein",
                      "t(14;18) translocation leads to overexpression of BCL-2 protein and subsequent survival advantage for mutated cells"
                    ]
                  },
                  {
                    "text": "BCL2 rearrangement is not sufficient to cause neoplastic transformationApproximately 90% of FL with t(14;18)(q32;q21) have additional genetic abnormalities",
                    "sub_points": [
                      "Approximately 90% of FL with t(14;18)(q32;q21) have additional genetic abnormalities"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "IncidenceSecond most common lymphoma worldwide (after DLBCL)Comprises ~ 20% of non-Hodgkin lymphomasUncommon in Asia and developing countriesMedian age at diagnosis = 55-59 yearsM:F ratio is approximately equalPediatric cases occur mostly in boys",
                    "sub_points": [
                      "Second most common lymphoma worldwide (after DLBCL)Comprises ~ 20% of non-Hodgkin lymphomas",
                      "Comprises ~ 20% of non-Hodgkin lymphomas",
                      "Uncommon in Asia and developing countries",
                      "Median age at diagnosis = 55-59 years",
                      "M:F ratio is approximately equalPediatric cases occur mostly in boys",
                      "Pediatric cases occur mostly in boys"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Often asymptomatic, but disseminated at presentation"
                  },
                  {
                    "text": "Generalized lymphadenopathy and splenomegalyCervical and inguinal lymph nodes are more frequently affected",
                    "sub_points": [
                      "Cervical and inguinal lymph nodes are more frequently affected"
                    ]
                  },
                  {
                    "text": "Commonly affected extranodal sitesBone marrowSpleenLiverPeripheral blood",
                    "sub_points": [
                      "Bone marrow",
                      "Spleen",
                      "Liver",
                      "Peripheral blood"
                    ]
                  },
                  {
                    "text": "FL also uncommonly arises in these areasSkinGastrointestinal tractThyroid glandTestis",
                    "sub_points": [
                      "Skin",
                      "Gastrointestinal tract",
                      "Thyroid gland",
                      "Testis"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Grade 1 and 2 FL treatment is directed at relief of symptoms rather than cureGrades 1 and 2 FL are not significantly affected by aggressive therapiesLocalized disease may undergo excision and local radiation",
                    "sub_points": [
                      "Grades 1 and 2 FL are not significantly affected by aggressive therapies",
                      "Localized disease may undergo excision and local radiation"
                    ]
                  },
                  {
                    "text": "When treatment is required, anti-CD20 immunotherapy (rituximab) and/or chemotherapy are used"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Grades 1 and 2 are indolent but incurable; eventually relapse and become refractory to treatment"
                  },
                  {
                    "text": "Grade 3 is more aggressive"
                  },
                  {
                    "text": "Overall 10-year survival is up to ~ 80% with FL stage I or stage II"
                  },
                  {
                    "text": "Adverse prognostic factors summarized in FLIPI 2Age > 60 yearsHigh serum β₂-microglobulinLargest involved lymph node > 6 cmBone marrow involvementHemoglobin < 12 g/dL",
                    "sub_points": [
                      "Age > 60 years",
                      "High serum β₂-microglobulin",
                      "Largest involved lymph node > 6 cm",
                      "Bone marrow involvement",
                      "Hemoglobin < 12 g/dL"
                    ]
                  },
                  {
                    "text": "Pathologic adverse prognostic factorsHigh histologic grade and > 25% diffuse areas of predominantly large cells (DLBCL)High proliferation indexComplex karyotypedel 6q25-27, and del17p and mutation ofTP53",
                    "sub_points": [
                      "High histologic grade and > 25% diffuse areas of predominantly large cells (DLBCL)",
                      "High proliferation index",
                      "Complex karyotype",
                      "del 6q25-27, and del17p and mutation ofTP53"
                    ]
                  },
                  {
                    "text": "Transformation to more aggressive B-cell lymphoma occurs in ~ 30% of patients with FLMost typically transforms into DLBCLTransformation may result in certain conditionsBurkitt lymphomaHigh-grade B-cell lymphoma unclassifiable, with features intermediate between Burkitt lymphoma and DLBCLB-lymphoblastic acute leukemia/lymphomaAssociated with aggressive disease and death",
                    "sub_points": [
                      "Most typically transforms into DLBCL",
                      "Transformation may result in certain conditionsBurkitt lymphomaHigh-grade B-cell lymphoma unclassifiable, with features intermediate between Burkitt lymphoma and DLBCLB-lymphoblastic acute leukemia/lymphoma",
                      "Burkitt lymphoma",
                      "High-grade B-cell lymphoma unclassifiable, with features intermediate between Burkitt lymphoma and DLBCL",
                      "B-lymphoblastic acute leukemia/lymphoma",
                      "Associated with aggressive disease and death"
                    ]
                  }
                ],
                "Grading of Follicular Lymphoma": [
                  {
                    "text": "Grading has prognostic and therapeutic significance"
                  },
                  {
                    "text": "Most reliable when performed on lymph node excisional biopsy specimens"
                  },
                  {
                    "text": "System is based on average number of centroblasts per HPF after counting 10 fieldsGrade 1: 0-5 centroblasts/HPFGrade 2: 6-15 centroblasts/HPFGrade 3: > 15 centroblasts/HPFGrade 3A: Centrocytes admixed with centroblastsGrade 3B: Sheets of centroblasts with rare or no centrocytesMinimal prognostic differences between FL grade 1 and 2Diffuse areas of grade 3 accounting for > 25% of lymph node should be diagnosed as DLBCL",
                    "sub_points": [
                      "Grade 1: 0-5 centroblasts/HPF",
                      "Grade 2: 6-15 centroblasts/HPF",
                      "Grade 3: > 15 centroblasts/HPFGrade 3A: Centrocytes admixed with centroblastsGrade 3B: Sheets of centroblasts with rare or no centrocytes",
                      "Grade 3A: Centrocytes admixed with centroblasts",
                      "Grade 3B: Sheets of centroblasts with rare or no centrocytes",
                      "Minimal prognostic differences between FL grade 1 and 2",
                      "Diffuse areas of grade 3 accounting for > 25% of lymph node should be diagnosed as DLBCL"
                    ]
                  }
                ],
                "Pediatric Follicular Lymphoma": [
                  {
                    "text": "Localized diseaseUsually involves head and neck lymph nodes, tonsilsExtranodal sites also affectedTestisWaldeyer ring",
                    "sub_points": [
                      "Usually involves head and neck lymph nodes, tonsils",
                      "Extranodal sites also affectedTestisWaldeyer ring",
                      "Testis",
                      "Waldeyer ring"
                    ]
                  },
                  {
                    "text": "High histological grade; 3A, usually with large follicles"
                  },
                  {
                    "text": "Usually Bcl-2(-) and lacks t(14;18)(q32;q21) orIgH-BCL2"
                  },
                  {
                    "text": "Expresses germinal center markers BCL6 and CD10, and are often CD43 positive"
                  },
                  {
                    "text": "Most patients have good prognosis without disease progression"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Lymph nodeClosely packed neoplastic follicles, fairly uniform in size and shapeFollicles lose polarization and often lack mantle zoneNeoplastic follicles composed of variable amounts of centrocytes and large centroblastsGrading has prognostic and therapeutic significance",
                    "sub_points": [
                      "Closely packed neoplastic follicles, fairly uniform in size and shape",
                      "Follicles lose polarization and often lack mantle zone",
                      "Neoplastic follicles composed of variable amounts of centrocytes and large centroblasts",
                      "Grading has prognostic and therapeutic significance"
                    ]
                  },
                  {
                    "text": "Bone marrowParatrabecular pattern of involvement of centrocytes and, less frequently, centroblastsInterstitial and diffuse patterns can be seen in advanced diseaseComposed primarily of centrocytes with rare centroblastsBone marrow involvement may not reflect grade of FL in lymph nodeDiscrepancy between marrow and lymph node grade occurs in 10-20% of patients with grade 3 FL or DLBCL",
                    "sub_points": [
                      "Paratrabecular pattern of involvement of centrocytes and, less frequently, centroblastsInterstitial and diffuse patterns can be seen in advanced disease",
                      "Interstitial and diffuse patterns can be seen in advanced disease",
                      "Composed primarily of centrocytes with rare centroblastsBone marrow involvement may not reflect grade of FL in lymph nodeDiscrepancy between marrow and lymph node grade occurs in 10-20% of patients with grade 3 FL or DLBCL",
                      "Bone marrow involvement may not reflect grade of FL in lymph nodeDiscrepancy between marrow and lymph node grade occurs in 10-20% of patients with grade 3 FL or DLBCL",
                      "Discrepancy between marrow and lymph node grade occurs in 10-20% of patients with grade 3 FL or DLBCL"
                    ]
                  },
                  {
                    "text": "Peripheral bloodMarked leukemic involvement in ~ 10% of patientsNeoplastic cells have highly indented or cleaved nucleiLow-level involvement is detected by molecular methods in ~ 90% of patients",
                    "sub_points": [
                      "Marked leukemic involvement in ~ 10% of patients",
                      "Neoplastic cells have highly indented or cleaved nuclei",
                      "Low-level involvement is detected by molecular methods in ~ 90% of patients"
                    ]
                  },
                  {
                    "text": "Unusual variantsFloral variantFL with plasmacytic differentiationFL with marginal zone differentiation",
                    "sub_points": [
                      "Floral variant",
                      "FL with plasmacytic differentiation",
                      "FL with marginal zone differentiation"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunophenotype": [
                  {
                    "text": "Positive for pan B-cell antigens; CD19, CD20, CD22, CD79a, and PAX-5"
                  },
                  {
                    "text": "Positive for BCL-2 and germinal center markers CD10, BCL-6, and GCET-1BCL-2(+) in 85-97% of FL grade 1 and grade 2; 50-75% in FL grade 3",
                    "sub_points": [
                      "BCL-2(+) in 85-97% of FL grade 1 and grade 2; 50-75% in FL grade 3"
                    ]
                  },
                  {
                    "text": "Typically negative for CD5, CD43, and MUM1/IRF4"
                  },
                  {
                    "text": "Follicular dendritic cells outline neoplastic follicles (CD21 and CD23 positive)"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Cytogenetic analysis"
                  },
                  {
                    "text": "Fluorescence in situ hybridization for t(14;18)"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Follicular Hyperplasia": [
                  {
                    "text": "Most common entity in differential diagnosis of FL"
                  },
                  {
                    "text": "Follicles more widely spaced, and follicles are polarized in follicular hyperplasia"
                  },
                  {
                    "text": "Immunohistochemistry for BCL-2 will be negative in follicles of follicular hyperplasia"
                  },
                  {
                    "text": "Will lack t(14;18)(q32;q21) rearrangement"
                  }
                ],
                "Other Mature B-cell Lymphomas": [
                  {
                    "text": "CLL/SLLDifferent immunophenotype; positive for CD5 and negative for CD10 and BCL-6Will lack t(14;18)(q32;q21) rearrangement",
                    "sub_points": [
                      "Different immunophenotype; positive for CD5 and negative for CD10 and BCL-6",
                      "Will lack t(14;18)(q32;q21) rearrangement"
                    ]
                  },
                  {
                    "text": "Mantle cell lymphomaDifferent immunophenotype; positive for CD5 and BCL-1/Cyclin D1 and negative for CD10 and BCL-6Will lack t(14;18)(q32;q21) rearrangement and be positive for t(11;14) rearrangement",
                    "sub_points": [
                      "Different immunophenotype; positive for CD5 and BCL-1/Cyclin D1 and negative for CD10 and BCL-6",
                      "Will lack t(14;18)(q32;q21) rearrangement and be positive for t(11;14) rearrangement"
                    ]
                  },
                  {
                    "text": "Marginal zone lymphomaExpanded marginal zone, neoplastic cells are monocytoid, and plasmacytic differentiation often presentDifferent immunophenotype; negative for CD10 and BCL-6, and follicles are BCL-2 negativeWill lack t(14;18)(q32;q21) rearrangement",
                    "sub_points": [
                      "Expanded marginal zone, neoplastic cells are monocytoid, and plasmacytic differentiation often present",
                      "Different immunophenotype; negative for CD10 and BCL-6, and follicles are BCL-2 negative",
                      "Will lack t(14;18)(q32;q21) rearrangement"
                    ]
                  }
                ],
                "Progressive Transformation of Germinal Centers": [
                  {
                    "text": "Will have partial replacement of lymph node"
                  },
                  {
                    "text": "Large follicles with expanded mantles, which disrupt germinal centers"
                  },
                  {
                    "text": "Different immunophenotype; polytypic B-cells, negative for CD10 and BCL-6, and follicles are BCL-2 negative"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Mantle Cell Lymphoma": {
            "name": "Mantle Cell Lymphoma",
            "url": "https://app.pathprimer.com/document/393d54de-62ae-466d-bb30-ff4bb43ec121/lesson/5fa09a8a-53fc-4bfc-9404-09d15374a7a2",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "MCL harbors a t(11;14)(q13;q32) genetic mutation, which placesCCND-1 (cyclin D1) at 11q13 adjacent toIgHat 14q32"
                  },
                  {
                    "text": "t(11;14) mutation results in cyclin D1 overexpression, deregulation of cell cycle, and proliferation of clonal B cells"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Bone marrow: Pattern of infiltration can be interstitial, nodular, paratrabecular, or most commonly a combination of these patterns"
                  },
                  {
                    "text": "Classic MCL: Composed of monotonous population of small to medium-sized lymphoid cells with variably irregular nuclear contours, condensed chromatin, scant cytoplasm, and inconspicuous nucleoli"
                  },
                  {
                    "text": "Blastoid MCL: Cells resemble blasts; intermediate in size, with immature chromatin and high mitotic rate (> 2-3 mitoses/HPF)"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Positive staining for Cyclin-D1 is almost universally presentOther malignancies that can be positive for cyclin D1 include plasma cell myeloma, hairy cell leukemia, and occasionally in proliferation centers of CLL/SLL",
                    "sub_points": [
                      "Other malignancies that can be positive for cyclin D1 include plasma cell myeloma, hairy cell leukemia, and occasionally in proliferation centers of CLL/SLL"
                    ]
                  },
                  {
                    "text": "Positive for B-cell markers, CD20, CD79a with aberrant coexpression of CD5 and Bcl-2"
                  },
                  {
                    "text": "Negative for CD3, CD10, CD23, BCL-6, and MUM-1/IRF4"
                  },
                  {
                    "text": "Proliferation activity is an important prognostic indicatorKi-67 staining with MIB-1 > 40% has worse prognosis than neoplasms with Ki-67 < 40%",
                    "sub_points": [
                      "Ki-67 staining with MIB-1 > 40% has worse prognosis than neoplasms with Ki-67 < 40%"
                    ]
                  },
                  {
                    "text": "Conventional cytogenetics detects the classic t(11;14) in up to 65% of MCL cases"
                  },
                  {
                    "text": "Fluorescent in situ hybridization (FISH) can be found in virtually all cases of MCL"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Mantle cell lymphoma (MCL)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "MCL: Mature B-cell lymphoma with an associated t(11;14)(q13;q32) and expression of cyclin D1"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Molecular": [
                  {
                    "text": "MCL harbors a t(11;14)(q13;q32) genetic mutation, which placesCCND-1 (cyclin D1) at 11q13 adjacent toIgHat 14q32"
                  },
                  {
                    "text": "Cyclin D1 normally functions in transition from G₁ → S phase of cell cycle during interphaseCyclin D1 is not normally expressed in lymphocytes",
                    "sub_points": [
                      "Cyclin D1 is not normally expressed in lymphocytes"
                    ]
                  },
                  {
                    "text": "t(11;14) mutation results in cyclin-D1 overexpression, deregulation of cell cycle, and proliferation of clonal B cells"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "Rare: Estimated at 0.42 per 100,000 personsRepresents 2.5-10% of all non-Hodgkin lymphomas",
                    "sub_points": [
                      "Represents 2.5-10% of all non-Hodgkin lymphomas"
                    ]
                  },
                  {
                    "text": "Median age of presentation ~ 60 years old (range: 29-85 years)"
                  },
                  {
                    "text": "Male predominance"
                  },
                  {
                    "text": "Clinically aggressive> 80% of patients present with stage III/IV disease",
                    "sub_points": [
                      "> 80% of patients present with stage III/IV disease"
                    ]
                  },
                  {
                    "text": "Lymphadenopathy (~ 80% of patients) and extranodal involvement are commonMost common extranodal sites include bone marrow (~ 70%), spleen (~ 50%), peripheral blood (~ 40%), liver (~ 20%)",
                    "sub_points": [
                      "Most common extranodal sites include bone marrow (~ 70%), spleen (~ 50%), peripheral blood (~ 40%), liver (~ 20%)"
                    ]
                  },
                  {
                    "text": "B symptoms in ~ 30% of patients"
                  },
                  {
                    "text": "Subset of patients present with very aggressive leukemia, similar to an acute leukemia (~ 10%)Typically have blastoid morphology, complex cytogenetic abnormalities, and rapid progression, with median survival of 3 months",
                    "sub_points": [
                      "Typically have blastoid morphology, complex cytogenetic abnormalities, and rapid progression, with median survival of 3 months"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Polychemotherapy in combination with rituximab immunotherapy (anti-CD20 therapy)Polychemotherapy may includeCHOP (cyclophosphamide, hydroxydaunomycin [doxorubincin], vincristine [Oncovin], and prednisone)Hyper-CVAD (dose-intense, hyperfractionated cyclophosphamide, in a CHOP-like combination, plus high-dose methotrexate and cytarabine)FCM (fludarabine, cyclophosphamide, and mitoxantrone)",
                    "sub_points": [
                      "Polychemotherapy may includeCHOP (cyclophosphamide, hydroxydaunomycin [doxorubincin], vincristine [Oncovin], and prednisone)Hyper-CVAD (dose-intense, hyperfractionated cyclophosphamide, in a CHOP-like combination, plus high-dose methotrexate and cytarabine)FCM (fludarabine, cyclophosphamide, and mitoxantrone)",
                      "CHOP (cyclophosphamide, hydroxydaunomycin [doxorubincin], vincristine [Oncovin], and prednisone)",
                      "Hyper-CVAD (dose-intense, hyperfractionated cyclophosphamide, in a CHOP-like combination, plus high-dose methotrexate and cytarabine)",
                      "FCM (fludarabine, cyclophosphamide, and mitoxantrone)"
                    ]
                  },
                  {
                    "text": "Autologous stem cell transplantation"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Median survival: 2-5 years"
                  },
                  {
                    "text": "Significant progression-free survival benefit in patients who undergo autologous stem cell transplantion"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Lymph nodesArchitectural lymph node effacement by monomorphic lymphoid proliferationCan have 1 of 3 growth patterns: Mantle zone, nodular, or diffuseClassic MCL is composed of a monotonous population of small to medium-sized lymphocytes with variably irregular nuclear contours, condensed chromatin, scant cytoplasm, and inconspicuous nucleoliTypically have expansion of follicle mantle zone around \"naked\" germinal centerHyalinized blood vessels and benign histiocytes with eosinophilic cytoplasm are frequently seenMore aggressive variants of MCL are recognized by 2008 WHO classificationBlastoid MCLCells resemble blasts; intermediate in size, with immature chromatin and high mitotic rate (> 2-3 mitoses/HPF)May have tingible-body macrophages and impart a \"starry-sky\" appearancePleomorphic MCLHeterogeneous population of cells, including large cells, often with prominent small nucleoli and finely dispersed chromatinMitotic index increase, but less than blastoid variant MCL",
                    "sub_points": [
                      "Architectural lymph node effacement by monomorphic lymphoid proliferationCan have 1 of 3 growth patterns: Mantle zone, nodular, or diffuse",
                      "Can have 1 of 3 growth patterns: Mantle zone, nodular, or diffuse",
                      "Classic MCL is composed of a monotonous population of small to medium-sized lymphocytes with variably irregular nuclear contours, condensed chromatin, scant cytoplasm, and inconspicuous nucleoliTypically have expansion of follicle mantle zone around \"naked\" germinal centerHyalinized blood vessels and benign histiocytes with eosinophilic cytoplasm are frequently seen",
                      "Typically have expansion of follicle mantle zone around \"naked\" germinal center",
                      "Hyalinized blood vessels and benign histiocytes with eosinophilic cytoplasm are frequently seen",
                      "More aggressive variants of MCL are recognized by 2008 WHO classificationBlastoid MCLCells resemble blasts; intermediate in size, with immature chromatin and high mitotic rate (> 2-3 mitoses/HPF)May have tingible-body macrophages and impart a \"starry-sky\" appearancePleomorphic MCLHeterogeneous population of cells, including large cells, often with prominent small nucleoli and finely dispersed chromatinMitotic index increase, but less than blastoid variant MCL",
                      "Blastoid MCLCells resemble blasts; intermediate in size, with immature chromatin and high mitotic rate (> 2-3 mitoses/HPF)May have tingible-body macrophages and impart a \"starry-sky\" appearance",
                      "Cells resemble blasts; intermediate in size, with immature chromatin and high mitotic rate (> 2-3 mitoses/HPF)",
                      "May have tingible-body macrophages and impart a \"starry-sky\" appearance",
                      "Pleomorphic MCLHeterogeneous population of cells, including large cells, often with prominent small nucleoli and finely dispersed chromatinMitotic index increase, but less than blastoid variant MCL",
                      "Heterogeneous population of cells, including large cells, often with prominent small nucleoli and finely dispersed chromatin",
                      "Mitotic index increase, but less than blastoid variant MCL"
                    ]
                  },
                  {
                    "text": "Bone marrowPattern of infiltration can be interstitial, nodular, paratrabecular, or most commonly a combination of these patternsClassic MCL is composed of monotonous population of small to medium-sized lymphoid cells with variably irregular nuclear contours, condensed chromatin, scant cytoplasm, and inconspicuous nucleoli",
                    "sub_points": [
                      "Pattern of infiltration can be interstitial, nodular, paratrabecular, or most commonly a combination of these patterns",
                      "Classic MCL is composed of monotonous population of small to medium-sized lymphoid cells with variably irregular nuclear contours, condensed chromatin, scant cytoplasm, and inconspicuous nucleoli"
                    ]
                  },
                  {
                    "text": "Peripheral bloodOvert leukemia in ~ 10% of patients, but occasional MCL cells are common (in ~ 75% of patients)Morphology of classic MCL is similar to that in lymph nodes and bone marrowMonotonous population of small to medium-sized lymphoid cells with variably irregular nuclear contours, condensed chromatin, scant cytoplasm, and inconspicuous nucleoliLeukemic blastoid MCL may appear similar to acute leukemia (lymphoblastic or myeloid)Intermediate-sized cells with fine chromatin, scant cytoplasm, and small nucleoli",
                    "sub_points": [
                      "Overt leukemia in ~ 10% of patients, but occasional MCL cells are common (in ~ 75% of patients)",
                      "Morphology of classic MCL is similar to that in lymph nodes and bone marrowMonotonous population of small to medium-sized lymphoid cells with variably irregular nuclear contours, condensed chromatin, scant cytoplasm, and inconspicuous nucleoli",
                      "Monotonous population of small to medium-sized lymphoid cells with variably irregular nuclear contours, condensed chromatin, scant cytoplasm, and inconspicuous nucleoli",
                      "Leukemic blastoid MCL may appear similar to acute leukemia (lymphoblastic or myeloid)Intermediate-sized cells with fine chromatin, scant cytoplasm, and small nucleoli",
                      "Intermediate-sized cells with fine chromatin, scant cytoplasm, and small nucleoli"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Positive staining for cyclin D1 is almost universally presentCyclin D1 also stains macrophages, endothelial cells, and epithelial cells, which provides a positive internal controlOther malignancies that can be positive for cyclin D1 include plasma cell myeloma, hairy cell leukemia, and occasionally in proliferation centers of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)Rare cyclin D1(-) variants described; these are generally positive for Sox-11",
                    "sub_points": [
                      "Cyclin D1 also stains macrophages, endothelial cells, and epithelial cells, which provides a positive internal control",
                      "Other malignancies that can be positive for cyclin D1 include plasma cell myeloma, hairy cell leukemia, and occasionally in proliferation centers of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)",
                      "Rare cyclin D1(-) variants described; these are generally positive for Sox-11"
                    ]
                  },
                  {
                    "text": "Positive for B-cell markers CD20, CD79a with aberrant coexpression of CD5 and Bcl-2"
                  },
                  {
                    "text": "Negative for CD3, CD10, CD23, BCL-6, and MUM-1/IRF4"
                  },
                  {
                    "text": "Variable staining for CD43"
                  },
                  {
                    "text": "Proliferation activity is important prognostic indicatorMitotic index of > 1.5-2.5/HPF indicates a more aggressive courseKi-67 staining with MIB-1 > 40% has worse prognosis than neoplasms with Ki-67 < 40%",
                    "sub_points": [
                      "Mitotic index of > 1.5-2.5/HPF indicates a more aggressive course",
                      "Ki-67 staining with MIB-1 > 40% has worse prognosis than neoplasms with Ki-67 < 40%"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Positive for B-cell markers CD19, CD20, CD22, CD79a, and FMC-7(+)"
                  },
                  {
                    "text": "Positive for CD5, and +/- CD43"
                  },
                  {
                    "text": "Negative for CD3, CD10, and CD23"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Conventional cytogenetics detects the classic t(11;14) in up to 65% of MCLTetraploidy is more frequent in pleomorphic MCL (~ 80%) and blastoid MCL (~ 36%) than classic-type MCL (~ 8%)",
                    "sub_points": [
                      "Tetraploidy is more frequent in pleomorphic MCL (~ 80%) and blastoid MCL (~ 36%) than classic-type MCL (~ 8%)"
                    ]
                  },
                  {
                    "text": "Fluorescent in situ hybridization (FISH) for t(11;14) can be found in virtually all cases of MCL"
                  },
                  {
                    "text": "Comparative genomic hybridization analysis often identifies additional secondary chromosomal abnormalities in MCL"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Other Small Mature B-Cell Lymphomas": [
                  {
                    "text": "CLL/SLLDemonstrates B cells with coexpression of CD5, but CLL/SLL should be positive for CD23Lacks the t(11;14) rearrangement and expression of cyclin D1 that is seen in MCL",
                    "sub_points": [
                      "Demonstrates B cells with coexpression of CD5, but CLL/SLL should be positive for CD23",
                      "Lacks the t(11;14) rearrangement and expression of cyclin D1 that is seen in MCL"
                    ]
                  },
                  {
                    "text": "Follicular lymphoma (FL)Demonstrates B cells with coexpression of CD10, but FL is negative for CD5 and cyclin-D1FL and MCL are both positive for Bcl-2, but FL has a t(14;18) rearrangement rather than the t(11;14) rearrangement seen in MCL",
                    "sub_points": [
                      "Demonstrates B cells with coexpression of CD10, but FL is negative for CD5 and cyclin-D1",
                      "FL and MCL are both positive for Bcl-2, but FL has a t(14;18) rearrangement rather than the t(11;14) rearrangement seen in MCL"
                    ]
                  },
                  {
                    "text": "Marginal zone B-cell lymphoma"
                  }
                ],
                "Diffuse Large B-Cell Lymphoma (DLBCL)": [
                  {
                    "text": "Pleomorphic MCL mimics DLBCL"
                  },
                  {
                    "text": "Positive expression of CD5 may be seen in subset of DLBCL, but cyclin D1 is generally negative"
                  },
                  {
                    "text": "DLBCL lacks the t(11;14) rearrangement seen in MCL"
                  }
                ],
                "Acute Leukemia": [
                  {
                    "text": "Blastoid MCL can have similar morphology to both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)"
                  },
                  {
                    "text": "Immunophenotyping is positive for immature markers TdT &/or CD34 in an acute leukemia, whereas MCL lymphoma is negativeMCL has expression of surface immunoglobulins, and cyclin D1",
                    "sub_points": [
                      "MCL has expression of surface immunoglobulins, and cyclin D1"
                    ]
                  },
                  {
                    "text": "MCL has a t(11;14) rearrangement, which is not characteristic of ALL or AML"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Nodal Marginal Zone Lymphoma": {
            "name": "Nodal Marginal Zone Lymphoma",
            "url": "https://app.pathprimer.com/document/e4919e80-2068-4120-ab62-29dd482e102e/lesson/5fa09a8a-53fc-4bfc-9404-09d15374a7a2",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "﻿Primary nodal B-cell lymphoma derived from post-germinal center B cells with resemblance to extranodal MZL or splenic MZL"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Painless waxing and waning lymphadenopathy"
                  },
                  {
                    "text": "Treatment with low-intensity chemotherapy"
                  },
                  {
                    "text": "Lower stage in pediatric than adult patients"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Perisinusoidal and interfollicular distribution"
                  },
                  {
                    "text": "Lymph nodes with polymorphic cytology including centrocyte-like cells, monocytoid differentiation, plasmacytoid differentiation, and admixed large cells"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Immunophenotype: positive for pan B-cell; aberrant CD43 (approximately 50%); and negative for CD5, CD10, Bcl-6, and cyclin-D1"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Reactive (inter)-follicular hyperplasia, CLL/SLL, MCL, FL, MALT lymphoma, LPL"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Nodal marginal zone B-cell lymphoma (NMZL)"
                  },
                  {
                    "text": "Marginal zone B-cell lymphoma (MZL)"
                  },
                  {
                    "text": "Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)"
                  },
                  {
                    "text": "Mantle cell lymphoma (MCL)"
                  },
                  {
                    "text": "Follicular lymphoma (FL)"
                  },
                  {
                    "text": "Mucosa-associated lymphoid tissue (MALT)"
                  },
                  {
                    "text": "Lymphoplasmacytic lymphoma (LPL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Monocytoid B-cell lymphoma"
                  },
                  {
                    "text": "Parafollicular B-cell lymphoma"
                  }
                ],
                "Definitions": [
                  {
                    "text": "﻿Primary nodal B-cell lymphoma derived from post-germinal center B cells"
                  },
                  {
                    "text": "Diagnosis of exclusionExclusion of extranodal MZL or splenic MZL",
                    "sub_points": [
                      "Exclusion of extranodal MZL or splenic MZL"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Infectious Agents": [
                  {
                    "text": "Associated with hepatitis C virus infection"
                  }
                ],
                "Autoimmune Association": [
                  {
                    "text": "Sjögren syndrome"
                  },
                  {
                    "text": "Hashimoto thyroiditis"
                  },
                  {
                    "text": "Autoimmune hemolytic anemia"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Approximately 2% of non-Hodgkin lymphomas"
                  }
                ],
                "Age": [
                  {
                    "text": "Adults > childrenMedian age in adults: 50-60 yrMedian age in children: 16 yr",
                    "sub_points": [
                      "Median age in adults: 50-60 yr",
                      "Median age in children: 16 yr"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "Female > male"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Painless generalized lymphadenopathyCervical (pediatric) > inguinal or retroperitoneal (adult)",
                    "sub_points": [
                      "Cervical (pediatric) > inguinal or retroperitoneal (adult)"
                    ]
                  },
                  {
                    "text": "B symptoms present in approximately 30% of patientsFever, weight loss, night sweats",
                    "sub_points": [
                      "Fever, weight loss, night sweats"
                    ]
                  },
                  {
                    "text": "Peripheral blood and bone marrow involvement uncommon"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Low-intensity chemotherapy"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Generally indolent in stage I or II"
                  },
                  {
                    "text": "Prognosis controversial in stage III or IV"
                  },
                  {
                    "text": "Lower stage in pediatric than adult patients"
                  },
                  {
                    "text": "Worse prognosis with transformation to diffuse large B-cell lymphoma≤ 15% of patients",
                    "sub_points": [
                      "≤ 15% of patients"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Primarily involves lymph nodes and bone marrow"
                  },
                  {
                    "text": "Partial or complete effacement of lymph node architectureResidual follicles with hyperplastic germinal centers and residual mantle zoneCan have numerous tingible body macrophages",
                    "sub_points": [
                      "Residual follicles with hyperplastic germinal centers and residual mantle zone",
                      "Can have numerous tingible body macrophages"
                    ]
                  },
                  {
                    "text": "Perisinusoidal and interfollicular distribution"
                  },
                  {
                    "text": "Capsular and trabecular fibrosis associated with tumor spread"
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Lymph nodes with polymorphic cytologyMonocytoid cellsRound to irregular nuclei, condensed chromatinAbundant pale cytoplasm and indistinct cell bordersCentrocyte-like cellsCoarse and clumped chromatin, irregular nucleiSmall to medium sized with scant cytoplasmVariable degrees of plasmacytoid differentiationAdmixed large lymphocytes can be seen",
                    "sub_points": [
                      "Monocytoid cellsRound to irregular nuclei, condensed chromatinAbundant pale cytoplasm and indistinct cell borders",
                      "Round to irregular nuclei, condensed chromatin",
                      "Abundant pale cytoplasm and indistinct cell borders",
                      "Centrocyte-like cellsCoarse and clumped chromatin, irregular nucleiSmall to medium sized with scant cytoplasm",
                      "Coarse and clumped chromatin, irregular nuclei",
                      "Small to medium sized with scant cytoplasm",
                      "Variable degrees of plasmacytoid differentiation",
                      "Admixed large lymphocytes can be seen"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Positive for pan B-lymphocyte antigensCD19, CD20, PAX-5",
                    "sub_points": [
                      "CD19, CD20, PAX-5"
                    ]
                  },
                  {
                    "text": "Typically negative for CD5, CD10, Bcl-6, cyclin-D1"
                  },
                  {
                    "text": "Aberrant CD43 expression in approximately 50% of cases"
                  },
                  {
                    "text": "Monotypic light chain restriction"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Positive for monotypic κ or λ surface light chains"
                  },
                  {
                    "text": "Positive for pan B-lymphocyte antigensCD19, CD20, CD22, CD79a",
                    "sub_points": [
                      "CD19, CD20, CD22, CD79a"
                    ]
                  },
                  {
                    "text": "Positive for CD43 in approximately 50% of cases"
                  },
                  {
                    "text": "Negative for CD10, Bcl-6, CD5 (except in rare cases)"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Iggene rearrangement"
                  },
                  {
                    "text": "No specific translocations"
                  },
                  {
                    "text": "Trisomy 3 more common than trisomies 7 and 18"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Reactive (Inter)-follicular Hyperplasia": [
                  {
                    "text": "Reactive (inter)-follicular hyperplasia distinguished byIntact lymph node architectureSpectrum of reactive lymphoid cells in interfollicular zonesPolytypic light chains in B lymphocytesAbsent monoclonalIggene rearrangements or translocations",
                    "sub_points": [
                      "Intact lymph node architecture",
                      "Spectrum of reactive lymphoid cells in interfollicular zones",
                      "Polytypic light chains in B lymphocytes",
                      "Absent monoclonalIggene rearrangements or translocations"
                    ]
                  }
                ],
                "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma": [
                  {
                    "text": "Interfollicular/parafollicular lymph node involvement and occasionally plasmacytoid differentiation that mimics NMZL"
                  },
                  {
                    "text": "CLL/SLL distinguished byMonotonous small cells with scant cytoplasmProliferation centersPositive for CD5, CD23, CD20 (dim)",
                    "sub_points": [
                      "Monotonous small cells with scant cytoplasm",
                      "Proliferation centers",
                      "Positive for CD5, CD23, CD20 (dim)"
                    ]
                  }
                ],
                "Mantle Cell Lymphoma": [
                  {
                    "text": "MCL distinguished byMore aggressive diseaseMore homogeneous population of small neoplastic cellsDispersed “pink” histiocytes without apoptotic bodiesPositive for CD5, cyclin-D1, and SOX-11t(11;14)(q13;q32) translocation",
                    "sub_points": [
                      "More aggressive disease",
                      "More homogeneous population of small neoplastic cells",
                      "Dispersed “pink” histiocytes without apoptotic bodies",
                      "Positive for CD5, cyclin-D1, and SOX-11",
                      "t(11;14)(q13;q32) translocation"
                    ]
                  }
                ],
                "Follicular Lymphoma": [
                  {
                    "text": "NMZL may colonize germinal centers, mimicking FL"
                  },
                  {
                    "text": "FL may show monocytoid/marginal B-cell differentiation, mimicking NMZL"
                  },
                  {
                    "text": "FL distinguished by:Presence of centroblastsPositive for CD10 and Bcl-6Presence of t(14;18)(q32;q21) translocation",
                    "sub_points": [
                      "Presence of centroblasts",
                      "Positive for CD10 and Bcl-6",
                      "Presence of t(14;18)(q32;q21) translocation"
                    ]
                  }
                ],
                "Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue": [
                  {
                    "text": "Resembles NMZL histologically and may involve lymph nodes"
                  },
                  {
                    "text": "MALT lymphoma distinguished byExtranodal involvementGastrointestinal tract, lung, skin, salivary glands, orbitIgD negativeOften with t(11;18)NMZL does not have t(11;18)",
                    "sub_points": [
                      "Extranodal involvementGastrointestinal tract, lung, skin, salivary glands, orbit",
                      "Gastrointestinal tract, lung, skin, salivary glands, orbit",
                      "IgD negative",
                      "Often with t(11;18)NMZL does not have t(11;18)",
                      "NMZL does not have t(11;18)"
                    ]
                  }
                ],
                "Lymphoplasmacytic Lymphoma": [
                  {
                    "text": "May mimic NMZL with plasmacytoid differentiationSimilar immunophenotypes",
                    "sub_points": [
                      "Similar immunophenotypes"
                    ]
                  },
                  {
                    "text": "LPL distinguished byMore monomorphic cytology than NMZLPreservation of lymph node sinuses in LPLAssociation of LPL with Waldenström macroglobulinemiaIgM monoclonal gammopathy6q gain or loss more common in LPLMYD88 L265Pmutation (90%)NMZL typically does not haveMYD88 L265Pmutation",
                    "sub_points": [
                      "More monomorphic cytology than NMZL",
                      "Preservation of lymph node sinuses in LPL",
                      "Association of LPL with Waldenström macroglobulinemiaIgM monoclonal gammopathy",
                      "IgM monoclonal gammopathy",
                      "6q gain or loss more common in LPL",
                      "MYD88 L265Pmutation (90%)NMZL typically does not haveMYD88 L265Pmutation",
                      "NMZL typically does not haveMYD88 L265Pmutation"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Lymphadenopathy without extranodal or splenic involvement"
                  },
                  {
                    "text": "Pediatric variant lower stages and better prognosis"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "﻿NMZL may colonize follicles and mimic FL"
                  },
                  {
                    "text": "Monocytoid B cells with variable degrees of plasmacytoid differentiation"
                  },
                  {
                    "text": "LPL may show similar morphology and immunophenotypeLPL is typically associated with Waldenström macroglobulinemia (monoclonal IgM serum protein)",
                    "sub_points": [
                      "LPL is typically associated with Waldenström macroglobulinemia (monoclonal IgM serum protein)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Lymphoplasmacytic Lymphoma": {
            "name": "Lymphoplasmacytic Lymphoma",
            "url": "https://app.pathprimer.com/document/0784ad64-cc95-4c06-b84d-3594b449d79d/lesson/5fa09a8a-53fc-4bfc-9404-09d15374a7a2",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "LPL/WM is characterized by clonal expansion of small mature B lymphocytes with variable plasmacytoid differentiation"
                  },
                  {
                    "text": "WM is found in significant subset of patients with LPL and is defined as LPL with bone marrow involvement and IgM monoclonal protein"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "MYD88mutation in > 90% of cases"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Bone marrow is primary site"
                  },
                  {
                    "text": "Typically associated with an IgM monoclonal paraprotein"
                  },
                  {
                    "text": "Hyperviscosity occurs in up to 20% of patients"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Blood and bone marrow show spectrum of lymphocytes, plasmacytoid lymphocytes, and plasma cells"
                  },
                  {
                    "text": "Mast cells typically increased; most prominent within particles on aspirate smears"
                  },
                  {
                    "text": "Variable amyloid deposition"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Molecular assessment forMYD88mutation (may be disease defining)"
                  },
                  {
                    "text": "Cell usually express IgM, CD19, CD20, CD22, CD79a, CD27"
                  },
                  {
                    "text": "Cells lack CD5, CD10, CD23, CD103"
                  },
                  {
                    "text": "Deletion 6q is reported in 40-50% of patients"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Lymphoplasmacytic lymphoma (LPL)"
                  },
                  {
                    "text": "Waldenström macroglobulinemia (WM)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "LPL/WM is characterized by clonal expansion of small mature B lymphocytes with variable plasmacytoid differentiation"
                  },
                  {
                    "text": "WM is found in significant subset of patients with LPL and is defined as LPL with bone marrow (BM) involvement and IgM monoclonal protein"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Etiology": [
                  {
                    "text": "Mature B cell; evidence indicates memory B cell is likely cell of origin"
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "MYD88mutation in > 90% cases"
                  },
                  {
                    "text": "Genetic factorsEvidence of familial clustering",
                    "sub_points": [
                      "Evidence of familial clustering"
                    ]
                  },
                  {
                    "text": "Chronic immune stimulationWM risk is elevated among individuals with autoimmune disordersWM risk is elevated in persons with hepatitis, human immunodeficiency virus infection, and rickettsiosis",
                    "sub_points": [
                      "WM risk is elevated among individuals with autoimmune disorders",
                      "WM risk is elevated in persons with hepatitis, human immunodeficiency virus infection, and rickettsiosis"
                    ]
                  },
                  {
                    "text": "PredispositionMonoclonal gammopathy of unknown significance (MGUS) of IgM type is associated with estimated annual progression rate of 10.5%Precursor lesionAlso exhibitsMYD88mutation in 50% of cases",
                    "sub_points": [
                      "Monoclonal gammopathy of unknown significance (MGUS) of IgM type is associated with estimated annual progression rate of 10.5%Precursor lesionAlso exhibitsMYD88mutation in 50% of cases",
                      "Precursor lesion",
                      "Also exhibitsMYD88mutation in 50% of cases"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Incidence: 0.55 per 100,000 individuals per year"
                  },
                  {
                    "text": "Mean age at diagnosis: > 70 years"
                  },
                  {
                    "text": "Male predominance"
                  }
                ],
                "Site": [
                  {
                    "text": "Bone marrow is primary site"
                  },
                  {
                    "text": "Blood, lymph nodes, and extranodal sites are often involved"
                  }
                ],
                "Presentation": [
                  {
                    "text": "20-30% of patients are asymptomatic at diagnosis"
                  },
                  {
                    "text": "Anemia-related symptoms: Fatigue, shortness of breath, and chest pain"
                  },
                  {
                    "text": "Thrombocytopenia-related bleeding tendency"
                  },
                  {
                    "text": "Hyperviscosity occurs in up to 20% of patients"
                  },
                  {
                    "text": "Constitutional symptoms including weight loss and night sweats"
                  },
                  {
                    "text": "Splenomegaly and adenopathy"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "CBCAnemia and thrombocytopeniaLymphocytosisMorphologic review",
                    "sub_points": [
                      "Anemia and thrombocytopenia",
                      "Lymphocytosis",
                      "Morphologic review"
                    ]
                  },
                  {
                    "text": "Cryoglobulin test is positive in subset of cases"
                  },
                  {
                    "text": "Serum/urine protein electrophoresis (SPEP/UPEP)Typically IgM monoclonal paraproteinRarely IgG or IgA",
                    "sub_points": [
                      "Typically IgM monoclonal paraprotein",
                      "Rarely IgG or IgA"
                    ]
                  },
                  {
                    "text": "Flow cytometry and genetic testing (see below)"
                  }
                ],
                "Treatment": [
                  {
                    "text": "\"Watch and wait\" policy for asymptomatic patients"
                  },
                  {
                    "text": "Initiation of therapy is considered in patients withConstitutional symptoms such as fever, fatigue, night sweats, weight lossHyperviscositySevere neuropathyAmyloidosisSymptomatic cryoglobulinemiaCold agglutinin diseaseEvidence of disease transformation",
                    "sub_points": [
                      "Constitutional symptoms such as fever, fatigue, night sweats, weight loss",
                      "Hyperviscosity",
                      "Severe neuropathy",
                      "Amyloidosis",
                      "Symptomatic cryoglobulinemia",
                      "Cold agglutinin disease",
                      "Evidence of disease transformation"
                    ]
                  },
                  {
                    "text": "Various combinations of chemotherapy for symptomatic patientsRituximab in combination with purine analogue &/or alkylating agentsThalidomide or bortezomib",
                    "sub_points": [
                      "Rituximab in combination with purine analogue &/or alkylating agents",
                      "Thalidomide or bortezomib"
                    ]
                  },
                  {
                    "text": "Plasmapheresis to reduce amount of circulating IgM"
                  },
                  {
                    "text": "Splenectomy for chemotherapy-resistant patients"
                  },
                  {
                    "text": "Stem cell transplantationAutologous stem cell transplantation (ASCT) is feasible, safe, and associated with significant cytoreduction in relapsed or refractory patientsAllogeneic stem cell transplantation is used only in patients with advanced and refractory disease for whom no other options are available",
                    "sub_points": [
                      "Autologous stem cell transplantation (ASCT) is feasible, safe, and associated with significant cytoreduction in relapsed or refractory patients",
                      "Allogeneic stem cell transplantation is used only in patients with advanced and refractory disease for whom no other options are available"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Median survival is 60 months"
                  },
                  {
                    "text": "Transformation to large cell lymphoma can occur"
                  },
                  {
                    "text": "Adverse prognostic factors (IPSS-WM)del 6q andTP53deletionsAge > 65 yearsPresence of constitutional symptomsAnemia &/or thrombocytopeniaMonoclonal IgM > 70g/dlIncreased β-2 microglobulin",
                    "sub_points": [
                      "del 6q andTP53deletions",
                      "Age > 65 years",
                      "Presence of constitutional symptoms",
                      "Anemia &/or thrombocytopenia",
                      "Monoclonal IgM > 70g/dl",
                      "Increased β-2 microglobulin"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "BloodMay show lymphocytosis with spectrum of lymphocytes, plasmacytoid lymphocytes, and plasma cellsRouleaux formation of red blood cellsCold agglutinin or cryoglobulin may be present",
                    "sub_points": [
                      "May show lymphocytosis with spectrum of lymphocytes, plasmacytoid lymphocytes, and plasma cells",
                      "Rouleaux formation of red blood cells",
                      "Cold agglutinin or cryoglobulin may be present"
                    ]
                  },
                  {
                    "text": "Bone marrowAlmost all cases have BM involvementOften, combination of paratrabecular, nonparatrabecular lymphoid nodules, and diffuse &/or interstitial infiltratesInfiltrate composed predominantly of small lymphocytes with variable number of plasmacytoid lymphocytes and plasma cellsPseudointranuclear (Dutcher bodies) and intracytoplasmic inclusions (Russell bodies) are most prominent on core biopsy sectionMast cells typically increased; most prominent within particles on aspirate smearsAmyloid deposition may be present (within vessel walls or interstitial deposits)",
                    "sub_points": [
                      "Almost all cases have BM involvement",
                      "Often, combination of paratrabecular, nonparatrabecular lymphoid nodules, and diffuse &/or interstitial infiltrates",
                      "Infiltrate composed predominantly of small lymphocytes with variable number of plasmacytoid lymphocytes and plasma cells",
                      "Pseudointranuclear (Dutcher bodies) and intracytoplasmic inclusions (Russell bodies) are most prominent on core biopsy section",
                      "Mast cells typically increased; most prominent within particles on aspirate smears",
                      "Amyloid deposition may be present (within vessel walls or interstitial deposits)"
                    ]
                  },
                  {
                    "text": "Lymph nodeNeoplastic cells infiltrate paracortex and hilum with patent or dilated sinusesMay have preserved architecture or attenuated germinal centersInfiltrate consists of monotonous small lymphocytes with variable number of plasmacytoid lymphocytes and plasma cellsIncreased mast cells and hemosiderin",
                    "sub_points": [
                      "Neoplastic cells infiltrate paracortex and hilum with patent or dilated sinuses",
                      "May have preserved architecture or attenuated germinal centers",
                      "Infiltrate consists of monotonous small lymphocytes with variable number of plasmacytoid lymphocytes and plasma cells",
                      "Increased mast cells and hemosiderin"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "CD20 is helpful to identify subtle infiltrate"
                  },
                  {
                    "text": "Congo red stain can identify amyloid deposits"
                  },
                  {
                    "text": "κ and λ in situ hybridizations reveal monoclonal plasma cells"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Positive: IgM, CD19, CD20, CD22, CD27, and CD79a"
                  },
                  {
                    "text": "Presence of cytoplasmic immunoglobulin"
                  },
                  {
                    "text": "Negative: CD5, CD10, CD23, CD103"
                  },
                  {
                    "text": "Variable expression of CD25, CD11c, and CD38"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "MYD88mutation > 90% of cases (may be disease defining)"
                  },
                  {
                    "text": "Cytogenetics: Deletion 6q is reported in 40-50% of patients"
                  },
                  {
                    "text": "IGH@gene rearrangedBiasedVH3andVH3-23usage",
                    "sub_points": [
                      "BiasedVH3andVH3-23usage"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Marginal Zone Lymphoma (MZL)": [
                  {
                    "text": "MYD88negative"
                  },
                  {
                    "text": "Difficulties in distinguishing LPL/WM from MZL by morphology and immunophenotypeSmall subset of extranodal lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) can have IgM paraproteinNodal MZL can involve bone marrow, and LPL/WM can involve lymph nodeFrequent bone marrow involvement and presence of IgM in splenic marginal zone lymphoma (SMZL)",
                    "sub_points": [
                      "Small subset of extranodal lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) can have IgM paraprotein",
                      "Nodal MZL can involve bone marrow, and LPL/WM can involve lymph node",
                      "Frequent bone marrow involvement and presence of IgM in splenic marginal zone lymphoma (SMZL)"
                    ]
                  },
                  {
                    "text": "MALT lymphomaIgM paraprotein is uncommon in MALTLPL/WM rarely involves extranodal sitesMALT often exhibits characteristic monocytoid B cells, lymphoepithelial lesions, reactive folliclesTranslocations of t(11;18)(q21;q21)API2-MALT1, t(14;18)(q32;q21)IGH@-MALT1, t(1;14)(p22;q32)BCL10-IGH@are seen in MALT but not LPL/WM",
                    "sub_points": [
                      "IgM paraprotein is uncommon in MALT",
                      "LPL/WM rarely involves extranodal sites",
                      "MALT often exhibits characteristic monocytoid B cells, lymphoepithelial lesions, reactive follicles",
                      "Translocations of t(11;18)(q21;q21)API2-MALT1, t(14;18)(q32;q21)IGH@-MALT1, t(1;14)(p22;q32)BCL10-IGH@are seen in MALT but not LPL/WM"
                    ]
                  },
                  {
                    "text": "Splenic marginal zone lymphomaMYD88negativeSplenomegaly prominentMay have villous lymphocytes in peripheral bloodSinusoidal infiltration pattern on bone marrow core biopsyStrong CD22 expression and subset of CD103(+) cases in SMZL; LPL/WM may express weak CD25, dim CD22, and be negative for CD103Deletion 7q usually associated with SMZLSpleen histology is diagnostic",
                    "sub_points": [
                      "MYD88negative",
                      "Splenomegaly prominent",
                      "May have villous lymphocytes in peripheral blood",
                      "Sinusoidal infiltration pattern on bone marrow core biopsy",
                      "Strong CD22 expression and subset of CD103(+) cases in SMZL; LPL/WM may express weak CD25, dim CD22, and be negative for CD103",
                      "Deletion 7q usually associated with SMZL",
                      "Spleen histology is diagnostic"
                    ]
                  }
                ],
                "IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS)": [
                  {
                    "text": "MYD88mutation in 50%"
                  },
                  {
                    "text": "Serum M-protein < 30 g/L"
                  },
                  {
                    "text": "Bone marrow clonal plasma cells < 10%"
                  },
                  {
                    "text": "No end-organ damage"
                  },
                  {
                    "text": "No evidence of B-cell lymphoma or other M-protein producing disease"
                  }
                ],
                "Other Chronic B-Cell Neoplasms": [
                  {
                    "text": "Expression of CD5, CD23 helpful to exclude chronic lymphocytic leukemia/small lymphocytic lymphoma"
                  },
                  {
                    "text": "Expression of CD5, cyclin D1, and cytogenetic finding of t(11;14) helpful to exclude mantle cell lymphoma"
                  },
                  {
                    "text": "Expression of CD10 and cytogenetic findings of t(14;18) helpful to exclude follicular lymphoma"
                  },
                  {
                    "text": "Histology features also helpful in differential diagnosis"
                  },
                  {
                    "text": "All listed above are typicallyMYD88negative"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Based on combination of following findingsPresence of spectrum lymphocytes, plasmacytoid lymphocytes, and plasma cellsFlow cytometric study demonstrates monoclonal B cells with typical immunophenotype and monoclonal plasma cellsMonoclonal IgM paraprotein by SPEP/UPEPMYD88mutation present",
                    "sub_points": [
                      "Presence of spectrum lymphocytes, plasmacytoid lymphocytes, and plasma cells",
                      "Flow cytometric study demonstrates monoclonal B cells with typical immunophenotype and monoclonal plasma cells",
                      "Monoclonal IgM paraprotein by SPEP/UPEP",
                      "MYD88mutation present"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "B-Cell Prolymphocytic Leukemia": {
            "name": "B-Cell Prolymphocytic Leukemia",
            "url": "https://app.pathprimer.com/document/6b16edff-c0a9-4aab-b55c-51e25be14073/lesson/5fa09a8a-53fc-4bfc-9404-09d15374a7a2",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Monoclonal B-cell neoplasm characterized byProminent nucleoli in > 55% of lymphocytesTransformation of chronic lymphocytic leukemia (CLL) must beexcludedt(11;14)(q13;q32) orCCND1/IGH@must beexcluded",
                    "sub_points": [
                      "Prominent nucleoli in > 55% of lymphocytes",
                      "Transformation of chronic lymphocytic leukemia (CLL) must beexcluded",
                      "t(11;14)(q13;q32) orCCND1/IGH@must beexcluded"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Exceedingly rare"
                  },
                  {
                    "text": "Typically clinically aggressive"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "No recurrent genetic abnormalities"
                  },
                  {
                    "text": "Deletions ofTP53common"
                  },
                  {
                    "text": "Mustlackt(11;14)(q13;q32)"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Prolymphocytoid transformation of CLL"
                  },
                  {
                    "text": "Splenomegalic mantle cell lymphoma (MCL)"
                  },
                  {
                    "text": "Hairy cell leukemia variant (HCLv)"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "B-cell prolymphocytic leukemia (B-PLL)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Monoclonal B-cell neoplasm characterized byMature B-cell phenotypeProminent nucleoli in > 55% of lymphocytesTransformation of chronic lymphocytic leukemia (CLL) must beexcludedt(11;14)(q13;q32) orCCND1/IGH﻿@﻿must beexcluded",
                    "sub_points": [
                      "Mature B-cell phenotype",
                      "Prominent nucleoli in > 55% of lymphocytes",
                      "Transformation of chronic lymphocytic leukemia (CLL) must beexcluded",
                      "t(11;14)(q13;q32) orCCND1/IGH﻿@﻿must beexcluded"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Unknown": [
                  {
                    "text": "MYCabnormalities common"
                  },
                  {
                    "text": "Resemblance to IgM only B cells by gene expression profiling"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Exceedingly rare"
                  }
                ],
                "Age": [
                  {
                    "text": "Most cases described in elderly"
                  },
                  {
                    "text": "Median age ~ 70 years"
                  }
                ],
                "Site": [
                  {
                    "text": "Leukemia involves primarily blood, bone marrow, spleen, and liver"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Complete blood count (CBC) with differential and morphologic review"
                  },
                  {
                    "text": "Other laboratory tests as needed to assess immunophenotype and other parameters"
                  }
                ],
                "Natural History": [
                  {
                    "text": "Typically clinically aggressive"
                  },
                  {
                    "text": "Rare patients experience more indolent disease course"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Due to rarity, no standardized treatment protocol"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Generally poor, rare exceptions"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Blood": [
                  {
                    "text": "Marked leukocytosis (median 150 x 10⁹/L)"
                  },
                  {
                    "text": "May see rapidly rising white blood cell count (WBC)"
                  },
                  {
                    "text": "ProlymphocytesGenerally have round nuclear contours, moderately condensed nuclear chromatin, central prominent nucleoliMust exceed 55% of lymphocytes; often > 90%Typically homogeneous",
                    "sub_points": [
                      "Generally have round nuclear contours, moderately condensed nuclear chromatin, central prominent nucleoli",
                      "Must exceed 55% of lymphocytes; often > 90%",
                      "Typically homogeneous"
                    ]
                  },
                  {
                    "text": "Variable cytopeniasNormocytic/normochromic anemia commonThrombocytopenia common",
                    "sub_points": [
                      "Normocytic/normochromic anemia common",
                      "Thrombocytopenia common"
                    ]
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "Hypercellular, diffuse infiltration"
                  },
                  {
                    "text": "Reduced hematopoietic cells"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Flow Cytometry": [
                  {
                    "text": "Monoclonal B cells"
                  },
                  {
                    "text": "Subset CD5(+), subset CD23(+)"
                  },
                  {
                    "text": "CD38 and ZAP70 expressed in most cases"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "No recurrent abnormalities"
                  },
                  {
                    "text": "Deletions ofTP53common"
                  },
                  {
                    "text": "Mustlackt(11;14)(q13;q32)"
                  }
                ],
                "Molecular": [
                  {
                    "text": "About 50% mutated and 50% unmutatedIGHV@"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Prolymphocytoid Transformation of CLL": [
                  {
                    "text": "History of CLL"
                  },
                  {
                    "text": "Spectrum of morphology including typical CLL cells"
                  },
                  {
                    "text": "Immunophenotype similar to CLL"
                  },
                  {
                    "text": "Cytogenetic/FISH findings similar to CLL"
                  }
                ],
                "Mantle Cell Lymphoma (MCL)": [
                  {
                    "text": "Spectrum of cells in blood"
                  },
                  {
                    "text": "Cyclin D1 positive"
                  },
                  {
                    "text": "t(11;14)(q13;q32) orCCND1-IGH@positive"
                  }
                ],
                "Hairy Cell Leukemia Variant (HCLv)": [
                  {
                    "text": "Subtype of splenic red pulp lymphoma"
                  },
                  {
                    "text": "Hybrid features between classic HCL and B-PLL"
                  },
                  {
                    "text": "Cytoplasmic hairy projections common"
                  }
                ],
                "Other Nucleolated Lymphoid Neoplasms": [
                  {
                    "text": "T-cell prolymphocytic leukemia (T-PLL)"
                  },
                  {
                    "text": "B-precursor lymphoblastic leukemiaImmature morphology and immunophenotype",
                    "sub_points": [
                      "Immature morphology and immunophenotype"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Confirm > 55% prolymphocytes in blood"
                  },
                  {
                    "text": "Confirm mature B-cell phenotype"
                  },
                  {
                    "text": "ExcludeMCL, HCLv, and prolymphocytoid transformation of CLL"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hairy Cell Leukemia": {
            "name": "Hairy Cell Leukemia",
            "url": "https://app.pathprimer.com/document/a597e330-0a34-4742-a4fd-66b1dfe51f63/lesson/5fa09a8a-53fc-4bfc-9404-09d15374a7a2",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Indolent, mature B-cell leukemia characterized by distinctive cytoplasmic (hairy) projections, unique immunophenotypic profile, and propensity for splenic red pulp involvement"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Derived from late-activated memory B cell"
                  },
                  {
                    "text": "BRAFV600E mutation recurrent in hairy cell leukemia (HCL)Positive in 85% of casesNot detected in other mature B-cell neoplasmsMAP2K1mutations common inBRAF(-) cases",
                    "sub_points": [
                      "Positive in 85% of cases",
                      "Not detected in other mature B-cell neoplasms",
                      "MAP2K1mutations common inBRAF(-) cases"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Splenomegaly and cytopenias prototypic"
                  },
                  {
                    "text": "Leukopenia due to neutropenia and monocytopeniaScanning for rare circulating hairy cells important",
                    "sub_points": [
                      "Scanning for rare circulating hairy cells important"
                    ]
                  },
                  {
                    "text": "10-year median survival > 90%"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "20% of cases of HCL show marked hypocellularity, and HCL can beeasilymissed"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Staining for CD20 can highlight inconspicuous infiltratesEspecially useful in hypocellular specimens for detection of occult HCL",
                    "sub_points": [
                      "Especially useful in hypocellular specimens for detection of occult HCL"
                    ]
                  },
                  {
                    "text": "Panel of IHC stains provides high diagnostic sensitivity and specificity for HCLAnnexin A1, CD123, TRAP, CD103, BRAF,CD200",
                    "sub_points": [
                      "Annexin A1, CD123, TRAP, CD103, BRAF,CD200"
                    ]
                  },
                  {
                    "text": "Immunophenotypic profile of HCL virtually diagnostic even when HCL numbers very lowCD103, CD25, CD11c, CD20, and CD22 all brightly expressed",
                    "sub_points": [
                      "CD103, CD25, CD11c, CD20, and CD22 all brightly expressed"
                    ]
                  },
                  {
                    "text": "BRAFV600E mutation in > 85% of cases (HCL definingamong mature B-cell neoplasms)"
                  }
                ],
                "Diagnostic Checklist": [
                  {
                    "text": "Pancytopenia, rare hairy cells (high index of suspicion)"
                  },
                  {
                    "text": "Generous use of IHC stains/flow cytometry essential in disease detection"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Hairy cell leukemia (HCL) in both International Consensus Classification (ICC) 2022 and WHO 5th edition"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Leukemic reticuloendotheliosis (old literature)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Indolent monoclonal B-cell neoplasm composed of cells withDistinct morphologyOval nuclei, abundant cytoplasm with circumferential, hairy projectionsDistinct immunophenotype by flow cytometryBright sIg, bright CD20, bright CD22, bright CD103, CD25, CD123, bright CD200, bright CD11c (+)Distinct IHC profileAnnexin A1, CD123, BRAF, CD200, weak cyclin-D1, DBA.44, TRAP, T-bet, and TCL1 (+)Propensity for diffuse BM involvement and splenic red pulp infiltration",
                    "sub_points": [
                      "Distinct morphologyOval nuclei, abundant cytoplasm with circumferential, hairy projections",
                      "Oval nuclei, abundant cytoplasm with circumferential, hairy projections",
                      "Distinct immunophenotype by flow cytometryBright sIg, bright CD20, bright CD22, bright CD103, CD25, CD123, bright CD200, bright CD11c (+)",
                      "Bright sIg, bright CD20, bright CD22, bright CD103, CD25, CD123, bright CD200, bright CD11c (+)",
                      "Distinct IHC profileAnnexin A1, CD123, BRAF, CD200, weak cyclin-D1, DBA.44, TRAP, T-bet, and TCL1 (+)",
                      "Annexin A1, CD123, BRAF, CD200, weak cyclin-D1, DBA.44, TRAP, T-bet, and TCL1 (+)",
                      "Propensity for diffuse BM involvement and splenic red pulp infiltration"
                    ]
                  },
                  {
                    "text": "BRAFV600E mutations in > ~ 90% of casesMAP2K1mutations in > 50% ofBRAF(-) cases",
                    "sub_points": [
                      "MAP2K1mutations in > 50% ofBRAF(-) cases"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Etiology": [
                  {
                    "text": "Derived from late-activated memory B-cell stage of maturation"
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "BRAFV600E mutation HCL defining among mature B-cell neoplasmsResults in constitutive activation of mitogen-activated protein kinase (MAPK)RareBRAF(-) cases haveMAP2K1mutationLinked toIGHV4-34usage",
                    "sub_points": [
                      "Results in constitutive activation of mitogen-activated protein kinase (MAPK)",
                      "RareBRAF(-) cases haveMAP2K1mutationLinked toIGHV4-34usage",
                      "Linked toIGHV4-34usage"
                    ]
                  },
                  {
                    "text": "> 85% of cases have undergone somatic mutations of IGHV genes"
                  },
                  {
                    "text": "Hairy cells express unique adhesion molecules and secrete many cytokines linked to distinctive featuresHairy projections and TRAP positivity linked to constitutive cell activationPropensity for splenic red pulp and hepatic sinusoidal infiltration linked to adhesion molecule surface membrane profileFibrosis in BM linked to fibronectin and TGF-β synthesisSuppression of normal hematopoietic cells linked to TGF-β and other cytokinesProlonged cell survival rates linked toConstitutive production of TNFConstitutive production of interleukin-6Overexpression of apoptosis inhibitor BCL2",
                    "sub_points": [
                      "Hairy projections and TRAP positivity linked to constitutive cell activation",
                      "Propensity for splenic red pulp and hepatic sinusoidal infiltration linked to adhesion molecule surface membrane profile",
                      "Fibrosis in BM linked to fibronectin and TGF-β synthesis",
                      "Suppression of normal hematopoietic cells linked to TGF-β and other cytokines",
                      "Prolonged cell survival rates linked toConstitutive production of TNFConstitutive production of interleukin-6Overexpression of apoptosis inhibitor BCL2",
                      "Constitutive production of TNF",
                      "Constitutive production of interleukin-6",
                      "Overexpression of apoptosis inhibitor BCL2"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Annual incidence: 0.3 cases/100,000"
                  },
                  {
                    "text": "Accounts for 2-3% of leukemias in adults in West"
                  }
                ],
                "Age": [
                  {
                    "text": "Median: 58 years"
                  },
                  {
                    "text": "Middle-aged to older adults (bimodal distribution proposed)"
                  },
                  {
                    "text": "Occasionally diagnosed in young adults (< 40 years), exceptional in children"
                  }
                ],
                "Sex": [
                  {
                    "text": "Male predominance (M:F = 4-5:1)"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "Substantially higher incidence in White vs. Black patients"
                  },
                  {
                    "text": "Higher incidence in males of Ashkenazi heritage"
                  }
                ],
                "Site": [
                  {
                    "text": "BM and spleen are primary sitesRarely, many other sites may be involvedLymph node, liver, bone, and skin",
                    "sub_points": [
                      "Rarely, many other sites may be involvedLymph node, liver, bone, and skin",
                      "Lymph node, liver, bone, and skin"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Incidental finding following routine CBC in 10% of cases"
                  },
                  {
                    "text": "Most patients present with signs/symptoms ofWeakness, fatigue due to anemiaConcurrent infection(s) due to neutropeniaLeft upper quadrant pain due to splenomegalyHemorrhagic phenomena (ecchymoses, purpura)",
                    "sub_points": [
                      "Weakness, fatigue due to anemia",
                      "Concurrent infection(s) due to neutropenia",
                      "Left upper quadrant pain due to splenomegaly",
                      "Hemorrhagic phenomena (ecchymoses, purpura)"
                    ]
                  },
                  {
                    "text": "Physical examination: Splenomegaly (60%), hepatomegaly (40-50%)Less frequent lymphadenopathy (20%)",
                    "sub_points": [
                      "Less frequent lymphadenopathy (20%)"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "CBC reveals anemia in most patients, leukopenia in 50%, and thrombocytopenia in 60% (pancytopenia common)Leukopenia due to significant neutropenia and profound monocytopeniaRare circulating hairy cells on careful inspection of blood smearHigh index of suspicion essential, especially important to search for hairy cells when monocytopenia present",
                    "sub_points": [
                      "Leukopenia due to significant neutropenia and profound monocytopenia",
                      "Rare circulating hairy cells on careful inspection of blood smearHigh index of suspicion essential, especially important to search for hairy cells when monocytopenia present",
                      "High index of suspicion essential, especially important to search for hairy cells when monocytopenia present"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "Indolent disease course"
                  },
                  {
                    "text": "Risk of secondary infections from neutropenia"
                  },
                  {
                    "text": "Increased incidence of 2nd malignancies, usually hematologicUnclear association with type of therapy",
                    "sub_points": [
                      "Unclear association with type of therapy"
                    ]
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "Splenectomy more commonly performed in past"
                  }
                ],
                "Drugs": [
                  {
                    "text": "Most active chemotherapeutic agents are purine nucleoside analogues: Cladribine usually with rituximabHigh response rate; complete response (CR) in > 50%Most patients who achieved CR did not need any additional therapy with up to 20 years of follow-up for some patientsAdditional therapy required in ~ 50% of patients",
                    "sub_points": [
                      "High response rate; complete response (CR) in > 50%Most patients who achieved CR did not need any additional therapy with up to 20 years of follow-up for some patients",
                      "Most patients who achieved CR did not need any additional therapy with up to 20 years of follow-up for some patients",
                      "Additional therapy required in ~ 50% of patients"
                    ]
                  },
                  {
                    "text": "Newer agents: BRAF inhibitors (vemurafenib), anti-CD25, anti-CD22 immunotoxinsCurrently used most often in patients who fail or relapse after frontline therapy",
                    "sub_points": [
                      "Currently used most often in patients who fail or relapse after frontline therapy"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "10-year median survival > 90%"
                  },
                  {
                    "text": "Secondary neoplasms occur in some patientsAdversely impacts outcome",
                    "sub_points": [
                      "Adversely impacts outcome"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "BloodCirculating hairy cells (95%), often very rareRecognition of distinct morphology essential, especially in cases with very low numbers of circulating cellsMust scan slide carefully for possible hairy cells, including feather edge and thicker areas of smearMonocytopenia (100%)Neutropenia (90%)Thrombocytopenia (80%)Anemia (80%)Pancytopenia (70%)",
                    "sub_points": [
                      "Circulating hairy cells (95%), often very rareRecognition of distinct morphology essential, especially in cases with very low numbers of circulating cellsMust scan slide carefully for possible hairy cells, including feather edge and thicker areas of smear",
                      "Recognition of distinct morphology essential, especially in cases with very low numbers of circulating cells",
                      "Must scan slide carefully for possible hairy cells, including feather edge and thicker areas of smear",
                      "Monocytopenia (100%)",
                      "Neutropenia (90%)",
                      "Thrombocytopenia (80%)",
                      "Anemia (80%)",
                      "Pancytopenia (70%)"
                    ]
                  },
                  {
                    "text": "BM aspirateTypically few hairy cells due to inaspirabilityMast cells often increasedMay see more obvious hairy cells on imprint preparations",
                    "sub_points": [
                      "Typically few hairy cells due to inaspirability",
                      "Mast cells often increased",
                      "May see more obvious hairy cells on imprint preparations"
                    ]
                  },
                  {
                    "text": "BM core biopsySubtle, patchy infiltrates of hairy cells may be very inconspicuous on H&EBland cells widely spaced due to abundant cytoplasmMay see fried egg appearance due to cytoplasmic retractionMinimal, if any, mitotic activity> 20% of cases of HCL show marked hypocellularity, and HCL can beeasilymissedIHC staining for CD20 essentialMisdiagnosis of aplastic anemia key issueSpindled, blastic, and pleomorphic variants described rarelyRare reports of large cell transformationRare cases of HCL are associated with osteosclerosisMay cause misdiagnosis of mastocytosis or other more typically osteosclerotic process",
                    "sub_points": [
                      "Subtle, patchy infiltrates of hairy cells may be very inconspicuous on H&E",
                      "Bland cells widely spaced due to abundant cytoplasm",
                      "May see fried egg appearance due to cytoplasmic retraction",
                      "Minimal, if any, mitotic activity",
                      "> 20% of cases of HCL show marked hypocellularity, and HCL can beeasilymissedIHC staining for CD20 essentialMisdiagnosis of aplastic anemia key issue",
                      "IHC staining for CD20 essential",
                      "Misdiagnosis of aplastic anemia key issue",
                      "Spindled, blastic, and pleomorphic variants described rarely",
                      "Rare reports of large cell transformation",
                      "Rare cases of HCL are associated with osteosclerosisMay cause misdiagnosis of mastocytosis or other more typically osteosclerotic process",
                      "May cause misdiagnosis of mastocytosis or other more typically osteosclerotic process"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Histochemistry": [
                  {
                    "text": "ReticulinReactivity: PositiveStaining pattern: Diffuse reticulin fibrosis associated with hairy cell infiltratesResponsible for inaspirability, dry tap",
                    "sub_points": [
                      "Reactivity: Positive",
                      "Staining pattern: Diffuse reticulin fibrosis associated with hairy cell infiltrates",
                      "Responsible for inaspirability, dry tap"
                    ]
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "Staining for CD20 can highlight inconspicuous infiltrates; key initial stain"
                  },
                  {
                    "text": "Panel of IHC stains provides high diagnostic sensitivity and specificity for HCLAnnexin A1, CD123, TRAP, T-bet, CD200, CD103, BRAF, and DBA.44 all usefulAnnexin A1 is highly sensitive and specific for HCL among B-cell neoplasms but also stains myeloid cells and T cellsNot useful for measurable residual disease (MRD) assessment due to staining of myeloid cellsCD200 expression very bright, which can be used to distinguish HCL from other positive B-cell neoplasmsT-bet nuclear stain useful in MRD detectionBRAF IHC stains availableInterference by type of fixative and decalcification agent is issue with robustness of this stainCostaining for PAX5/CD103 or PAX5/TRAP useful for MRD assessment",
                    "sub_points": [
                      "Annexin A1, CD123, TRAP, T-bet, CD200, CD103, BRAF, and DBA.44 all usefulAnnexin A1 is highly sensitive and specific for HCL among B-cell neoplasms but also stains myeloid cells and T cellsNot useful for measurable residual disease (MRD) assessment due to staining of myeloid cellsCD200 expression very bright, which can be used to distinguish HCL from other positive B-cell neoplasmsT-bet nuclear stain useful in MRD detectionBRAF IHC stains availableInterference by type of fixative and decalcification agent is issue with robustness of this stainCostaining for PAX5/CD103 or PAX5/TRAP useful for MRD assessment",
                      "Annexin A1 is highly sensitive and specific for HCL among B-cell neoplasms but also stains myeloid cells and T cellsNot useful for measurable residual disease (MRD) assessment due to staining of myeloid cells",
                      "Not useful for measurable residual disease (MRD) assessment due to staining of myeloid cells",
                      "CD200 expression very bright, which can be used to distinguish HCL from other positive B-cell neoplasms",
                      "T-bet nuclear stain useful in MRD detection",
                      "BRAF IHC stains availableInterference by type of fixative and decalcification agent is issue with robustness of this stain",
                      "Interference by type of fixative and decalcification agent is issue with robustness of this stain",
                      "Costaining for PAX5/CD103 or PAX5/TRAP useful for MRD assessment"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Immunophenotypic profile of HCL virtually diagnostic, even when HCL numbers very lowBright coexpression of slg, CD20, CD22, CD11c, CD103, CD200; moderate CD25 and CD123 expressionHigher side scatter than normal lymphocytes or other neoplastic B cellsCD10 expressed in small subset of HCL",
                    "sub_points": [
                      "Bright coexpression of slg, CD20, CD22, CD11c, CD103, CD200; moderate CD25 and CD123 expression",
                      "Higher side scatter than normal lymphocytes or other neoplastic B cells",
                      "CD10 expressed in small subset of HCL"
                    ]
                  }
                ],
                "PCR": [
                  {
                    "text": "Clonal B-cell neoplasm withIGHgene rearrangement"
                  },
                  {
                    "text": "Somatic mutations of IGHV genes in > 90% of cases"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "BRAFV600E mutation in > 85% of casesUseful in distinguishing HCL from leukemias that mimic HCL",
                    "sub_points": [
                      "Useful in distinguishing HCL from leukemias that mimic HCL"
                    ]
                  }
                ],
                "Electron Microscopy": [
                  {
                    "text": "Ribosome lamellar complexes unique in HCL"
                  },
                  {
                    "text": "Not currently utilized as routine diagnostic test as in past"
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "Homogeneous pattern of gene expression distinct from other B-cell leukemias/lymphomas"
                  },
                  {
                    "text": "In comparison with normal B-cell subpopulations, HCL cells are related to memory B cells"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Splenic Marginal Zone Lymphoma": [
                  {
                    "text": "WBC usually elevated with absolute lymphocytosis"
                  },
                  {
                    "text": "Spectrum of lymphocyte morphology, some with bipolar projections"
                  },
                  {
                    "text": "By flow cytometry, neoplastic cells typically lack CD103, CD25 (may be weak), CD123Exhibit brighter CD79b than HCL",
                    "sub_points": [
                      "Exhibit brighter CD79b than HCL"
                    ]
                  },
                  {
                    "text": "Discrete lymphoid infiltrates in BM; may contain germinal centers"
                  },
                  {
                    "text": "White pulp infiltration in spleenMay exhibit targetoid appearance of white pulp due to expanded marginal zone of follicles",
                    "sub_points": [
                      "May exhibit targetoid appearance of white pulp due to expanded marginal zone of follicles"
                    ]
                  },
                  {
                    "text": "By IHC, splenic marginal zone lymphoma (SMZL) usually negative for CD103, CD200, CD123, BRAF"
                  },
                  {
                    "text": "LackBRAFmutations"
                  }
                ],
                "Hairy Cell Leukemia Variant (Subtype of Splenic B-Cell Leukemia, Unclassifiable in International Consensus Classification 2022)": [
                  {
                    "text": "Elevated WBC with predominance of atypical lymphocytes"
                  },
                  {
                    "text": "Lymphocytes have abundant villous cytoplasm, and nuclei may contain prominent nucleoli"
                  },
                  {
                    "text": "Hybrid features between HCL and B-cell prolymphocytic leukemia (B-PLL)"
                  },
                  {
                    "text": "Immunophenotype somewhat variable but generally distinct from prototypic HCL [CD25, CD200, CD123 (-)]"
                  },
                  {
                    "text": "May be DBA.44(+)"
                  },
                  {
                    "text": "Intrasinusoidal infiltrates may predominate in BMSome cases may closely mimic HCL on core biopsy sections",
                    "sub_points": [
                      "Some cases may closely mimic HCL on core biopsy sections"
                    ]
                  },
                  {
                    "text": "LackBRAFmutations"
                  }
                ],
                "Other Neoplasms With Shaggy Cytoplasmic Contours": [
                  {
                    "text": "Plasma cell leukemia can rarely exhibit prominent cytoplasmic projections mimicking HCL"
                  },
                  {
                    "text": "Hairy projections can be artifact on blood smear"
                  }
                ],
                "B-Cell Neoplasms With Marked Splenomegaly": [
                  {
                    "text": "SMZL"
                  },
                  {
                    "text": "Leukemic, nonnodal mantle cell lymphoma"
                  },
                  {
                    "text": "HCL variant (HCLv)"
                  },
                  {
                    "text": "B-PLL (not recognized in WHO 5th edition)"
                  }
                ],
                "Hypocellular Bone Marrow Disorders With Cytopenias": [
                  {
                    "text": "Aplastic anemia"
                  },
                  {
                    "text": "T-cell large granular lymphocytic leukemia"
                  },
                  {
                    "text": "Hypocellular myelodysplasia"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Splenomegaly"
                  },
                  {
                    "text": "Recurrent infections"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Pancytopenia/monocytopenia in blood: Search for hairy cells"
                  },
                  {
                    "text": "Morphology: Distinctive hairy cells, may be rare in blood"
                  },
                  {
                    "text": "Best diagnostic cluesPancytopenia, monocytopenia, rare hairy cells (high index of suspicion)Inaspirable BMDiffuse, subtle, patchy infiltrates on core biopsy sectionsAbsence of discrete lymphoid aggregates",
                    "sub_points": [
                      "Pancytopenia, monocytopenia, rare hairy cells (high index of suspicion)",
                      "Inaspirable BM",
                      "Diffuse, subtle, patchy infiltrates on core biopsy sectionsAbsence of discrete lymphoid aggregates",
                      "Absence of discrete lymphoid aggregates"
                    ]
                  },
                  {
                    "text": "May see sinusoidal infiltrates in conjunction with diffuse infiltrates"
                  },
                  {
                    "text": "Multicolor flow cytometry profile highly specific even when low numbers of hairy cells in sample"
                  },
                  {
                    "text": "High utility of IHC and flow cytometry in establishing diagnosisInitial IHC staining for CD20If CD20(+) in HCL pattern, pursue more HCL-specific markers (annexin A1, CD123, BRAF, TRAP)",
                    "sub_points": [
                      "Initial IHC staining for CD20",
                      "If CD20(+) in HCL pattern, pursue more HCL-specific markers (annexin A1, CD123, BRAF, TRAP)"
                    ]
                  },
                  {
                    "text": "20% of cases hypocellular, mimicking aplastic anemia"
                  }
                ]
              },
              "REPORTING": {
                "Key Components in Report": [
                  {
                    "text": "Integration of CBC, morphology, and IHC or flow cytometry essential"
                  },
                  {
                    "text": "Provide information that confirms diagnosis"
                  },
                  {
                    "text": "Provide extent of BM effacement"
                  },
                  {
                    "text": "Provide IHC information of utility in monitoring response to therapy"
                  }
                ],
                "Misdiagnosis of Hairy Cell Leukemia": [
                  {
                    "text": "Subtle infiltrates may be easily overlooked"
                  },
                  {
                    "text": "CD10(+) cases can be misdiagnosed as follicular lymphomaSide scatter by flow cytometry and pattern of BM involvement may help distinguish",
                    "sub_points": [
                      "Side scatter by flow cytometry and pattern of BM involvement may help distinguish"
                    ]
                  },
                  {
                    "text": "Correlate with clinical findings and CBC"
                  },
                  {
                    "text": "Multiparameter flow cytometry highly sensitive and specific for HCL even when low numbers of HCL cells present"
                  },
                  {
                    "text": "Misdiagnosis of hypocellular HCL especially problematicCytopenias should resolve with therapyHCL highly responsive to therapy",
                    "sub_points": [
                      "Cytopenias should resolve with therapy",
                      "HCL highly responsive to therapy"
                    ]
                  },
                  {
                    "text": "In untreated patients due to undetected HCL, persistent cytopenias increase morbidity/mortalitySecondary infections major issue",
                    "sub_points": [
                      "Secondary infections major issue"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Diffuse Large B-Cell Lymphoma (DLBCL)": {
            "name": "Diffuse Large B-Cell Lymphoma (DLBCL)",
            "url": "https://app.pathprimer.com/document/e138416c-2e6d-4fa7-bf4c-8ba047b95b03/lesson/5fa09a8a-53fc-4bfc-9404-09d15374a7a2",
            "content": {
              "KEY FACTS": {
                "Clinical Issues": [
                  {
                    "text": "Older adults (median age 64 yr)"
                  },
                  {
                    "text": "Rapidly enlarging lymph nodes or extranodal mass"
                  },
                  {
                    "text": "Primary (de novo) more common than secondary (transformation from less aggressive lymphoma)"
                  },
                  {
                    "text": "Prognosis stratified by International Prognostic Index, immunohistochemistry-based classifications (e.g., Hans), and molecular genetics"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Diffuse effacement of lymph node architecture"
                  },
                  {
                    "text": "Large lymphoid cells with nuclear size greater than or equal to histiocyte nucleus (or 2x size of normal mature lymphocyte)"
                  },
                  {
                    "text": "Open and vesicular chromatin; variably sized nucleoli"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Immunohistochemistry: pan B-cell positive (CD19, CD20, CD22, PAX-5); rituximab can greatly reduce expression of CD20 and may affect immunohistochemical staining"
                  },
                  {
                    "text": "Classification systems using immunohistochemistry to distinguish GCB and non-GCB type (Hans classification most commonly used)GCB type: CD10+, Bcl-6+ or CD10-, Bcl-6+, MUM1-Non-GCB type: CD10-, Bcl-6- or CD10-, Bcl-6+, MUM1+",
                    "sub_points": [
                      "GCB type: CD10+, Bcl-6+ or CD10-, Bcl-6+, MUM1-",
                      "Non-GCB type: CD10-, Bcl-6- or CD10-, Bcl-6+, MUM1+"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "BL, plasma cell myeloma, BCL unclassifiable with features between DLBCL and Burkitt lymphoma, BCL unclassifiable with features between DLBCL and classical Hodgkin lymphoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Diffuse large B-cell lymphoma (DLBCL)"
                  },
                  {
                    "text": "Epstein-Barr virus (EBV)"
                  },
                  {
                    "text": "Not otherwise specified (NOS)"
                  },
                  {
                    "text": "Germinal center B cell-like (GCB)"
                  },
                  {
                    "text": "B-cell lymphoma (BCL)"
                  },
                  {
                    "text": "Activated B cell-like (ABC)"
                  },
                  {
                    "text": "Central nervous system (CNS)"
                  },
                  {
                    "text": "Primary mediastinal large B-cell lymphoma (PMBCL)"
                  },
                  {
                    "text": "Anaplastic lymphoma kinase (ALK)"
                  },
                  {
                    "text": "Human herpesvirus (HHV)"
                  },
                  {
                    "text": "Rituximab + cyclophosphamide, hydroxydaunomycin, Oncovin (vincristine) prednisone (R-CHOP)"
                  },
                  {
                    "text": "Lactate dehydrogenase (LDH)"
                  },
                  {
                    "text": "Major histocompatibility complex (MHC)"
                  },
                  {
                    "text": "Burkitt lymphoma (BL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Lymphosarcoma"
                  },
                  {
                    "text": "Large cell lymphoma"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Heterogeneous neoplasm composed of sheets of large B cells with nuclear size greater than or equal to macrophage nucleus (or 2x size of mature normal lymphocyte)"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Infectious Agents": [
                  {
                    "text": "Can be associated with EBV or underlying immunodeficiency"
                  }
                ],
                "Subtypes": [
                  {
                    "text": "DLBCL, NOSCommon morphologic variantsCentroblasticImmunoblasticAnaplasticImmunophenotypic subgroupsGerminal center typeNon-germinal center typeCD5+ DLBCLMolecular subgroupsGCB40%-50%ABC",
                    "sub_points": [
                      "Common morphologic variantsCentroblasticImmunoblasticAnaplastic",
                      "Centroblastic",
                      "Immunoblastic",
                      "Anaplastic",
                      "Immunophenotypic subgroupsGerminal center typeNon-germinal center typeCD5+ DLBCL",
                      "Germinal center type",
                      "Non-germinal center type",
                      "CD5+ DLBCL",
                      "Molecular subgroupsGCB40%-50%ABC",
                      "GCB40%-50%",
                      "40%-50%",
                      "ABC"
                    ]
                  },
                  {
                    "text": "DLBCL subtypesT-cell/histiocyte-rich large BCLPrimary DLBCL of CNSPrimary cutaneous DLBCL, leg typeEBV-positive DLBCL of the elderly",
                    "sub_points": [
                      "T-cell/histiocyte-rich large BCL",
                      "Primary DLBCL of CNS",
                      "Primary cutaneous DLBCL, leg type",
                      "EBV-positive DLBCL of the elderly"
                    ]
                  },
                  {
                    "text": "Other lymphomas of large B cellsPMBCLIntravascular large BCLDLBCL associated with chronic inflammationLymphomatoid granulomatosisALK-positive large BCLPlasmablastic lymphomaLarge BCL arising in HHV-8-associated multicentric Castleman diseasePrimary effusion lymphoma",
                    "sub_points": [
                      "PMBCL",
                      "Intravascular large BCL",
                      "DLBCL associated with chronic inflammation",
                      "Lymphomatoid granulomatosis",
                      "ALK-positive large BCL",
                      "Plasmablastic lymphoma",
                      "Large BCL arising in HHV-8-associated multicentric Castleman disease",
                      "Primary effusion lymphoma"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Accounts for 25%-30% of adult non-Hodgkin lymphomas in Western countries"
                  },
                  {
                    "text": "Older adults (median age 64 yr)"
                  }
                ],
                "Site": [
                  {
                    "text": "Usually nodal"
                  },
                  {
                    "text": "Extranodal involvement ≤ 40% (e.g., gastrointestinal tract, skin)Bone marrow in 11%-27% of patients",
                    "sub_points": [
                      "Bone marrow in 11%-27% of patients"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Rapidly enlarging lymph nodes or extranodal mass"
                  },
                  {
                    "text": "Frequent B symptomsFever, night sweats, weight loss",
                    "sub_points": [
                      "Fever, night sweats, weight loss"
                    ]
                  },
                  {
                    "text": "Early stages (I or II) in approximately 50% of cases"
                  },
                  {
                    "text": "Primary (de novo) more common than secondary (transformation from less aggressive lymphoma)"
                  }
                ],
                "Natural History": [
                  {
                    "text": "May progress from low-grade BCLE.g. CLL/SLL, follicular lymphoma, marginal zone lymphoma, and nodular lymphocyte predominant Hodgkin lymphoma",
                    "sub_points": [
                      "E.g. CLL/SLL, follicular lymphoma, marginal zone lymphoma, and nodular lymphocyte predominant Hodgkin lymphoma"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Primary treatmentR-CHOP",
                    "sub_points": [
                      "R-CHOP"
                    ]
                  },
                  {
                    "text": "Limited-stage disease and specific subtypesRadiation",
                    "sub_points": [
                      "Radiation"
                    ]
                  },
                  {
                    "text": "RelapseBortezomib",
                    "sub_points": [
                      "Bortezomib"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "High response and cure rates (> 60%-70%)"
                  },
                  {
                    "text": "Overall 5-year survival approximately 50%"
                  },
                  {
                    "text": "Prognosis stratified by International Prognostic IndexWorse prognosisAge > 60 yrHigh LDHPoor performance statusAdvanced stageExtranodal involvement ≥ 2 sites",
                    "sub_points": [
                      "Worse prognosisAge > 60 yrHigh LDHPoor performance statusAdvanced stageExtranodal involvement ≥ 2 sites",
                      "Age > 60 yr",
                      "High LDH",
                      "Poor performance status",
                      "Advanced stage",
                      "Extranodal involvement ≥ 2 sites"
                    ]
                  },
                  {
                    "text": "Rituximab improves progression-free and overall survival"
                  },
                  {
                    "text": "Immunophenotype with unfavorable prognosisHigh Ki-67> 80%Non-GCBCD10-, Bcl-6+/-, MUM1+",
                    "sub_points": [
                      "High Ki-67> 80%",
                      "> 80%",
                      "Non-GCBCD10-, Bcl-6+/-, MUM1+",
                      "CD10-, Bcl-6+/-, MUM1+"
                    ]
                  },
                  {
                    "text": "Gene expression with favorable prognosis﻿MHC﻿class IILymph node signatureExtracellular matrix and connective tissue growth factor",
                    "sub_points": [
                      "﻿MHC﻿class II",
                      "Lymph node signatureExtracellular matrix and connective tissue growth factor",
                      "Extracellular matrix and connective tissue growth factor"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "Slight male predominanceException is PMBCLFemale predominance",
                    "sub_points": [
                      "Exception is PMBCLFemale predominance",
                      "Female predominance"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Diffuse effacement of lymph node architecturePartial effacement (interfollicular > sinusoidal pattern) less common",
                    "sub_points": [
                      "Partial effacement (interfollicular > sinusoidal pattern) less common"
                    ]
                  },
                  {
                    "text": "Often infiltrative into perinodal tissue"
                  },
                  {
                    "text": "Centroblastic morphologic variantMost common, especially in pediatric casesMedium to large-sized lymphoid cellsOval to round nuclei with fine, vesicular chromatin2-4 nuclear membrane-bound nucleoliScanty amphophilic to basophilic cytoplasm",
                    "sub_points": [
                      "Most common, especially in pediatric cases",
                      "Medium to large-sized lymphoid cells",
                      "Oval to round nuclei with fine, vesicular chromatin",
                      "2-4 nuclear membrane-bound nucleoli",
                      "Scanty amphophilic to basophilic cytoplasm"
                    ]
                  },
                  {
                    "text": "Immunoblastic morphologic variant> 90% neoplastic cells are immunoblastsMedium to large-sized lymphoid cellsOval to round nuclei with a single, large, centrally located nucleolusBasophilic cytoplasmPlasmacytoid differentiation can be seen",
                    "sub_points": [
                      "> 90% neoplastic cells are immunoblasts",
                      "Medium to large-sized lymphoid cells",
                      "Oval to round nuclei with a single, large, centrally located nucleolus",
                      "Basophilic cytoplasm",
                      "Plasmacytoid differentiation can be seen"
                    ]
                  },
                  {
                    "text": "Anaplastic morphologic variant (rare)Large to very large oval or polygonal cells in sheetsBizarre pleomorphic multinucleated nucleiCan mimic Hodgkin lymphoma, anaplastic large cell lymphoma, carcinoma",
                    "sub_points": [
                      "Large to very large oval or polygonal cells in sheets",
                      "Bizarre pleomorphic multinucleated nuclei",
                      "Can mimic Hodgkin lymphoma, anaplastic large cell lymphoma, carcinoma"
                    ]
                  },
                  {
                    "text": "Rare morphologic variantsMyxoid/fibrillary stromaPseudorosettesSpindled or signet ring neoplastic cellsCytoplasmic granules, microvilli, intercellular junctions",
                    "sub_points": [
                      "Myxoid/fibrillary stroma",
                      "Pseudorosettes",
                      "Spindled or signet ring neoplastic cells",
                      "Cytoplasmic granules, microvilli, intercellular junctions"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Large lymphoid cells with nuclear size greater than or equal to histiocyte nucleus (or 2x size of normal mature lymphocyte)"
                  },
                  {
                    "text": "Open and vesicular chromatinVariably sized nucleoli",
                    "sub_points": [
                      "Variably sized nucleoli"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Pan B-cell positiveCD19, CD20, CD22, PAX-5Rituximab can greatly reduce expression of CD20 and may affect immunohistochemical staining",
                    "sub_points": [
                      "CD19, CD20, CD22, PAX-5",
                      "Rituximab can greatly reduce expression of CD20 and may affect immunohistochemical staining"
                    ]
                  },
                  {
                    "text": "Surface immunoglobulin in ≥ 50% casesIgM > IgG > IgA",
                    "sub_points": [
                      "IgM > IgG > IgA"
                    ]
                  },
                  {
                    "text": "CD30 positivity can be seen in anaplastic variant"
                  },
                  {
                    "text": "CD5 positive in approximately 10% of casesDe novo more common than transformation from low-grade BCL",
                    "sub_points": [
                      "De novo more common than transformation from low-grade BCL"
                    ]
                  },
                  {
                    "text": "Classification systems using immunohistochemistry to distinguish GCB and non-GCB typeHans, Visco-Young, Choi, Muris , Nyman, TallyHans classification (most common)ExpressionCD10 (30%-60% cases)Bcl-6 (60%-90% cases)MUM1 (35%-65% cases)GCB type (often with t(14;18))CD10+, Bcl-6+CD10-, Bcl-6+, MUM1-Non-GCB typeCD10-, Bcl-6-CD10-, Bcl-6+, MUM1+Positivity defined as > 30% cells with positive staining for a given marker",
                    "sub_points": [
                      "Hans, Visco-Young, Choi, Muris , Nyman, Tally",
                      "Hans classification (most common)ExpressionCD10 (30%-60% cases)Bcl-6 (60%-90% cases)MUM1 (35%-65% cases)GCB type (often with t(14;18))CD10+, Bcl-6+CD10-, Bcl-6+, MUM1-Non-GCB typeCD10-, Bcl-6-CD10-, Bcl-6+, MUM1+",
                      "ExpressionCD10 (30%-60% cases)Bcl-6 (60%-90% cases)MUM1 (35%-65% cases)",
                      "CD10 (30%-60% cases)",
                      "Bcl-6 (60%-90% cases)",
                      "MUM1 (35%-65% cases)",
                      "GCB type (often with t(14;18))CD10+, Bcl-6+CD10-, Bcl-6+, MUM1-",
                      "CD10+, Bcl-6+",
                      "CD10-, Bcl-6+, MUM1-",
                      "Non-GCB typeCD10-, Bcl-6-CD10-, Bcl-6+, MUM1+",
                      "CD10-, Bcl-6-",
                      "CD10-, Bcl-6+, MUM1+",
                      "Positivity defined as > 30% cells with positive staining for a given marker"
                    ]
                  },
                  {
                    "text": "c-MycImmunochemistry may not correlate withMYCtranslocation or disruptionsPositive immunophenotype may correlate with poorer prognosis",
                    "sub_points": [
                      "Immunochemistry may not correlate withMYCtranslocation or disruptions",
                      "Positive immunophenotype may correlate with poorer prognosis"
                    ]
                  },
                  {
                    "text": "Ki-67High expression (> 80%) may confer worse prognosis",
                    "sub_points": [
                      "High expression (> 80%) may confer worse prognosis"
                    ]
                  },
                  {
                    "text": "p5320%-60% of cases",
                    "sub_points": [
                      "20%-60% of cases"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Flow cytometry has role in cell size estimation and immunophenotypingDLBCL cells can be fragile and may be destroyed in processing",
                    "sub_points": [
                      "DLBCL cells can be fragile and may be destroyed in processing"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Molecular geneticsAberrant somatic hypermutation inBCL6and other genes implicated in oncogenesis (e.g.,MYC,PAX-5)",
                    "sub_points": [
                      "Aberrant somatic hypermutation inBCL6and other genes implicated in oncogenesis (e.g.,MYC,PAX-5)"
                    ]
                  },
                  {
                    "text": "Gene expression profilingDLBCL stratified into 3 groups for prognosticationGCB45%-50%Gains at 12q12ABCApproximately 35%Gains at 3q, 18q21-q22Losses at 6q21-q22Type 3Approximately 10%",
                    "sub_points": [
                      "DLBCL stratified into 3 groups for prognosticationGCB45%-50%Gains at 12q12ABCApproximately 35%Gains at 3q, 18q21-q22Losses at 6q21-q22Type 3Approximately 10%",
                      "GCB45%-50%Gains at 12q12",
                      "45%-50%",
                      "Gains at 12q12",
                      "ABCApproximately 35%Gains at 3q, 18q21-q22Losses at 6q21-q22",
                      "Approximately 35%",
                      "Gains at 3q, 18q21-q22",
                      "Losses at 6q21-q22",
                      "Type 3Approximately 10%",
                      "Approximately 10%"
                    ]
                  },
                  {
                    "text": "CytogeneticsUsed for detection of translocations or disruptionsTranslocation ofIGHat 14q32 withBCL2at 18q21 (20%-30%)Translocation ofIGHwithBCL6at 3q27 (30%) andMYCat 8q24\"Double-hit\" or \"triple-hit\"MYCtranslocation withBCL2±BCL6 ﻿translocations﻿",
                    "sub_points": [
                      "Used for detection of translocations or disruptionsTranslocation ofIGHat 14q32 withBCL2at 18q21 (20%-30%)Translocation ofIGHwithBCL6at 3q27 (30%) andMYCat 8q24",
                      "Translocation ofIGHat 14q32 withBCL2at 18q21 (20%-30%)",
                      "Translocation ofIGHwithBCL6at 3q27 (30%) andMYCat 8q24",
                      "\"Double-hit\" or \"triple-hit\"MYCtranslocation withBCL2±BCL6 ﻿translocations﻿",
                      "MYCtranslocation withBCL2±BCL6 ﻿translocations﻿"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Burkitt Lymphoma": [
                  {
                    "text": "Monotonous medium-sized cells with numerous mitoses and tingible-body macrophages“Starry sky” appearance",
                    "sub_points": [
                      "“Starry sky” appearance"
                    ]
                  },
                  {
                    "text": "Immunohistochemical stains show CD20+, CD10-, Bcl-6+, Bcl-2-"
                  },
                  {
                    "text": "Translocation ofMYCgene at 8q24"
                  },
                  {
                    "text": "Ki-67 > 95% of neoplastic cells and generally near 100%"
                  }
                ],
                "B-Cell Lymphoma Unclassifiable, With Features Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma": [
                  {
                    "text": "Aggressive lymphomas that have morphologic and genetic features of both DLBCL and BL"
                  },
                  {
                    "text": "Some cases with translocation ofMYC,BCL-2, orBCL-6"
                  }
                ],
                "B-Cell Lymphoma Unclassifiable, With Features Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma": [
                  {
                    "text": "Associated with PMBCL"
                  },
                  {
                    "text": "B-cell markers often aberrantly expressed with markers of classical Hodgkin lymphomaBOB.1/OCT.2 can help differentiate from DLBCL",
                    "sub_points": [
                      "BOB.1/OCT.2 can help differentiate from DLBCL"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Primary Mediastinal (Thymic) Large B-Cell Lymphoma": {
            "name": "Primary Mediastinal (Thymic) Large B-Cell Lymphoma",
            "url": "https://app.pathprimer.com/document/fbdd1199-094d-4074-b107-577a7067fb13/lesson/5fa09a8a-53fc-4bfc-9404-09d15374a7a2",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Diffuse large B-cell lymphoma (DLBCL) arising in mediastinum of putative thymic B-cell origin"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Most frequent from 20-35 years"
                  },
                  {
                    "text": "M:F ratio = 1:2"
                  },
                  {
                    "text": "Enlarging mass in anterior-superior mediastinum"
                  },
                  {
                    "text": "Frequent infiltration of mediastinal structures and organs"
                  },
                  {
                    "text": "Prognosis is similar to patients with other types of DLBCL60-70% chance of cure with appropriate therapy",
                    "sub_points": [
                      "60-70% chance of cure with appropriate therapy"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Diffuse to vaguely nodular growth pattern usually associated with variable degrees of sclerosis"
                  },
                  {
                    "text": "Interstitial sclerosis with compartmentalization of tumor cells"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "CD20(+), CD45/LCA(+), IRF-4/MUM1(+/-)"
                  },
                  {
                    "text": "CD30(+) ~ 75%, usually weak &/or focal"
                  },
                  {
                    "text": "CD10(-), CD15(-), Cyclin-E(-)"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Primary mediastinal (thymic) large B-cell lymphoma (PMLBCL)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Diffuse large B-cell lymphoma (DLBCL) arising in mediastinum of putative thymic B-cell origin"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "2% of all non-Hodgkin lymphomas"
                  }
                ],
                "Age": [
                  {
                    "text": "Most frequent from 20-35 years"
                  }
                ],
                "Sex": [
                  {
                    "text": "M:F ratio = 1:2"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Enlarging mass in anterior-superior mediastinum"
                  },
                  {
                    "text": "Often manifests as bulky disease defined as > 10 cm in diameter~ 75% of patients",
                    "sub_points": [
                      "~ 75% of patients"
                    ]
                  },
                  {
                    "text": "B symptoms in 20-30%"
                  },
                  {
                    "text": "PMLBCL patients have distinctive serum chemistry profileLow serum β2 microglobulin and high lactate dehydrogenase (LDH) levels",
                    "sub_points": [
                      "Low serum β2 microglobulin and high lactate dehydrogenase (LDH) levels"
                    ]
                  },
                  {
                    "text": "Locally aggressive with compression of contiguous organsSuperior vena cava syndrome occurs in up to 30% of patients",
                    "sub_points": [
                      "Superior vena cava syndrome occurs in up to 30% of patients"
                    ]
                  },
                  {
                    "text": "Frequent infiltration of local structures and organsLung parenchyma, chest wall, pleura, and pericardium",
                    "sub_points": [
                      "Lung parenchyma, chest wall, pleura, and pericardium"
                    ]
                  },
                  {
                    "text": "Extrathoracic disease at diagnosis is rare"
                  },
                  {
                    "text": "Bone marrow infiltration at presentation is also rare"
                  },
                  {
                    "text": "Extrathoracic sites are often involved at relapseCentral nervous system, liver, adrenals, ovaries, and kidneys",
                    "sub_points": [
                      "Central nervous system, liver, adrenals, ovaries, and kidneys"
                    ]
                  }
                ],
                "Treatment": [],
                "Drugs": [
                  {
                    "text": "Systemic chemotherapy is required; many regimens can be used"
                  },
                  {
                    "text": "If risk factors are present, central nervous system prophylaxis is recommendedHigh-dose methotrexate therapy",
                    "sub_points": [
                      "High-dose methotrexate therapy"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "60-70% chance of cure with appropriate therapyOutcome similar to that of patients with nodal DLBCL",
                    "sub_points": [
                      "Outcome similar to that of patients with nodal DLBCL"
                    ]
                  },
                  {
                    "text": "Recurrences are almost always seen in 1st 2 years of follow-up"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Diffuse to vaguely nodular growth pattern usually associated with variable degrees of sclerosis"
                  },
                  {
                    "text": "Interstitial sclerosis surrounds and compartmentalizes small groups of tumor cells"
                  },
                  {
                    "text": "Broad collagenous bands divide tumor into large nodules"
                  },
                  {
                    "text": "Intermediate to large lymphoid cellsPale cytoplasm, often result of retraction artifactHRS-like cells can be present",
                    "sub_points": [
                      "Pale cytoplasm, often result of retraction artifact",
                      "HRS-like cells can be present"
                    ]
                  },
                  {
                    "text": "Reactive infiltrate of small T lymphocytes and histiocytes± plasma cells and eosinophils",
                    "sub_points": [
                      "± plasma cells and eosinophils"
                    ]
                  },
                  {
                    "text": "Thymic components, such as Hassall corpuscles, may be identifiedIf present, supports thymic involvement and diagnosis of PMLBCL",
                    "sub_points": [
                      "If present, supports thymic involvement and diagnosis of PMLBCL"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Positive for common pan-B-cell markersCD19, CD20, CD22, CD79a",
                    "sub_points": [
                      "CD19, CD20, CD22, CD79a"
                    ]
                  },
                  {
                    "text": "Positive for B-cell transcription factorsBOB1, OCT2, PU.1, PAX-5",
                    "sub_points": [
                      "BOB1, OCT2, PU.1, PAX-5"
                    ]
                  },
                  {
                    "text": "CD45/LCA(+), p63(+) in ~ 95%"
                  },
                  {
                    "text": "CD30(+/-), in ~ 75% of casesExpression is usually weak &/or focal",
                    "sub_points": [
                      "Expression is usually weak &/or focal"
                    ]
                  },
                  {
                    "text": "IRF-4/MUM-1(+) in ~ 75%"
                  },
                  {
                    "text": "CD10(-), CD15(-)"
                  },
                  {
                    "text": "T-cell antigens(-)"
                  },
                  {
                    "text": "EBV LMP is usually negative"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "B-cell immunophenotype"
                  },
                  {
                    "text": "Discordance in B-cell receptor expression is common in PMLBCLSurface Ig(-) and CD79a(+)",
                    "sub_points": [
                      "Surface Ig(-) and CD79a(+)"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "High frequency ofBCL6gene mutations"
                  },
                  {
                    "text": "SOCS1mutations in subset of cases"
                  },
                  {
                    "text": "Comparative genomic hybridizationCommon regions of gainGains in 9p24 ~ 75% and 2p15 ~ 50%Gains in chromosome X and in 12q31Common regions of loss1p, 3p, 13q, 15q, and 17p",
                    "sub_points": [
                      "Common regions of gainGains in 9p24 ~ 75% and 2p15 ~ 50%Gains in chromosome X and in 12q31",
                      "Gains in 9p24 ~ 75% and 2p15 ~ 50%",
                      "Gains in chromosome X and in 12q31",
                      "Common regions of loss1p, 3p, 13q, 15q, and 17p",
                      "1p, 3p, 13q, 15q, and 17p"
                    ]
                  },
                  {
                    "text": "Well-characterized chromosomal translocations are rare/absent in PMLBCLCCND1,BCL2,BCL6, andMYC",
                    "sub_points": [
                      "CCND1,BCL2,BCL6, andMYC"
                    ]
                  }
                ],
                "Activation of NF-κB": [
                  {
                    "text": "Nuclear location of c-REL"
                  },
                  {
                    "text": "Cytoplasmic expression of TRAF1"
                  },
                  {
                    "text": "Combination of nuclear c-REL with expression of TRAF1 is highly specific for PMLBCL"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Nodular Sclerosis (NS) Classical Hodgkin Lymphoma (CHL)": [
                  {
                    "text": "Usually young patients"
                  },
                  {
                    "text": "Slight female predominance"
                  },
                  {
                    "text": "Mediastinal involvement in ~ 80%"
                  },
                  {
                    "text": "Histologic featuresNodular growth pattern with fibrosisDense collagenous bands surround nodulesCollagenous bands are polarizableVariable numbers of large Hodgkin/lacunar and Reed-Sternberg (HRS) cellsMany inflammatory cells presentEosinophils, neutrophils, plasma cells",
                    "sub_points": [
                      "Nodular growth pattern with fibrosisDense collagenous bands surround nodulesCollagenous bands are polarizable",
                      "Dense collagenous bands surround nodules",
                      "Collagenous bands are polarizable",
                      "Variable numbers of large Hodgkin/lacunar and Reed-Sternberg (HRS) cells",
                      "Many inflammatory cells presentEosinophils, neutrophils, plasma cells",
                      "Eosinophils, neutrophils, plasma cells"
                    ]
                  },
                  {
                    "text": "Immunophenotype of CHLCD30(+), CD15(+/-)PAX-5 (+) with characteristic weaker (dim) expression than reactive B cellsCD20(-/+), CD79a(-/+)Weakly &/or variably positive in 20% of casesOther B-cell transcription factors absent or dimly expressedCD45/LCA(-), EMA usually negativeSmall subset (~ 5%) of CHL can express T-cell antigens",
                    "sub_points": [
                      "CD30(+), CD15(+/-)",
                      "PAX-5 (+) with characteristic weaker (dim) expression than reactive B cells",
                      "CD20(-/+), CD79a(-/+)Weakly &/or variably positive in 20% of cases",
                      "Weakly &/or variably positive in 20% of cases",
                      "Other B-cell transcription factors absent or dimly expressed",
                      "CD45/LCA(-), EMA usually negative",
                      "Small subset (~ 5%) of CHL can express T-cell antigens"
                    ]
                  }
                ],
                "B-Cell Lymphoma With Features Intermediate Between DLBCL and CHL": [
                  {
                    "text": "Lymphoma with clinical, morphologic, &/or immunophenotypic features between DLBCL and CHL"
                  },
                  {
                    "text": "Usually young patients"
                  },
                  {
                    "text": "Male predominance"
                  },
                  {
                    "text": "Mediastinum is most commonly involvedSupraclavicular lymph nodes can be involved",
                    "sub_points": [
                      "Supraclavicular lymph nodes can be involved"
                    ]
                  },
                  {
                    "text": "Mixed immunophenotypeExpression of common markers of CHLCD30(+) all cases &/or CD15(+/-)pax-5(+) and IRF-4/MUM-1(+)Expression of markers usually absent in CHLCD45/LCA(+), CD20(+) uniform and strong, and C79a(+)OCT-2(+), BOB1(+)Cells with this \"mixed immunophenotype\" constitute predominant neoplastic cell population",
                    "sub_points": [
                      "Expression of common markers of CHLCD30(+) all cases &/or CD15(+/-)pax-5(+) and IRF-4/MUM-1(+)",
                      "CD30(+) all cases &/or CD15(+/-)",
                      "pax-5(+) and IRF-4/MUM-1(+)",
                      "Expression of markers usually absent in CHLCD45/LCA(+), CD20(+) uniform and strong, and C79a(+)OCT-2(+), BOB1(+)",
                      "CD45/LCA(+), CD20(+) uniform and strong, and C79a(+)",
                      "OCT-2(+), BOB1(+)",
                      "Cells with this \"mixed immunophenotype\" constitute predominant neoplastic cell population"
                    ]
                  }
                ],
                "Diffuse Large B-Cell Lymphoma": [
                  {
                    "text": "Older adults, but it also occurs in children and young adults"
                  },
                  {
                    "text": "Histologic featuresDiffuse growth patternLarge neoplastic cells (centroblasts &/or immunoblasts)Sclerosis is frequent in extranodal sites",
                    "sub_points": [
                      "Diffuse growth pattern",
                      "Large neoplastic cells (centroblasts &/or immunoblasts)",
                      "Sclerosis is frequent in extranodal sites"
                    ]
                  },
                  {
                    "text": "ImmunophenotypeCD19(+), CD20(+), CD22(+), CD79a(+)PAX-5(+), OCT2(+), BOB1(+)CD10(+) and Bcl-6(+) in variable proportion of casesCD30(-/+); if positive, often weak and focal except anaplastic variantMonotypic Ig(+)Cytoplasmic, in cases with plasmacytoid differentiationSurface; best shown by flow cytometry",
                    "sub_points": [
                      "CD19(+), CD20(+), CD22(+), CD79a(+)",
                      "PAX-5(+), OCT2(+), BOB1(+)",
                      "CD10(+) and Bcl-6(+) in variable proportion of cases",
                      "CD30(-/+); if positive, often weak and focal except anaplastic variant",
                      "Monotypic Ig(+)Cytoplasmic, in cases with plasmacytoid differentiationSurface; best shown by flow cytometry",
                      "Cytoplasmic, in cases with plasmacytoid differentiation",
                      "Surface; best shown by flow cytometry"
                    ]
                  }
                ],
                "T-Lymphoblastic Leukemia/Lymphoma": [
                  {
                    "text": "Adolescents and young adults"
                  },
                  {
                    "text": "Male predominance"
                  },
                  {
                    "text": "High leukocyte count and bone marrow involvement common"
                  },
                  {
                    "text": "Large mediastinal mass in ~ 75% of patients"
                  },
                  {
                    "text": "Histologic featuresDiffuse pattern of small to medium-sized lymphoblasts with fine (\"dusty\") nuclear chromatinSclerosis can be present compartmentalizing lymphoma cells in groupsThis feature can mimic PMLBCL",
                    "sub_points": [
                      "Diffuse pattern of small to medium-sized lymphoblasts with fine (\"dusty\") nuclear chromatin",
                      "Sclerosis can be present compartmentalizing lymphoma cells in groupsThis feature can mimic PMLBCL",
                      "This feature can mimic PMLBCL"
                    ]
                  },
                  {
                    "text": "ImmunophenotypeImmature T-cell lineage",
                    "sub_points": [
                      "Immature T-cell lineage"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Age: 20-35 years"
                  },
                  {
                    "text": "Gender: Female predominance"
                  },
                  {
                    "text": "Localization: Anterior mediastinum"
                  },
                  {
                    "text": "No systemic lymphadenopathy at presentation"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Morphology: Sclerosis"
                  },
                  {
                    "text": "Immunophenotype characteristicCD45/LCA(+), CD20(+)CD30(+) variable and weakIRF-4/MUM1(+/-), Bcl-2(+/-), Bcl-6(+/-)EBV(-), CD10(-), T-cell markers(-)",
                    "sub_points": [
                      "CD45/LCA(+), CD20(+)",
                      "CD30(+) variable and weak",
                      "IRF-4/MUM1(+/-), Bcl-2(+/-), Bcl-6(+/-)",
                      "EBV(-), CD10(-), T-cell markers(-)"
                    ]
                  }
                ],
                "Current Definition of PMLBCL Is Problematic": [
                  {
                    "text": "Criteria for diagnosis are in large part clinical in patients with DLBCLLocation of diseaseAge and sex of patient",
                    "sub_points": [
                      "Location of disease",
                      "Age and sex of patient"
                    ]
                  },
                  {
                    "text": "Cases of nodal DLBCL can involve mediastinal lymph nodesIn small biopsy specimens, PMLBCL and nodal DLBCL can be indistinguishable",
                    "sub_points": [
                      "In small biopsy specimens, PMLBCL and nodal DLBCL can be indistinguishable"
                    ]
                  },
                  {
                    "text": "In effect, this makes the category of PMLBCL somewhat impure~ 25% of all cases classified as PMLBCL may instead be nodal DLBCL",
                    "sub_points": [
                      "~ 25% of all cases classified as PMLBCL may instead be nodal DLBCL"
                    ]
                  },
                  {
                    "text": "Immunophenotypic or molecular makers that specifically recognize PMLBCL and can be assessed routinely in clinical laboratories are needed"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Intravascular Large B-Cell Lymphoma": {
            "name": "Intravascular Large B-Cell Lymphoma",
            "url": "https://app.pathprimer.com/document/1c989a05-5b0e-47d0-8862-3a589cadedb7/lesson/5fa09a8a-53fc-4bfc-9404-09d15374a7a2",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Rare large B-cell lymphoma characterized by selective intravascular growth"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Absence of marked lymphadenopathy"
                  },
                  {
                    "text": "Middle-aged or elderly patients"
                  },
                  {
                    "text": "Predominant neurologic and dermatologic manifestations (Western countries)"
                  },
                  {
                    "text": "Patients from Asia (mainly Japan) preferentially show hemophagocytic syndrome (Asian variant)"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "IVLBCL cells are large, with vesicular nuclear chromatin, distinct nucleoli, and frequent mitoses"
                  },
                  {
                    "text": "Lymphoma cells are mainly located in lumina of small vessels"
                  },
                  {
                    "text": "Sinusoidal involvement of liver, spleen, and bone marrow"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Pan-B-cell markers(+), Bcl-2(+), MUM1(+)"
                  },
                  {
                    "text": "CD5([+] 30%); other T-cell markers(-)"
                  },
                  {
                    "text": "Ki-67 high"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Intravascular large B-cell lymphoma (IVLBCL)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Large B-cell lymphoma characterized by selective intravascular growth"
                  },
                  {
                    "text": "Preferential intravascular growth is aconditio sine qua nonfor diagnosing IVLBCLConcomitant and minimal extravascular location of neoplastic cells, usually surrounding involved vessels, can be seen",
                    "sub_points": [
                      "Concomitant and minimal extravascular location of neoplastic cells, usually surrounding involved vessels, can be seen"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Site": [
                  {
                    "text": "Selective tumor growth within lumina of small blood vessels, particularly capillaries"
                  },
                  {
                    "text": "Widely disseminated"
                  },
                  {
                    "text": "Any organ can be involved"
                  },
                  {
                    "text": "Absence of marked lymphadenopathy"
                  },
                  {
                    "text": "Mechanisms responsible for selective growth of neoplastic cells within blood vessel lumina are unknown"
                  },
                  {
                    "text": "Possible explanations includeChemokine-chemokine receptor interactionse.g., CXCL9 (expressed in endothelium) and CXCR3 (expressed in IVLBCL)Decreased expression of adhesion molecules on surface of IVLBCL cellse.g., CD29 and CD54",
                    "sub_points": [
                      "Chemokine-chemokine receptor interactionse.g., CXCL9 (expressed in endothelium) and CXCR3 (expressed in IVLBCL)",
                      "e.g., CXCL9 (expressed in endothelium) and CXCR3 (expressed in IVLBCL)",
                      "Decreased expression of adhesion molecules on surface of IVLBCL cellse.g., CD29 and CD54",
                      "e.g., CD29 and CD54"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Middle-aged or elderly patients; median: 67 years"
                  },
                  {
                    "text": "M:F ratio = 1.3:1"
                  },
                  {
                    "text": "IVLBCL can involve any organ with heterogeneous, often nonspecific symptomsFever of unknown originGeneral fatigueDeterioration in performance status",
                    "sub_points": [
                      "Fever of unknown origin",
                      "General fatigue",
                      "Deterioration in performance status"
                    ]
                  },
                  {
                    "text": "Diagnosis can be clinically difficult and some cases are diagnosed postmortem"
                  },
                  {
                    "text": "2 major patterns of clinical presentationWestern IVLBCLPredominant neurologic and dermatologic manifestationsCentral nervous system is involved in most patientsAsian IVLBCLHemophagocytic syndromeFever and B symptomsPancytopenia and bone marrow infiltrationSkin and central nervous system involvement are uncommon",
                    "sub_points": [
                      "Western IVLBCLPredominant neurologic and dermatologic manifestationsCentral nervous system is involved in most patients",
                      "Predominant neurologic and dermatologic manifestations",
                      "Central nervous system is involved in most patients",
                      "Asian IVLBCLHemophagocytic syndromeFever and B symptomsPancytopenia and bone marrow infiltrationSkin and central nervous system involvement are uncommon",
                      "Hemophagocytic syndrome",
                      "Fever and B symptoms",
                      "Pancytopenia and bone marrow infiltration",
                      "Skin and central nervous system involvement are uncommon"
                    ]
                  },
                  {
                    "text": "Skin lesionsHeterogeneous clinical presentation: Plaques, telangiectatic patches, cellulitis, ulcerated nodulesSkin involvement is sometimes detected by random skin biopsy of grossly unremarkable skinCutaneous variantMost frequent in femalesYounger than other IVLBCL patientsBetter prognosis",
                    "sub_points": [
                      "Heterogeneous clinical presentation: Plaques, telangiectatic patches, cellulitis, ulcerated nodules",
                      "Skin involvement is sometimes detected by random skin biopsy of grossly unremarkable skin",
                      "Cutaneous variantMost frequent in femalesYounger than other IVLBCL patientsBetter prognosis",
                      "Most frequent in females",
                      "Younger than other IVLBCL patients",
                      "Better prognosis"
                    ]
                  },
                  {
                    "text": "KidneyIncreased creatinineProteinuriaRenal insufficiency",
                    "sub_points": [
                      "Increased creatinine",
                      "Proteinuria",
                      "Renal insufficiency"
                    ]
                  },
                  {
                    "text": "LiverHepatomegalyIncreased bilirubin and liver enzymes",
                    "sub_points": [
                      "Hepatomegaly",
                      "Increased bilirubin and liver enzymes"
                    ]
                  },
                  {
                    "text": "Central nervous systemAlteration of consciousnessMotor and sensory deficitsSeizureDementia",
                    "sub_points": [
                      "Alteration of consciousness",
                      "Motor and sensory deficits",
                      "Seizure",
                      "Dementia"
                    ]
                  },
                  {
                    "text": "LungsDyspnea and hypoxia",
                    "sub_points": [
                      "Dyspnea and hypoxia"
                    ]
                  },
                  {
                    "text": "Hematopoietic systemSplenomegalyHemophagocytosisAnemia, thrombocytopenia, and leukopenia",
                    "sub_points": [
                      "Splenomegaly",
                      "Hemophagocytosis",
                      "Anemia, thrombocytopenia, and leukopenia"
                    ]
                  },
                  {
                    "text": "OtherIncreased LDHAscitesEndocrine dysfunction (hypopituitarism)Multiorgan failure",
                    "sub_points": [
                      "Increased LDH",
                      "Ascites",
                      "Endocrine dysfunction (hypopituitarism)",
                      "Multiorgan failure"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Rituximab-containing chemotherapy plus central nervous system-oriented therapyR-CHOP plus high-dose methotrexate",
                    "sub_points": [
                      "R-CHOP plus high-dose methotrexate"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Aggressive behavior and often fatal course"
                  },
                  {
                    "text": "Predictive factors that are useful for risk-stratification are not established"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Lymphoma cells are mainly located in lumina of small vessels"
                  },
                  {
                    "text": "Minimal extravascular location of tumor cells can be seenUsually surrounding involved vesselsExtravascular masses can be detected at autopsy in some patients",
                    "sub_points": [
                      "Usually surrounding involved vessels",
                      "Extravascular masses can be detected at autopsy in some patients"
                    ]
                  },
                  {
                    "text": "Sinusoidal involvement of liver, spleen, and bone marrow"
                  },
                  {
                    "text": "Spleen: Red pulp involvement"
                  },
                  {
                    "text": "Kidney: Neoplastic cells within glomerular capillaries and peritubular capillaries"
                  },
                  {
                    "text": "Brain: Neoplastic cells within small vessels"
                  },
                  {
                    "text": "Circulating lymphoma cells can be occasionally seen in peripheral blood"
                  },
                  {
                    "text": "Fibrin thrombi, hemorrhage, and necrosis"
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Usually tumor cells are large, with vesicular nuclear chromatin with distinct nucleoli"
                  },
                  {
                    "text": "In some cases, tumor cells have coarse nuclear chromatin and irregular or indented nuclei"
                  },
                  {
                    "text": "Mitoses are frequent"
                  },
                  {
                    "text": "IVLBCL cell size may be smaller than usual in some cases"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Pan-B-cell markers(+)CD19, CD20, CD22, CD79a, and pax-5",
                    "sub_points": [
                      "CD19, CD20, CD22, CD79a, and pax-5"
                    ]
                  },
                  {
                    "text": "CD5([+] 30%), CD10([+] 10%), Bcl-6([+] 25%)"
                  },
                  {
                    "text": "Bcl-2([+] 90%), MUM1([+] 95%)"
                  },
                  {
                    "text": "Ki-67 reveals high proliferative activity"
                  },
                  {
                    "text": "CD2(-), CD3(-)"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Monoclonal rearrangements of theIgHgene can be detected by PCR"
                  },
                  {
                    "text": "TCRgenes in germline configuration"
                  },
                  {
                    "text": "Pathognomonic cytogenetic abnormalities have not been reported"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Peripheral T- or NK-cell Lymphomas with Intravascular Pattern": [
                  {
                    "text": "Rare cases of T-cell lymphoma or NK-cell lymphoma can be intravascular"
                  },
                  {
                    "text": "Positive for T-cell or NK markers"
                  },
                  {
                    "text": "These rare lymphomas do not exist as diagnostic categories in 2008 WHO classification"
                  }
                ],
                "Hepatosplenic T-cell Lymphoma": [
                  {
                    "text": "Some reported cases of intravascular T-cell lymphomas are probablyγ-δ T-cell lymphoma or hepatosplenic T-cell lymphoma",
                    "sub_points": [
                      "γ-δ T-cell lymphoma or hepatosplenic T-cell lymphoma"
                    ]
                  },
                  {
                    "text": "Splenomegaly and hepatomegaly"
                  },
                  {
                    "text": "T-cell markers: CD2(+), CD3(+), and cytotoxic markers TIA(+), GZM-B(+)"
                  },
                  {
                    "text": "B-cell markers(-)"
                  },
                  {
                    "text": "Isochromosome 7q is consistent abnormality"
                  }
                ],
                "T-cell Large Granular Lymphocytic Leukemia (T-LGL)": [
                  {
                    "text": "Indolent clinical course with long survival"
                  },
                  {
                    "text": "Commonly associated with infections"
                  },
                  {
                    "text": "Peripheral blood: Increased large granular lymphocytes"
                  },
                  {
                    "text": "Bone marrow, usually interstitial pattern, but sinusoidal pattern can be seen"
                  },
                  {
                    "text": "CD8(+), GZM-B(+), perforin(+), CD16(+), CD57(+), CD5([+]dim)"
                  }
                ],
                "Aggressive NK-cell Leukemia/Lymphoma": [
                  {
                    "text": "Leukemic cells can have cytoplasmic azurophilic granules"
                  },
                  {
                    "text": "NK-cell markers(+), GZM-B(+), perforin(+), EBV(+/-)"
                  },
                  {
                    "text": "Surface CD3(-), CD5(-)"
                  },
                  {
                    "text": "NoTCRgene rearrangements"
                  }
                ],
                "Splenic B-cell Marginal Zone Lymphoma": [
                  {
                    "text": "Spleen: Infiltration of white and red pulp"
                  },
                  {
                    "text": "Small neoplastic cells with abundant pale cytoplasm"
                  },
                  {
                    "text": "Patients often present with cytopeniasVillous lymphocytes in peripheral blood smear",
                    "sub_points": [
                      "Villous lymphocytes in peripheral blood smear"
                    ]
                  },
                  {
                    "text": "Pan-B-cell markers(+), CD3(-), CD10(-)"
                  },
                  {
                    "text": "Allelic loss of chromosome 7q22-36 (40%)"
                  }
                ],
                "Diffuse Large B-cell Lymphoma (DLBCL)": [
                  {
                    "text": "Tumor cells are cytologically (and can be immunophenotypically) identicalIVLBCL does not present with lymphadenopathy or mass, unlike DLBCL",
                    "sub_points": [
                      "IVLBCL does not present with lymphadenopathy or mass, unlike DLBCL"
                    ]
                  },
                  {
                    "text": "Cases of nodal DLBCL can relapse with the appearance of IVLBCL"
                  },
                  {
                    "text": "Rare cases of IVLBCL may have derived from low-grade B-cell lymphomasIdenticalIgHgene rearrangements in low-grade and IVLBCL (in some cases)",
                    "sub_points": [
                      "IdenticalIgHgene rearrangements in low-grade and IVLBCL (in some cases)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Plasmablastic Lymphoma": {
            "name": "Plasmablastic Lymphoma",
            "url": "https://app.pathprimer.com/document/5e833d97-048b-44e7-a535-5930f2b3afc0/lesson/5fa09a8a-53fc-4bfc-9404-09d15374a7a2",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Diffuse neoplasm with immunoblastic or plasmablastic features"
                  },
                  {
                    "text": "Immunophenotype overlaps with neoplastic plasma cells"
                  },
                  {
                    "text": "Aggressive clinical course"
                  },
                  {
                    "text": "Poor prognosis"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Associated with immunodeficiencyHIV infection most common",
                    "sub_points": [
                      "HIV infection most common"
                    ]
                  },
                  {
                    "text": "Subset occurs in immunocompetent"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Predominantly extranodal diseaseNodal disease in < 10% of patients",
                    "sub_points": [
                      "Nodal disease in < 10% of patients"
                    ]
                  },
                  {
                    "text": "Frequently originates in mucosa of oral cavity"
                  },
                  {
                    "text": "Nonoral cases also occur"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Large neoplastic cells with variable degree of immunoblastic or plasmablastic featuresImmunoblastic morphology in oral cavity of HIV(+) patients",
                    "sub_points": [
                      "Immunoblastic morphology in oral cavity of HIV(+) patients"
                    ]
                  },
                  {
                    "text": "\"Starry sky\" pattern frequent"
                  },
                  {
                    "text": "High mitotic and apoptotic rates"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Pan-B-cell antigens: Weak or absent"
                  },
                  {
                    "text": "Plasma cell markers(+)"
                  },
                  {
                    "text": "EBER(+), HHV8(-)"
                  },
                  {
                    "text": "High proliferation index (Ki-67), Myc(+)"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Diffuse large B-cell lymphoma, immunoblastic variant"
                  },
                  {
                    "text": "Plasmablastic plasma cell myeloma"
                  },
                  {
                    "text": "HHV8-associated multicentric Castleman disease"
                  },
                  {
                    "text": "ALK(+) large B-cell lymphoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Plasmablastic lymphoma (PBL)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "PBL was initially described as rare variant of diffuse large B-cell lymphoma (DLBCL) involving oral cavity15 of 16 patients were immunodeficient as result of human immunodeficiency virus (HIV) infection",
                    "sub_points": [
                      "15 of 16 patients were immunodeficient as result of human immunodeficiency virus (HIV) infection"
                    ]
                  },
                  {
                    "text": "PBL is currently defined as diffuse proliferation of large neoplastic cellsImmunoblastic or plasmablastic cytologic featuresPlasma cell immunophenotype: CD38(+), CD138(+), CD20(-)",
                    "sub_points": [
                      "Immunoblastic or plasmablastic cytologic features",
                      "Plasma cell immunophenotype: CD38(+), CD138(+), CD20(-)"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Infectious Agents": [
                  {
                    "text": "Epstein-Barr virus (EBV) positive"
                  },
                  {
                    "text": "Strongly associated with HIV infection"
                  },
                  {
                    "text": "Has been reported in patients with immunodeficiency due to other causesPost-transplantation, autoimmune disease, elderly",
                    "sub_points": [
                      "Post-transplantation, autoimmune disease, elderly"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "UnknownFrequency: PBL represents < 1% of all non-Hodgkin lymphomas",
                    "sub_points": [
                      "Frequency: PBL represents < 1% of all non-Hodgkin lymphomas"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Depends on clinical settingHIV(+) patients: Median age = 40 yearsHIV(-) patients: Children or elderly",
                    "sub_points": [
                      "HIV(+) patients: Median age = 40 years",
                      "HIV(-) patients: Children or elderly"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "Male predominance: 7:1Related to HIV(+) population affected",
                    "sub_points": [
                      "Related to HIV(+) population affected"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "PBL most often originates in mucosal extranodal sites2 general groups: Oral and nonoral sitesRapidly growing and often painful mass",
                    "sub_points": [
                      "2 general groups: Oral and nonoral sites",
                      "Rapidly growing and often painful mass"
                    ]
                  },
                  {
                    "text": "Oral cavity is most common site90% of patients are HIV(+)Patients have very low CD4(+) countsMean duration of HIV(+) prior to PBL: 5 years60% have localized disease (stage I) at diagnosisPBL frequently arises near mucosaOften involves gingivaFrequently infiltrates adjacent bone",
                    "sub_points": [
                      "90% of patients are HIV(+)Patients have very low CD4(+) counts",
                      "Patients have very low CD4(+) counts",
                      "Mean duration of HIV(+) prior to PBL: 5 years",
                      "60% have localized disease (stage I) at diagnosis",
                      "PBL frequently arises near mucosaOften involves gingivaFrequently infiltrates adjacent bone",
                      "Often involves gingiva",
                      "Frequently infiltrates adjacent bone"
                    ]
                  },
                  {
                    "text": "Non-oral type PBLLess frequently HIV(+)60% are disseminated disease (stage IV) at diagnosisMost common nonoral sitesMaxillary sinus, nasopharynx, gastrointestinal tractLess common nonoral sitesOrbit, skin, lung, gastrointestinal tract, soft tissuesRare sites of PBL (case reports)Mediastinum, vulva, bone marrow",
                    "sub_points": [
                      "Less frequently HIV(+)",
                      "60% are disseminated disease (stage IV) at diagnosis",
                      "Most common nonoral sitesMaxillary sinus, nasopharynx, gastrointestinal tract",
                      "Maxillary sinus, nasopharynx, gastrointestinal tract",
                      "Less common nonoral sitesOrbit, skin, lung, gastrointestinal tract, soft tissues",
                      "Orbit, skin, lung, gastrointestinal tract, soft tissues",
                      "Rare sites of PBL (case reports)Mediastinum, vulva, bone marrow",
                      "Mediastinum, vulva, bone marrow"
                    ]
                  },
                  {
                    "text": "PBL uncommonly (7%) involves lymph nodes"
                  },
                  {
                    "text": "PBL can widely disseminate during course of disease"
                  },
                  {
                    "text": "International prognostic Index (IPI): Usually intermediate or high score"
                  },
                  {
                    "text": "Some cases are reported in patients with history of myeloma or lymphomaBetter considered as plasmablastic transformation of underlying neoplasm",
                    "sub_points": [
                      "Better considered as plasmablastic transformation of underlying neoplasm"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)Some regimens have included rituximab &/or radiotherapy",
                    "sub_points": [
                      "Some regimens have included rituximab &/or radiotherapy"
                    ]
                  },
                  {
                    "text": "More aggressive chemotherapy regimens have been employed without benefit"
                  },
                  {
                    "text": "Addition of antiretroviral therapy (HAART) improves prognosis"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Poor prognosis in all subgroups: HIV(+), HIV(-) and immunocompetent"
                  },
                  {
                    "text": "Most patients die within first year after diagnosis"
                  },
                  {
                    "text": "In large review, prognosis did not correlate withAge, sex, CD4(+) count, HIV loadStage, anatomic site of PBL, EBV statusUse of CHOP chemotherapy",
                    "sub_points": [
                      "Age, sex, CD4(+) count, HIV load",
                      "Stage, anatomic site of PBL, EBV status",
                      "Use of CHOP chemotherapy"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Radiographic Findings": [
                  {
                    "text": "PBL is PET scan positive"
                  },
                  {
                    "text": "PET or CT scan can show widespread bone involvement"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Diffuse growth pattern"
                  },
                  {
                    "text": "Frequent \"starry sky\" pattern with tingible body macrophages"
                  },
                  {
                    "text": "Apoptotic bodies and mitoses are usually numerous"
                  },
                  {
                    "text": "Confluent areas of necrosis are common"
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Monotonous proliferation of large neoplastic cells in histologic sectionsMore cytologic variability in smear/imprint preparations",
                    "sub_points": [
                      "More cytologic variability in smear/imprint preparations"
                    ]
                  },
                  {
                    "text": "PBL cases can exhibit cytologic spectrumImmunoblasticCells have prominent central nucleoliMore common in oral cavity and HIV(+) patientsPlasmablasticCells have more abundant cytoplasm and eccentrically located nucleiMore common in nonoral sites in HIV(-) patients",
                    "sub_points": [
                      "ImmunoblasticCells have prominent central nucleoliMore common in oral cavity and HIV(+) patients",
                      "Cells have prominent central nucleoli",
                      "More common in oral cavity and HIV(+) patients",
                      "PlasmablasticCells have more abundant cytoplasm and eccentrically located nucleiMore common in nonoral sites in HIV(-) patients",
                      "Cells have more abundant cytoplasm and eccentrically located nuclei",
                      "More common in nonoral sites in HIV(-) patients"
                    ]
                  },
                  {
                    "text": "Binucleation or multinucleation is common in PBL"
                  },
                  {
                    "text": "Cytoplasm of PBL cells is usually deeply basophilicDutcher and Russell bodies are usually absent in PBL",
                    "sub_points": [
                      "Dutcher and Russell bodies are usually absent in PBL"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Immunophenotype is essential to establish diagnosis of PBL"
                  },
                  {
                    "text": "Common pan-B-cell markers commonly absentCD20, CD22, and pax-5Weak expression reported in small subset of casesCD79a is more often positive; also often weak intensity",
                    "sub_points": [
                      "CD20, CD22, and pax-5",
                      "Weak expression reported in small subset of cases",
                      "CD79a is more often positive; also often weak intensity"
                    ]
                  },
                  {
                    "text": "Strong positivity for plasma cell-associated markersIRF-4/MUM1(+), CD38(+), CD138/syndecan-1(+), VS38/p63(+)PRMD1/BLIMP1(+), XBP1(+)",
                    "sub_points": [
                      "IRF-4/MUM1(+), CD38(+), CD138/syndecan-1(+), VS38/p63(+)",
                      "PRMD1/BLIMP1(+), XBP1(+)"
                    ]
                  },
                  {
                    "text": "Ki-67 is high: > 70% in most cases"
                  },
                  {
                    "text": "Monotypic cytoplasmic light chain positive in 50-70% of cases"
                  },
                  {
                    "text": "Myc expression is common"
                  },
                  {
                    "text": "EMA is often positive; CD30(+) in subset"
                  },
                  {
                    "text": "Aberrant expression of T-cell markers in some casesCD3, CD4, CD7, CD43",
                    "sub_points": [
                      "CD3, CD4, CD7, CD43"
                    ]
                  },
                  {
                    "text": "Germinal center B-cell antigens positive in subset of PBLBcl-6 uncommon; CD10 (+ in ~ 40%)",
                    "sub_points": [
                      "Bcl-6 uncommon; CD10 (+ in ~ 40%)"
                    ]
                  },
                  {
                    "text": "CD56 can be positive in cases with plasmablastic cytologic featuresCD56 is commonly expressed in plasma cell myeloma",
                    "sub_points": [
                      "CD56 is commonly expressed in plasma cell myeloma"
                    ]
                  },
                  {
                    "text": "Bcl-2 is usually negative"
                  },
                  {
                    "text": "CD45/LCA is negative or weakly positive in subset of cases"
                  },
                  {
                    "text": "ALK1(-), CD117(-), Cyclin-D1(-)"
                  },
                  {
                    "text": "HHV8(-)"
                  },
                  {
                    "text": "EBV-LMP 1 and 2 are not expressedConsistent with restricted latencyIn contrast to AIDS-related immunoblastic lymphomas that usually express EBV-LMP 1",
                    "sub_points": [
                      "Consistent with restricted latency",
                      "In contrast to AIDS-related immunoblastic lymphomas that usually express EBV-LMP 1"
                    ]
                  },
                  {
                    "text": "No significant differences in frequency of expression of any immunohistochemical marker between PBL and plasmablastic myeloma"
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "EBV small encoded RNA (EBER) is positive in ~ 75% of casesEBER useful for distinguishing PBL from plasmablastic plasma cell myeloma (EBER[-])",
                    "sub_points": [
                      "EBER useful for distinguishing PBL from plasmablastic plasma cell myeloma (EBER[-])"
                    ]
                  }
                ],
                "PCR": [
                  {
                    "text": "MonoclonalIgHgene rearrangements"
                  },
                  {
                    "text": "﻿T-cell receptor﻿genes usually in germline configurationSingle case reports showing bothIgHandTCRgene rearrangements",
                    "sub_points": [
                      "Single case reports showing bothIgHandTCRgene rearrangements"
                    ]
                  },
                  {
                    "text": "IgHgenes commonly show somatic mutations ofIgHvariable regions"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "t(8;14)(q24;q32) orMYC-IgHfusion identified in subset of PBLHIV(+) patients",
                    "sub_points": [
                      "HIV(+) patients"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified (DLBCL, NOS)": [
                  {
                    "text": "DLBCL often has centroblastic cytologic featuresPlasmacytoid differentiation is uncommon",
                    "sub_points": [
                      "Plasmacytoid differentiation is uncommon"
                    ]
                  },
                  {
                    "text": "Immunophenotype of DLBCL is distinct from PBLCD19(+), CD20(+), CD22(+), pax-5(+)CD45/LCA is usually positiveLarge subset is strongly positive for CD10 &/or Bcl-6",
                    "sub_points": [
                      "CD19(+), CD20(+), CD22(+), pax-5(+)",
                      "CD45/LCA is usually positive",
                      "Large subset is strongly positive for CD10 &/or Bcl-6"
                    ]
                  }
                ],
                "Diffuse Large B-Cell Lymphoma, Immunoblastic Variant (DLBCL-IB)": [
                  {
                    "text": "Morphologic overlap between DLBCL-IB and PBLImmunophenotype is needed to make this distinctionDLBCL-IB is usually CD20(+) &/or pax-5(+)CD45/LCA often positiveCD10(+/-), Bcl-6(+/-)CD4(+) is extremely rare in DLBCL-IB",
                    "sub_points": [
                      "Immunophenotype is needed to make this distinction",
                      "DLBCL-IB is usually CD20(+) &/or pax-5(+)",
                      "CD45/LCA often positive",
                      "CD10(+/-), Bcl-6(+/-)",
                      "CD4(+) is extremely rare in DLBCL-IB"
                    ]
                  },
                  {
                    "text": "By contrast, PBL is CD20(-), CD38(+), CD138/syndecan-1(+), and VS38/p63(+)CD4 or CD56 can be positive",
                    "sub_points": [
                      "CD4 or CD56 can be positive"
                    ]
                  }
                ],
                "Plasma Cell Myeloma (PCM)": [
                  {
                    "text": "Clinically important to distinguish between PCM and PBLTreatment regimens for these 2 diseases are different",
                    "sub_points": [
                      "Treatment regimens for these 2 diseases are different"
                    ]
                  },
                  {
                    "text": "Usually, cytologic features of PCM are readily identifiable as plasma cellsNot blastic; lower number of mitoses or proliferation rate",
                    "sub_points": [
                      "Not blastic; lower number of mitoses or proliferation rate"
                    ]
                  },
                  {
                    "text": "Plasmablastic myeloma can closely resemble PBLClinical features of plasmablastic PCM also apply to PCM in general",
                    "sub_points": [
                      "Clinical features of plasmablastic PCM also apply to PCM in general"
                    ]
                  }
                ],
                "Plasmablastic PCM": [
                  {
                    "text": "Plasmablastic PCM and PBL greatly overlap histologicallyClinical correlation often needed to be distinguishedPlasmablastic PCM and PBL can have virtually identical immunophenotypic profile",
                    "sub_points": [
                      "Clinical correlation often needed to be distinguished",
                      "Plasmablastic PCM and PBL can have virtually identical immunophenotypic profile"
                    ]
                  },
                  {
                    "text": "Features that favor diagnosis of plasmablastic PCMPresence of serum monoclonal protein (paraprotein)Detection of paraproteinemia in blood &/or excess light chains (Bence Jones protein) in urineBone marrow involvement with radiologic evidence of lytic lesionsEBER(-)",
                    "sub_points": [
                      "Presence of serum monoclonal protein (paraprotein)",
                      "Detection of paraproteinemia in blood &/or excess light chains (Bence Jones protein) in urine",
                      "Bone marrow involvement with radiologic evidence of lytic lesions",
                      "EBER(-)"
                    ]
                  },
                  {
                    "text": "Positivity for HIV does not favor diagnosis of PBL over plasmablastic plasma cell myeloma"
                  },
                  {
                    "text": "Presence of atypical but more mature plasma cells supports diagnosis of plasmablastic PCM"
                  }
                ],
                "HHV8-Associated Multicentric Castleman Disease": [
                  {
                    "text": "Patients have clinical and histologic features of multicentric Castleman diseaseUsually HIV(+)",
                    "sub_points": [
                      "Usually HIV(+)"
                    ]
                  },
                  {
                    "text": "Characteristically involves lymph nodes &/or spleen"
                  },
                  {
                    "text": "Immunophenotype is helpfulHHV8(+) in all casesIg λ(+), CD20(+/-)CD138/syndecan-1(-), EBER(-)",
                    "sub_points": [
                      "HHV8(+) in all cases",
                      "Ig λ(+), CD20(+/-)",
                      "CD138/syndecan-1(-), EBER(-)"
                    ]
                  }
                ],
                "ALK(+) Diffuse Large B-Cell Lymphoma": [
                  {
                    "text": "Most common in children"
                  },
                  {
                    "text": "Immunoblastic/plasmablastic cytology"
                  },
                  {
                    "text": "Intrasinusoidal growth pattern common"
                  },
                  {
                    "text": "Immunophenotype is distinctiveALK(+) in all casesCD138/syndecan-1(+), VS38/p63(+), and monotypic cytoplasmic light chainCD4(+) and CD45/LCA(+) commonCD79a(-/+), CD20(-), CD30(-)",
                    "sub_points": [
                      "ALK(+) in all cases",
                      "CD138/syndecan-1(+), VS38/p63(+), and monotypic cytoplasmic light chain",
                      "CD4(+) and CD45/LCA(+) common",
                      "CD79a(-/+), CD20(-), CD30(-)"
                    ]
                  },
                  {
                    "text": "ALK pattern correlates with cytogenetic abnormalitiesMost cases carry t(2;17)(p23;q23)/clathrin-ALKPattern is cytoplasmic and granularCorrelates with location of clathrin in cytoplasmic vesiclesSome cases carry t(2;5)(p23;q35)/nucleophosmin-ALKPattern is nuclear and cytoplasmicCorrelates with location of nucleophosmin",
                    "sub_points": [
                      "Most cases carry t(2;17)(p23;q23)/clathrin-ALKPattern is cytoplasmic and granularCorrelates with location of clathrin in cytoplasmic vesicles",
                      "Pattern is cytoplasmic and granular",
                      "Correlates with location of clathrin in cytoplasmic vesicles",
                      "Some cases carry t(2;5)(p23;q35)/nucleophosmin-ALKPattern is nuclear and cytoplasmicCorrelates with location of nucleophosmin",
                      "Pattern is nuclear and cytoplasmic",
                      "Correlates with location of nucleophosmin"
                    ]
                  }
                ],
                "Myeloid Sarcoma": [
                  {
                    "text": "Also known as extramedullary myeloid cell tumor or granulocytic sarcoma"
                  },
                  {
                    "text": "Cells have immature (blastic) chromatin and thin nuclear membranes"
                  },
                  {
                    "text": "Eosinophilic metamyelocytes in ~ 50% of cases"
                  },
                  {
                    "text": "Immunophenotype helpfulMPO(+), lysozyme(+), CD68(+), CD117(+), CD11cTdT(+/-), CD34(+/-)Plasma cell markers(-)",
                    "sub_points": [
                      "MPO(+), lysozyme(+), CD68(+), CD117(+), CD11c",
                      "TdT(+/-), CD34(+/-)",
                      "Plasma cell markers(-)"
                    ]
                  }
                ],
                "Burkitt Lymphoma (BL)": [
                  {
                    "text": "BL and PBL can share extranodal location, \"starry sky\" pattern, and high proliferation rate"
                  },
                  {
                    "text": "BL can occur in HIV(+) patients and rarely shows plasmacytoid differentiation"
                  },
                  {
                    "text": "Immunophenotype is helpfulBL is positive for pan-B-cell antigens (CD19, CD20, pax-5)CD10(+), Bcl-6(+), CD45/LCA(+), Bcl-2(-)",
                    "sub_points": [
                      "BL is positive for pan-B-cell antigens (CD19, CD20, pax-5)",
                      "CD10(+), Bcl-6(+), CD45/LCA(+), Bcl-2(-)"
                    ]
                  }
                ],
                "Poorly Differentiated or Undifferentiated Carcinoma": [
                  {
                    "text": "Diffuse or sinusoidal pattern and high mitotic rate may partially mimic PBL"
                  },
                  {
                    "text": "Carcinomas can express CD138/syndecan-1"
                  },
                  {
                    "text": "Immunophenotype helpfulCarcinomas are cytokeratin(+), CD38(-), IRF-4/MUM1(-)Epithelial neoplasms can express CD138",
                    "sub_points": [
                      "Carcinomas are cytokeratin(+), CD38(-), IRF-4/MUM1(-)Epithelial neoplasms can express CD138",
                      "Epithelial neoplasms can express CD138"
                    ]
                  },
                  {
                    "text": "Electron microscopy often shows desmosomes or cellular junctions"
                  }
                ],
                "Malignant Melanoma": [
                  {
                    "text": "Melanoma cells can have abundant eosinophilic cytoplasm resembling plasmacytoid featuresMelanin pigment can be identified",
                    "sub_points": [
                      "Melanin pigment can be identified"
                    ]
                  },
                  {
                    "text": "Immunophenotype helpfulS100(+), HMB-45(+), Melan-A(+)Melanomas are CD38(-), IRF-4/MUM1(-)",
                    "sub_points": [
                      "S100(+), HMB-45(+), Melan-A(+)",
                      "Melanomas are CD38(-), IRF-4/MUM1(-)"
                    ]
                  },
                  {
                    "text": "Electron microscopy often shows melanosomes"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Primary Effusion Lymphoma": {
            "name": "Primary Effusion Lymphoma",
            "url": "https://app.pathprimer.com/document/17e56157-1671-4d73-8839-045ae501c261/lesson/5fa09a8a-53fc-4bfc-9404-09d15374a7a2",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "PEL arises from HHV8-infected B cells frequently coinfected by EBV"
                  },
                  {
                    "text": "Associated with HIV infection or other severe acquired immunodeficiencies"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "4% of all HIV-related lymphomas"
                  },
                  {
                    "text": "Presentation as lymphomatous growth in pleural, peritoneal, &/or pericardial effusions"
                  },
                  {
                    "text": "Extracavitary presentation has been describedSolid variant of PEL",
                    "sub_points": [
                      "Solid variant of PEL"
                    ]
                  },
                  {
                    "text": "Some patients have coexistent Kaposi sarcoma"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Diagnosis is usually made on cytological preparations"
                  },
                  {
                    "text": "Cytologic features range from immunoblastic to anaplastic; plasmablastic differentiation common"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Plasma cell-associated markers(+)"
                  },
                  {
                    "text": "Pan-B-cell markers(-)"
                  },
                  {
                    "text": "HHV8(+) is essential for diagnosis"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Primary effusion lymphoma (PEL)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Human herpes virus 8 (HHV8)-associated large B-cell neoplasm most often involving body cavitiesPleural, pericardial, or peritoneal cavity",
                    "sub_points": [
                      "Pleural, pericardial, or peritoneal cavity"
                    ]
                  },
                  {
                    "text": "HHV8(+) lymphomas indistinguishable from PEL rarely present as solid tumor massThese tumors are designated as extracavitary or solid variants of PEL",
                    "sub_points": [
                      "These tumors are designated as extracavitary or solid variants of PEL"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Infectious Agents": [
                  {
                    "text": "PEL arises from HHV8-infected B cells that are frequently coinfected by Epstein-Barr virus (EBV)"
                  },
                  {
                    "text": "HHV8 virusγ herpes double-stranded DNA lymphotropic virusEndemic in sub-Saharan Africa and Mediterranean regionIn addition to PEL, HHV8 is associated withKaposi sarcomaMulticentric Castleman disease (MCD)MCD-associated plasmablastic lymphomaEncodes number of homologues of cellular genesInvolved in cell proliferation and apoptosis",
                    "sub_points": [
                      "γ herpes double-stranded DNA lymphotropic virus",
                      "Endemic in sub-Saharan Africa and Mediterranean region",
                      "In addition to PEL, HHV8 is associated withKaposi sarcomaMulticentric Castleman disease (MCD)MCD-associated plasmablastic lymphoma",
                      "Kaposi sarcoma",
                      "Multicentric Castleman disease (MCD)",
                      "MCD-associated plasmablastic lymphoma",
                      "Encodes number of homologues of cellular genesInvolved in cell proliferation and apoptosis",
                      "Involved in cell proliferation and apoptosis"
                    ]
                  }
                ],
                "Clinical Associations": [
                  {
                    "text": "HIV infection or other severe acquired immunodeficienciesPreexisting acquired immunodeficiency syndrome (AIDS) is very common",
                    "sub_points": [
                      "Preexisting acquired immunodeficiency syndrome (AIDS) is very common"
                    ]
                  },
                  {
                    "text": "PEL also can occur in patients without immunodeficiencyElderly patients in 8th to 9th decades in HHV8 endemic areasUsually these tumors are EBV(-)",
                    "sub_points": [
                      "Elderly patients in 8th to 9th decades in HHV8 endemic areasUsually these tumors are EBV(-)",
                      "Usually these tumors are EBV(-)"
                    ]
                  },
                  {
                    "text": "Rare cases of PEL are associated with hepatitis C &/or B"
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "In PEL, B-cell differentiation program is blockedIn part due to overexpression of activated B-cell factor 1 (ABF-1) and inhibitor of differentiation 2 (ID2)These molecules inhibit E2A (B-cell transcription factor)E2A inhibition downregulates B-cell specific genesRestoration ofE2Aactivity in PEL induces apoptosis of tumor cells",
                    "sub_points": [
                      "In part due to overexpression of activated B-cell factor 1 (ABF-1) and inhibitor of differentiation 2 (ID2)These molecules inhibit E2A (B-cell transcription factor)E2A inhibition downregulates B-cell specific genes",
                      "These molecules inhibit E2A (B-cell transcription factor)",
                      "E2A inhibition downregulates B-cell specific genes",
                      "Restoration ofE2Aactivity in PEL induces apoptosis of tumor cells"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Rare0.3% of all aggressive lymphomas in HIV(-) patients4% of all HIV-related lymphomas",
                    "sub_points": [
                      "0.3% of all aggressive lymphomas in HIV(-) patients",
                      "4% of all HIV-related lymphomas"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Lymphoma cells grow in pleural, peritoneal, &/or pericardial effusions"
                  },
                  {
                    "text": "Usually no distinct extracavitary tumor masses &/or organomegaly"
                  },
                  {
                    "text": "Frequent B symptoms"
                  },
                  {
                    "text": "Symptoms commonly result from massive malignant effusionDyspnea is frequent (from pleural or pericardial disease)Abdominal distension (from peritoneal disease)",
                    "sub_points": [
                      "Dyspnea is frequent (from pleural or pericardial disease)",
                      "Abdominal distension (from peritoneal disease)"
                    ]
                  },
                  {
                    "text": "Systemic dissemination can occur during course of disease"
                  },
                  {
                    "text": "Associated with clinical and laboratory findings of severe immunosuppressionMarked depletion of CD4(+) T cells",
                    "sub_points": [
                      "Marked depletion of CD4(+) T cells"
                    ]
                  },
                  {
                    "text": "Involvement of central nervous system and bone marrow is rare"
                  },
                  {
                    "text": "Standard Ann Arbor staging is not useful as, by definition, all PEL cases are stage IV"
                  },
                  {
                    "text": "Some patients have coexistent Kaposi sarcoma"
                  },
                  {
                    "text": "HHV8(+) lymphomas can present as masses involving organs (extracavitary or solid variant of PEL)Gastrointestinal tract most frequently involvedLymph nodes can be involvedPatients with extracavitary mass often develop malignant effusion over disease course",
                    "sub_points": [
                      "Gastrointestinal tract most frequently involved",
                      "Lymph nodes can be involved",
                      "Patients with extracavitary mass often develop malignant effusion over disease course"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Highly active antiretroviral therapy (HAART) improves prognosis"
                  },
                  {
                    "text": "Traditional chemotherapy, usually cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)"
                  },
                  {
                    "text": "Bortezomib, a proteosome inhibitor that inhibits NF-kB pathway"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Usually poor; median survival < 6 months"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Diagnosis is usually made on cytological preparations of involved effusion fluid"
                  },
                  {
                    "text": "Biopsy specimens of cavity lining tissue also may show small number of neoplastic cells adherent to mesothelial surfaces"
                  },
                  {
                    "text": "Large lymphoid cells with round to irregular nuclei, prominent nucleoli, and variable morphologyImmunoblasticRound nuclei with centrally located nucleoliPlasmablasticEccentric nuclei with abundant cytoplasm, sometimes with perinuclear hofAnaplasticMultinucleated and Reed-Sternberg-like cells",
                    "sub_points": [
                      "ImmunoblasticRound nuclei with centrally located nucleoli",
                      "Round nuclei with centrally located nucleoli",
                      "PlasmablasticEccentric nuclei with abundant cytoplasm, sometimes with perinuclear hof",
                      "Eccentric nuclei with abundant cytoplasm, sometimes with perinuclear hof",
                      "AnaplasticMultinucleated and Reed-Sternberg-like cells",
                      "Multinucleated and Reed-Sternberg-like cells"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Medium- to large-sized atypical cells, many with irregular nuclear contours, prominent nucleoli, and abundant cytoplasm (± vacuolated)"
                  },
                  {
                    "text": "Cytomorphologic appearances ranging from immunoblastic to anaplastic and exhibiting frequent plasmablastic differentiation"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "HHV8(+) is essential for diagnosis"
                  },
                  {
                    "text": "Plasma cell-associated markers(+)CD138, VS38c, IRF-4/MUM1CD38, EMA",
                    "sub_points": [
                      "CD138, VS38c, IRF-4/MUM1",
                      "CD38, EMA"
                    ]
                  },
                  {
                    "text": "Cytoplasmic Ig λ light chain(+/-)"
                  },
                  {
                    "text": "CD30(+), CD45/LCA(+) may be weak"
                  },
                  {
                    "text": "Notch(+) in most casesNuclear and cytoplasmic pattern of expression",
                    "sub_points": [
                      "Nuclear and cytoplasmic pattern of expression"
                    ]
                  },
                  {
                    "text": "Pan-B-cell markers(-)CD19, CD20, CD79a, pax-5",
                    "sub_points": [
                      "CD19, CD20, CD79a, pax-5"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Similar immunophenotype to that observed by immunohistochemistry"
                  },
                  {
                    "text": "ResultsCD45/LCA(+), CD71(+)HLA-DR(+); CD23(+) in ~ 20%Surface Ig light chain expression is rareCD19(-), CD20(-), CD22(-)~ 10% of cases have dim CD20 expressionAberrant T-cell markers are positive in subset of casesCD45RO (~ 90%), CD7 (~ 30%), CD4 (~ 20%)",
                    "sub_points": [
                      "CD45/LCA(+), CD71(+)",
                      "HLA-DR(+); CD23(+) in ~ 20%",
                      "Surface Ig light chain expression is rare",
                      "CD19(-), CD20(-), CD22(-)~ 10% of cases have dim CD20 expression",
                      "~ 10% of cases have dim CD20 expression",
                      "Aberrant T-cell markers are positive in subset of casesCD45RO (~ 90%), CD7 (~ 30%), CD4 (~ 20%)",
                      "CD45RO (~ 90%), CD7 (~ 30%), CD4 (~ 20%)"
                    ]
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "EBER(+) in ~ 80% of cases"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "MonoclonalIgHgene rearrangements"
                  },
                  {
                    "text": "Usually complex karyotype"
                  },
                  {
                    "text": "No recurrent chromosomal abnormalities identified"
                  }
                ],
                "Array CGH": [
                  {
                    "text": "Gains of Iq21-41, 4q28-35, 7q, 8q, 11, 12, 17q, 19p, 20q"
                  },
                  {
                    "text": "Losses of 4q, 11q25, 14q32Amplification of selectin-P ligand (12q24.11)",
                    "sub_points": [
                      "Amplification of selectin-P ligand (12q24.11)"
                    ]
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "PEL in HIV(+) patients has been assessedProfile is distinctiveFeatures of plasma cells and EBV-transformed lymphocytes",
                    "sub_points": [
                      "Profile is distinctiveFeatures of plasma cells and EBV-transformed lymphocytes",
                      "Features of plasma cells and EBV-transformed lymphocytes"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Body Cavity Involvement by Systemic Diffuse Large B-Cell Lymphoma": [
                  {
                    "text": "Patients with non-Hodgkin lymphoma present with or subsequently develop body cavity involvement during course of disease"
                  },
                  {
                    "text": "Any systemic lymphoma may involve any serosal cavitiesMost frequent type is diffuse large B-cell lymphoma, NOS",
                    "sub_points": [
                      "Most frequent type is diffuse large B-cell lymphoma, NOS"
                    ]
                  },
                  {
                    "text": "Pleural involvement can be unilateral or bilateralUnilateral involvement is more common on left side",
                    "sub_points": [
                      "Unilateral involvement is more common on left side"
                    ]
                  },
                  {
                    "text": "Immunophenotypic and molecular findings similar to DLBCL, NOS elsewhere"
                  },
                  {
                    "text": "HHV8(-)"
                  }
                ],
                "Plasmablastic Lymphoma Arising in HHV8-Associated Multicentric Castleman Disease": [
                  {
                    "text": "Patients usually have clinical and histologic features of multicentric Castleman diseaseUsually HIV(+), EBER(+)",
                    "sub_points": [
                      "Usually HIV(+), EBER(+)"
                    ]
                  },
                  {
                    "text": "Characteristically involves lymph nodes &/or spleen"
                  },
                  {
                    "text": "ImmunophenotypeHHV8(+) in all casesIgλ(+), CD20(+/-), CD79a(-)CD38(-/+), CD138(-)",
                    "sub_points": [
                      "HHV8(+) in all cases",
                      "Igλ(+), CD20(+/-), CD79a(-)",
                      "CD38(-/+), CD138(-)"
                    ]
                  }
                ],
                "Plasmablastic Lymphoma (PBL)": [
                  {
                    "text": "Oral and nonoral types"
                  },
                  {
                    "text": "Associated with HIV(+) and EBV(+)"
                  },
                  {
                    "text": "ImmunophenotypePlasma cell-associated markers strongly positiveIRF-4/MUM1, CD38, CD138, VS38/p63Cytoplasmic Ig(+) ~ 60-70%CD79a(+) ~ 70-80%Other pan-B-cell markers negativeCD19, CD20, CD22, and pax-5CD45/LCA(-) or weakly positive in subset of casesHHV8(-)",
                    "sub_points": [
                      "Plasma cell-associated markers strongly positiveIRF-4/MUM1, CD38, CD138, VS38/p63",
                      "IRF-4/MUM1, CD38, CD138, VS38/p63",
                      "Cytoplasmic Ig(+) ~ 60-70%",
                      "CD79a(+) ~ 70-80%",
                      "Other pan-B-cell markers negativeCD19, CD20, CD22, and pax-5",
                      "CD19, CD20, CD22, and pax-5",
                      "CD45/LCA(-) or weakly positive in subset of cases",
                      "HHV8(-)"
                    ]
                  }
                ],
                "Plasmablastic Plasma Cell Myeloma (PCM)": [
                  {
                    "text": "Evidence of plasma cell myeloma is usually presentParaprotein in blood &/or excess light chains (Bence Jones protein) in urineBone marrow involvementRadiologic evidence of lytic bone lesions",
                    "sub_points": [
                      "Paraprotein in blood &/or excess light chains (Bence Jones protein) in urine",
                      "Bone marrow involvement",
                      "Radiologic evidence of lytic bone lesions"
                    ]
                  },
                  {
                    "text": "Presence of atypical but more mature plasma cells"
                  }
                ],
                "Burkitt Lymphoma (BL)": [
                  {
                    "text": "BL and PEL can share extranodal location and high proliferation rate"
                  },
                  {
                    "text": "BL can occur in HIV(+) patients but rarely shows plasmacytoid differentiation"
                  },
                  {
                    "text": "ImmunophenotypePan-B-cell antigens(+)CD19, CD20, and pax-5Bcl-6(+), CD10(-), Bcl-2(-)MIB-1/Ki-67 high (~ 100%)",
                    "sub_points": [
                      "Pan-B-cell antigens(+)CD19, CD20, and pax-5",
                      "CD19, CD20, and pax-5",
                      "Bcl-6(+), CD10(-), Bcl-2(-)",
                      "MIB-1/Ki-67 high (~ 100%)"
                    ]
                  },
                  {
                    "text": "MYC-associated translocations in almost all casest(8;14)(q24;q32) ~ in 80%t(2;8)(p12;q24) or t(8;22)(q24;q11) ~ in 20%",
                    "sub_points": [
                      "t(8;14)(q24;q32) ~ in 80%",
                      "t(2;8)(p12;q24) or t(8;22)(q24;q11) ~ in 20%"
                    ]
                  }
                ],
                "Malignant Melanoma": [
                  {
                    "text": "Melanoma cells can have abundant eosinophilic cytoplasm resembling plasmacytoid differentiation"
                  },
                  {
                    "text": "Immunophenotype helpfulS100(+), HMB-45(+), Melan-A(+)",
                    "sub_points": [
                      "S100(+), HMB-45(+), Melan-A(+)"
                    ]
                  },
                  {
                    "text": "Electron microscopy often shows melanosomes"
                  }
                ],
                "Poorly Differentiated or Undifferentiated Carcinoma": [
                  {
                    "text": "Carcinomas can be CD138(+)"
                  },
                  {
                    "text": "Immunophenotype helpfulCytokeratin(+), CD38(-), IRF-4/MUM1(-)",
                    "sub_points": [
                      "Cytokeratin(+), CD38(-), IRF-4/MUM1(-)"
                    ]
                  },
                  {
                    "text": "Electron microscopy often shows desmosomes or cellular junctions"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Burkitt Leukemia/Lymphoma": {
            "name": "Burkitt Leukemia/Lymphoma",
            "url": "https://app.pathprimer.com/document/7f5c0194-7d57-4a3c-82ac-2980590e4096/lesson/5fa09a8a-53fc-4bfc-9404-09d15374a7a2",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Burkitt lymphoma (BL) is highly aggressive B-cell neoplasm"
                  },
                  {
                    "text": "eBL: Occurs in equatorial Africa, correlating with endemic zone ofPlasmodium falciparummalaria and Epstein-Barr virus (EBV) infection"
                  },
                  {
                    "text": "sBL: Occurs throughout world, sporadic"
                  },
                  {
                    "text": "iBL: Occurs in setting of immunodeficiency"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "BL is derived from germinal center B cells or postgerminal center B cells"
                  },
                  {
                    "text": "Translocation ofMYCis characteristic"
                  },
                  {
                    "text": "Relationship of endemicP.falciparum malaria, EBV infection, and BL has long been recognized"
                  },
                  {
                    "text": "EBV reactivation, expansion of B cells, and reduced T-cell function may play roles in pathogenesis of endemic BL"
                  },
                  {
                    "text": "BL is more common in HIV immunodeficiency than other types of immunodeficiency"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "eBL: Most common childhood malignancy in endemic area, jaws and facial bones are most common sites of involvement"
                  },
                  {
                    "text": "iBL: Predominantly seen in HIV(+) patients; accounting for 30% of all HIV-associated lymphomasCNS and bone marrow involvement common",
                    "sub_points": [
                      "CNS and bone marrow involvement common"
                    ]
                  },
                  {
                    "text": "Incidence peaks from 4-7 years"
                  },
                  {
                    "text": "Ileum and cecum are most frequently involved in sporadic BL"
                  },
                  {
                    "text": "Circulating neoplastic cells can be seen when blood is involved"
                  },
                  {
                    "text": "Typically, patients have symptoms of only few weeks duration"
                  },
                  {
                    "text": "Lymphoma cell doubling time is 24-26 hours, and tumor size could double within 1 day"
                  },
                  {
                    "text": "Intensive combination of chemotherapy is mainstay of treatment"
                  },
                  {
                    "text": "BL is highly chemosensitive and potentially curable"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Medium-sized lymphoma cells with deeply basophilic cytoplasm with distinct cytoplasmic lipid vacuoles"
                  },
                  {
                    "text": "Brisk mitotic and apoptotic bodies form starry-sky pattern on tissue sections"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "CD20(+), CD10(+), BCL6(+), and CD43(+); BCL2(-)"
                  },
                  {
                    "text": "Ki-67(+) in ~ 100% of neoplastic cells"
                  },
                  {
                    "text": "t(8;14)(q24;q32)MYC::IGHas sole abnormality"
                  },
                  {
                    "text": "Alternative translocations includet(2;8)(p12;q24)IGK::MYCt(8;22)(q24;q11)MYC::IGL",
                    "sub_points": [
                      "t(2;8)(p12;q24)IGK::MYC",
                      "t(8;22)(q24;q11)MYC::IGL"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Burkitt lymphoma (BL)"
                  },
                  {
                    "text": "International Consensus Classification (ICC)"
                  },
                  {
                    "text": "WHO 5th edition (WHO-HAEM5)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Burkitt lymphoma/leukemia (WHO-HAEM5)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Highly aggressive mature B-cell neoplasm"
                  },
                  {
                    "text": "Endemic BL (eBL): Occurs in equatorial Africa, correlating with endemic zone ofPlasmodium falciparummalaria and Epstein-Barr virus (EBV) infections"
                  },
                  {
                    "text": "Sporadic BL (sBL): Occurs throughout world"
                  },
                  {
                    "text": "Immunodeficiency-associated BL (iBL): Occurs primarily in setting of HIV infection"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Cell of Origin": [
                  {
                    "text": "BL is derived from dark zone germinal center B cells (GCB)"
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "Translocation ofMYCis highly characteristic in BLActivation-induced cytidine deaminase-mediated immunoglobulin class switch recombination is primary mechanism forIGH::MYCtranslocation in sBLSomatic hypermutation is another mechanism forIGH::MYCtranslocation in sBL",
                    "sub_points": [
                      "Activation-induced cytidine deaminase-mediated immunoglobulin class switch recombination is primary mechanism forIGH::MYCtranslocation in sBL",
                      "Somatic hypermutation is another mechanism forIGH::MYCtranslocation in sBL"
                    ]
                  },
                  {
                    "text": "Relationship ofP.falciparummalaria and EBV infection with eBL has long been recognizedP.falciparumis proposed in pathogenesis of eBLInduces B-cell expansion and EBV reactivationDecreased EBV-specific T cells, thus loss of control of EBV(+) B cellsIncreases chance ofMYCtranslocation during expansion of EBV(+) B cellsEBV(+) status is related to unique genomic mutation profilingGenome-wide increase in somatic hypermutationsIncreased activation-induced cytidine deaminase (AICDA) activityFewer driver mutations despite greater mutational load",
                    "sub_points": [
                      "P.falciparumis proposed in pathogenesis of eBLInduces B-cell expansion and EBV reactivationDecreased EBV-specific T cells, thus loss of control of EBV(+) B cellsIncreases chance ofMYCtranslocation during expansion of EBV(+) B cells",
                      "Induces B-cell expansion and EBV reactivation",
                      "Decreased EBV-specific T cells, thus loss of control of EBV(+) B cells",
                      "Increases chance ofMYCtranslocation during expansion of EBV(+) B cells",
                      "EBV(+) status is related to unique genomic mutation profilingGenome-wide increase in somatic hypermutationsIncreased activation-induced cytidine deaminase (AICDA) activityFewer driver mutations despite greater mutational load",
                      "Genome-wide increase in somatic hypermutations",
                      "Increased activation-induced cytidine deaminase (AICDA) activity",
                      "Fewer driver mutations despite greater mutational load"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "eBLMost common childhood malignancy in endemic areas30-50% of all childhood lymphomas",
                    "sub_points": [
                      "Most common childhood malignancy in endemic areas30-50% of all childhood lymphomas",
                      "30-50% of all childhood lymphomas"
                    ]
                  },
                  {
                    "text": "sBL1-2% of all lymphomas in western Europe and USA",
                    "sub_points": [
                      "1-2% of all lymphomas in western Europe and USA"
                    ]
                  },
                  {
                    "text": "iBLPredominantly seen in HIV(+) patients; BL accounts for 30% of all HIV-associated lymphomasOccurs early in infectionOccurs despite antiretroviral therapy",
                    "sub_points": [
                      "Predominantly seen in HIV(+) patients; BL accounts for 30% of all HIV-associated lymphomas",
                      "Occurs early in infection",
                      "Occurs despite antiretroviral therapy"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "eBL: Peak incidence between 6-8 years"
                  },
                  {
                    "text": "sBL: Age-dependent incidence peaks at 10, 30, and 70 years"
                  },
                  {
                    "text": "iBL: Primarily adults"
                  }
                ],
                "Sex": [
                  {
                    "text": "M:F = 2-3:1 in all types of BL"
                  }
                ],
                "Site": [
                  {
                    "text": "eBLJaws or periorbital facial bones are most common sites of involvement; seen in 50% of casesDistal ileum, cecum, omentum, gonads, kidneys, long bones, thyroid, salivary glands, and breast can be affectedBone marrow and CNS can be involved",
                    "sub_points": [
                      "Jaws or periorbital facial bones are most common sites of involvement; seen in 50% of cases",
                      "Distal ileum, cecum, omentum, gonads, kidneys, long bones, thyroid, salivary glands, and breast can be affected",
                      "Bone marrow and CNS can be involved"
                    ]
                  },
                  {
                    "text": "sBLIleum or cecum are most frequent sites of involvementHead and neck (particularly Waldeyer ring) followsOvaries, kidneys, and breasts are other common sitesBilateral and massive breast involvement often coincident with onset of pubertyCNS can be involvedJaw is rarely involved",
                    "sub_points": [
                      "Ileum or cecum are most frequent sites of involvementHead and neck (particularly Waldeyer ring) follows",
                      "Head and neck (particularly Waldeyer ring) follows",
                      "Ovaries, kidneys, and breasts are other common sites",
                      "Bilateral and massive breast involvement often coincident with onset of puberty",
                      "CNS can be involved",
                      "Jaw is rarely involved"
                    ]
                  },
                  {
                    "text": "iBLFrequent bone marrow and CNS involvement",
                    "sub_points": [
                      "Frequent bone marrow and CNS involvement"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "2/3 of patients present with advanced-stage disease with rapidly growing bulky disease of only few weeks duration"
                  },
                  {
                    "text": "eBLJaw/facial bone mass is most frequent presentation in younger childrenAbdomen involvement in older children",
                    "sub_points": [
                      "Jaw/facial bone mass is most frequent presentation in younger children",
                      "Abdomen involvement in older children"
                    ]
                  },
                  {
                    "text": "sBLAbdominal mass is most common presentation due to ileum or cecum involvementRetroperitoneal mass or lymphadenopathy can be seen",
                    "sub_points": [
                      "Abdominal mass is most common presentation due to ileum or cecum involvement",
                      "Retroperitoneal mass or lymphadenopathy can be seen"
                    ]
                  },
                  {
                    "text": "iBLCommonly manifests as leukemia with blood and bone marrow involvementHigh incidence of CNS involvement",
                    "sub_points": [
                      "Commonly manifests as leukemia with blood and bone marrow involvement",
                      "High incidence of CNS involvement"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Cytopenia(s) when bone marrow is involved"
                  },
                  {
                    "text": "Circulating lymphoma cells when blood is involved"
                  },
                  {
                    "text": "Serum lactate dehydrogenase (LDH) level very high"
                  }
                ],
                "Natural History": [
                  {
                    "text": "Lymphoma cell doubling time is 24-26 hours, and tumor size may double within 1 day"
                  },
                  {
                    "text": "Patients die of disease within weeks if left untreated"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Intensive combination of chemotherapy is mainstay of treatment"
                  },
                  {
                    "text": "Tumor lysis syndrome often occurs at initiation of therapyMajor manifestations of tumor lysis syndrome include hyperuricemia, hyperkalemia, and hyperphosphatemiaHyperkalemia is most serious complication; it may cause fatal cardiac arrest within hours of initiation of therapyCan be prevented by maintaining high urine output by diuresis in combination with use of allopurinolHemodialysis is occasionally required to control azotemia, hyperkalemia, hyperuricemia, or hyperphosphatemia",
                    "sub_points": [
                      "Major manifestations of tumor lysis syndrome include hyperuricemia, hyperkalemia, and hyperphosphatemia",
                      "Hyperkalemia is most serious complication; it may cause fatal cardiac arrest within hours of initiation of therapy",
                      "Can be prevented by maintaining high urine output by diuresis in combination with use of allopurinol",
                      "Hemodialysis is occasionally required to control azotemia, hyperkalemia, hyperuricemia, or hyperphosphatemia"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "BL is highly chemosensitive and potentially curable"
                  },
                  {
                    "text": "Cure rate in low-stage disease is > 90% and 60-80% in advanced-stage disease for eBL"
                  },
                  {
                    "text": "Survival is better in children than in adults"
                  },
                  {
                    "text": "Adverse prognostic findingsBone marrow and CNS involvementUnresectable tumor > 10 cm in diameterHigh serum LDH level",
                    "sub_points": [
                      "Bone marrow and CNS involvement",
                      "Unresectable tumor > 10 cm in diameter",
                      "High serum LDH level"
                    ]
                  },
                  {
                    "text": "Relapse may occur in subset of patients, usually within 1st year after diagnosis, and carries dismal prognosis"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Microscopic Features": [
                  {
                    "text": "BloodMedium-sized lymphoma cells with moderate deeply basophilic cytoplasm and cytoplasmic lipid vacuolesRound nuclei with finely clumped chromatin and multiple nucleoli",
                    "sub_points": [
                      "Medium-sized lymphoma cells with moderate deeply basophilic cytoplasm and cytoplasmic lipid vacuoles",
                      "Round nuclei with finely clumped chromatin and multiple nucleoli"
                    ]
                  },
                  {
                    "text": "Bone marrow aspirateBL cells typically admixed with hematopoietic cellsBL cells are variably sized on bone marrow aspirate smears despite typical small to intermediate cell size in tissue sectionsMay mimic large cell lymphoma",
                    "sub_points": [
                      "BL cells typically admixed with hematopoietic cells",
                      "BL cells are variably sized on bone marrow aspirate smears despite typical small to intermediate cell size in tissue sectionsMay mimic large cell lymphoma",
                      "May mimic large cell lymphoma"
                    ]
                  },
                  {
                    "text": "Bone marrow core biopsyInterstitial aggregates or diffuse interstitial patterns in early bone marrow involvementSolid infiltration pattern in late stage of involvementBrisk mitotic and apoptotic rateMay exhibit starry-sky pattern on low power due to increased tingible body macrophages containing apoptotic tumor cellsMay demonstrate areas of necrosisFrequently exhibits plasmacytoid differentiation in iBL",
                    "sub_points": [
                      "Interstitial aggregates or diffuse interstitial patterns in early bone marrow involvement",
                      "Solid infiltration pattern in late stage of involvement",
                      "Brisk mitotic and apoptotic rate",
                      "May exhibit starry-sky pattern on low power due to increased tingible body macrophages containing apoptotic tumor cells",
                      "May demonstrate areas of necrosis",
                      "Frequently exhibits plasmacytoid differentiation in iBL"
                    ]
                  },
                  {
                    "text": "Lymph node/tissue biopsyComplete effacement of normal architectureUniform, medium-sized cells with \"squared-off\" bordersHigh rate of mitosis and apoptosisStarry-sky pattern on low powerFocal or diffuse necrosis may occur",
                    "sub_points": [
                      "Complete effacement of normal architecture",
                      "Uniform, medium-sized cells with \"squared-off\" borders",
                      "High rate of mitosis and apoptosis",
                      "Starry-sky pattern on low power",
                      "Focal or diffuse necrosis may occur"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Typically used in conjunction with flow cytometric analysis"
                  },
                  {
                    "text": "No single stain is diagnostic"
                  },
                  {
                    "text": "Panel of stains is required, including CD20, CD10, BCL6, BCL2, CD43, Ki-67, EBER"
                  },
                  {
                    "text": "CD20, CD10, BCL6, and CD43 usually (+)"
                  },
                  {
                    "text": "BCL2(-) or very weak"
                  },
                  {
                    "text": "TdT(-)"
                  },
                  {
                    "text": "Ki-67(+) in ~ 100% of neoplastic cells"
                  },
                  {
                    "text": "EBER(+) inAlmost all eBL cases30% of sBL cases2/3 of iBL with plasmacytoid differentiation1/3 of iBL with typical morphologyMajority of posttransplant BL~ 30% of iatrogenic immunosuppression-associated BL",
                    "sub_points": [
                      "Almost all eBL cases",
                      "30% of sBL cases",
                      "2/3 of iBL with plasmacytoid differentiation",
                      "1/3 of iBL with typical morphology",
                      "Majority of posttransplant BL",
                      "~ 30% of iatrogenic immunosuppression-associated BL"
                    ]
                  },
                  {
                    "text": "EBNA1 is only latent protein consistently expressed"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Flow needs to be done very quickly due to rapid cell death during transportation"
                  },
                  {
                    "text": "Typically reveals CD10 and surface immunoglobulin (+) monoclonal B-cell population"
                  },
                  {
                    "text": "CD5, CD23 typically (-); helpful to exclude other lymphomas/leukemias"
                  },
                  {
                    "text": "CD34, TdT (-); excludes B-acute lymphoblastic leukemia (B-ALL)"
                  },
                  {
                    "text": "Medium to large size on forward scatter"
                  }
                ],
                "PCR": [
                  {
                    "text": "RearrangedIGHgene"
                  },
                  {
                    "text": "Next-generation sequencing (NGS) detects mutations in various pathwaysPi3K signaling pathwayTranscription factorTCF3or its negative regulatorID3present in ~ 70% of sBL and iBL and 40% of eBL casesTumor suppressor genesMutations inTP53,ARF,USP7,DDX3Xgenes have been implicatedCell cycle regulation genesMutations inCCND3,CDKN2A,P2RY8,GNA13,FBXO11,RASgenes are commonEBV status is related to mutation profilingEBV(+) BL exhibits high expression of activation-induced cytidine deaminase and, thus, much higher mutational burdenEBV(-) BL more commonly reveal activate cyclin D3 and inactive p53 either byTP53mutations or by inactivating ARF or USP7",
                    "sub_points": [
                      "Pi3K signaling pathwayTranscription factorTCF3or its negative regulatorID3present in ~ 70% of sBL and iBL and 40% of eBL cases",
                      "Transcription factorTCF3or its negative regulatorID3present in ~ 70% of sBL and iBL and 40% of eBL cases",
                      "Tumor suppressor genesMutations inTP53,ARF,USP7,DDX3Xgenes have been implicated",
                      "Mutations inTP53,ARF,USP7,DDX3Xgenes have been implicated",
                      "Cell cycle regulation genesMutations inCCND3,CDKN2A,P2RY8,GNA13,FBXO11,RASgenes are common",
                      "Mutations inCCND3,CDKN2A,P2RY8,GNA13,FBXO11,RASgenes are common",
                      "EBV status is related to mutation profilingEBV(+) BL exhibits high expression of activation-induced cytidine deaminase and, thus, much higher mutational burdenEBV(-) BL more commonly reveal activate cyclin D3 and inactive p53 either byTP53mutations or by inactivating ARF or USP7",
                      "EBV(+) BL exhibits high expression of activation-induced cytidine deaminase and, thus, much higher mutational burden",
                      "EBV(-) BL more commonly reveal activate cyclin D3 and inactive p53 either byTP53mutations or by inactivating ARF or USP7"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "t(8;14)(q24;q32)MYC::IGHin 80% of BL cases"
                  },
                  {
                    "text": "Alternative translocations includet(2;8)(p12;q24)IGK::MYC(15%)t(8;22)(q24;q11)MYC::IGL(5%)",
                    "sub_points": [
                      "t(2;8)(p12;q24)IGK::MYC(15%)",
                      "t(8;22)(q24;q11)MYC::IGL(5%)"
                    ]
                  },
                  {
                    "text": "By itselfMYC::IGHis not specific and can be seen in other lymphomas, such as diffuse large B-cell lymphoma (DLBCL), especially with additional abnormalities"
                  },
                  {
                    "text": "Complex karyotype in majority of patients at relapse; most common are 1q gain, 7q gain, del(13q), 11q aberration, del(17p), tri12, del(6q)"
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "Consistent gene expression signature for BL, which is different from DLBCL"
                  },
                  {
                    "text": "Intermediate cases are also seen"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "High-Grade B-Cell Lymphoma With 11q Aberration": [
                  {
                    "text": "Formerly called Burkitt-like lymphoma in WHO revised 4th edition, now classified as high-grade B-cell lymphoma (HGBCL)"
                  },
                  {
                    "text": "Subtype of GCB lymphoma"
                  },
                  {
                    "text": "11q aberration characteristic"
                  },
                  {
                    "text": "Some similarities to either BL or DLBCL based on various studiesSome cases resemble BL both morphologically and immunophenotypicallyStarry-sky morphology and GCB phenotypeImportant differences include absence ofMYCexpression and also absence ofMYCrearrangementCytogenetically more complex than BLSome cases resemble DLBCL or HGBCLThese cases are more morphologically and biologically similar to large cell lymphomas based on molecular genetic studies",
                    "sub_points": [
                      "Some cases resemble BL both morphologically and immunophenotypicallyStarry-sky morphology and GCB phenotypeImportant differences include absence ofMYCexpression and also absence ofMYCrearrangementCytogenetically more complex than BL",
                      "Starry-sky morphology and GCB phenotype",
                      "Important differences include absence ofMYCexpression and also absence ofMYCrearrangement",
                      "Cytogenetically more complex than BL",
                      "Some cases resemble DLBCL or HGBCLThese cases are more morphologically and biologically similar to large cell lymphomas based on molecular genetic studies",
                      "These cases are more morphologically and biologically similar to large cell lymphomas based on molecular genetic studies"
                    ]
                  }
                ],
                "High-Grade B-Cell Lymphoma WithMYCandBCL2orMYCandBCL6Rearrangements": [
                  {
                    "text": "HGBCL with MYC andBCL2rearrangements (HGBCL-DH-BCL2)Accounts for 80-90% of double-hit/triple-hit (DH/TH) lymphomas and 2% of overall non-Hodgkin lymphomasMedian age ~ 60 years with slight male predominanceMost patients present with advanced-stage diseaseLimited response to R-CHOP [rituximab, cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), prednisone/prednisolone] or show early relapse after complete remission",
                    "sub_points": [
                      "Accounts for 80-90% of double-hit/triple-hit (DH/TH) lymphomas and 2% of overall non-Hodgkin lymphomas",
                      "Median age ~ 60 years with slight male predominance",
                      "Most patients present with advanced-stage disease",
                      "Limited response to R-CHOP [rituximab, cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), prednisone/prednisolone] or show early relapse after complete remission"
                    ]
                  },
                  {
                    "text": "HGBCL with MYC andBCL6rearrangements (HGBCL-DH-BCL6)Provisional entity in ICC classificationAccounts for 10-20% of DH-TH lymphomasLess well defined than HGBCL-DH-BCL2Demographic features similar to HGBCL-DH-BCL2May have particular predilection to extranodal diseaseOnly 1/2 of cases exhibit GCB originLess CD10 expression than HGBCL-DH-BCL2IRF4/MUM1 expressed in 40-90% of casesBCL2 expressed in 20-80% of casesPrognosis controversial",
                    "sub_points": [
                      "Provisional entity in ICC classification",
                      "Accounts for 10-20% of DH-TH lymphomas",
                      "Less well defined than HGBCL-DH-BCL2",
                      "Demographic features similar to HGBCL-DH-BCL2",
                      "May have particular predilection to extranodal disease",
                      "Only 1/2 of cases exhibit GCB origin",
                      "Less CD10 expression than HGBCL-DH-BCL2",
                      "IRF4/MUM1 expressed in 40-90% of cases",
                      "BCL2 expressed in 20-80% of cases",
                      "Prognosis controversial"
                    ]
                  },
                  {
                    "text": "Cases with rearrangements ofMYC,BCL2, andBCL6are classified under HGBCL-DH-BCL2since significance ofBCL6rearrangement in this setting is unclear"
                  },
                  {
                    "text": "Pathologic characteristicsImmunohistochemical stains cannot be used to assign DH or TH lymphomas (FISH required)1/2 of cases show morphology of DLBCL and other 1/2 mimic BLStarry-sky pattern may be present, may be focalLymphoma cells often have more abundant, less basophilic cytoplasm than BLCD10 and BCL6 are expressed in majority of HGBCL-DH-BCL2and HGBCL-DH-BCL6casesOften strongBCL2expression, in contrast to negativeBCL2in BLOften have complex karyotype with many other structural and numerical abnormalitiesFISH forMYC,BCL2, andBCL6rearrangements helps to distinguish from BL",
                    "sub_points": [
                      "Immunohistochemical stains cannot be used to assign DH or TH lymphomas (FISH required)",
                      "1/2 of cases show morphology of DLBCL and other 1/2 mimic BL",
                      "Starry-sky pattern may be present, may be focal",
                      "Lymphoma cells often have more abundant, less basophilic cytoplasm than BL",
                      "CD10 and BCL6 are expressed in majority of HGBCL-DH-BCL2and HGBCL-DH-BCL6cases",
                      "Often strongBCL2expression, in contrast to negativeBCL2in BL",
                      "Often have complex karyotype with many other structural and numerical abnormalities",
                      "FISH forMYC,BCL2, andBCL6rearrangements helps to distinguish from BL"
                    ]
                  },
                  {
                    "text": "Lymphomas with history of preexistent or coexistent indolent lymphoma should be diagnosed as suchHGBCL-DH-BCL2, transformed from follicular lymphoma",
                    "sub_points": [
                      "HGBCL-DH-BCL2, transformed from follicular lymphoma"
                    ]
                  },
                  {
                    "text": "Short median survival (4.5-18.5 months)"
                  }
                ],
                "B-Acute Lymphoblastic Leukemia": [
                  {
                    "text": "Primarily occurs in children who present with signs and symptoms related to marrow failure or extramedullary leukemic infiltration"
                  },
                  {
                    "text": "Blasts have scant cytoplasm, fine chromatin pattern, small to prominent nucleoli, no cytoplasmic vacuoles"
                  },
                  {
                    "text": "Immunophenotype demonstrates surface immunoglobulin (-), CD10(+)/CD19(+) B-cell population"
                  },
                  {
                    "text": "Expression of immature cell markers, such as CD34, TdT"
                  },
                  {
                    "text": "Lack ofMYCrearrangement; not EBV associated"
                  },
                  {
                    "text": "Frequent presence of B-ALL-associated cytogenetic changes"
                  }
                ],
                "EBV(+) Diffuse Large B-Cell Lymphoma, Not Otherwise Specified": [
                  {
                    "text": "Usually affects older patients > 70 years old"
                  },
                  {
                    "text": "Predominates in Asia, Latin America"
                  },
                  {
                    "text": "Morphologic and immunophenotypic spectrum"
                  },
                  {
                    "text": "Main overlap with Burkitt lymphoma is EBV positivity"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Classical Hodgkin Lymphoma": {
            "name": "Classical Hodgkin Lymphoma",
            "url": "https://app.pathprimer.com/document/b8ea9b81-c23d-4fe6-a983-247e64af006a/lesson/5fa09a8a-53fc-4bfc-9404-09d15374a7a2",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Lymphoma characterized by heterogeneous mixture of nonneoplastic inflammatory and accessory cells and minor component of large neoplastic HRS cells"
                  },
                  {
                    "text": "Histologically and biologically distinct from NLPHL with 4 histologic subtypes: NS, MC, LD, LR"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Bimodal peaks: 15-35 yr; > 54 yr"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Neoplastic mononuclear Hodgkin cells and multinucleated RS cells (pathognomonic)Nuclei of HRS cells are large and pleomorphic, each containing single prominent eosinophilic nucleolus; cytoplasm is eosinophilic/amphophilicLacunar cells are large cells with lobated nuclei and less prominent nucleoli than other HRS cells, surrounded by clear space imparting lacunar appearance",
                    "sub_points": [
                      "Nuclei of HRS cells are large and pleomorphic, each containing single prominent eosinophilic nucleolus; cytoplasm is eosinophilic/amphophilic",
                      "Lacunar cells are large cells with lobated nuclei and less prominent nucleoli than other HRS cells, surrounded by clear space imparting lacunar appearance"
                    ]
                  },
                  {
                    "text": "Non-neoplastic cells: Lymphocytes (CD4+ T cells >> CD8+ T cells), eosinophils, immunoblasts, plasma cells, neutrophils, histiocytes, fibroblasts"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Flow cytometry typically does not detect HRS cells because of of relative paucity of cells"
                  },
                  {
                    "text": "Immunohistochemistry: HRS cells are CD30+, CD15+/-, weakly PAX-5 positive, CD45-"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Anaplastic large cell lymphoma, peripheral T-cell lymphoma, NLPHL, DLBCL"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Classical Hodgkin lymphoma (CHL)"
                  },
                  {
                    "text": "Hodgkin Reed-Sternberg (HRS)"
                  },
                  {
                    "text": "Nodular sclerosis (NS)"
                  },
                  {
                    "text": "Mixed cellularity (MC)"
                  },
                  {
                    "text": "Lymphocyte-rich (LR)"
                  },
                  {
                    "text": "Lymphocyte-depleted (LD)"
                  },
                  {
                    "text": "Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)"
                  },
                  {
                    "text": "Epstein-Barr virus (EBV)"
                  },
                  {
                    "text": "Human immunodeficiency virus (HIV)"
                  },
                  {
                    "text": "T-helper (Th)"
                  },
                  {
                    "text": "Adriamycin (doxorubicin), bleomycin, vinblastine, dacarbazine (ABVD)"
                  },
                  {
                    "text": "Reed-Sternberg (RS)"
                  },
                  {
                    "text": "Acid-fast bacillus (AFB)"
                  },
                  {
                    "text": "Periodic acid-Schiff/Gomori methenamine silver (PAS/GMS)"
                  },
                  {
                    "text": "Epstein-Barr encoded RNA (EBER)"
                  },
                  {
                    "text": "Comparative genomic hybridization (CGH)"
                  },
                  {
                    "text": "Anaplastic lymphoma kinase (ALK)"
                  },
                  {
                    "text": "Epithelial membrane antigen (EMA)"
                  },
                  {
                    "text": "Latent membrane protein-1 (LMP-1)"
                  },
                  {
                    "text": "Diffuse large B-cell lymphoma (DLBCL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Hodgkin disease"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Lymphoma characterized by heterogeneous mixture of nonneoplastic inflammatory and accessory cells and minor component of large neoplastic HRS cells"
                  },
                  {
                    "text": "Histologic subtypesNSMCLRLD",
                    "sub_points": [
                      "NS",
                      "MC",
                      "LR",
                      "LD"
                    ]
                  },
                  {
                    "text": "Histologically and biologically distinct from NLPHL"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Environmental Exposure": [
                  {
                    "text": "EBV postulated to play roleEBV-encoded RNA is present in subset of CHL casesPatients in advanced stagesElderly patientsHIV-positive patientsInfectious mononucleosis may predispose to Hodgkin lymphoma",
                    "sub_points": [
                      "EBV-encoded RNA is present in subset of CHL casesPatients in advanced stagesElderly patientsHIV-positive patients",
                      "Patients in advanced stages",
                      "Elderly patients",
                      "HIV-positive patients",
                      "Infectious mononucleosis may predispose to Hodgkin lymphoma"
                    ]
                  },
                  {
                    "text": "HIV infection and immunosuppression (iatrogenic)"
                  },
                  {
                    "text": "Neoplastic HRS cells of germinal center B-cell originClonalIGVHgene mutationsEscape apoptosisAcquire dysregulated signaling pathwaysExpress various Th1-related and Th2-related cytokinesAttracts nonneoplastic inflammatory cellsCreates pro-survival and proliferative microenvironment",
                    "sub_points": [
                      "ClonalIGVHgene mutations",
                      "Escape apoptosis",
                      "Acquire dysregulated signaling pathways",
                      "Express various Th1-related and Th2-related cytokinesAttracts nonneoplastic inflammatory cellsCreates pro-survival and proliferative microenvironment",
                      "Attracts nonneoplastic inflammatory cells",
                      "Creates pro-survival and proliferative microenvironment"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Incidence3-5 cases per 100,000 people per year20%-30% of all lymphomas",
                    "sub_points": [
                      "3-5 cases per 100,000 people per year",
                      "20%-30% of all lymphomas"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Bimodal peaks15-35 yr> 54 yr",
                    "sub_points": [
                      "15-35 yr",
                      "> 54 yr"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "M > F (except NS CHL)"
                  }
                ],
                "Site": [
                  {
                    "text": "Cervical and supraclavicular lymph nodes75% of cases",
                    "sub_points": [
                      "75% of cases"
                    ]
                  },
                  {
                    "text": "Mediastinal, axillary, and para-aortic lymph nodes"
                  },
                  {
                    "text": "Splenic involvement20% of cases",
                    "sub_points": [
                      "20% of cases"
                    ]
                  },
                  {
                    "text": "Bone marrow5% of casesIndicates vascular invasion (stage IV disease)",
                    "sub_points": [
                      "5% of cases",
                      "Indicates vascular invasion (stage IV disease)"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Peripheral lymphadenopathy"
                  },
                  {
                    "text": "Mediastinal massMore common in NS CHL",
                    "sub_points": [
                      "More common in NS CHL"
                    ]
                  },
                  {
                    "text": "B symptomsFevers, night sweats, weight loss, pruritus, anorexia, fatigue, generalized weakness30%-40% of patients",
                    "sub_points": [
                      "Fevers, night sweats, weight loss, pruritus, anorexia, fatigue, generalized weakness",
                      "30%-40% of patients"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "ChemotherapyFavorable prognosisABVD",
                    "sub_points": [
                      "Favorable prognosis",
                      "ABVD"
                    ]
                  },
                  {
                    "text": "Radiation after chemotherapyUnfavorable prognosis",
                    "sub_points": [
                      "Unfavorable prognosis"
                    ]
                  },
                  {
                    "text": "Chemotherapy and autologous stem cell transplantRecurrent disease",
                    "sub_points": [
                      "Recurrent disease"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "At early stage > 80% 5-yr survival"
                  },
                  {
                    "text": "Adverse prognostic factorsAdvanced stageMassive mediastinal involvementOlder age, usually > 45 yrMale sex",
                    "sub_points": [
                      "Advanced stage",
                      "Massive mediastinal involvement",
                      "Older age, usually > 45 yr",
                      "Male sex"
                    ]
                  },
                  {
                    "text": "Factors most commonly related to deathSecondary malignancyTherapeutic toxicityOlder age",
                    "sub_points": [
                      "Secondary malignancy",
                      "Therapeutic toxicity",
                      "Older age"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Nonneoplastic cellsMixed inflammatory cellsLymphocytes (CD4+ T cells >> CD8+ T cells)EosinophilsImmunoblastsPlasma cellsNeutrophilsHistiocytesFibroblastsComposition varies with histologic subtypeCytokine-mediated response to HRS cells",
                    "sub_points": [
                      "Mixed inflammatory cellsLymphocytes (CD4+ T cells >> CD8+ T cells)EosinophilsImmunoblastsPlasma cellsNeutrophilsHistiocytesFibroblasts",
                      "Lymphocytes (CD4+ T cells >> CD8+ T cells)",
                      "Eosinophils",
                      "Immunoblasts",
                      "Plasma cells",
                      "Neutrophils",
                      "Histiocytes",
                      "Fibroblasts",
                      "Composition varies with histologic subtype",
                      "Cytokine-mediated response to HRS cells"
                    ]
                  },
                  {
                    "text": "Neoplastic HRS cells (pathognomonic)Mononuclear Hodgkin cells and multinucleated RS cells with prominent nucleoli \"owl eyes\"",
                    "sub_points": [
                      "Mononuclear Hodgkin cells and multinucleated RS cells with prominent nucleoli \"owl eyes\""
                    ]
                  },
                  {
                    "text": "NS CHLMediastinal involvement more common (80%)Nodules surrounded by broad, interconnecting bands of fibrocollagenous tissueEBV positive in 10%-40% cases",
                    "sub_points": [
                      "Mediastinal involvement more common (80%)",
                      "Nodules surrounded by broad, interconnecting bands of fibrocollagenous tissue",
                      "EBV positive in 10%-40% cases"
                    ]
                  },
                  {
                    "text": "MC CHLPeripheral lymph nodes more commonly involvedProminent mixed cellular infiltrateLymphocytes, plasma cells, eosinophils, histocytes, neutrophilsFrequent HRS cells and Hodgkin cellsEBV positive in 75% cases",
                    "sub_points": [
                      "Peripheral lymph nodes more commonly involved",
                      "Prominent mixed cellular infiltrateLymphocytes, plasma cells, eosinophils, histocytes, neutrophilsFrequent HRS cells and Hodgkin cellsEBV positive in 75% cases",
                      "Lymphocytes, plasma cells, eosinophils, histocytes, neutrophils",
                      "Frequent HRS cells and Hodgkin cells",
                      "EBV positive in 75% cases"
                    ]
                  },
                  {
                    "text": "LR CHLPeripheral lymph nodes more commonEarly stagePredominance of lymphocytesMay resemble NLPHLNo lymphocytic and histiocytic \"popcorn\" cells of NLPHLFew HRS cells",
                    "sub_points": [
                      "Peripheral lymph nodes more common",
                      "Early stage",
                      "Predominance of lymphocytesMay resemble NLPHLNo lymphocytic and histiocytic \"popcorn\" cells of NLPHL",
                      "May resemble NLPHLNo lymphocytic and histiocytic \"popcorn\" cells of NLPHL",
                      "No lymphocytic and histiocytic \"popcorn\" cells of NLPHL",
                      "Few HRS cells"
                    ]
                  },
                  {
                    "text": "LD CHLPredilection for retroperitoneal lymph nodes and abdominal organsRelative predominance of HRS cells in relation to background lymphocytesMost aggressive form of CHL",
                    "sub_points": [
                      "Predilection for retroperitoneal lymph nodes and abdominal organs",
                      "Relative predominance of HRS cells in relation to background lymphocytes",
                      "Most aggressive form of CHL"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Nuclei of HRS cellsLarge and pleomorphicEach cell contains single prominent eosinophilic nucleolusCytoplasm is eosinophilic/amphophilic",
                    "sub_points": [
                      "Large and pleomorphic",
                      "Each cell contains single prominent eosinophilic nucleolus",
                      "Cytoplasm is eosinophilic/amphophilic"
                    ]
                  },
                  {
                    "text": "RS cellsLarge binucleate cells with very prominent nucleoli",
                    "sub_points": [
                      "Large binucleate cells with very prominent nucleoli"
                    ]
                  },
                  {
                    "text": "Hodgkin cellsLarge mononuclear cells with prominent nucleoli",
                    "sub_points": [
                      "Large mononuclear cells with prominent nucleoli"
                    ]
                  },
                  {
                    "text": "Lacunar cellsLarge cells with lobated nuclei and less prominent nucleoli than other HRS cells surrounded by clear space imparting lacunar appearance",
                    "sub_points": [
                      "Large cells with lobated nuclei and less prominent nucleoli than other HRS cells surrounded by clear space imparting lacunar appearance"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Histochemistry": [
                  {
                    "text": "In cases with prominent histiocytes, granulomas, or necrosisAFB stain to rule out acid-fast bacilliPAS/GMS stain to rule out fungal organisms",
                    "sub_points": [
                      "AFB stain to rule out acid-fast bacilli",
                      "PAS/GMS stain to rule out fungal organisms"
                    ]
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "Basic immunohistochemical panelCD3, CD20, CD30, CD15, CD45, PAX-5HRS cells show CD30 positive staining in Golgi and membranous pattern",
                    "sub_points": [
                      "CD3, CD20, CD30, CD15, CD45, PAX-5HRS cells show CD30 positive staining in Golgi and membranous pattern",
                      "HRS cells show CD30 positive staining in Golgi and membranous pattern"
                    ]
                  },
                  {
                    "text": "Additional stainsCD79a, OCT.2, BOB.1",
                    "sub_points": [
                      "CD79a, OCT.2, BOB.1"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Typically does not detect HRS cells because of relative paucity of cells"
                  },
                  {
                    "text": "Polytypic B cellsUseful to exclude involvement by B-cell non-Hodgkin lymphoma",
                    "sub_points": [
                      "Useful to exclude involvement by B-cell non-Hodgkin lymphoma"
                    ]
                  },
                  {
                    "text": "Polytypic T cells with normal immunophenotypeIncreased CD4-to-CD8 ratio can be seen in CHL",
                    "sub_points": [
                      "Increased CD4-to-CD8 ratio can be seen in CHL"
                    ]
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "EBER positive in approximately 20% of cases (depending on histologic subtypes)"
                  }
                ],
                "PCR": [
                  {
                    "text": "Clonal immunoglobulin gene rearrangement variable regions (IGHV@) in > 98% of cases"
                  },
                  {
                    "text": "ClonalTCRgene rearrangement rare"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Cytogenetic evaluation difficult due to low frequency of neoplastic CHL cells"
                  },
                  {
                    "text": "Recurrent chromosomal abnormalities on CGH arrayChromosomal aberrations and hyperdiploidy detected in 100% of cases of CHLAmplified region on 2p13 (RELoncogene)",
                    "sub_points": [
                      "Chromosomal aberrations and hyperdiploidy detected in 100% of cases of CHL",
                      "Amplified region on 2p13 (RELoncogene)"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Anaplastic Large Cell Lymphoma": [
                  {
                    "text": "Can mimic CHL with anaplastic cells"
                  },
                  {
                    "text": "Different from CHLALK+/-, cytotoxic T-cell markers positive (granzyme B, perforin), CD45+/-, EMA+, and T-cell markers often positiveStrong and uniform CD30 expressionRare CD15 expressionTCRclonal rearrangement in 80%-90% cases",
                    "sub_points": [
                      "ALK+/-, cytotoxic T-cell markers positive (granzyme B, perforin), CD45+/-, EMA+, and T-cell markers often positive",
                      "Strong and uniform CD30 expression",
                      "Rare CD15 expression",
                      "TCRclonal rearrangement in 80%-90% cases"
                    ]
                  }
                ],
                "Peripheral T-Cell Lymphoma": [
                  {
                    "text": "Mimicking featuresPolymorphous inflammatory backgroundRS-like giant cells (can coexpress CD15 and CD30)",
                    "sub_points": [
                      "Polymorphous inflammatory background",
                      "RS-like giant cells (can coexpress CD15 and CD30)"
                    ]
                  },
                  {
                    "text": "Different from CHLNeoplastic cells positive for T-cell markers",
                    "sub_points": [
                      "Neoplastic cells positive for T-cell markers"
                    ]
                  }
                ],
                "Nodular Lymphocyte Predominant Hodgkin Lymphoma": [
                  {
                    "text": "Can mimic LR CHL"
                  },
                  {
                    "text": "Different from CHLBackground mixed B and T lymphocytesEosinophils, neutrophils, plasma cells unusualNodular progressively transformed germinal centersImmunophenotype of neoplastic cells differentStrongly positive: CD20, CD45, EMA, CD79a, J chain, BOB.1, OCT.2Negative: CD15, CD30, EBV LMP1",
                    "sub_points": [
                      "Background mixed B and T lymphocytesEosinophils, neutrophils, plasma cells unusual",
                      "Eosinophils, neutrophils, plasma cells unusual",
                      "Nodular progressively transformed germinal centers",
                      "Immunophenotype of neoplastic cells differentStrongly positive: CD20, CD45, EMA, CD79a, J chain, BOB.1, OCT.2Negative: CD15, CD30, EBV LMP1",
                      "Strongly positive: CD20, CD45, EMA, CD79a, J chain, BOB.1, OCT.2",
                      "Negative: CD15, CD30, EBV LMP1"
                    ]
                  }
                ],
                "Diffuse Large B-Cell Lymphoma": [
                  {
                    "text": "In contrast to CHL, RS-like giant cells of DLBCL typically lack large eosinophilic nucleoli and thick nuclear membranePrimary mediastinal (thymic) large B-cell lymphomaMay mimic NS CHL of mediastinumDifferent from CHLExpress B-cell markers: CD19, CD20, CD22, CD79aCD15 rarely presentT-cell/histiocyte-rich large B-cell lymphomaMay mimic CHL and NLPHLDifferent from CHLExpress pan B-cell antigens: strong CD20 and Bcl-6CD30-, CD15-, EMA+/-",
                    "sub_points": [
                      "Primary mediastinal (thymic) large B-cell lymphomaMay mimic NS CHL of mediastinumDifferent from CHLExpress B-cell markers: CD19, CD20, CD22, CD79aCD15 rarely present",
                      "May mimic NS CHL of mediastinum",
                      "Different from CHLExpress B-cell markers: CD19, CD20, CD22, CD79aCD15 rarely present",
                      "Express B-cell markers: CD19, CD20, CD22, CD79a",
                      "CD15 rarely present",
                      "T-cell/histiocyte-rich large B-cell lymphomaMay mimic CHL and NLPHLDifferent from CHLExpress pan B-cell antigens: strong CD20 and Bcl-6CD30-, CD15-, EMA+/-",
                      "May mimic CHL and NLPHL",
                      "Different from CHLExpress pan B-cell antigens: strong CD20 and Bcl-6CD30-, CD15-, EMA+/-",
                      "Express pan B-cell antigens: strong CD20 and Bcl-6",
                      "CD30-, CD15-, EMA+/-"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Bimodal age distribution in adults"
                  },
                  {
                    "text": "Rare in children"
                  },
                  {
                    "text": "Increased incidence in immunocompromised patients"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Histologic subtypes based on inflammatory background and architecture (e.g., fibrosis)"
                  },
                  {
                    "text": "HRS cells in inflammatory background are required"
                  },
                  {
                    "text": "HRS cell are CD30+, CD15+/-, weakly PAX-5 positive, and CD45-"
                  },
                  {
                    "text": "Distinct immunohistochemistry between CHL and NLPHL"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Nodular Lymphocyte Predominant Hodgkin Lymphoma": {
            "name": "Nodular Lymphocyte Predominant Hodgkin Lymphoma",
            "url": "https://app.pathprimer.com/document/6ba50e67-9791-4aa3-b3d7-8e5bc1229618/lesson/5fa09a8a-53fc-4bfc-9404-09d15374a7a2",
            "content": {
              "KEY FACTS": {
                "Clinical Issues": [
                  {
                    "text": "Peak incidence in fourth decade, affects all age groups"
                  },
                  {
                    "text": "Patients often present with stage I or II nodal disease"
                  },
                  {
                    "text": "Cervical, axillary, or inguinal lymph nodes"
                  },
                  {
                    "text": "Slow progression and frequent relapses"
                  },
                  {
                    "text": "Excellent prognosis"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "LP cells scattered in background of small lymphocytes and histiocytesLP cells have vesicular chromatin, inconspicuous nucleolus, and thin nuclear membrane",
                    "sub_points": [
                      "LP cells have vesicular chromatin, inconspicuous nucleolus, and thin nuclear membrane"
                    ]
                  },
                  {
                    "text": "Mixture of different cell types gives \"moth-eaten\" pattern on low-power view"
                  },
                  {
                    "text": "No necrosis or thick fibrous bands"
                  },
                  {
                    "text": "Uninvolved lymph node shows reactive follicular hyperplasia &/or PTGC"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Immunophenotype of LP cellsCD20(+), CD22(+), CD45/LCA(+), CD79a(+)BCL-6(+), PAX-5(+), OCT2(+), BOB1(+)CD15(-), CD30(-), EBV(-), Bcl-2(-)",
                    "sub_points": [
                      "CD20(+), CD22(+), CD45/LCA(+), CD79a(+)",
                      "BCL-6(+), PAX-5(+), OCT2(+), BOB1(+)",
                      "CD15(-), CD30(-), EBV(-), Bcl-2(-)"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Nodular proliferation of scattered large neoplastic B cells associated with numerous inflammatory cellsNeoplastic cells are designated as lymphocyte-predominant (LP) cellsa.k.a. \"popcorn\" cells because of their hyperlobated nuclei with vesicular chromatinFormerly called L&H (lymphocytic &/or histiocytic) cellsNeoplastic cells are usually confined within follicular dendritic cell meshworksBackground infiltrate of nonneoplastic small lymphocytes and histiocytesInflammatory cells greatly outnumber neoplastic LP cells",
                    "sub_points": [
                      "Neoplastic cells are designated as lymphocyte-predominant (LP) cellsa.k.a. \"popcorn\" cells because of their hyperlobated nuclei with vesicular chromatinFormerly called L&H (lymphocytic &/or histiocytic) cells",
                      "a.k.a. \"popcorn\" cells because of their hyperlobated nuclei with vesicular chromatin",
                      "Formerly called L&H (lymphocytic &/or histiocytic) cells",
                      "Neoplastic cells are usually confined within follicular dendritic cell meshworks",
                      "Background infiltrate of nonneoplastic small lymphocytes and histiocytesInflammatory cells greatly outnumber neoplastic LP cells",
                      "Inflammatory cells greatly outnumber neoplastic LP cells"
                    ]
                  },
                  {
                    "text": "Diffuse form of NLPHLTerm derived from Lukes and Butler classification, but its existence has been challengedMost cases in this category have been reclassified asT-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)NLPHL with diffuse THRLBCL-like areasClassical Hodgkin lymphoma (CHL)Rare cases of diffuse NLPHL probably exist, i.e., \"moth-eaten\" B-cell-rich pattern of NLPHL",
                    "sub_points": [
                      "Term derived from Lukes and Butler classification, but its existence has been challenged",
                      "Most cases in this category have been reclassified asT-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)NLPHL with diffuse THRLBCL-like areasClassical Hodgkin lymphoma (CHL)",
                      "T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)",
                      "NLPHL with diffuse THRLBCL-like areas",
                      "Classical Hodgkin lymphoma (CHL)",
                      "Rare cases of diffuse NLPHL probably exist, i.e., \"moth-eaten\" B-cell-rich pattern of NLPHL"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Postulated Normal Counterpart": [
                  {
                    "text": "Germinal center B lymphocyte at centroblast stage of differentiation"
                  }
                ],
                "Associated Lesions": [
                  {
                    "text": "NLPHL is associated with progressive transformation of germinal centers (PTGC)PTGC and NLPHL can involve same lymph node biopsy specimenIn past, PTGC often identified in staging laparotomy specimens of NLPHL patientsHowever, prospective studies of patients with PTGC show no increased risk of NLPHL",
                    "sub_points": [
                      "PTGC and NLPHL can involve same lymph node biopsy specimen",
                      "In past, PTGC often identified in staging laparotomy specimens of NLPHL patients",
                      "However, prospective studies of patients with PTGC show no increased risk of NLPHL"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "5-6% of all Hodgkin lymphomas"
                  }
                ],
                "Age": [
                  {
                    "text": "Median: 35 years"
                  },
                  {
                    "text": "All age groups are affected"
                  }
                ],
                "Sex": [
                  {
                    "text": "Male to female ratio > 2:1"
                  }
                ],
                "Site": [
                  {
                    "text": "Lymph nodes"
                  },
                  {
                    "text": "Most commonly affected groups include cervical, axillary, or inguinal lymph nodesPara-aortic and iliac lymph nodes less often involved",
                    "sub_points": [
                      "Para-aortic and iliac lymph nodes less often involved"
                    ]
                  },
                  {
                    "text": "Liver &/or spleen involved in ~ 10% of cases"
                  },
                  {
                    "text": "Mediastinum involved in ~ 7%"
                  },
                  {
                    "text": "Bone marrow rarely involved (~ 2%)Bone marrow involvement is usually evidence of transformation to large B-cell lymphoma",
                    "sub_points": [
                      "Bone marrow involvement is usually evidence of transformation to large B-cell lymphoma"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Peripheral lymphadenopathyStage I or II in ~ 80% of patients",
                    "sub_points": [
                      "Stage I or II in ~ 80% of patients"
                    ]
                  },
                  {
                    "text": "B symptoms are uncommon (~ 10%)"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Normal complete blood count; no leukemic phase"
                  },
                  {
                    "text": "Serum lactate dehydrogenase (LDH) or β-2-microglobulin levels are rarely elevated"
                  }
                ],
                "Natural History": [
                  {
                    "text": "NLPHL is clinically indolent disease with frequent relapses"
                  },
                  {
                    "text": "Relapse-free survival curves show \"staircase\"No plateau suggestive of cureEarly and late (> 10 years) relapses occurRisk of relapse is independent of stage of disease or therapyRelapse can be localized or generalized (~ 20%) disease",
                    "sub_points": [
                      "No plateau suggestive of cure",
                      "Early and late (> 10 years) relapses occur",
                      "Risk of relapse is independent of stage of disease or therapy",
                      "Relapse can be localized or generalized (~ 20%) disease"
                    ]
                  },
                  {
                    "text": "~ 3-5% of NLPHL transform to large B-cell lymphoma (LBCL)"
                  },
                  {
                    "text": "~ 15% of patients die of disease with prolonged follow-up"
                  }
                ],
                "Treatment": [],
                "Options, risks, complications": [
                  {
                    "text": "\"Watch and wait\" has been advocated for pediatric patients with localized disease"
                  }
                ],
                "Drugs": [
                  {
                    "text": "Combination chemotherapy employed most often"
                  },
                  {
                    "text": "Rituximab (anti-CD20) monoclonal antibody is often used"
                  }
                ],
                "Radiation": [
                  {
                    "text": "Localized disease may be treated with involved field radiation aloneThis option is avoided in pediatric and adolescent patients to avoid injuring growth plates of bones",
                    "sub_points": [
                      "This option is avoided in pediatric and adolescent patients to avoid injuring growth plates of bones"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Good prognosis with > 80% 10-year survivalBetter survival for patients with low- vs. high-stage diseasePatients with NLPHL have better survival than patients with classical Hodgkin lymphoma",
                    "sub_points": [
                      "Better survival for patients with low- vs. high-stage disease",
                      "Patients with NLPHL have better survival than patients with classical Hodgkin lymphoma"
                    ]
                  },
                  {
                    "text": "Transformation to diffuse large B-cell lymphoma or THRLBCL is often associated with poorer prognosisBone marrow involvement is associated with aggressive clinical behaviorPrognosis may not be impacted if large B-cell lymphoma is localized and treated appropriately",
                    "sub_points": [
                      "Bone marrow involvement is associated with aggressive clinical behavior",
                      "Prognosis may not be impacted if large B-cell lymphoma is localized and treated appropriately"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Complete or partial effacement of lymph node architectureNodular or nodular and diffuse patternsExpansile nodules composed mostly of small lymphocytes and fewer histiocytesReactive lymphoid follicles usually absent within nodulesAbsent or rare centrocytes or centroblasts within nodulesNodules larger than normal lymphoid follicles",
                    "sub_points": [
                      "Nodular or nodular and diffuse patterns",
                      "Expansile nodules composed mostly of small lymphocytes and fewer histiocytesReactive lymphoid follicles usually absent within nodulesAbsent or rare centrocytes or centroblasts within nodules",
                      "Reactive lymphoid follicles usually absent within nodules",
                      "Absent or rare centrocytes or centroblasts within nodules",
                      "Nodules larger than normal lymphoid follicles"
                    ]
                  },
                  {
                    "text": "LP cells are large and scattered amongst abundant small lymphocytes and histiocytesRepresent ~ 1% of all cellsLP cells have variety of appearancesMultilobated \"popcorn\" cells with vesicular chromatin and multiple small nucleoliMultinucleated or mummified cellsLP cells also can be round without multilobation",
                    "sub_points": [
                      "Represent ~ 1% of all cells",
                      "LP cells have variety of appearancesMultilobated \"popcorn\" cells with vesicular chromatin and multiple small nucleoliMultinucleated or mummified cellsLP cells also can be round without multilobation",
                      "Multilobated \"popcorn\" cells with vesicular chromatin and multiple small nucleoli",
                      "Multinucleated or mummified cells",
                      "LP cells also can be round without multilobation"
                    ]
                  },
                  {
                    "text": "Histiocytes may be epithelioid &/or form small granulomasMay form \"wreath\" around neoplastic nodules",
                    "sub_points": [
                      "May form \"wreath\" around neoplastic nodules"
                    ]
                  },
                  {
                    "text": "Residual/uninvolved lymph node in biopsy specimens of NLPHLReactive follicular hyperplasia is usually presentPTGC commonly present",
                    "sub_points": [
                      "Reactive follicular hyperplasia is usually present",
                      "PTGC commonly present"
                    ]
                  }
                ],
                "Transformation of NLPHL to Large Cell Lymphoma": [
                  {
                    "text": "Large cell lymphoma may coexist with or follow NLPHLLarge cells may form sheets, as in de novo diffuse large B-cell lymphoma, or be scattered, as in THRLBCL",
                    "sub_points": [
                      "Large cells may form sheets, as in de novo diffuse large B-cell lymphoma, or be scattered, as in THRLBCL"
                    ]
                  },
                  {
                    "text": "Transformation of NLPHL to THRLBCL can be diagnosed whenDiffuse areas of THRLBCL are identified, andPatients have high-stage disease, including bone marrow involvement, &/or other clinical evidence of transformation, such asHigh serum lactate dehydrogenase or β-2-microglobulin levelsLytic bone lesions",
                    "sub_points": [
                      "Diffuse areas of THRLBCL are identified, and",
                      "Patients have high-stage disease, including bone marrow involvement, &/or other clinical evidence of transformation, such asHigh serum lactate dehydrogenase or β-2-microglobulin levelsLytic bone lesions",
                      "High serum lactate dehydrogenase or β-2-microglobulin levels",
                      "Lytic bone lesions"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "LP cellsCD20(+), CD22(+), CD79a(+),PAX-5(+), OCT2(+), BOB1(+), BCL-6(+)CD45/LCA(+), Ki-67 (proliferation) highEMA and MUM1(+) in ~ 50% of casesIgD(+) in ~ 25% of casesIgD correlates with younger patient agePan-T-cell antigens(-), Bcl-2(-)CD15(-) and CD30(-)Epstein-Barr virus (EBV)-LMP1(-)",
                    "sub_points": [
                      "CD20(+), CD22(+), CD79a(+),",
                      "PAX-5(+), OCT2(+), BOB1(+), BCL-6(+)",
                      "CD45/LCA(+), Ki-67 (proliferation) high",
                      "EMA and MUM1(+) in ~ 50% of cases",
                      "IgD(+) in ~ 25% of casesIgD correlates with younger patient age",
                      "IgD correlates with younger patient age",
                      "Pan-T-cell antigens(-), Bcl-2(-)",
                      "CD15(-) and CD30(-)",
                      "Epstein-Barr virus (EBV)-LMP1(-)"
                    ]
                  },
                  {
                    "text": "Background inflammatory infiltrateSmall lymphocytes are mixture of B and T cellsB cells; normal mature B-cell staining patternCD19(+), CD20(+), CD22(+), pax-5(+)CD10(-), Bcl-6(-)T cells form \"rosettes\" around LP cellsCD2(+), CD3(+), CD5(+), CD7(+)Minor population of CD3(+) cells is of follicular T-helper cell lineageCD3(+), CD4(+), CD57(+)CD10(+), Bcl-6(+), PD-1(+)Form \"rosettes\" around LP cells in ~ 50% of casesFollicular dendritic cell meshworks are present in nodular areasCD21(+), CD23(+), &/or CD35(+)Histiocytes",
                    "sub_points": [
                      "Small lymphocytes are mixture of B and T cells",
                      "B cells; normal mature B-cell staining patternCD19(+), CD20(+), CD22(+), pax-5(+)CD10(-), Bcl-6(-)",
                      "CD19(+), CD20(+), CD22(+), pax-5(+)",
                      "CD10(-), Bcl-6(-)",
                      "T cells form \"rosettes\" around LP cellsCD2(+), CD3(+), CD5(+), CD7(+)",
                      "CD2(+), CD3(+), CD5(+), CD7(+)",
                      "Minor population of CD3(+) cells is of follicular T-helper cell lineageCD3(+), CD4(+), CD57(+)CD10(+), Bcl-6(+), PD-1(+)Form \"rosettes\" around LP cells in ~ 50% of cases",
                      "CD3(+), CD4(+), CD57(+)",
                      "CD10(+), Bcl-6(+), PD-1(+)",
                      "Form \"rosettes\" around LP cells in ~ 50% of cases",
                      "Follicular dendritic cell meshworks are present in nodular areasCD21(+), CD23(+), &/or CD35(+)",
                      "CD21(+), CD23(+), &/or CD35(+)",
                      "Histiocytes"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Large neoplastic cells are lost or overlooked in routine flow cytometric analysis"
                  }
                ],
                "PCR": [
                  {
                    "text": "MonoclonalIgHor light chain gene rearrangements when using single-cell PCR analysis"
                  },
                  {
                    "text": "Rearrangements often not detectable using standard PCR or Southern blot methods and whole biopsy specimens"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Frequent somatic mutations ofIgHvariable regionEvidence of ongoing mutations",
                    "sub_points": [
                      "Evidence of ongoing mutations"
                    ]
                  },
                  {
                    "text": "BCL6gene rearrangements in ~ 50% of casesIgHis most common partnerOther partners: Chromosome loci 2q23; 5q31, 6q22, 9q22, and 17p21",
                    "sub_points": [
                      "IgHis most common partner",
                      "Other partners: Chromosome loci 2q23; 5q31, 6q22, 9q22, and 17p21"
                    ]
                  },
                  {
                    "text": "Usually complex structural karyotypic aberrations"
                  },
                  {
                    "text": "Chromosome 3q27 (BCL6locus) involved in up to 60% of cases"
                  }
                ],
                "Array CGH": [
                  {
                    "text": "30-60% of cases may show gains or losses of chromosomesGains: Chromosomes 1, 2q, 3, 4q, 5q, 6, 8q, 11q, 12q, and XLoss: Chromosome 17",
                    "sub_points": [
                      "Gains: Chromosomes 1, 2q, 3, 4q, 5q, 6, 8q, 11q, 12q, and X",
                      "Loss: Chromosome 17"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Lymphocyte-Rich Classical Hodgkin Lymphoma, Nodular Variant": [
                  {
                    "text": "Form of classical Hodgkin lymphoma with prominent nodular pattern that can closely mimic NLPHL"
                  },
                  {
                    "text": "Nodules composed of prominent mantle zones with atrophic or absent germinal centers"
                  },
                  {
                    "text": "HRS cells in mantle zones of enlarged lymphoid follicles"
                  },
                  {
                    "text": "ImmunophenotypeHRS cells are CD15(+), CD30(+), EBV-LMP1(+/-), CD45/LCA(-)",
                    "sub_points": [
                      "HRS cells are CD15(+), CD30(+), EBV-LMP1(+/-), CD45/LCA(-)"
                    ]
                  }
                ],
                "T-Cell/Histiocyte-Rich Large B-Cell (THRLBCL) Lymphoma": [
                  {
                    "text": "Affects elderly patients; rare in children and adolescents"
                  },
                  {
                    "text": "B symptoms, high stage, and elevated serum LDH levels"
                  },
                  {
                    "text": "Usually not associated with reactive follicular hyperplasia or PTGC"
                  },
                  {
                    "text": "Diffuse growth pattern"
                  },
                  {
                    "text": "Large neoplastic cells represent < 10% of all cells in specimen"
                  }
                ],
                "Nodular Sclerosis Hodgkin Lymphoma": [
                  {
                    "text": "Uncommonly, cases of NLPHL are associated with fibrosisInguinal region is common site of fibrosisFibrosis is more often present at time of relapse",
                    "sub_points": [
                      "Inguinal region is common site of fibrosis",
                      "Fibrosis is more often present at time of relapse"
                    ]
                  },
                  {
                    "text": "Fibrosis in NLPHL is not birefringent/polarizableFibrous bands surrounding nodules are not present",
                    "sub_points": [
                      "Fibrous bands surrounding nodules are not present"
                    ]
                  },
                  {
                    "text": "ImmunophenotypeHRS cells are CD15(+), CD30(+), EBV-LMP1(+/-), CD45/LCA(-)",
                    "sub_points": [
                      "HRS cells are CD15(+), CD30(+), EBV-LMP1(+/-), CD45/LCA(-)"
                    ]
                  }
                ],
                "Follicular Lymphoma": [
                  {
                    "text": "Usually stage IV disease on presentation"
                  },
                  {
                    "text": "Neoplastic follicles typically smaller than those seen in NLPHLNeoplastic follicles commonly found in perinodal soft tissue",
                    "sub_points": [
                      "Neoplastic follicles commonly found in perinodal soft tissue"
                    ]
                  },
                  {
                    "text": "Abundant neoplastic small and large centrocytes and large centroblasts"
                  },
                  {
                    "text": "ImmunophenotypeCD10(+), Bcl-6(+), Bcl-2(+)Flow cytometry immunophenotype shows monotypic B-lymphocytes, CD10(+)",
                    "sub_points": [
                      "CD10(+), Bcl-6(+), Bcl-2(+)",
                      "Flow cytometry immunophenotype shows monotypic B-lymphocytes, CD10(+)"
                    ]
                  }
                ],
                "Progressive Transformation of Germinal Centers": [
                  {
                    "text": "Rare patients can present with florid syndrome with generalized lymphadenopathy"
                  },
                  {
                    "text": "Lymph node architecture is preserved"
                  },
                  {
                    "text": "Markedly enlarged lymphoid follicles (often 3-4x larger than typical reactive follicle)"
                  },
                  {
                    "text": "Lymphoid follicles extensively colonized by mantle zone lymphocytesCan infiltrate and obliterate germinal centers",
                    "sub_points": [
                      "Can infiltrate and obliterate germinal centers"
                    ]
                  },
                  {
                    "text": "Enlarged follicles with underlying follicular dendritic cell meshwork"
                  },
                  {
                    "text": "LP cells are absent"
                  },
                  {
                    "text": "CD4(+), CD8(+) T cells are increased (similar to NLPHL)"
                  }
                ],
                "Reactive Lymphoid Hyperplasia": [
                  {
                    "text": "Lymph node architecture is preserved"
                  },
                  {
                    "text": "Well-defined germinal centers with polarization and distinct mantle zones"
                  },
                  {
                    "text": "Small and large centrocytes and centroblasts without atypia"
                  },
                  {
                    "text": "Tingible body macrophages usually abundant and prominent"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "T-Cell and NK-Cell Neoplasms": {
        "name": "T-Cell and NK-Cell Neoplasms",
        "url": "https://app.pathprimer.com/lesson/7f0bcc37-552c-40e6-b672-243b3ec2231e",
        "topics": {
          "T-Cell Large Granular Lymphocytic Leukemia": {
            "name": "T-Cell Large Granular Lymphocytic Leukemia",
            "url": "https://app.pathprimer.com/document/9ef37edc-e0a1-4597-bdcc-ce2704fd95ce/lesson/7f0bcc37-552c-40e6-b672-243b3ec2231e",
            "content": {
              "KEY FACTS": {
                "Clinical Issues": [
                  {
                    "text": "Asymptomatic"
                  },
                  {
                    "text": "Symptomatic: Recurrent infections (neutropenia)"
                  },
                  {
                    "text": "Rheumatoid arthritis/other autoimmune diseases"
                  },
                  {
                    "text": "Splenomegaly"
                  },
                  {
                    "text": "Pure red cell aplasia"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Peripheral bloodLGL lymphocytosisLGLs generally > 2 x 10⁹/L",
                    "sub_points": [
                      "LGL lymphocytosis",
                      "LGLs generally > 2 x 10⁹/L"
                    ]
                  },
                  {
                    "text": "Bone marrow (BM)Extent of involvement is variableInterstitial/intrasinusoidal patterns commonMay be morphologically occultImmunostains helpful to identify T-LGL infiltrate",
                    "sub_points": [
                      "Extent of involvement is variable",
                      "Interstitial/intrasinusoidal patterns common",
                      "May be morphologically occult",
                      "Immunostains helpful to identify T-LGL infiltrate"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "ImmunophenotypeCD3(+), CD8(+), CD57(+), CD94(+), TCR-α/β(+)Cytoplasmic granules TIA-1, perforin, GZMM(+)Uniform expression of TCR-Vβ or KIR molecules",
                    "sub_points": [
                      "CD3(+), CD8(+), CD57(+), CD94(+), TCR-α/β(+)",
                      "Cytoplasmic granules TIA-1, perforin, GZMM(+)",
                      "Uniform expression of TCR-Vβ or KIR molecules"
                    ]
                  },
                  {
                    "text": "MolecularT-cell receptor genes rearranged",
                    "sub_points": [
                      "T-cell receptor genes rearranged"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "T-cell large granular lymphocytic leukemia (T-LGL leukemia)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Persistent clonal proliferation of T-cell large granular lymphocytes (T-LGLs)"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Hypotheses": [
                  {
                    "text": "Chronic antigenic stimulation resulting in proliferation of T-cell large granular lymphocytes (T-LGLs)Exogenous antigens such as HTLVEndogenous autoantigens",
                    "sub_points": [
                      "Exogenous antigens such as HTLV",
                      "Endogenous autoantigens"
                    ]
                  },
                  {
                    "text": "Inhibition of apoptosis resulting in accumulation of T-LGLsDysregulation of FAS/FAS-L",
                    "sub_points": [
                      "Dysregulation of FAS/FAS-L"
                    ]
                  }
                ],
                "Infectious Agents": [
                  {
                    "text": "Role of retroviral infection unclear"
                  },
                  {
                    "text": "Most patients do not show evidence of HTLV-I or HTLV-II infection"
                  },
                  {
                    "text": "Reactivity against small peptide derived from an HTLV-I envelope protein has been reported"
                  }
                ],
                "Etiology of Neutropenia": [
                  {
                    "text": "FAS/FAS-L-induced premature apoptosis of granulocytic precursors"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Comprises 2-3% of chronic lymphocytic leukemias"
                  }
                ],
                "Age": [
                  {
                    "text": "Median age: 60 years"
                  },
                  {
                    "text": "Predominantly affects adults"
                  }
                ],
                "Sex": [
                  {
                    "text": "No gender predilection"
                  }
                ],
                "Site": [
                  {
                    "text": "Peripheral blood (PB)"
                  },
                  {
                    "text": "Bone marrow (BM)"
                  },
                  {
                    "text": "Spleen"
                  },
                  {
                    "text": "Liver"
                  }
                ],
                "Presentation": [
                  {
                    "text": "AsymptomaticIncidental discovery of T-LGL lymphocytosis",
                    "sub_points": [
                      "Incidental discovery of T-LGL lymphocytosis"
                    ]
                  },
                  {
                    "text": "AsymptomaticCytopeniasNo clinically appreciated effectsRheumatoid arthritis or autoimmune disorder (25-35% of patients)Splenomegaly (20-50% of patients)",
                    "sub_points": [
                      "CytopeniasNo clinically appreciated effects",
                      "No clinically appreciated effects",
                      "Rheumatoid arthritis or autoimmune disorder (25-35% of patients)",
                      "Splenomegaly (20-50% of patients)"
                    ]
                  },
                  {
                    "text": "SymptomaticDevelopment of cytopeniasNeutropeniaThrombocytopeniaAnemia: May be due to red cell aplasiaDevelopment of recurrent infectionsOften bacterialMucocutaneousSplenomegalySystemic symptoms",
                    "sub_points": [
                      "Development of cytopeniasNeutropeniaThrombocytopeniaAnemia: May be due to red cell aplasia",
                      "Neutropenia",
                      "Thrombocytopenia",
                      "Anemia: May be due to red cell aplasia",
                      "Development of recurrent infectionsOften bacterialMucocutaneous",
                      "Often bacterial",
                      "Mucocutaneous",
                      "Splenomegaly",
                      "Systemic symptoms"
                    ]
                  },
                  {
                    "text": "LGL lymphocytosis: LGLs generally > 2 x 10⁹/L"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Clinical examination"
                  },
                  {
                    "text": "Complete blood cell count with differential"
                  },
                  {
                    "text": "PB examination"
                  },
                  {
                    "text": "BM examination if needed"
                  },
                  {
                    "text": "Flow cytometry of PB &/or BM"
                  },
                  {
                    "text": "T-cell receptor clonality studies"
                  }
                ],
                "Natural History": [
                  {
                    "text": "Clinically heterogeneous"
                  },
                  {
                    "text": "Some spontaneous regressions"
                  },
                  {
                    "text": "Association with immune disorders"
                  },
                  {
                    "text": "High proportion of patients will require treatment at some point"
                  }
                ],
                "Treatment": [
                  {
                    "text": "AsymptomaticCareful observation",
                    "sub_points": [
                      "Careful observation"
                    ]
                  },
                  {
                    "text": "SymptomaticMethotrexate or cyclophosphamide or cyclosporine ATreatment should be continued for at least 4 months to assess responseCorticosteroidsAs monotherapy, not very effective long-termRapid improvements in symptoms/cytopenias if used in conjunction with methotrexate, cyclophosphamide, cyclosporine AProphylactic use of antibiotics if severe neutropeniaHematopoietic growth factorsGM-CSF or G-CSF for neutropeniaErythropoietin (EPO) for anemiaClinical trialAs availableProgressive diseaseNucleoside analoguesAlemtuzumab: Anti-CD25 monoclonal antibodyHematopoietic stem cell transplantation",
                    "sub_points": [
                      "Methotrexate or cyclophosphamide or cyclosporine ATreatment should be continued for at least 4 months to assess response",
                      "Treatment should be continued for at least 4 months to assess response",
                      "CorticosteroidsAs monotherapy, not very effective long-termRapid improvements in symptoms/cytopenias if used in conjunction with methotrexate, cyclophosphamide, cyclosporine A",
                      "As monotherapy, not very effective long-term",
                      "Rapid improvements in symptoms/cytopenias if used in conjunction with methotrexate, cyclophosphamide, cyclosporine A",
                      "Prophylactic use of antibiotics if severe neutropenia",
                      "Hematopoietic growth factorsGM-CSF or G-CSF for neutropeniaErythropoietin (EPO) for anemia",
                      "GM-CSF or G-CSF for neutropenia",
                      "Erythropoietin (EPO) for anemia",
                      "Clinical trialAs available",
                      "As available",
                      "Progressive diseaseNucleoside analoguesAlemtuzumab: Anti-CD25 monoclonal antibodyHematopoietic stem cell transplantation",
                      "Nucleoside analogues",
                      "Alemtuzumab: Anti-CD25 monoclonal antibody",
                      "Hematopoietic stem cell transplantation"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Generally indolent"
                  },
                  {
                    "text": "Related to control of cytopenias and associated symptoms"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Peripheral Blood": [
                  {
                    "text": "LGL lymphocytosisLGLs generally > 2 x 10⁹/LOccasional cases LGLs < 2 x 10⁹/L",
                    "sub_points": [
                      "LGLs generally > 2 x 10⁹/L",
                      "Occasional cases LGLs < 2 x 10⁹/L"
                    ]
                  },
                  {
                    "text": "Circulating T-LGLsIntermediate sizeRound/slightly indented nucleusInconspicuous nucleoliAbundant pale cytoplasmCytoplasmic azurophilic granules",
                    "sub_points": [
                      "Intermediate size",
                      "Round/slightly indented nucleus",
                      "Inconspicuous nucleoli",
                      "Abundant pale cytoplasm",
                      "Cytoplasmic azurophilic granules"
                    ]
                  },
                  {
                    "text": "Variable degrees/types of cytopenias"
                  },
                  {
                    "text": "Generally unremarkable red blood cell, platelet, and myeloid morphology"
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "Variably cellularUsually normo- or hypocellular",
                    "sub_points": [
                      "Usually normo- or hypocellular"
                    ]
                  },
                  {
                    "text": "GranulopoiesisLeft-shifted maturation is common",
                    "sub_points": [
                      "Left-shifted maturation is common"
                    ]
                  },
                  {
                    "text": "ErythropoiesisAbsent if associated pure red cell aplasia",
                    "sub_points": [
                      "Absent if associated pure red cell aplasia"
                    ]
                  },
                  {
                    "text": "T-LGL lymphocytosisExtent of BM involvement is variableInterstitial/intrasinusoidal patterns commonMorphologically occultImmunostains helpful to identify T-LGL infiltrate",
                    "sub_points": [
                      "Extent of BM involvement is variable",
                      "Interstitial/intrasinusoidal patterns commonMorphologically occultImmunostains helpful to identify T-LGL infiltrate",
                      "Morphologically occult",
                      "Immunostains helpful to identify T-LGL infiltrate"
                    ]
                  },
                  {
                    "text": "Mild reticulin fibrosis"
                  },
                  {
                    "text": "Normal bony trabeculae"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Typical immunophenotypeCytotoxic T-cellSurface markers: CD3(+), CD8(+), usually CD16 and CD57(+), CD94(+), T-cell receptor α/β(+)Cytoplasmic granules: TIA-1, perforin, granzyme MBM core immunohistochemistry useful to identify T-LGL infiltrates",
                    "sub_points": [
                      "Cytotoxic T-cellSurface markers: CD3(+), CD8(+), usually CD16 and CD57(+), CD94(+), T-cell receptor α/β(+)Cytoplasmic granules: TIA-1, perforin, granzyme M",
                      "Surface markers: CD3(+), CD8(+), usually CD16 and CD57(+), CD94(+), T-cell receptor α/β(+)",
                      "Cytoplasmic granules: TIA-1, perforin, granzyme M",
                      "BM core immunohistochemistry useful to identify T-LGL infiltrates"
                    ]
                  },
                  {
                    "text": "Less common phenotypesCD4(+), T-cell receptor α/β(+)CD4(+), T-cell receptor γ/δ(+)CD8(+), T-cell receptor γ/δ(+)CD4 and CD8 negative",
                    "sub_points": [
                      "CD4(+), T-cell receptor α/β(+)",
                      "CD4(+), T-cell receptor γ/δ(+)",
                      "CD8(+), T-cell receptor γ/δ(+)",
                      "CD4 and CD8 negative"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Cytotoxic T-cell phenotype as described in the immunohistochemistry section"
                  },
                  {
                    "text": "T-cell antigen aberrancy"
                  },
                  {
                    "text": "Surrogates of clonalityUniform expression of a single KIR antigenCD157b, CD158a, CD158eUniform expression of a T-cell receptor Vβ region",
                    "sub_points": [
                      "Uniform expression of a single KIR antigenCD157b, CD158a, CD158e",
                      "CD157b, CD158a, CD158e",
                      "Uniform expression of a T-cell receptor Vβ region"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "T-cell receptor gene clonally rearranged"
                  },
                  {
                    "text": "No distinct genetic abnormality"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Reactive/Persistent LGL Lymphocytosis": [
                  {
                    "text": "EtiologiesViral infectionsAdvancing ageAfter hematopoietic stem cell transplantationCombined variable immunodeficiency",
                    "sub_points": [
                      "Viral infections",
                      "Advancing age",
                      "After hematopoietic stem cell transplantation",
                      "Combined variable immunodeficiency"
                    ]
                  },
                  {
                    "text": "Cytologic featuresTypical LGL morphology",
                    "sub_points": [
                      "Typical LGL morphology"
                    ]
                  },
                  {
                    "text": "ImmunophenotypeNo antigenic aberrancy",
                    "sub_points": [
                      "No antigenic aberrancy"
                    ]
                  },
                  {
                    "text": "Molecular studiesPolyclonal T-cell receptor gamma",
                    "sub_points": [
                      "Polyclonal T-cell receptor gamma"
                    ]
                  }
                ],
                "Aggressive T-LGL Leukemia": [
                  {
                    "text": "Rare"
                  },
                  {
                    "text": "Controversial entity"
                  },
                  {
                    "text": "Rapid disease progressionHepatosplenomegalyLymphadenopathyShort survival: < 2 years",
                    "sub_points": [
                      "Hepatosplenomegaly",
                      "Lymphadenopathy",
                      "Short survival: < 2 years"
                    ]
                  },
                  {
                    "text": "PathologyCytology similar to indolent T-LGL leukemiaImmunophenotype similar to indolent T-LGL leukemiaOften shows CD56 expression",
                    "sub_points": [
                      "Cytology similar to indolent T-LGL leukemia",
                      "Immunophenotype similar to indolent T-LGL leukemiaOften shows CD56 expression",
                      "Often shows CD56 expression"
                    ]
                  }
                ],
                "Chronic Natural Killer (NK)-cell Lymphocytosis/Leukemia": [
                  {
                    "text": "Lymphocytosis: Indolent"
                  },
                  {
                    "text": "PathologyDifficult to establish clonalityCD2(+), surface CD3(-), CD16(+), CD56(+)",
                    "sub_points": [
                      "Difficult to establish clonality",
                      "CD2(+), surface CD3(-), CD16(+), CD56(+)"
                    ]
                  }
                ],
                "Aggressive NK-cell Leukemia": [
                  {
                    "text": "Poor prognosis"
                  },
                  {
                    "text": "Epstein-Barr virus clonal"
                  },
                  {
                    "text": "CD2(+), surface CD3(-), CD56(+), EBV(+)"
                  },
                  {
                    "text": "T-cell clonality studies: Nonclonal"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Asymptomatic, clinically occult"
                  },
                  {
                    "text": "Symptomatic, cytopenias"
                  },
                  {
                    "text": "Rheumatoid arthritis"
                  },
                  {
                    "text": "Splenomegaly"
                  },
                  {
                    "text": "Pure red cell aplasia"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Clonal T-LGL proliferation"
                  },
                  {
                    "text": "BM may be hypocellular"
                  },
                  {
                    "text": "BM infiltrates often morphologically subtle"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Adult T-Cell Leukemia/Lymphoma": {
            "name": "Adult T-Cell Leukemia/Lymphoma",
            "url": "https://app.pathprimer.com/document/64784d64-fbac-4aa9-bf70-e6e499d986d8/lesson/7f0bcc37-552c-40e6-b672-243b3ec2231e",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Mature helper T-cell neoplasm linked to chronic infection with human T-cell leukemia virus (HTLV)-1"
                  },
                  {
                    "text": "Endemic area disease distribution"
                  },
                  {
                    "text": "Long latency period"
                  },
                  {
                    "text": "Only small proportion (2-5%) of HTLV-1 carriers develop overt neoplasms"
                  },
                  {
                    "text": "Wide spectrum of disease manifestation"
                  },
                  {
                    "text": "Acute (leukemic) form most aggressive"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Marked lymphocytosis in acute form (ATLL)"
                  },
                  {
                    "text": "Leukemic cells exhibit polylobated nuclei (often referred to as \"flower cells\")"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "CD3(+), CD4(+), CD7(-), CD25(+), mature helper T cell"
                  },
                  {
                    "text": "Confirm HTLV-1 infection"
                  },
                  {
                    "text": "Assess for hypercalcemia and bone lesions"
                  },
                  {
                    "text": "Clonal T-cell receptor gene rearrangement"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Adult T-cell leukemia/lymphoma (ATLL)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Mature helper T-cell neoplasm linked to chronic infection with human T-cell leukemia virus (HTLV)-1"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "HTLV-1 Infection": [
                  {
                    "text": "Viral transmission in endemic areasVertical transmission associated with prolonged nursingSexual transmission; blood transfusion transmission",
                    "sub_points": [
                      "Vertical transmission associated with prolonged nursing",
                      "Sexual transmission; blood transfusion transmission"
                    ]
                  },
                  {
                    "text": "HTLV-1 infection of post-thymic helper T cellsNeoplastic cells have clonally integrated HTLV-1Strong T-cell immunosuppressive activity",
                    "sub_points": [
                      "Neoplastic cells have clonally integrated HTLV-1",
                      "Strong T-cell immunosuppressive activity"
                    ]
                  },
                  {
                    "text": "Hypercalcemia-lytic bone lesions linked to constitutive production of parathyroid hormone-related protein"
                  },
                  {
                    "text": "HTLV-1 infection aloneInsufficient for oncogeneses; additional oncogenic factors necessary",
                    "sub_points": [
                      "Insufficient for oncogeneses; additional oncogenic factors necessary"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Largely restricted to endemic HTLV-1 areasSouthwestern Japan, Caribbean basin, northern Iran, central Africa",
                    "sub_points": [
                      "Southwestern Japan, Caribbean basin, northern Iran, central Africa"
                    ]
                  },
                  {
                    "text": "Only small proportion (2-5%) of HTLV-1 carriers develop overt neoplasms"
                  }
                ],
                "Age": [
                  {
                    "text": "Due to decades-long latency period, manifests exclusively in adults"
                  }
                ],
                "Sex": [
                  {
                    "text": "Slight male predominance"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "Originally described in southwestern Japan"
                  },
                  {
                    "text": "Disease closely linked to prevalence of HTLV-1 virus infection in given population"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Multiple clinical formsSmoldering and chronicLymphomatousAcute (leukemic)",
                    "sub_points": [
                      "Smoldering and chronic",
                      "Lymphomatous",
                      "Acute (leukemic)"
                    ]
                  },
                  {
                    "text": "ATLLSystemic manifestations includingSkin rashHypercalcemiaElevated LDHLytic bone lesionsMultiple organs may be involvedHepatosplenomegaly common",
                    "sub_points": [
                      "Systemic manifestations includingSkin rashHypercalcemiaElevated LDHLytic bone lesions",
                      "Skin rash",
                      "Hypercalcemia",
                      "Elevated LDH",
                      "Lytic bone lesions",
                      "Multiple organs may be involvedHepatosplenomegaly common",
                      "Hepatosplenomegaly common"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Complete blood count (CBC) with differential and morphologic review"
                  },
                  {
                    "text": "Serologic &/or other testing to confirm HTLV-1 infection"
                  },
                  {
                    "text": "Assess calcium levels"
                  }
                ],
                "Natural History": [
                  {
                    "text": "Leukemic (acute) type typically aggressive"
                  },
                  {
                    "text": "Progression from indolent to acute form common"
                  },
                  {
                    "text": "High morbidity and mortality from secondary infections"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Treatment strategies focus on chronic ATLL prior to development of fulminant disease"
                  },
                  {
                    "text": "ATL resistant to most chemotherapy"
                  },
                  {
                    "text": "Allogeneic stem cell transplant may be of benefit"
                  },
                  {
                    "text": "Alemtuzumab (anti-CD52) has some efficacy"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "BloodMarked lymphocytosis in acute form (ATLL)Leukemic cells exhibit polylobated nuclei (often referred to as \"flower cells\")Condensed hyperchromatic chromatin",
                    "sub_points": [
                      "Marked lymphocytosis in acute form (ATLL)",
                      "Leukemic cells exhibit polylobated nuclei (often referred to as \"flower cells\")",
                      "Condensed hyperchromatic chromatin"
                    ]
                  },
                  {
                    "text": "Bone marrowDiffuse interstitial infiltrationOften less pronounced than peripheral bloodOsteoclasts may be increased with increased bone resorption",
                    "sub_points": [
                      "Diffuse interstitial infiltration",
                      "Often less pronounced than peripheral blood",
                      "Osteoclasts may be increased with increased bone resorption"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Flow Cytometry": [
                  {
                    "text": "CD3(+), CD4(+), CD7(-), CD25(+), mature helper T cell"
                  },
                  {
                    "text": "CD52 typically positive"
                  },
                  {
                    "text": "CD3 expression may be aberrantly reduced"
                  },
                  {
                    "text": "Rare cases: CD8(+), double CD4(+), CD8(+), or double CD4(-), CD8(-)"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Clonal T-cell receptor gene rearrangement"
                  },
                  {
                    "text": "Clonal integration of HTLV-1 in helper T cells"
                  },
                  {
                    "text": "No recurrent abnormalities"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "T-cell Leukemias with Nuclear Abnormalities": [
                  {
                    "text": "T-cell prolymphocytic leukemia"
                  },
                  {
                    "text": "Sézary syndrome"
                  },
                  {
                    "text": "Leukemic peripheral T-cell lymphomas"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Integrate morphology and immunophenotype"
                  },
                  {
                    "text": "Confirm HTLV-1 infection"
                  },
                  {
                    "text": "Assess for hypercalcemia and lytic bone lesions"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "T-Cell Prolymphocytic Leukemia": {
            "name": "T-Cell Prolymphocytic Leukemia",
            "url": "https://app.pathprimer.com/document/74e9462d-b205-425d-a1c7-9b114205e3d6/lesson/7f0bcc37-552c-40e6-b672-243b3ec2231e",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "Translocations ofTCL1gene(s) into promoter/enhancer regions of TCRα/δ"
                  },
                  {
                    "text": "TCL-1 oncoprotein overexpression is leukemogenic"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Striking lymphocytosis in blood"
                  },
                  {
                    "text": "Extensive diffuse bone marrow effacement with variable reticulin fibrosis"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Flow cytometry useful in distinguishing T-PLL from other T-cell leukemias"
                  },
                  {
                    "text": "Recurrent abnormality ofTCL1in 90% of casesinv(14)(q11q32) results in translocation ofTCL1",
                    "sub_points": [
                      "inv(14)(q11q32) results in translocation ofTCL1"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Sézary syndrome"
                  },
                  {
                    "text": "Adult T-cell leukemia/lymphoma"
                  },
                  {
                    "text": "T-cell large granular lymphocytic leukemia"
                  },
                  {
                    "text": "T-lymphoblastic leukemia"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "T-cell prolymphocytic leukemia (T-PLL)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Mature T-cell leukemia composed of small to medium-sized lymphocytes with variably prominent nucleoli"
                  },
                  {
                    "text": "Recurrent cytogenetic finding: inv(14)(q11q32)"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Leukemogenesis": [
                  {
                    "text": "Key leukemogenic role of TCL1 oncoprotein overexpression"
                  },
                  {
                    "text": "Translocations ofTCL1gene(s) into promoter/enhancer regions of TCRα/δ dysregulates TCL1"
                  },
                  {
                    "text": "ATMdeletions and haploinsufficiency ofCDKN1Balso leukemogenic"
                  },
                  {
                    "text": "STAT5Bmutations in most cases"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "2% of chronic leukemias in adults"
                  },
                  {
                    "text": "Increased incidence in patients with ataxia telangiectasia"
                  },
                  {
                    "text": "No association with environmental exposure"
                  },
                  {
                    "text": "No link to infections established"
                  }
                ],
                "Age": [
                  {
                    "text": "Median: 65 years (range: 30-90 years)"
                  }
                ],
                "Sex": [
                  {
                    "text": "Male predominance (3:1)"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "No key ethnic associations"
                  }
                ],
                "Site": [
                  {
                    "text": "Blood, bone marrow, spleen, liver, lymph nodes"
                  },
                  {
                    "text": "Less often skin, effusions"
                  }
                ],
                "Presentation": [
                  {
                    "text": "90% of patients symptomatic"
                  },
                  {
                    "text": "Key symptoms include abdominal distension, bulky lymph nodes, skin rash"
                  },
                  {
                    "text": "Marked splenomegaly and hepatomegaly typical"
                  },
                  {
                    "text": "Skin lesions and pleural effusions in subset"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Key laboratory tests include CBC with differential, flow cytometric immunophenotyping, and conventional cytogenetics"
                  },
                  {
                    "text": "CBC shows lymphocytosis; often striking"
                  },
                  {
                    "text": "Anemia (25%) and thrombocytopenia (50%)"
                  }
                ],
                "Natural History": [
                  {
                    "text": "Aggressive disease; 20% overall 5-year survival rate"
                  },
                  {
                    "text": "Better outcome for responders to CAMPATH-1H"
                  }
                ],
                "Treatment": [],
                "Drugs": [
                  {
                    "text": "Various agents used, including purine analogs"
                  },
                  {
                    "text": "Best results achieved with humanized monoclonal antibody alemtuzumab (anti-CD52) (CAMPATH-1H)"
                  },
                  {
                    "text": "Newer treatments includeOther monoclonal antibody agentsRadioimmunotherapyStem cell transplantPotential STAT5 inhibition therapy",
                    "sub_points": [
                      "Other monoclonal antibody agents",
                      "Radioimmunotherapy",
                      "Stem cell transplant",
                      "Potential STAT5 inhibition therapy"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Poor; median survival of non-CAMPATH-1H responders is 4 months"
                  },
                  {
                    "text": "Overall median survival is about 2 years; 4 years for CAMPATH responder"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Microscopic Features in Blood and Bone Marrow": [
                  {
                    "text": "Lymphocytosis in blood; may be pronounced"
                  },
                  {
                    "text": "Prolymphocytic, knobby, cerebriform, and other variant forms described (broad spectrum)"
                  },
                  {
                    "text": "Blood may be indistinguishable from CLL"
                  },
                  {
                    "text": "Extensive diffuse bone marrow effacement with variable reticulin fibrosis"
                  }
                ],
                "Lymph Node": [
                  {
                    "text": "Paracortical infiltrates"
                  }
                ],
                "Spleen": [
                  {
                    "text": "Red pulp infiltrates"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Pan T-cell antigens expressed"
                  },
                  {
                    "text": "Unique marker is nuclear and cytoplasmic positivity for TCL-1 oncoprotein"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Key test to determine lineage and stage of maturation"
                  },
                  {
                    "text": "Useful in distinguishing T-PLL from other mature T-cell leukemias"
                  },
                  {
                    "text": "Pan T-cell antigens expressed (CD2, CD3, CD5, CD7)"
                  },
                  {
                    "text": "CD52 strongly positive in virtually all cases"
                  },
                  {
                    "text": "CD4, CD8 coexpression in 40% of cases"
                  },
                  {
                    "text": "Immature markers (CD34, TdT, CD1a) negative"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Recurrent abnormality ofTCL1in 90% of casesinv(14)(q11q32) results in translocation ofTCL1oncogene into promoter/enhancer regions of TCRα/δ",
                    "sub_points": [
                      "inv(14)(q11q32) results in translocation ofTCL1oncogene into promoter/enhancer regions of TCRα/δ"
                    ]
                  },
                  {
                    "text": "Other translocations involvingTCL1orMTCP1genes"
                  },
                  {
                    "text": "Other cytogenetic abnormalities common, including del(11)(q22-23) resulting inATMdeletion and del(12)(p13) resulting in haploinsufficiency ofCDKN1B"
                  },
                  {
                    "text": "STAT5B mutation 75%"
                  },
                  {
                    "text": "Clonal by TCR rearrangement studies"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Sézary Syndrome": [
                  {
                    "text": "Cutaneous disease, erythroderma"
                  },
                  {
                    "text": "Circulating cells have cerebriform nucleiGiant (monstrosity) cells",
                    "sub_points": [
                      "Giant (monstrosity) cells"
                    ]
                  },
                  {
                    "text": "CD4 positive, CD7 negative"
                  }
                ],
                "Adult T-Cell Leukemia/Lymphoma": [
                  {
                    "text": "Endemic disease distribution"
                  },
                  {
                    "text": "HTLV-I associated"
                  },
                  {
                    "text": "Long-term carrier state"
                  },
                  {
                    "text": "Occurs in < 5% of chronic HTLV-I carriers"
                  },
                  {
                    "text": "Hypercalcemia common"
                  },
                  {
                    "text": "Marked nuclear lobulations"
                  },
                  {
                    "text": "CD4 positive, CD25 positive, CD7 negative"
                  }
                ],
                "T-Cell Large Granular Lymphocytic Leukemia": [
                  {
                    "text": "Association with rheumatoid arthritis"
                  },
                  {
                    "text": "Cytopenias"
                  },
                  {
                    "text": "Increased large granular lymphocytes"
                  },
                  {
                    "text": "Absolute lymphocyte count may be modest"
                  },
                  {
                    "text": "CD3 positive, CD8 positive, CD4 negative"
                  },
                  {
                    "text": "Spontaneous remissions described"
                  }
                ],
                "T-Lymphoblastic Leukemia/Lymphoma": [
                  {
                    "text": "T-acute lymphoblastic leukemia/lymphoma (T-ALL)"
                  },
                  {
                    "text": "Patient may have mediastinal mass, lymphadenopathy"
                  },
                  {
                    "text": "Extent of bone marrow and blood involvement variable"
                  },
                  {
                    "text": "Some cases show marked leukocytosis"
                  },
                  {
                    "text": "Cells have blastic morphology"
                  },
                  {
                    "text": "Immature phenotype by flow cytometry includingWeak CD45CD34TdTCD1a",
                    "sub_points": [
                      "Weak CD45",
                      "CD34",
                      "TdT",
                      "CD1a"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Confirm clinical profile of marked hepatosplenomegaly and lymphadenopathy"
                  },
                  {
                    "text": "T-PLL more common than B-PLL"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "CBC and blood smear morphology"
                  },
                  {
                    "text": "Rapidly rising white blood cell count (WBC)"
                  },
                  {
                    "text": "Mature small to medium-sized lymphocytes with variable nuclear irregularity and variably prominent nucleoli"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Aggressive NK-Cell Leukemia": {
            "name": "Aggressive NK-Cell Leukemia",
            "url": "https://app.pathprimer.com/document/74f4f9d0-a858-4f18-9afe-2037c98729ab/lesson/7f0bcc37-552c-40e6-b672-243b3ec2231e",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Neoplasm of true NK cells characterized by EBV positivity and aggressive multisystem disease"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "EBV positivity supports viral oncogenic role"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Very rare"
                  },
                  {
                    "text": "Highest incidence in Asian and Native American populations"
                  },
                  {
                    "text": "Fever and constitutional symptoms; acute coagulopathy common"
                  },
                  {
                    "text": "Clinically aggressive, with median survival times usually < 6 months"
                  },
                  {
                    "text": "Multiorgan failure common"
                  },
                  {
                    "text": "Responses to therapy usually transient"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Circulating ANKL cells may be inconspicuous"
                  },
                  {
                    "text": "Highly variable extent of bone marrow infiltration"
                  },
                  {
                    "text": "High association with HS by benign macrophages"
                  },
                  {
                    "text": "Hemophagocytosis may mask ANKL infiltrates"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Typically positive for CD3, CD56, TIA-1, and EBER"
                  },
                  {
                    "text": "Key flow feature is cytoplasmic CD3 positivity ﻿without﻿surface CD3"
                  },
                  {
                    "text": "Frequent ﻿clonal EBV﻿integration"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Chronic lymphoproliferative disorder of NK cells"
                  },
                  {
                    "text": "Secondary HS due to EBV"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Acute myeloid leukemia (AML)"
                  },
                  {
                    "text": "Aggressive natural killer cell leukemia (ANKL)"
                  },
                  {
                    "text": "Blastic plasmacytoid dendritic cell neoplasm (BPDCN)"
                  },
                  {
                    "text": "Complete blood count (CBC)"
                  },
                  {
                    "text": "EBV-encoded RNA (EBER)"
                  },
                  {
                    "text": "Epstein-Barr virus (EBV)"
                  },
                  {
                    "text": "Hemophagocytic syndromes (HS)"
                  },
                  {
                    "text": "Natural killer (NK)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Neoplasm of true NK cells characterized by EBV positivity and aggressive multisystem disease"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Unknown": [
                  {
                    "text": "EBV positivity supports viral oncogenic role"
                  },
                  {
                    "text": "Relationship to extranodal NK/T-cell lymphoma, nasal type unclear"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Very rare"
                  }
                ],
                "Age": [
                  {
                    "text": "Predominates in young to middle-aged adults"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "Highest incidence in Asian and Native American populations"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Generally acute onset"
                  },
                  {
                    "text": "Fever and constitutional symptoms"
                  },
                  {
                    "text": "Acute coagulopathy common"
                  },
                  {
                    "text": "Variable splenomegaly, hepatomegaly"
                  },
                  {
                    "text": "Other organs occasionally involved"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "CBC with differential and morphologic review"
                  },
                  {
                    "text": "Coagulation testing"
                  },
                  {
                    "text": "EBV serologic testing"
                  },
                  {
                    "text": "Assessment for cell turnover, underlying infection, liver and other organ function as needed"
                  }
                ],
                "Natural History": [
                  {
                    "text": "Clinically aggressive, with median survival usually < 6 months"
                  },
                  {
                    "text": "Multiorgan failure common"
                  }
                ],
                "Treatment": [
                  {
                    "text": "No standardized therapy"
                  },
                  {
                    "text": "Responses to therapy usually transient, relapses common"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Very poor prognosis"
                  },
                  {
                    "text": "Coagulopathy and multiorgan failure contribute to morbidity and mortality"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Blood": [
                  {
                    "text": "Highly variable WBC"
                  },
                  {
                    "text": "Circulating ANKL cells may be inconspicuous or obvious"
                  },
                  {
                    "text": "Nuclear features range from mature to blastic; variably prominent nucleoli"
                  },
                  {
                    "text": "Cytoplasm generally moderate in amount with sparse, variably prominent granules"
                  },
                  {
                    "text": "Occasional cases exhibit features of mature large granular lymphocytes"
                  },
                  {
                    "text": "Some cases are morphologically indistinguishable from AML"
                  },
                  {
                    "text": "Cytopenias present and generally significant"
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "Highly variable extent of bone marrow infiltration"
                  },
                  {
                    "text": "Infiltrates typically patchy and interstitial; may be prominentHighly variable cytologic features, bland to pleomorphic",
                    "sub_points": [
                      "Highly variable cytologic features, bland to pleomorphic"
                    ]
                  },
                  {
                    "text": "Bone marrow necrosis may be present"
                  },
                  {
                    "text": "Frequent apoptotic bodies on biopsy sections"
                  },
                  {
                    "text": "High association with hemophagocytosis by nonneoplastic macrophagesHemophagocytosis may mask ANKL",
                    "sub_points": [
                      "Hemophagocytosis may mask ANKL"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Key to identification of subtle infiltrates"
                  },
                  {
                    "text": "Key to delineation of NK cell lineage"
                  },
                  {
                    "text": "Typically positive for CD3, CD56, TIA-1, and EBER"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Useful in delineating NK cell lineage (CD56, CD16)"
                  },
                  {
                    "text": "Key feature is cytoplasmic CD3 positivity ﻿without﻿surface CD3"
                  }
                ],
                "PCR": [
                  {
                    "text": "T-cell receptors and IgH are in germline configuration; frequent ﻿clonal EBV﻿integration"
                  }
                ],
                "Cytogenetics/Fluorescence in situ Hybridization": [
                  {
                    "text": "No recurrent cytogenetic abnormalities"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Chronic Lymphoproliferative Disorder of NK Cells": [
                  {
                    "text": "Patients may be asymptomatic"
                  },
                  {
                    "text": "Mature large granular lymphocyte morphology"
                  },
                  {
                    "text": "NK immunophenotype; no EBV association"
                  }
                ],
                "Blastic Plasmacytoid Dendritic Cell Neoplasm": [
                  {
                    "text": "Hematodermic neoplasm expressing CD4, CD56"
                  },
                  {
                    "text": "Blood and bone marrow involvement may mimic ANKL"
                  },
                  {
                    "text": "EBV negative"
                  }
                ],
                "Extranodal NK/T-cell Lymphoma, Nasal Type": [
                  {
                    "text": "Morphologically and immunophenotypically similar to ANKL; EBV-associated"
                  },
                  {
                    "text": "Affects older patients; may rarely precede ANKL"
                  }
                ],
                "Secondary Hemophagocytic Syndromes Due to EBV": [
                  {
                    "text": "EBER positivity of infected B cells mimics ANKL"
                  },
                  {
                    "text": "Blood and clinical picture of acute EBV infection"
                  },
                  {
                    "text": "Positive EBV serology for acute infection/reactivation"
                  }
                ],
                "AML": [
                  {
                    "text": "Some morphologic overlap with ANKL; some cases express CD56"
                  },
                  {
                    "text": "Flow cytometric immunophenotyping confirms myeloid lineage derivation"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Appreciate ethnic predilection (Asian and Native American populations)"
                  },
                  {
                    "text": "Generous use of immunohistochemistry, EBER, and flow immunophenotyping to detect subtle infiltrates"
                  },
                  {
                    "text": "Confirmation of EBV positivity essential"
                  },
                  {
                    "text": "Secondary florid hemophagocytic syndrome can mask occult ANKL infiltrates"
                  },
                  {
                    "text": "Acute EBV infection linked to secondary HS"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Mycosis Fungoides/Sézary Syndrome": {
            "name": "Mycosis Fungoides/Sézary Syndrome",
            "url": "https://app.pathprimer.com/document/ea350a7c-a3ba-4ee9-8188-c8721c680df6/lesson/7f0bcc37-552c-40e6-b672-243b3ec2231e",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Sézary syndrome (SS) clonal cutaneous T-cell neoplasm, helper T-cell phenotype"
                  },
                  {
                    "text": "Triad of erythroderma, generalized lymphadenopathy, and blood involvementat presentation"
                  },
                  {
                    "text": "Some patients have generalized pruritus rather than erythroderma"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Onset of erythroderma is abrupt in SS"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Variable WBC count"
                  },
                  {
                    "text": "Lymphocytes exhibit distinctive cytologic features"
                  },
                  {
                    "text": "Distinctly cerebriform nuclear configuration"
                  },
                  {
                    "text": "Subtle, patchy, diffuse infiltrates of SS cells in bone marrowMay be morphologically occultDetection enhanced by IHC stains",
                    "sub_points": [
                      "May be morphologically occult",
                      "Detection enhanced by IHC stains"
                    ]
                  },
                  {
                    "text": "SS cell infiltrates may lack epidermotropism in skin"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Prototypic profile CD3(+), CD4(+), CD7(-), CD25(-), CD26(-)"
                  },
                  {
                    "text": "Helper T cell loss of CD7 in ≥ 40% and CD26 in ≥ 80% is highly sensitive and specific for SS"
                  },
                  {
                    "text": "Aberrant patterns of pan-T-cell antigen expression also present; patterns stable over timeMay be more sensitive for long term monitoring than CD(7)- or CD26(-) subsets",
                    "sub_points": [
                      "May be more sensitive for long term monitoring than CD(7)- or CD26(-) subsets"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Reactive lymphocytoses"
                  },
                  {
                    "text": "Mycosis fungoides (MF) patientwithouterythroderma may have blood involvement; diagnose as \"MF with leukemic involvement\""
                  },
                  {
                    "text": "Helper T-cell neoplasms involving bloodT-cell prolymphocytic leukemiaRare anaplastic large cell lymphomaPeripheral T-cell lymphomas, various subtypesAdult T-cell leukemia in patients residing in endemic regions",
                    "sub_points": [
                      "T-cell prolymphocytic leukemia",
                      "Rare anaplastic large cell lymphoma",
                      "Peripheral T-cell lymphomas, various subtypes",
                      "Adult T-cell leukemia in patients residing in endemic regions"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Sézary syndrome (SS)"
                  },
                  {
                    "text": "Mycosis fungoides (MF)"
                  },
                  {
                    "text": "Cutaneous T-cell lymphoma (CTCL)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Clonal cutaneous helper T-cell neoplasm characterized by erythroderma, generalized lymphadenopathy, and blood involvement at diagnosisBlood involvement defined asAbsolute Sézary count ≥ 1.0 X 10⁹/LorCD4:CD8 ratio > 10orAberrant T-cell antigen expression by flow cytometric immunophenotyping (FCI)Clonality confirmed by TCR molecular assessment or biphasic flow cytometry for TRBC1",
                    "sub_points": [
                      "Blood involvement defined asAbsolute Sézary count ≥ 1.0 X 10⁹/LorCD4:CD8 ratio > 10orAberrant T-cell antigen expression by flow cytometric immunophenotyping (FCI)",
                      "Absolute Sézary count ≥ 1.0 X 10⁹/Lor",
                      "CD4:CD8 ratio > 10or",
                      "Aberrant T-cell antigen expression by flow cytometric immunophenotyping (FCI)",
                      "Clonality confirmed by TCR molecular assessment or biphasic flow cytometry for TRBC1"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Possible Role of UV Light Exposure or Chronic Inflammation": [
                  {
                    "text": "Proposed cell of originCentral memory T cellorSkin-homing CD4(+) T-cell",
                    "sub_points": [
                      "Central memory T cellor",
                      "Skin-homing CD4(+) T-cell"
                    ]
                  },
                  {
                    "text": "Significant array of comparative genomic hybridization and gene expression profiling differences between MF and SSSS and MF are considered to be separate neoplasms with overlapping features",
                    "sub_points": [
                      "SS and MF are considered to be separate neoplasms with overlapping features"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "SS much less common than MF; only 5% of CTCL (0.1/million adults)Incidence increases with age",
                    "sub_points": [
                      "Incidence increases with age"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Median for SS: ~ 60 yearsYounger median age in patients of African ancestry",
                    "sub_points": [
                      "Younger median age in patients of African ancestry"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "Male predominance"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "Higher incidence and younger age at presentation in patients of African ancestry"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Erythroderma involving > 80% of skin surfaceMay manifest as generalized severe pruritus",
                    "sub_points": [
                      "May manifest as generalized severe pruritus"
                    ]
                  },
                  {
                    "text": "Generalized lymphadenopathy"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "CBC with differentialAbnormal lymphocytes in SSBlood criteria for SSAbsolute SS count of ≥ 1.0 x 10⁹/LCD4:CD8 ratio ≥ 10Aberrant T-cell antigen expression: CD7(-), CD26(-), aberrant expression patterns of pan-T-cell antigens",
                    "sub_points": [
                      "Abnormal lymphocytes in SSBlood criteria for SSAbsolute SS count of ≥ 1.0 x 10⁹/LCD4:CD8 ratio ≥ 10Aberrant T-cell antigen expression: CD7(-), CD26(-), aberrant expression patterns of pan-T-cell antigens",
                      "Blood criteria for SSAbsolute SS count of ≥ 1.0 x 10⁹/LCD4:CD8 ratio ≥ 10Aberrant T-cell antigen expression: CD7(-), CD26(-), aberrant expression patterns of pan-T-cell antigens",
                      "Absolute SS count of ≥ 1.0 x 10⁹/L",
                      "CD4:CD8 ratio ≥ 10",
                      "Aberrant T-cell antigen expression: CD7(-), CD26(-), aberrant expression patterns of pan-T-cell antigens"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "Generally aggressive disease course with 5-year overall survival rate of 10-30%"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Both cutaneous treatments and systemic chemotherapy may be used depending upon clinical featuresMany new treatment options available, including various combinations of skin-directed therapies, biologic-response modifiers, and systemic chemotherapy",
                    "sub_points": [
                      "Many new treatment options available, including various combinations of skin-directed therapies, biologic-response modifiers, and systemic chemotherapy"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Blood": [
                  {
                    "text": "Variable WBC count depending on extent of lymphocytosis and eosinophilia"
                  },
                  {
                    "text": "Lymphocytes exhibit distinctive cytologic featuresMedium to large overall sizeDistinctly cerebriform nuclear configurationNuclear chromatin typically highly condensed",
                    "sub_points": [
                      "Medium to large overall size",
                      "Distinctly cerebriform nuclear configurationNuclear chromatin typically highly condensed",
                      "Nuclear chromatin typically highly condensed"
                    ]
                  },
                  {
                    "text": "Variable eosinophilia; variable cytopenias"
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "Subtle, patchy, diffuse infiltrates of SS cellsMay be morphologically occultCerebriform nuclei best assessed on sectionsExtent of infiltration highly variableIHC assessment keyHematopoietic lineages generally preservedVariable eosinophilia",
                    "sub_points": [
                      "May be morphologically occult",
                      "Cerebriform nuclei best assessed on sections",
                      "Extent of infiltration highly variable",
                      "IHC assessment key",
                      "Hematopoietic lineages generally preserved",
                      "Variable eosinophilia"
                    ]
                  }
                ],
                "Skin": [
                  {
                    "text": "Skin infiltrates may lack epidermotropism or show minimal epidermotropism"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Helper T-cell infiltrates highlighted by CD3 and CD4"
                  },
                  {
                    "text": "CD7, CD26, and, less often, CD5 expression attenuated/absent"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Prototypic profile CD3(+), CD4(+), CD7(-), CD25(-), CD26(-)Helper T cell loss of CD7 in ≥ 40% and CD26 in ≥ 80% is highly sensitive and specific for SSAberrant patterns of pan-T-cell antigen expression common and stable over disease course",
                    "sub_points": [
                      "Helper T cell loss of CD7 in ≥ 40% and CD26 in ≥ 80% is highly sensitive and specific for SS",
                      "Aberrant patterns of pan-T-cell antigen expression common and stable over disease course"
                    ]
                  },
                  {
                    "text": "Restricted TCR-Vβ antigen profileUse of TRBC1 antibody useful for T-cell clonality assessment",
                    "sub_points": [
                      "Use of TRBC1 antibody useful for T-cell clonality assessment"
                    ]
                  }
                ],
                "PCR": [
                  {
                    "text": "Clonal byTCRstudiesSame clone in skin and blood and other sites",
                    "sub_points": [
                      "Same clone in skin and blood and other sites"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "No recurrent cytogenetic abnormalities; complex karyotype common"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Reactive Lymphocytoses": [
                  {
                    "text": "T cells predominate"
                  },
                  {
                    "text": "Admixture of helper and suppression T cells"
                  },
                  {
                    "text": "Normal cytology or reactive featuresSpectrum of activated lymphocytes often with immunoblasts",
                    "sub_points": [
                      "Spectrum of activated lymphocytes often with immunoblasts"
                    ]
                  }
                ],
                "Atypical Lymphocytosis in Association With Inflammatory Cutaneous Disorders": [
                  {
                    "text": "Not well delineated"
                  },
                  {
                    "text": "T cells predominateSpectrum of TCR-Vβ antigens expressedSome cases may exhibit clonal TCR rearrangements",
                    "sub_points": [
                      "Spectrum of TCR-Vβ antigens expressed",
                      "Some cases may exhibit clonal TCR rearrangements"
                    ]
                  }
                ],
                "Overlap Between Sézary Syndrome and Mycosis Fungoides": [
                  {
                    "text": "Rare case of SS preceded by classic MF: Diagnose as \"SS preceded by MF\""
                  },
                  {
                    "text": "MF patientwithouterythroderma may have blood involvement: Diagnose as \"MF with leukemic involvement\""
                  }
                ],
                "Helper T-Cell Neoplasms Involving Blood": [
                  {
                    "text": "Rare anaplastic large cell lymphoma (ALCL)Patients usually have concurrent lymphadenopathy or skin diseaseCirculating ALCL cells may be small with nuclear irregularitiesLeukemic picture in ALCL more common in younger patientsALK and CD30 (+) by IHCt(2;5)(p23;q35); multiple ALK fusion partners described",
                    "sub_points": [
                      "Patients usually have concurrent lymphadenopathy or skin disease",
                      "Circulating ALCL cells may be small with nuclear irregularities",
                      "Leukemic picture in ALCL more common in younger patients",
                      "ALK and CD30 (+) by IHC",
                      "t(2;5)(p23;q35); multiple ALK fusion partners described"
                    ]
                  },
                  {
                    "text": "Peripheral T-cell lymphoma, various subtypesMay manifest with leukemic blood pictureVariable size of circulating lymphoma cellsWBC often elevated but not typically strikingly elevated",
                    "sub_points": [
                      "May manifest with leukemic blood picture",
                      "Variable size of circulating lymphoma cells",
                      "WBC often elevated but not typically strikingly elevated"
                    ]
                  },
                  {
                    "text": "Adult T-cell leukemiaHTLV-1 associated; endemic distributionVariable, often marked, leukocytosisSkin manifestations common",
                    "sub_points": [
                      "HTLV-1 associated; endemic distribution",
                      "Variable, often marked, leukocytosis",
                      "Skin manifestations common"
                    ]
                  },
                  {
                    "text": "T-cell prolymphocytic leukemiaUsually marked leukocytosis, often rapidly rising WBCUsually CD4(+), but subset of cases exhibit coexpression of CD4 and CD8, despite mature immunophenotypeMarked hepatosplenomegalyVariable skin manifestations",
                    "sub_points": [
                      "Usually marked leukocytosis, often rapidly rising WBCUsually CD4(+), but subset of cases exhibit coexpression of CD4 and CD8, despite mature immunophenotype",
                      "Usually CD4(+), but subset of cases exhibit coexpression of CD4 and CD8, despite mature immunophenotype",
                      "Marked hepatosplenomegaly",
                      "Variable skin manifestations"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Assess blood by morphology/immunophenotypingAberrant pan-T-cell antigen expression commonAberrant patterns stable over time and may be more reliable for SS monitoring than number of SS cells lacking CD7 and CD26",
                    "sub_points": [
                      "Aberrant pan-T-cell antigen expression commonAberrant patterns stable over time and may be more reliable for SS monitoring than number of SS cells lacking CD7 and CD26",
                      "Aberrant patterns stable over time and may be more reliable for SS monitoring than number of SS cells lacking CD7 and CD26"
                    ]
                  },
                  {
                    "text": "Report percentage of CD4(+) cells thatlackCD7 &/or CD26Multiple flow reporting requirements, including percentage of lymphocytes or percentage of T cells",
                    "sub_points": [
                      "Multiple flow reporting requirements, including percentage of lymphocytes or percentage of T cells"
                    ]
                  },
                  {
                    "text": "Determine lower limit threshold of CD4(+), CD7(-) cells in control subjects"
                  },
                  {
                    "text": "Appreciate size spectrum of circulating SS cells"
                  },
                  {
                    "text": "IHC key in bone marrow core biopsy/clot sections"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Extranodal NK-/T-Cell Lymphoma, Nasal Type": {
            "name": "Extranodal NK-/T-Cell Lymphoma, Nasal Type",
            "url": "https://app.pathprimer.com/document/d5633f6d-8660-4505-b9d8-8b9a25730fba/lesson/7f0bcc37-552c-40e6-b672-243b3ec2231e",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "EBV is constant finding, present in clonal episomal form, and is likely involved in pathogenesis"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Nasal or extranasal"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Cytologic spectrum of nasal-type extranodal NK/T-cell lymphoma is wideSmall cell neoplasms can be misinterpreted as chronic inflammation",
                    "sub_points": [
                      "Small cell neoplasms can be misinterpreted as chronic inflammation"
                    ]
                  },
                  {
                    "text": "Necrosis and superimposed acute and chronic inflammation can lead to incorrect diagnosis"
                  },
                  {
                    "text": "Angiocentricity and angiodestruction are helpful findings but are not constant"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Approximately 2/3 of tumors are of NK-cell lineage: Positive for CD2, cytoplasmic CD3-ε, CD56, andTCRgene rearrangements(-)"
                  },
                  {
                    "text": "Approximately 1/3 of tumors are of cytotoxic T-cell lineage: Positive for CD2, CD3-ε, CD5, CD8, TCR-β (BF1), CD56(-/+),TCRgene rearrangements(+)"
                  },
                  {
                    "text": "All tumors are positive for cytotoxic proteins and EBV (best shown by in situ hybridization for EBER)"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Peripheral T-cell lymphoma, not otherwise specified"
                  },
                  {
                    "text": "B-cell lymphomas involving upper aerodigestive tract (usually diffuse large B-cell lymphoma)"
                  },
                  {
                    "text": "Wegener granulomatosis"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Predominantly extranodal lymphoma of either natural killer-cell (NK) or T-cell lineageCharacterized by necrosis, cytotoxic immunophenotype, and Epstein-Barr virus (EBV) infectionVascular destruction is common",
                    "sub_points": [
                      "Characterized by necrosis, cytotoxic immunophenotype, and Epstein-Barr virus (EBV) infection",
                      "Vascular destruction is common"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Infectious Agents": [
                  {
                    "text": "EBV is consistently present in these neoplasms, suggesting its involvement in pathogenesisEBV is usually type A",
                    "sub_points": [
                      "EBV is usually type A"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Disease is common in Asia and in Native Americans of Central and South America"
                  },
                  {
                    "text": "Disease is rare in United States, but its incidence has risen since 1992"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "Mass that is nasal or extranasalNasal cases are usually defined as a neoplasm involving upper aerodigestive tractNasal cavity, nasopharynx, paranasal sinuses, palatePatients suffer from obstruction, epistaxis, or midline destructive lesionThese neoplasms can disseminateExtranasal cases are defined as neoplasm involving any site but without nasal involvementSkin is most common extranasal siteOther sites: Testis, gastrointestinal tract, kidney, salivary glandsPrimary involvement of lymph nodes is rare but has been reportedBone marrow obtained as part of staging can be involved",
                    "sub_points": [
                      "Nasal cases are usually defined as a neoplasm involving upper aerodigestive tractNasal cavity, nasopharynx, paranasal sinuses, palatePatients suffer from obstruction, epistaxis, or midline destructive lesionThese neoplasms can disseminate",
                      "Nasal cavity, nasopharynx, paranasal sinuses, palate",
                      "Patients suffer from obstruction, epistaxis, or midline destructive lesion",
                      "These neoplasms can disseminate",
                      "Extranasal cases are defined as neoplasm involving any site but without nasal involvementSkin is most common extranasal siteOther sites: Testis, gastrointestinal tract, kidney, salivary glandsPrimary involvement of lymph nodes is rare but has been reportedBone marrow obtained as part of staging can be involved",
                      "Skin is most common extranasal site",
                      "Other sites: Testis, gastrointestinal tract, kidney, salivary glands",
                      "Primary involvement of lymph nodes is rare but has been reported",
                      "Bone marrow obtained as part of staging can be involved"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "Extranodal nasal-type NK/T-cell lymphoma can disseminateRegional lymph node involvement is not uncommonBone marrow involvement and leukemic phase can occurThese neoplasms can disseminate to virtually any anatomic site",
                    "sub_points": [
                      "Regional lymph node involvement is not uncommon",
                      "Bone marrow involvement and leukemic phase can occur",
                      "These neoplasms can disseminate to virtually any anatomic site"
                    ]
                  }
                ],
                "Treatment": [],
                "Options, risks, complications": [
                  {
                    "text": "Chemotherapy and radiation therapy are usually employed for nasal cases"
                  },
                  {
                    "text": "Platelet-derived growth factor α overexpression shown by gene expression studies suggests role for imatinib"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Patients with nasal-type extranodal NK/T-cell lymphoma, in general, have poor prognosisPatients with extranasal tumors have poorest prognosisFactors associated with poorer prognosis for nasal cases includeHigh International Prognostic Index (IPI) or Korean NK/T-cell Prognostic ScoreElevated C-reactive protein, anemia (< 11g/dL), or thrombocytopenia (< normal)Large cells > 40%Ki-67 (proliferation rate) > 50%",
                    "sub_points": [
                      "Patients with extranasal tumors have poorest prognosis",
                      "Factors associated with poorer prognosis for nasal cases includeHigh International Prognostic Index (IPI) or Korean NK/T-cell Prognostic ScoreElevated C-reactive protein, anemia (< 11g/dL), or thrombocytopenia (< normal)Large cells > 40%Ki-67 (proliferation rate) > 50%",
                      "High International Prognostic Index (IPI) or Korean NK/T-cell Prognostic Score",
                      "Elevated C-reactive protein, anemia (< 11g/dL), or thrombocytopenia (< normal)",
                      "Large cells > 40%",
                      "Ki-67 (proliferation rate) > 50%"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Nasal-type NK/T lymphoma has diffuse pattern; commonly associated with coagulative necrosisCell size is variable, ranging from small to largeMitotic figures are usually identifiedIn touch imprints, neoplastic cells can have azurophilic cytoplasmic granulesAngiocentricity and angiodestruction are common but variableUlcer and superimposed inflammation are common at mucosal sitesOverlying epithelium at mucosal sites can show pseudoepitheliomatous hyperplasiaErythrophagocytosis can complicate clinical course; can be fatal",
                    "sub_points": [
                      "Cell size is variable, ranging from small to large",
                      "Mitotic figures are usually identified",
                      "In touch imprints, neoplastic cells can have azurophilic cytoplasmic granules",
                      "Angiocentricity and angiodestruction are common but variable",
                      "Ulcer and superimposed inflammation are common at mucosal sites",
                      "Overlying epithelium at mucosal sites can show pseudoepitheliomatous hyperplasia",
                      "Erythrophagocytosis can complicate clinical course; can be fatal"
                    ]
                  },
                  {
                    "text": "Lymph nodeNasal-type NK/T preferentially involves paracortex ± medulla",
                    "sub_points": [
                      "Nasal-type NK/T preferentially involves paracortex ± medulla"
                    ]
                  },
                  {
                    "text": "Bone marrowStaging bone marrow is involved in ~ 10-20% of patientsCommonly an interstitial infiltrate without discrete aggregatesIn situ hybridization for EBER helpful to detect disease",
                    "sub_points": [
                      "Staging bone marrow is involved in ~ 10-20% of patientsCommonly an interstitial infiltrate without discrete aggregatesIn situ hybridization for EBER helpful to detect disease",
                      "Commonly an interstitial infiltrate without discrete aggregates",
                      "In situ hybridization for EBER helpful to detect disease"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "NK-cell lineage in ~ 65-75% of casesPositive for CD2, cytoplasmic CD3-ε, CD56, and cytotoxic markers (TIA, GZM-B, perforin)Both T and NK cells express epsilon chain of CD3 (CD3-ε)Negative for CD4, CD5, CD8, TCR-β (BF1)",
                    "sub_points": [
                      "Positive for CD2, cytoplasmic CD3-ε, CD56, and cytotoxic markers (TIA, GZM-B, perforin)Both T and NK cells express epsilon chain of CD3 (CD3-ε)",
                      "Both T and NK cells express epsilon chain of CD3 (CD3-ε)",
                      "Negative for CD4, CD5, CD8, TCR-β (BF1)"
                    ]
                  },
                  {
                    "text": "True T-cell lineage in approximately 25-35% of casesPositive for CD2, CD3-ε, CD5, CD8, TCR-β (BF1), CD56(-/+), cytotoxic markers",
                    "sub_points": [
                      "Positive for CD2, CD3-ε, CD5, CD8, TCR-β (BF1), CD56(-/+), cytotoxic markers"
                    ]
                  },
                  {
                    "text": "Both NK- and T-cell neoplasms are positive for Epstein-Barr virusCan be shown by variety of molecular methods (Southern blotting, in situ hybridization)In situ hybridization for EBV small-encoded RNA (EBER) is convenient and sensitiveEBV latent membrane protein is variably expressed (usually many less cells than EBER)",
                    "sub_points": [
                      "Can be shown by variety of molecular methods (Southern blotting, in situ hybridization)In situ hybridization for EBV small-encoded RNA (EBER) is convenient and sensitive",
                      "In situ hybridization for EBV small-encoded RNA (EBER) is convenient and sensitive",
                      "EBV latent membrane protein is variably expressed (usually many less cells than EBER)"
                    ]
                  }
                ],
                "PCR": [
                  {
                    "text": "NK-cell tumors do not carry monoclonal T-cell receptor(TCR) rearrangements"
                  },
                  {
                    "text": "T-cell tumors carry monoclonalTCRrearrangements"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Various gene deletions or mutations have been identifiedFAS,P53,β-catenin,KRAS,C-KITMore common in large cell tumors",
                    "sub_points": [
                      "FAS,P53,β-catenin,KRAS,C-KIT",
                      "More common in large cell tumors"
                    ]
                  }
                ],
                "Array CGH": [
                  {
                    "text": "Comparative genomic hybridization studies have shown multiple gains and lossesMost common site of gain: 2q",
                    "sub_points": [
                      "Most common site of gain: 2q"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Wegener Granulomatosis": [
                  {
                    "text": "Typically patients also have lung and kidney disease"
                  },
                  {
                    "text": "Classic histologic triad is uncommon (< 25% of cases)Vasculitis, granulomatous inflammation, and geographic necrosis",
                    "sub_points": [
                      "Vasculitis, granulomatous inflammation, and geographic necrosis"
                    ]
                  },
                  {
                    "text": "Epithelial ulceration is common"
                  },
                  {
                    "text": "Inflammatory infiltrate is mixedGranulocytes (including eosinophils), lymphocytes, histiocytes, and plasma cells are presentWegener granulomatosis is not lymphocyte-rich",
                    "sub_points": [
                      "Granulocytes (including eosinophils), lymphocytes, histiocytes, and plasma cells are present",
                      "Wegener granulomatosis is not lymphocyte-rich"
                    ]
                  }
                ],
                "B-Cell Lymphomas Involving Upper Aerodigestive Tract": [
                  {
                    "text": "Most often diffuse large B-cell lymphoma"
                  },
                  {
                    "text": "Blood vessel involvement is less common than in nasal-type extranodal NK/T-cell lymphoma"
                  },
                  {
                    "text": "Immunophenotype: CD19(+), CD20(+), CD79a(+), pax-5(+), CD3(-), EBV(-)"
                  }
                ],
                "Peripheral T-cell Lymphoma, Not Otherwise Specified, Involving Upper Aerodigestive Tract": [
                  {
                    "text": "Histologic features can mimic nasal-type extranodal NK/T-cell lymphomaNecrosis and involvement of vesselsThese tumors usually lack CD56 and are negative for EBV",
                    "sub_points": [
                      "Necrosis and involvement of vessels",
                      "These tumors usually lack CD56 and are negative for EBV"
                    ]
                  }
                ],
                "Infections": [
                  {
                    "text": "A number of infectious organisms can involve nasal region"
                  },
                  {
                    "text": "Mixed inflammatory infiltrate with granulocytes"
                  },
                  {
                    "text": "No evidence of monoclonal gene rearrangements"
                  },
                  {
                    "text": "EBV(-)"
                  }
                ]
              },
              "STAGING": {
                "Staging": [
                  {
                    "text": "Ann Arbor staging is not ideal for nasal-type extranodal NK/T-cell lymphoma3-tier system for staging has been suggested in KoreaLimited stage upper aerodigestive tract disease without local invasionAdvanced stage upper aerodigestive tract disease or limited stage with extensive local invasionInvolvement of non-nasal sites",
                    "sub_points": [
                      "3-tier system for staging has been suggested in KoreaLimited stage upper aerodigestive tract disease without local invasionAdvanced stage upper aerodigestive tract disease or limited stage with extensive local invasionInvolvement of non-nasal sites",
                      "Limited stage upper aerodigestive tract disease without local invasion",
                      "Advanced stage upper aerodigestive tract disease or limited stage with extensive local invasion",
                      "Involvement of non-nasal sites"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Enteropathy-Associated T-Cell Lymphoma": {
            "name": "Enteropathy-Associated T-Cell Lymphoma",
            "url": "https://app.pathprimer.com/document/672d4398-7f4f-4e5d-939d-07e4f235ee0c/lesson/7f0bcc37-552c-40e6-b672-243b3ec2231e",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "Available data suggest that EATL can be divided into 2 types: 1 (classical) and 2 (monomorphous)"
                  },
                  {
                    "text": "Classical cases of EATL arise in patients with evidence of celiac diseaseSerologic tests (+); evidence of celiac disease (+)Associated clinical findings: Gluten intolerance, dermatitis herpetiformis, and hyposplenismRefractory celiac disease is precursor lesion",
                    "sub_points": [
                      "Serologic tests (+); evidence of celiac disease (+)",
                      "Associated clinical findings: Gluten intolerance, dermatitis herpetiformis, and hyposplenism",
                      "Refractory celiac disease is precursor lesion"
                    ]
                  },
                  {
                    "text": "In monomorphic variant of EATL, association with celiac disease is not proven"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Most commonly involves jejunum or ileum"
                  },
                  {
                    "text": "EATL is often initially diagnosed by intestinal resection at time of acute abdomen"
                  },
                  {
                    "text": "Prognosis is very poor due to late diagnosis"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Array CGHChromosomal gain of 9q31.33-qter or deletions within 16q12.1 (23% of cases)",
                    "sub_points": [
                      "Chromosomal gain of 9q31.33-qter or deletions within 16q12.1 (23% of cases)"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Enteropathy-associated T-cell lymphoma (EATL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Intestinal T-cell lymphoma"
                  }
                ],
                "Definitions": [
                  {
                    "text": "T-cell lymphoma of intestine arising from intraepithelial T cells"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Classical Variant EATL (EATL Type 1)": [
                  {
                    "text": "Type 1 comprises 80-90% of cases of EATL"
                  },
                  {
                    "text": "These tumors are associated with celiac diseaseSerological tests (+); association with HLA DQ2 or HLA DQ8Pathologic evidence of celiac disease in uninvolved intestinal mucosaAssociated clinical findings: Gluten intolerance, dermatitis herpetiformis, and hyposplenism",
                    "sub_points": [
                      "Serological tests (+); association with HLA DQ2 or HLA DQ8",
                      "Pathologic evidence of celiac disease in uninvolved intestinal mucosa",
                      "Associated clinical findings: Gluten intolerance, dermatitis herpetiformis, and hyposplenism"
                    ]
                  },
                  {
                    "text": "Refractory celiac disease (RCD) is precursor lesionDefinitionPersistent enteropathy-associated histologic changes on biopsy despite strict gluten-free diet for > 12 monthsorSevere persistent symptoms necessitating clinical intervention independent of duration of gluten-free dietIn some cases of RCD, intraepithelial lymphocytes showImmunophenotypic aberrancyMonoclonal T-cell receptor gene rearrangementGain of chromosome 1qThese cases may be considered as EATL in situ",
                    "sub_points": [
                      "DefinitionPersistent enteropathy-associated histologic changes on biopsy despite strict gluten-free diet for > 12 monthsorSevere persistent symptoms necessitating clinical intervention independent of duration of gluten-free diet",
                      "Persistent enteropathy-associated histologic changes on biopsy despite strict gluten-free diet for > 12 monthsor",
                      "Severe persistent symptoms necessitating clinical intervention independent of duration of gluten-free diet",
                      "In some cases of RCD, intraepithelial lymphocytes showImmunophenotypic aberrancyMonoclonal T-cell receptor gene rearrangementGain of chromosome 1qThese cases may be considered as EATL in situ",
                      "Immunophenotypic aberrancy",
                      "Monoclonal T-cell receptor gene rearrangement",
                      "Gain of chromosome 1q",
                      "These cases may be considered as EATL in situ"
                    ]
                  }
                ],
                "Monomorphic Variant (EATL Type 2)": [
                  {
                    "text": "Association with celiac disease or other risk factors is not proven"
                  },
                  {
                    "text": "10-20% of cases"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Annual rate of 0.5-1 per 1,000,000 people in Western countriesGreatest frequency in areas with high prevalence of celiac disease, particularly Northern EuropeAccounts for ~ 35% of all small intestinal lymphomas< 5% of all gastrointestinal tract lymphomas",
                    "sub_points": [
                      "Greatest frequency in areas with high prevalence of celiac disease, particularly Northern Europe",
                      "Accounts for ~ 35% of all small intestinal lymphomas",
                      "< 5% of all gastrointestinal tract lymphomas"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Median: 60 years"
                  }
                ],
                "Sex": [
                  {
                    "text": "Affects males and females equally"
                  }
                ],
                "Site": [
                  {
                    "text": "EATL most commonly arises in jejunum or ileumOften involves mesenteric lymph nodes",
                    "sub_points": [
                      "Often involves mesenteric lymph nodes"
                    ]
                  },
                  {
                    "text": "Presentation in duodenum, stomach, colon may occur rarelyLymphomas arising in these sites show genetic alterations similar to classic EATL in jejunum or ileumRCD can involve duodenum, stomach, or colon",
                    "sub_points": [
                      "Lymphomas arising in these sites show genetic alterations similar to classic EATL in jejunum or ileum",
                      "RCD can involve duodenum, stomach, or colon"
                    ]
                  },
                  {
                    "text": "Patients usually do not have peripheral lymphadenopathy"
                  },
                  {
                    "text": "EATL can disseminate to liver, bone marrow, spleen, skin, and other organs"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Clinical history of celiac diseaseSmall proportion of patients have childhood-onset celiac diseaseMost patients have adult-onset celiac diseaseTypical symptoms of celiac diseaseDiarrhea with bulky, foul-smelling, floating stoolsMalabsorption: Anemia, weight loss, vitamin deficiencyDermatitis herpetiformisMost patients with monomorphic variant of EATL do not have clinical history of celiac disease",
                    "sub_points": [
                      "Small proportion of patients have childhood-onset celiac disease",
                      "Most patients have adult-onset celiac disease",
                      "Typical symptoms of celiac diseaseDiarrhea with bulky, foul-smelling, floating stoolsMalabsorption: Anemia, weight loss, vitamin deficiencyDermatitis herpetiformis",
                      "Diarrhea with bulky, foul-smelling, floating stools",
                      "Malabsorption: Anemia, weight loss, vitamin deficiency",
                      "Dermatitis herpetiformis",
                      "Most patients with monomorphic variant of EATL do not have clinical history of celiac disease"
                    ]
                  },
                  {
                    "text": "Clinical findings at time EATL is initially diagnosedSome patients can have B symptomsSubstantial subset of patients present with small bowel obstruction or perforationIn patients with known celiac disease, lymphoma occurs ~ 5-10 years after celiac disease diagnosisOften heralded by clinical relapse after a period of good response to gluten withdrawalIn some patients, lymphoma develops in course of progressive deterioration of RCDPresentation of patients with monomorphic EATL is similar, except there is no history of celiac disease",
                    "sub_points": [
                      "Some patients can have B symptoms",
                      "Substantial subset of patients present with small bowel obstruction or perforation",
                      "In patients with known celiac disease, lymphoma occurs ~ 5-10 years after celiac disease diagnosisOften heralded by clinical relapse after a period of good response to gluten withdrawalIn some patients, lymphoma develops in course of progressive deterioration of RCD",
                      "Often heralded by clinical relapse after a period of good response to gluten withdrawal",
                      "In some patients, lymphoma develops in course of progressive deterioration of RCD",
                      "Presentation of patients with monomorphic EATL is similar, except there is no history of celiac disease"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Celiac diseaseSerologyIgA anti-tissue transglutaminase and IgA endomysial antibody are most sensitive and specific testsAnti-gliadin antibody tests have low sensitivity and specificity, no longer used routinelyHLA typingFor DQ2 and DQ8 may be useful in individuals with equivocal findings",
                    "sub_points": [
                      "SerologyIgA anti-tissue transglutaminase and IgA endomysial antibody are most sensitive and specific testsAnti-gliadin antibody tests have low sensitivity and specificity, no longer used routinely",
                      "IgA anti-tissue transglutaminase and IgA endomysial antibody are most sensitive and specific tests",
                      "Anti-gliadin antibody tests have low sensitivity and specificity, no longer used routinely",
                      "HLA typingFor DQ2 and DQ8 may be useful in individuals with equivocal findings",
                      "For DQ2 and DQ8 may be useful in individuals with equivocal findings"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "~ 50% of patients require laparotomy for complications of hemorrhage, perforation, or obstruction"
                  },
                  {
                    "text": "Combination chemotherapy is often used"
                  },
                  {
                    "text": "Stem cell transplant"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Poor due to late diagnosis and associated featuresPoor performance statusMalabsorption and malnutritionComplications: Gastrointestinal bleeding and perforation",
                    "sub_points": [
                      "Poor performance status",
                      "Malabsorption and malnutrition",
                      "Complications: Gastrointestinal bleeding and perforation"
                    ]
                  },
                  {
                    "text": "Cases of celiac disease without immunophenotypic or genetic abnormalities are unlikely to progress to lymphoma"
                  }
                ]
              },
              "IMAGING": {
                "General Features": [
                  {
                    "text": "Small bowel bariumCeliac disease-related changesDilatation of small intestine; coarsening or obliteration of mucosaFragmentation or flocculation of barium in intestinal lumenLymphoma-related changesUlcer(s), ulcerating &/or exophytic mass lesions",
                    "sub_points": [
                      "Celiac disease-related changesDilatation of small intestine; coarsening or obliteration of mucosaFragmentation or flocculation of barium in intestinal lumen",
                      "Dilatation of small intestine; coarsening or obliteration of mucosa",
                      "Fragmentation or flocculation of barium in intestinal lumen",
                      "Lymphoma-related changesUlcer(s), ulcerating &/or exophytic mass lesions",
                      "Ulcer(s), ulcerating &/or exophytic mass lesions"
                    ]
                  },
                  {
                    "text": "Computerized topography (CT) often insensitive, especially when disease is confined to mucosa"
                  },
                  {
                    "text": "MR offers high-contrast resolution; better than CT to identify mass lesion and to assess treatment response"
                  },
                  {
                    "text": "Positron emission tomography (PET) shows increased uptake in EATL compared with celiac diseaseMay use in patients with suspected EATL arising from RCDMay use to monitor EATL post therapy",
                    "sub_points": [
                      "May use in patients with suspected EATL arising from RCD",
                      "May use to monitor EATL post therapy"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Multiple ulcerating raised mucosal mass(es), or 1 or more ulcers, or large exophytic massInfiltrates intestinal wallPerforation ± peritonitisLymph nodes may be enlarged, either due to lymphoma involvement or reactive hyperplasia",
                    "sub_points": [
                      "Infiltrates intestinal wallPerforation ± peritonitis",
                      "Perforation ± peritonitis",
                      "Lymph nodes may be enlarged, either due to lymphoma involvement or reactive hyperplasia"
                    ]
                  },
                  {
                    "text": "Remaining small intestinal mucosa may be thickened with reduced mucosal folds"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "EATL type 1 (classical variant)In most cases, lymphoma cells are medium to large in size and relatively monotonousRound or angulated vesicular nuclei, prominent nucleoli, and moderate to abundant pale-staining cytoplasmIn smaller subset of casesLymphoma cells are highly pleomorphic, mimicking anaplastic large cell lymphomaOften have inflammatory backgroundHistiocytes, eosinophils, neutrophils, small lymphocytes, and plasma cellsRemaining small intestinal mucosa often shows enteropathy-associated changesVillous atrophy, crypt hyperplasiaIncreased intraepithelial lymphocytesIncreased lamina propria lymphocytes and plasma cells",
                    "sub_points": [
                      "In most cases, lymphoma cells are medium to large in size and relatively monotonousRound or angulated vesicular nuclei, prominent nucleoli, and moderate to abundant pale-staining cytoplasm",
                      "Round or angulated vesicular nuclei, prominent nucleoli, and moderate to abundant pale-staining cytoplasm",
                      "In smaller subset of casesLymphoma cells are highly pleomorphic, mimicking anaplastic large cell lymphoma",
                      "Lymphoma cells are highly pleomorphic, mimicking anaplastic large cell lymphoma",
                      "Often have inflammatory backgroundHistiocytes, eosinophils, neutrophils, small lymphocytes, and plasma cells",
                      "Histiocytes, eosinophils, neutrophils, small lymphocytes, and plasma cells",
                      "Remaining small intestinal mucosa often shows enteropathy-associated changesVillous atrophy, crypt hyperplasiaIncreased intraepithelial lymphocytesIncreased lamina propria lymphocytes and plasma cells",
                      "Villous atrophy, crypt hyperplasia",
                      "Increased intraepithelial lymphocytes",
                      "Increased lamina propria lymphocytes and plasma cells"
                    ]
                  },
                  {
                    "text": "EATL type 2 (monomorphic variant)Lymphoma cells are small to medium-sized, round, and have dark nuclei with pale cytoplasmLess inflammatory backgroundRemaining small intestinal mucosa often shows enteropathy-associated changesVillous atrophy and crypt hyperplasiaProminent intraepithelial lymphocytosisThese changes are usually not associated with celiac disease",
                    "sub_points": [
                      "Lymphoma cells are small to medium-sized, round, and have dark nuclei with pale cytoplasm",
                      "Less inflammatory background",
                      "Remaining small intestinal mucosa often shows enteropathy-associated changesVillous atrophy and crypt hyperplasiaProminent intraepithelial lymphocytosisThese changes are usually not associated with celiac disease",
                      "Villous atrophy and crypt hyperplasia",
                      "Prominent intraepithelial lymphocytosis",
                      "These changes are usually not associated with celiac disease"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "EATL type 1CD3(+), CD7(+), CD103(+), cytotoxic proteins(+)CD8(-/+), TCR-β(+/-), CD4(-), CD5(-), CD56(-)CD30 focally (+) in subset of cases",
                    "sub_points": [
                      "CD3(+), CD7(+), CD103(+), cytotoxic proteins(+)",
                      "CD8(-/+), TCR-β(+/-), CD4(-), CD5(-), CD56(-)CD30 focally (+) in subset of cases",
                      "CD30 focally (+) in subset of cases"
                    ]
                  },
                  {
                    "text": "EATL type 2CD3(+), CD8(+), CD56(+), TCR-β(+), CD4(-)Rare cases that are TCR-γδ(+) have been reported",
                    "sub_points": [
                      "CD3(+), CD8(+), CD56(+), TCR-β(+), CD4(-)Rare cases that are TCR-γδ(+) have been reported",
                      "Rare cases that are TCR-γδ(+) have been reported"
                    ]
                  },
                  {
                    "text": "Adjacent intraepithelial lymphocytes often show similar aberrant immunophenotype in types 1 and 2 EATL"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "MonoclonalTCRgene rearrangements in types 1 and 2 EATL"
                  },
                  {
                    "text": "Conventional cytogenetics rarely performed on cases of EATL"
                  }
                ],
                "Array CGH": [
                  {
                    "text": "Chromosomal gain of 9q31.33-qter (58-70% cases)or"
                  },
                  {
                    "text": "Deletions in 16q12.1 (23% cases)These changes are almost mutually exclusiveSeen in both types of EATL",
                    "sub_points": [
                      "These changes are almost mutually exclusive",
                      "Seen in both types of EATL"
                    ]
                  },
                  {
                    "text": "EATL type specific CGH changesType 1 EATL: More frequent gains of 1q and 5qType 2 EATL: More frequent gains of MYC oncogene locus at 8q24",
                    "sub_points": [
                      "Type 1 EATL: More frequent gains of 1q and 5q",
                      "Type 2 EATL: More frequent gains of MYC oncogene locus at 8q24"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS)": [
                  {
                    "text": "PTCL-NOS arising in intestines is uncommonOften represents involvement by systemic disease",
                    "sub_points": [
                      "Often represents involvement by systemic disease"
                    ]
                  },
                  {
                    "text": "Morphologic features overlap with EATL, types 1 or 2"
                  },
                  {
                    "text": "No enteropathy-associated changes in adjacent intestinal epithelium"
                  },
                  {
                    "text": "Most case are CD4(+), cytotoxic proteins(-)"
                  }
                ],
                "Anaplastic Large Cell Lymphoma (ALCL)": [
                  {
                    "text": "Uncommonly involves small intestineMost common extranodal sites are bone, skin, and soft tissue",
                    "sub_points": [
                      "Most common extranodal sites are bone, skin, and soft tissue"
                    ]
                  },
                  {
                    "text": "Morphologic features overlap with some EATL, type 1"
                  },
                  {
                    "text": "No enteropathy-associated changes"
                  },
                  {
                    "text": "CD30 strong and uniformly (+) in ALK(+) and ALK(-) ALCL"
                  },
                  {
                    "text": "ALK(+) andALKgene abnormalities in ALK-positive ALCL"
                  }
                ],
                "Extranodal NK-/T-cell Lymphoma, Nasal Type": [
                  {
                    "text": "No enteropathy-associated changes"
                  },
                  {
                    "text": "Often show angiocentric and angiodestructive growth pattern"
                  },
                  {
                    "text": "Surface CD3(-), cytoplasmic CD3-ε(+)"
                  },
                  {
                    "text": "CD2(+), CD4(-), CD8(-), CD5(-), CD56(+)"
                  },
                  {
                    "text": "Cytotoxic proteins(+)"
                  },
                  {
                    "text": "EBV-encoded RNA (EBER)(+) in virtually all cases"
                  }
                ],
                "T-Lymphoblastic Lymphoma": [
                  {
                    "text": "Small to medium-sized blasts with high nuclear to cytoplasmic ratio"
                  },
                  {
                    "text": "No enteropathy-associated changes"
                  },
                  {
                    "text": "Immature T-cell immunophenotype; TdT(+), CD1a(+/-), CD34(+/-)"
                  }
                ],
                "Adult T-cell Leukemia/Lymphoma (ATLL)": [
                  {
                    "text": "Can present as small intestine mass"
                  },
                  {
                    "text": "Most cases are CD4(+), CD8(-)CD25 is strongly (+) in virtually all casesFew cases are CD4(-), CD8(+) or CD4(+), CD8(+)",
                    "sub_points": [
                      "CD25 is strongly (+) in virtually all cases",
                      "Few cases are CD4(-), CD8(+) or CD4(+), CD8(+)"
                    ]
                  },
                  {
                    "text": "Associated with HTLV-1 infection"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Clinicopathologic and genetic data suggest that EATL can be divided into types 1 and type 2"
                  },
                  {
                    "text": "Enteropathy-associated changes are almost always present in both types"
                  },
                  {
                    "text": "Association with celiac disease is proven for type 1"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hepatosplenic T-Cell Lymphoma": {
            "name": "Hepatosplenic T-Cell Lymphoma",
            "url": "https://app.pathprimer.com/document/f14ee5ca-d904-4d98-bc8b-d2a57b4c2680/lesson/7f0bcc37-552c-40e6-b672-243b3ec2231e",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Aggressive, mature T-cell lymphoma (often γδ-positive T cells) with sinusoidal infiltration of spleen, liver, and bone marrow"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Systemic B symptoms (fever, weight loss, night sweats)"
                  },
                  {
                    "text": "Splenomegaly, minimal/absent lymphadenopathy"
                  },
                  {
                    "text": "Poor prognosis (median survival < 2 yr)"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "TCR-δ usually positive for γδ T cells but can be lost as disease progresses"
                  },
                  {
                    "text": "CD3+, CD5-, CD7+, CD56+/-"
                  },
                  {
                    "text": "CD4-, CD8- common"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "T-cell large granular lymphocytic leukemia, aggressive NK cell leukemia/lymphoma, splenic marginal zone lymphoma, hairy cell leukemia"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Hepatosplenic T-cell lymphoma (HSTCL)"
                  },
                  {
                    "text": "Tumor necrosis factor α (TNFα)"
                  },
                  {
                    "text": "Lactate dehydrogenase (LDH)"
                  },
                  {
                    "text": "Fluorescence in situ hybridization (FISH)"
                  },
                  {
                    "text": "Epstein-Barr encoded RNA (EBER)"
                  },
                  {
                    "text": "Natural killer (NK)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Erythrophagocytic T gamma lymphoma"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Aggressive systemic extranodal T-cell lymphoma (often γδ-positive T cells) with sinusoidal infiltration of spleen, liver, and bone marrow"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Etiology": [
                  {
                    "text": "Chronic immunosuppression (20% of cases)Solid-organ transplant recipientsPatients with inflammatory bowel disease receiving TNFα antagonists (infliximab) or thiopurines (azathioprine)",
                    "sub_points": [
                      "Solid-organ transplant recipients",
                      "Patients with inflammatory bowel disease receiving TNFα antagonists (infliximab) or thiopurines (azathioprine)"
                    ]
                  },
                  {
                    "text": "Idiopathic in 80% of cases"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "IncidenceRare: < 1% of non-Hodgkin lymphomas",
                    "sub_points": [
                      "Rare: < 1% of non-Hodgkin lymphomas"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Adolescents and young adults"
                  },
                  {
                    "text": "Median age: approximately 35 yr"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Systemic B symptoms (fever, weight loss, night sweats)"
                  },
                  {
                    "text": "Splenomegaly"
                  },
                  {
                    "text": "Hepatomegaly in approximately 50% of patients"
                  },
                  {
                    "text": "Cytopenias common"
                  },
                  {
                    "text": "Minimal or absent lymphadenopathy"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Thrombocytopenia and anemia commonSeverity correlates with progression",
                    "sub_points": [
                      "Severity correlates with progression"
                    ]
                  },
                  {
                    "text": "Leukemic phase occursUncommon at presentation",
                    "sub_points": [
                      "Uncommon at presentation"
                    ]
                  },
                  {
                    "text": "High serum LDH level"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Platinum-based chemotherapyRelapses common",
                    "sub_points": [
                      "Relapses common"
                    ]
                  },
                  {
                    "text": "Stem cell transplantation can be curative"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "PoorMedian survival: < 2 yrNo good prognostic factors",
                    "sub_points": [
                      "Median survival: < 2 yr",
                      "No good prognostic factors"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "SpleenRed pulp sinuses and cords infiltrated by neoplastic T cellsMonotonous cytologically bland tumor cellsSmall to intermediate in size with irregular nuclear contoursNuclear chromatin loosely condensed with small nucleoliPale, agranular cytoplasmAtrophic white pulpHemophagocytosis can be seen",
                    "sub_points": [
                      "Red pulp sinuses and cords infiltrated by neoplastic T cells",
                      "Monotonous cytologically bland tumor cellsSmall to intermediate in size with irregular nuclear contoursNuclear chromatin loosely condensed with small nucleoliPale, agranular cytoplasm",
                      "Small to intermediate in size with irregular nuclear contours",
                      "Nuclear chromatin loosely condensed with small nucleoli",
                      "Pale, agranular cytoplasm",
                      "Atrophic white pulp",
                      "Hemophagocytosis can be seen"
                    ]
                  },
                  {
                    "text": "LiverSinusoidal infiltration by neoplastic T cellsMild portal and periportal infiltrate can be seen",
                    "sub_points": [
                      "Sinusoidal infiltration by neoplastic T cells",
                      "Mild portal and periportal infiltrate can be seen"
                    ]
                  },
                  {
                    "text": "Lymph nodesEnlarged splenic hilar nodes (approximately 10% of cases)Neoplastic infiltration usually confined to sinuses",
                    "sub_points": [
                      "Enlarged splenic hilar nodes (approximately 10% of cases)",
                      "Neoplastic infiltration usually confined to sinuses"
                    ]
                  },
                  {
                    "text": "Bone marrowOften involvedHypercellular marrow with trilineage hematopoiesisSinusoidal pattern most commonH&E findings can be subtleImmunohistochemistry useful for detectionInterstitial/diffuse pattern in late-stage disease",
                    "sub_points": [
                      "Often involved",
                      "Hypercellular marrow with trilineage hematopoiesis",
                      "Sinusoidal pattern most commonH&E findings can be subtleImmunohistochemistry useful for detection",
                      "H&E findings can be subtle",
                      "Immunohistochemistry useful for detection",
                      "Interstitial/diffuse pattern in late-stage disease"
                    ]
                  },
                  {
                    "text": "Peripheral bloodThrombocytopenia and anemiaMedium to large lymphoid cells with prominent nucleoliCan mimic leukemic blasts",
                    "sub_points": [
                      "Thrombocytopenia and anemia",
                      "Medium to large lymphoid cells with prominent nucleoliCan mimic leukemic blasts",
                      "Can mimic leukemic blasts"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "TCR-δ usually positive for γδ T cells but can be lost as disease progresses"
                  },
                  {
                    "text": "CD3+, CD5-, CD7+, CD56+/-"
                  },
                  {
                    "text": "CD4-, CD8- common"
                  },
                  {
                    "text": "TIA1 positive, granzyme-M positive, granzyme-B negative, and perforin negative (nonactivated cytotoxic immunophenotype)"
                  },
                  {
                    "text": "Negative for CD19, CD20, CD25, CD30"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "TCR-γδ+ >> TCR-αβ+CD2+, CD3+, CD7+, CD16-/+, CD56+/-KIR+, CD94 dim +/-CD4-, CD5-, CD8-/+, CD57-",
                    "sub_points": [
                      "CD2+, CD3+, CD7+, CD16-/+, CD56+/-",
                      "KIR+, CD94 dim +/-",
                      "CD4-, CD5-, CD8-/+, CD57-"
                    ]
                  },
                  {
                    "text": "Negative for B-cell and myeloid antigens"
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "FISH tests show 2-5 copies of i(7)(q10)"
                  },
                  {
                    "text": "EBER negative"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "TRGgene rearrangementMonoclonal rearrangement of TCR-γ >> TCR-β",
                    "sub_points": [
                      "Monoclonal rearrangement of TCR-γ >> TCR-β"
                    ]
                  },
                  {
                    "text": "Isochromosome 7q10 common (70%) but not specificAmplified with disease progression",
                    "sub_points": [
                      "Amplified with disease progression"
                    ]
                  },
                  {
                    "text": "Trisomy 8 or loss of Y chromosome in subset of cases"
                  },
                  {
                    "text": "Ring chromosome 7 and t(7;15)(p22;q21) rare"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "T-Cell Large Granular Lymphocytic Leukemia": [
                  {
                    "text": "More chronic indolent clinical course than HSTCL"
                  },
                  {
                    "text": "Large lymphocytes with azurophilic granules in peripheral blood interstitial pattern > sinusoidal pattern in marrow (opposite of HSTCL)"
                  },
                  {
                    "text": "CD3+, CD8+, CD57+, TCR-αβ+"
                  }
                ],
                "Aggressive Natural Killer Cell Leukemia/Lymphoma": [
                  {
                    "text": "Hepatosplenomegaly and aggressive course (similar to HSTCL)"
                  },
                  {
                    "text": "Cytoplasmic azurophilic granules (in contrast to HSTCL)"
                  },
                  {
                    "text": "NK cell markers positive, surface CD3-, TCR-, EBV+ (in contrast to HSTCL)"
                  },
                  {
                    "text": "Activated cytotoxic immunophenotype (TIA1 positive, granzyme-B positive, perforin positive) vs. nonactivated cytotoxic immunophenotype in HSTCL"
                  }
                ],
                "Splenic Marginal Zone Lymphoma": [
                  {
                    "text": "CD3-, CD19+, CD20+, CD22+, PAX-5+ (B-cell markers vs. HSTCL)"
                  }
                ],
                "Hairy Cell Leukemia": [
                  {
                    "text": "More chronic indolent clinical course than HSTCL"
                  },
                  {
                    "text": "CD3-, CD19+, CD20+, CD25+, CD103+, annexin-A1+, PAX-5+ (B-cell markers vs. HSTCL)"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Angioimmunoblastic T-Cell Lymphoma": {
            "name": "Angioimmunoblastic T-Cell Lymphoma",
            "url": "https://app.pathprimer.com/document/d0b09957-f381-47a6-b75d-48ae8f8d962e/lesson/7f0bcc37-552c-40e6-b672-243b3ec2231e",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Nodal peripheral T-cell lymphoma derived from CD4+ follicular helper T cells, characterized by T cell immunoblast clusters in background of polymorphic inflammatory cells, hypervascularity, and follicular dendritic cell network"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Often advanced-stage disease and aggressive course"
                  },
                  {
                    "text": "Aggressive; median survival ~ 1-2 years"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Tumor cells often forming small clusters around follicles and high endothelial venules"
                  },
                  {
                    "text": "Marked proliferation of arborizing HEV and FDC"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Pan T-cell antigens present (CD2+, CD3+, CD5+, and CD7+) ± aberrant loss of some (e.g., CD7)"
                  },
                  {
                    "text": "Expression of CD10+, Bcl-6+, CXCL13+, CXCR5+, PD-1+ (follicular T-helper phenotype)"
                  },
                  {
                    "text": "Usually CD4+ and CD8- (T-helper cell phenotype)"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Viral infection, drug reaction, classical Hodgkin lymphoma (mixed cellularity variant), T-cell/histiocyte-rich large B-cell lymphoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD)"
                  },
                  {
                    "text": "Angioimmunoblastic T-cell lymphoma (AITL)"
                  },
                  {
                    "text": "Follicular dendritic cells (FDC)"
                  },
                  {
                    "text": "High endothelial venules (HEV)"
                  },
                  {
                    "text": "Hodgkin Reed-Sternberg (HRS)"
                  },
                  {
                    "text": "T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)"
                  },
                  {
                    "text": "T-cell receptor (TCR)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Angioimmunoblastic lymphadenopathy with dysproteinemia"
                  },
                  {
                    "text": "AILD-like T-cell lymphoma"
                  },
                  {
                    "text": "Immunoblastic lymphadenopathy"
                  },
                  {
                    "text": "Lymphogranulomatosis X"
                  },
                  {
                    "text": "Immunodysplastic disease"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Nodal peripheral T-cell lymphoma derived from CD4+ follicular helper T cells"
                  },
                  {
                    "text": "Histologically characterized by T-cell immunoblast clusters in background of polymorphic inflammatory cells, hypervascularity, and follicular dendritic cell networks"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "EBV Infection": [
                  {
                    "text": "EBV detected in B cells (but not in neoplastic T cells) in most cases"
                  }
                ],
                "Immunodysregulation": [
                  {
                    "text": "Activated/dysregulated follicular helper T cells upregulate CXCR5 and CXCL13"
                  },
                  {
                    "text": "CXCL13 recruits B cells through enhanced adherence on HEV"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "~ 1000 new cases/year in United States"
                  }
                ],
                "Age": [
                  {
                    "text": "Middle-aged to elderly (median age: 59-65 years)"
                  }
                ],
                "Sex": [
                  {
                    "text": "M ~ F"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "White patients > patients of African or Asian descent"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Often advanced-stage disease"
                  },
                  {
                    "text": "Generalized lymphadenopathy"
                  },
                  {
                    "text": "B symptoms (fever, weight loss, night sweats)"
                  },
                  {
                    "text": "Hepatosplenomegaly"
                  },
                  {
                    "text": "Skin rash"
                  },
                  {
                    "text": "Pruritis"
                  },
                  {
                    "text": "Edema"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Complete blood countAnemia (autoimmune hemolytic)Hypereosinophilia (30%)Plasmacytosis (10%)",
                    "sub_points": [
                      "Anemia (autoimmune hemolytic)",
                      "Hypereosinophilia (30%)",
                      "Plasmacytosis (10%)"
                    ]
                  },
                  {
                    "text": "Polyclonal hypergammaglobulinemia on serum protein electrophoresis"
                  },
                  {
                    "text": "Cold agglutinins seen on peripheral smear or identified by cold agglutinin assay"
                  },
                  {
                    "text": "Autoantibodies (anti-smooth muscle, antinuclear, rheumatoid factor)"
                  }
                ],
                "Natural History": [
                  {
                    "text": "Death from infection is common"
                  },
                  {
                    "text": "May progress to large B-cell lymphoma"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Chemotherapy +/- autologous hematopoietic stem cell transplantation"
                  },
                  {
                    "text": "May respond to steroids"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Aggressive; median survival ~ 1-2 years"
                  },
                  {
                    "text": "Not correlated with histologic features"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Lymph nodeOften diagnosticPartial or complete effacement of nodal architecture, often with pericapsular extensionParacortical infiltrate of neoplastic T cells, immunoblasts with clear to pale cytoplasm, distinct cell membranes, and minimal atypiaTumor cells often form small clusters around follicles and HEVMarked proliferation of arborizing HEV and FDCBackground cells in variable numbers and polymorphousSmall reactive lymphocytesEosinophilsPlasma cellsHistiocytes± EBV+ large cellsThree architectural patternsI: Partially preserved node with hyperplastic/normal folliclesII: Completely replaced node with \"burned out” folliclesIII: Mostly effaced node with atypical lymphoid aggregates and vascular proliferation",
                    "sub_points": [
                      "Often diagnostic",
                      "Partial or complete effacement of nodal architecture, often with pericapsular extension",
                      "Paracortical infiltrate of neoplastic T cells, immunoblasts with clear to pale cytoplasm, distinct cell membranes, and minimal atypia",
                      "Tumor cells often form small clusters around follicles and HEV",
                      "Marked proliferation of arborizing HEV and FDC",
                      "Background cells in variable numbers and polymorphousSmall reactive lymphocytesEosinophilsPlasma cellsHistiocytes± EBV+ large cells",
                      "Small reactive lymphocytes",
                      "Eosinophils",
                      "Plasma cells",
                      "Histiocytes",
                      "± EBV+ large cells",
                      "Three architectural patternsI: Partially preserved node with hyperplastic/normal folliclesII: Completely replaced node with \"burned out” folliclesIII: Mostly effaced node with atypical lymphoid aggregates and vascular proliferation",
                      "I: Partially preserved node with hyperplastic/normal follicles",
                      "II: Completely replaced node with \"burned out” follicles",
                      "III: Mostly effaced node with atypical lymphoid aggregates and vascular proliferation"
                    ]
                  },
                  {
                    "text": "Bone marrowNodular/interstitial aggregatesNeoplastic cells with small size ± clear cytoplasmNeoplastic cells in aggregates with blood vessel proliferationReactive cells (similar to lymph nodes)Classical HRS-like cells may be presentUninvolved marrowErythroid hyperplasia, polyclonal plasmacytosis, eosinophilia, fibrosis",
                    "sub_points": [
                      "Nodular/interstitial aggregatesNeoplastic cells with small size ± clear cytoplasmNeoplastic cells in aggregates with blood vessel proliferationReactive cells (similar to lymph nodes)Classical HRS-like cells may be present",
                      "Neoplastic cells with small size ± clear cytoplasm",
                      "Neoplastic cells in aggregates with blood vessel proliferation",
                      "Reactive cells (similar to lymph nodes)",
                      "Classical HRS-like cells may be present",
                      "Uninvolved marrowErythroid hyperplasia, polyclonal plasmacytosis, eosinophilia, fibrosis",
                      "Erythroid hyperplasia, polyclonal plasmacytosis, eosinophilia, fibrosis"
                    ]
                  },
                  {
                    "text": "Peripheral bloodCytopenia and eosinophiliaAtypical lymphocytes or immunocytes (activated lymphocytes) uncommon",
                    "sub_points": [
                      "Cytopenia and eosinophilia",
                      "Atypical lymphocytes or immunocytes (activated lymphocytes) uncommon"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Diagnosis on fine needle aspiration can be difficult due to polymorphous cell compositionCorrelation with clinical features and ancillary studies (immunophenotype or clonality) are necessary",
                    "sub_points": [
                      "Correlation with clinical features and ancillary studies (immunophenotype or clonality) are necessary"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Pan T-cell antigens (CD2+, CD3+, CD5+, and CD7+) ± aberrant loss of some (e.g., CD7)"
                  },
                  {
                    "text": "Usually CD4+ and CD8- (T-helper cell phenotype)"
                  },
                  {
                    "text": "CD10+, Bcl-6+, CXCL13+, CXCR5+, PD-1+ (follicular T-helper phenotype)"
                  },
                  {
                    "text": "CD21, CD23, CD35, and clusterin highlighting FDC proliferation around HEV"
                  },
                  {
                    "text": "CD19+, CD20+, PAX-5+, CD79a+"
                  },
                  {
                    "text": "EBER+ in scattered B-immunoblasts"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Normal CD4:CD8 ratio common (because reactive, CD8+ T cells >> neoplastic T cells)"
                  },
                  {
                    "text": "Aberrant expression or loss of CD7 +/- CD26, surface CD3"
                  },
                  {
                    "text": "Aberrant coexpression of CD10 by subset of T cells"
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "EBER+ > 80% of cases"
                  }
                ],
                "PCR": [
                  {
                    "text": "Clonal TCR rearrangements in 75-90% of cases"
                  },
                  {
                    "text": "Clonal Ig rearrangements in 25-30% of cases (expanded EBV+ B cells)"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Trisomies 3, 5, and gain of X most common"
                  },
                  {
                    "text": "Gain of 22q, 11q13, and 19"
                  },
                  {
                    "text": "Loss of 13q"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Viral Infection": [
                  {
                    "text": "More uniform CD10 expression in germinal center cells"
                  },
                  {
                    "text": "No atypical clear T cells that are positive for CD10 or follicular T helper cell markers"
                  },
                  {
                    "text": "No FDC expansion or increased HEV"
                  },
                  {
                    "text": "Often CD8+ T cells"
                  },
                  {
                    "text": "EBV- except in infectious mononucleosis"
                  }
                ],
                "Drug Reaction": [
                  {
                    "text": "May have similar clinical presentations and microscopic findingsParacortical expansion by polymorphous infiltrate, HEV proliferation, and rarely clonal TCR gene rearrangements",
                    "sub_points": [
                      "Paracortical expansion by polymorphous infiltrate, HEV proliferation, and rarely clonal TCR gene rearrangements"
                    ]
                  },
                  {
                    "text": "No atypical clear cells or immunophenotypic evidence of follicular T helper cell markers"
                  }
                ],
                "Classical Hodgkin Lymphoma (Mixed Cellularity Variant)": [
                  {
                    "text": "EBV+ HRS-like cells are seen in some cases of AITL"
                  },
                  {
                    "text": "EBV+ HRS-like cells in AITL are CD15- and CD45- (unlike classic HL HRS cells)"
                  },
                  {
                    "text": "Classical Hodgkin lymphoma lacks certain featuresNeoplastic T cells with clear cytoplasmIncrease in HEV or FDCAberrant T-cell immunophenotype or clonal TCR gene rearrangements",
                    "sub_points": [
                      "Neoplastic T cells with clear cytoplasm",
                      "Increase in HEV or FDC",
                      "Aberrant T-cell immunophenotype or clonal TCR gene rearrangements"
                    ]
                  }
                ],
                "T-Cell/Histiocyte-Rich Large B-cell Lymphoma": [
                  {
                    "text": "AITL may show large B cells mimicking THRLBCL"
                  },
                  {
                    "text": "B cells (neoplastic) are large in THRLBCLvs. small B cells and B immunoblasts in AITL",
                    "sub_points": [
                      "vs. small B cells and B immunoblasts in AITL"
                    ]
                  },
                  {
                    "text": "T-cell atypia, FDC proliferation, EBV positivity in AITLGenerally not seen in THRLBCL",
                    "sub_points": [
                      "Generally not seen in THRLBCL"
                    ]
                  },
                  {
                    "text": "Monoclonal Ig gene rearrangements in THRLBCL"
                  }
                ],
                "T-Cell-Rich Large B-Cell Variant of Diffuse Large B-Cell Lymphoma": [
                  {
                    "text": "Lacks clusters of T-cell immunoblasts; likely to be light-chain restricted"
                  },
                  {
                    "text": "No clonal TCR rearrangement"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Anaplastic Large Cell Lymphoma in Blood and Bone Marrow": {
            "name": "Anaplastic Large Cell Lymphoma in Blood and Bone Marrow",
            "url": "https://app.pathprimer.com/document/e60c2986-d9fa-4ff6-b94b-0a274078c8a3/lesson/7f0bcc37-552c-40e6-b672-243b3ec2231e",
            "content": {
              "KEY FACTS": {
                "Clinical Issues": [
                  {
                    "text": "ALK-positive anaplastic large cell lymphomaOverall 5-year survival at ~ 80%No differences in survival between cases with t(2;5) and those with variant translocations",
                    "sub_points": [
                      "Overall 5-year survival at ~ 80%No differences in survival between cases with t(2;5) and those with variant translocations",
                      "No differences in survival between cases with t(2;5) and those with variant translocations"
                    ]
                  },
                  {
                    "text": "ALK-negative anaplastic large cell lymphomaWorse prognosis compared with ALK(+) ALCLOverall 5-year survival at ~ 48%",
                    "sub_points": [
                      "Worse prognosis compared with ALK(+) ALCL",
                      "Overall 5-year survival at ~ 48%"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Histologic subtypes of ALK-positive ALCL"
                  },
                  {
                    "text": "Common type with predominantly large cellsPredominance of large cells and frequent large hallmark cells",
                    "sub_points": [
                      "Predominance of large cells and frequent large hallmark cells"
                    ]
                  },
                  {
                    "text": "Lymphohistiocytic variantHistiocytes may mask neoplastic cellsOften misdiagnosed as peripheral T-cell lymphoma (PTCL), NOS",
                    "sub_points": [
                      "Histiocytes may mask neoplastic cells",
                      "Often misdiagnosed as peripheral T-cell lymphoma (PTCL), NOS"
                    ]
                  },
                  {
                    "text": "Small cell variantPredominance of small to medium-sized cellsHallmark cells are always present",
                    "sub_points": [
                      "Predominance of small to medium-sized cells",
                      "Hallmark cells are always present"
                    ]
                  },
                  {
                    "text": "Hodgkin-like variant (so-called Hodgkin-like ALCL)Mimic nodular sclerosis Hodgkin lymphomaIntrasinusoidal growth tumor infiltration present in most cases",
                    "sub_points": [
                      "Mimic nodular sclerosis Hodgkin lymphoma",
                      "Intrasinusoidal growth tumor infiltration present in most cases"
                    ]
                  },
                  {
                    "text": "Peripheral blood involvement (leukemic presentation)Seen in subset of small cell variant subtype of ALK(+) ALCL",
                    "sub_points": [
                      "Seen in subset of small cell variant subtype of ALK(+) ALCL"
                    ]
                  },
                  {
                    "text": "Bone marrow involvementDetected in about 30% of cases when immunohistochemistry is added",
                    "sub_points": [
                      "Detected in about 30% of cases when immunohistochemistry is added"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "ALK-positive anaplastic large cell lymphomaUniform expression of CD30 antigen with membrane and Golgi patterns of stainingExpression of ALK protein",
                    "sub_points": [
                      "Uniform expression of CD30 antigen with membrane and Golgi patterns of staining",
                      "Expression of ALK protein"
                    ]
                  },
                  {
                    "text": "ALK rearrangements in ALK(+) anaplastic large cell lymphomat(2;5)/ALK-NPM1detected in ~ 72% of casesAllALKtranslocations upregulate ALK protein",
                    "sub_points": [
                      "t(2;5)/ALK-NPM1detected in ~ 72% of cases",
                      "AllALKtranslocations upregulate ALK protein"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALK[+] ALCL)"
                  },
                  {
                    "text": "ALK-negative ALCL (ALK[-] ALCL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Ki-1 anaplastic large cell lymphoma (initial designation, 1982)"
                  },
                  {
                    "text": "Also published extensively as \"CD30(+) anaplastic large cell lymphoma\" in the past"
                  }
                ],
                "Definitions": [
                  {
                    "text": "ALK-positive anaplastic large cell lymphomaDistinct subtype of T-cell lymphoma with T- or null cell immunophenotypeUniform expression of CD30 and ALK protein",
                    "sub_points": [
                      "Distinct subtype of T-cell lymphoma with T- or null cell immunophenotype",
                      "Uniform expression of CD30 and ALK protein"
                    ]
                  },
                  {
                    "text": "ALK-negative anaplastic large cell lymphoma (provisional entity, 2008 WHO)Uniformly CD30(+) T-cell lymphoma with similar morphology to ALK(+) ALCL but lacks ALK protein",
                    "sub_points": [
                      "Uniformly CD30(+) T-cell lymphoma with similar morphology to ALK(+) ALCL but lacks ALK protein"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "ALK(+) Anaplastic Large Cell Lymphoma": [
                  {
                    "text": "Upregulation of ALK protein due to ALK-NPM or variant translocations"
                  }
                ],
                "ALK(-) Anaplastic Large Cell Lymphoma": [
                  {
                    "text": "Distinct gene expression profile suggested in some studies"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "ALK-positive anaplastic large cell lymphoma10-20% of childhood lymphomas3% of adult non-Hodgkin lymphomasMost common in first 3 decades of lifeM:F = 1.5:1",
                    "sub_points": [
                      "10-20% of childhood lymphomas",
                      "3% of adult non-Hodgkin lymphomas",
                      "Most common in first 3 decades of life",
                      "M:F = 1.5:1"
                    ]
                  },
                  {
                    "text": "ALK-negative anaplastic large cell lymphomaPeak incidence in adultsM:F = 1.5:1",
                    "sub_points": [
                      "Peak incidence in adults",
                      "M:F = 1.5:1"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "B symptoms, common"
                  },
                  {
                    "text": "High-stage (III-IV) disease in majority of casesPeripheral and intraabdominal lymphadenopathyExtranodal involvementSkin, bone, soft tissue, and bone marrowPeripheral blood involvement in subset of small cell variant of ALK(+) ALCLALKgene rearrangements in ALK-positive ALCL",
                    "sub_points": [
                      "Peripheral and intraabdominal lymphadenopathy",
                      "Extranodal involvementSkin, bone, soft tissue, and bone marrow",
                      "Skin, bone, soft tissue, and bone marrow",
                      "Peripheral blood involvement in subset of small cell variant of ALK(+) ALCL",
                      "ALKgene rearrangements in ALK-positive ALCL"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "ALK-positive anaplastic large cell lymphomaOverall 5-year survival at approximately 80%Less favorable prognosis in small cell variant due to disseminated disease at diagnosisNo differences in survival between cases with t(2;5) and those with variant translocationsRelapsed cases remain sensitive to chemotherapy",
                    "sub_points": [
                      "Overall 5-year survival at approximately 80%",
                      "Less favorable prognosis in small cell variant due to disseminated disease at diagnosis",
                      "No differences in survival between cases with t(2;5) and those with variant translocations",
                      "Relapsed cases remain sensitive to chemotherapy"
                    ]
                  },
                  {
                    "text": "ALK-negative anaplastic large cell lymphomaWorse prognosis compared with ALK(+) ALCLOverall 5-year survival at approximately 48%",
                    "sub_points": [
                      "Worse prognosis compared with ALK(+) ALCL",
                      "Overall 5-year survival at approximately 48%"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "ALK-positive anaplastic large cell lymphoma"
                  },
                  {
                    "text": "Broad spectrum of morphologic range including cases with small or large cell predominant"
                  },
                  {
                    "text": "Variable numbers of so-called hallmark cellsCells with eccentric \"horse shoe\" or kidney-shaped or embryo-shaped nuclei in all casesIntense, eosinophilic-appearing Golgi zoneUsually large in size but can be smaller in size",
                    "sub_points": [
                      "Cells with eccentric \"horse shoe\" or kidney-shaped or embryo-shaped nuclei in all cases",
                      "Intense, eosinophilic-appearing Golgi zone",
                      "Usually large in size but can be smaller in size"
                    ]
                  },
                  {
                    "text": "Sinusoidal and perivascular infiltrate common"
                  },
                  {
                    "text": "Fibrosis with sclerotic bands in some cases"
                  },
                  {
                    "text": "Inflammatory background including abundant histiocytes &/or plasma cells may be present"
                  },
                  {
                    "text": "Histologic subtypes of ALK-positive ALCLCommon type with predominantly large cellsPredominance of large cells with irregular nuclei and frequent large hallmark cellsLymphohistiocytic variantNeoplastic cells admixed with abundant reactive histiocytesHistiocytes may mask neoplastic cellsPerivascular clustering of tumor cells commonOften misdiagnosed as peripheral T-cell lymphoma (PTCL), NOSSmall cell variantPredominance of small to medium-sized neoplastic cells with irregular nucleiCells with pale cytoplasm and \"fried egg\" appearance may be presentHallmark cells are always presentHodgkin-like variant (a.k.a. Hodgkin-like ALCL)Nodular pattern with thick, sclerotic bands mimicking nodular sclerosis Hodgkin lymphomaNeoplastic cells can be sparse or forms sheetsOccasional Reed-Sternberg-like cells presentBackground inflammatory cells are rareIntrasinusoidal pattern present in most casesSarcomatoid variantStoriform growth pattern of neoplastic ALCL cellsMyxoid stroma can be seenRare reported histologic variantsNeutrophil or eosinophil-rich or signet ring variants",
                    "sub_points": [
                      "Common type with predominantly large cellsPredominance of large cells with irregular nuclei and frequent large hallmark cells",
                      "Predominance of large cells with irregular nuclei and frequent large hallmark cells",
                      "Lymphohistiocytic variantNeoplastic cells admixed with abundant reactive histiocytesHistiocytes may mask neoplastic cellsPerivascular clustering of tumor cells commonOften misdiagnosed as peripheral T-cell lymphoma (PTCL), NOS",
                      "Neoplastic cells admixed with abundant reactive histiocytes",
                      "Histiocytes may mask neoplastic cells",
                      "Perivascular clustering of tumor cells common",
                      "Often misdiagnosed as peripheral T-cell lymphoma (PTCL), NOS",
                      "Small cell variantPredominance of small to medium-sized neoplastic cells with irregular nucleiCells with pale cytoplasm and \"fried egg\" appearance may be presentHallmark cells are always present",
                      "Predominance of small to medium-sized neoplastic cells with irregular nuclei",
                      "Cells with pale cytoplasm and \"fried egg\" appearance may be present",
                      "Hallmark cells are always present",
                      "Hodgkin-like variant (a.k.a. Hodgkin-like ALCL)Nodular pattern with thick, sclerotic bands mimicking nodular sclerosis Hodgkin lymphomaNeoplastic cells can be sparse or forms sheetsOccasional Reed-Sternberg-like cells presentBackground inflammatory cells are rareIntrasinusoidal pattern present in most cases",
                      "Nodular pattern with thick, sclerotic bands mimicking nodular sclerosis Hodgkin lymphoma",
                      "Neoplastic cells can be sparse or forms sheets",
                      "Occasional Reed-Sternberg-like cells present",
                      "Background inflammatory cells are rare",
                      "Intrasinusoidal pattern present in most cases",
                      "Sarcomatoid variantStoriform growth pattern of neoplastic ALCL cellsMyxoid stroma can be seen",
                      "Storiform growth pattern of neoplastic ALCL cells",
                      "Myxoid stroma can be seen",
                      "Rare reported histologic variantsNeutrophil or eosinophil-rich or signet ring variants",
                      "Neutrophil or eosinophil-rich or signet ring variants"
                    ]
                  },
                  {
                    "text": "ALK-negative anaplastic large cell lymphomaSolid sheets of cohesive large neoplastic cellsSinusoidal &/or interfollicular pattern in lymph node with partial involvementMorphologic spectrum similar to ALK(+) ALCL, except for small cell variant not reportedVariable numbers of hallmark cells presentNeoplastic cells typically more pleomorphic and larger than those present in common ALK(+) ALCLNeoplastic cells may show high N:C ratio that could overlap with PTCL, NOS cells",
                    "sub_points": [
                      "Solid sheets of cohesive large neoplastic cells",
                      "Sinusoidal &/or interfollicular pattern in lymph node with partial involvement",
                      "Morphologic spectrum similar to ALK(+) ALCL, except for small cell variant not reported",
                      "Variable numbers of hallmark cells present",
                      "Neoplastic cells typically more pleomorphic and larger than those present in common ALK(+) ALCL",
                      "Neoplastic cells may show high N:C ratio that could overlap with PTCL, NOS cells"
                    ]
                  }
                ],
                "Blood and Bone Marrow Findings": [
                  {
                    "text": "Peripheral blood involvement (leukemic presentation)Seen in subset of small cell variant of ALK(+) ALCLVariably sized circulating lymphoma cells with irregular to lobated nucleiScattered large cells with hyperchromatic eccentric nuclei and numerous fine cytoplasmic vacuolesReed-Sternberg-like cells may be presentCirculating large anaplastic cells often found at feather edge of blood smear",
                    "sub_points": [
                      "Seen in subset of small cell variant of ALK(+) ALCL",
                      "Variably sized circulating lymphoma cells with irregular to lobated nuclei",
                      "Scattered large cells with hyperchromatic eccentric nuclei and numerous fine cytoplasmic vacuoles",
                      "Reed-Sternberg-like cells may be present",
                      "Circulating large anaplastic cells often found at feather edge of blood smear"
                    ]
                  },
                  {
                    "text": "Bone marrow involvementDetected in ~ 10% of the cases on pure H&E examinationDetected in ~ 30% of cases when immunohistochemistry is addedPattern of marrow involvement includes intra-sinusoidal and interstitialMost cases show low to minimal level of involvement",
                    "sub_points": [
                      "Detected in ~ 10% of the cases on pure H&E examination",
                      "Detected in ~ 30% of cases when immunohistochemistry is added",
                      "Pattern of marrow involvement includes intra-sinusoidal and interstitial",
                      "Most cases show low to minimal level of involvement"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "ALK-positive anaplastic large cell lymphomaUniform expression of CD30 antigen with membrane and Golgi patterns of stainingExpression of CD30 stronger in large cells but weak to negative in smaller cellsExpression of ALK proteinALK positivity, cytoplasmic and nuclear in most cases with t(2;5)/NPM-ALKtranslocationALK positivity, nuclear only in small cell variant of ALCLALK positivity, membranous or cytoplasmic in cases with variant translocationsAberrant cytoplasmic expression of nucleophosmin (NPM) only in cases with t(2;5)/NPM-ALKtranslocationExpression of epithelial membrane antigen (EMA) in majority of casesExpression of 1 or more T-cell-associated antigens in vast majority of casesCD2, CD5, and CD4 expressed in ~ 70% of casesCD3 is negative in vast majority of the casesCytotoxic-associated markers TIA-1, granzyme B, &/or perforin expressed in most casesCD8 expression reported in only rare casesCD43 antigen (nonlineage antigen) expressed in most casesSome cases exhibit \"null cell\" phenotype due to loss of several pan-T-cell antigensVariable expression of CD45 and CD45RO in most casesExpression of CD15 can rarely be seen in minority of neoplastic cellsEBV is consistently absent",
                    "sub_points": [
                      "Uniform expression of CD30 antigen with membrane and Golgi patterns of stainingExpression of CD30 stronger in large cells but weak to negative in smaller cells",
                      "Expression of CD30 stronger in large cells but weak to negative in smaller cells",
                      "Expression of ALK proteinALK positivity, cytoplasmic and nuclear in most cases with t(2;5)/NPM-ALKtranslocationALK positivity, nuclear only in small cell variant of ALCLALK positivity, membranous or cytoplasmic in cases with variant translocations",
                      "ALK positivity, cytoplasmic and nuclear in most cases with t(2;5)/NPM-ALKtranslocation",
                      "ALK positivity, nuclear only in small cell variant of ALCL",
                      "ALK positivity, membranous or cytoplasmic in cases with variant translocations",
                      "Aberrant cytoplasmic expression of nucleophosmin (NPM) only in cases with t(2;5)/NPM-ALKtranslocation",
                      "Expression of epithelial membrane antigen (EMA) in majority of cases",
                      "Expression of 1 or more T-cell-associated antigens in vast majority of casesCD2, CD5, and CD4 expressed in ~ 70% of casesCD3 is negative in vast majority of the casesCytotoxic-associated markers TIA-1, granzyme B, &/or perforin expressed in most casesCD8 expression reported in only rare casesCD43 antigen (nonlineage antigen) expressed in most casesSome cases exhibit \"null cell\" phenotype due to loss of several pan-T-cell antigens",
                      "CD2, CD5, and CD4 expressed in ~ 70% of cases",
                      "CD3 is negative in vast majority of the cases",
                      "Cytotoxic-associated markers TIA-1, granzyme B, &/or perforin expressed in most cases",
                      "CD8 expression reported in only rare cases",
                      "CD43 antigen (nonlineage antigen) expressed in most cases",
                      "Some cases exhibit \"null cell\" phenotype due to loss of several pan-T-cell antigens",
                      "Variable expression of CD45 and CD45RO in most cases",
                      "Expression of CD15 can rarely be seen in minority of neoplastic cells",
                      "EBV is consistently absent"
                    ]
                  },
                  {
                    "text": "ALK-negative anaplastic large cell lymphomaStrong and equal expression of CD30 antigen in all tumor cells with membrane and Golgi patternsExpression of 1 or more T-cell-associated antigens in majority of casesCD2 and CD3 are expressed more often than CD5Cytotoxic-associated markers TIA, granzyme B, &/or perforin expressed in most casesCD4 expressed in most cases, but CD8 positive cases are rareExpression of EMA in minority of casesEBV is consistently negative",
                    "sub_points": [
                      "Strong and equal expression of CD30 antigen in all tumor cells with membrane and Golgi patterns",
                      "Expression of 1 or more T-cell-associated antigens in majority of casesCD2 and CD3 are expressed more often than CD5Cytotoxic-associated markers TIA, granzyme B, &/or perforin expressed in most casesCD4 expressed in most cases, but CD8 positive cases are rare",
                      "CD2 and CD3 are expressed more often than CD5",
                      "Cytotoxic-associated markers TIA, granzyme B, &/or perforin expressed in most cases",
                      "CD4 expressed in most cases, but CD8 positive cases are rare",
                      "Expression of EMA in minority of cases",
                      "EBV is consistently negative"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Antigen receptor genesT-cell receptor (TCR) gene rearrangementsClonal T-cell population detected in > 90% of ALCL cases of both T- and null cell phenotypes",
                    "sub_points": [
                      "T-cell receptor (TCR) gene rearrangementsClonal T-cell population detected in > 90% of ALCL cases of both T- and null cell phenotypes",
                      "Clonal T-cell population detected in > 90% of ALCL cases of both T- and null cell phenotypes"
                    ]
                  },
                  {
                    "text": "ALK rearrangements in ALK(+)anaplastic large cell lymphomat(2;5)/ALK-NPM1detected in ~ 72% of casest(1;2)/TPM3-ALKdetected in ~ 17% of casest(2;3)/ALK-TFGdetected in < 2.5% of casesinv(2)/ATIC-ALKdetected in ~ 2.5% of casest(2;22)/ALK-CLTCLdetected in 2.5% of cases",
                    "sub_points": [
                      "t(2;5)/ALK-NPM1detected in ~ 72% of cases",
                      "t(1;2)/TPM3-ALKdetected in ~ 17% of cases",
                      "t(2;3)/ALK-TFGdetected in < 2.5% of cases",
                      "inv(2)/ATIC-ALKdetected in ~ 2.5% of cases",
                      "t(2;22)/ALK-CLTCLdetected in 2.5% of cases"
                    ]
                  },
                  {
                    "text": "All above translocations upregulate ALK proteinALK protein expressed in cytoplasm and nucleus inNPM-ALKfusionALK protein expressed only in cytoplasm in variantALKtranslocations",
                    "sub_points": [
                      "ALK protein expressed in cytoplasm and nucleus inNPM-ALKfusion",
                      "ALK protein expressed only in cytoplasm in variantALKtranslocations"
                    ]
                  },
                  {
                    "text": "ALKrearrangements can also be detected by targeted or break-apart probes"
                  },
                  {
                    "text": "ALK-NPMcan also be detected by RT-PCR"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "ALK-positive Large B-cell Lymphoma": [
                  {
                    "text": "Frequent sinusoidal pattern similar to ALCL"
                  },
                  {
                    "text": "Expression of EMA and cytoplasmic expression of ALK"
                  },
                  {
                    "text": "Lack of CD30 antigen helpful in separating this lymphoma from ALK(+) ALCL"
                  }
                ],
                "Nonhematopoietic Neoplasms": [
                  {
                    "text": "ALK expressing inflammatory myofibroblastic tumors and rhabdomyosarcoma"
                  },
                  {
                    "text": "Morphology and absence of CD30 and EMA can distinguish these 2 entities from ALK(+) ALCL"
                  },
                  {
                    "text": "Epithelial tumors, melanoma, germ cell tumorsCan be distinguished by immunohistochemistry",
                    "sub_points": [
                      "Can be distinguished by immunohistochemistry"
                    ]
                  }
                ],
                "Peripheral T-cell Lymphoma, NOS with CD30(+) Cells": [
                  {
                    "text": "Main differential diagnosis of ALK-negative ALCL"
                  },
                  {
                    "text": "Separation from ALK-negative ALCL not always clear cut"
                  },
                  {
                    "text": "Strong and uniform CD30 expression typically seen in ALK-negative ALCL"
                  }
                ],
                "Classical Hodgkin Lymphoma": [
                  {
                    "text": "Complete immunophenotype including Pax-5 and genetic studies can separate CHL from ALCL"
                  }
                ],
                "Primary Cutaneous ALCL": [
                  {
                    "text": "Must be distinguished from secondary involvement by a systemic, ALK-negative ALCL"
                  },
                  {
                    "text": "Clinical correlation and staging is crucial to distinguish the 2 entities"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Plasma Cell Neoplasms": {
        "name": "Plasma Cell Neoplasms",
        "url": "https://app.pathprimer.com/lesson/49ffa39e-ce5b-411c-b9ea-948b60136015",
        "topics": {
          "Overview of Plasma Cell Neoplasms": {
            "name": "Overview of Plasma Cell Neoplasms",
            "url": "https://app.pathprimer.com/document/05625dc1-9d05-4f31-8dbf-9cc67a87d749/lesson/49ffa39e-ce5b-411c-b9ea-948b60136015",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "PCNs are neoplasms derived from clonal expansion of plasma cells"
                  },
                  {
                    "text": "Cells typically secrete monoclonal immunoglobulin (a.k.a. paraprotein or M protein) in serum or urine"
                  },
                  {
                    "text": "Presence of paraprotein is termed \"monoclonal gammopathy\""
                  },
                  {
                    "text": "MGUSDiagnosis must show serum M protein < 30 g/L and < 10% clonal plasma cells in bone marrow and no myeloma-related organ or tissue impairment (hypercalcemia, renal insufficiency, anemia, or bone lesions)Risk of progression to plasma cell myeloma 1% per year",
                    "sub_points": [
                      "Diagnosis must show serum M protein < 30 g/L and < 10% clonal plasma cells in bone marrow and no myeloma-related organ or tissue impairment (hypercalcemia, renal insufficiency, anemia, or bone lesions)",
                      "Risk of progression to plasma cell myeloma 1% per year"
                    ]
                  },
                  {
                    "text": "PCMDiagnosis requires evidence of myeloma-related organ damage or tissue impairment (hypercalcemia,renal insufficiency,anemia, orbone lesions [CRAB]) and > 30 g/L serum M component or ≥ 10% clonal plasma cells in bone marrow",
                    "sub_points": [
                      "Diagnosis requires evidence of myeloma-related organ damage or tissue impairment (hypercalcemia,renal insufficiency,anemia, orbone lesions [CRAB]) and > 30 g/L serum M component or ≥ 10% clonal plasma cells in bone marrow"
                    ]
                  },
                  {
                    "text": "Primary amyloidosis is deposition of β-pleated sheets of Ig light chains (AL amyloid)Secreted light chains are ingested, processed, and distributed to extracellular matrix by macrophages; deposition in subcutaneous fat, kidney, heart, liver, gastrointestinal tract, peripheral nerves, and bone marrowAmyloid appears amorphous and pink with characteristic cracking artifact or \"glass-like\" appearance on H&E sections; Congo red stain highlights amyloid pink to red with characteristic \"apple-green\" birefringence under polarized light",
                    "sub_points": [
                      "Secreted light chains are ingested, processed, and distributed to extracellular matrix by macrophages; deposition in subcutaneous fat, kidney, heart, liver, gastrointestinal tract, peripheral nerves, and bone marrow",
                      "Amyloid appears amorphous and pink with characteristic cracking artifact or \"glass-like\" appearance on H&E sections; Congo red stain highlights amyloid pink to red with characteristic \"apple-green\" birefringence under polarized light"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "General Information": [
                  {
                    "text": "Plasma cell neoplasms (PCNs) are neoplasms derived from clonal expansion of plasma cells"
                  },
                  {
                    "text": "Cells typically secrete monoclonal immunoglobulin (a.k.a. paraprotein or M protein) in serum or urine"
                  },
                  {
                    "text": "Presence of paraprotein is termed \"monoclonal gammopathy\""
                  }
                ],
                "Classification of Plasma Cell Neoplasms": [
                  {
                    "text": "Monoclonal gammopathy of undetermined significance (MGUS)"
                  },
                  {
                    "text": "Plasma cell myeloma (PCM)"
                  },
                  {
                    "text": "Plasmacytoma"
                  },
                  {
                    "text": "Immunoglobulin deposition diseases"
                  },
                  {
                    "text": "Osteosclerotic myeloma (POEMS syndrome)"
                  }
                ],
                "Monoclonal Gammopathy of Undetermined Significance": [
                  {
                    "text": "One of the most prevalent premalignant conditions worldwideApproximately 3% of people > 50 yr oldApproximately 5% of people > 70 yr old",
                    "sub_points": [
                      "Approximately 3% of people > 50 yr old",
                      "Approximately 5% of people > 70 yr old"
                    ]
                  },
                  {
                    "text": "Two forms include plasma cell MGUS and lymphoid (lymphoplasmacytoid) MGUSPlasma cell MGUSDiagnosis must show each of followingSerum monoclonal (M) protein < 30 g/LBone marrow biopsy shows < 10% clonal plasma cellsNo myeloma-related organ or tissue impairment (hypercalcemia,renal insufficiency,anemia, orbone lesions [CRAB])Risk of progression to plasma cell myeloma 1%/yrLymphoid (lymphoplasmacytoid) MGUSComprises only 15%-20% of MGUSIgM paraprotein with < 10% clonal lymphoplasmacytic cells in bone marrowAbsence of end-organ damage attributable to lymphoproliferative disorderCan progress to Waldenström macroglobulinemia or lymphoproliferative disorder",
                    "sub_points": [
                      "Plasma cell MGUSDiagnosis must show each of followingSerum monoclonal (M) protein < 30 g/LBone marrow biopsy shows < 10% clonal plasma cellsNo myeloma-related organ or tissue impairment (hypercalcemia,renal insufficiency,anemia, orbone lesions [CRAB])Risk of progression to plasma cell myeloma 1%/yr",
                      "Diagnosis must show each of followingSerum monoclonal (M) protein < 30 g/LBone marrow biopsy shows < 10% clonal plasma cellsNo myeloma-related organ or tissue impairment (hypercalcemia,renal insufficiency,anemia, orbone lesions [CRAB])",
                      "Serum monoclonal (M) protein < 30 g/L",
                      "Bone marrow biopsy shows < 10% clonal plasma cells",
                      "No myeloma-related organ or tissue impairment (hypercalcemia,renal insufficiency,anemia, orbone lesions [CRAB])",
                      "Risk of progression to plasma cell myeloma 1%/yr",
                      "Lymphoid (lymphoplasmacytoid) MGUSComprises only 15%-20% of MGUSIgM paraprotein with < 10% clonal lymphoplasmacytic cells in bone marrowAbsence of end-organ damage attributable to lymphoproliferative disorderCan progress to Waldenström macroglobulinemia or lymphoproliferative disorder",
                      "Comprises only 15%-20% of MGUS",
                      "IgM paraprotein with < 10% clonal lymphoplasmacytic cells in bone marrow",
                      "Absence of end-organ damage attributable to lymphoproliferative disorder",
                      "Can progress to Waldenström macroglobulinemia or lymphoproliferative disorder"
                    ]
                  }
                ],
                "Plasma Cell Myeloma": [
                  {
                    "text": "Generally affects older adults, peak incidence in 8th decade of lifeIncidence of approximately 4/100,000 in Caucasians and approximately 9.5/100,000 in African Americans",
                    "sub_points": [
                      "Incidence of approximately 4/100,000 in Caucasians and approximately 9.5/100,000 in African Americans"
                    ]
                  },
                  {
                    "text": "Triad of bone marrow plasmacytosis, osteolytic bone lesions, and monoclonal gammopathy"
                  },
                  {
                    "text": "Diagnosis of PCM requires> 30 g/L serum M component or≥ 10% clonal plasma cells in bone marrowEvidence of myeloma-related organ damage or tissue impairment (CRAB)",
                    "sub_points": [
                      "> 30 g/L serum M component or",
                      "≥ 10% clonal plasma cells in bone marrow",
                      "Evidence of myeloma-related organ damage or tissue impairment (CRAB)"
                    ]
                  },
                  {
                    "text": "Clinical variants include asymptomatic (smoldering) myeloma, nonsecretory myeloma, plasma cell leukemiaAsymptomatic (smoldering) myeloma requires> 30 g/L serum M component or≥ 10% clonal plasma cells in bone marrowNo related tissue or organ impairment or bone lesionsNonsecretory myeloma (NSM)Absence of M protein on electrophoresisAccounts for approximately 3% of plasma cell myelomasApproximately 85% have cytoplasmic M protein by immunohistochemistryClinical features are similar to other PCM except lower incidence of renal insufficiency and hypercalcemia in NSMPlasma cell leukemia (PCL)Clonal plasma cells in peripheral blood are > 20% of white blood cell count or absolute count > 2 x 10⁹/LMay manifest initially as PCL (primary PCL) or as progression from myeloma (secondary PCL)Cytologic features of leukemic plasma cells vary from cells that resemble small plasmacytoid lymphocytes to cells with plasmablastic featuresPCL is aggressive disease with short survival",
                    "sub_points": [
                      "Asymptomatic (smoldering) myeloma requires> 30 g/L serum M component or≥ 10% clonal plasma cells in bone marrowNo related tissue or organ impairment or bone lesions",
                      "> 30 g/L serum M component or",
                      "≥ 10% clonal plasma cells in bone marrow",
                      "No related tissue or organ impairment or bone lesions",
                      "Nonsecretory myeloma (NSM)Absence of M protein on electrophoresisAccounts for approximately 3% of plasma cell myelomasApproximately 85% have cytoplasmic M protein by immunohistochemistryClinical features are similar to other PCM except lower incidence of renal insufficiency and hypercalcemia in NSM",
                      "Absence of M protein on electrophoresis",
                      "Accounts for approximately 3% of plasma cell myelomas",
                      "Approximately 85% have cytoplasmic M protein by immunohistochemistry",
                      "Clinical features are similar to other PCM except lower incidence of renal insufficiency and hypercalcemia in NSM",
                      "Plasma cell leukemia (PCL)Clonal plasma cells in peripheral blood are > 20% of white blood cell count or absolute count > 2 x 10⁹/LMay manifest initially as PCL (primary PCL) or as progression from myeloma (secondary PCL)Cytologic features of leukemic plasma cells vary from cells that resemble small plasmacytoid lymphocytes to cells with plasmablastic featuresPCL is aggressive disease with short survival",
                      "Clonal plasma cells in peripheral blood are > 20% of white blood cell count or absolute count > 2 x 10⁹/L",
                      "May manifest initially as PCL (primary PCL) or as progression from myeloma (secondary PCL)",
                      "Cytologic features of leukemic plasma cells vary from cells that resemble small plasmacytoid lymphocytes to cells with plasmablastic features",
                      "PCL is aggressive disease with short survival"
                    ]
                  }
                ],
                "Plasmacytoma": [
                  {
                    "text": "Localized monoclonal lesions of plasma cells involving bone (solitary plasmacytoma of bone) or nonosseous tissues (extraosseous plasmacytoma)No radiographic evidence of other lesionsNo clinical evidence of PCM (CRAB)No monoclonal plasma cell population in bone marrow",
                    "sub_points": [
                      "No radiographic evidence of other lesions",
                      "No clinical evidence of PCM (CRAB)",
                      "No monoclonal plasma cell population in bone marrow"
                    ]
                  },
                  {
                    "text": "UncommonEach type comprises 3%-5% of PCN",
                    "sub_points": [
                      "Each type comprises 3%-5% of PCN"
                    ]
                  },
                  {
                    "text": "Affects adultsM:F = 2:1",
                    "sub_points": [
                      "M:F = 2:1"
                    ]
                  },
                  {
                    "text": "Complete clinical and radiographic work-up must be negative for evidence of PCM"
                  },
                  {
                    "text": "Treated by local radiation therapy"
                  },
                  {
                    "text": "Solitary plasmacytoma of bone has greater propensity to recur or progress to generalized myeloma (two-thirds of patients)"
                  },
                  {
                    "text": "Extraosseous plasmacytoma has more indolent course70% of patients remain disease-free after treatment",
                    "sub_points": [
                      "70% of patients remain disease-free after treatment"
                    ]
                  }
                ],
                "Immunoglobulin Deposition Diseases": [
                  {
                    "text": "Related monoclonal immunoglobulin disorders that cause organ damage through immunoglobulin deposition in soft tissue and viscera"
                  },
                  {
                    "text": "Underlying cause is typically PCN or rarely lymphoplasmacytic neoplasmDysfunction due to immunoglobulin deposition precedes symptoms of underlying disease",
                    "sub_points": [
                      "Dysfunction due to immunoglobulin deposition precedes symptoms of underlying disease"
                    ]
                  },
                  {
                    "text": "Generally categorized as primary amyloidosis and light chain deposition disease (LCDD)Rarely categorized as light and heavy chain disease or heavy chain deposition disease",
                    "sub_points": [
                      "Rarely categorized as light and heavy chain disease or heavy chain deposition disease"
                    ]
                  },
                  {
                    "text": "Primary amyloidosisDeposition of β-pleated sheets of Ig light chains (AL amyloid)Affects older adultsMedian age 64 yrMen account for 60%-70% of casesSecreted light chains are ingested, processed, and distributed to extracellular matrix by macrophagesLambda > kappaDeposition in subcutaneous fat, kidney, heart, liver, gastrointestinal tract, peripheral nerves, bone marrowM protein in serum or urine in > 90% of casesMost meet criteria for MGUSApproximately 20% meet criteria for plasma cell myelomaBone marrow biopsy commonly shows slight increase in plasma cells and variable amounts of replacement by amyloid (none to extensive)Amyloid appears amorphous and pink with characteristic cracking artifact or \"glass-like\" appearance on H&E sectionsCongo red stain highlights amyloid pink to red with characteristic \"apple-green\" birefringence under polarized lightElectron microscopy shows fibrillary depositsMedian survival 2 yr",
                    "sub_points": [
                      "Deposition of β-pleated sheets of Ig light chains (AL amyloid)",
                      "Affects older adultsMedian age 64 yrMen account for 60%-70% of cases",
                      "Median age 64 yr",
                      "Men account for 60%-70% of cases",
                      "Secreted light chains are ingested, processed, and distributed to extracellular matrix by macrophages",
                      "Lambda > kappa",
                      "Deposition in subcutaneous fat, kidney, heart, liver, gastrointestinal tract, peripheral nerves, bone marrow",
                      "M protein in serum or urine in > 90% of casesMost meet criteria for MGUSApproximately 20% meet criteria for plasma cell myeloma",
                      "Most meet criteria for MGUS",
                      "Approximately 20% meet criteria for plasma cell myeloma",
                      "Bone marrow biopsy commonly shows slight increase in plasma cells and variable amounts of replacement by amyloid (none to extensive)",
                      "Amyloid appears amorphous and pink with characteristic cracking artifact or \"glass-like\" appearance on H&E sections",
                      "Congo red stain highlights amyloid pink to red with characteristic \"apple-green\" birefringence under polarized light",
                      "Electron microscopy shows fibrillary deposits",
                      "Median survival 2 yr"
                    ]
                  },
                  {
                    "text": "LCDDDeposition of light chains in tissues without formation of β-pleated sheetsAffects adultsMedian age 56 yrMultiple mutations in variable region of Ig light chain cause structural abnormalitiesKappa > lambdaMost commonly affects kidneys, but also heart, liver, nerves, blood vessels, and joints, and rarely lungsAppears as refractile, nonamyloid, nonfibrillary, amorphous eosinophilic materialNegative by Congo red stainLCDD is diagnosed by renal biopsy and highlighting by anti-light chain antibodiesHallmark feature: prominent linear, ribbon-like monoclonal immunoglobulin deposits along outer edge of tubular basement membraneElectron microscopy also employed to show discrete, dense, granular, nonfibrillary deposits without β-pleated sheet structureMedian survival 4 yr",
                    "sub_points": [
                      "Deposition of light chains in tissues without formation of β-pleated sheets",
                      "Affects adultsMedian age 56 yr",
                      "Median age 56 yr",
                      "Multiple mutations in variable region of Ig light chain cause structural abnormalities",
                      "Kappa > lambda",
                      "Most commonly affects kidneys, but also heart, liver, nerves, blood vessels, and joints, and rarely lungs",
                      "Appears as refractile, nonamyloid, nonfibrillary, amorphous eosinophilic material",
                      "Negative by Congo red stain",
                      "LCDD is diagnosed by renal biopsy and highlighting by anti-light chain antibodies",
                      "Hallmark feature: prominent linear, ribbon-like monoclonal immunoglobulin deposits along outer edge of tubular basement membrane",
                      "Electron microscopy also employed to show discrete, dense, granular, nonfibrillary deposits without β-pleated sheet structure",
                      "Median survival 4 yr"
                    ]
                  }
                ],
                "Osteosclerotic Myeloma (POEMS Syndrome)": [
                  {
                    "text": "Rare disease entityAccounts for only 1%-2% of plasma cell dyscrasias",
                    "sub_points": [
                      "Accounts for only 1%-2% of plasma cell dyscrasias"
                    ]
                  },
                  {
                    "text": "Generally affects adultsMedian age 50 yrSlight male predominanceM:F = 1.4:1",
                    "sub_points": [
                      "Median age 50 yr",
                      "Slight male predominanceM:F = 1.4:1",
                      "M:F = 1.4:1"
                    ]
                  },
                  {
                    "text": "Etiology stems from imbalance in proinflammatory cytokines often with increase in vascular endothelial growth factor (VEGF)Some reports associated with human herpesvirus 8 (HHV8)",
                    "sub_points": [
                      "Some reports associated with human herpesvirus 8 (HHV8)"
                    ]
                  },
                  {
                    "text": "Clinical featuresPOEMSChronic progressivePolyneuropathyOrganomegaly—present in approximately one-half of patientsEndocrinopathy—two-thirds of patientsMonoclonal gammopathyLow level serum M protein of either IgG or IgA lambda (median measurement 1.1 g/dL) in 75%-85% of casesUrine M protein found in < 50% of casesSkin changes—two-thirds of patientsNot all features are needed for diagnosis",
                    "sub_points": [
                      "POEMSChronic progressivePolyneuropathyOrganomegaly—present in approximately one-half of patientsEndocrinopathy—two-thirds of patientsMonoclonal gammopathyLow level serum M protein of either IgG or IgA lambda (median measurement 1.1 g/dL) in 75%-85% of casesUrine M protein found in < 50% of casesSkin changes—two-thirds of patients",
                      "Chronic progressivePolyneuropathy",
                      "Organomegaly—present in approximately one-half of patients",
                      "Endocrinopathy—two-thirds of patients",
                      "Monoclonal gammopathyLow level serum M protein of either IgG or IgA lambda (median measurement 1.1 g/dL) in 75%-85% of casesUrine M protein found in < 50% of cases",
                      "Low level serum M protein of either IgG or IgA lambda (median measurement 1.1 g/dL) in 75%-85% of cases",
                      "Urine M protein found in < 50% of cases",
                      "Skin changes—two-thirds of patients",
                      "Not all features are needed for diagnosis"
                    ]
                  },
                  {
                    "text": "Radiographic bone abnormalities are present in most cases"
                  },
                  {
                    "text": "Bone lesions morphologically show osteosclerotic plasmacytomasThickened trabecular bone and associated paratrabecular fibrosis containing entrapped plasma cellsCan be single or multiple lesionsRemaining uninvolved bone marrow generally has < 5% plasma cellsFew patients have > 10% plasma cells on random bone marrow biopsy",
                    "sub_points": [
                      "Thickened trabecular bone and associated paratrabecular fibrosis containing entrapped plasma cells",
                      "Can be single or multiple lesions",
                      "Remaining uninvolved bone marrow generally has < 5% plasma cells",
                      "Few patients have > 10% plasma cells on random bone marrow biopsy"
                    ]
                  },
                  {
                    "text": "Plasma cells have cytoplasmic Ig (IgG or IgA)Light chain is lambda in almost all cases",
                    "sub_points": [
                      "Light chain is lambda in almost all cases"
                    ]
                  },
                  {
                    "text": "Median overall survival is 14.7 yr"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Monoclonal Gammopathy of Undetermined Significance": {
            "name": "Monoclonal Gammopathy of Undetermined Significance",
            "url": "https://app.pathprimer.com/document/0851a778-750e-47df-9734-7fbc77e171d9/lesson/49ffa39e-ce5b-411c-b9ea-948b60136015",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Among the most prevalent premalignant disorders in the world"
                  },
                  {
                    "text": "Plasma cell MGUSSerum monoclonal (M) protein < 3 g/dL< 10% clonal plasma cells in bone marrowAbsence of end-organ damage attributable to plasma cell proliferative disorder",
                    "sub_points": [
                      "Serum monoclonal (M) protein < 3 g/dL",
                      "< 10% clonal plasma cells in bone marrow",
                      "Absence of end-organ damage attributable to plasma cell proliferative disorder"
                    ]
                  },
                  {
                    "text": "Lymphoid (or lymphoplasmacytoid) MGUS< 10% clonal lymphoplasmacytic cellsSerum IgM paraprotein",
                    "sub_points": [
                      "< 10% clonal lymphoplasmacytic cells",
                      "Serum IgM paraprotein"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Absence of specific M-protein related signs or symptomsMGUS is underdiagnosed in general populationOften found incidentally",
                    "sub_points": [
                      "MGUS is underdiagnosed in general population",
                      "Often found incidentally"
                    ]
                  },
                  {
                    "text": "Screening tests for MGUSSerum protein electrophoresisUrine protein electrophoresis or serum free light chain assay",
                    "sub_points": [
                      "Serum protein electrophoresis",
                      "Urine protein electrophoresis or serum free light chain assay"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Bone marrow with < 10% clonal plasma cellsUsually mature appearance with mild atypiaScattered interstitial distribution in biopsy sections",
                    "sub_points": [
                      "Usually mature appearance with mild atypia",
                      "Scattered interstitial distribution in biopsy sections"
                    ]
                  },
                  {
                    "text": "< 10% clonal lymphoplasmacytic cells in IgM MGUS"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "CD138, κ and λ light chain stainsBest enumerates clonal plasma cells in biopsies",
                    "sub_points": [
                      "Best enumerates clonal plasma cells in biopsies"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Monoclonal gammopathy of undetermined significance (MGUS)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "International Myeloma Working Group 2010 guidelines for diagnosis of plasma cell MGUS requires all of the followingSerum monoclonal (M) protein < 3 g/dL< 10% clonal plasma cells in bone marrowAbsence of end-organ damage attributable to plasma cell proliferative disorderCRAB: Hypercalcemia, renal insufficiency, anemia,﻿b﻿one lesions",
                    "sub_points": [
                      "Serum monoclonal (M) protein < 3 g/dL",
                      "< 10% clonal plasma cells in bone marrow",
                      "Absence of end-organ damage attributable to plasma cell proliferative disorderCRAB: Hypercalcemia, renal insufficiency, anemia,﻿b﻿one lesions",
                      "CRAB: Hypercalcemia, renal insufficiency, anemia,﻿b﻿one lesions"
                    ]
                  },
                  {
                    "text": "Two types of MGUS are recognizedPlasma cell MGUSSecretes IgG > IgA > light chain > IgD > IgEProgresses to plasma cell myeloma (PCM), plasma cell leukemiaAssociated with primary amyloidosisLymphoid (or lymphoplasmacytoid) MGUS15-20% of MGUSSecretes IgMNo evidence of other B-cell proliferative disorder< 10% clonal lymphoplasmacytic cells in bone marrowAbsence of end-organ damage attributable to lymphoproliferative disorder (anemia, hyperviscosity, lymphadenopathy, hepatosplenomegaly)Progresses to Waldenström macroglobulinemia, lymphoma, or other malignant lymphoproliferative disorderProvisional new entity is \"light chain\" MGUSProposal to separate this subgroup from plasma cell MGUSAbnormal free light chain (FLC) ratioProgresses to idiopathic Bence Jones proteinuria, light chain PCM",
                    "sub_points": [
                      "Plasma cell MGUSSecretes IgG > IgA > light chain > IgD > IgEProgresses to plasma cell myeloma (PCM), plasma cell leukemiaAssociated with primary amyloidosis",
                      "Secretes IgG > IgA > light chain > IgD > IgE",
                      "Progresses to plasma cell myeloma (PCM), plasma cell leukemia",
                      "Associated with primary amyloidosis",
                      "Lymphoid (or lymphoplasmacytoid) MGUS15-20% of MGUSSecretes IgMNo evidence of other B-cell proliferative disorder< 10% clonal lymphoplasmacytic cells in bone marrowAbsence of end-organ damage attributable to lymphoproliferative disorder (anemia, hyperviscosity, lymphadenopathy, hepatosplenomegaly)Progresses to Waldenström macroglobulinemia, lymphoma, or other malignant lymphoproliferative disorder",
                      "15-20% of MGUS",
                      "Secretes IgM",
                      "No evidence of other B-cell proliferative disorder",
                      "< 10% clonal lymphoplasmacytic cells in bone marrow",
                      "Absence of end-organ damage attributable to lymphoproliferative disorder (anemia, hyperviscosity, lymphadenopathy, hepatosplenomegaly)",
                      "Progresses to Waldenström macroglobulinemia, lymphoma, or other malignant lymphoproliferative disorder",
                      "Provisional new entity is \"light chain\" MGUSProposal to separate this subgroup from plasma cell MGUSAbnormal free light chain (FLC) ratioProgresses to idiopathic Bence Jones proteinuria, light chain PCM",
                      "Proposal to separate this subgroup from plasma cell MGUS",
                      "Abnormal free light chain (FLC) ratio",
                      "Progresses to idiopathic Bence Jones proteinuria, light chain PCM"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Environmental Exposure": [
                  {
                    "text": "History of exposure to toxinsPesticides, fertilizers, aromatic hydrocarbons, paintsRadiation, mineral oils, petroleum, asbestos",
                    "sub_points": [
                      "Pesticides, fertilizers, aromatic hydrocarbons, paints",
                      "Radiation, mineral oils, petroleum, asbestos"
                    ]
                  }
                ],
                "Proposed Pathogenesis": [
                  {
                    "text": "Abnormal response to antigenic stimulationPossibly mediated byAberrant expression of toll-like receptorsOverexpression of interleukin (IL)-6 receptorsOverexpression of IL-1βDevelop primary cytogenetic abnormalitiesHyperdiploidyImmunoglobulin heavy (IgH) chain translocations",
                    "sub_points": [
                      "Possibly mediated byAberrant expression of toll-like receptorsOverexpression of interleukin (IL)-6 receptorsOverexpression of IL-1β",
                      "Aberrant expression of toll-like receptors",
                      "Overexpression of interleukin (IL)-6 receptors",
                      "Overexpression of IL-1β",
                      "Develop primary cytogenetic abnormalitiesHyperdiploidyImmunoglobulin heavy (IgH) chain translocations",
                      "Hyperdiploidy",
                      "Immunoglobulin heavy (IgH) chain translocations"
                    ]
                  },
                  {
                    "text": "Random secondary genetic hit associated with progression to PCMSpecific mechanism unknownRASmutations,TP53mutations, p16 methylation,MYCabnormalities seen",
                    "sub_points": [
                      "Specific mechanism unknownRASmutations,TP53mutations, p16 methylation,MYCabnormalities seen",
                      "RASmutations,TP53mutations, p16 methylation,MYCabnormalities seen"
                    ]
                  },
                  {
                    "text": "Bony lytic lesions caused byIncreased osteoblast receptor activator of nuclear factor κB ligand (RANKL) expressionActivates osteoclastsIncreased IL-3, IL-7, dickkopf1 levelsInhibit osteoblast differentiation",
                    "sub_points": [
                      "Increased osteoblast receptor activator of nuclear factor κB ligand (RANKL) expressionActivates osteoclasts",
                      "Activates osteoclasts",
                      "Increased IL-3, IL-7, dickkopf1 levelsInhibit osteoblast differentiation",
                      "Inhibit osteoblast differentiation"
                    ]
                  },
                  {
                    "text": "IgG and IgA MGUSPost-germinal center plasma cells with somatic hypermutation ofIGHVgenes and class switch",
                    "sub_points": [
                      "Post-germinal center plasma cells with somatic hypermutation ofIGHVgenes and class switch"
                    ]
                  },
                  {
                    "text": "IgM MGUSMYD88mutation common",
                    "sub_points": [
                      "MYD88mutation common"
                    ]
                  }
                ],
                "Increased Risk Association": [
                  {
                    "text": "Chronic antigen stimulation"
                  },
                  {
                    "text": "Familial clusteringThree times higher than general population if first-degree relative has MGUSHigher risk if first-degree relative has PCM",
                    "sub_points": [
                      "Three times higher than general population if first-degree relative has MGUS",
                      "Higher risk if first-degree relative has PCM"
                    ]
                  },
                  {
                    "text": "ImmunosuppressionPatients receiving immunosuppressive therapyHIV-infected individuals",
                    "sub_points": [
                      "Patients receiving immunosuppressive therapy",
                      "HIV-infected individuals"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Prevalence estimates for individuals > 50 years of age3.2% of Caucasians6-7% of blacks or obese individuals (non-IgM)",
                    "sub_points": [
                      "3.2% of Caucasians",
                      "6-7% of blacks or obese individuals (non-IgM)"
                    ]
                  },
                  {
                    "text": "IgM MGUS occurs less commonly in African Americans"
                  }
                ],
                "Age": [
                  {
                    "text": "Median age at diagnosis is 70 years< 2% of patients with MGUS are < 40 years old",
                    "sub_points": [
                      "< 2% of patients with MGUS are < 40 years old"
                    ]
                  },
                  {
                    "text": "Risk increases with age for CaucasiansPrevalence estimate of 6.6% for > 80 years of age",
                    "sub_points": [
                      "Prevalence estimate of 6.6% for > 80 years of age"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Absence of specific M-protein-related signs or symptomsMGUS is underdiagnosed in general populationOften found incidentally during work-up of various symptoms and disordersEasily detected in blood tests",
                    "sub_points": [
                      "MGUS is underdiagnosed in general population",
                      "Often found incidentally during work-up of various symptoms and disordersEasily detected in blood tests",
                      "Easily detected in blood tests"
                    ]
                  },
                  {
                    "text": "Medical problems associated with MGUSIncreased osteoporosis/osteopeniaAssociated skeletal problems include increased risk of vertebral and hip fracturesPeripheral neuropathyAssociated with MGUS in some but not all studiesIgM (60%), IgG (30%), IgA (10%)Serum anti-myelin-associated glycoprotein antibodies often seen in IgM-related neuropathyThrombotic events, especially deep vein thrombosisAssociated with MGUS in some but not all studiesGreatest risk for deep vein thrombosis within first year after MGUS diagnosis",
                    "sub_points": [
                      "Increased osteoporosis/osteopeniaAssociated skeletal problems include increased risk of vertebral and hip fractures",
                      "Associated skeletal problems include increased risk of vertebral and hip fractures",
                      "Peripheral neuropathyAssociated with MGUS in some but not all studiesIgM (60%), IgG (30%), IgA (10%)Serum anti-myelin-associated glycoprotein antibodies often seen in IgM-related neuropathy",
                      "Associated with MGUS in some but not all studies",
                      "IgM (60%), IgG (30%), IgA (10%)",
                      "Serum anti-myelin-associated glycoprotein antibodies often seen in IgM-related neuropathy",
                      "Thrombotic events, especially deep vein thrombosisAssociated with MGUS in some but not all studiesGreatest risk for deep vein thrombosis within first year after MGUS diagnosis",
                      "Associated with MGUS in some but not all studies",
                      "Greatest risk for deep vein thrombosis within first year after MGUS diagnosis"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Screening tests for MGUSSerum protein electrophoresis (SPEP)If positive, perform immunofixation (IFE) to identify immunoglobulin typeReduction of uninvolved immunoglobulins seen in 20-30% of MGUSUrine protein electrophoresis (UPEP) or serum free light chain (FLC) assayIf abnormal FLC assay on screening, UPEP is recommendedUPEP shows monoclonal light chain in ~ one-third of MGUS; requires 24-hour collection",
                    "sub_points": [
                      "Serum protein electrophoresis (SPEP)If positive, perform immunofixation (IFE) to identify immunoglobulin typeReduction of uninvolved immunoglobulins seen in 20-30% of MGUS",
                      "If positive, perform immunofixation (IFE) to identify immunoglobulin type",
                      "Reduction of uninvolved immunoglobulins seen in 20-30% of MGUS",
                      "Urine protein electrophoresis (UPEP) or serum free light chain (FLC) assayIf abnormal FLC assay on screening, UPEP is recommendedUPEP shows monoclonal light chain in ~ one-third of MGUS; requires 24-hour collection",
                      "If abnormal FLC assay on screening, UPEP is recommended",
                      "UPEP shows monoclonal light chain in ~ one-third of MGUS; requires 24-hour collection"
                    ]
                  },
                  {
                    "text": "Tests to be performed at initial diagnosis (help to exclude PCM or amyloidosis)Complete blood count and routine chemistryRed cell indices, calcium, and creatinine to evaluate for \"CRAB\" (hypercalcemia, renal insufficiency, anemia, ﻿b﻿one lesions)Vitamin D levelsBone marrow evaluationDepends on clinical indication; may not be necessary for low-risk disease",
                    "sub_points": [
                      "Complete blood count and routine chemistryRed cell indices, calcium, and creatinine to evaluate for \"CRAB\" (hypercalcemia, renal insufficiency, anemia, ﻿b﻿one lesions)",
                      "Red cell indices, calcium, and creatinine to evaluate for \"CRAB\" (hypercalcemia, renal insufficiency, anemia, ﻿b﻿one lesions)",
                      "Vitamin D levels",
                      "Bone marrow evaluationDepends on clinical indication; may not be necessary for low-risk disease",
                      "Depends on clinical indication; may not be necessary for low-risk disease"
                    ]
                  }
                ],
                "Treatment": [],
                "Drugs": [
                  {
                    "text": "Anti-bone resorptive therapy (bisphosphonates) if osteoporosis or fractures"
                  },
                  {
                    "text": "Corticosteroids or rituximab if peripheral neuropathy"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Risk based on 3 factors: Serum M-protein < 1.5 g/dL; IgG subtype; normal FLC ratio (0.26-1.65)Listed factors are considered \"normal\" (absolute risk of progression at 20 years)Low risk: All 3 factors normal (5%)Low to intermediate risk: Any 1 abnormal (21%)High to intermediate risk: Any 2 abnormal (37%)High risk: All 3 factors abnormal (58%)",
                    "sub_points": [
                      "Listed factors are considered \"normal\" (absolute risk of progression at 20 years)Low risk: All 3 factors normal (5%)Low to intermediate risk: Any 1 abnormal (21%)High to intermediate risk: Any 2 abnormal (37%)High risk: All 3 factors abnormal (58%)",
                      "Low risk: All 3 factors normal (5%)",
                      "Low to intermediate risk: Any 1 abnormal (21%)",
                      "High to intermediate risk: Any 2 abnormal (37%)",
                      "High risk: All 3 factors abnormal (58%)"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Cytologic Features": [
                  {
                    "text": "Peripheral bloodMild rouleaux formation if higher M-componentPlasma cells are associated with high-risk MGUS",
                    "sub_points": [
                      "Mild rouleaux formation if higher M-component",
                      "Plasma cells are associated with high-risk MGUS"
                    ]
                  },
                  {
                    "text": "Bone marrow with < 10% clonal plasma cellsMedian of 3% plasma cells in plasma cell MGUSUsually mature appearanceMild atypia in occasional cells, including cytoplasmic inclusions, enlarged size, nucleoliScattered interstitial distribution in biopsies< 10% clonal lymphoplasmacytic cells in IgM MGUSIncreased mast cells may be seen",
                    "sub_points": [
                      "Median of 3% plasma cells in plasma cell MGUSUsually mature appearanceMild atypia in occasional cells, including cytoplasmic inclusions, enlarged size, nucleoliScattered interstitial distribution in biopsies",
                      "Usually mature appearance",
                      "Mild atypia in occasional cells, including cytoplasmic inclusions, enlarged size, nucleoli",
                      "Scattered interstitial distribution in biopsies",
                      "< 10% clonal lymphoplasmacytic cells in IgM MGUSIncreased mast cells may be seen",
                      "Increased mast cells may be seen"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "CD138, kappa and lambda light chainsBest quantifies clonal plasma cells in biopsiesIn situ hybridization is best for light chain analysis",
                    "sub_points": [
                      "Best quantifies clonal plasma cells in biopsies",
                      "In situ hybridization is best for light chain analysis"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Cytoplasmic light chain restricted plasma cellsCD138(+), CD38(+), CD19(-), CD45(+/-), CD56(+/-)Often weaker CD38 expression than normalAnalysis underestimates plasma cell %",
                    "sub_points": [
                      "CD138(+), CD38(+), CD19(-), CD45(+/-), CD56(+/-)Often weaker CD38 expression than normal",
                      "Often weaker CD38 expression than normal",
                      "Analysis underestimates plasma cell %"
                    ]
                  },
                  {
                    "text": "Concurrent polyclonal plasma cell population common (CD19[+], CD56[-])"
                  },
                  {
                    "text": "Clonal B-cell population in lymphoid MGUS"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Numerous gene mutations similar to PCMOnly 5% of MGUS have activatingKRASandNRASmutations",
                    "sub_points": [
                      "Only 5% of MGUS have activatingKRASandNRASmutations"
                    ]
                  },
                  {
                    "text": "MYD88mutation in IgM MGUS"
                  },
                  {
                    "text": "Requires IL-4 stimulation to proliferateAbnormal karyotypes are rare",
                    "sub_points": [
                      "Abnormal karyotypes are rare"
                    ]
                  },
                  {
                    "text": "FISH identifies abnormalities in most casesDeletions of 13q present in 40-50% (non-IgM)",
                    "sub_points": [
                      "Deletions of 13q present in 40-50% (non-IgM)"
                    ]
                  },
                  {
                    "text": "Identifies primary pathogenetic eventHyperdiploidy ~ 40-50%Similar abnormalities as PCM, trisomies commonIgH translocations ~ 50%t(11;14)(q13;q32):CCND115-25%t(4;14)((p16;q32):FGFR-3andMMSET2-9%t(14;16)(q32;q23):CMAF1-5%t(6;14)(p21;q32):CCND3t(14;20)(q32;q11):MAFB",
                    "sub_points": [
                      "Hyperdiploidy ~ 40-50%Similar abnormalities as PCM, trisomies common",
                      "Similar abnormalities as PCM, trisomies common",
                      "IgH translocations ~ 50%t(11;14)(q13;q32):CCND115-25%t(4;14)((p16;q32):FGFR-3andMMSET2-9%t(14;16)(q32;q23):CMAF1-5%t(6;14)(p21;q32):CCND3t(14;20)(q32;q11):MAFB",
                      "t(11;14)(q13;q32):CCND115-25%",
                      "t(4;14)((p16;q32):FGFR-3andMMSET2-9%",
                      "t(14;16)(q32;q23):CMAF1-5%",
                      "t(6;14)(p21;q32):CCND3",
                      "t(14;20)(q32;q11):MAFB"
                    ]
                  },
                  {
                    "text": "Karyotypic abnormalities do not predict risk of progression to PCM"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Smoldering PCM": [
                  {
                    "text": "More advanced premalignant stage of plasma cell proliferation in non-IgM MGUS"
                  },
                  {
                    "text": "Higher rate of progression to PCM"
                  }
                ],
                "Monoclonal B-Lymphocytosis": [
                  {
                    "text": "Small clonal B-cell population"
                  },
                  {
                    "text": "Clonal plasma cells and IgM paraprotein favor lymphoid MGUS"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Plasmacytoma": {
            "name": "Plasmacytoma",
            "url": "https://app.pathprimer.com/document/e23efc0b-5906-4a99-9a05-528e70018a21/lesson/49ffa39e-ce5b-411c-b9ea-948b60136015",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "SPB: Localized bone tumor consisting of monoclonal plasma cells; absent or low serum or urine M protein"
                  },
                  {
                    "text": "EMP: Localized plasma cell neoplasm arising in tissues other than bone; must exclude lymphoma with predominant plasmacytic differentiation"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "SPB: Overall median survival 7.5-12 yr"
                  },
                  {
                    "text": "EMP: Approximately 15% of cases develop plasma cell myeloma; 10-yr disease-free survival approximately 70%"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Distinguishing EMP from extranodal marginal zone (MALT) lymphoma can be especially difficult if skin or GI sites are involvedCD20 positivity favors diagnosis of lymphoma over plasmacytomaFlow cytometry can be performed to identify clonal related lymphocyte population",
                    "sub_points": [
                      "CD20 positivity favors diagnosis of lymphoma over plasmacytoma",
                      "Flow cytometry can be performed to identify clonal related lymphocyte population"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Solitary plasmacytoma of bone (SPB)"
                  },
                  {
                    "text": "Extramedullary plasmacytoma (EMP)"
                  },
                  {
                    "text": "Gastrointestinal (GI)"
                  },
                  {
                    "text": "Central nervous system (CNS)"
                  },
                  {
                    "text": "Hypercalcemia,renal insufficiency,anemia, andbone lesions (CRAB)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "SPBSolitary bone plasmacytomaOsseous plasmacytoma",
                    "sub_points": [
                      "Solitary bone plasmacytoma",
                      "Osseous plasmacytoma"
                    ]
                  },
                  {
                    "text": "EMPSolitary extramedullary plasmacytomaSoft tissue or nonosseous extramedullary plasmacytoma",
                    "sub_points": [
                      "Solitary extramedullary plasmacytoma",
                      "Soft tissue or nonosseous extramedullary plasmacytoma"
                    ]
                  }
                ],
                "Definitions": [
                  {
                    "text": "SPB: Localized bone tumor consisting of monoclonal plasma cellsMust exclude evidence of plasma cell neoplasm in bone marrowAbsent or low serum or urine M proteinNo radiographic evidence of other bone lesions",
                    "sub_points": [
                      "Must exclude evidence of plasma cell neoplasm in bone marrow",
                      "Absent or low serum or urine M protein",
                      "No radiographic evidence of other bone lesions"
                    ]
                  },
                  {
                    "text": "EMP: Localized plasma cell neoplasm arising in tissues other than boneMust exclude lymphoma with predominant plasmacytic differentiationMust exclude evidence of plasma cell neoplasm in bone marrowNo radiographic evidence of other bone lesions",
                    "sub_points": [
                      "Must exclude lymphoma with predominant plasmacytic differentiation",
                      "Must exclude evidence of plasma cell neoplasm in bone marrow",
                      "No radiographic evidence of other bone lesions"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "SPBUncommonComprise approximately 3%-5% of all plasma cell neoplasmsAdultsMedian age at diagnosis 55 yrMale > female",
                    "sub_points": [
                      "UncommonComprise approximately 3%-5% of all plasma cell neoplasms",
                      "Comprise approximately 3%-5% of all plasma cell neoplasms",
                      "AdultsMedian age at diagnosis 55 yrMale > female",
                      "Median age at diagnosis 55 yr",
                      "Male > female"
                    ]
                  },
                  {
                    "text": "EMPUncommonComprise approximately 3%-5% of all plasma cell neoplasmsAdultsMedian age at diagnosis 55 yrMale > female",
                    "sub_points": [
                      "UncommonComprise approximately 3%-5% of all plasma cell neoplasms",
                      "Comprise approximately 3%-5% of all plasma cell neoplasms",
                      "AdultsMedian age at diagnosis 55 yrMale > female",
                      "Median age at diagnosis 55 yr",
                      "Male > female"
                    ]
                  }
                ],
                "Site": [
                  {
                    "text": "SPBBones with active hematopoiesis most common site of involvementVertebrae (40%-50%)RibsSkullPelvisFemurClavicleScapulaThoracic vertebrae are more often involved than cervical or lumbar vertebraeLong bone involvement of either upper or lower distal extremities is rare",
                    "sub_points": [
                      "Bones with active hematopoiesis most common site of involvementVertebrae (40%-50%)RibsSkullPelvisFemurClavicleScapula",
                      "Vertebrae (40%-50%)",
                      "Ribs",
                      "Skull",
                      "Pelvis",
                      "Femur",
                      "Clavicle",
                      "Scapula",
                      "Thoracic vertebrae are more often involved than cervical or lumbar vertebrae",
                      "Long bone involvement of either upper or lower distal extremities is rare"
                    ]
                  },
                  {
                    "text": "EMPUpper respiratory tract (oropharynx, nasopharynx, sinuses, larynx) involved in 80% of casesOther less commonly involved sitesLymph nodesGI tractBladderBreastCNSThyroidParotidTestisSkinRegional spread to cervical lymph nodes in approximately 15% of cases with primary upper respiratory tract involvement",
                    "sub_points": [
                      "Upper respiratory tract (oropharynx, nasopharynx, sinuses, larynx) involved in 80% of cases",
                      "Other less commonly involved sitesLymph nodesGI tractBladderBreastCNSThyroidParotidTestisSkin",
                      "Lymph nodes",
                      "GI tract",
                      "Bladder",
                      "Breast",
                      "CNS",
                      "Thyroid",
                      "Parotid",
                      "Testis",
                      "Skin",
                      "Regional spread to cervical lymph nodes in approximately 15% of cases with primary upper respiratory tract involvement"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "SPBPatients commonly present with bone pain from expansive lesion or pathologic fractureSymptomatic cord compression may occur if vertebrae are involvedNo clinical features of plasma cell myeloma (CRAB)",
                    "sub_points": [
                      "Patients commonly present with bone pain from expansive lesion or pathologic fracture",
                      "Symptomatic cord compression may occur if vertebrae are involved",
                      "No clinical features of plasma cell myeloma (CRAB)"
                    ]
                  },
                  {
                    "text": "EMPPatients often present with rhinorrhea, epistaxis, or nasal obstruction due to tumor mass effectNo clinical features of plasma cell myeloma (CRAB)",
                    "sub_points": [
                      "Patients often present with rhinorrhea, epistaxis, or nasal obstruction due to tumor mass effect",
                      "No clinical features of plasma cell myeloma (CRAB)"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Excision"
                  },
                  {
                    "text": "Local radiotherapy"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "SPBOne-third of patients remain disease-free at 10 yrTwo-thirds of patients develop additional solitary or multiple plasmacytomas or generalized myelomaHigher rates of disease progression associated withOlder ageTumor size > 5 cmPersistence of M protein after radiotherapyOverall median survival 7.5-12 yr",
                    "sub_points": [
                      "One-third of patients remain disease-free at 10 yr",
                      "Two-thirds of patients develop additional solitary or multiple plasmacytomas or generalized myelomaHigher rates of disease progression associated withOlder ageTumor size > 5 cmPersistence of M protein after radiotherapy",
                      "Higher rates of disease progression associated withOlder ageTumor size > 5 cmPersistence of M protein after radiotherapy",
                      "Older age",
                      "Tumor size > 5 cm",
                      "Persistence of M protein after radiotherapy",
                      "Overall median survival 7.5-12 yr"
                    ]
                  },
                  {
                    "text": "EMP25% of patients experience regional recurrence10-yr disease-free survival approximately 70%Approximately 15% of cases develop plasma cell myeloma",
                    "sub_points": [
                      "25% of patients experience regional recurrence",
                      "10-yr disease-free survival approximately 70%",
                      "Approximately 15% of cases develop plasma cell myeloma"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Radiographic Findings": [
                  {
                    "text": "SPBComplete skeletal radiographs must be negative for other lesions",
                    "sub_points": [
                      "Complete skeletal radiographs must be negative for other lesions"
                    ]
                  },
                  {
                    "text": "EMPRadiographic and morphologic examination of bone marrow must be negative for marrow involvement",
                    "sub_points": [
                      "Radiographic and morphologic examination of bone marrow must be negative for marrow involvement"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Localized neoplasm composed of monoclonal plasma cells in both SPB and EMP"
                  },
                  {
                    "text": "In extraosseous sites, distinction between lymphomas with extreme plasma cell differentiation and plasmacytoma may be difficult"
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Plasma cells withEccentrically placed nucleiMature chromatin with clumped \"clock-face\" patternParanuclear hof (unless poorly differentiated)",
                    "sub_points": [
                      "Eccentrically placed nuclei",
                      "Mature chromatin with clumped \"clock-face\" pattern",
                      "Paranuclear hof (unless poorly differentiated)"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Monotypic﻿immunoglobulin light chains by i﻿n situ﻿hybridization or immunohistochemistryDifferentiate neoplastic plasma cells (monotypic) from reactive infiltrates (polytypic)",
                    "sub_points": [
                      "Differentiate neoplastic plasma cells (monotypic) from reactive infiltrates (polytypic)"
                    ]
                  },
                  {
                    "text": "Immunophenotype and genetic features not well establishedAppear to be similar to plasma cell myeloma",
                    "sub_points": [
                      "Appear to be similar to plasma cell myeloma"
                    ]
                  },
                  {
                    "text": "CD20 positivity favors diagnosis of lymphoma over plasmacytoma"
                  },
                  {
                    "text": "Expression of mu, rather than gamma, heavy chains favors lymphoma over plasmacytoma"
                  }
                ],
                "Serologic Testing": [
                  {
                    "text": "SPBM protein found in serum or urine in 24%-72% of patients",
                    "sub_points": [
                      "M protein found in serum or urine in 24%-72% of patients"
                    ]
                  },
                  {
                    "text": "EMPSmall M protein, most commonly IgA, in 20% of patients",
                    "sub_points": [
                      "Small M protein, most commonly IgA, in 20% of patients"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Solitary Plasmacytoma of Bone": [
                  {
                    "text": "Plasma cell myelomaMust exclude through radiographs, bone marrow biopsy, and evaluation for clinical evidence of plasma cell myeloma (CRAB)",
                    "sub_points": [
                      "Must exclude through radiographs, bone marrow biopsy, and evaluation for clinical evidence of plasma cell myeloma (CRAB)"
                    ]
                  }
                ],
                "Extramedullary Plasmacytoma": [
                  {
                    "text": "Plasma cell myelomaMust exclude through radiographs, bone marrow biopsy, and evaluation for clinical evidence of plasma cell myeloma (CRAB)",
                    "sub_points": [
                      "Must exclude through radiographs, bone marrow biopsy, and evaluation for clinical evidence of plasma cell myeloma (CRAB)"
                    ]
                  },
                  {
                    "text": "Extranodal marginal zone (MALT) lymphomaDistinguishing EMP from extranodal marginal zone (MALT) lymphoma can be especially difficult if skin or GI sites are involvedFlow cytometry can be performed to identify clonal related lymphocyte population",
                    "sub_points": [
                      "Distinguishing EMP from extranodal marginal zone (MALT) lymphoma can be especially difficult if skin or GI sites are involvedFlow cytometry can be performed to identify clonal related lymphocyte population",
                      "Flow cytometry can be performed to identify clonal related lymphocyte population"
                    ]
                  },
                  {
                    "text": "Lymphoplasmacytic lymphomaDistinguish by positive B-cell immunohistochemical markers: CD20, CD79aBone marrow often involved",
                    "sub_points": [
                      "Distinguish by positive B-cell immunohistochemical markers: CD20, CD79a",
                      "Bone marrow often involved"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Monoclonal plasma cells"
                  },
                  {
                    "text": "Solitary lesion (no bone marrow involvement or other bone lesions)"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Plasma Cell Myeloma": {
            "name": "Plasma Cell Myeloma",
            "url": "https://app.pathprimer.com/document/10afadbb-abc0-4559-bf6a-515436d32bd4/lesson/49ffa39e-ce5b-411c-b9ea-948b60136015",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Plasma cell myeloma (PCM) diagnosis requires> 30g/L serum M-componentor> 10% clonal plasma cells in bone marroworEvidence of myeloma-related symptoms",
                    "sub_points": [
                      "> 30g/L serum M-componentor",
                      "> 10% clonal plasma cells in bone marrowor",
                      "Evidence of myeloma-related symptoms"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Unique triad of clinical features: Bone marrow plasmacytosis, osteolytic bone lesions, monoclonal gammopathyAccounts for 10-15% of hematopoietic malignancies",
                    "sub_points": [
                      "Accounts for 10-15% of hematopoietic malignancies"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Peripheral blood: Rouleaux formation"
                  },
                  {
                    "text": "Bone marrow: Clonal PC infiltrate, amyloid, osteoclastic bone lesions"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Cytogenetic/FISH should be performed on all newly diagnosed patientsHave prognostic and therapeutic implications",
                    "sub_points": [
                      "Have prognostic and therapeutic implications"
                    ]
                  },
                  {
                    "text": "High-risk diseaseCytogenetics: Deletion 13 or hypodiploidyFISH: t(4;14)(p16;q32), t(14;16)(q32;q23), del(17)p13.1",
                    "sub_points": [
                      "Cytogenetics: Deletion 13 or hypodiploidy",
                      "FISH: t(4;14)(p16;q32), t(14;16)(q32;q23), del(17)p13.1"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Plasma cell myeloma (PCM)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Accumulation of clonal PCs in bone marrowAssociated monoclonal (M) protein in serum &/or urine in majority of cases",
                    "sub_points": [
                      "Associated monoclonal (M) protein in serum &/or urine in majority of cases"
                    ]
                  },
                  {
                    "text": "2008 WHO classification of tumors of plasma cell neoplasmsPCM diagnosis requires > 30g/L serum M-componentor> 10% clonal plasma cells in bone marroworEvidence of myeloma-related symptoms",
                    "sub_points": [
                      "PCM diagnosis requires > 30g/L serum M-componentor",
                      "> 10% clonal plasma cells in bone marrowor",
                      "Evidence of myeloma-related symptoms"
                    ]
                  },
                  {
                    "text": "Multifocal disseminated bone marrow involvement in most casesAsymptomatic (smoldering) PCM: No related organ or tissue impairmentSymptomatic PCM: End-organ damage or bone lesions",
                    "sub_points": [
                      "Asymptomatic (smoldering) PCM: No related organ or tissue impairment",
                      "Symptomatic PCM: End-organ damage or bone lesions"
                    ]
                  },
                  {
                    "text": "Preceded by monoclonal gammopathy of undetermined significance (MGUS) in all patients"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Environmental Exposure": [
                  {
                    "text": "Increased susceptibility among older people (declining immune system)"
                  },
                  {
                    "text": "Linked to chemical, toxin, or radiation exposureHerbicides, insecticides, asbestosisRubber, plastic, wood, or petroleum productsRadiation from atom bomb (Japan), nuclear plants",
                    "sub_points": [
                      "Herbicides, insecticides, asbestosis",
                      "Rubber, plastic, wood, or petroleum products",
                      "Radiation from atom bomb (Japan), nuclear plants"
                    ]
                  }
                ],
                "Proposed Pathogenesis": [
                  {
                    "text": "Immature B cells, after VDJ recombination, migrate from bone marrow to lymphoid tissueCells undergo antigen selection in germinal centersB cells that survive antigen selection have marked intrinsic genetic instabilityDevelop primary genetic abnormalities from errors in IgH switch recombination or, less frequently, somatic hypermutationGenetically abnormal plasma cells/plasmablasts home to bone marrowPCs have primarily hyperdiploid or immunoglobulin heavy (IgH) chain abnormalitiesInduce stromal cells to produce numerous cytokines, particularly interleukin (IL)-6PCs undergo additional genetic alterations that prevent normal cell differentiation and apoptosisUltimate immortalization of PC cloneMGUS precedes PCM100x more common than PCM1% MGUS converts to PCM per year indefinitelyPCMRandom secondary genetic hit is associated with MGUS progression to PCMDistinct miRNAs (miRNA-15a, miRNA-16) play a role in transformation and disease progressionExtramedullary PCMAdditional genetic hits allow for PC growth independent of marrow microenvironment",
                    "sub_points": [
                      "Cells undergo antigen selection in germinal centersB cells that survive antigen selection have marked intrinsic genetic instabilityDevelop primary genetic abnormalities from errors in IgH switch recombination or, less frequently, somatic hypermutation",
                      "B cells that survive antigen selection have marked intrinsic genetic instability",
                      "Develop primary genetic abnormalities from errors in IgH switch recombination or, less frequently, somatic hypermutation",
                      "Genetically abnormal plasma cells/plasmablasts home to bone marrowPCs have primarily hyperdiploid or immunoglobulin heavy (IgH) chain abnormalitiesInduce stromal cells to produce numerous cytokines, particularly interleukin (IL)-6PCs undergo additional genetic alterations that prevent normal cell differentiation and apoptosisUltimate immortalization of PC clone",
                      "PCs have primarily hyperdiploid or immunoglobulin heavy (IgH) chain abnormalities",
                      "Induce stromal cells to produce numerous cytokines, particularly interleukin (IL)-6",
                      "PCs undergo additional genetic alterations that prevent normal cell differentiation and apoptosis",
                      "Ultimate immortalization of PC clone",
                      "MGUS precedes PCM100x more common than PCM1% MGUS converts to PCM per year indefinitely",
                      "100x more common than PCM",
                      "1% MGUS converts to PCM per year indefinitely",
                      "PCMRandom secondary genetic hit is associated with MGUS progression to PCMDistinct miRNAs (miRNA-15a, miRNA-16) play a role in transformation and disease progression",
                      "Random secondary genetic hit is associated with MGUS progression to PCM",
                      "Distinct miRNAs (miRNA-15a, miRNA-16) play a role in transformation and disease progression",
                      "Extramedullary PCMAdditional genetic hits allow for PC growth independent of marrow microenvironment",
                      "Additional genetic hits allow for PC growth independent of marrow microenvironment"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "~ 20,000 cases diagnosed in USA in 200810-15% of hematopoietic malignanciesIncidence is increasing as population ages",
                    "sub_points": [
                      "10-15% of hematopoietic malignancies",
                      "Incidence is increasing as population ages"
                    ]
                  },
                  {
                    "text": "Genetic predispositionFamilial clustering40% of PCM patients have 1st-degree relative with cancer; 10% of these are hematologic neoplasms",
                    "sub_points": [
                      "Familial clustering",
                      "40% of PCM patients have 1st-degree relative with cancer; 10% of these are hematologic neoplasms"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Peak incidence is 8th decade of lifeRarely observed in people < 35 years old",
                    "sub_points": [
                      "Rarely observed in people < 35 years old"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "Slight male predominanceM:F ratio is 3:2",
                    "sub_points": [
                      "M:F ratio is 3:2"
                    ]
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "High incidence in African Americans: 9.5/100,000"
                  },
                  {
                    "text": "Caucasian American incidence is 4.1/100,000"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Unique triad: Bone marrow plasmacytosis, osteolytic bone lesions, monoclonal gammopathyClinical and laboratory findings reflect or are secondary to these abnormalitiesMost common presenting symptoms are bone pain, fatigue, weight lossAnemia of chronic diseaseRenal failure if excess light chainRecurrent bacterial infections from hypogammopathy and immunodeficiency",
                    "sub_points": [
                      "Clinical and laboratory findings reflect or are secondary to these abnormalitiesMost common presenting symptoms are bone pain, fatigue, weight lossAnemia of chronic diseaseRenal failure if excess light chainRecurrent bacterial infections from hypogammopathy and immunodeficiency",
                      "Most common presenting symptoms are bone pain, fatigue, weight loss",
                      "Anemia of chronic disease",
                      "Renal failure if excess light chain",
                      "Recurrent bacterial infections from hypogammopathy and immunodeficiency"
                    ]
                  },
                  {
                    "text": "Asymptomatic (smoldering myeloma) myelomaDistinguish from symptomatic PCM by absence of end-organ damageDevelop symptomatic PCM at 10% per year in 1st 5 years, 3% per year in next 5 years, 1% per year for last 10 years50x increased risk for amyloidosisDifferentiated from MGUS due to higher risk of progression",
                    "sub_points": [
                      "Distinguish from symptomatic PCM by absence of end-organ damageDevelop symptomatic PCM at 10% per year in 1st 5 years, 3% per year in next 5 years, 1% per year for last 10 years50x increased risk for amyloidosis",
                      "Develop symptomatic PCM at 10% per year in 1st 5 years, 3% per year in next 5 years, 1% per year for last 10 years",
                      "50x increased risk for amyloidosis",
                      "Differentiated from MGUS due to higher risk of progression"
                    ]
                  },
                  {
                    "text": "Plasma cell leukemia (PCL)Primary PCL comprises 2-5% of PCMPeripheral blood plasmacytosis (> 20% of WBCs or > 2 x 10⁹/L)Present with renal failure, lymphadenopathy, &/or organomegalyDecreased incidence of bone lesionsSecondary PCLCirculating plasmacytosis late in course of PCM",
                    "sub_points": [
                      "Primary PCL comprises 2-5% of PCMPeripheral blood plasmacytosis (> 20% of WBCs or > 2 x 10⁹/L)Present with renal failure, lymphadenopathy, &/or organomegalyDecreased incidence of bone lesions",
                      "Peripheral blood plasmacytosis (> 20% of WBCs or > 2 x 10⁹/L)",
                      "Present with renal failure, lymphadenopathy, &/or organomegaly",
                      "Decreased incidence of bone lesions",
                      "Secondary PCLCirculating plasmacytosis late in course of PCM",
                      "Circulating plasmacytosis late in course of PCM"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Serum protein electrophoresis (SPEP)Identifies and quantifies monoclonal protein (M-component)Immunofixation electrophoresis to determine immunoglobulin typeDecrease in uninvolved immunoglobulins (~ 90% of cases)",
                    "sub_points": [
                      "Identifies and quantifies monoclonal protein (M-component)",
                      "Immunofixation electrophoresis to determine immunoglobulin type",
                      "Decrease in uninvolved immunoglobulins (~ 90% of cases)"
                    ]
                  },
                  {
                    "text": "Urine protein electrophoresis (UPEP) or serum free light chain (FLC) assayFLC is best for screeningIf abnormal, perform UPEP; requires 24-hour urine collection",
                    "sub_points": [
                      "FLC is best for screeningIf abnormal, perform UPEP; requires 24-hour urine collection",
                      "If abnormal, perform UPEP; requires 24-hour urine collection"
                    ]
                  },
                  {
                    "text": "Nephelometric quantitation of immunoglobulins"
                  },
                  {
                    "text": "Peripheral blood and bone marrow examinationPerform ancillary tests on bone marrow",
                    "sub_points": [
                      "Perform ancillary tests on bone marrow"
                    ]
                  },
                  {
                    "text": "Chemistry panelIncreased β2 microglobulin (75% at diagnosis)Surrogate marker for tumor burdenSubset of PCM patients haveIncreased uric acid, creatinine, or calciumDecreased albumin",
                    "sub_points": [
                      "Increased β2 microglobulin (75% at diagnosis)Surrogate marker for tumor burden",
                      "Surrogate marker for tumor burden",
                      "Subset of PCM patients haveIncreased uric acid, creatinine, or calciumDecreased albumin",
                      "Increased uric acid, creatinine, or calcium",
                      "Decreased albumin"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Tandem stem cell transplantationStandard-risk diseaseCurrent standard of care but likely to change with new drug alternativesMultiple trials using different drugs for pretransplant induction and maintenance therapy",
                    "sub_points": [
                      "Standard-risk diseaseCurrent standard of care but likely to change with new drug alternativesMultiple trials using different drugs for pretransplant induction and maintenance therapy",
                      "Current standard of care but likely to change with new drug alternatives",
                      "Multiple trials using different drugs for pretransplant induction and maintenance therapy"
                    ]
                  },
                  {
                    "text": "Bisphosphonates for bone disease"
                  },
                  {
                    "text": "Anti-PCM drugs including novel agentsUtilized in specific subsets of patients (many in clinical trials)Elderly patients, patients with relapsed/refractory disease, severe renal failureHigh-risk myeloma with poor response to standard therapyImmunomodulatory drugs (IMiDS): Thalidomide, lenalidomide, pomalidomideProtease inhibitors: Bortezomib, carfilzomibNovel agentsMultikinase inhibitors, farnesyl transferase inhibitors, histone deacetylase inhibitors, heat shock protein-90 inhibitorsVarious monoclonal proteins: IL-6, CS1",
                    "sub_points": [
                      "Utilized in specific subsets of patients (many in clinical trials)Elderly patients, patients with relapsed/refractory disease, severe renal failureHigh-risk myeloma with poor response to standard therapy",
                      "Elderly patients, patients with relapsed/refractory disease, severe renal failure",
                      "High-risk myeloma with poor response to standard therapy",
                      "Immunomodulatory drugs (IMiDS): Thalidomide, lenalidomide, pomalidomide",
                      "Protease inhibitors: Bortezomib, carfilzomib",
                      "Novel agentsMultikinase inhibitors, farnesyl transferase inhibitors, histone deacetylase inhibitors, heat shock protein-90 inhibitorsVarious monoclonal proteins: IL-6, CS1",
                      "Multikinase inhibitors, farnesyl transferase inhibitors, histone deacetylase inhibitors, heat shock protein-90 inhibitors",
                      "Various monoclonal proteins: IL-6, CS1"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Features associated with worse prognosisIncreased proliferative rateHigh plasma cell labeling indexIncreased mitoses and high Ki-67 indexAbnormal karyotype on conventional cytogeneticsHigh proliferative gene expression signatureIncreased tumor burdenInternational staging system: Utilizes β2 microglobulin and albumin levelsCirculating PCsHigh-risk genetic featuresBased on cytogenetic and FISH analysisPlasmablastic morphology is associated with high-risk cytogenetics",
                    "sub_points": [
                      "Increased proliferative rateHigh plasma cell labeling indexIncreased mitoses and high Ki-67 indexAbnormal karyotype on conventional cytogeneticsHigh proliferative gene expression signature",
                      "High plasma cell labeling index",
                      "Increased mitoses and high Ki-67 index",
                      "Abnormal karyotype on conventional cytogenetics",
                      "High proliferative gene expression signature",
                      "Increased tumor burdenInternational staging system: Utilizes β2 microglobulin and albumin levelsCirculating PCs",
                      "International staging system: Utilizes β2 microglobulin and albumin levels",
                      "Circulating PCs",
                      "High-risk genetic featuresBased on cytogenetic and FISH analysisPlasmablastic morphology is associated with high-risk cytogenetics",
                      "Based on cytogenetic and FISH analysis",
                      "Plasmablastic morphology is associated with high-risk cytogenetics"
                    ]
                  },
                  {
                    "text": "International Myeloma Working Group proposed molecular classificationMore favorable prognosis ifHyperdiploid (45%)Cyclin D translocations (18%): t(11;14)(q13;q32), t(6;14)(p21;q32), t(12;14)(p13;q32)More aggressive disease ifNonhyperdiploid (40%), especially hypodiploidMMSETtranslocation (15%): t(4;14)(p16;q32)MAFtranslocation (~ 8%): t(14;16)(q32;q23), t(14;20)(q32;q11), t(8;14)(q24;q32)Other (15%): IncludesTP53deletion",
                    "sub_points": [
                      "More favorable prognosis ifHyperdiploid (45%)Cyclin D translocations (18%): t(11;14)(q13;q32), t(6;14)(p21;q32), t(12;14)(p13;q32)",
                      "Hyperdiploid (45%)",
                      "Cyclin D translocations (18%): t(11;14)(q13;q32), t(6;14)(p21;q32), t(12;14)(p13;q32)",
                      "More aggressive disease ifNonhyperdiploid (40%), especially hypodiploidMMSETtranslocation (15%): t(4;14)(p16;q32)MAFtranslocation (~ 8%): t(14;16)(q32;q23), t(14;20)(q32;q11), t(8;14)(q24;q32)Other (15%): IncludesTP53deletion",
                      "Nonhyperdiploid (40%), especially hypodiploid",
                      "MMSETtranslocation (15%): t(4;14)(p16;q32)",
                      "MAFtranslocation (~ 8%): t(14;16)(q32;q23), t(14;20)(q32;q11), t(8;14)(q24;q32)",
                      "Other (15%): IncludesTP53deletion"
                    ]
                  },
                  {
                    "text": "Asymptomatic PCM with > 10% clonal PCsFLC ratio < 0.125 or > 8High risk of progression in first 2 years",
                    "sub_points": [
                      "FLC ratio < 0.125 or > 8High risk of progression in first 2 years",
                      "High risk of progression in first 2 years"
                    ]
                  },
                  {
                    "text": "Median overall survival≥ 5 years for standard risk PCM after tandem stem cell transplantation2-3 years for high-risk disease after therapy",
                    "sub_points": [
                      "≥ 5 years for standard risk PCM after tandem stem cell transplantation",
                      "2-3 years for high-risk disease after therapy"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Cytologic Features": [
                  {
                    "text": "Peripheral bloodRouleaux formationCaused by increased immunoglobulinNormochromic normocytic anemiaCirculating plasma cellsNeed to exclude plasma cell leukemiaLeukopenia or thrombocytopenia< 20% of cases at diagnosis",
                    "sub_points": [
                      "Rouleaux formationCaused by increased immunoglobulin",
                      "Caused by increased immunoglobulin",
                      "Normochromic normocytic anemia",
                      "Circulating plasma cellsNeed to exclude plasma cell leukemia",
                      "Need to exclude plasma cell leukemia",
                      "Leukopenia or thrombocytopenia< 20% of cases at diagnosis",
                      "< 20% of cases at diagnosis"
                    ]
                  },
                  {
                    "text": "Bone marrowPC infiltrateAssess % PCInfiltration pattern, associated fibrosisAmyloidOsteoclastic bone lesions",
                    "sub_points": [
                      "PC infiltrateAssess % PCInfiltration pattern, associated fibrosis",
                      "Assess % PC",
                      "Infiltration pattern, associated fibrosis",
                      "Amyloid",
                      "Osteoclastic bone lesions"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "CD138, κ and λ light chainsQuantify clonal PC population in tissueExpression of CD56 (~ 70%) or cyclin D1 (~ 33%)",
                    "sub_points": [
                      "Quantify clonal PC population in tissue",
                      "Expression of CD56 (~ 70%) or cyclin D1 (~ 33%)"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Routinely underestimates plasma cells by 60-70%Technical difficulties in evaluating PCsPCs stick to things that alter expression patternsPC autofluorescence may produce false-positive results",
                    "sub_points": [
                      "Technical difficulties in evaluating PCsPCs stick to things that alter expression patternsPC autofluorescence may produce false-positive results",
                      "PCs stick to things that alter expression patterns",
                      "PC autofluorescence may produce false-positive results"
                    ]
                  },
                  {
                    "text": "PCM are CD138(+), CD38(+), CD19(-), CD45(+/-), CD56(+/-)Often weaker CD38, brighter CD138 than normalAberrant expression of other lineage antigens, i.e., CD20 (15-20%), CD28 (40%), CD33 (15%), CD52 (30%), CD117 (27%)",
                    "sub_points": [
                      "Often weaker CD38, brighter CD138 than normal",
                      "Aberrant expression of other lineage antigens, i.e., CD20 (15-20%), CD28 (40%), CD33 (15%), CD52 (30%), CD117 (27%)"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Multiple genetic lesions associated with progressionActivating mutationsMAPK/STAT3pathway:NRAS, KRAS,FGFR3NFκBpathwayInactivating mutationsRB1pathway,TP53pathwayMyc dysregulation",
                    "sub_points": [
                      "Activating mutationsMAPK/STAT3pathway:NRAS, KRAS,FGFR3NFκBpathway",
                      "MAPK/STAT3pathway:NRAS, KRAS,FGFR3",
                      "NFκBpathway",
                      "Inactivating mutationsRB1pathway,TP53pathway",
                      "RB1pathway,TP53pathway",
                      "Myc dysregulation"
                    ]
                  },
                  {
                    "text": "Should be performed on all newly diagnosed patientsRequires IL-4 to stimulate growth due to typically low PC proliferative activityInformative in 30-40% of PCM",
                    "sub_points": [
                      "Requires IL-4 to stimulate growth due to typically low PC proliferative activity",
                      "Informative in 30-40% of PCM"
                    ]
                  },
                  {
                    "text": "Any abnormal karyotype indicates increased proliferationWorse prognosis than normal karyotypeHigh-risk disease if deletion 13 or hypodiploidy1q amplification associated with shorter survivalMost prevalent findingsGains in chromosomes 1q, 3, 5, 7, 8, 11, 15, 19, 21Losses in chromosomes 1p, 6q, 8, 13q, 14q, 16qTranslocations involving 14q32 (IgH@)",
                    "sub_points": [
                      "Worse prognosis than normal karyotypeHigh-risk disease if deletion 13 or hypodiploidy1q amplification associated with shorter survival",
                      "High-risk disease if deletion 13 or hypodiploidy",
                      "1q amplification associated with shorter survival",
                      "Most prevalent findingsGains in chromosomes 1q, 3, 5, 7, 8, 11, 15, 19, 21Losses in chromosomes 1p, 6q, 8, 13q, 14q, 16qTranslocations involving 14q32 (IgH@)",
                      "Gains in chromosomes 1q, 3, 5, 7, 8, 11, 15, 19, 21",
                      "Losses in chromosomes 1p, 6q, 8, 13q, 14q, 16q",
                      "Translocations involving 14q32 (IgH@)"
                    ]
                  },
                  {
                    "text": "Interphase fluorescent in situ hybridization (FISH)Detects chromosomal abnormalities in > 90% PCMBetter identification of specific genetic lesionsMonosomy or partial deletion of chromosome 13(13q14) is common~ 50% of PCM",
                    "sub_points": [
                      "Detects chromosomal abnormalities in > 90% PCM",
                      "Better identification of specific genetic lesions",
                      "Monosomy or partial deletion of chromosome 13(13q14) is common~ 50% of PCM",
                      "~ 50% of PCM"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Reactive Polyclonal Plasmacytosis": [
                  {
                    "text": "Systemic infectionsHIV, other bacterial or viral infections",
                    "sub_points": [
                      "HIV, other bacterial or viral infections"
                    ]
                  },
                  {
                    "text": "Autoimmune disordersSystemic lupus erythematosus, rheumatoid arthritis",
                    "sub_points": [
                      "Systemic lupus erythematosus, rheumatoid arthritis"
                    ]
                  },
                  {
                    "text": "Drug-induced agranulocytosis, hypersensitivityLevamisole (in cocaine), others",
                    "sub_points": [
                      "Levamisole (in cocaine), others"
                    ]
                  },
                  {
                    "text": "Carcinomas, lymphomas, rare leukemiasClassical Hodgkin lymphoma",
                    "sub_points": [
                      "Classical Hodgkin lymphoma"
                    ]
                  }
                ],
                "MGUS": [
                  {
                    "text": "Small clonal PC population (< 10%), small paraproteinNo signs of disease-related, end-organ damage or bone lesions",
                    "sub_points": [
                      "No signs of disease-related, end-organ damage or bone lesions"
                    ]
                  }
                ],
                "Solitary Plasmacytoma of Bone or Extraosseous Plasmacytoma": [
                  {
                    "text": "Clonal PCs in lesionNo clonal population in random bone biopsyNo evidence of lymphoma with plasmacytic differentiation",
                    "sub_points": [
                      "No clonal population in random bone biopsy",
                      "No evidence of lymphoma with plasmacytic differentiation"
                    ]
                  },
                  {
                    "text": "Negative skeletal surveyMR useful to exclude occult lesions",
                    "sub_points": [
                      "MR useful to exclude occult lesions"
                    ]
                  },
                  {
                    "text": "No anemia, hypercalcemia, or renal involvement"
                  }
                ],
                "Osteosclerotic Myeloma (POEMS Syndrome)": [
                  {
                    "text": "Osteosclerotic bone lesions associated withPolyneuropathy,Organomegaly,Endocrine abnormalities,M-protein (~ 1.1 g/dL),Skin changesPossible Castleman disease",
                    "sub_points": [
                      "Polyneuropathy,Organomegaly,Endocrine abnormalities,M-protein (~ 1.1 g/dL),Skin changes",
                      "Possible Castleman disease"
                    ]
                  }
                ],
                "Monoclonal Immunoglobulin Deposition Diseases": [
                  {
                    "text": "Primary amyloidosis"
                  },
                  {
                    "text": "Monoclonal light and heavy chain deposition diseases"
                  }
                ],
                "Lymphoplasmacytic Lymphoma": [
                  {
                    "text": "Monoclonal B-cell and monoclonal PC populationsIntact IgM monoclonal proteinHyperviscosity, often associated with Waldenström macroglobulinemia",
                    "sub_points": [
                      "Intact IgM monoclonal protein",
                      "Hyperviscosity, often associated with Waldenström macroglobulinemia"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Nonneoplastic Disorders of the Bone Marrow and Lymph Nodes": {
        "name": "Nonneoplastic Disorders of the Bone Marrow and Lymph Nodes",
        "url": "https://app.pathprimer.com/lesson/6e5627b8-d0a0-4739-ae70-d53f34f8cfcd",
        "topics": {
          "Epstein-Barr Virus": {
            "name": "Epstein-Barr Virus",
            "url": "https://app.pathprimer.com/document/d0597c7f-3144-4e97-aefa-e980726b3813/lesson/6e5627b8-d0a0-4739-ae70-d53f34f8cfcd",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "EBV, also known as human herpesvirus 4, is viral cause of infectious mononucelosis in immunocompetent hosts, and benign B-cell hyperplasia and malignant lymphoproliferative disorders in immunocompromised host"
                  },
                  {
                    "text": "EBV enters body through oropharyngeal epithelial and lymphoid tissuesBinding to CD21 on B cells triggers fusion of viral envelope with cell membrane",
                    "sub_points": [
                      "Binding to CD21 on B cells triggers fusion of viral envelope with cell membrane"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Based on serology, > 90% of immunocompetent adults have evidence of prior EBV infection"
                  },
                  {
                    "text": "Vague onset of flu-like symptoms"
                  },
                  {
                    "text": "Splenomegaly is present in ~50% of patients with infectious mononucelosis, and splenic rupture is a rare ,but classic, adverse outcome"
                  },
                  {
                    "text": "Monospot test is based on agglutination of horse erythrocytes and is sensitive and specific"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Architecture of lymph nodes and tonsils is distorted but not effacedLarge immunoblasts may resemble classic Reed-Sternberg cells in a background of plasmacytic inflammationImmunoblasts may stain for CD30 but are CD15 negative",
                    "sub_points": [
                      "Large immunoblasts may resemble classic Reed-Sternberg cells in a background of plasmacytic inflammation",
                      "Immunoblasts may stain for CD30 but are CD15 negative"
                    ]
                  },
                  {
                    "text": "EBER in situ hybridization is most useful test for tissue diagnosis of EBV infection (positive in small and large cells)"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Large cell lymphoma, Hodgkin lymphoma, other infections (CMV, toxoplasmosis)"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Epstein-Barr virus (EBV)"
                  },
                  {
                    "text": "Infectious mononucleosis (IM)"
                  },
                  {
                    "text": "Complete blood count (CBC)"
                  },
                  {
                    "text": "Natural killer (NK)"
                  },
                  {
                    "text": "Epstein-Barr encoded RNA (EBER)"
                  },
                  {
                    "text": "Cytomegalovirus (CMV)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Human herpesvirus 4"
                  }
                ],
                "Definitions": [
                  {
                    "text": "EBV: Viral cause of IM in immunocompetent host, and benign B-cell hyperplasia and malignant lymphoproliferative disorders in immunocompromised host"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Etiology": [
                  {
                    "text": "EBV enters body through oropharyngeal epithelial and lymphoid tissues"
                  },
                  {
                    "text": "Binding to CD21 on B cells triggers fusion of viral envelope with cell membraneVirus enters B cellCirculating B cells spread infection through reticular endothelial system (liver, spleen, peripheral lymph nodes)",
                    "sub_points": [
                      "Virus enters B cell",
                      "Circulating B cells spread infection through reticular endothelial system (liver, spleen, peripheral lymph nodes)"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Based on serology, > 90% of immunocompetent adults have evidence of prior EBV infection"
                  },
                  {
                    "text": "Most infections occur in children < 5 yr old and are asymptomatic"
                  },
                  {
                    "text": "One-third of infections in adolescents are symptomatic"
                  },
                  {
                    "text": "Infections in older individuals are more commonly symptomaticSymptoms are more severe",
                    "sub_points": [
                      "Symptoms are more severe"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "IMIncubation period 2-5 weeksVague onset of symptomsFlu-likeFeverSore throatMalaiseYounger children are less symptomatic than adolescents and adultsLymphadenopathyPosterior cervical nodes most commonly involvedMarkedly enlarged tonsilsSplenomegalyPresent in one-half of all patients with IMSplenic rupture from trauma is a rare but classically described adverse outcomeMild hepatitisMost cases have elevated transaminasesClinical jaundice is rare",
                    "sub_points": [
                      "Incubation period 2-5 weeks",
                      "Vague onset of symptomsFlu-likeFeverSore throatMalaiseYounger children are less symptomatic than adolescents and adults",
                      "Flu-likeFeverSore throatMalaise",
                      "Fever",
                      "Sore throat",
                      "Malaise",
                      "Younger children are less symptomatic than adolescents and adults",
                      "LymphadenopathyPosterior cervical nodes most commonly involved",
                      "Posterior cervical nodes most commonly involved",
                      "Markedly enlarged tonsils",
                      "SplenomegalyPresent in one-half of all patients with IMSplenic rupture from trauma is a rare but classically described adverse outcome",
                      "Present in one-half of all patients with IM",
                      "Splenic rupture from trauma is a rare but classically described adverse outcome",
                      "Mild hepatitisMost cases have elevated transaminasesClinical jaundice is rare",
                      "Most cases have elevated transaminases",
                      "Clinical jaundice is rare"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "CBCLeukocytosis (usually 12-25 × 10⁹/L)Atypical lymphocytosisOften > 10% large atypical lymphocytes in peripheral blood (mostly T cells)Monocytoid lymphocytes thought to correspond to immunoblasts seen in lymph nodeDevelops 3-4 days after onset of symptoms and typically normalizes within 3 weeksTransient monocytosisEarly in course, absolute and relative neutropeniaLeft shift in maturation, toxic granulation, and Döhle bodiesHalf of cases demonstrate mild thrombocytopeniaHemolytic anemia (rare)Polyclonal cold agglutinins, IgM, directed at the anit-I antigen on RBCs",
                    "sub_points": [
                      "Leukocytosis (usually 12-25 × 10⁹/L)Atypical lymphocytosisOften > 10% large atypical lymphocytes in peripheral blood (mostly T cells)Monocytoid lymphocytes thought to correspond to immunoblasts seen in lymph nodeDevelops 3-4 days after onset of symptoms and typically normalizes within 3 weeksTransient monocytosisEarly in course, absolute and relative neutropeniaLeft shift in maturation, toxic granulation, and Döhle bodies",
                      "Atypical lymphocytosisOften > 10% large atypical lymphocytes in peripheral blood (mostly T cells)Monocytoid lymphocytes thought to correspond to immunoblasts seen in lymph nodeDevelops 3-4 days after onset of symptoms and typically normalizes within 3 weeks",
                      "Often > 10% large atypical lymphocytes in peripheral blood (mostly T cells)",
                      "Monocytoid lymphocytes thought to correspond to immunoblasts seen in lymph node",
                      "Develops 3-4 days after onset of symptoms and typically normalizes within 3 weeks",
                      "Transient monocytosis",
                      "Early in course, absolute and relative neutropeniaLeft shift in maturation, toxic granulation, and Döhle bodies",
                      "Left shift in maturation, toxic granulation, and Döhle bodies",
                      "Half of cases demonstrate mild thrombocytopenia",
                      "Hemolytic anemia (rare)Polyclonal cold agglutinins, IgM, directed at the anit-I antigen on RBCs",
                      "Polyclonal cold agglutinins, IgM, directed at the anit-I antigen on RBCs"
                    ]
                  },
                  {
                    "text": "MonospotTests for heterophile antibodies (IgM) of IMBased on agglutination of horse erythrocytesHighly sensitive and specificFalse-negative results most common in children due to limited production of heterophile antibodies",
                    "sub_points": [
                      "Tests for heterophile antibodies (IgM) of IM",
                      "Based on agglutination of horse erythrocytes",
                      "Highly sensitive and specificFalse-negative results most common in children due to limited production of heterophile antibodies",
                      "False-negative results most common in children due to limited production of heterophile antibodies"
                    ]
                  },
                  {
                    "text": "Antibodies against EBVOften against viral capsid antigenUsed for diagnosis if false-negative result on monospot is suspected",
                    "sub_points": [
                      "Often against viral capsid antigen",
                      "Used for diagnosis if false-negative result on monospot is suspected"
                    ]
                  },
                  {
                    "text": "Heterophile antibody (Paul-Bunnell-Davidsohn test)﻿Based on absorption of IM heterophile antibodies by beef erythrocytes and not by guinea pig kidney (Forssman antigen)",
                    "sub_points": [
                      "Based on absorption of IM heterophile antibodies by beef erythrocytes and not by guinea pig kidney (Forssman antigen)"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Supportive"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Complications occur in < 5% of cases"
                  },
                  {
                    "text": "Rare complications with high morbidity and mortality related to infection of T cells and NK cells instead of B cellsChronic active EBV infectionEBV hemophagocytic syndrome",
                    "sub_points": [
                      "Chronic active EBV infection",
                      "EBV hemophagocytic syndrome"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Biopsy of bone marrow uncommon in IMFeatures nonspecificIncreased cellularityLymphoid aggregatesCD8+ lymphocytes increasedAtypical forms also foundMyeloid-to-erythroid ratio increasedMyeloid maturation left-shiftedLoose granulomas of mononuclear cells",
                    "sub_points": [
                      "Features nonspecificIncreased cellularityLymphoid aggregatesCD8+ lymphocytes increasedAtypical forms also foundMyeloid-to-erythroid ratio increasedMyeloid maturation left-shiftedLoose granulomas of mononuclear cells",
                      "Increased cellularity",
                      "Lymphoid aggregates",
                      "CD8+ lymphocytes increasedAtypical forms also found",
                      "Atypical forms also found",
                      "Myeloid-to-erythroid ratio increased",
                      "Myeloid maturation left-shifted",
                      "Loose granulomas of mononuclear cells"
                    ]
                  },
                  {
                    "text": "Lymph nodes and tonsilsEarly in diseaseFollicular hyperplasiaEpithelioid histocytesMonocytoid B-cell aggregatesLater in diseaseArchitecture distorted but not effacedParacortical expansionPolymorphous inflammatory cell infiltrate with mottled appearanceLarge immunoblasts may resemble classic Reed-Sternberg cellsLarge immunoblasts may stain positively for CD30 but are CD15 negativeBackground of small-to-medium sized lymphocytes and plasma cellsProminent high endothelial venulesSinuses expanded with monocytoid B cells, lymphocytes, and immunoblastsEBER in situ hybridization highlights EBV-positive cells (small and large cells)Most useful test for tissue diagnosis of EBV",
                    "sub_points": [
                      "Early in diseaseFollicular hyperplasiaEpithelioid histocytesMonocytoid B-cell aggregates",
                      "Follicular hyperplasia",
                      "Epithelioid histocytes",
                      "Monocytoid B-cell aggregates",
                      "Later in diseaseArchitecture distorted but not effacedParacortical expansionPolymorphous inflammatory cell infiltrate with mottled appearanceLarge immunoblasts may resemble classic Reed-Sternberg cellsLarge immunoblasts may stain positively for CD30 but are CD15 negativeBackground of small-to-medium sized lymphocytes and plasma cellsProminent high endothelial venulesSinuses expanded with monocytoid B cells, lymphocytes, and immunoblastsEBER in situ hybridization highlights EBV-positive cells (small and large cells)Most useful test for tissue diagnosis of EBV",
                      "Architecture distorted but not effaced",
                      "Paracortical expansionPolymorphous inflammatory cell infiltrate with mottled appearanceLarge immunoblasts may resemble classic Reed-Sternberg cellsLarge immunoblasts may stain positively for CD30 but are CD15 negativeBackground of small-to-medium sized lymphocytes and plasma cells",
                      "Polymorphous inflammatory cell infiltrate with mottled appearance",
                      "Large immunoblasts may resemble classic Reed-Sternberg cells",
                      "Large immunoblasts may stain positively for CD30 but are CD15 negative",
                      "Background of small-to-medium sized lymphocytes and plasma cells",
                      "Prominent high endothelial venules",
                      "Sinuses expanded with monocytoid B cells, lymphocytes, and immunoblasts",
                      "EBER in situ hybridization highlights EBV-positive cells (small and large cells)Most useful test for tissue diagnosis of EBV",
                      "Most useful test for tissue diagnosis of EBV"
                    ]
                  },
                  {
                    "text": "SpleenMorphologic findings varyExpansion of red and white pulp equallySimilar morphologic findings to lymph nodes and tonsilsSpectrum of large immunoblasts, lymphocytes, and plasma cells",
                    "sub_points": [
                      "Morphologic findings vary",
                      "Expansion of red and white pulp equallySimilar morphologic findings to lymph nodes and tonsilsSpectrum of large immunoblasts, lymphocytes, and plasma cells",
                      "Similar morphologic findings to lymph nodes and tonsils",
                      "Spectrum of large immunoblasts, lymphocytes, and plasma cells"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Large-Cell Lymphoma": [
                  {
                    "text": "Proliferation of immunoblasts lacking background of plasma cells and small to medium sized lymphocytes"
                  },
                  {
                    "text": "High endothelial venules not present"
                  },
                  {
                    "text": "EBER is positive only in large neoplastic cells in EBV-positive diffuse large B-cell lymphomas"
                  }
                ],
                "Hodgkin Lymphoma": [
                  {
                    "text": "True Reed-Sternberg cells positive for CD30 and CD15"
                  }
                ],
                "Other Infections": [
                  {
                    "text": "CMVMost common cause of clinical mononucleosis that is heterophile antibody negativeDemonstrates viral inclusions",
                    "sub_points": [
                      "Most common cause of clinical mononucleosis that is heterophile antibody negative",
                      "Demonstrates viral inclusions"
                    ]
                  },
                  {
                    "text": "ToxoplasmosisToxoplasmic lymphadenitis has similar histologic features to early IM lymph nodes",
                    "sub_points": [
                      "Toxoplasmic lymphadenitis has similar histologic features to early IM lymph nodes"
                    ]
                  },
                  {
                    "text": "Human herpesvirus 6"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Syphilis": {
            "name": "Syphilis",
            "url": "https://app.pathprimer.com/document/3b952298-721c-4b0c-9893-1fe1f980e198/lesson/6e5627b8-d0a0-4739-ae70-d53f34f8cfcd",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Syphilis: Chronic systemic infection caused byT. pallidum(Gram-negative spirochete)"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Course of disease divided into 3 stages: Primary, secondary, and tertiary"
                  },
                  {
                    "text": "Penicillin G is drug of choice for all stages of syphilis"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Capsular and pericapsular inflammation and sclerosis"
                  },
                  {
                    "text": "Diffuse plasma cell infiltration; sheets of plasma cells in medulla"
                  },
                  {
                    "text": "Proliferation of blood vessels with endothelial swelling, phlebitis, and endarteritis"
                  },
                  {
                    "text": "Follicular hyperplasia"
                  },
                  {
                    "text": "Spirochetes most frequently found in walls of blood vessels (silver stains)"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Lymphadenitis in course of syphilisSyphilis: Chronic systemic infection caused byTreponema pallidum(T. pallidum)Infection usually sexually transmitted, characterized by periods of active disease and latency",
                    "sub_points": [
                      "Syphilis: Chronic systemic infection caused byTreponema pallidum(T. pallidum)Infection usually sexually transmitted, characterized by periods of active disease and latency",
                      "Infection usually sexually transmitted, characterized by periods of active disease and latency"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Infectious Agents": [
                  {
                    "text": "T. pallidumis gram-negative spirochete"
                  },
                  {
                    "text": "At least 4 known subspeciesT. pallidum pallidum: Causes syphilisT. pallidum pertenue: Causes yawsT. pallidum carateum: Causes pintaT. pallidum endemicum: Causes endemic syphilis or bejel",
                    "sub_points": [
                      "T. pallidum pallidum: Causes syphilis",
                      "T. pallidum pertenue: Causes yaws",
                      "T. pallidum carateum: Causes pinta",
                      "T. pallidum endemicum: Causes endemic syphilis or bejel"
                    ]
                  },
                  {
                    "text": "T. pallidumis slender, spiral organism 5-15 μm long and 0.2 μm thickCannot be cultured in vitroHuman is only known natural host",
                    "sub_points": [
                      "Cannot be cultured in vitro",
                      "Human is only known natural host"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "Three stages of disease coursePrimary syphilisChancre: Usually 1 painless papule that becomes eroded/indurated; lesion heals within 6 weeksRegional (usually inguinal) lymphadenopathy within 1 week of onsetUnilateral or bilateral; usually nonsuppurative and painlessLymphadenopathy may persist for monthsSecondary syphilisGeneralized nontender lymphadenopathyLocalized or diffuse mucocutaneous lesions (nonpruritic skin rashes)Constitutional symptoms: Sore throat, fever, weight loss, malaise, anorexiaTertiary syphilisIn industrialized countries, tertiary disease is nearly eliminatedMost common type before antibiotic eraGumma (skin and skeletal system): Granulomatous lesion with central area of necrosis due to endarteritis obliteransCardiovascular syphilis (usually involving vasa vasorum of ascending aorta)Symptomatic neurosyphilis (tabes dorsalis and paresis)",
                    "sub_points": [
                      "Primary syphilisChancre: Usually 1 painless papule that becomes eroded/indurated; lesion heals within 6 weeksRegional (usually inguinal) lymphadenopathy within 1 week of onsetUnilateral or bilateral; usually nonsuppurative and painlessLymphadenopathy may persist for months",
                      "Chancre: Usually 1 painless papule that becomes eroded/indurated; lesion heals within 6 weeks",
                      "Regional (usually inguinal) lymphadenopathy within 1 week of onset",
                      "Unilateral or bilateral; usually nonsuppurative and painless",
                      "Lymphadenopathy may persist for months",
                      "Secondary syphilisGeneralized nontender lymphadenopathyLocalized or diffuse mucocutaneous lesions (nonpruritic skin rashes)Constitutional symptoms: Sore throat, fever, weight loss, malaise, anorexia",
                      "Generalized nontender lymphadenopathy",
                      "Localized or diffuse mucocutaneous lesions (nonpruritic skin rashes)",
                      "Constitutional symptoms: Sore throat, fever, weight loss, malaise, anorexia",
                      "Tertiary syphilisIn industrialized countries, tertiary disease is nearly eliminatedMost common type before antibiotic eraGumma (skin and skeletal system): Granulomatous lesion with central area of necrosis due to endarteritis obliteransCardiovascular syphilis (usually involving vasa vasorum of ascending aorta)Symptomatic neurosyphilis (tabes dorsalis and paresis)",
                      "In industrialized countries, tertiary disease is nearly eliminated",
                      "Most common type before antibiotic era",
                      "Gumma (skin and skeletal system): Granulomatous lesion with central area of necrosis due to endarteritis obliterans",
                      "Cardiovascular syphilis (usually involving vasa vasorum of ascending aorta)",
                      "Symptomatic neurosyphilis (tabes dorsalis and paresis)"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Two types of serologic tests: Nontreponemal and treponemalNontreponemal antibody tests: Rapid plasma reagin and venereal disease research laboratory tests (screening)Measures IgG and IgM antibodies directed against cardiolipin-lecithin-cholesterol antigen complexTreponemal tests (fluorescent treponemal antibody-absorbed test and several agglutination assays)Measures antibodies to native or recombinantT. pallidumantigens",
                    "sub_points": [
                      "Nontreponemal antibody tests: Rapid plasma reagin and venereal disease research laboratory tests (screening)Measures IgG and IgM antibodies directed against cardiolipin-lecithin-cholesterol antigen complex",
                      "Measures IgG and IgM antibodies directed against cardiolipin-lecithin-cholesterol antigen complex",
                      "Treponemal tests (fluorescent treponemal antibody-absorbed test and several agglutination assays)Measures antibodies to native or recombinantT. pallidumantigens",
                      "Measures antibodies to native or recombinantT. pallidumantigens"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Penicillin G drug of choice for all stages of syphilisFor penicillin-allergic patients, doxycycline or tetracycline is recommended",
                    "sub_points": [
                      "For penicillin-allergic patients, doxycycline or tetracycline is recommended"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Infection eradicated with antibiotic therapy"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Capsular and pericapsular inflammation and sclerosis"
                  },
                  {
                    "text": "Diffuse plasma cell infiltration; sheets of plasma cells in medulla"
                  },
                  {
                    "text": "Proliferation of blood vessels with endothelial swelling, phlebitis, and endarteritis"
                  },
                  {
                    "text": "Follicular hyperplasia"
                  },
                  {
                    "text": "Noncaseating epithelioid granulomas"
                  },
                  {
                    "text": "T. pallidumis too thin to be visualized with Gram stain"
                  },
                  {
                    "text": "Silver stains, Warthin-Starry or Levaditi stains reveal spirochetesMore often found in walls of blood vessels",
                    "sub_points": [
                      "More often found in walls of blood vessels"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Systemic Lupus Lymphadenopathy (SLE)": [
                  {
                    "text": "In common with lues: SLE shows follicular hyperplasia, increased vascularization, scattered immunoblasts, and plasma cellsSLE lacks vasculitis and contains accumulations of basophilic material derived from DNA (hematoxylin bodies)",
                    "sub_points": [
                      "SLE lacks vasculitis and contains accumulations of basophilic material derived from DNA (hematoxylin bodies)"
                    ]
                  }
                ],
                "Rheumatoid Arthritis (RA)": [
                  {
                    "text": "In common with luesRA shows follicular hyperplasiaVascular proliferationPlasma cell proliferationCapsular infiltration by lymphocytes",
                    "sub_points": [
                      "RA shows follicular hyperplasia",
                      "Vascular proliferation",
                      "Plasma cell proliferation",
                      "Capsular infiltration by lymphocytes"
                    ]
                  },
                  {
                    "text": "RA usually lacks vasculitis and perivasculitis"
                  },
                  {
                    "text": "Warthin-Starry stain to detect spirochetes may help"
                  }
                ],
                "Follicular Lymphoma": [
                  {
                    "text": "In lues, follicles can be prominent"
                  },
                  {
                    "text": "Follicles show reactive features (tingible body histiocytes and mitosis)"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Parvovirus B19 Infection": {
            "name": "Parvovirus B19 Infection",
            "url": "https://app.pathprimer.com/document/7f5146df-0f22-498f-b66c-88794114247c/lesson/6e5627b8-d0a0-4739-ae70-d53f34f8cfcd",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "Parvovirus B19 propagates efficiently only in human erythroid progenitor cellsViral entry requires activated β1 integrin core receptors on erythroid precursorsVirus is cytotoxic to cells",
                    "sub_points": [
                      "Viral entry requires activated β1 integrin core receptors on erythroid precursors",
                      "Virus is cytotoxic to cells"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Clinical manifestations of parvovirus B19 depend onAgeUnderlying hematologic disordersImmune status",
                    "sub_points": [
                      "Age",
                      "Underlying hematologic disorders",
                      "Immune status"
                    ]
                  },
                  {
                    "text": "Acute infectionFifth disease in normal childrenTransient aplastic crisis in individuals with requirement for increased erythropoiesis",
                    "sub_points": [
                      "Fifth disease in normal children",
                      "Transient aplastic crisis in individuals with requirement for increased erythropoiesis"
                    ]
                  },
                  {
                    "text": "Chronic infectionArthropathy in normal adults",
                    "sub_points": [
                      "Arthropathy in normal adults"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Bone marrowGiant proerythroblasts are hallmark of infectionMinimal erythroid maturation beyond proerythroblast stage unless immunosuppressedProerythroblasts have dark blue, often vacuolated cytoplasm with nuclear viral inclusionsAlso referred to as \"lantern cells\"",
                    "sub_points": [
                      "Giant proerythroblasts are hallmark of infectionMinimal erythroid maturation beyond proerythroblast stage unless immunosuppressed",
                      "Minimal erythroid maturation beyond proerythroblast stage unless immunosuppressed",
                      "Proerythroblasts have dark blue, often vacuolated cytoplasm with nuclear viral inclusions",
                      "Also referred to as \"lantern cells\""
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Immunohistochemistry or in situ hybridization for virus in biopsy sections confirms infection"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Parvovirus B19 (B19V)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Erythema infectiosum"
                  },
                  {
                    "text": "Fifth disease"
                  },
                  {
                    "text": "\"Slapped cheek\" disease"
                  }
                ],
                "Definitions": [
                  {
                    "text": "At least 4 different parvoviruses infect humansSmall, single-stranded, nonenveloped DNA virusesB19V is best characterizedMember of Parvoviridae familyGenusErythrovirus",
                    "sub_points": [
                      "Small, single-stranded, nonenveloped DNA viruses",
                      "B19V is best characterizedMember of Parvoviridae familyGenusErythrovirus",
                      "Member of Parvoviridae family",
                      "GenusErythrovirus"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "B19V Pathogenesis": [
                  {
                    "text": "TransmissionPrimarily through respiratory routeVertically from mother to fetusStem cell and organ transplantsBlood transfusion products",
                    "sub_points": [
                      "Primarily through respiratory route",
                      "Vertically from mother to fetus",
                      "Stem cell and organ transplants",
                      "Blood transfusion products"
                    ]
                  },
                  {
                    "text": "Virus binds blood group P antigen receptorsP antigen receptors present onErythroid precursors, megakaryocytes, endothelial cells",
                    "sub_points": [
                      "P antigen receptors present onErythroid precursors, megakaryocytes, endothelial cells",
                      "Erythroid precursors, megakaryocytes, endothelial cells"
                    ]
                  },
                  {
                    "text": "Viral entry into cell requires activated β1 integrin core receptorsPresent only on erythroid progenitorsInduces cell cycle arrestCytotoxic to erythroid cells4-8 day cessation of red cell productionHemoglobin drop of approximately 1g/dL in normal individuals",
                    "sub_points": [
                      "Present only on erythroid progenitorsInduces cell cycle arrestCytotoxic to erythroid cells4-8 day cessation of red cell productionHemoglobin drop of approximately 1g/dL in normal individuals",
                      "Induces cell cycle arrest",
                      "Cytotoxic to erythroid cells",
                      "4-8 day cessation of red cell production",
                      "Hemoglobin drop of approximately 1g/dL in normal individuals"
                    ]
                  },
                  {
                    "text": "Virus propagates efficiently only in human erythroid progenitor cells"
                  },
                  {
                    "text": "Viral proteins have toxic effects on other cell populationsMyeloid precursorsMegakaryocytes",
                    "sub_points": [
                      "Myeloid precursors",
                      "Megakaryocytes"
                    ]
                  },
                  {
                    "text": "Immune response develops against virusAnemia resolves in 10-19 days",
                    "sub_points": [
                      "Anemia resolves in 10-19 days"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Common in childhoodDetectable IgG found in ~ 50% of children by 15 years of age",
                    "sub_points": [
                      "Detectable IgG found in ~ 50% of children by 15 years of age"
                    ]
                  },
                  {
                    "text": "Yearly seroconversion rate of ~ 1% in women of childbearing age"
                  },
                  {
                    "text": "Detectable antibody in 80% of older individuals"
                  },
                  {
                    "text": "Seasonal variation in temperate climates"
                  },
                  {
                    "text": "More common during winter and early spring"
                  },
                  {
                    "text": "Epidemics every 3-4 years"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Erythema infectiosumMost common form of B19V infectionAcute disease of childrenAlso termed fifth diseaseNonspecific prodromal illnessFever, coryza, headache, &/or mild gastrointestinal distress\"Slapped cheek\" rash develops in 2-5 daysBright red eruption on the cheek with surrounding pallorPossible second rash in 2-3 daysErythematous maculopapular exanthem may develop on trunk and limbs",
                    "sub_points": [
                      "Most common form of B19V infection",
                      "Acute disease of children",
                      "Also termed fifth disease",
                      "Nonspecific prodromal illnessFever, coryza, headache, &/or mild gastrointestinal distress\"Slapped cheek\" rash develops in 2-5 daysBright red eruption on the cheek with surrounding pallorPossible second rash in 2-3 daysErythematous maculopapular exanthem may develop on trunk and limbs",
                      "Fever, coryza, headache, &/or mild gastrointestinal distress",
                      "\"Slapped cheek\" rash develops in 2-5 days",
                      "Bright red eruption on the cheek with surrounding pallor",
                      "Possible second rash in 2-3 days",
                      "Erythematous maculopapular exanthem may develop on trunk and limbs"
                    ]
                  },
                  {
                    "text": "Arthralgias and arthritisAcute or chronic infection of adults60% females, 30% malesSymmetrical arthralgiasMainly small joints of hands and feetUsually last 1-3 weeksMay persist or recur for months or yearsAssociation of B19V with juvenile rheumatic disease described",
                    "sub_points": [
                      "Acute or chronic infection of adults60% females, 30% males",
                      "60% females, 30% males",
                      "Symmetrical arthralgiasMainly small joints of hands and feetUsually last 1-3 weeksMay persist or recur for months or yearsAssociation of B19V with juvenile rheumatic disease described",
                      "Mainly small joints of hands and feet",
                      "Usually last 1-3 weeks",
                      "May persist or recur for months or years",
                      "Association of B19V with juvenile rheumatic disease described"
                    ]
                  },
                  {
                    "text": "Transient aplastic crisisHypoproliferative anemiaMarked erythroid hypoplasia in marrowPatients have underlying hemolytic disordersHereditary spherocytosisThalassemiaRed cell enzyme deficienciesAutoimmune hemolytic anemiaPatients with concurrent erythroid \"stress\"HemorrhageIron deficiency anemiaRenal or stem cell transplant patientsSymptoms relate to worsening anemiaDyspnea, lassitudeCongestive heart failureCardiovascular complicationsBone marrow necrosis (may be fatal)Primary cause for community acquired aplastic crisisMay develop varying degrees of neutropenia and thrombocytopenia",
                    "sub_points": [
                      "Hypoproliferative anemiaMarked erythroid hypoplasia in marrow",
                      "Marked erythroid hypoplasia in marrow",
                      "Patients have underlying hemolytic disordersHereditary spherocytosisThalassemiaRed cell enzyme deficienciesAutoimmune hemolytic anemia",
                      "Hereditary spherocytosis",
                      "Thalassemia",
                      "Red cell enzyme deficiencies",
                      "Autoimmune hemolytic anemia",
                      "Patients with concurrent erythroid \"stress\"HemorrhageIron deficiency anemiaRenal or stem cell transplant patients",
                      "Hemorrhage",
                      "Iron deficiency anemia",
                      "Renal or stem cell transplant patients",
                      "Symptoms relate to worsening anemiaDyspnea, lassitudeCongestive heart failureCardiovascular complicationsBone marrow necrosis (may be fatal)",
                      "Dyspnea, lassitude",
                      "Congestive heart failure",
                      "Cardiovascular complications",
                      "Bone marrow necrosis (may be fatal)",
                      "Primary cause for community acquired aplastic crisis",
                      "May develop varying degrees of neutropenia and thrombocytopenia"
                    ]
                  },
                  {
                    "text": "Pure red cell aplasiaChronic infection in immunosuppressed patientsCongenital immunodeficiencyAcquired immunodeficiency syndrome (AIDS)Hematopoietic disordersTransplant recipients",
                    "sub_points": [
                      "Chronic infection in immunosuppressed patientsCongenital immunodeficiencyAcquired immunodeficiency syndrome (AIDS)Hematopoietic disordersTransplant recipients",
                      "Congenital immunodeficiency",
                      "Acquired immunodeficiency syndrome (AIDS)",
                      "Hematopoietic disorders",
                      "Transplant recipients"
                    ]
                  },
                  {
                    "text": "Associated hemophagocytic syndromesB19V is rare causeOccurs in healthy and immunosuppressed individuals",
                    "sub_points": [
                      "B19V is rare causeOccurs in healthy and immunosuppressed individuals",
                      "Occurs in healthy and immunosuppressed individuals"
                    ]
                  },
                  {
                    "text": "Fetal infectionNonimmune hydrops fetalisB19V causes 10-15%AbortionsConfined to first 20 weeks of pregnancyRare, average ~ 9% among infected women",
                    "sub_points": [
                      "Nonimmune hydrops fetalisB19V causes 10-15%",
                      "B19V causes 10-15%",
                      "AbortionsConfined to first 20 weeks of pregnancyRare, average ~ 9% among infected women",
                      "Confined to first 20 weeks of pregnancy",
                      "Rare, average ~ 9% among infected women"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Arthralgias and arthritisRespond to nonsteroidal anti-inflammatory drugs",
                    "sub_points": [
                      "Respond to nonsteroidal anti-inflammatory drugs"
                    ]
                  },
                  {
                    "text": "Immunocompetent patients with transient aplastic crisisRed blood cell transfusionsSupportive therapy",
                    "sub_points": [
                      "Red blood cell transfusions",
                      "Supportive therapy"
                    ]
                  },
                  {
                    "text": "Immunosuppressed patients with persistent infectionTemporary cessation of immunosuppression if feasibleAdminister intravenous immunoglobulin",
                    "sub_points": [
                      "Temporary cessation of immunosuppression if feasible",
                      "Administer intravenous immunoglobulin"
                    ]
                  },
                  {
                    "text": "Maternal B19V infectionMonitor fetus by Doppler ultrasoundIntrauterine blood transfusionsTreatment of hydrops fetalis, severe fetal anemia",
                    "sub_points": [
                      "Monitor fetus by Doppler ultrasound",
                      "Intrauterine blood transfusionsTreatment of hydrops fetalis, severe fetal anemia",
                      "Treatment of hydrops fetalis, severe fetal anemia"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Benign and self-limiting infectionMajority of children and adultsResults in lifelong immunity",
                    "sub_points": [
                      "Majority of children and adultsResults in lifelong immunity",
                      "Results in lifelong immunity"
                    ]
                  },
                  {
                    "text": "Immunosuppressed patientsMay be fatal if severely immunosuppressed",
                    "sub_points": [
                      "May be fatal if severely immunosuppressed"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Peripheral Blood": [
                  {
                    "text": "Normochromic normocytic anemiaReticulocytopeniaResistant to erythropoietin therapyNonspecific anisopoikilocytosisImmunocompromised patientsCirculating nRBCs may have rare nuclear inclusions",
                    "sub_points": [
                      "ReticulocytopeniaResistant to erythropoietin therapy",
                      "Resistant to erythropoietin therapy",
                      "Nonspecific anisopoikilocytosisImmunocompromised patientsCirculating nRBCs may have rare nuclear inclusions",
                      "Immunocompromised patients",
                      "Circulating nRBCs may have rare nuclear inclusions"
                    ]
                  },
                  {
                    "text": "Evaluate for underlying hematologic disorderRed cell shapesSpherocytes in hereditary spherocytosisSickle cells in sickle cell anemiaRed cell sizeHypochromic microcytes in thalassemia and iron deficiency",
                    "sub_points": [
                      "Red cell shapesSpherocytes in hereditary spherocytosisSickle cells in sickle cell anemia",
                      "Spherocytes in hereditary spherocytosis",
                      "Sickle cells in sickle cell anemia",
                      "Red cell sizeHypochromic microcytes in thalassemia and iron deficiency",
                      "Hypochromic microcytes in thalassemia and iron deficiency"
                    ]
                  },
                  {
                    "text": "Normal or slightly decreased white blood cell countMild lymphopeniaMild neutropenia",
                    "sub_points": [
                      "Mild lymphopenia",
                      "Mild neutropenia"
                    ]
                  },
                  {
                    "text": "Normal or decreased platelets"
                  },
                  {
                    "text": "Possible plasmacytosis6-10 days after initial infection",
                    "sub_points": [
                      "6-10 days after initial infection"
                    ]
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "Giant proerythroblasts are hallmark of B19V infectionAlso referred to as \"lantern cells\"Nuclei have fine megaloblastoid chromatinNuclear viral inclusionsDark blue, often vacuolated cytoplasm in earliest cellsAs develop, become larger in size and lose cytoplasmic basophiliaCytoplasmic pseudopodiaBroad-based or \"dog ear\" cytoplasmic projections",
                    "sub_points": [
                      "Also referred to as \"lantern cells\"Nuclei have fine megaloblastoid chromatinNuclear viral inclusionsDark blue, often vacuolated cytoplasm in earliest cellsAs develop, become larger in size and lose cytoplasmic basophiliaCytoplasmic pseudopodiaBroad-based or \"dog ear\" cytoplasmic projections",
                      "Nuclei have fine megaloblastoid chromatin",
                      "Nuclear viral inclusions",
                      "Dark blue, often vacuolated cytoplasm in earliest cells",
                      "As develop, become larger in size and lose cytoplasmic basophilia",
                      "Cytoplasmic pseudopodia",
                      "Broad-based or \"dog ear\" cytoplasmic projections"
                    ]
                  },
                  {
                    "text": "Immunocompetent patientsMinimal erythroid maturation beyond proerythroblast stageDue to viral cytopathic effectsVariably increased megakaryocytes and small lymphocytes",
                    "sub_points": [
                      "Minimal erythroid maturation beyond proerythroblast stageDue to viral cytopathic effects",
                      "Due to viral cytopathic effects",
                      "Variably increased megakaryocytes and small lymphocytes"
                    ]
                  },
                  {
                    "text": "Immunosuppressed patientsOften hypercellular bone marrowErythroid lineage present in normal numberViral tolerance with maturation of infected erythroid cells",
                    "sub_points": [
                      "Often hypercellular bone marrowErythroid lineage present in normal numberViral tolerance with maturation of infected erythroid cells",
                      "Erythroid lineage present in normal number",
                      "Viral tolerance with maturation of infected erythroid cells"
                    ]
                  },
                  {
                    "text": "Viral-associated suppression of myeloid or megakaryocytic lineages possible"
                  },
                  {
                    "text": "Severe bone marrow necrosisRare",
                    "sub_points": [
                      "Rare"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Stain for B19V antigens"
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "Evaluate for B19V DNA in paraffin tissue"
                  }
                ],
                "PCR": [
                  {
                    "text": "PCR for B19V DNADetectable for > 4 months in serum after acute infectionImmunocompetent peopleReal-time PCR helpful in diagnosis of acute or chronic infectionImmunocompromised individuals also",
                    "sub_points": [
                      "Detectable for > 4 months in serum after acute infectionImmunocompetent people",
                      "Immunocompetent people",
                      "Real-time PCR helpful in diagnosis of acute or chronic infectionImmunocompromised individuals also",
                      "Immunocompromised individuals also"
                    ]
                  }
                ],
                "Serology": [
                  {
                    "text": "IgM assay, preferably by capture technique90% of cases positiveBy third day of transient aplastic crisisorAt time of rash in erythema infectiosumIgM antibody present 10-12 days after infection and up to 4 months or moreMay be negative in immunosuppressed patients or pregnant women",
                    "sub_points": [
                      "90% of cases positiveBy third day of transient aplastic crisisorAt time of rash in erythema infectiosum",
                      "By third day of transient aplastic crisisor",
                      "At time of rash in erythema infectiosum",
                      "IgM antibody present 10-12 days after infection and up to 4 months or moreMay be negative in immunosuppressed patients or pregnant women",
                      "May be negative in immunosuppressed patients or pregnant women"
                    ]
                  },
                  {
                    "text": "IgG antibodyAppears shortly after IgMPersists lifelong, but titers slowly decrease unless boosted by B19V encounter",
                    "sub_points": [
                      "Appears shortly after IgM",
                      "Persists lifelong, but titers slowly decrease unless boosted by B19V encounter"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Transient Erythroblastopenia of Childhood": [
                  {
                    "text": "Failure of erythropoiesis"
                  },
                  {
                    "text": "High platelet counts, unlike B19V infection"
                  }
                ],
                "Aplastic Anemia": [
                  {
                    "text": "Bone marrow failure disorder"
                  },
                  {
                    "text": "Hypocellular bone marrow with trilineage hypoplasiaNo viral inclusions",
                    "sub_points": [
                      "No viral inclusions"
                    ]
                  }
                ],
                "Rheumatoid Arthritis": [
                  {
                    "text": "Presenting with acute arthritisNeed to exclude B19V infection",
                    "sub_points": [
                      "Need to exclude B19V infection"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Serologic assays for B19V infection may be negative in immunosuppressed individuals"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Perform immunohistochemical or in situ hybridization stains for B19VOn bone marrows from HIV-positive patients with persistent anemiaMay show erythroid maturation",
                    "sub_points": [
                      "On bone marrows from HIV-positive patients with persistent anemiaMay show erythroid maturation",
                      "May show erythroid maturation"
                    ]
                  },
                  {
                    "text": "Presence or absence of giant proerythroblasts with inclusionsNot diagnostic of B19V infectionNeed confirmatory studies",
                    "sub_points": [
                      "Not diagnostic of B19V infectionNeed confirmatory studies",
                      "Need confirmatory studies"
                    ]
                  },
                  {
                    "text": "Viral inclusionsOften better visualized in biopsy sections than in aspirate smearsSmear interpretation is improved after formalin fixation for 15 minutes",
                    "sub_points": [
                      "Often better visualized in biopsy sections than in aspirate smears",
                      "Smear interpretation is improved after formalin fixation for 15 minutes"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hantavirus Pulmonary Syndrome": {
            "name": "Hantavirus Pulmonary Syndrome",
            "url": "https://app.pathprimer.com/document/de1e3bd8-713f-45b3-99ec-cf630860bcdc/lesson/6e5627b8-d0a0-4739-ae70-d53f34f8cfcd",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "Hantaviruses cause HPSEach hantavirus has specific rodent reservoirSin Nombre virus infects deer mice in AmericaTransmission to humans occurs through infected animal excreta",
                    "sub_points": [
                      "Each hantavirus has specific rodent reservoir",
                      "Sin Nombre virus infects deer mice in America",
                      "Transmission to humans occurs through infected animal excreta"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Clinical findings in prodromal phase are insufficient to make diagnosisConsider in patient with appropriate rodent exposureRequires high index of suspicion",
                    "sub_points": [
                      "Consider in patient with appropriate rodent exposure",
                      "Requires high index of suspicion"
                    ]
                  },
                  {
                    "text": "Infected individuals developBilateral interstitial pulmonary infiltratesRapid onset of respiratory failure and cardiogenic shock",
                    "sub_points": [
                      "Bilateral interstitial pulmonary infiltrates",
                      "Rapid onset of respiratory failure and cardiogenic shock"
                    ]
                  },
                  {
                    "text": "Treatment is primarily supportive36% case fatality rate",
                    "sub_points": [
                      "36% case fatality rate"
                    ]
                  },
                  {
                    "text": "Serologic tests are sensitive and specificEnzyme-linked immunosorbent assays (ELISAs)",
                    "sub_points": [
                      "Enzyme-linked immunosorbent assays (ELISAs)"
                    ]
                  },
                  {
                    "text": "Cases reported from 31 statesPrimarily rural areas",
                    "sub_points": [
                      "Primarily rural areas"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Combined peripheral blood findings are predictive of infectionPresent if all 5 morphologic criteria are seenIf 4 of 5 morphologic criteria identified, highly predictive of diffuse pulmonary infiltrates",
                    "sub_points": [
                      "Present if all 5 morphologic criteria are seen",
                      "If 4 of 5 morphologic criteria identified, highly predictive of diffuse pulmonary infiltrates"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Acute respiratory distress syndrome"
                  },
                  {
                    "text": "Other viral infections"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Hantavirus pulmonary syndrome (HPS)"
                  },
                  {
                    "text": "Sin Nombre virus (SNV)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Hantavirus cardiopulmonary syndrome"
                  },
                  {
                    "text": "Four Corners disease"
                  }
                ],
                "Definitions": [
                  {
                    "text": "GenusHantavirusresides in family Bunyaviridae"
                  },
                  {
                    "text": "> 22 different hantaviruses are pathogenic to humansOld World strains of hantavirusPrimarily in Asia and EuropeAssociated disease is hemorrhagic fever with renal syndromeNew World strains of hantavirusPrimarily in AmericasAssociated disease is HPS> 15 hantaviruses associated with HPSHPS in North AmericaSNV strain is most common in US and CanadaAlso Monongahela, New York, Black Creek Canal, and Bayou viruses in USA",
                    "sub_points": [
                      "Old World strains of hantavirusPrimarily in Asia and EuropeAssociated disease is hemorrhagic fever with renal syndrome",
                      "Primarily in Asia and Europe",
                      "Associated disease is hemorrhagic fever with renal syndrome",
                      "New World strains of hantavirusPrimarily in AmericasAssociated disease is HPS> 15 hantaviruses associated with HPS",
                      "Primarily in Americas",
                      "Associated disease is HPS",
                      "> 15 hantaviruses associated with HPS",
                      "HPS in North AmericaSNV strain is most common in US and CanadaAlso Monongahela, New York, Black Creek Canal, and Bayou viruses in USA",
                      "SNV strain is most common in US and Canada",
                      "Also Monongahela, New York, Black Creek Canal, and Bayou viruses in USA"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Environmental Exposure": [
                  {
                    "text": "Each hantavirus is closely associated with a specific rodent reservoirSNVinfectsPeromyscus maniculatusor deer mouseResides in most of North America except few states in southeastern USA and southern MexicoCotton rat in Florida; swamp rat in Texas, LouisianaRodents have chronic persistent infections",
                    "sub_points": [
                      "SNVinfectsPeromyscus maniculatusor deer mouseResides in most of North America except few states in southeastern USA and southern Mexico",
                      "Resides in most of North America except few states in southeastern USA and southern Mexico",
                      "Cotton rat in Florida; swamp rat in Texas, Louisiana",
                      "Rodents have chronic persistent infections"
                    ]
                  },
                  {
                    "text": "Hantavirus transmission to humansOccurs through infected animal excretaInhalation of contaminated aerosolized saliva, urine, or fecesSNV withstands desiccation for daysInactivated by ultraviolet light outdoorsHigher concentrations of virus in closed areas",
                    "sub_points": [
                      "Occurs through infected animal excreta",
                      "Inhalation of contaminated aerosolized saliva, urine, or feces",
                      "SNV withstands desiccation for daysInactivated by ultraviolet light outdoorsHigher concentrations of virus in closed areas",
                      "Inactivated by ultraviolet light outdoors",
                      "Higher concentrations of virus in closed areas"
                    ]
                  }
                ],
                "Infectious Agents": [
                  {
                    "text": "Hantavirus is spherical and encapsulated by bilayered phospholipid membraneAverages 80-120 nm in diameterLarger viral glycoproteins interact with receptors on host cellsSNV binds to β3 integrin proteins and possibly other receptors for cell entry",
                    "sub_points": [
                      "Averages 80-120 nm in diameter",
                      "Larger viral glycoproteins interact with receptors on host cellsSNV binds to β3 integrin proteins and possibly other receptors for cell entry",
                      "SNV binds to β3 integrin proteins and possibly other receptors for cell entry"
                    ]
                  },
                  {
                    "text": "Hantaviruses primarily target vascular endothelial cellsAlso infect alveolar macrophages and follicular dendritic cells",
                    "sub_points": [
                      "Also infect alveolar macrophages and follicular dendritic cells"
                    ]
                  }
                ],
                "HPS Pathogenesis": [
                  {
                    "text": "Virus replicates in endothelial cells and macrophagesHigh levels of viral antigens in pulmonary vasculatureInduces immune activation with inflammatory cell recruitment to lungsMacrophages and activated hantavirus-specific T cells produce excess cytokinesCauses changes in vascular permeabilityMinimal direct viral cytopathic effects",
                    "sub_points": [
                      "High levels of viral antigens in pulmonary vasculature",
                      "Induces immune activation with inflammatory cell recruitment to lungsMacrophages and activated hantavirus-specific T cells produce excess cytokinesCauses changes in vascular permeability",
                      "Macrophages and activated hantavirus-specific T cells produce excess cytokines",
                      "Causes changes in vascular permeability",
                      "Minimal direct viral cytopathic effects"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "HPS first recognized in May 1993 in Four Corners region of southwest USA~75% of reported cases from rural areas~ 50% of reported cases from Four Corners area",
                    "sub_points": [
                      "~75% of reported cases from rural areas",
                      "~ 50% of reported cases from Four Corners area"
                    ]
                  },
                  {
                    "text": "~ 200 cases of HPS per year reported in AmericasNorth America: Canada, US, MexicoCentral America: PanamaSouth America: Argentina, Bolivia, Brazil, Chile, Paraguay, Uruguay",
                    "sub_points": [
                      "North America: Canada, US, Mexico",
                      "Central America: Panama",
                      "South America: Argentina, Bolivia, Brazil, Chile, Paraguay, Uruguay"
                    ]
                  },
                  {
                    "text": "Incidence of HPS is likely underreportedAsymptomatic or nonspecific mild infectionsSome species linked to less severe disease",
                    "sub_points": [
                      "Asymptomatic or nonspecific mild infections",
                      "Some species linked to less severe disease"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Average age is 38 yearsRange is 10-83 yearsRare among prepubertal individuals",
                    "sub_points": [
                      "Range is 10-83 years",
                      "Rare among prepubertal individuals"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "4 clinical phasesProdromal phase lasts 3-5 daysMost frequent: Fever, chills, myalgiasFrequent: Headaches, nausea, vomiting, abdominal pain, diarrhea, cough, malaiseOther: Shortness of breath, dizziness, arthralgias, sweatsIncubation period after exposure is 9-33 days (usually 14-17 days)Pulmonary edema and shockProgression from prodromal phase is often abruptLung capillary leakage with respiratory failureAcute onset of pulmonary edemaTachypnea, tachycardia, postural hypotensionIntravascular volume depletionProgressive myocardial insufficiencyMortality from cardiogenic shock usually occurs in first 24 hoursPhase lasts from 3-6 days in survivorsDiuresisUrine flow rates of 300-500 mL/hRapid resolution of respiratory and hemodynamic abnormalities (24-48 hours)ConvalescenceFew months to 2 years for full recovery",
                    "sub_points": [
                      "Prodromal phase lasts 3-5 daysMost frequent: Fever, chills, myalgiasFrequent: Headaches, nausea, vomiting, abdominal pain, diarrhea, cough, malaiseOther: Shortness of breath, dizziness, arthralgias, sweatsIncubation period after exposure is 9-33 days (usually 14-17 days)",
                      "Most frequent: Fever, chills, myalgias",
                      "Frequent: Headaches, nausea, vomiting, abdominal pain, diarrhea, cough, malaise",
                      "Other: Shortness of breath, dizziness, arthralgias, sweats",
                      "Incubation period after exposure is 9-33 days (usually 14-17 days)",
                      "Pulmonary edema and shockProgression from prodromal phase is often abruptLung capillary leakage with respiratory failureAcute onset of pulmonary edemaTachypnea, tachycardia, postural hypotensionIntravascular volume depletionProgressive myocardial insufficiencyMortality from cardiogenic shock usually occurs in first 24 hoursPhase lasts from 3-6 days in survivors",
                      "Progression from prodromal phase is often abrupt",
                      "Lung capillary leakage with respiratory failure",
                      "Acute onset of pulmonary edema",
                      "Tachypnea, tachycardia, postural hypotension",
                      "Intravascular volume depletion",
                      "Progressive myocardial insufficiency",
                      "Mortality from cardiogenic shock usually occurs in first 24 hours",
                      "Phase lasts from 3-6 days in survivors",
                      "DiuresisUrine flow rates of 300-500 mL/hRapid resolution of respiratory and hemodynamic abnormalities (24-48 hours)",
                      "Urine flow rates of 300-500 mL/h",
                      "Rapid resolution of respiratory and hemodynamic abnormalities (24-48 hours)",
                      "ConvalescenceFew months to 2 years for full recovery",
                      "Few months to 2 years for full recovery"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "CBC and peripheral smear reviewRepeat CBC if hantavirus infection is suspectedEvery 4 hours if findings are suggestive but not sufficient to meet criteria",
                    "sub_points": [
                      "Repeat CBC if hantavirus infection is suspectedEvery 4 hours if findings are suggestive but not sufficient to meet criteria",
                      "Every 4 hours if findings are suggestive but not sufficient to meet criteria"
                    ]
                  },
                  {
                    "text": "Blood chemistry panelFall in serum albumin (along with increase in hematocrit)Indicates fluid shift from vasculature to lungsIncreased AST, ALT, LDH",
                    "sub_points": [
                      "Fall in serum albumin (along with increase in hematocrit)Indicates fluid shift from vasculature to lungs",
                      "Indicates fluid shift from vasculature to lungs",
                      "Increased AST, ALT, LDH"
                    ]
                  },
                  {
                    "text": "Serologic testsPlaque reduction neutralization test (PRNT)Gold standard testDiscriminates between different species of HantavirusRequires biosafety level 3 laboratory, which limits availabilityEnzyme-linked immunosorbent assays (ELISAs)Indirect IgG and IgM ELISA to nucleocapsid (N) antigenIgM-capture ELISAEnzyme immunoassay (EIA), strip immunoblot assay (SIA)",
                    "sub_points": [
                      "Plaque reduction neutralization test (PRNT)Gold standard testDiscriminates between different species of HantavirusRequires biosafety level 3 laboratory, which limits availability",
                      "Gold standard test",
                      "Discriminates between different species of Hantavirus",
                      "Requires biosafety level 3 laboratory, which limits availability",
                      "Enzyme-linked immunosorbent assays (ELISAs)Indirect IgG and IgM ELISA to nucleocapsid (N) antigenIgM-capture ELISA",
                      "Indirect IgG and IgM ELISA to nucleocapsid (N) antigen",
                      "IgM-capture ELISA",
                      "Enzyme immunoassay (EIA), strip immunoblot assay (SIA)"
                    ]
                  },
                  {
                    "text": "RT-PCR for hantavirus-specific RNA sequence"
                  },
                  {
                    "text": "Immunohistochemistry for hantavirus antigen in formalin-fixed tissues"
                  }
                ],
                "Treatment": [
                  {
                    "text": "No FDA-approved antivirals, vaccines, or immunotherapeutics available"
                  },
                  {
                    "text": "Treatment is primarily supportiveEarly admission to hospital if compatible historyThrombocytopenia or atypical lymphocytes presentIntensive care unit if evidence of pulmonary interstitial edemaIntubation and mechanical ventilation as requiredContinuous cardiac output monitoringExtracorporeal membrane oxygenation (ECMO) if available",
                    "sub_points": [
                      "Early admission to hospital if compatible historyThrombocytopenia or atypical lymphocytes present",
                      "Thrombocytopenia or atypical lymphocytes present",
                      "Intensive care unit if evidence of pulmonary interstitial edemaIntubation and mechanical ventilation as requiredContinuous cardiac output monitoringExtracorporeal membrane oxygenation (ECMO) if available",
                      "Intubation and mechanical ventilation as required",
                      "Continuous cardiac output monitoring",
                      "Extracorporeal membrane oxygenation (ECMO) if available"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Poor if pulmonary edema and cardiac arrhythmias develop36% case fatality rate as of December 2009",
                    "sub_points": [
                      "36% case fatality rate as of December 2009"
                    ]
                  },
                  {
                    "text": "Neuropsychological impairments in some survivors"
                  }
                ],
                "Prevention": [
                  {
                    "text": "Reduce human exposure to rodent excrementReduce ability for rodents to enter dwellingsAppropriate cleaning of rodent-contaminated areasInactivate virus by detergents, heat, UV radiation, organic solvents, hypochlorite solutionsPreventive measures for individuals with occupational exposure (i.e., masks)",
                    "sub_points": [
                      "Reduce ability for rodents to enter dwellings",
                      "Appropriate cleaning of rodent-contaminated areasInactivate virus by detergents, heat, UV radiation, organic solvents, hypochlorite solutions",
                      "Inactivate virus by detergents, heat, UV radiation, organic solvents, hypochlorite solutions",
                      "Preventive measures for individuals with occupational exposure (i.e., masks)"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Peripheral Blood Findings": [
                  {
                    "text": "Thrombocytopenia is early finding~ 80% of patients at presentation",
                    "sub_points": [
                      "~ 80% of patients at presentation"
                    ]
                  },
                  {
                    "text": "White blood cellsCommonly increased with neutrophilia without significant toxic changesCirculating myelocytes and metamyelocytesLymphocytes are often normal or decreased in numberCirculatory immunoblasts/plasma cells",
                    "sub_points": [
                      "Commonly increased with neutrophilia without significant toxic changesCirculating myelocytes and metamyelocytes",
                      "Circulating myelocytes and metamyelocytes",
                      "Lymphocytes are often normal or decreased in number",
                      "Circulatory immunoblasts/plasma cells"
                    ]
                  },
                  {
                    "text": "Increased hematocritIndicates capillary leakage and hemoconcentration",
                    "sub_points": [
                      "Indicates capillary leakage and hemoconcentration"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Acute Respiratory Disease Syndrome (ARDS)": [
                  {
                    "text": "Frequent history of predisposing medical conditionChronic pulmonary disease, malignancy, trauma, burn, surgery",
                    "sub_points": [
                      "Chronic pulmonary disease, malignancy, trauma, burn, surgery"
                    ]
                  }
                ],
                "Other Viral Infections": [
                  {
                    "text": "Clinical findings indistinguishable from prodromal phase of HPSUsually do not have left-shifted neutrophilia with myelocytes",
                    "sub_points": [
                      "Usually do not have left-shifted neutrophilia with myelocytes"
                    ]
                  }
                ],
                "Acute Cardiopulmonary Deterioration in Immunocompetent Individuals": [
                  {
                    "text": "InfectionsLeptospirosis, Legionnaires disease, mycoplasma, Q fever, chlamydiaSepticemic plague, tularemia, coccidioidomycosis, and histoplasmosis in endemic areas",
                    "sub_points": [
                      "Leptospirosis, Legionnaires disease, mycoplasma, Q fever, chlamydia",
                      "Septicemic plague, tularemia, coccidioidomycosis, and histoplasmosis in endemic areas"
                    ]
                  },
                  {
                    "text": "NoninfectiousGoodpasture syndrome",
                    "sub_points": [
                      "Goodpasture syndrome"
                    ]
                  }
                ],
                "Hemorrhagic Fever with Renal Syndrome": [
                  {
                    "text": "Primarily found in Asia"
                  },
                  {
                    "text": "Peripheral blood findings may be similar to HPSLeukocytosis, immunoblasts, thrombocytopenia",
                    "sub_points": [
                      "Leukocytosis, immunoblasts, thrombocytopenia"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Combined peripheral blood findings impart high index of suspicion for HPS"
                  },
                  {
                    "text": "Left-shifted neutrophilia without toxic features is unusual for other viral infections"
                  },
                  {
                    "text": "Increase of immunoblasts/plasma cells helps to exclude ARDS"
                  },
                  {
                    "text": "Add HPS to differential diagnosis if increased circulating immunoblasts/plasma cellsIn combination with at least 1 of the followingCirculating neutrophilic precursors without toxic featuresHemoconcentrationLow normal to normal platelet count",
                    "sub_points": [
                      "In combination with at least 1 of the followingCirculating neutrophilic precursors without toxic featuresHemoconcentrationLow normal to normal platelet count",
                      "Circulating neutrophilic precursors without toxic features",
                      "Hemoconcentration",
                      "Low normal to normal platelet count"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Whipple Disease": {
            "name": "Whipple Disease",
            "url": "https://app.pathprimer.com/document/68de9280-9f86-4c51-bfd1-53bab97d85ac/lesson/6e5627b8-d0a0-4739-ae70-d53f34f8cfcd",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Systemic infection caused byT. whipplei"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "T. whippleiis gram-positive bacillus ubiquitously found in soil, animals, and healthy individuals"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Extremely rare disease with middle-aged male predominance"
                  },
                  {
                    "text": "Four cardinal manifestations: arthralgia, diarrhea, abdominal pain, weight loss"
                  },
                  {
                    "text": "Prolonged antibiotic therapy needed with potential IRIS"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "PAS (with diastase)-positive and AFB-negative foamy macrophages in lymph node sinuses and small bowel mucosa"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Positive on Gram stain, Gomori methenamine silver stain, and Giemsa stain; PCR performed on CSF is required to rule out CNS involvement"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Mycobacterial infections includingM. avium-intracellularecomplex infection,M. leprae,M. tuberculosis"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Central nervous system (CNS)"
                  },
                  {
                    "text": "Erythrocyte sedimentation rate (ESR)"
                  },
                  {
                    "text": "Immune reconstitution inflammatory syndrome (IRIS)"
                  },
                  {
                    "text": "Periodic acid-Schiff (PAS)"
                  },
                  {
                    "text": "Acid-fast bacillus (AFB)"
                  },
                  {
                    "text": "Polymerase chain reaction (PCR)"
                  },
                  {
                    "text": "Cerebrospinal fluid (CSF)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Whipple disease"
                  },
                  {
                    "text": "Intestinal lipodystrophy"
                  },
                  {
                    "text": "Tropheryma whippleiinfection"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Systemic infectious disease caused by bacteriumT. whipplei(formerlyTropheryma whippelii)"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Environmental Exposure": [
                  {
                    "text": "Ubiquitously found in soil, animals, and healthy individuals (especially farm and sewage workers)"
                  },
                  {
                    "text": "Fecal-oral transmission postulated"
                  }
                ],
                "Infectious Agents": [
                  {
                    "text": "T. whippleiGram-positive bacillus related to ActinomycetalesPhagocytosed by macrophages",
                    "sub_points": [
                      "Gram-positive bacillus related to Actinomycetales",
                      "Phagocytosed by macrophages"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Extremely rare—approximately 30 cases annually"
                  }
                ],
                "Age": [
                  {
                    "text": "Common in middle-aged adultsMean age 49 yr",
                    "sub_points": [
                      "Mean age 49 yr"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "Male (86%) > female"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Diarrheal symptoms (e.g., steatorrhea) with weight loss"
                  },
                  {
                    "text": "Abdominal lymphadenopathy in approximately 50% of patients"
                  },
                  {
                    "text": "Extraintestinal sitesCNSCognitive changesHeart valvesEndocarditisJointsArthralgiasSkinHyperpigmentation in approximately 40% of cases secondary to malabsorption of vitamin D",
                    "sub_points": [
                      "CNSCognitive changes",
                      "Cognitive changes",
                      "Heart valvesEndocarditis",
                      "Endocarditis",
                      "JointsArthralgias",
                      "Arthralgias",
                      "SkinHyperpigmentation in approximately 40% of cases secondary to malabsorption of vitamin D",
                      "Hyperpigmentation in approximately 40% of cases secondary to malabsorption of vitamin D"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Anemia"
                  },
                  {
                    "text": "Elevated ESR"
                  },
                  {
                    "text": "Hypoalbuminemia"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Prolonged antibiotic therapyIntravenous penicillin or ceftriaxone for 2-4 weeksFollowed by maintenance oral trimethoprim-sulfamethoxazole for 1-2 yrImportant to select antibiotic that crosses blood-brain barrier",
                    "sub_points": [
                      "Intravenous penicillin or ceftriaxone for 2-4 weeksFollowed by maintenance oral trimethoprim-sulfamethoxazole for 1-2 yr",
                      "Followed by maintenance oral trimethoprim-sulfamethoxazole for 1-2 yr",
                      "Important to select antibiotic that crosses blood-brain barrier"
                    ]
                  },
                  {
                    "text": "IRIS may occur in first few weeks after antibiotic treatmentHigh fever or other symptoms mimicking relapse/progression",
                    "sub_points": [
                      "High fever or other symptoms mimicking relapse/progression"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Fatal without antiobiotic treatment"
                  },
                  {
                    "text": "Relapses in a subset of patients (< 1/3)"
                  },
                  {
                    "text": "CNS involvement associated with poorer response and prognosis"
                  }
                ]
              },
              "IMAGING": {
                "Radiographic Findings": [
                  {
                    "text": "X-ray films of small bowel may reveal thickened folds"
                  },
                  {
                    "text": "Lymphadenopathy"
                  }
                ]
              },
              "MACROSCOPIC": {
                "Endoscopy of Small Bowel": [
                  {
                    "text": "May reveal dilated bowel with multiple pale yellow-white nodules and erythematous eroded patches"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Lymph nodeSinuses with increased number of large, pale histiocytes with vacuoles that are PAS-positiveCystic spaces and poorly formed granulomas may be present",
                    "sub_points": [
                      "Sinuses with increased number of large, pale histiocytes with vacuoles that are PAS-positive",
                      "Cystic spaces and poorly formed granulomas may be present"
                    ]
                  },
                  {
                    "text": "Small intestinePAS-positive foamy macrophages in lamina propriaLoss of villous architecture or lymphatic obstruction may be seen",
                    "sub_points": [
                      "PAS-positive foamy macrophages in lamina propria",
                      "Loss of villous architecture or lymphatic obstruction may be seen"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Histochemistry": [
                  {
                    "text": "Positive stainsPAS (with diastase)Gram stainGomori methenamine silver stainGiemsa stain",
                    "sub_points": [
                      "PAS (with diastase)",
                      "Gram stain",
                      "Gomori methenamine silver stain",
                      "Giemsa stain"
                    ]
                  },
                  {
                    "text": "Pertinent negative stainAFB",
                    "sub_points": [
                      "AFB"
                    ]
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "Anti-T. whippleiantibody stain is positive for bacteria"
                  }
                ],
                "PCR": [
                  {
                    "text": "Detects unique bacterial 16S ribosomal RNA inT. whippleiorganismsPerformed on tissue biopsy specimens or cerebrospinal fluid (CSF)PCR on CSF is required even in the absence of neurologic symptomsUseful for staging and disease monitoring",
                    "sub_points": [
                      "Performed on tissue biopsy specimens or cerebrospinal fluid (CSF)",
                      "PCR on CSF is required even in the absence of neurologic symptoms",
                      "Useful for staging and disease monitoring"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Mycobacterial infection": [
                  {
                    "text": "Mycobacterium avium-intracellularecomplex infectionPAS and acid-fast positive",
                    "sub_points": [
                      "PAS and acid-fast positive"
                    ]
                  },
                  {
                    "text": "Mycobacterium lepraeinfection (leprosy)PAS positive and AFB negative",
                    "sub_points": [
                      "PAS positive and AFB negative"
                    ]
                  },
                  {
                    "text": "Mycobacterium tuberculosisNecrotizing granulomasPAS negative and AFB positive",
                    "sub_points": [
                      "Necrotizing granulomas",
                      "PAS negative and AFB positive"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Cardinal manifestations of arthralgia, diarrhea, abdominal pain, weight loss"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "PAS (with diastase) positive and AFB negative"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Bacillary Angiomatosis": {
            "name": "Bacillary Angiomatosis",
            "url": "https://app.pathprimer.com/document/d7ccd9d6-e921-434a-bab9-4426ce1c197d/lesson/6e5627b8-d0a0-4739-ae70-d53f34f8cfcd",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Nodules of small blood vessels resulting from infection by bacteriumB. henselae"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "B. henselaeandB. quintanaare most common agents isolated from BA"
                  },
                  {
                    "text": "Domestic cats are major reservoir forB. henselae; transmitted by fleas from cat to cat"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Most affected patients are immunosuppressed (e.g., AIDS)"
                  },
                  {
                    "text": "Cutaneous lesions can be 1 or many (up to hundreds)Red to violaceous, dome-shaped papules and nodules",
                    "sub_points": [
                      "Red to violaceous, dome-shaped papules and nodules"
                    ]
                  },
                  {
                    "text": "Lymphadenopathy may be regional or localized to area of trauma"
                  },
                  {
                    "text": "Bacteria can be cultured from clinical specimens such as blood, tissues, or cytologic specimens"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Blood vessels can show spectrum of differentiation"
                  },
                  {
                    "text": "Interstitium shows edema, scattered spindle cells, neutrophils, or foamy histiocytes"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "WS or Giemsa stain can highlight organisms"
                  },
                  {
                    "text": "Monoclonal antibodies specific forB. henselaecan identify bacterial organisms"
                  },
                  {
                    "text": "PCR is helpful to identify organism"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Bacillary angiomatosis (BA)"
                  },
                  {
                    "text": "Warthin-Starry (WS)"
                  },
                  {
                    "text": "Immunofluorescence antibody (IFA)"
                  },
                  {
                    "text": "Kaposi sarcoma (KS)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Epithelioid angiomatosis"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Nodules of small blood vessels resulting from infection by bacteriumBartonella henselae"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Infectious Agents": [
                  {
                    "text": "B. henselaeis most common agent isolated from BASmall, curved, motile, gram-negative bacilli, oxidase-negativeCulture is difficult, and bacteria may take 2-6 weeks to growGrowth requires CO₂ rich environment and enriched mediaBetter yield in patients with systemic disease; poor yield from tissuesIsolates may be obtained in 40% of cases of BA and 6% of cases with cat-scratch disease",
                    "sub_points": [
                      "Small, curved, motile, gram-negative bacilli, oxidase-negative",
                      "Culture is difficult, and bacteria may take 2-6 weeks to growGrowth requires CO₂ rich environment and enriched mediaBetter yield in patients with systemic disease; poor yield from tissuesIsolates may be obtained in 40% of cases of BA and 6% of cases with cat-scratch disease",
                      "Growth requires CO₂ rich environment and enriched media",
                      "Better yield in patients with systemic disease; poor yield from tissues",
                      "Isolates may be obtained in 40% of cases of BA and 6% of cases with cat-scratch disease"
                    ]
                  },
                  {
                    "text": "Bartonella quintana, the agent of trench fever, also can cause BA"
                  },
                  {
                    "text": "Bartonellaenters endothelial cells by endocytosisGives rise toBartonella-containing vacuoles or by invasome-mediated internalizationInvasome involves formation of cell surface-associated bacterial aggregates, which are engulfed",
                    "sub_points": [
                      "Gives rise toBartonella-containing vacuoles or by invasome-mediated internalization",
                      "Invasome involves formation of cell surface-associated bacterial aggregates, which are engulfed"
                    ]
                  },
                  {
                    "text": "Bartonellaeffector protein A BepA and VirB/VirD4 type IV secretion system are associated with vascular sprout formation"
                  },
                  {
                    "text": "B. henselaeis name adopted since 1993Earlier name:Rochalimaea henselae",
                    "sub_points": [
                      "Earlier name:Rochalimaea henselae"
                    ]
                  }
                ],
                "Susceptibility": [
                  {
                    "text": "B. henselaeinfections in patients with HIV infection can manifest as BAHIV(+) homosexual patients, intravenous drug users, and transfusion recipients are at riskRarely, patients with other types of immunosuppression can develop BA",
                    "sub_points": [
                      "HIV(+) homosexual patients, intravenous drug users, and transfusion recipients are at risk",
                      "Rarely, patients with other types of immunosuppression can develop BA"
                    ]
                  },
                  {
                    "text": "B. henselaeinfections in immunocompetent patients can result in cat-scratch disease"
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "Domestic cats are major reservoir forB. henselaeTransmitted by cat fleas from cat to catUp to 1/2 of domestic cats carry anti-B. henselaeantibodies",
                    "sub_points": [
                      "Transmitted by cat fleas from cat to cat",
                      "Up to 1/2 of domestic cats carry anti-B. henselaeantibodies"
                    ]
                  },
                  {
                    "text": "B. henselaecauses bacteremia in cats; organism colonizes erythrocytes"
                  },
                  {
                    "text": "Bacilli are transmitted to humans through bite or scratch of infested cat"
                  },
                  {
                    "text": "B. quintanais unusual cause of BAB. quintanais more frequently associated with \"urban trench fever\"Trench fever is characterized by recurrent and cycling fevers, malaise, bone pain, and splenomegalyHomeless persons exposed to human louse (Pediculus humanus corporis) are more susceptible toB. quintana",
                    "sub_points": [
                      "B. quintanais more frequently associated with \"urban trench fever\"Trench fever is characterized by recurrent and cycling fevers, malaise, bone pain, and splenomegalyHomeless persons exposed to human louse (Pediculus humanus corporis) are more susceptible toB. quintana",
                      "Trench fever is characterized by recurrent and cycling fevers, malaise, bone pain, and splenomegaly",
                      "Homeless persons exposed to human louse (Pediculus humanus corporis) are more susceptible toB. quintana"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Most affected patients are immunosuppressed as a result of HIV infectionBA is uncommon but can occur in patients with other types of immunosuppressionVery rare cases of BA occur in immunocompetent persons",
                    "sub_points": [
                      "BA is uncommon but can occur in patients with other types of immunosuppression",
                      "Very rare cases of BA occur in immunocompetent persons"
                    ]
                  },
                  {
                    "text": "Many patients are men; 31-56 yr oldIn large part, this correlates with high percentage of HIV(+) men",
                    "sub_points": [
                      "In large part, this correlates with high percentage of HIV(+) men"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Cutaneous BA may show concomitant involvement of other sitesMucous membranes, lymph nodes, soft tissues, spleen, liver, and bones",
                    "sub_points": [
                      "Mucous membranes, lymph nodes, soft tissues, spleen, liver, and bones"
                    ]
                  },
                  {
                    "text": "Cutaneous lesionsSingle up to many (hundreds), red to violaceous, dome-shaped papules and nodulesTrunk and extremities are preferentially affected",
                    "sub_points": [
                      "Single up to many (hundreds), red to violaceous, dome-shaped papules and nodules",
                      "Trunk and extremities are preferentially affected"
                    ]
                  },
                  {
                    "text": "Lymph node involvement is more frequently associated withB. henselaethan withB. quintanaLymphadenopathy may be regional or localized to area of trauma",
                    "sub_points": [
                      "Lymphadenopathy may be regional or localized to area of trauma"
                    ]
                  },
                  {
                    "text": "Extracutaneous involvement can occur in absence of concurrent skin lesions"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "No specific hematologic changes"
                  },
                  {
                    "text": "Bacteria can be cultured from clinical specimensBloodTissuesCytologic specimens",
                    "sub_points": [
                      "Blood",
                      "Tissues",
                      "Cytologic specimens"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Patients with BA can benefit from erythromycin or doxycycline"
                  },
                  {
                    "text": "Hepatosplenic disease may benefit from trimethoprim-sulfamethoxazole, gentamicin, ciprofloxacin, and rifampin"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Most skin lesions resolve spontaneously"
                  },
                  {
                    "text": "Early diagnosis of various affected organs leads to cure"
                  },
                  {
                    "text": "Unrecognized progressive disease can be fatal"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Lymph nodes involved by BA typically drain skin lesionsNodules composed of blood vessels of variable size and shapeVascular nodules can become confluent and form large massesBlood vessels show spectrum of differentiationRound, large, irregular, or ectatic to small solid clusters with barely visible luminaEndothelial nuclei are prominent, with single or multiple small nucleoliUsually no multilayering of endothelial cells lining vesselsMitotic figures are present; up to 3-5 per high-power fieldBlood vessels can be surrounded by deeply eosinophilic interstitial materialCorresponds to bacterial aggregatesInterstitium may show loculated edema, scattered spindle cells, and inflammatory cells",
                    "sub_points": [
                      "Nodules composed of blood vessels of variable size and shapeVascular nodules can become confluent and form large masses",
                      "Vascular nodules can become confluent and form large masses",
                      "Blood vessels show spectrum of differentiationRound, large, irregular, or ectatic to small solid clusters with barely visible lumina",
                      "Round, large, irregular, or ectatic to small solid clusters with barely visible lumina",
                      "Endothelial nuclei are prominent, with single or multiple small nucleoliUsually no multilayering of endothelial cells lining vessels",
                      "Usually no multilayering of endothelial cells lining vessels",
                      "Mitotic figures are present; up to 3-5 per high-power field",
                      "Blood vessels can be surrounded by deeply eosinophilic interstitial materialCorresponds to bacterial aggregates",
                      "Corresponds to bacterial aggregates",
                      "Interstitium may show loculated edema, scattered spindle cells, and inflammatory cells"
                    ]
                  },
                  {
                    "text": "SkinSkin lesions can affect upper or deep dermis and subcutisLobules of newly formed blood vesselsCytologically similar to those in lymph nodeOverlying epidermis may be thin",
                    "sub_points": [
                      "Skin lesions can affect upper or deep dermis and subcutis",
                      "Lobules of newly formed blood vesselsCytologically similar to those in lymph node",
                      "Cytologically similar to those in lymph node",
                      "Overlying epidermis may be thin"
                    ]
                  },
                  {
                    "text": "Peliosis hepatis &/or peliosis splenis can occurCystic, blood-filled spaces in liver and spleenCan occur in immunocompromised patients",
                    "sub_points": [
                      "Cystic, blood-filled spaces in liver and spleen",
                      "Can occur in immunocompromised patients"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Histochemistry": [
                  {
                    "text": "WS stain highlights bacteria that appear as clumps of rods or as individual small rodsBacteria can be found within endothelial cells or in macrophagesWS stain is technically difficultSkill is required to avoid precipitate that mimics bacterial organismsInterpretation of good quality stain can be time consumingClusters of bacteria appear around blood vesselsCorrespond to perivascular eosinophilic deposition seen on H&E stain",
                    "sub_points": [
                      "Bacteria can be found within endothelial cells or in macrophagesWS stain is technically difficultSkill is required to avoid precipitate that mimics bacterial organismsInterpretation of good quality stain can be time consuming",
                      "WS stain is technically difficultSkill is required to avoid precipitate that mimics bacterial organisms",
                      "Skill is required to avoid precipitate that mimics bacterial organisms",
                      "Interpretation of good quality stain can be time consuming",
                      "Clusters of bacteria appear around blood vesselsCorrespond to perivascular eosinophilic deposition seen on H&E stain",
                      "Correspond to perivascular eosinophilic deposition seen on H&E stain"
                    ]
                  },
                  {
                    "text": "Giemsa stain may also highlight bacteria; appear violaceous"
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "FVIIIRAg(+), ULEX-1(+)Highlight endothelial cellsReactivity correlates with degree of differentiation",
                    "sub_points": [
                      "Highlight endothelial cells",
                      "Reactivity correlates with degree of differentiation"
                    ]
                  },
                  {
                    "text": "CD31(+), CD34(+) in most cases"
                  },
                  {
                    "text": "Monoclonal anti-B. henselaeantibody reacts in fixed paraffin-embedded tissueCan confirm presence of bacteria",
                    "sub_points": [
                      "Can confirm presence of bacteria"
                    ]
                  }
                ],
                "PCR": [
                  {
                    "text": "Primer sets specific for organism are available"
                  },
                  {
                    "text": "Useful for identifying disease"
                  },
                  {
                    "text": "Amplification ofB. henselae ﻿16S rRNA﻿gene, citrate synthasegltAorhtrAgenes have been usedSensitivity 45%-75%Specificity near 100%",
                    "sub_points": [
                      "Sensitivity 45%-75%",
                      "Specificity near 100%"
                    ]
                  }
                ],
                "Serologic Testing": [
                  {
                    "text": "Variable results due to variable methodologies and antigenic preparations"
                  },
                  {
                    "text": "As a result of immunosuppression, BA patients do not mount good serologic responseIn 1 study, 2% of patients had antibodies toB. henselaeby IFA25% of patients had antibodies toB. quintanaby IFA",
                    "sub_points": [
                      "In 1 study, 2% of patients had antibodies toB. henselaeby IFA25% of patients had antibodies toB. quintanaby IFA",
                      "25% of patients had antibodies toB. quintanaby IFA"
                    ]
                  },
                  {
                    "text": "Prevalence ofBartonellaantibodies in general population is approximately 5%"
                  },
                  {
                    "text": "Patients with \"urban trench fever\" develop significant titers toBartonella"
                  }
                ],
                "Electron Microscopy": [
                  {
                    "text": "Organisms are intracellular and extracellularClumps in endothelial cells or surrounding blood vessels0.2-0.3 μm; pleomorphic; trilaminar walls",
                    "sub_points": [
                      "Clumps in endothelial cells or surrounding blood vessels",
                      "0.2-0.3 μm; pleomorphic; trilaminar walls"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Kaposi Sarcoma": [
                  {
                    "text": "Clinical presentation and susceptible patient population identical to BA"
                  },
                  {
                    "text": "KS develops initially in lymph node capsule and then infiltrates along trabeculae and vessels"
                  },
                  {
                    "text": "Blood vessels can show spectrum of differentiationSlit-like and poorly formed as well as ectatic irregular blood vessels",
                    "sub_points": [
                      "Slit-like and poorly formed as well as ectatic irregular blood vessels"
                    ]
                  },
                  {
                    "text": "Neoplastic spindle cells are arranged in fascicles with extravasation of erythrocytes"
                  },
                  {
                    "text": "KS is associated withPlasma cell infiltrate and hemosiderin depositionEosinophilic hyaline globules",
                    "sub_points": [
                      "Plasma cell infiltrate and hemosiderin deposition",
                      "Eosinophilic hyaline globules"
                    ]
                  },
                  {
                    "text": "Less neutrophils in KS than in BA"
                  }
                ],
                "Vascular Transformation of Lymph Node Sinuses": [
                  {
                    "text": "Preserved lymph node architecture with expanded sinuses"
                  },
                  {
                    "text": "Sinuses are transformed into blood-filled vascular spaces with flat endothelial cellsAbsence of inflammatory cellsMinimal or substantial sclerotic stroma",
                    "sub_points": [
                      "Absence of inflammatory cells",
                      "Minimal or substantial sclerotic stroma"
                    ]
                  }
                ],
                "Vascular Proliferation in HIV(+) Lymphadenopathy": [
                  {
                    "text": "Interfollicular small blood vessel proliferation associated with floridly hyperplastic germinal centers"
                  },
                  {
                    "text": "Small vessels are numerous, mature, and thick-walled with small endothelial cells"
                  }
                ],
                "Angiosarcoma": [
                  {
                    "text": "Infiltrative pattern with interanastomosing vessels"
                  },
                  {
                    "text": "Multilayering of endothelial cells"
                  },
                  {
                    "text": "Nuclear atypia and frequent mitoses"
                  }
                ],
                "Epithelioid Hemangioendothelioma": [
                  {
                    "text": "Histologically may simulate BA with solid growth pattern but rare in lymph nodes"
                  },
                  {
                    "text": "Cytoplasm of tumor cells is hyaline rather than pale appearance of BA"
                  }
                ],
                "Pyogenic Granuloma of Skin": [
                  {
                    "text": "Lobules composed of small blood vessels in upper or lower dermis or subcutaneousCollarette is more frequent in pyogenic granuloma than in BA",
                    "sub_points": [
                      "Collarette is more frequent in pyogenic granuloma than in BA"
                    ]
                  },
                  {
                    "text": "Endothelial cells are flat; no atypia"
                  },
                  {
                    "text": "Neutrophils mainly in superficial dermis, not throughout skin as in BA"
                  }
                ],
                "Verruca Peruana (Carrion Disease)": [
                  {
                    "text": "Endemic disease in Andean Mountains of South America, caused byB. bacilliformisInitially manifests as acute hemolytic anemia with intraerythrocytic bacteria and high fever (Oroya fever)Survivors of acute phase present with eruptive phase; numerous macules and papules in skin of extremities",
                    "sub_points": [
                      "Initially manifests as acute hemolytic anemia with intraerythrocytic bacteria and high fever (Oroya fever)",
                      "Survivors of acute phase present with eruptive phase; numerous macules and papules in skin of extremities"
                    ]
                  },
                  {
                    "text": "Vascular nodules are histologically identical to BA"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Usually occurs in setting of immunosuppression"
                  },
                  {
                    "text": "Recognition of organisms can lead to antibiotic therapy"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Vascular proliferation of poorly and well-formed blood vessels; plump endothelial cell nuclei"
                  },
                  {
                    "text": "Background of inflammatory cells"
                  },
                  {
                    "text": "Immunohistochemistry or PCR may be used to identify organism and confirm diagnosis"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Cat-Scratch Disease": {
            "name": "Cat-Scratch Disease",
            "url": "https://app.pathprimer.com/document/5df85585-ab63-425a-908e-e8eeb972b94d/lesson/6e5627b8-d0a0-4739-ae70-d53f34f8cfcd",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "B. henselaecauses most cases of CSD"
                  },
                  {
                    "text": "Approximately 90% of patients report contact with cats"
                  },
                  {
                    "text": "B. henselaein immunocompromised patients can cause bacillary angiomatosis"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Primary lesion in skin appears as 0.5-1 cm erythematous papule at site of cat scratch"
                  },
                  {
                    "text": "Regional lymphadenopathy appears 1-3 weeks after inoculation"
                  },
                  {
                    "text": "In immunocompetent patients, disease is self-limited and confined to lymph nodes"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Follicular lymphoid hyperplasia with prominent germinal centers"
                  },
                  {
                    "text": "Early lesions show eosinophilic necrosis admixed with neutrophils in subcapsular sinus"
                  },
                  {
                    "text": "Advanced changes show stellate necrotizing microabscesses and granulomas"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Bacteria are more easily identified by immunohistochemistry than by Warthin-Starry stain"
                  },
                  {
                    "text": "Serology is considered a practical method for diagnosis, but it has shortcomings"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Cat-scratch disease (CSD)"
                  },
                  {
                    "text": "Indirect fluorescence assay (IFA)"
                  },
                  {
                    "text": "Enzyme immunoassay (EIA)"
                  },
                  {
                    "text": "Gomori methenamine silver (GMS)"
                  },
                  {
                    "text": "Periodic acid-Schiff (PAS)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Parinaud oculoglandular syndrome"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Necrotizing inflammation caused byBartonella henselae"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Infectious Agents": [
                  {
                    "text": "B. henselaecauses most cases of CSDBartonellaquintanacauses a few CSD casesPatients with CSD are usually immunocompetent",
                    "sub_points": [
                      "Bartonellaquintanacauses a few CSD cases",
                      "Patients with CSD are usually immunocompetent"
                    ]
                  },
                  {
                    "text": "B. henselaeis name adopted since 1993Earlier names wereAfipia felisandRochalimaea henselaeBacteria are small, pleomorphic, curved, motile, gram-negative bacilli, oxidase-negativeCulture is difficultBacteria can take 2-6 weeks to growBetter yield in systemic diseasePoor yield from lymph node",
                    "sub_points": [
                      "Earlier names wereAfipia felisandRochalimaea henselae",
                      "Bacteria are small, pleomorphic, curved, motile, gram-negative bacilli, oxidase-negative",
                      "Culture is difficultBacteria can take 2-6 weeks to growBetter yield in systemic diseasePoor yield from lymph node",
                      "Bacteria can take 2-6 weeks to grow",
                      "Better yield in systemic diseasePoor yield from lymph node",
                      "Poor yield from lymph node"
                    ]
                  },
                  {
                    "text": "Patients report contact with cats in 90% of casesApproximately 60% of patients report antecedent cat scratch",
                    "sub_points": [
                      "Approximately 60% of patients report antecedent cat scratch"
                    ]
                  },
                  {
                    "text": "Bacilli are transmitted to humans through bite or scratch of infested cat"
                  },
                  {
                    "text": "Healthy cats with fleas are reservoir forB. henselaeB. henselaeresides in erythrocytes of cats and does not cause illnessB. henselaehas also been isolated from fleas of cats carrying bacilli",
                    "sub_points": [
                      "B. henselaeresides in erythrocytes of cats and does not cause illnessB. henselaehas also been isolated from fleas of cats carrying bacilli",
                      "B. henselaehas also been isolated from fleas of cats carrying bacilli"
                    ]
                  },
                  {
                    "text": "Granuloma formation results from activation and accumulation of histiocytesThought to be secondary to interferon-γ-mediated TH1 cell response",
                    "sub_points": [
                      "Thought to be secondary to interferon-γ-mediated TH1 cell response"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "B. henselaehas worldwide distribution"
                  },
                  {
                    "text": "Approximately 22,000 cases of CSD are diagnosed each year in United StatesCSD is most frequent cause of benign lymphadenopathy in children and young adults",
                    "sub_points": [
                      "CSD is most frequent cause of benign lymphadenopathy in children and young adults"
                    ]
                  },
                  {
                    "text": "Seasonal distributionMost cases occur between July and January",
                    "sub_points": [
                      "Most cases occur between July and January"
                    ]
                  },
                  {
                    "text": "Relative incidence of CSD in adults is increasingIncidence currently approximately 40%",
                    "sub_points": [
                      "Incidence currently approximately 40%"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Spectrum of disease ranges from localized to systemicMost patients have mild disease with malaise, generalized achingApproximately 2/3 of patients have fever",
                    "sub_points": [
                      "Most patients have mild disease with malaise, generalized aching",
                      "Approximately 2/3 of patients have fever"
                    ]
                  },
                  {
                    "text": "Primary lesion in skin appears as 0.5-1 cm erythematous papuleAt site of cat scratchSkin lesion appears 3-10 days after inoculationInitial papular lesion is followed by vesicle that oozes fluid and eventually dries",
                    "sub_points": [
                      "At site of cat scratch",
                      "Skin lesion appears 3-10 days after inoculation",
                      "Initial papular lesion is followed by vesicle that oozes fluid and eventually dries"
                    ]
                  },
                  {
                    "text": "Upper extremities are more frequently affected, followed by cervical and facial regions"
                  },
                  {
                    "text": "Regional lymphadenopathy appears 1-3 weeks after inoculationLymphadenopathy is tender with erythematous overlying skinSuppuration occurs in approximately 10% of casesLymphadenopathy is localized or regional in 85% of patients, but it can affect multiple areas",
                    "sub_points": [
                      "Lymphadenopathy is tender with erythematous overlying skinSuppuration occurs in approximately 10% of cases",
                      "Suppuration occurs in approximately 10% of cases",
                      "Lymphadenopathy is localized or regional in 85% of patients, but it can affect multiple areas"
                    ]
                  },
                  {
                    "text": "Parinaud syndrome consists of conjunctivitis and preauricular lymphadenopathyConjunctiva shows ulceration, chronic inflammation, and necrotic granulomas",
                    "sub_points": [
                      "Conjunctiva shows ulceration, chronic inflammation, and necrotic granulomas"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Minimal leukocytosis with or without eosinophilia can occur"
                  },
                  {
                    "text": "Bacteria can be isolated and cultured from clinical specimens"
                  },
                  {
                    "text": "Intradermal skin test is obsolete because lack of standardization and risk of transmissible diseasesTest required use of aspirated suppurative material from clinical specimens",
                    "sub_points": [
                      "Test required use of aspirated suppurative material from clinical specimens"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "In immunocompetent patients, CSD is self-limited and confined to lymph nodesUsually lasts 2-4 months if no therapy is administered1%-2% of patients may have prolonged fever, suppurative lymphadenitis, or systemic symptoms",
                    "sub_points": [
                      "Usually lasts 2-4 months if no therapy is administered",
                      "1%-2% of patients may have prolonged fever, suppurative lymphadenitis, or systemic symptoms"
                    ]
                  },
                  {
                    "text": "In immunocompromised patients, disease may become systemic, severe, and life-threateningMultiorgan involvement in these patients",
                    "sub_points": [
                      "Multiorgan involvement in these patients"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Varies depending on clinical presentation and immune status of patientCSD usually does not respond to therapySeveral studies could not demonstrate that antibiotic therapy changes course of diseaseNo decrease in duration of disease or probability of suppuration",
                    "sub_points": [
                      "CSD usually does not respond to therapy",
                      "Several studies could not demonstrate that antibiotic therapy changes course of diseaseNo decrease in duration of disease or probability of suppuration",
                      "No decrease in duration of disease or probability of suppuration"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "CSD is self-limited disease with excellent prognosis in immunocompetent patients"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Lymph nodes are enlarged, matted, and adherent to surrounding soft tissues or skin"
                  },
                  {
                    "text": "Focal areas of necrosis or microabscesses are grossly visible"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Early lesions in lymph nodesFollicular lymphoid hyperplasia with germinal centers showing abundant tingible body macrophagesEosinophilic necrosis admixed with neutrophils or karyorrhexis in subcapsular sinusTends to extend into adjacent germinal centersPatches of monocytoid cells within sinuses are also notedDilated sinuses contain lymphocytes, histiocytes, and immunoblasts",
                    "sub_points": [
                      "Follicular lymphoid hyperplasia with germinal centers showing abundant tingible body macrophages",
                      "Eosinophilic necrosis admixed with neutrophils or karyorrhexis in subcapsular sinusTends to extend into adjacent germinal centers",
                      "Tends to extend into adjacent germinal centers",
                      "Patches of monocytoid cells within sinuses are also noted",
                      "Dilated sinuses contain lymphocytes, histiocytes, and immunoblasts"
                    ]
                  },
                  {
                    "text": "Progressive changes in lymph nodesSmall abscesses with necrosis and clusters of neutrophilsInitially in subcapsular sinus; subsequently in cortex and then medulla",
                    "sub_points": [
                      "Small abscesses with necrosis and clusters of neutrophilsInitially in subcapsular sinus; subsequently in cortex and then medulla",
                      "Initially in subcapsular sinus; subsequently in cortex and then medulla"
                    ]
                  },
                  {
                    "text": "Advanced changes in lymph nodesClassic stellate necrotizing granulomas of CSDMacrophages surround abscess-forming rim of epithelioid cellsEpithelioid cells include rare multinucleated, Langhans-type cells",
                    "sub_points": [
                      "Classic stellate necrotizing granulomas of CSD",
                      "Macrophages surround abscess-forming rim of epithelioid cellsEpithelioid cells include rare multinucleated, Langhans-type cells",
                      "Epithelioid cells include rare multinucleated, Langhans-type cells"
                    ]
                  },
                  {
                    "text": "Warthin-Starry silver stain is useful to visualize bacteriaChances of visualizing bacteria in lymph nodes is highest in early lesions",
                    "sub_points": [
                      "Chances of visualizing bacteria in lymph nodes is highest in early lesions"
                    ]
                  },
                  {
                    "text": "Skin lesionsRarely biopsiedHistologic features similar to those described in lymph nodes",
                    "sub_points": [
                      "Rarely biopsied",
                      "Histologic features similar to those described in lymph nodes"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Histochemistry": [
                  {
                    "text": "Warthin-Starry satin is positive"
                  },
                  {
                    "text": "Bacteria are present in patchy distributionAffected areas can be devoid of bacteria; in other areas bacteria are present in clusters",
                    "sub_points": [
                      "Affected areas can be devoid of bacteria; in other areas bacteria are present in clusters"
                    ]
                  },
                  {
                    "text": "Brown-Hopps Gram stain can confirm presence of bacteria"
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "Monoclonal anti-B. henselaeantibodies are reactive in fixed paraffin-embedded tissueUseful for confirming identity of bacteriaBacteria appear in clusters in areas of necrosis; less frequent within macrophagesBacteria are more easily identified with immunohistochemistry than with Warthin-Starry stain",
                    "sub_points": [
                      "Useful for confirming identity of bacteria",
                      "Bacteria appear in clusters in areas of necrosis; less frequent within macrophages",
                      "Bacteria are more easily identified with immunohistochemistry than with Warthin-Starry stain"
                    ]
                  }
                ],
                "PCR": [
                  {
                    "text": "PCR analysis of bacterial DNA is useful in clinical specimens including fixed paraffin-embedded tissuesAmplification ofB. henselae16S﻿ rRNA﻿gene, citrate synthasegltAorhtrAgenesSensitivity 45%-75%Specificity near 100%",
                    "sub_points": [
                      "Amplification ofB. henselae16S﻿ rRNA﻿gene, citrate synthasegltAorhtrAgenesSensitivity 45%-75%Specificity near 100%",
                      "Sensitivity 45%-75%",
                      "Specificity near 100%"
                    ]
                  }
                ],
                "Serologic Testing": [
                  {
                    "text": "Practical method for diagnosis, but it has shortcomingsSerologic IgG testing with IFA has sensitivity of 20%-90%EIA is less sensitiveCross reactivity withB. quintanaLess frequent with other genera such asCoxiellaIgM antibodies suggest recent (< 3 months) infectionTiters may be undetectable very early in diseaseDetectable titers can persist for > 1 yrIgM titers are significantly lower (1:32 to 1:128) than IgG titers (1:256 to 1:2,048)",
                    "sub_points": [
                      "Serologic IgG testing with IFA has sensitivity of 20%-90%",
                      "EIA is less sensitive",
                      "Cross reactivity withB. quintanaLess frequent with other genera such asCoxiella",
                      "Less frequent with other genera such asCoxiella",
                      "IgM antibodies suggest recent (< 3 months) infectionTiters may be undetectable very early in diseaseDetectable titers can persist for > 1 yrIgM titers are significantly lower (1:32 to 1:128) than IgG titers (1:256 to 1:2,048)",
                      "Titers may be undetectable very early in disease",
                      "Detectable titers can persist for > 1 yr",
                      "IgM titers are significantly lower (1:32 to 1:128) than IgG titers (1:256 to 1:2,048)"
                    ]
                  }
                ],
                "Electron Microscopy": [
                  {
                    "text": "Organisms are intracellular or extracellular or bothWithin endothelial cells and macrophagesExtracellular in areas of necrosis",
                    "sub_points": [
                      "Within endothelial cells and macrophages",
                      "Extracellular in areas of necrosis"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Tuberculous Lymphadenitis": [
                  {
                    "text": "Patients may present with bilateral lymphadenopathy and pulmonary symptoms"
                  },
                  {
                    "text": "Necrosis is caseating; usually without nuclear remnants or tissue debris"
                  },
                  {
                    "text": "Acid-fast stain may show scant or absent thin bacilli"
                  },
                  {
                    "text": "Cultures or DNA testing may help to detect presence ofMycobacterium tuberculosis"
                  }
                ],
                "Fungal Lymphadenitis": [
                  {
                    "text": "Agents includeCryptococcus,Candida,Histoplasma, andAspergillusCultures are essential for definitive identification",
                    "sub_points": [
                      "Cultures are essential for definitive identification"
                    ]
                  },
                  {
                    "text": "Necrotizing granulomatous inflammationYeast forms and hyphae can be seen occasionally in routine H&E stainsGMS stain reveals yeasts or hyphaePAS stain highlightsCandidaspecies",
                    "sub_points": [
                      "Yeast forms and hyphae can be seen occasionally in routine H&E stains",
                      "GMS stain reveals yeasts or hyphae",
                      "PAS stain highlightsCandidaspecies"
                    ]
                  }
                ],
                "Lymphogranuloma Venereum": [
                  {
                    "text": "Clinical history of exposure to sexually transmitted diseases; usually inguinal lymphadenopathy"
                  },
                  {
                    "text": "Histologically similar to CSD including stellate necrotizing microabscesses and granulomas"
                  },
                  {
                    "text": "Distinction relies on serologic testing for CSD"
                  }
                ],
                "Kikuchi-Fujimoto Lymphadenitis": [
                  {
                    "text": "Paracortical patternOften appears wedge-shaped underneath lymph node capsule",
                    "sub_points": [
                      "Often appears wedge-shaped underneath lymph node capsule"
                    ]
                  },
                  {
                    "text": "Patchy necrosis and abundant nuclear debris"
                  },
                  {
                    "text": "Small blood vessel thrombosis and C-shaped histiocytes are useful features"
                  },
                  {
                    "text": "Follicular hyperplasia is often present"
                  },
                  {
                    "text": "Neutrophils and plasma cells are absent"
                  },
                  {
                    "text": "No epithelioid histiocytes"
                  },
                  {
                    "text": "Early proliferative phase composed mostly of histiocytes can simulate lymphoma"
                  }
                ],
                "Suppurative Lymphadenitis": [
                  {
                    "text": "Various bacteria may cause necrosis with acute inflammatory infiltrate"
                  }
                ],
                "Tularemia": [
                  {
                    "text": "Zoonosis caused by gram-negative coccobacillary bacteriaFrancisella tularensis"
                  },
                  {
                    "text": "Acute illness with ulceroglandular form being most common"
                  },
                  {
                    "text": "History of handling animals or of cat bitesInfection acquired through inhalation or skin abrasion",
                    "sub_points": [
                      "Infection acquired through inhalation or skin abrasion"
                    ]
                  },
                  {
                    "text": "Lymphadenopathy starts with focal necrosis and transforms into necrotizing granulomas"
                  },
                  {
                    "text": "Confirm diagnosis with serology or DNA (PCR) testingPCR testing can be performed on formalin-fixed tissue",
                    "sub_points": [
                      "PCR testing can be performed on formalin-fixed tissue"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Patients report contact with cats in approximately 90% of cases"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Follicular hyperplasia with germinal centers showing abundant tingible body macrophages"
                  },
                  {
                    "text": "Advanced changes include classic stellate necrotizing microabscesses and granulomas"
                  },
                  {
                    "text": "Bacteria are more easily identified by immunohistochemistry than by Warthin-Starry stain"
                  },
                  {
                    "text": "Chances of visualizing bacteria are much higher in early than in advanced lesions"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "ToxoplasmaLymphadenitis": {
            "name": "ToxoplasmaLymphadenitis",
            "url": "https://app.pathprimer.com/document/74dd0127-b824-4e9e-8f00-43dbd24b6577/lesson/6e5627b8-d0a0-4739-ae70-d53f34f8cfcd",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "Toxoplasma gondii isparasitic protozoan"
                  },
                  {
                    "text": "Cat is definitive host for sexual stage of reproduction"
                  },
                  {
                    "text": "Oocysts containing trophozoites are generated that are eliminated in feces"
                  },
                  {
                    "text": "Humans and animals are intermediate hosts"
                  },
                  {
                    "text": "Humans ingest oocysts from contaminated soil or undercooked meat"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Self-limited clinical course in most patients"
                  },
                  {
                    "text": "Children and young adults (65%) most often affected"
                  },
                  {
                    "text": "Unilateral lymphadenopathy, commonly posterior cervical"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Diagnostic triadFlorid reactive follicular hyperplasiaMonocytoid B-cell hyperplasia in sinusesEpithelioid histiocytes in paracortical areas that encroach into germinal centers",
                    "sub_points": [
                      "Florid reactive follicular hyperplasia",
                      "Monocytoid B-cell hyperplasia in sinuses",
                      "Epithelioid histiocytes in paracortical areas that encroach into germinal centers"
                    ]
                  },
                  {
                    "text": "No multinucleated giant cells; no necrosis"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Sabin-Feldman dye test"
                  },
                  {
                    "text": "IgM screening antibody test positive in 1st 3 months"
                  },
                  {
                    "text": "PositiveToxoplasma-specific antibodies are detected by enzyme immunoassays"
                  },
                  {
                    "text": "Anti-Toxoplasmaimmunohistochemistry detects presence of parasites"
                  },
                  {
                    "text": "Toxoplasmagenomes can be detected by PCR"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Inflammation of lymph node caused by infection byToxoplasma gondii"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Toxoplasma gondiiInfection": [
                  {
                    "text": "T. gondii isprotozoan that can invade many cell types"
                  },
                  {
                    "text": "Cat is definitive host for sexual stage of reproductionTrophozoites reproduce in intestinal epitheliumOocysts are generated that are eliminated in feces",
                    "sub_points": [
                      "Trophozoites reproduce in intestinal epithelium",
                      "Oocysts are generated that are eliminated in feces"
                    ]
                  },
                  {
                    "text": "Humans and animals are intermediate hostsIngest oocysts from contaminated soilHumans can ingest oocysts from undercooked meat",
                    "sub_points": [
                      "Ingest oocysts from contaminated soil",
                      "Humans can ingest oocysts from undercooked meat"
                    ]
                  },
                  {
                    "text": "In humans and animals, oocysts are digested by digestive enzymesTrophozoites are released into intestineOrganisms are carried by macrophagesSpread via lymphatics and blood vessels to internal organsWithin macrophages, trophozoites can multiply and become crescent-shaped tachyzoites",
                    "sub_points": [
                      "Trophozoites are released into intestineOrganisms are carried by macrophagesSpread via lymphatics and blood vessels to internal organs",
                      "Organisms are carried by macrophages",
                      "Spread via lymphatics and blood vessels to internal organs",
                      "Within macrophages, trophozoites can multiply and become crescent-shaped tachyzoites"
                    ]
                  },
                  {
                    "text": "In immunocompetent patients, tachyzoites usually become segregated into cysts synthesized by hostWithin cysts, organisms are slow-growing bradyzoitesInfection typically resolves",
                    "sub_points": [
                      "Within cysts, organisms are slow-growing bradyzoites",
                      "Infection typically resolves"
                    ]
                  },
                  {
                    "text": "In immunodeficient patients, tachyzoites widely disseminate, causing acute infection"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Toxoplasmosis is common parasitic disease worldwideMore prevalent in warm and humid climates",
                    "sub_points": [
                      "More prevalent in warm and humid climates"
                    ]
                  },
                  {
                    "text": "In USA, toxoplasmosis is most common parasitic infection50% of USA citizens have serum antibodies toT. gondii: Evidence of chronic infection",
                    "sub_points": [
                      "50% of USA citizens have serum antibodies toT. gondii: Evidence of chronic infection"
                    ]
                  },
                  {
                    "text": "T. gondiican be spread transplacentally from mother to fetus1 in every 1,000 live births in USA~ 3,000 births are affected annuallyPotential damage to fetus is greatest with infection in 1st trimester",
                    "sub_points": [
                      "1 in every 1,000 live births in USA",
                      "~ 3,000 births are affected annually",
                      "Potential damage to fetus is greatest with infection in 1st trimester"
                    ]
                  },
                  {
                    "text": "Rarely,T. gondiiinfection can be transmitted via transplanted organ"
                  },
                  {
                    "text": "Active infection may result from reactivation of earlier infectionCommon in patients with cancers and diabetes mellitus",
                    "sub_points": [
                      "Common in patients with cancers and diabetes mellitus"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Children and young adults most often affected"
                  }
                ],
                "Sex": [
                  {
                    "text": "No sex preference"
                  }
                ],
                "Site": [
                  {
                    "text": "Lymph nodes are commonly affectedPosterior cervical lymph nodes are characteristic siteOften unilateralAny group of lymph nodes can be involvedOther cervical, supraclavicular, occipital, parotid, intramammary regionsGeneralized lymphadenopathy or hepatosplenomegaly can occur but is unusual",
                    "sub_points": [
                      "Posterior cervical lymph nodes are characteristic siteOften unilateral",
                      "Often unilateral",
                      "Any group of lymph nodes can be involvedOther cervical, supraclavicular, occipital, parotid, intramammary regions",
                      "Other cervical, supraclavicular, occipital, parotid, intramammary regions",
                      "Generalized lymphadenopathy or hepatosplenomegaly can occur but is unusual"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Asymptomatic infection is common in immunocompetent individuals"
                  },
                  {
                    "text": "Mild illness also can occur manifested by malaise, fever, myalgia"
                  },
                  {
                    "text": "Physical examination of lymph nodesTender or nontenderFirm but not rock hard0.5-3.0 cm",
                    "sub_points": [
                      "Tender or nontender",
                      "Firm but not rock hard",
                      "0.5-3.0 cm"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Sabin-Feldman dye testHighly sensitive and specificT. gondiiorganisms do not stain with alkaline methylene blue if they have been exposed to serum anti-T. gondiiantibodiesPositive result: Change from negative to positive or rapidly increasing titers",
                    "sub_points": [
                      "Highly sensitive and specific",
                      "T. gondiiorganisms do not stain with alkaline methylene blue if they have been exposed to serum anti-T. gondiiantibodies",
                      "Positive result: Change from negative to positive or rapidly increasing titers"
                    ]
                  },
                  {
                    "text": "Antibodies toT. gondiican be detected by enzyme immunoassays or indirect immunofluorescenceIgM or IgG antibodies against cell wall antigensIgM antibodies present within few days after infectionTiters of 1:80 or higher indicate recent infectionIgG antibody titers of 1:1,000 occur at 6-8 weeks after infectionCan persist for years",
                    "sub_points": [
                      "IgM or IgG antibodies against cell wall antigens",
                      "IgM antibodies present within few days after infectionTiters of 1:80 or higher indicate recent infection",
                      "Titers of 1:80 or higher indicate recent infection",
                      "IgG antibody titers of 1:1,000 occur at 6-8 weeks after infectionCan persist for years",
                      "Can persist for years"
                    ]
                  },
                  {
                    "text": "Latex agglutination test and ELISA assays available"
                  },
                  {
                    "text": "PCR can be used to amplifyT. gondiiDNACommonly used on amniotic fluid",
                    "sub_points": [
                      "Commonly used on amniotic fluid"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Pyrimethamine/sulfadiazine"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "In immunocompetent patients, infection is self-limiting"
                  },
                  {
                    "text": "In immunodeficient patients, great risk of acute disseminationEncephalitis, chorioretinitis, pneumonia, and cardiac involvementDeath as result of above conditions",
                    "sub_points": [
                      "Encephalitis, chorioretinitis, pneumonia, and cardiac involvement",
                      "Death as result of above conditions"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Lymph nodeArchitecture: PreservedCapsule/pericapsule: Minimal involvementSinuses: Distended by monocytoid B cellsLarge cells with sharp, visible cell borders, clear cytoplasm, and small darkly stained nucleiFollicles: Florid reactive follicular hyperplasiaNumerous tingible body macrophagesGerminal centers can have ragged, indistinct marginsNumerous epithelioid histiocytes in interfollicular and paracortical regionsEncroach upon and invade into germinal centersForm collections of less than 25 epithelioid cells (microgranulomas)Plasma cells and immunoblasts in medullary cordsToxoplasma cysts and bradyzoites are rare (1% of cases)Can identify by routine histologic examination in ~ 1% of casesNecrosis is absentWell-formed (sarcoid-like) granulomas do not occurNo multinucleated giant cells; no fibrosis",
                    "sub_points": [
                      "Architecture: Preserved",
                      "Capsule/pericapsule: Minimal involvement",
                      "Sinuses: Distended by monocytoid B cellsLarge cells with sharp, visible cell borders, clear cytoplasm, and small darkly stained nuclei",
                      "Large cells with sharp, visible cell borders, clear cytoplasm, and small darkly stained nuclei",
                      "Follicles: Florid reactive follicular hyperplasiaNumerous tingible body macrophagesGerminal centers can have ragged, indistinct margins",
                      "Numerous tingible body macrophages",
                      "Germinal centers can have ragged, indistinct margins",
                      "Numerous epithelioid histiocytes in interfollicular and paracortical regionsEncroach upon and invade into germinal centersForm collections of less than 25 epithelioid cells (microgranulomas)",
                      "Encroach upon and invade into germinal centers",
                      "Form collections of less than 25 epithelioid cells (microgranulomas)",
                      "Plasma cells and immunoblasts in medullary cords",
                      "Toxoplasma cysts and bradyzoites are rare (1% of cases)Can identify by routine histologic examination in ~ 1% of cases",
                      "Can identify by routine histologic examination in ~ 1% of cases",
                      "Necrosis is absent",
                      "Well-formed (sarcoid-like) granulomas do not occur",
                      "No multinucleated giant cells; no fibrosis"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Diagnosis can be established by fine needle aspiration of lymph nodeDiff-Quik smears show polymorphous cell populationSmall and large lymphocytesClusters of epithelioid histiocytes (microgranulomas)Plasma cellsRarely, parasitic cysts can be detected",
                    "sub_points": [
                      "Diff-Quik smears show polymorphous cell populationSmall and large lymphocytesClusters of epithelioid histiocytes (microgranulomas)Plasma cells",
                      "Small and large lymphocytes",
                      "Clusters of epithelioid histiocytes (microgranulomas)",
                      "Plasma cells",
                      "Rarely, parasitic cysts can be detected"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Anti-T. gondiiantibodies can be used to detect presence of parasites in tissues"
                  }
                ],
                "PCR": [
                  {
                    "text": "Toxoplasmagenomes are detected by conventional and nested polymerase chain reactionOften not detected in lymph nodes with changes ofToxoplasmalymphadenitis",
                    "sub_points": [
                      "Often not detected in lymph nodes with changes ofToxoplasmalymphadenitis"
                    ]
                  },
                  {
                    "text": "Does not distinguish active from latent infection"
                  }
                ],
                "Electron Microscopy": [
                  {
                    "text": "T. gondiihas distinctive featuresPaired organelles, dense bodiesConoid nuclei at rounded posterior endDouble-layered pellicles",
                    "sub_points": [
                      "Paired organelles, dense bodies",
                      "Conoid nuclei at rounded posterior end",
                      "Double-layered pellicles"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Human Immunodeficiency Virus (HIV) Lymphadenitis": [
                  {
                    "text": "Early stage of HIV infection can be associated with changes that can mimic toxoplasmosis"
                  },
                  {
                    "text": "Explosive follicular hyperplasia"
                  },
                  {
                    "text": "Sinusoidal and paracortical monocytoid B-cell proliferation"
                  },
                  {
                    "text": "Epithelioid histiocytes can be present or absent"
                  },
                  {
                    "text": "Positive immunohistochemical staining for HIV p24"
                  }
                ],
                "Leishmaniasis Lymphadenitis": [
                  {
                    "text": "Histologic findings can closely mimic toxoplasmosis"
                  },
                  {
                    "text": "Multinucleated giant cells are usually present"
                  },
                  {
                    "text": "Leishman-Donovan bodies may be seen in cytoplasm of histiocytes"
                  }
                ],
                "Dermatopathic Lymphadenopathy": [
                  {
                    "text": "Paracortical distributionNumerous histiocytes, many with twisted nucleiS100 protein(+), CD1a([+], subset)Melanin pigment",
                    "sub_points": [
                      "Numerous histiocytes, many with twisted nucleiS100 protein(+), CD1a([+], subset)",
                      "S100 protein(+), CD1a([+], subset)",
                      "Melanin pigment"
                    ]
                  }
                ],
                "Sarcoidosis": [
                  {
                    "text": "Well-formed granulomas unlike toxoplasmosis"
                  },
                  {
                    "text": "Multinucleated giant cells often present"
                  },
                  {
                    "text": "Usually monocytoid B-cell hyperplasia is absent or minimal"
                  }
                ],
                "Systemic Lupus Erythematosus (SLE) Lymphadenopathy": [
                  {
                    "text": "Areas of paracortical necrosis; ± hematoxylin bodies"
                  },
                  {
                    "text": "Clinical history and serologic findings of SLE"
                  }
                ],
                "Infectious Mononucleosis": [
                  {
                    "text": "Paracortical and polymorphous lymphoid proliferation"
                  },
                  {
                    "text": "Numerous immunoblasts and foci of necrosis"
                  },
                  {
                    "text": "No epithelioid histiocytes encroaching on germinal centers"
                  }
                ],
                "Non-Hodgkin Lymphoma (NHL)": [
                  {
                    "text": "Clusters of epithelioid histiocytes can be present in many NHL typesLymphoepithelioid variant of peripheral T-cell lymphoma (so-called Lennert lymphoma)",
                    "sub_points": [
                      "Lymphoepithelioid variant of peripheral T-cell lymphoma (so-called Lennert lymphoma)"
                    ]
                  },
                  {
                    "text": "Lymph node architecture is altered"
                  },
                  {
                    "text": "Monocytoid B-cell hyperplasia absent or minimal"
                  }
                ],
                "Nodular Lymphocyte Predominant Hodgkin Lymphoma": [
                  {
                    "text": "Epithelioid histiocytes can be numerous"
                  },
                  {
                    "text": "Large, vague nodules that are closely packed and lack mantle zonesFollicular dendritic cell networks in nodules",
                    "sub_points": [
                      "Follicular dendritic cell networks in nodules"
                    ]
                  },
                  {
                    "text": "LP cells (a.k.a. \"popcorn\" or L&H cells) are presentCD20(+), pax-5([+], strong), CD45/LCA(+)",
                    "sub_points": [
                      "CD20(+), pax-5([+], strong), CD45/LCA(+)"
                    ]
                  }
                ],
                "Classical Hodgkin Lymphoma": [
                  {
                    "text": "Epithelioid histiocytes can be numerous"
                  },
                  {
                    "text": "Most common in mixed cellularity type"
                  },
                  {
                    "text": "Reed-Sternberg and Hodgkin cells presentCD15(+), CD30(+), CD45/LCA(-)",
                    "sub_points": [
                      "CD15(+), CD30(+), CD45/LCA(-)"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Persistent unilateral lymphadenopathyPosterior cervical lymph nodes commonly affected",
                    "sub_points": [
                      "Posterior cervical lymph nodes commonly affected"
                    ]
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Diagnostic triad is characteristic ofToxoplasmalymphadenitis and correlates with serologic dataMarked reactive follicular hyperplasiaMonocytoid B-cell hyperplasia in sinusesEpithelioid histiocytes in paracortex that encroach upon and invade germinal centers",
                    "sub_points": [
                      "Marked reactive follicular hyperplasia",
                      "Monocytoid B-cell hyperplasia in sinuses",
                      "Epithelioid histiocytes in paracortex that encroach upon and invade germinal centers"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Dermatopathic Lymphadenitis": {
            "name": "Dermatopathic Lymphadenitis",
            "url": "https://app.pathprimer.com/document/be358152-fd85-4f43-a230-5da99fb7b1dc/lesson/6e5627b8-d0a0-4739-ae70-d53f34f8cfcd",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Paracortical hyperplasia characterized byInterdigitating dendritic cells (IDCs), Langerhans cells (LCs), and macrophagesMelanin pigment (variable)",
                    "sub_points": [
                      "Interdigitating dendritic cells (IDCs), Langerhans cells (LCs), and macrophages",
                      "Melanin pigment (variable)"
                    ]
                  },
                  {
                    "text": "Usually associated with skin disordersExfoliative or eczematoid dermatitis",
                    "sub_points": [
                      "Exfoliative or eczematoid dermatitis"
                    ]
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "T-cell response to skin antigens processed and presented by IDCs and LCs"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Prognosis is related to underlying skin disease or other associated systemic diseasesSpecific therapy is not required for DLA",
                    "sub_points": [
                      "Specific therapy is not required for DLA"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "ImmunohistochemistryIDCs and LCs are S100(+)Only LCs are CD1a(+)Macrophages are CD68(+); Tcells are CD3(+)",
                    "sub_points": [
                      "IDCs and LCs are S100(+)",
                      "Only LCs are CD1a(+)",
                      "Macrophages are CD68(+); Tcells are CD3(+)"
                    ]
                  },
                  {
                    "text": "Flow cytometry immunophenotyping and gene rearrangement analysisUseful to exclude T-cell clone and early involvement by MF/SS",
                    "sub_points": [
                      "Useful to exclude T-cell clone and early involvement by MF/SS"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Langerhans cell histiocytosis"
                  },
                  {
                    "text": "Classical Hodgkin lymphoma"
                  },
                  {
                    "text": "Mycosis fungoides/Sézary syndrome"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Dermatopathic lymphadenopathy (DLA)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Dermatopathic lymphadenitis"
                  },
                  {
                    "text": "Lipomelanosis reticularis of Pautrier"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Reactive lymphadenopathy characterized by paracortical hyperplasia that containsInterdigitating dendritic cells (IDCs), Langerhans cells (LCs), and macrophages containing melanin",
                    "sub_points": [
                      "Interdigitating dendritic cells (IDCs), Langerhans cells (LCs), and macrophages containing melanin"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Disease Associations": [
                  {
                    "text": "Usually associated with chronic skin diseaseBenign or malignant",
                    "sub_points": [
                      "Benign or malignant"
                    ]
                  }
                ],
                "T-Cell Response to Skin Antigen Processing": [
                  {
                    "text": "Skin antigens processed and presented by LCs and IDCs"
                  },
                  {
                    "text": "LCs are specialized dendritic cells that reside in skinUpon activation, LCs migrate to lymph node",
                    "sub_points": [
                      "Upon activation, LCs migrate to lymph node"
                    ]
                  },
                  {
                    "text": "IDCs are specialized dendritic cells that reside in lymph node paracortexIDCs may be derived from LC",
                    "sub_points": [
                      "IDCs may be derived from LC"
                    ]
                  },
                  {
                    "text": "Both LCs and IDCs are derived from bone marrow precursor cells"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Age": [
                  {
                    "text": "All ages, but often middle-aged to elderly patients"
                  }
                ],
                "Sex": [
                  {
                    "text": "Males affected more frequently"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "No preference"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Lymphadenopathy; usually superficialMost often axillary or inguinal lymph nodesGeneralized lymphadenopathy is less common",
                    "sub_points": [
                      "Most often axillary or inguinal lymph nodes",
                      "Generalized lymphadenopathy is less common"
                    ]
                  },
                  {
                    "text": "May occur in association with any chronic inflammatory skin disorderUsually generalized dermatitis, especially exfoliative and eczematoid dermatitisToxic shock syndrome, pemphigus, psoriasis, neurodermatitis, eczema, atrophia senilisSkin conditions may precede lymphadenopathy by months to yearsMild to moderate dermatopathic changes also can occur in patients without skin disease~ 10% of patients do not have skin disease",
                    "sub_points": [
                      "Usually generalized dermatitis, especially exfoliative and eczematoid dermatitisToxic shock syndrome, pemphigus, psoriasis, neurodermatitis, eczema, atrophia senilis",
                      "Toxic shock syndrome, pemphigus, psoriasis, neurodermatitis, eczema, atrophia senilis",
                      "Skin conditions may precede lymphadenopathy by months to years",
                      "Mild to moderate dermatopathic changes also can occur in patients without skin disease~ 10% of patients do not have skin disease",
                      "~ 10% of patients do not have skin disease"
                    ]
                  },
                  {
                    "text": "DLA often associated with mycosis fungoides (MF) or Sézary syndrome (SS)~ 75% of patients with MF/SS present with lymphadenopathyDLA, involvement by MF/SS, or both",
                    "sub_points": [
                      "~ 75% of patients with MF/SS present with lymphadenopathyDLA, involvement by MF/SS, or both",
                      "DLA, involvement by MF/SS, or both"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Increased erythrocyte sedimentation rate"
                  },
                  {
                    "text": "Hypereosinophilia"
                  },
                  {
                    "text": "Autoimmune antibodies can be detected in some patients, related to skin conditions"
                  }
                ],
                "Treatment": [
                  {
                    "text": "No current guidelines exist on appropriate management of patients with DLABenign DLA requires no specific therapyIf DLA is associated with lymphoma, appropriate diagnosis and staging of lymphoma is neededTherapy is directed at lymphoma",
                    "sub_points": [
                      "Benign DLA requires no specific therapy",
                      "If DLA is associated with lymphoma, appropriate diagnosis and staging of lymphoma is neededTherapy is directed at lymphoma",
                      "Therapy is directed at lymphoma"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "In benign DLA, related to underlying skin or systemic disease"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Lymph node is enlarged"
                  },
                  {
                    "text": "Cut surface is bulging, pale yellow"
                  },
                  {
                    "text": "In some extreme cases, black peripheral lines can be observed due to clumps of melanin pigment"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Continuum exists between early changes & fully developed DLAEarly stage/mildAccumulation of IDCs, LCs, and macrophages in paracortical zonesSubset of macrophages contain melanin pigmentFollicular hyperplasiaLymph node architecture generally preservedMiddle stage/moderateContinuous expansion of paracortical zones by IDCs, LCs, and macrophagesLymphoid follicles are compressed, become atrophicLater stage/severeNodular or confluent expansion of paracortical zones with further accumulation of IDCs, LCs, and macrophagesRelative depletion of small lymphocytesAtrophic/compressed folliclesPlasmacytosis in medullary cords can be prominentPlasma cells, eosinophils, and immunoblasts can be prominent",
                    "sub_points": [
                      "Early stage/mildAccumulation of IDCs, LCs, and macrophages in paracortical zonesSubset of macrophages contain melanin pigmentFollicular hyperplasiaLymph node architecture generally preserved",
                      "Accumulation of IDCs, LCs, and macrophages in paracortical zones",
                      "Subset of macrophages contain melanin pigment",
                      "Follicular hyperplasia",
                      "Lymph node architecture generally preserved",
                      "Middle stage/moderateContinuous expansion of paracortical zones by IDCs, LCs, and macrophagesLymphoid follicles are compressed, become atrophic",
                      "Continuous expansion of paracortical zones by IDCs, LCs, and macrophages",
                      "Lymphoid follicles are compressed, become atrophic",
                      "Later stage/severeNodular or confluent expansion of paracortical zones with further accumulation of IDCs, LCs, and macrophagesRelative depletion of small lymphocytesAtrophic/compressed folliclesPlasmacytosis in medullary cords can be prominentPlasma cells, eosinophils, and immunoblasts can be prominent",
                      "Nodular or confluent expansion of paracortical zones with further accumulation of IDCs, LCs, and macrophages",
                      "Relative depletion of small lymphocytes",
                      "Atrophic/compressed follicles",
                      "Plasmacytosis in medullary cords can be prominent",
                      "Plasma cells, eosinophils, and immunoblasts can be prominent"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Clusters of IDCs and LCs are present in paracortexIDCs and LCs are morphologically indistinguishable by light microscopyElongated convoluted nuclei with linear grooves (\"twisted towel\" appearance)Pale or eosinophilic cytoplasm and pseudonucleoli",
                    "sub_points": [
                      "IDCs and LCs are morphologically indistinguishable by light microscopyElongated convoluted nuclei with linear grooves (\"twisted towel\" appearance)Pale or eosinophilic cytoplasm and pseudonucleoli",
                      "Elongated convoluted nuclei with linear grooves (\"twisted towel\" appearance)",
                      "Pale or eosinophilic cytoplasm and pseudonucleoli"
                    ]
                  },
                  {
                    "text": "Macrophages with variable pigmentMostly melanin but hemosiderin also can be presentHistiocytes can have cytoplasmic lipid droplets",
                    "sub_points": [
                      "Mostly melanin but hemosiderin also can be present",
                      "Histiocytes can have cytoplasmic lipid droplets"
                    ]
                  },
                  {
                    "text": "Absent or rare tingible body macrophages"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "IDCs, LCs, and subset of macrophages are S100(+)"
                  },
                  {
                    "text": "IDCs and LCs are CD4([+] weak), CD68([+] variable), and TCL-1(+)"
                  },
                  {
                    "text": "IDCs and LCs are CD21(-), CD35(-), CD123(-), and CD163(-)"
                  },
                  {
                    "text": "LCs are CD1a(+) and can show variable lysozyme(+)"
                  },
                  {
                    "text": "Macrophages are CD68(+)"
                  }
                ],
                "Cytochemistry": [
                  {
                    "text": "Fontana silver: Melanin"
                  },
                  {
                    "text": "Prussian blue: Hemosiderin"
                  },
                  {
                    "text": "Oil red O: Lipid"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Langerhans Cell Histiocytosis (LCH)": [
                  {
                    "text": "Early involvement by LCH tends to be sinusoidal"
                  },
                  {
                    "text": "Partial or total effacement of lymph node with more extensive involvement by LCH"
                  },
                  {
                    "text": "LCs often associated with eosinophils &/or necrosis"
                  },
                  {
                    "text": "LCs are CD1a(+), langerin/CD207(+), and S100(+)"
                  },
                  {
                    "text": "Electron microscopy shows Birbeck granules"
                  },
                  {
                    "text": "Patients with LCH can have visceral involvement (unlike patients with DLA)"
                  }
                ],
                "Classical Hodgkin Lymphoma": [
                  {
                    "text": "The interfollicular pattern may mimic paracortical hyperplasia"
                  },
                  {
                    "text": "HRS cells are always present"
                  },
                  {
                    "text": "The HRS cells are typically CD15(+/-), CD30(+), pax-5 (+ dim), CD20(-/+), CD45/LCA(-)"
                  }
                ],
                "Mycosis Fungoides/Sézary Syndrome": [
                  {
                    "text": "Early lymph node involvement is almost identical to DLAOnly interstitial or small clusters of cerebriform lymphocytes in paracortex",
                    "sub_points": [
                      "Only interstitial or small clusters of cerebriform lymphocytes in paracortex"
                    ]
                  },
                  {
                    "text": "Flow cytometry immunophenotyping is often more sensitiveAltered expression of CD2, CD3, CD4, CD5, or CD7Decreased or absent CD26 expression",
                    "sub_points": [
                      "Altered expression of CD2, CD3, CD4, CD5, or CD7",
                      "Decreased or absent CD26 expression"
                    ]
                  },
                  {
                    "text": "TCRgene rearrangement analysis is helpful to identify minimal/early MF/SSIdentification of monoclonalTCRgene rearrangement",
                    "sub_points": [
                      "Identification of monoclonalTCRgene rearrangement"
                    ]
                  }
                ],
                "Myeloid Sarcoma": [
                  {
                    "text": "Paracortical expansion by leukemic cells with preservation of follicles"
                  },
                  {
                    "text": "Blasts/immature monocytes are of medium to large size with delicate nuclear membranes and distinct cytoplasmic borders"
                  },
                  {
                    "text": "CD34(+/-), CD43(+), CD68(+), CD117(+), lysozyme(+), MPO usually (-)"
                  },
                  {
                    "text": "Patients usually have bone marrow and systemic disease (unlike DLA)"
                  }
                ],
                "Metastatic Malignant Melanoma": [
                  {
                    "text": "In florid cases of DLA, melanin pigment and S100(+) may suggest possibility of melanoma"
                  },
                  {
                    "text": "DLA lacks nuclear atypia and increased mitoses of metastatic melanoma"
                  }
                ],
                "Lymph Nodes with Other Pigments": [
                  {
                    "text": "Drainage from tattoo; black pigment"
                  },
                  {
                    "text": "Hemosiderosis following blood transfusions"
                  },
                  {
                    "text": "Drainage after local trauma or surgery; hemosiderin"
                  },
                  {
                    "text": "Anthracotic pigment"
                  },
                  {
                    "text": "In most cases, IDCs and LCs are not markedly increased"
                  },
                  {
                    "text": "Dermatitis is not present"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Often associated with skin disordersEspecially generalized and exfoliative dermatitis",
                    "sub_points": [
                      "Especially generalized and exfoliative dermatitis"
                    ]
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Grossly enlarged lymph nodes; sometimes pigmented"
                  },
                  {
                    "text": "Paracortical hyperplasia withIDCs, LCs, and macrophages containing melanin pigment and lipid vacuoles",
                    "sub_points": [
                      "IDCs, LCs, and macrophages containing melanin pigment and lipid vacuoles"
                    ]
                  },
                  {
                    "text": "Histologic features of DLA do not exclude early involvement by MF/SS"
                  },
                  {
                    "text": "Ancillary testing for clonality assessment can be helpfulFlow cytometry immunophenotype may reveal aberrant patterns of T lymphocytesPolyclonalTCRgene rearrangement favors a reactive process",
                    "sub_points": [
                      "Flow cytometry immunophenotype may reveal aberrant patterns of T lymphocytes",
                      "PolyclonalTCRgene rearrangement favors a reactive process"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Unicentric Plasma Cell Variant Castleman Disease": {
            "name": "Unicentric Plasma Cell Variant Castleman Disease",
            "url": "https://app.pathprimer.com/document/67ada3c3-972e-4427-a0af-dc8f002432f0/lesson/6e5627b8-d0a0-4739-ae70-d53f34f8cfcd",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Histologically distinctive reaction pattern in lymph node characterized byMarked interfollicular plasmacytosisRegressive (hyaline vascular) changes in small subset of follicles",
                    "sub_points": [
                      "Marked interfollicular plasmacytosis",
                      "Regressive (hyaline vascular) changes in small subset of follicles"
                    ]
                  },
                  {
                    "text": "Defined as HHV8(-) and not associated with either multicentric Castleman disease (CD) or peripheral neuropathy,organomegaly,endocrinopathy,monoclonal M protein,skin lesions (POEMS) syndrome"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Dysregulation of interleukin-6 (IL-6) likely involved in pathogenesis"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "~ 10-20% of localized/unicentric cases of CD"
                  },
                  {
                    "text": "Broad age range; median: 3rd-4th decades"
                  },
                  {
                    "text": "Peripheral lymph nodes are most commonly affected"
                  },
                  {
                    "text": "~ 10-20% of patients have systemic symptoms &/or laboratory abnormalitiesSubset of cases reported with these abnormalities may be unrecognized multicentric CD",
                    "sub_points": [
                      "Subset of cases reported with these abnormalities may be unrecognized multicentric CD"
                    ]
                  },
                  {
                    "text": "Usually cured by surgical excision"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Preserved lymph node architecture"
                  },
                  {
                    "text": "Marked plasmacytosis in interfollicular areasNo cytologic atypia",
                    "sub_points": [
                      "No cytologic atypia"
                    ]
                  },
                  {
                    "text": "Germinal centers are hyperplastic, and usually subset are atretic with changes resembling hyaline vascular CD"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "No evidence of HHV8 infection or monoclonality"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "HHV8(+) multicentric CD"
                  },
                  {
                    "text": "Autoimmune diseases"
                  },
                  {
                    "text": "Marginal zone B-cell lymphoma"
                  },
                  {
                    "text": "Hyaline vascular variant CD"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Plasma cell variant Castleman disease (PC-CD)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Unicentric Castleman disease, plasma cell variant"
                  },
                  {
                    "text": "Angiofollicular lymph node hyperplasia"
                  },
                  {
                    "text": "Giant lymph node hyperplasia"
                  },
                  {
                    "text": "Angiomatous lymphoid hamartoma"
                  },
                  {
                    "text": "Benign giant lymphoma"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Histologically distinctive reaction pattern in lymph node characterized byMarked interfollicular plasmacytosisRegressive (hyaline vascular) changes in small subset of follicles in subset of cases",
                    "sub_points": [
                      "Marked interfollicular plasmacytosis",
                      "Regressive (hyaline vascular) changes in small subset of follicles in subset of cases"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Unknown": [
                  {
                    "text": "Data supporting role for dysregulation of interleukin-6 (IL-6) in pathogenesisLymphocytes in PC-CD express IL-6B cells express IL-6 receptor (CD126)Autocrine or paracrine mechanisms may be involvedIn mice, forced expression of IL-6 in bone marrow cells causes syndrome that resembles, in part, PC-CD",
                    "sub_points": [
                      "Lymphocytes in PC-CD express IL-6",
                      "B cells express IL-6 receptor (CD126)Autocrine or paracrine mechanisms may be involved",
                      "Autocrine or paracrine mechanisms may be involved",
                      "In mice, forced expression of IL-6 in bone marrow cells causes syndrome that resembles, in part, PC-CD"
                    ]
                  },
                  {
                    "text": "Immune dysregulation also may be involved"
                  },
                  {
                    "text": "There is no evidence of human herpesvirus 8 (HHV8) infection"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Accounts for 10-20% of localized or unicentric cases of CD"
                  }
                ],
                "Age": [
                  {
                    "text": "Broad range; median: 3rd-4th decades"
                  }
                ],
                "Sex": [
                  {
                    "text": "No preference"
                  }
                ],
                "Site": [
                  {
                    "text": "Peripheral lymph nodes most common"
                  },
                  {
                    "text": "Mediastinal involvement much less common [than hyaline vascular CD (HV-CD)]"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Most patients present with lymphadenopathy without systemic symptoms"
                  },
                  {
                    "text": "10-20% of patients reported in literature had systemic symptomsFever, night sweats, weight loss, malaiseHowever, it seems likely that many of these patients were HHV8(+)Therefore better classified as HHV8-associated &/or multicentric CD",
                    "sub_points": [
                      "Fever, night sweats, weight loss, malaise",
                      "However, it seems likely that many of these patients were HHV8(+)Therefore better classified as HHV8-associated &/or multicentric CD",
                      "Therefore better classified as HHV8-associated &/or multicentric CD"
                    ]
                  },
                  {
                    "text": "Small subset of patients reported were associated with POEMS syndromePOEMS:Peripheral neuropathy,organomegaly,endocrinopathy,monoclonal M protein,skin lesionsSubset of these patients are HHV8(+)",
                    "sub_points": [
                      "POEMS:Peripheral neuropathy,organomegaly,endocrinopathy,monoclonal M protein,skin lesions",
                      "Subset of these patients are HHV8(+)"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Many patients lack laboratory abnormalities"
                  },
                  {
                    "text": "Subset of patients (~ 10-20%) can have cytopeniasAnemia and thrombocytopenia",
                    "sub_points": [
                      "Anemia and thrombocytopenia"
                    ]
                  },
                  {
                    "text": "Serum IL-6 levels can be increased"
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "Usually cured by excision"
                  },
                  {
                    "text": "Siltuximab is not indicated for unicentric PC-CDFDA approved chimeric monoclonal antibody that targets IL-6",
                    "sub_points": [
                      "FDA approved chimeric monoclonal antibody that targets IL-6"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Good"
                  },
                  {
                    "text": "Small subset of patients may evolve to multicentric CDPossibly were cases of multicentric CD at time of initial biopsySiltuximab may be indicated for multicentric CD",
                    "sub_points": [
                      "Possibly were cases of multicentric CD at time of initial biopsy",
                      "Siltuximab may be indicated for multicentric CD"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Radiographic Findings": [
                  {
                    "text": "LymphadenopathyOften multiple lymph nodes in anatomic group are large",
                    "sub_points": [
                      "Often multiple lymph nodes in anatomic group are large"
                    ]
                  },
                  {
                    "text": "PET scan shows increased FDG uptake"
                  }
                ]
              },
              "MACROSCOPIC": {
                "Size": [
                  {
                    "text": "Usually lymphadenopathy is of modest size"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Less well defined than HV-CD"
                  },
                  {
                    "text": "Preserved overall lymph node architecture"
                  },
                  {
                    "text": "Marked plasmacytosis in interfollicular areasSome plasma cells can be binucleated",
                    "sub_points": [
                      "Some plasma cells can be binucleated"
                    ]
                  },
                  {
                    "text": "Vascularity in interfollicular areas can be prominent"
                  },
                  {
                    "text": "Sinuses usually patent"
                  },
                  {
                    "text": "Widely spaced lymphoid follicles"
                  },
                  {
                    "text": "Lymphoid follicles contain hyperplastic germinal centers, but small subset of germinal centers often show regressive changesResemble follicles seen in HV-CDOthers have used term mixed or transitional type because of these folliclesAtretic follicles are usually present and part of spectrum of PC-CD",
                    "sub_points": [
                      "Resemble follicles seen in HV-CD",
                      "Others have used term mixed or transitional type because of these follicles",
                      "Atretic follicles are usually present and part of spectrum of PC-CD"
                    ]
                  },
                  {
                    "text": "Mantle zones are usually well defined and can be expandedPlasmablasts are absent or rare in mantle zones",
                    "sub_points": [
                      "Plasmablasts are absent or rare in mantle zones"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Plasma cells are cytologically normal without atypia"
                  },
                  {
                    "text": "Lymphocytes show range in cytologic appearance"
                  },
                  {
                    "text": "Difficult to establish specific diagnosis of PC-CD by fine needle aspiration"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Interfollicular plasma cells express polytypic Ig light chains"
                  },
                  {
                    "text": "Follicles composed of polytypic B cells and T cellsGerminal centers are Bcl-2(-)Atretic follicles show increased follicular dendritic cellsCD21(+), CD23(+), CD35(+)",
                    "sub_points": [
                      "Germinal centers are Bcl-2(-)",
                      "Atretic follicles show increased follicular dendritic cellsCD21(+), CD23(+), CD35(+)",
                      "CD21(+), CD23(+), CD35(+)"
                    ]
                  },
                  {
                    "text": "Rare cases are reported with monoclonal plasma cellsThese cases most likely HHV8(+) &/or multicentric CD",
                    "sub_points": [
                      "These cases most likely HHV8(+) &/or multicentric CD"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Polytypic B cells and normal T cells"
                  },
                  {
                    "text": "Specific diagnosis cannot be suggested based on immunophenotype"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Very few cases studied"
                  },
                  {
                    "text": "No specific abnormalities reported"
                  },
                  {
                    "text": "Human androgen receptor assay (HUMARA)Monoclonal pattern in few cases",
                    "sub_points": [
                      "Monoclonal pattern in few cases"
                    ]
                  }
                ],
                "Molecular Studies": [
                  {
                    "text": "Most cases lack monoclonalIGHrearrangementsSmall subset of cases carryIGHrearrangementsMonoclonal cases may be HHV8(+) &/or multicentric CD in retrospect",
                    "sub_points": [
                      "Small subset of cases carryIGHrearrangements",
                      "Monoclonal cases may be HHV8(+) &/or multicentric CD in retrospect"
                    ]
                  },
                  {
                    "text": "No specific chromosomal translocations"
                  }
                ],
                "Associated Lymphoid Neoplasms": [
                  {
                    "text": "Small subset of PC-CD can be associated with lymphomaClassic Hodgkin lymphoma (HL) is most commonMixed cellularity typeCD changes can obscure large RS+H cellsNon-Hodgkin lymphomas also occurDiffuse large B-cell lymphomaMantle cell lymphomaPeripheral T-cell lymphoma",
                    "sub_points": [
                      "Classic Hodgkin lymphoma (HL) is most commonMixed cellularity typeCD changes can obscure large RS+H cells",
                      "Mixed cellularity type",
                      "CD changes can obscure large RS+H cells",
                      "Non-Hodgkin lymphomas also occurDiffuse large B-cell lymphomaMantle cell lymphomaPeripheral T-cell lymphoma",
                      "Diffuse large B-cell lymphoma",
                      "Mantle cell lymphoma",
                      "Peripheral T-cell lymphoma"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "HHV8(+) Multicentric CD": [
                  {
                    "text": "Clinically aggressive disease commonly associated with HIV infection and rarely POEMS syndrome"
                  },
                  {
                    "text": "Affected lymph nodes usually show blurred boundaries between germinal centers and mantle zonesPlasmablasts in mantle zones are HHV8(+)Can be identified using antibody specific for latency-associated nuclear antigen (LANA1)",
                    "sub_points": [
                      "Plasmablasts in mantle zones are HHV8(+)Can be identified using antibody specific for latency-associated nuclear antigen (LANA1)",
                      "Can be identified using antibody specific for latency-associated nuclear antigen (LANA1)"
                    ]
                  },
                  {
                    "text": "Plasmablasts can be present in clusters and are monotypic Igλ(+), known as microlymphoma"
                  }
                ],
                "Autoimmune Diseases": [
                  {
                    "text": "Rheumatoid arthritis may be best example"
                  },
                  {
                    "text": "Lymph nodes show florid interfollicular plasmacytosis and follicular hyperplasia"
                  },
                  {
                    "text": "Serological studies, such as testing for anti-CCP antibody, helpful to confirm diagnosis"
                  },
                  {
                    "text": "No evidence of monoclonality"
                  }
                ],
                "Marginal Zone B-Cell Lymphoma With Marked Plasmacytic Differentiation": [
                  {
                    "text": "Follicular hyperplasia and sheets of plasma cells can be prominent in some cases"
                  },
                  {
                    "text": "Nodal architecture is usually replaced by lymphomaNeoplastic B cells often with monocytoid featuresMonotypic Ig expression; monoclonalIGHrearrangements",
                    "sub_points": [
                      "Neoplastic B cells often with monocytoid features",
                      "Monotypic Ig expression; monoclonalIGHrearrangements"
                    ]
                  }
                ],
                "Plasmacytoma": [
                  {
                    "text": "Plasma cells form sheets that replace lymph node architecturePlasma cells are cytologically atypicalResidual follicles are usually small and overtaken by neoplastic cell proliferationNeoplasm may extend into perinodal adipose tissue",
                    "sub_points": [
                      "Plasma cells are cytologically atypical",
                      "Residual follicles are usually small and overtaken by neoplastic cell proliferation",
                      "Neoplasm may extend into perinodal adipose tissue"
                    ]
                  },
                  {
                    "text": "Plasma cells are monotypic and monoclonal"
                  }
                ],
                "Classic Hodgkin Lymphoma": [
                  {
                    "text": "Marked plasmacytosis can occur in some cases of classic HL"
                  },
                  {
                    "text": "RS+H cells in classic HLCD15(+), CD30(+), pax-5(dim +), CD45/LCA(-)",
                    "sub_points": [
                      "CD15(+), CD30(+), pax-5(dim +), CD45/LCA(-)"
                    ]
                  }
                ],
                "Angioimmunoblastic T-Cell Lymphoma": [
                  {
                    "text": "Rare cases have marked plasmacytosis and hyaline vascular type changes in germinal centers"
                  },
                  {
                    "text": "Lymph node architecture is replacedPolymorphous cell population including cells with pale/clear cytoplasm",
                    "sub_points": [
                      "Polymorphous cell population including cells with pale/clear cytoplasm"
                    ]
                  },
                  {
                    "text": "T cells express CD10, Bcl-6, CXCL13, or PD-1 in many cases"
                  },
                  {
                    "text": "Monoclonal TCR rearrangements"
                  }
                ],
                "Hyaline Vascular Variant Castleman Disease": [
                  {
                    "text": "Usually presents as unicentric mass; often above diaphragm"
                  },
                  {
                    "text": "Lymph nodes showLarge follicles with prominent hyaline vascular (\"lollipop\") lesionsLinear (\"onion skin\") mantle zonesInterfollicular stroma; no plasmacytosis",
                    "sub_points": [
                      "Large follicles with prominent hyaline vascular (\"lollipop\") lesions",
                      "Linear (\"onion skin\") mantle zones",
                      "Interfollicular stroma; no plasmacytosis"
                    ]
                  },
                  {
                    "text": "No association with HHV8 infection"
                  },
                  {
                    "text": "Surgical excision is curative"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Patients with unicentric/localized PC-CDHave variable clinical presentation associated with lymphadenopathyAre HHV8(-) and usually lack systemic symptoms or laboratory abnormalities",
                    "sub_points": [
                      "Have variable clinical presentation associated with lymphadenopathy",
                      "Are HHV8(-) and usually lack systemic symptoms or laboratory abnormalities"
                    ]
                  },
                  {
                    "text": "Small subset of patients reported in literature have symptoms or laboratory abnormalitiesPart of multicentric CD that initially presented with unicentric lymphadenopathyAssociated with unappreciated HHV8 &/or HIV infectionAssociated with POEMS syndrome",
                    "sub_points": [
                      "Part of multicentric CD that initially presented with unicentric lymphadenopathy",
                      "Associated with unappreciated HHV8 &/or HIV infection",
                      "Associated with POEMS syndrome"
                    ]
                  },
                  {
                    "text": "Once other conditions are excluded, unicentric PC-CD may not be true diseaseMore research is needed to clarify relationship between HV-CD, PC-CD, and multicentric CDPossibly nonspecific reaction pattern in lymph nodes",
                    "sub_points": [
                      "More research is needed to clarify relationship between HV-CD, PC-CD, and multicentric CD",
                      "Possibly nonspecific reaction pattern in lymph nodes"
                    ]
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Preserved lymph node architecture"
                  },
                  {
                    "text": "Marked interfollicular polytypic plasmacytosis"
                  },
                  {
                    "text": "Histologic features are not specific and can be observed in other conditions"
                  },
                  {
                    "text": "Must exclude HHV8(+) multicentric CD"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Kimura Disease": {
            "name": "Kimura Disease",
            "url": "https://app.pathprimer.com/document/6dece054-2776-4d28-bfd5-96e47dea311b/lesson/6e5627b8-d0a0-4739-ae70-d53f34f8cfcd",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Chronic inflammatory disease that affects deep subcutaneous tissue and regional lymph nodes"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Mainly occurs in young Asian males"
                  },
                  {
                    "text": "Head and neck regionNontender subcutaneous massesRegional lymphadenopathy",
                    "sub_points": [
                      "Nontender subcutaneous masses",
                      "Regional lymphadenopathy"
                    ]
                  },
                  {
                    "text": "Peripheral blood eosinophilia and elevated serum IgE"
                  },
                  {
                    "text": "Benign clinical course; recurrence common"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "SkinTypically located in deep subcutaneous tissueReactive follicles with prominent germinal centersEosinophilia and vascular hyperplasia",
                    "sub_points": [
                      "Typically located in deep subcutaneous tissue",
                      "Reactive follicles with prominent germinal centers",
                      "Eosinophilia and vascular hyperplasia"
                    ]
                  },
                  {
                    "text": "Lymph nodesHyperplastic folliclesEosinophilia with eosinophilic microabscessesStromal and perivascular sclerosis",
                    "sub_points": [
                      "Hyperplastic follicles",
                      "Eosinophilia with eosinophilic microabscesses",
                      "Stromal and perivascular sclerosis"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Immunohistochemistry and molecular studiesIgE deposits in germinal centersPolytypic B cells and normal T cells",
                    "sub_points": [
                      "IgE deposits in germinal centers",
                      "Polytypic B cells and normal T cells"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Kimura disease (KD)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Rare chronic inflammatory disorder of unknown etiologyCommonly occurs in head and neck region and involves subcutaneous tissues and lymph nodes",
                    "sub_points": [
                      "Commonly occurs in head and neck region and involves subcutaneous tissues and lymph nodes"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Infectious Agents": [
                  {
                    "text": "History and histologic findings suggest infectious etiologyNo definite pathogen has been identified",
                    "sub_points": [
                      "No definite pathogen has been identified"
                    ]
                  }
                ],
                "Other Proposed Causes": [
                  {
                    "text": "Allergy"
                  },
                  {
                    "text": "Autoimmunity"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Age": [
                  {
                    "text": "Mainly occurs in young adultsPeak age of onset in 3rd decade",
                    "sub_points": [
                      "Peak age of onset in 3rd decade"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "Predominantly males"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "Asians are most commonly afflicted"
                  }
                ],
                "Site": [
                  {
                    "text": "Typically in head and neck region"
                  },
                  {
                    "text": "Involves deep subcutaneous tissuesRegional lymph nodes",
                    "sub_points": [
                      "Regional lymph nodes"
                    ]
                  },
                  {
                    "text": "Often involves major salivary glandsParotidSubmandibular",
                    "sub_points": [
                      "Parotid",
                      "Submandibular"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Nontender masses in head and neckMost often in periauricular regionSlow-growing massInterval from onset of swelling to presentation may be several yearsOften persists unchanged for years",
                    "sub_points": [
                      "Most often in periauricular region",
                      "Slow-growing massInterval from onset of swelling to presentation may be several yearsOften persists unchanged for years",
                      "Interval from onset of swelling to presentation may be several years",
                      "Often persists unchanged for years"
                    ]
                  },
                  {
                    "text": "Rarely patients have generalized lymphadenopathy"
                  },
                  {
                    "text": "Systemic symptoms are uncommon"
                  },
                  {
                    "text": "Nephrotic syndrome may occur in up to 60% of patients"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Peripheral blood eosinophilia almost invariable"
                  },
                  {
                    "text": "Elevated serum IgE level"
                  },
                  {
                    "text": "Elevated erythrocyte sedimentation rate (ESR)"
                  },
                  {
                    "text": "Imbalance between Th1 and Th2 cytokines withIncreased TNF-α, IL-4, IL-5, and IL-13",
                    "sub_points": [
                      "Increased TNF-α, IL-4, IL-5, and IL-13"
                    ]
                  }
                ],
                "Treatment": [],
                "Adjuvant therapy": [
                  {
                    "text": "Radiation therapy usually yields best outcome"
                  },
                  {
                    "text": "Patients treated with surgical excision &/or steroid therapy have high rate of recurrenceAdvantages of surgical excision: Short treatment duration and provides tissue for histopathologic diagnosis",
                    "sub_points": [
                      "Advantages of surgical excision: Short treatment duration and provides tissue for histopathologic diagnosis"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Indolent clinical course"
                  },
                  {
                    "text": "Recurrence after excision is common"
                  }
                ]
              },
              "IMAGING": {
                "General Features": [
                  {
                    "text": "Ultrasound, CT, or MR scans are useful for determining extent of disease"
                  },
                  {
                    "text": "Combination of ultrasonography and MR has been shown to have high diagnostic valueHypoechoic center and hyperechoic margin with enriched blood vessels on ultrasonography and DopplerHypointensity replaces normal hyperintense subcutaneous fat on MRLymph nodes are enlarged with well-defined outline",
                    "sub_points": [
                      "Hypoechoic center and hyperechoic margin with enriched blood vessels on ultrasonography and Doppler",
                      "Hypointensity replaces normal hyperintense subcutaneous fat on MR",
                      "Lymph nodes are enlarged with well-defined outline"
                    ]
                  },
                  {
                    "text": "CT scan shows nonspecific findings"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Lymphoid infiltrate in deep subcutisFormation of follicles with germinal centersAccompanied by many eosinophils, plasma cells, and mast cellsEosinophilic microabscesses can be presentVascular hyperplasia",
                    "sub_points": [
                      "Formation of follicles with germinal centers",
                      "Accompanied by many eosinophils, plasma cells, and mast cellsEosinophilic microabscesses can be present",
                      "Eosinophilic microabscesses can be present",
                      "Vascular hyperplasia"
                    ]
                  },
                  {
                    "text": "Lymph nodes show preserved but distorted overall architecture withHyperplastic follicles with well-formed germinal centers and mantle zonesDeposition of IgE in germinal centers forms hyaline proteinaceous materialEosinophiliaEosinophilic microabscesses and eosinophilic follicle lysisInvolvement of perinodal soft tissuesNecrosis (±); usually not extensiveVascular proliferation in interfollicular regionsStromal and perivascular sclerosis",
                    "sub_points": [
                      "Hyperplastic follicles with well-formed germinal centers and mantle zones",
                      "Deposition of IgE in germinal centers forms hyaline proteinaceous material",
                      "EosinophiliaEosinophilic microabscesses and eosinophilic follicle lysisInvolvement of perinodal soft tissues",
                      "Eosinophilic microabscesses and eosinophilic follicle lysis",
                      "Involvement of perinodal soft tissues",
                      "Necrosis (±); usually not extensive",
                      "Vascular proliferation in interfollicular regions",
                      "Stromal and perivascular sclerosis"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Fine needle aspiration (FNA) yields polymorphous cell population with many eosinophilsDifficult to establish diagnosis of KD based on FNA findings alone",
                    "sub_points": [
                      "Difficult to establish diagnosis of KD based on FNA findings alone"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "IgE deposits in the germinal centers can be shown by immunohistochemistry or immunofluorescence"
                  },
                  {
                    "text": "Polytypic B cells and normal T cells"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "No evidence of monoclonal gene rearrangements"
                  },
                  {
                    "text": "No known translocations or oncogene abnormalities"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Angiolymphoid Hyperplasia with Eosinophilia (ALHE)": [
                  {
                    "text": "ALHE has number of other namesEpithelioid hemangioma, pseudo- or atypical pyogenic granuloma, inflammatory angiomatous nodule, histiocytoid hemangioma",
                    "sub_points": [
                      "Epithelioid hemangioma, pseudo- or atypical pyogenic granuloma, inflammatory angiomatous nodule, histiocytoid hemangioma"
                    ]
                  },
                  {
                    "text": "Histologic findings of ALHE differ from Kimura disease as followsLocated in superficial dermisLesion has low-power lobular pattern of capillary or medium-sized blood vesselsHypertrophic cuboidal/polygonal endothelial cellsProtrude into or occlude vascular luminaDescribed as \"hobnail\" or \"tombstone\" appearanceNo lymph node involvement",
                    "sub_points": [
                      "Located in superficial dermis",
                      "Lesion has low-power lobular pattern of capillary or medium-sized blood vessels",
                      "Hypertrophic cuboidal/polygonal endothelial cellsProtrude into or occlude vascular luminaDescribed as \"hobnail\" or \"tombstone\" appearance",
                      "Protrude into or occlude vascular lumina",
                      "Described as \"hobnail\" or \"tombstone\" appearance",
                      "No lymph node involvement"
                    ]
                  }
                ],
                "Langerhans Cell Histiocytosis": [
                  {
                    "text": "Can involve lymph nodes or extranodal sitesSuperficial dermis; however, deep subcutis is unlikely site of involvement (in contrast with KD)",
                    "sub_points": [
                      "Superficial dermis; however, deep subcutis is unlikely site of involvement (in contrast with KD)"
                    ]
                  },
                  {
                    "text": "Characteristic Langerhans cells cytologic featuresConvoluted nuclei with linear grooves and thin nuclear membranes",
                    "sub_points": [
                      "Convoluted nuclei with linear grooves and thin nuclear membranes"
                    ]
                  },
                  {
                    "text": "Inflammatory background: Eosinophils, neutrophils, lymphocytes, and histiocytes"
                  },
                  {
                    "text": "Necrosis and eosinophilic microabscesses common"
                  },
                  {
                    "text": "Immunohistochemistry: CD1a(+), S100(+), langerin(+)"
                  },
                  {
                    "text": "Birbeck granules shown by electron microscopy"
                  }
                ],
                "Dermatopathic Lymphadenopathy": [
                  {
                    "text": "Most patients (but not all) have skin disease"
                  },
                  {
                    "text": "Affects lymph nodes without extranodal diseaseAxillary or inguinal lymphadenopathy most common",
                    "sub_points": [
                      "Axillary or inguinal lymphadenopathy most common"
                    ]
                  },
                  {
                    "text": "Paracortical expansion byIncreased interdigitating dendritic cells and Langerhans cellsScattered plasma cells and eosinophilsDeposits of hemosiderin, melanin, and lipids",
                    "sub_points": [
                      "Increased interdigitating dendritic cells and Langerhans cells",
                      "Scattered plasma cells and eosinophils",
                      "Deposits of hemosiderin, melanin, and lipids"
                    ]
                  }
                ],
                "Parasitic Infection": [
                  {
                    "text": "Histologic findings can overlap with KDReactive folliclesEosinophiliaGranulomatous inflammation",
                    "sub_points": [
                      "Reactive follicles",
                      "Eosinophilia",
                      "Granulomatous inflammation"
                    ]
                  },
                  {
                    "text": "Identification of parasitic remnants helpful for diagnosis"
                  }
                ],
                "Drug Reactions": [
                  {
                    "text": "History of medications very helpful"
                  },
                  {
                    "text": "Onset immediately after beginning drug therapy or can occur later"
                  },
                  {
                    "text": "Associated fever &/or skin rash common"
                  },
                  {
                    "text": "Generalized or localized lymphadenopathy"
                  },
                  {
                    "text": "Regresses after cessation of medication"
                  }
                ],
                "Castleman Disease, Hyaline Vascular Type": [
                  {
                    "text": "Most often involves peripheral lymph nodes or mediastinum"
                  },
                  {
                    "text": "Does not usually involve deep subcutis and lacks eosinophilia (unlike KD)"
                  },
                  {
                    "text": "Large follicles with lymphocyte depletion of germinal centersSmall atretic germinal centers with hyaline depositsPenetrating sclerotic arterioles (hyaline-vascular or \"lollipop\" lesions)Concentric layering of mantle zone lymphocytes (\"onion skin\")",
                    "sub_points": [
                      "Small atretic germinal centers with hyaline deposits",
                      "Penetrating sclerotic arterioles (hyaline-vascular or \"lollipop\" lesions)",
                      "Concentric layering of mantle zone lymphocytes (\"onion skin\")"
                    ]
                  }
                ],
                "Florid Reactive Follicular Hyperplasia, Unspecified": [
                  {
                    "text": "Large follicles with reactive germinal centersFrequent mitoses, apoptotic bodies, and tingible-body macrophages",
                    "sub_points": [
                      "Frequent mitoses, apoptotic bodies, and tingible-body macrophages"
                    ]
                  },
                  {
                    "text": "Prominent eosinophilia and vascular proliferation are not present"
                  }
                ],
                "Angioimmunoblastic T-cell Lymphoma": [
                  {
                    "text": "Patients typically present with systemic symptoms and have aggressive clinical courseGeneralized lymphadenopathy: Almost all patientsHepatosplenomegaly common",
                    "sub_points": [
                      "Generalized lymphadenopathy: Almost all patients",
                      "Hepatosplenomegaly common"
                    ]
                  },
                  {
                    "text": "Lymph nodes, bone marrow, spleen, liver, and skin are frequently involved"
                  },
                  {
                    "text": "Histologic findingsParacortical or complete effacement of lymph node architecturePolymorphous cellular proliferation with spectrum of lymphocytes, histiocytes, eosinophils, and plasma cellsArborizing high endothelial venules",
                    "sub_points": [
                      "Paracortical or complete effacement of lymph node architecture",
                      "Polymorphous cellular proliferation with spectrum of lymphocytes, histiocytes, eosinophils, and plasma cells",
                      "Arborizing high endothelial venules"
                    ]
                  },
                  {
                    "text": "Thought to be neoplasm of follicular T-helper cell originPositive for CD10, BCL-6, CXCL13, and PD-1Follicular dendritic cells (CD21[+]) surrounding blood vessels",
                    "sub_points": [
                      "Positive for CD10, BCL-6, CXCL13, and PD-1",
                      "Follicular dendritic cells (CD21[+]) surrounding blood vessels"
                    ]
                  },
                  {
                    "text": "EBV(+) in B cells common"
                  }
                ],
                "Hodgkin Disease, Mixed Cellularity Type": [
                  {
                    "text": "Typically involves lymph nodes"
                  },
                  {
                    "text": "Extranodal involvement is rare without adjacent nodal disease"
                  },
                  {
                    "text": "Hodgkin and Reed-Sternberg cellsCD15(+), CD30(+), pax-5(+ dim), CD45/LCA(-)",
                    "sub_points": [
                      "CD15(+), CD30(+), pax-5(+ dim), CD45/LCA(-)"
                    ]
                  },
                  {
                    "text": "Mixed population of small lymphocytes, plasma cells, eosinophils, and histiocytes"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Peripheral blood eosinophilia and elevated serum IgE level"
                  },
                  {
                    "text": "Organ distributionSubcutaneous tissue and regional lymph nodesHead and neck regionPeripheral blood eosinophilia and elevated serum IgE level",
                    "sub_points": [
                      "Subcutaneous tissue and regional lymph nodes",
                      "Head and neck region",
                      "Peripheral blood eosinophilia and elevated serum IgE level"
                    ]
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Reactive follicular hyperplasia"
                  },
                  {
                    "text": "IgE deposits in germinal centers"
                  },
                  {
                    "text": "Eosinophilia"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Rosai-Dorfman Disease": {
            "name": "Rosai-Dorfman Disease",
            "url": "https://app.pathprimer.com/document/cae10c68-6136-4905-8604-9fefa434ed06/lesson/6e5627b8-d0a0-4739-ae70-d53f34f8cfcd",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Rosai-Dorfman disease (RDD) and sinus histiocytosis with massive lymphadenopathy are equivalent terms"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Unknown; histologic features are suggestive of virus"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Spontaneous regression occurs in most patients"
                  },
                  {
                    "text": "No specific therapy required"
                  }
                ],
                "Macroscopic": [
                  {
                    "text": "Large, often massive lymph nodes"
                  },
                  {
                    "text": "Often matted with capsular fibrosis"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Lymph nodes show dilated sinuses"
                  },
                  {
                    "text": "Associated small lymphocytes and plasma cells"
                  },
                  {
                    "text": "RDD histiocytes characterized byAbundant eosinophilic cytoplasmCentral vesicular nucleusSmall but distinct, central nucleolusEmperipolesis",
                    "sub_points": [
                      "Abundant eosinophilic cytoplasm",
                      "Central vesicular nucleus",
                      "Small but distinct, central nucleolus",
                      "Emperipolesis"
                    ]
                  },
                  {
                    "text": "In extranodal sitesEmperipolesis often focal or absent",
                    "sub_points": [
                      "Emperipolesis often focal or absent"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "ImmunohistochemistryS100(+), CD1a(-)",
                    "sub_points": [
                      "S100(+), CD1a(-)"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Rosai-Dorfman disease (RDD)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Sinus histiocytosis with massive lymphadenopathy (SHML)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Benign proliferation of histiocytes with characteristic cytologic featuresHistiocytes show emperipolesis (engulfment of lymphocytes)Histiocytes express S100",
                    "sub_points": [
                      "Histiocytes show emperipolesis (engulfment of lymphocytes)",
                      "Histiocytes express S100"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Unknown": [
                  {
                    "text": "RDD has been reported in identical twins or families suggesting genetic predisposition"
                  },
                  {
                    "text": "Associated with autoimmune lymphoproliferative syndrome"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Rare; worldwide geographic distribution"
                  }
                ],
                "Age": [
                  {
                    "text": "Wide rangeNewborn to ~ 75 years; more common in children",
                    "sub_points": [
                      "Newborn to ~ 75 years; more common in children"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "M:F = 3:2 (1.5)"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "All races affected"
                  }
                ],
                "Site": [
                  {
                    "text": "Lymph nodes"
                  },
                  {
                    "text": "Extranodal sites in ~ 40% of patientsHead and neck region commonUpper respiratory tract, skinOther common sitesSkin, soft tissues, gastrointestinal tractBones, breast, duraAlmost any site can be involved",
                    "sub_points": [
                      "Head and neck region commonUpper respiratory tract, skin",
                      "Upper respiratory tract, skin",
                      "Other common sitesSkin, soft tissues, gastrointestinal tractBones, breast, duraAlmost any site can be involved",
                      "Skin, soft tissues, gastrointestinal tract",
                      "Bones, breast, dura",
                      "Almost any site can be involved"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Lymphadenopathy, often without any symptomsUsually localizedCervical lymph nodes most often involvedOften bilateral with massive enlargement",
                    "sub_points": [
                      "Usually localized",
                      "Cervical lymph nodes most often involved",
                      "Often bilateral with massive enlargement"
                    ]
                  },
                  {
                    "text": "B symptoms are uncommon but can occurFever, night sweats can precede lymphadenopathy",
                    "sub_points": [
                      "Fever, night sweats can precede lymphadenopathy"
                    ]
                  },
                  {
                    "text": "Laboratory abnormalities in subset of patientsPolyclonal hypergammaglobulinemia commonBlood lymphocytes with low CD4 to CD8 ratioHemolytic anemia",
                    "sub_points": [
                      "Polyclonal hypergammaglobulinemia common",
                      "Blood lymphocytes with low CD4 to CD8 ratio",
                      "Hemolytic anemia"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "In most patients, RDD regresses spontaneouslyNo specific therapy neededRDD often persists for months before regressionRarely RDD can persist for years before regression",
                    "sub_points": [
                      "No specific therapy needed",
                      "RDD often persists for months before regression",
                      "Rarely RDD can persist for years before regression"
                    ]
                  },
                  {
                    "text": "Rare subset of patients have aggressive RDD and require therapyTherapies: Steroids, radiation therapy, chemotherapySurgical excision for patients with obstruction/compression-type symptoms",
                    "sub_points": [
                      "Therapies: Steroids, radiation therapy, chemotherapy",
                      "Surgical excision for patients with obstruction/compression-type symptoms"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Excellent for most affected patients"
                  },
                  {
                    "text": "Rare cases can be clinically aggressiveNo effective therapy for these rare aggressive casesFatalities can occur as a result ofAccompanying immune dysregulationMass effect in vital organs",
                    "sub_points": [
                      "No effective therapy for these rare aggressive cases",
                      "Fatalities can occur as a result ofAccompanying immune dysregulationMass effect in vital organs",
                      "Accompanying immune dysregulation",
                      "Mass effect in vital organs"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Radiographic Findings": [
                  {
                    "text": "Lymphadenopathy"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Enlarged lymph nodes: Often massiveOften matted with capsular fibrosis",
                    "sub_points": [
                      "Often matted with capsular fibrosis"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Lymph nodesOverall lymph node architecture is intact but distortedMarked dilatation of sinusesFilled with RDD histiocytesAssociated with small lymphocytes and plasma cellsGranulocytes not present, unless superimposed necrosis or infectionRDD histiocytes show emperipolesisEngulf cells that become located in histiocyte cytoplasmSmall lymphocytes, plasma cells, or erythrocytesCells surrounded by intracytoplasmic vacuoleEngulfed cells are usually viableOften marked plasmacytosis between sinusesReactive follicles often presentMitotic figures are uncommonRarely affected lymph nodes can undergo infarct",
                    "sub_points": [
                      "Overall lymph node architecture is intact but distorted",
                      "Marked dilatation of sinusesFilled with RDD histiocytesAssociated with small lymphocytes and plasma cellsGranulocytes not present, unless superimposed necrosis or infection",
                      "Filled with RDD histiocytes",
                      "Associated with small lymphocytes and plasma cells",
                      "Granulocytes not present, unless superimposed necrosis or infection",
                      "RDD histiocytes show emperipolesisEngulf cells that become located in histiocyte cytoplasmSmall lymphocytes, plasma cells, or erythrocytesCells surrounded by intracytoplasmic vacuoleEngulfed cells are usually viable",
                      "Engulf cells that become located in histiocyte cytoplasm",
                      "Small lymphocytes, plasma cells, or erythrocytes",
                      "Cells surrounded by intracytoplasmic vacuole",
                      "Engulfed cells are usually viable",
                      "Often marked plasmacytosis between sinuses",
                      "Reactive follicles often present",
                      "Mitotic figures are uncommon",
                      "Rarely affected lymph nodes can undergo infarct"
                    ]
                  },
                  {
                    "text": "Extranodal sitesRDD histiocytes can be sparse in areasEmperipolesis can be absentSmall lymphocytes and plasma cells often numerousFibrosis can be prominent",
                    "sub_points": [
                      "RDD histiocytes can be sparse in areasEmperipolesis can be absent",
                      "Emperipolesis can be absent",
                      "Small lymphocytes and plasma cells often numerous",
                      "Fibrosis can be prominent"
                    ]
                  },
                  {
                    "text": "RDD can be associated with Hodgkin or non-Hodgkin lymphomasMost common typesNodular lymphocyte predominant Hodgkin lymphomaFollicular lymphomaRDD is often a small focus in this settingIncidental finding without impact on prognosis",
                    "sub_points": [
                      "Most common typesNodular lymphocyte predominant Hodgkin lymphomaFollicular lymphoma",
                      "Nodular lymphocyte predominant Hodgkin lymphoma",
                      "Follicular lymphoma",
                      "RDD is often a small focus in this setting",
                      "Incidental finding without impact on prognosis"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "RDD histiocytes are characterized byLarge size with abundant eosinophilic cytoplasmWell-defined cell bordersCentral, often round nucleusDistinct central nucleolus± emperipolesis",
                    "sub_points": [
                      "Large size with abundant eosinophilic cytoplasmWell-defined cell borders",
                      "Well-defined cell borders",
                      "Central, often round nucleusDistinct central nucleolus",
                      "Distinct central nucleolus",
                      "± emperipolesis"
                    ]
                  }
                ],
                "Predominant Pattern/Injury Type": [
                  {
                    "text": "Sinusoidal"
                  }
                ],
                "Predominant Cell/Compartment Type": [
                  {
                    "text": "Histiocyte"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "RDD histiocytes areS100(+), CD1a(-), langerin(-)Histiocyte markers: CD4(+/-), CD14(+), CD68(+), CD163(+)Adhesion molecules: CD11b(+), CD11c(+), CD18(+), CD31(+)B-cell antigens(-), T-cell antigens(-)",
                    "sub_points": [
                      "S100(+), CD1a(-), langerin(-)",
                      "Histiocyte markers: CD4(+/-), CD14(+), CD68(+), CD163(+)",
                      "Adhesion molecules: CD11b(+), CD11c(+), CD18(+), CD31(+)",
                      "B-cell antigens(-), T-cell antigens(-)"
                    ]
                  },
                  {
                    "text": "Intracytoplasmic lymphocytes include both B and T cells"
                  },
                  {
                    "text": "Plasma cells are polytypic"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Polytypic B cells"
                  },
                  {
                    "text": "T cells with normal immunophenotype"
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "Epstein-Barr virus(-)"
                  },
                  {
                    "text": "Human herpes virus: HHV6(-), HHV8(-)"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Langerhans Cell Histiocytosis (LCH)": [
                  {
                    "text": "LCH can be confined to lymph node sinusoids similar to RDD"
                  },
                  {
                    "text": "Eosinophils and necrosis are common"
                  },
                  {
                    "text": "LCH cells have twisted nuclei with nuclear groovesLess cytoplasm than RDD histiocytesNo emperipolesis",
                    "sub_points": [
                      "Less cytoplasm than RDD histiocytes",
                      "No emperipolesis"
                    ]
                  },
                  {
                    "text": "Birbeck granules present as shown by electron microscopy"
                  },
                  {
                    "text": "ImmunohistochemistryS100(+), CD1a(+), langerin/CD207(+)",
                    "sub_points": [
                      "S100(+), CD1a(+), langerin/CD207(+)"
                    ]
                  },
                  {
                    "text": "HUMARA assay"
                  }
                ],
                "Chronic Granulomatous Inflammation": [
                  {
                    "text": "Usually not confined to lymph node sinuses"
                  },
                  {
                    "text": "Associated necrosis and acute and chronic inflammation"
                  },
                  {
                    "text": "Epithelioid histiocytes and multinucleated cellsHistiocytes do not resemble RDD histiocytesS100([-/+] focal)",
                    "sub_points": [
                      "Histiocytes do not resemble RDD histiocytes",
                      "S100([-/+] focal)"
                    ]
                  }
                ],
                "Metastatic Melanoma or Carcinoma": [
                  {
                    "text": "Metastases to lymph node often involve sinuses"
                  },
                  {
                    "text": "Cytologic atypia present; mitoses common"
                  },
                  {
                    "text": "Immunohistochemistry of melanomaS100(+), HMB-45(+), Mart-1(+)",
                    "sub_points": [
                      "S100(+), HMB-45(+), Mart-1(+)"
                    ]
                  },
                  {
                    "text": "Immunohistochemistry of carcinomaKeratins(+), S100(-)",
                    "sub_points": [
                      "Keratins(+), S100(-)"
                    ]
                  },
                  {
                    "text": "Clinical history of primary tumor"
                  }
                ],
                "Anaplastic Large Cell Lymphoma": [
                  {
                    "text": "Can selectively involve and expand lymph node sinuses"
                  },
                  {
                    "text": "Neoplastic cells are large with horseshoe-shaped nuclei (hallmark cells)"
                  },
                  {
                    "text": "ImmunohistochemistryCD30(+), T-cell antigens(+), ALK1(+/-), S100(-)",
                    "sub_points": [
                      "CD30(+), T-cell antigens(+), ALK1(+/-), S100(-)"
                    ]
                  },
                  {
                    "text": "Monoclonal T-cell receptor gene rearrangements(+)"
                  },
                  {
                    "text": "t(2;5)(p23;q35) in up to 75% of ALK(+) cases"
                  }
                ],
                "Histiocytic Sarcoma": [
                  {
                    "text": "Typically replaces lymph node architecture, not sinusoidal"
                  },
                  {
                    "text": "Cytologic atypia and mitotic figures"
                  },
                  {
                    "text": "Neoplastic histiocytes lack cytologic features of RDD histiocytes"
                  },
                  {
                    "text": "Phagocytosis by neoplastic histiocytes can occurUsually not prominent and not true emperipolesis",
                    "sub_points": [
                      "Usually not prominent and not true emperipolesis"
                    ]
                  }
                ],
                "Classical Hodgkin Lymphoma": [
                  {
                    "text": "Can rarely be localized to lymph node sinuses"
                  },
                  {
                    "text": "Hodgkin and Reed-Sternberg cells are present"
                  },
                  {
                    "text": "± associated granulocytes and plasma cells"
                  },
                  {
                    "text": "ImmunohistochemistryCD15(+/-), CD30(+), CD45/LCA(-), S100(-)",
                    "sub_points": [
                      "CD15(+/-), CD30(+), CD45/LCA(-), S100(-)"
                    ]
                  }
                ],
                "Toxoplasma Lymphadenitis": [
                  {
                    "text": "Caused by infection byToxoplasma gondii"
                  },
                  {
                    "text": "Diagnostic histologic triad includesSinusoidal expansion by monocytoid B cellsFollicular hyperplasiaEpithelioid histiocytes encroaching upon reactive germinal centers",
                    "sub_points": [
                      "Sinusoidal expansion by monocytoid B cells",
                      "Follicular hyperplasia",
                      "Epithelioid histiocytes encroaching upon reactive germinal centers"
                    ]
                  },
                  {
                    "text": "No RDD histiocytes; no emperipolesis"
                  }
                ],
                "Sinus Histiocytosis": [
                  {
                    "text": "Nonspecific reaction pattern in lymph node sinuses"
                  },
                  {
                    "text": "Histiocytes do not cytologically resemble RDD histiocytesSmaller, less cytoplasm; no emperipolesis",
                    "sub_points": [
                      "Smaller, less cytoplasm; no emperipolesis"
                    ]
                  },
                  {
                    "text": "ImmunohistochemistryS100([-/+] focal): Different pattern than RDD",
                    "sub_points": [
                      "S100([-/+] focal): Different pattern than RDD"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Usually asymptomatic lymphadenopathy in young patient"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Lymph nodesSinusoidal distributionLarge histiocytes with abundant cytoplasmCentral vesicular nuclei and small, distinct nucleoliEmperipolesis present in lymph nodesS100(+), CD1a(-)Associated small lymphocytes and plasma cells",
                    "sub_points": [
                      "Sinusoidal distribution",
                      "Large histiocytes with abundant cytoplasmCentral vesicular nuclei and small, distinct nucleoliEmperipolesis present in lymph nodesS100(+), CD1a(-)",
                      "Central vesicular nuclei and small, distinct nucleoli",
                      "Emperipolesis present in lymph nodes",
                      "S100(+), CD1a(-)",
                      "Associated small lymphocytes and plasma cells"
                    ]
                  },
                  {
                    "text": "Extranodal sitesEmperipolesis can be absent or very focal",
                    "sub_points": [
                      "Emperipolesis can be absent or very focal"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Sarcoid Lymphadenopathy": {
            "name": "Sarcoid Lymphadenopathy",
            "url": "https://app.pathprimer.com/document/19d2c461-2ad2-41ce-8144-261fbd2911fb/lesson/6e5627b8-d0a0-4739-ae70-d53f34f8cfcd",
            "content": {
              "KEY FACTS": {
                "Clinical Issues": [
                  {
                    "text": "Multisystemic chronic granulomatous diseaseBilateral hilar lymphadenopathy, many with lung nodules, PET active",
                    "sub_points": [
                      "Bilateral hilar lymphadenopathy, many with lung nodules, PET active"
                    ]
                  },
                  {
                    "text": "Therapy may not be required if asymptomatic"
                  },
                  {
                    "text": "Prognosis depends on involvement of critical organs"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "\"Hard\" granulomas without acute inflammation or necrosis"
                  },
                  {
                    "text": "Foci of fibrosis can be associated with granulomas"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Serum angiotensin converting enzyme (ACE) increased in 75% of patients"
                  },
                  {
                    "text": "Bronchoalveolar lavage fluid for CD4:CD8 ratioFlow cytometry shows CD4:CD8 > 4:1",
                    "sub_points": [
                      "Flow cytometry shows CD4:CD8 > 4:1"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Tuberculosis"
                  },
                  {
                    "text": "Atypical mycobacteria"
                  },
                  {
                    "text": "Fungal lymphadenitis"
                  }
                ],
                "Diagnostic Checklist": [
                  {
                    "text": "Compatible clinical and radiographic manifestations"
                  },
                  {
                    "text": "Biopsy shows granulomatous lymphadenitis without identifiable causative agents"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Multisystemic granulomatous disease of unknown etiology"
                  },
                  {
                    "text": "Diagnosis of exclusion"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Exact Etiology and Pathogenesis Unknown": [
                  {
                    "text": "Occupational and environmental exposureInorganic particles, insecticides, and moldy environments",
                    "sub_points": [
                      "Inorganic particles, insecticides, and moldy environments"
                    ]
                  },
                  {
                    "text": "Probable role of genetics as shown by assessment of major histocompatibility complexPositive association with HLA-A1, -B8, and -DR3Negative association with HLA-B12 and -DR4",
                    "sub_points": [
                      "Positive association with HLA-A1, -B8, and -DR3",
                      "Negative association with HLA-B12 and -DR4"
                    ]
                  },
                  {
                    "text": "Possible role of infectious agentsMycobacterium tuberculosisPropionibacterium acnes",
                    "sub_points": [
                      "Mycobacterium tuberculosis",
                      "Propionibacterium acnes"
                    ]
                  },
                  {
                    "text": "T-cell abnormalitiesIncreased CD4(+) T cells and CD4(+) and CD25(+) regulatory T- cellsDecreased CD1d-restricted natural killer cellsOligoclonal TCR-αβ T-cell repertoire",
                    "sub_points": [
                      "Increased CD4(+) T cells and CD4(+) and CD25(+) regulatory T- cells",
                      "Decreased CD1d-restricted natural killer cells",
                      "Oligoclonal TCR-αβ T-cell repertoire"
                    ]
                  },
                  {
                    "text": "Cytokines: Increased interferon-γ and interleukin-2"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "10-20 per 100,000 population"
                  }
                ],
                "Age": [
                  {
                    "text": "All ages; peak 20-39 years"
                  }
                ],
                "Sex": [
                  {
                    "text": "Female preponderance"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "Lifetime risk in USA is 2.4% in African Americans and 0.85% in Caucasians"
                  },
                  {
                    "text": "More likely to be chronic and fatal in African Americans"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Constitutional symptoms are commonFatigue, malaise, fever, night sweats, and weight loss",
                    "sub_points": [
                      "Fatigue, malaise, fever, night sweats, and weight loss"
                    ]
                  },
                  {
                    "text": "Symptoms related to organ involvementLungs: Dyspnea and coughHeart: Loss of ventricular function and sudden deathEyes: Keratoconjunctivitis, uveitis, retinal vasculitisSkin: Maculopapular eruptions, nodules, plaque-like lesionsErythema nodosumPainful, red, subcutaneous lesions on anterior surface of legsAssociated with sarcoidosis but not specificMusculoskeletal: ArthritisKidneys and electrolytes: Abnormal calcium metabolismExtrarenal production of calcitriol by activated macrophagesNervous system: Central and peripheral nervous system can be affectedHypothalamic hypopituitarismDiabetes insipidusLymphocytic meningitisOther organs: Symptoms directly related to organ involvementEndocrine system, reproductive system, gastrointestinal tract",
                    "sub_points": [
                      "Lungs: Dyspnea and cough",
                      "Heart: Loss of ventricular function and sudden death",
                      "Eyes: Keratoconjunctivitis, uveitis, retinal vasculitis",
                      "Skin: Maculopapular eruptions, nodules, plaque-like lesions",
                      "Erythema nodosumPainful, red, subcutaneous lesions on anterior surface of legsAssociated with sarcoidosis but not specific",
                      "Painful, red, subcutaneous lesions on anterior surface of legs",
                      "Associated with sarcoidosis but not specific",
                      "Musculoskeletal: Arthritis",
                      "Kidneys and electrolytes: Abnormal calcium metabolismExtrarenal production of calcitriol by activated macrophages",
                      "Extrarenal production of calcitriol by activated macrophages",
                      "Nervous system: Central and peripheral nervous system can be affectedHypothalamic hypopituitarismDiabetes insipidusLymphocytic meningitis",
                      "Hypothalamic hypopituitarism",
                      "Diabetes insipidus",
                      "Lymphocytic meningitis",
                      "Other organs: Symptoms directly related to organ involvementEndocrine system, reproductive system, gastrointestinal tract",
                      "Endocrine system, reproductive system, gastrointestinal tract"
                    ]
                  },
                  {
                    "text": "Lofgren syndrome: Occurs in subset of patientsErythema nodosum, hilar lymphadenopathy, migratory polyarthralgias, and fever",
                    "sub_points": [
                      "Erythema nodosum, hilar lymphadenopathy, migratory polyarthralgias, and fever"
                    ]
                  },
                  {
                    "text": "In approximately 50% of cases, patients are asymptomatic when 1st diagnosedIncidental detection by radiographic studiesMost children are asymptomatic",
                    "sub_points": [
                      "Incidental detection by radiographic studies",
                      "Most children are asymptomatic"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Anemia, leukopenia, and thrombocytopeniaUncommon but can be observed",
                    "sub_points": [
                      "Uncommon but can be observed"
                    ]
                  },
                  {
                    "text": "Erythrocyte sedimentation rate is often increased"
                  },
                  {
                    "text": "Hypercalciuria and hypercalcemia"
                  },
                  {
                    "text": "Liver involvement results in increased serum alkaline phosphatase levels"
                  },
                  {
                    "text": "Serum angiotensin converting enzyme (ACE) increased in 75% of patients"
                  },
                  {
                    "text": "D-dimer levels can be increased"
                  },
                  {
                    "text": "Bronchoalveolar lavageFlow cytometry immunophenotypic analysisIncreased lymphocyte percentageIncreased CD4:CD8 ratioDecreased CD3(+), CD56(+) cytotoxic T cells",
                    "sub_points": [
                      "Flow cytometry immunophenotypic analysisIncreased lymphocyte percentageIncreased CD4:CD8 ratioDecreased CD3(+), CD56(+) cytotoxic T cells",
                      "Increased lymphocyte percentage",
                      "Increased CD4:CD8 ratio",
                      "Decreased CD3(+), CD56(+) cytotoxic T cells"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Indications for treatmentMost patients do not require therapyAsymptomatic patients with low stage of disease have high rate of spontaneous remissionIndication for treatment of pulmonary sarcoidosisDeteriorating lung functionWorsening symptomsProgressive radiographic changesIndications for treatment of extrapulmonary sarcoidosisOcular, neurologic, myocardial, or renal sarcoidosis or hypercalcemia need treatment to avoid consequencesVision loss, impaired nervous system function, fatal arrhythmias, or renal damage",
                    "sub_points": [
                      "Most patients do not require therapyAsymptomatic patients with low stage of disease have high rate of spontaneous remission",
                      "Asymptomatic patients with low stage of disease have high rate of spontaneous remission",
                      "Indication for treatment of pulmonary sarcoidosisDeteriorating lung functionWorsening symptomsProgressive radiographic changes",
                      "Deteriorating lung function",
                      "Worsening symptoms",
                      "Progressive radiographic changes",
                      "Indications for treatment of extrapulmonary sarcoidosisOcular, neurologic, myocardial, or renal sarcoidosis or hypercalcemia need treatment to avoid consequencesVision loss, impaired nervous system function, fatal arrhythmias, or renal damage",
                      "Ocular, neurologic, myocardial, or renal sarcoidosis or hypercalcemia need treatment to avoid consequences",
                      "Vision loss, impaired nervous system function, fatal arrhythmias, or renal damage"
                    ]
                  },
                  {
                    "text": "Treatment modalitiesOral or inhaled glucocorticoidsOther treatment modalities are largely experimentalImmunosuppressive and cytotoxic drugs: Methotrexate, cyclophosphamide, cyclosporinTNF-α blockers: Infliximab, etanerceptNonsteroidal anti-inflammatory agentsHeart and lung transplantation",
                    "sub_points": [
                      "Oral or inhaled glucocorticoids",
                      "Other treatment modalities are largely experimentalImmunosuppressive and cytotoxic drugs: Methotrexate, cyclophosphamide, cyclosporinTNF-α blockers: Infliximab, etanerceptNonsteroidal anti-inflammatory agents",
                      "Immunosuppressive and cytotoxic drugs: Methotrexate, cyclophosphamide, cyclosporin",
                      "TNF-α blockers: Infliximab, etanercept",
                      "Nonsteroidal anti-inflammatory agents",
                      "Heart and lung transplantation"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Varies from patient to patient and depends onSymptomatic vs. asymptomaticOrgan involvement and severityProper treatment received",
                    "sub_points": [
                      "Symptomatic vs. asymptomatic",
                      "Organ involvement and severity",
                      "Proper treatment received"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Lymph nodes can be partially or completely replacedOften have firm and white cut surface; can mimic metastatic carcinoma",
                    "sub_points": [
                      "Often have firm and white cut surface; can mimic metastatic carcinoma"
                    ]
                  },
                  {
                    "text": "Peribronchial or cervical lymph nodes are most often biopsied"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Architectural effacement by small granulomas"
                  },
                  {
                    "text": "Granulomas composed of epithelioid cells with scattered Langhans giant cells and lymphocytes"
                  },
                  {
                    "text": "So-called \"hard\" granulomasWell-formed, closely packed, sharp margins",
                    "sub_points": [
                      "Well-formed, closely packed, sharp margins"
                    ]
                  },
                  {
                    "text": "Classical sarcoid granulomas lack necrosisSmall central foci of fibrinoid necrosis can be observed in some granulomas",
                    "sub_points": [
                      "Small central foci of fibrinoid necrosis can be observed in some granulomas"
                    ]
                  },
                  {
                    "text": "Schaumann bodies, asteroid bodies, and Hamazaki-Wesenburg inclusions can be seenAsteroid bodies: Star-like structures containing calcium, phosphorous, silica, aluminumSchaumann bodies: Round with concentric laminations containing iron and calciumHamazaki-Wesenburg inclusions: Yellow-brown, ovoid large lysosomes with hemosiderin or lipofuscinThese structures are not specific for sarcoidosis",
                    "sub_points": [
                      "Asteroid bodies: Star-like structures containing calcium, phosphorous, silica, aluminum",
                      "Schaumann bodies: Round with concentric laminations containing iron and calcium",
                      "Hamazaki-Wesenburg inclusions: Yellow-brown, ovoid large lysosomes with hemosiderin or lipofuscin",
                      "These structures are not specific for sarcoidosis"
                    ]
                  },
                  {
                    "text": "Foci of fibrosis can be associated with granulomas"
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Numerous histiocytes with abundant cytoplasm; normal small lymphocytes"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Histochemistry": [
                  {
                    "text": "AFB, GMS, PAS, Warthin-Starry to rule out infectious granulomasReactivity: Negative in sarcoidosisStaining Pattern: Not applicable",
                    "sub_points": [
                      "Reactivity: Negative in sarcoidosis",
                      "Staining Pattern: Not applicable"
                    ]
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "Epithelioid histiocytes have immunoprofile similar to macrophagesCD4(dim +), CD15(+/-), CD68(+), CD163(+)",
                    "sub_points": [
                      "CD4(dim +), CD15(+/-), CD68(+), CD163(+)"
                    ]
                  },
                  {
                    "text": "Mostly T-lymphocytesCD4(+) T-cells within granulomasCD8(+) T-cells surrounding granulomas",
                    "sub_points": [
                      "CD4(+) T-cells within granulomas",
                      "CD8(+) T-cells surrounding granulomas"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Lymphocytes in granulomas are mostly T-helper cellsMarkedly increased CD4:CD8 ratio",
                    "sub_points": [
                      "Markedly increased CD4:CD8 ratio"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "No evidence of monoclonalIgorTCRrearrangements"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Mycobacterium tuberculosis (TB)": [
                  {
                    "text": "Often involves cervical lymph nodes"
                  },
                  {
                    "text": "Large granulomas with caseating necrosis (typical picture)However, small epithelioid granulomas reminiscent of sarcoidosis can be present",
                    "sub_points": [
                      "However, small epithelioid granulomas reminiscent of sarcoidosis can be present"
                    ]
                  },
                  {
                    "text": "Langhans giant cells of sarcoidosis are smaller and have fewer nuclei than tuberculosis giant cells"
                  },
                  {
                    "text": "Acid-fast stain, culture, or PCR are necessary to establish diagnosisAcid-fast stain: Search for organisms within necrosisOrganisms not numerous unless patient is immunosuppressedExamination with oil immersion lens (1,000x) usually requiredDirect immunofluorescence, PCR, or cultureCulture results can take up to 30 days (TB organism grows slowly)",
                    "sub_points": [
                      "Acid-fast stain: Search for organisms within necrosisOrganisms not numerous unless patient is immunosuppressedExamination with oil immersion lens (1,000x) usually required",
                      "Organisms not numerous unless patient is immunosuppressed",
                      "Examination with oil immersion lens (1,000x) usually required",
                      "Direct immunofluorescence, PCR, or cultureCulture results can take up to 30 days (TB organism grows slowly)",
                      "Culture results can take up to 30 days (TB organism grows slowly)"
                    ]
                  }
                ],
                "Atypical Mycobacteria": [
                  {
                    "text": "Typically involves lateral lymph nodes in mid neckSo-called scrofula in children",
                    "sub_points": [
                      "So-called scrofula in children"
                    ]
                  },
                  {
                    "text": "Caseating granulomas with suppurative changesGranulomas often ill defined, irregular, or serpiginous (nonpalisading)Langhans-type giant cells; variable plasma cells and neutrophils",
                    "sub_points": [
                      "Granulomas often ill defined, irregular, or serpiginous (nonpalisading)",
                      "Langhans-type giant cells; variable plasma cells and neutrophils"
                    ]
                  },
                  {
                    "text": "Immunosuppressed patients may develop spindle cell pseudotumorMost common in patients with HIV infection",
                    "sub_points": [
                      "Most common in patients with HIV infection"
                    ]
                  },
                  {
                    "text": "Acid-fast stain, culture, or PCR to confirm diagnosis"
                  }
                ],
                "Fungal Lymphadenitis": [
                  {
                    "text": "Type of fungus related, in part, to geographic locationsHistoplasmosis in Southeastern USACoccidiomycosis in Southwestern USA",
                    "sub_points": [
                      "Histoplasmosis in Southeastern USA",
                      "Coccidiomycosis in Southwestern USA"
                    ]
                  },
                  {
                    "text": "Other common types of fungi causing lymphadenopathy and chronic granulomatous inflammationBlastomycosis, paracoccidioidomycosis, aspergillosis, cryptococcosis, mucormycosis, and candidiasis",
                    "sub_points": [
                      "Blastomycosis, paracoccidioidomycosis, aspergillosis, cryptococcosis, mucormycosis, and candidiasis"
                    ]
                  },
                  {
                    "text": "Chronic granulomatous inflammation usually associated with acute inflammationAcute inflammation is virtually never seen in sarcoidosis",
                    "sub_points": [
                      "Acute inflammation is virtually never seen in sarcoidosis"
                    ]
                  },
                  {
                    "text": "Proof of infectious organism is required for diagnosisGomori methenamine silver (GMS) or periodic acid-Schiff (PAS)PCR or culture often required",
                    "sub_points": [
                      "Gomori methenamine silver (GMS) or periodic acid-Schiff (PAS)",
                      "PCR or culture often required"
                    ]
                  }
                ],
                "Leprosy": [
                  {
                    "text": "Lepromatous form of disease can involve lymph nodes"
                  },
                  {
                    "text": "Large, pale, round histiocytes (so-called \"lepra\" cells)"
                  },
                  {
                    "text": "Typically no granulomas or necrosis"
                  },
                  {
                    "text": "Proof of infectious organism is required for diagnosisWade-Fite and Fite-Faraco stains; PCR",
                    "sub_points": [
                      "Wade-Fite and Fite-Faraco stains; PCR"
                    ]
                  }
                ],
                "Sarcoid-like Granulomas in Patients with Malignant Tumors": [
                  {
                    "text": "Patients do not have clinical or laboratory evidence of sarcoidosis"
                  },
                  {
                    "text": "Granulomas histologically similar to those observed in sarcoidosisGranulomas may or may not be directly associated with malignant neoplasm",
                    "sub_points": [
                      "Granulomas may or may not be directly associated with malignant neoplasm"
                    ]
                  },
                  {
                    "text": "Can occur in association with Hodgkin and non-Hodgkin lymphomas, myeloma, and rarely carcinoma"
                  }
                ],
                "Classical Hodgkin Lymphoma (HL)": [
                  {
                    "text": "Rarely, HL can be associated with numerous granulomasGranulomas can almost obscure Hodgkin and Reed-Sternberg (HRS) cellsHRS cells: CD15(+/-), CD30(+), pax-5(dim +), CD45/LCA(-)",
                    "sub_points": [
                      "Granulomas can almost obscure Hodgkin and Reed-Sternberg (HRS) cells",
                      "HRS cells: CD15(+/-), CD30(+), pax-5(dim +), CD45/LCA(-)"
                    ]
                  },
                  {
                    "text": "Tends to involve mediastinal lymph nodesSarcoidosis more often involves peribronchial lymph nodes",
                    "sub_points": [
                      "Sarcoidosis more often involves peribronchial lymph nodes"
                    ]
                  },
                  {
                    "text": "Etiology unknown"
                  },
                  {
                    "text": "Some data suggest that HL patients with sarcoid-like granulomas have better prognosis than those without"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Kikuchi-Fujimoto Disease": {
            "name": "Kikuchi-Fujimoto Disease",
            "url": "https://app.pathprimer.com/document/338c41f2-6258-46bb-a845-72bb0b762382/lesson/6e5627b8-d0a0-4739-ae70-d53f34f8cfcd",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Self-limited, lymphadenopathy characterized byProliferation of histiocytes and plasmacytoid dendritic cellsApoptosis with abundant karyorrhectic debrisSystemic symptoms and low-grade fever",
                    "sub_points": [
                      "Proliferation of histiocytes and plasmacytoid dendritic cells",
                      "Apoptosis with abundant karyorrhectic debris",
                      "Systemic symptoms and low-grade fever"
                    ]
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Viral, infectious, or autoimmune cause has been suggested"
                  },
                  {
                    "text": "Exuberant T-cell-mediated response to variety of stimuli in genetically susceptible people"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Young patients; usually self-limited clinical course"
                  },
                  {
                    "text": "Might represent end-stage phenotype of diverse disease entities"
                  },
                  {
                    "text": "Acute tender cervical lymphadenopathy"
                  },
                  {
                    "text": "Low-grade fever; systemic symptoms"
                  },
                  {
                    "text": "Systemic survey and follow-up recommended to rule out systemic lupus erythematosus"
                  },
                  {
                    "text": "Lymphadenopathy: Cervical lymph nodes most often involved"
                  },
                  {
                    "text": "No specific serologic tests are available for detecting KFD"
                  },
                  {
                    "text": "Diagnosis is usually established by lymph node biopsyExcisional biopsy is often required; often patchy involvement",
                    "sub_points": [
                      "Excisional biopsy is often required; often patchy involvement"
                    ]
                  },
                  {
                    "text": "Spontaneous resolution occurs, usually within 1-4 months"
                  },
                  {
                    "text": "No specific therapy required"
                  },
                  {
                    "text": "Young; usually < 30 years (range: 2-75 years)"
                  },
                  {
                    "text": "Women are affected more often"
                  },
                  {
                    "text": "Negative serologic studies for"
                  },
                  {
                    "text": "EBV, cytomegalovirus, influenza, adenovirus"
                  },
                  {
                    "text": "Usually negative autoimmune laboratory studies"
                  },
                  {
                    "text": "Excellent prognosis"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Multiple, pale circumscribed foci are found in paracortical area of lymph node"
                  },
                  {
                    "text": "Lack of extension of process into perinodal tissue"
                  },
                  {
                    "text": "Partial or extensive lymph node involvement"
                  },
                  {
                    "text": "3 phases: Proliferative, necrotizing, xanthomatous"
                  },
                  {
                    "text": "Proliferative phase; thought to be early stagePlasmacytoid dendritic cells and activated lymphocytesHistiocytes with C-shaped forms",
                    "sub_points": [
                      "Plasmacytoid dendritic cells and activated lymphocytes",
                      "Histiocytes with C-shaped forms"
                    ]
                  },
                  {
                    "text": "Necrotizing phaseParacortical areas of coagulative necrosisAbundant karyorrhexis and eosinophilic debrisAbsence of neutrophils",
                    "sub_points": [
                      "Paracortical areas of coagulative necrosis",
                      "Abundant karyorrhexis and eosinophilic debris",
                      "Absence of neutrophils"
                    ]
                  },
                  {
                    "text": "Xanthomatous phase; thought to be late stageHistiocytes with foamy cytoplasm",
                    "sub_points": [
                      "Histiocytes with foamy cytoplasm"
                    ]
                  },
                  {
                    "text": "Hyperplastic lymphoid follicles in uninvolved areas"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Many T cells: CD3(+), CD8(+)Predominance of CD8(+) T cells without aberrancies",
                    "sub_points": [
                      "Predominance of CD8(+) T cells without aberrancies"
                    ]
                  },
                  {
                    "text": "Histiocytes: Myeloperoxidase (+), lysozyme (+), CD68(+)"
                  },
                  {
                    "text": "Plasmacytoid dendritic cells: CD68(+), CD123(+), Tcl-1(+)"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Systemic lupus erythematosus lymphadenitis"
                  },
                  {
                    "text": "Herpes simplex-associated lymphadenitis"
                  },
                  {
                    "text": "Necrotizing granulomatous lesions"
                  },
                  {
                    "text": "Cat-scratch disease"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Kikuchi-Fujimoto disease (KFD)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Necrotizing lymphadenitis without granulocytic infiltration"
                  },
                  {
                    "text": "Histiocytic necrotizing lymphadenitis"
                  },
                  {
                    "text": "Kikuchi-Fujimoto lymphadenopathy"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Self-limited, benign form of lymphadenopathy characterized byProliferation of histiocytes and plasmacytoid monocytesApoptosis with abundant karyorrhectic debrisSystemic symptoms and low-grade fever in subset of patients",
                    "sub_points": [
                      "Proliferation of histiocytes and plasmacytoid monocytes",
                      "Apoptosis with abundant karyorrhectic debris",
                      "Systemic symptoms and low-grade fever in subset of patients"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Unknown": [
                  {
                    "text": "Viral, infectious, or autoimmune cause has been suggested"
                  },
                  {
                    "text": "Exuberant T-cell-mediated response to variety of stimuli in genetically susceptible people"
                  },
                  {
                    "text": "Cytokine-mediated mechanisms↑ interleukin-6, interferon-α, FAS ligand",
                    "sub_points": [
                      "↑ interleukin-6, interferon-α, FAS ligand"
                    ]
                  },
                  {
                    "text": "Viruses suggested to be involved in KFD includeEpstein-Barr virus (EBV) and human herpesvirus 6 (HHV-6)Identified in small subset of cases; unlikely to be cause",
                    "sub_points": [
                      "Epstein-Barr virus (EBV) and human herpesvirus 6 (HHV-6)",
                      "Identified in small subset of cases; unlikely to be cause"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Age": [
                  {
                    "text": "Young; usually < 30 years (range: 2-75 years)"
                  }
                ],
                "Sex": [
                  {
                    "text": "Women are affected more oftenF:M = 4:1",
                    "sub_points": [
                      "F:M = 4:1"
                    ]
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "KFD has been described in variety of ethnic backgroundsAsian descent is common",
                    "sub_points": [
                      "Asian descent is common"
                    ]
                  }
                ],
                "Site": [
                  {
                    "text": "LymphadenopathyCervical lymph nodes most often involved",
                    "sub_points": [
                      "Cervical lymph nodes most often involved"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Fever typically lasts for 1 weekCan persist for up to 1 month",
                    "sub_points": [
                      "Can persist for up to 1 month"
                    ]
                  },
                  {
                    "text": "Upper respiratory symptoms"
                  },
                  {
                    "text": "Most common initial manifestations areTender and painful lymphadenopathyLymphadenopathy with fever",
                    "sub_points": [
                      "Tender and painful lymphadenopathy",
                      "Lymphadenopathy with fever"
                    ]
                  },
                  {
                    "text": "Uncommon manifestationsWeight loss, night sweats, nausea, vomitingGeneralized lymphadenopathyJoint painExtranodal involvement by KFDSplenomegaly, hepatomegaly",
                    "sub_points": [
                      "Weight loss, night sweats, nausea, vomiting",
                      "Generalized lymphadenopathy",
                      "Joint pain",
                      "Extranodal involvement by KFD",
                      "Splenomegaly, hepatomegaly"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Rule out other causes of necrotizing lymphadenopathy"
                  },
                  {
                    "text": "No specific tests are available for detecting KFD"
                  },
                  {
                    "text": "Anemia"
                  },
                  {
                    "text": "Elevated lactate dehydrogenase levels"
                  },
                  {
                    "text": "Granulocytopenia and atypical lymphocytosis in peripheral blood (50%)"
                  },
                  {
                    "text": "Elevated erythrocyte sedimentation rates"
                  },
                  {
                    "text": "Polyclonal hypergammaglobulinemia"
                  },
                  {
                    "text": "Negative serologic studies forEBV, cytomegalovirus, influenza, adenovirusToxoplasmosis,Mycoplasma, Q fever",
                    "sub_points": [
                      "EBV, cytomegalovirus, influenza, adenovirus",
                      "Toxoplasmosis,Mycoplasma, Q fever"
                    ]
                  },
                  {
                    "text": "Usually negative autoimmune laboratory studiesAntinuclear antibodies, rheumatoid factor, anti-double-strand DNA antibodiesRare patients with KFD are subsequently diagnosed to have systemic lupus erythematosus",
                    "sub_points": [
                      "Antinuclear antibodies, rheumatoid factor, anti-double-strand DNA antibodies",
                      "Rare patients with KFD are subsequently diagnosed to have systemic lupus erythematosus"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "Diagnosis is usually established by lymph node biopsyExcisional biopsy is often required because KFD can be patchyAssessment of lymph node architecture is very helpful in establishing diagnosis",
                    "sub_points": [
                      "Excisional biopsy is often required because KFD can be patchyAssessment of lymph node architecture is very helpful in establishing diagnosis",
                      "Assessment of lymph node architecture is very helpful in establishing diagnosis"
                    ]
                  },
                  {
                    "text": "Spontaneous resolution occurs, usually within 1-4 months"
                  },
                  {
                    "text": "Small (~ 3%) subset of patients develop relapse"
                  }
                ],
                "Treatment": [
                  {
                    "text": "No specific therapy required"
                  },
                  {
                    "text": "Antiinflammatory agents"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Excellent"
                  }
                ]
              },
              "IMAGING": {
                "CT Findings": [
                  {
                    "text": "CT is preferred modality"
                  },
                  {
                    "text": "Cervical lymph nodes in KFD tend to be located in posterior triangle"
                  },
                  {
                    "text": "Lymph nodes appear as clusters< 4 cm in greatest dimensionNonenhancing necrosis",
                    "sub_points": [
                      "< 4 cm in greatest dimension",
                      "Nonenhancing necrosis"
                    ]
                  },
                  {
                    "text": "Any lymph node group can be involved in KFD"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Size: 0.5-4.0 cm"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Lymph nodeArchitecture: Partial or extensive involvementOften patchy in early stagesKFD begins in paracortex and near capsuleDegree of apoptosis/necrosis varies from one case to anotherNo granulocytes identified in necrotic areasPlasma cells usually absent or rareProcess does not extend into perinodal tissuesImmunoblasts are numerous in viable paracortex contiguous with necrosisNo hematoxylin bodies identifiedSinuses are patent or compressedCan be filled by histiocytes or monocytoid B cellsHyperplastic lymphoid follicles in uninvolved areas± thrombosed blood vessels3 histologic subtypes of KFD have been describedLymphohistiocytic/proliferative; thought to be early stageNecroticPhagocytic/foamy cell; thought to be late stage> 1 stage of KFD can be present within lymph nodeLymphohistiocytic/proliferative typeProliferation of histiocytes (including C-shaped forms)Increased plasmacytoid dendritic cellsSmall lymphocytes and immunoblasts are presentRelatively little apoptosis or necrotic debrisNecrotic typeAbundant apoptosis within distinct foci of necrosis associated with eosinophilic debrisHistiocytes and plasmacytoid dendritic cells undergo apoptosisFibrin thrombi may be present in blood vesselsPhagocytic/foamy cell typeNumerous histiocytes containing phagocytosed debris (foamy cytoplasm)Histiocytes often form rim surrounding necrotic areas",
                    "sub_points": [
                      "Architecture: Partial or extensive involvementOften patchy in early stages",
                      "Often patchy in early stages",
                      "KFD begins in paracortex and near capsuleDegree of apoptosis/necrosis varies from one case to anotherNo granulocytes identified in necrotic areasPlasma cells usually absent or rareProcess does not extend into perinodal tissuesImmunoblasts are numerous in viable paracortex contiguous with necrosisNo hematoxylin bodies identified",
                      "Degree of apoptosis/necrosis varies from one case to another",
                      "No granulocytes identified in necrotic areas",
                      "Plasma cells usually absent or rare",
                      "Process does not extend into perinodal tissues",
                      "Immunoblasts are numerous in viable paracortex contiguous with necrosis",
                      "No hematoxylin bodies identified",
                      "Sinuses are patent or compressedCan be filled by histiocytes or monocytoid B cells",
                      "Can be filled by histiocytes or monocytoid B cells",
                      "Hyperplastic lymphoid follicles in uninvolved areas",
                      "± thrombosed blood vessels",
                      "3 histologic subtypes of KFD have been describedLymphohistiocytic/proliferative; thought to be early stageNecroticPhagocytic/foamy cell; thought to be late stage",
                      "Lymphohistiocytic/proliferative; thought to be early stage",
                      "Necrotic",
                      "Phagocytic/foamy cell; thought to be late stage",
                      "> 1 stage of KFD can be present within lymph node",
                      "Lymphohistiocytic/proliferative typeProliferation of histiocytes (including C-shaped forms)Increased plasmacytoid dendritic cellsSmall lymphocytes and immunoblasts are presentRelatively little apoptosis or necrotic debris",
                      "Proliferation of histiocytes (including C-shaped forms)",
                      "Increased plasmacytoid dendritic cells",
                      "Small lymphocytes and immunoblasts are present",
                      "Relatively little apoptosis or necrotic debris",
                      "Necrotic typeAbundant apoptosis within distinct foci of necrosis associated with eosinophilic debrisHistiocytes and plasmacytoid dendritic cells undergo apoptosisFibrin thrombi may be present in blood vessels",
                      "Abundant apoptosis within distinct foci of necrosis associated with eosinophilic debris",
                      "Histiocytes and plasmacytoid dendritic cells undergo apoptosis",
                      "Fibrin thrombi may be present in blood vessels",
                      "Phagocytic/foamy cell typeNumerous histiocytes containing phagocytosed debris (foamy cytoplasm)Histiocytes often form rim surrounding necrotic areas",
                      "Numerous histiocytes containing phagocytosed debris (foamy cytoplasm)",
                      "Histiocytes often form rim surrounding necrotic areas"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Diagnosis can be suggested in touch imprints of lymph nodeHighlights cytologic characteristics of plasmacytoid dendritic cells (pDC)Touch imprint often better than fine-needle aspiration (FNA) smears",
                    "sub_points": [
                      "Highlights cytologic characteristics of plasmacytoid dendritic cells (pDC)",
                      "Touch imprint often better than fine-needle aspiration (FNA) smears"
                    ]
                  },
                  {
                    "text": "Frequency of CD123(+) pDC is high in KFDValuable indicator for diagnosis of KFDUseful for distinguishing KFD from reactive lymphadenopathy and neoplasms",
                    "sub_points": [
                      "Valuable indicator for diagnosis of KFD",
                      "Useful for distinguishing KFD from reactive lymphadenopathy and neoplasms"
                    ]
                  }
                ],
                "Skin": [
                  {
                    "text": "Most frequently located on face or upper body"
                  },
                  {
                    "text": "KFD in skin can grossly present asErythematous papulesIndurated lesions or plaquesUlcers",
                    "sub_points": [
                      "Erythematous papules",
                      "Indurated lesions or plaques",
                      "Ulcers"
                    ]
                  },
                  {
                    "text": "Histologic findings in skin includeDermal lymphohistiocytic infiltrate; most commonEpidermal changesNecrotic keratinocytesNonneutrophilic karyorrhectic debrisBasal vacuolar changeEdema of papillary dermis",
                    "sub_points": [
                      "Dermal lymphohistiocytic infiltrate; most common",
                      "Epidermal changesNecrotic keratinocytesNonneutrophilic karyorrhectic debrisBasal vacuolar change",
                      "Necrotic keratinocytes",
                      "Nonneutrophilic karyorrhectic debris",
                      "Basal vacuolar change",
                      "Edema of papillary dermis"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Histiocytes are CD4(+), CD68(+), lysozyme (+), myeloperoxidase (+) (dim)"
                  },
                  {
                    "text": "Plasmacytoid dendritic cells areCD68(+), CD123(+), CD303(+)Myeloperoxidase (-), fascin (-)",
                    "sub_points": [
                      "CD68(+), CD123(+), CD303(+)",
                      "Myeloperoxidase (-), fascin (-)"
                    ]
                  },
                  {
                    "text": "T cells are predominantly CD8(+)"
                  },
                  {
                    "text": "Immunoblasts are CD30(+) and of CD8(+) T-cell lineage"
                  },
                  {
                    "text": "B cells are rare or absent in areas of necrosis"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Predominance of CD8(+) T cells without aberrancies"
                  },
                  {
                    "text": "Rare polytypic B cells"
                  },
                  {
                    "text": "Insufficient to establish diagnosis of KFDHelpful to exclude non-Hodgkin lymphoma",
                    "sub_points": [
                      "Helpful to exclude non-Hodgkin lymphoma"
                    ]
                  }
                ],
                "PCR": [
                  {
                    "text": "No evidence of monoclonalIGHgene rearrangements"
                  },
                  {
                    "text": "No evidence of monoclonalTRBV20OR9-2rearrangements"
                  },
                  {
                    "text": "No known chromosomal translocations or gene mutations"
                  }
                ],
                "Electron Microscopy": [
                  {
                    "text": "KFD has high frequency of cytoplasmic inclusions in histiocytes and immunoblasts, includingIntracytoplasmic rodletsTubuloreticular structuresInterferon-α is related to presence of tubuloreticular structuresInterferon-α has been identified in many histiocytes of KFD",
                    "sub_points": [
                      "Intracytoplasmic rodlets",
                      "Tubuloreticular structuresInterferon-α is related to presence of tubuloreticular structuresInterferon-α has been identified in many histiocytes of KFD",
                      "Interferon-α is related to presence of tubuloreticular structures",
                      "Interferon-α has been identified in many histiocytes of KFD"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Systemic Lupus Erythematosus Lymphadenitis": [
                  {
                    "text": "Pattern of lymph node involvement can be similar to KFDProminent foci of necrosis and histiocytic infiltratesDegenerated nuclear debris (hematoxylin bodies)Azzopardi phenomenon can be presentEncrustation of blood vessel walls by degenerated nuclear materialPlasma cells can be numerous",
                    "sub_points": [
                      "Prominent foci of necrosis and histiocytic infiltrates",
                      "Degenerated nuclear debris (hematoxylin bodies)",
                      "Azzopardi phenomenon can be presentEncrustation of blood vessel walls by degenerated nuclear material",
                      "Encrustation of blood vessel walls by degenerated nuclear material",
                      "Plasma cells can be numerous"
                    ]
                  },
                  {
                    "text": "Serologic studies for anti-nuclear antibodies and anti-double-strand DNA antibodies support SLE"
                  },
                  {
                    "text": "SLE patients often have other systemic manifestations of disease"
                  }
                ],
                "Herpes Simplex Lymphadenitis": [
                  {
                    "text": "\"Punched out\" lesions in paracortex of lymph node can mimic KFDNecrotic debris and histiocytic infiltrate often prominent",
                    "sub_points": [
                      "Necrotic debris and histiocytic infiltrate often prominent"
                    ]
                  },
                  {
                    "text": "Features of herpes lymphadenitis that distinguish it from KFDViral inclusions; both Cowdry type A and multinucleated cellsAbundant neutrophilsSkin and mucous membranes have ulcerative lesions near sites of lymphadenopathy",
                    "sub_points": [
                      "Viral inclusions; both Cowdry type A and multinucleated cells",
                      "Abundant neutrophils",
                      "Skin and mucous membranes have ulcerative lesions near sites of lymphadenopathy"
                    ]
                  }
                ],
                "Necrotizing Granulomatous Lesions": [
                  {
                    "text": "Tuberculosis, atypical mycobacteria, and fungiUsually not restricted to paracortical regions of lymph nodeEpithelioid cells, giant cells, and granuloma formationNeutrophils and plasma cells are usually numerousIdentification of etiologic agents by special stains",
                    "sub_points": [
                      "Usually not restricted to paracortical regions of lymph node",
                      "Epithelioid cells, giant cells, and granuloma formation",
                      "Neutrophils and plasma cells are usually numerous",
                      "Identification of etiologic agents by special stains"
                    ]
                  }
                ],
                "Cat-Scratch Disease": [
                  {
                    "text": "Paracortical areas of necrosis show some resemblance to KFD butStellate-shaped necrosis with abundant neutrophils in earlier stagesGranulomatous inflammation in later stagesCaused byBartonella henselaeCan detect in Warthin-Starry stain in some cases",
                    "sub_points": [
                      "Stellate-shaped necrosis with abundant neutrophils in earlier stages",
                      "Granulomatous inflammation in later stages",
                      "Caused byBartonella henselaeCan detect in Warthin-Starry stain in some cases",
                      "Can detect in Warthin-Starry stain in some cases"
                    ]
                  }
                ],
                "Kawasaki Disease": [
                  {
                    "text": "Mostly occurs in children younger than 5 years old"
                  },
                  {
                    "text": "Geographic necrosis; fibrinoid thrombosis"
                  },
                  {
                    "text": "Neutrophilic infiltration is usually present"
                  }
                ],
                "Diffuse Large B-Cell Lymphoma": [
                  {
                    "text": "Early proliferative phase of KFD can mimic diffuse large B-cell lymphoma (DLBCL)Sheets of histiocytes and plasmacytoid dendritic cells can be mistaken for sheets of large B cellsHistiocytes are CD68(+), CD123(+), and B-cell antigen (-)",
                    "sub_points": [
                      "Sheets of histiocytes and plasmacytoid dendritic cells can be mistaken for sheets of large B cells",
                      "Histiocytes are CD68(+), CD123(+), and B-cell antigen (-)"
                    ]
                  },
                  {
                    "text": "Rare cases of DLBCL can show abundant apoptosis and mimic proliferative phase of KFDB-cell antigen (+) supports diagnosis of DLBCLMonoclonalIGHrearrangements",
                    "sub_points": [
                      "B-cell antigen (+) supports diagnosis of DLBCL",
                      "MonoclonalIGHrearrangements"
                    ]
                  }
                ],
                "Peripheral T-Cell Lymphoma": [
                  {
                    "text": "Proliferative/early necrotic phases of KFD can mimic peripheral T-cell lymphoma (PTCL)T immunoblasts and CD8(+) predominance can be mistaken for neoplastic T cells",
                    "sub_points": [
                      "T immunoblasts and CD8(+) predominance can be mistaken for neoplastic T cells"
                    ]
                  },
                  {
                    "text": "Features against diagnosis of PTCLNo proliferation of C-shaped histiocytes and plasmacytoid dendritic cellsPTCL are often CD4(+)Histiocytes in PTCL are MPO(-)No evidence of aberrant T-cell immunophenotype in KFDNo evidence of monoclonal TCR gene rearrangements in KFD",
                    "sub_points": [
                      "No proliferation of C-shaped histiocytes and plasmacytoid dendritic cells",
                      "PTCL are often CD4(+)",
                      "Histiocytes in PTCL are MPO(-)",
                      "No evidence of aberrant T-cell immunophenotype in KFD",
                      "No evidence of monoclonal TCR gene rearrangements in KFD"
                    ]
                  }
                ],
                "Classic Hodgkin Lymphoma": [
                  {
                    "text": "Paracortical areas of necrosis can occur in classic Hodgkin lymphoma (HL) possibly mimicking KFD"
                  },
                  {
                    "text": "Features against diagnosis of KFDNeutrophils, eosinophils, &/or plasma cells often numerousHodgkin and Reed-Sternberg cellsOften located around necrotic fociCD15(+), CD30(+), pax-5(+) (dim), CD45/LCA(-)",
                    "sub_points": [
                      "Neutrophils, eosinophils, &/or plasma cells often numerous",
                      "Hodgkin and Reed-Sternberg cellsOften located around necrotic fociCD15(+), CD30(+), pax-5(+) (dim), CD45/LCA(-)",
                      "Often located around necrotic foci",
                      "CD15(+), CD30(+), pax-5(+) (dim), CD45/LCA(-)"
                    ]
                  }
                ],
                "Acute Myeloid Leukemia/Myeloid Sarcoma": [
                  {
                    "text": "Sheets of neoplastic cells, especially monocytes, can mimic early phase of KFD"
                  },
                  {
                    "text": "Features against diagnosis of KFDNeoplastic cells have immature nuclear chromatinImmunophenotype is myeloid or monocyticCD13(+), CD33(+), CD34(+), CD117(+), HLA-DR(+), CD123(-)CD68 is not helpful in this differential diagnosis",
                    "sub_points": [
                      "Neoplastic cells have immature nuclear chromatin",
                      "Immunophenotype is myeloid or monocyticCD13(+), CD33(+), CD34(+), CD117(+), HLA-DR(+), CD123(-)CD68 is not helpful in this differential diagnosis",
                      "CD13(+), CD33(+), CD34(+), CD117(+), HLA-DR(+), CD123(-)",
                      "CD68 is not helpful in this differential diagnosis"
                    ]
                  },
                  {
                    "text": "Most patients with acute myeloid leukemia (AML) are older and have systemic manifestations of diseasePeripheral blood and bone marrow involvementHistory of AML",
                    "sub_points": [
                      "Peripheral blood and bone marrow involvement",
                      "History of AML"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Young patients"
                  },
                  {
                    "text": "Acute tender cervical lymphadenopathy"
                  },
                  {
                    "text": "± low-grade fever"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "3 general, often overlapping types or phases of diseaseLymphohistiocytic/proliferativeStriking infiltrate of histiocytes and plasmacytoid dendritic cells with minimal apoptosisType of KFD most often misdiagnosed as non-Hodgkin lymphomaNecroticParacortical areas of necrosisAbundant apoptosis with eosinophilic debrisLack of neutrophilsAbundance of CD3(+), CD8(+) T cellsPhagocytic/foamy cell typeNumerous lipid-laden or foamy histiocytes surround areas of necrosis",
                    "sub_points": [
                      "Lymphohistiocytic/proliferativeStriking infiltrate of histiocytes and plasmacytoid dendritic cells with minimal apoptosisType of KFD most often misdiagnosed as non-Hodgkin lymphoma",
                      "Striking infiltrate of histiocytes and plasmacytoid dendritic cells with minimal apoptosis",
                      "Type of KFD most often misdiagnosed as non-Hodgkin lymphoma",
                      "NecroticParacortical areas of necrosisAbundant apoptosis with eosinophilic debrisLack of neutrophilsAbundance of CD3(+), CD8(+) T cells",
                      "Paracortical areas of necrosis",
                      "Abundant apoptosis with eosinophilic debris",
                      "Lack of neutrophils",
                      "Abundance of CD3(+), CD8(+) T cells",
                      "Phagocytic/foamy cell typeNumerous lipid-laden or foamy histiocytes surround areas of necrosis",
                      "Numerous lipid-laden or foamy histiocytes surround areas of necrosis"
                    ]
                  },
                  {
                    "text": "Systemic lupus erythematosus can closely mimic KFDRecommend serologic testing for every patient in whom diagnosis of KFD is considered",
                    "sub_points": [
                      "Recommend serologic testing for every patient in whom diagnosis of KFD is considered"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Progressive Transformation of Germinal Centers": {
            "name": "Progressive Transformation of Germinal Centers",
            "url": "https://app.pathprimer.com/document/06e879c0-5700-4c53-ae1a-5839d449a088/lesson/6e5627b8-d0a0-4739-ae70-d53f34f8cfcd",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Progressive transformation of germinal centers (PTGC)"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Young adults most commonly affected"
                  },
                  {
                    "text": "Asymptomatic localized lymphadenopathy in most patientsCervical lymph nodes in ~ 50%",
                    "sub_points": [
                      "Cervical lymph nodes in ~ 50%"
                    ]
                  },
                  {
                    "text": "Generalized lymphadenopathy occurs in subset of patients"
                  },
                  {
                    "text": "Can be incidental finding in patients with lymphomaNLPHL most common",
                    "sub_points": [
                      "NLPHL most common"
                    ]
                  },
                  {
                    "text": "PTGC usually resolves spontaneouslyCan recur",
                    "sub_points": [
                      "Can recur"
                    ]
                  },
                  {
                    "text": "PTGC not associated with HIV"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Scattered large follicles in otherwise reactive lymph node with follicular hyperplasia"
                  },
                  {
                    "text": "Mantle zone cells migrate into and disrupt hyperplastic germinal centers"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Progressive transformation of germinal centers (PTGC)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Reactive hyperplasia of follicles characterized byLarge follicles with hyperplastic germinal centersDisruption of germinal centers due to infiltration by mantle zone B cellsAffected follicles typically are at different stages of dissolution",
                    "sub_points": [
                      "Large follicles with hyperplastic germinal centers",
                      "Disruption of germinal centers due to infiltration by mantle zone B cells",
                      "Affected follicles typically are at different stages of dissolution"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Unknown": [
                  {
                    "text": "Viral cause suspected"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "PTGC can occur at any age but is common in young adultsMedian age: 28 years~ 20% of cases occur in children",
                    "sub_points": [
                      "Median age: 28 years",
                      "~ 20% of cases occur in children"
                    ]
                  },
                  {
                    "text": "Men are more often affected than women"
                  },
                  {
                    "text": "PTGC usually involves peripheral lymph nodesCervical lymph nodes are most commonly involved (50% of cases)Axillary and inguinal lymph nodes less common",
                    "sub_points": [
                      "Cervical lymph nodes are most commonly involved (50% of cases)",
                      "Axillary and inguinal lymph nodes less common"
                    ]
                  },
                  {
                    "text": "PTGC can be the predominant change in lymph nodes prompting biopsy"
                  },
                  {
                    "text": "Patients with PTGC can present with or without symptomsMost frequent presentation is asymptomatic and localized lymphadenopathyGeneralized lymphadenopathy can occur in subset of patientsAdolescents who present with viral-like illnessPatients with autoimmune diseasesPTGC can be incidental finding in patients with lymphomaPTGC can be detected at initial diagnosis or after therapyInterval between PTGC and lymphoma can be > 10 yearsPTGC also rarely can precede diagnosis of lymphoma",
                    "sub_points": [
                      "Most frequent presentation is asymptomatic and localized lymphadenopathy",
                      "Generalized lymphadenopathy can occur in subset of patientsAdolescents who present with viral-like illnessPatients with autoimmune diseases",
                      "Adolescents who present with viral-like illness",
                      "Patients with autoimmune diseases",
                      "PTGC can be incidental finding in patients with lymphomaPTGC can be detected at initial diagnosis or after therapyInterval between PTGC and lymphoma can be > 10 yearsPTGC also rarely can precede diagnosis of lymphoma",
                      "PTGC can be detected at initial diagnosis or after therapy",
                      "Interval between PTGC and lymphoma can be > 10 years",
                      "PTGC also rarely can precede diagnosis of lymphoma"
                    ]
                  },
                  {
                    "text": "PTGC usually spontaneously resolves but can recurSame or different lymph nodesRecurrence occurs more often in children than adults",
                    "sub_points": [
                      "Same or different lymph nodes",
                      "Recurrence occurs more often in children than adults"
                    ]
                  },
                  {
                    "text": "PTGC is not associated with human immunodeficiency virus infection"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Observation"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Excellent"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Follicles with PTGC are usually large4-5x the size of normal reactive secondary follicles",
                    "sub_points": [
                      "4-5x the size of normal reactive secondary follicles"
                    ]
                  },
                  {
                    "text": "PTGC is usually focal; involves only a few follicles in lymph node"
                  },
                  {
                    "text": "Process of PTGC appears to proceed in stagesInitially germinal centers become hyperplastic\"Starry sky\" pattern can occur but unusual2-3 germinal centers per follicle fuse togetherMantle zone B cells infiltrate and disrupt germinal centersEventually germinal centers disappearCentroblasts and follicular dendritic cells are scattered among small mantle zone B cells",
                    "sub_points": [
                      "Initially germinal centers become hyperplastic\"Starry sky\" pattern can occur but unusual",
                      "\"Starry sky\" pattern can occur but unusual",
                      "2-3 germinal centers per follicle fuse together",
                      "Mantle zone B cells infiltrate and disrupt germinal centers",
                      "Eventually germinal centers disappearCentroblasts and follicular dendritic cells are scattered among small mantle zone B cells",
                      "Centroblasts and follicular dendritic cells are scattered among small mantle zone B cells"
                    ]
                  },
                  {
                    "text": "PTGC is almost always accompanied by follicular hyperplasiaInterfollicular hyperplasia often present",
                    "sub_points": [
                      "Interfollicular hyperplasia often present"
                    ]
                  },
                  {
                    "text": "PTGC can coexist with Hodgkin or non-Hodgkin lymphomaNodular lymphocyte predominant Hodgkin lymphoma (NLPHL) most commonNo data to support PTGC as precursor of NLPHLOther lymphoma types uncommonly associated with PTGCClassical Hodgkin lymphoma (nodular sclerosis or mixed cellularity)Plasma cell myelomaPTGC may involve same lymph node involved by lymphoma or different lymph node",
                    "sub_points": [
                      "Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) most commonNo data to support PTGC as precursor of NLPHL",
                      "No data to support PTGC as precursor of NLPHL",
                      "Other lymphoma types uncommonly associated with PTGCClassical Hodgkin lymphoma (nodular sclerosis or mixed cellularity)Plasma cell myeloma",
                      "Classical Hodgkin lymphoma (nodular sclerosis or mixed cellularity)",
                      "Plasma cell myeloma",
                      "PTGC may involve same lymph node involved by lymphoma or different lymph node"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Preserved B-cell and T-cell compartments of lymph nodeProminent follicular pattern",
                    "sub_points": [
                      "Prominent follicular pattern"
                    ]
                  },
                  {
                    "text": "In PTGC folliclesGerminal centersB-cell antigens(+), T-cell antigens(-)CD10(+), Bcl-6(+), Bcl-2(-)Disruption of follicular dendritic cells that are CD21(+), CD23(+)Mantle zonesB-cell antigens(+), T-cell antigens(-)IgD(+), Bcl-2(+)CD10(-), Bcl-6(-)",
                    "sub_points": [
                      "Germinal centersB-cell antigens(+), T-cell antigens(-)CD10(+), Bcl-6(+), Bcl-2(-)Disruption of follicular dendritic cells that are CD21(+), CD23(+)",
                      "B-cell antigens(+), T-cell antigens(-)",
                      "CD10(+), Bcl-6(+), Bcl-2(-)",
                      "Disruption of follicular dendritic cells that are CD21(+), CD23(+)",
                      "Mantle zonesB-cell antigens(+), T-cell antigens(-)IgD(+), Bcl-2(+)CD10(-), Bcl-6(-)",
                      "B-cell antigens(+), T-cell antigens(-)",
                      "IgD(+), Bcl-2(+)",
                      "CD10(-), Bcl-6(-)"
                    ]
                  },
                  {
                    "text": "T cells are relatively few in PTGC follicles"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)": [
                  {
                    "text": "Neoplastic nodules are more numerous and replace lymph node architecture"
                  },
                  {
                    "text": "Neoplastic nodules more irregular than those of PTGC"
                  },
                  {
                    "text": "Lymphocyte predominant (LP) cells are presentPreviously known as L&H or \"popcorn\" cellsLarge with multilobated contours, clear nucleoplasm, and inconspicuous nucleoliCD20(+), CD45/LCA(+), CD15(-), CD30(-/+)Bcl-6(+), Bcl-2(-)CD3(+) CD57(+) T cells form rosettes around LP cells",
                    "sub_points": [
                      "Previously known as L&H or \"popcorn\" cells",
                      "Large with multilobated contours, clear nucleoplasm, and inconspicuous nucleoli",
                      "CD20(+), CD45/LCA(+), CD15(-), CD30(-/+)",
                      "Bcl-6(+), Bcl-2(-)",
                      "CD3(+) CD57(+) T cells form rosettes around LP cells"
                    ]
                  }
                ],
                "Lymphocyte-rich Classical Hodgkin Lymphoma, Nodular Variant": [
                  {
                    "text": "Neoplastic nodules are more numerous and replace lymph node architecture"
                  },
                  {
                    "text": "Residual germinal centers are common within neoplastic nodulesOften eccentrically located and small",
                    "sub_points": [
                      "Often eccentrically located and small"
                    ]
                  },
                  {
                    "text": "HRS cells are presentLarge cells; usually 1-2 prominent nucleoliCD15(+/-), CD30(+), CD45/LCA(-)CD20(-/+; weak), Bcl-2(+/-)",
                    "sub_points": [
                      "Large cells; usually 1-2 prominent nucleoli",
                      "CD15(+/-), CD30(+), CD45/LCA(-)",
                      "CD20(-/+; weak), Bcl-2(+/-)"
                    ]
                  }
                ],
                "Follicular Lymphoma, Floral Variant": [
                  {
                    "text": "Neoplastic follicles are numerous; back to back"
                  },
                  {
                    "text": "Composition of follicles is relatively homogeneousMixture of centrocytes and centroblasts",
                    "sub_points": [
                      "Mixture of centrocytes and centroblasts"
                    ]
                  },
                  {
                    "text": "No LP cells identified"
                  },
                  {
                    "text": "Monotypic Ig(+), CD10(+), Bcl-6(+), and Bcl-2(+)"
                  }
                ],
                "HIV-associated Lymphadenopathy": [
                  {
                    "text": "Follicle lysis is common in HIV(+) lymphadenopathyMost common in early stages of infection",
                    "sub_points": [
                      "Most common in early stages of infection"
                    ]
                  },
                  {
                    "text": "Follicle lysis superficially resembles PTGC butFollicles are usually not enlarged (unlike PTGC)Hemorrhage is common in affected folliclesFollicles are infiltrated by T cells",
                    "sub_points": [
                      "Follicles are usually not enlarged (unlike PTGC)",
                      "Hemorrhage is common in affected follicles",
                      "Follicles are infiltrated by T cells"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Young patients; male > female"
                  },
                  {
                    "text": "Most patients are asymptomaticSingle enlarged lymph node",
                    "sub_points": [
                      "Single enlarged lymph node"
                    ]
                  },
                  {
                    "text": "Small number of cases are associated with lymphomaNodular lymphocyte predominant Hodgkin lymphoma is most commonPTGC may precede, coexist with, or follow diagnosis of lymphoma",
                    "sub_points": [
                      "Nodular lymphocyte predominant Hodgkin lymphoma is most common",
                      "PTGC may precede, coexist with, or follow diagnosis of lymphoma"
                    ]
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Lymph node architecture is preserved"
                  },
                  {
                    "text": "Large and well-defined follicles that have expanded mantle zones and disrupted germinal centers"
                  },
                  {
                    "text": "Usually involve small number of follicles in background of follicular hyperplasia"
                  },
                  {
                    "text": "No evidence of monoclonal B-cell population"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Gelatinous Transformation": {
            "name": "Gelatinous Transformation",
            "url": "https://app.pathprimer.com/document/c989c723-dd66-4a8c-8d4c-8fe79961b699/lesson/6e5627b8-d0a0-4739-ae70-d53f34f8cfcd",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Synonyms: Gelatinous bone marrow transformation (GMT), serous atrophy, starvation marrow"
                  },
                  {
                    "text": "Lesion of marrow characterized by deposition of extracellular gelatinous mucopolysaccharides rich in hyaluronic acid, loss of hematopoietic cells, and shrunken adipocytes"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Associated with protein catabolic conditionsMalnutrition states are most common (anorexia nervosa, cachexia, starvation)Other common causes include malignancies, HIV infection, and chemotherapy",
                    "sub_points": [
                      "Malnutrition states are most common (anorexia nervosa, cachexia, starvation)",
                      "Other common causes include malignancies, HIV infection, and chemotherapy"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "May be reversible with treatment of underlying condition"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "May diffusely involve marrow or be present as focal lesion"
                  },
                  {
                    "text": "Loss of hematopoietic cells with fat cell atrophy"
                  },
                  {
                    "text": "Accumulation of extracellular gelatinous material that stains pink with Giemsa, strongly positive with alcian blue, and negative with Congo red"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Amyloidosis, marrow edema, marrow necrosis"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Gelatinous transformation (GMT)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Gelatinous bone marrow transformation (GMT)"
                  },
                  {
                    "text": "Serous atrophy"
                  },
                  {
                    "text": "Starvation marrow"
                  }
                ],
                "Definitions": [
                  {
                    "text": "GMT: Lesion of marrow characterized by deposition of extracellular gelatinous mucopolysaccharides rich in hyaluronic acid, loss of hematopoietic cells, and shrunken adipocytes"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Etiology": [
                  {
                    "text": "Associated with protein catabolic conditionsMalnutrition states are most commonAnorexia nervosaCachexiaStarvationAlcoholismHIV infectionAutoimmune disorders (SLE)MalignanciesChemotherapy",
                    "sub_points": [
                      "Malnutrition states are most commonAnorexia nervosaCachexiaStarvation",
                      "Anorexia nervosa",
                      "Cachexia",
                      "Starvation",
                      "Alcoholism",
                      "HIV infection",
                      "Autoimmune disorders (SLE)",
                      "Malignancies",
                      "Chemotherapy"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "Nonspecific symptoms that vary with underlying condition"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Treatment based on underlying condition"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "May be reversible with treatment of underlying condition"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Hypoplasia of hematopoietic cells"
                  },
                  {
                    "text": "Atrophy of adipocytesMay contain intracellular granular eosinophilic material",
                    "sub_points": [
                      "May contain intracellular granular eosinophilic material"
                    ]
                  },
                  {
                    "text": "Accumulation of extracellular gelatinous materialStainingGiemsa: Pink-amphophilicPeriodic acid-Schiff: Weakly positiveAlcian blue at pH 2.5: Strongly positiveCongo red: Negative for apple-green birefringence",
                    "sub_points": [
                      "StainingGiemsa: Pink-amphophilicPeriodic acid-Schiff: Weakly positiveAlcian blue at pH 2.5: Strongly positiveCongo red: Negative for apple-green birefringence",
                      "Giemsa: Pink-amphophilic",
                      "Periodic acid-Schiff: Weakly positive",
                      "Alcian blue at pH 2.5: Strongly positive",
                      "Congo red: Negative for apple-green birefringence"
                    ]
                  },
                  {
                    "text": "May diffusely involve marrow or be present as focal lesion"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Amyloidosis": [
                  {
                    "text": "Positive Congo red staining with apple-green birefringence on examination with polarized light"
                  }
                ],
                "Marrow edema": [
                  {
                    "text": "Adipocytes are normal sized and surrounded by substance that is negative for alcian blue"
                  }
                ],
                "Marrow necrosis": [
                  {
                    "text": "Necrotic debris less homogenous, more granular, and stains differently than GMT"
                  },
                  {
                    "text": "Necrosis of adjacent bone may be present"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Gaucher Disease": {
            "name": "Gaucher Disease",
            "url": "https://app.pathprimer.com/document/4c8badff-e190-4ed0-8761-2df57ed33876/lesson/6e5627b8-d0a0-4739-ae70-d53f34f8cfcd",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "Gaucher disease: Lysosomal storage disorder caused by mutation inGABgeneMutations inGABgene result in deficiency of lysosomal enzyme β-glucocerebrosidaseDeficiency results in accumulation of glucocerebrosides in lysosomes of macrophages",
                    "sub_points": [
                      "Mutations inGABgene result in deficiency of lysosomal enzyme β-glucocerebrosidase",
                      "Deficiency results in accumulation of glucocerebrosides in lysosomes of macrophages"
                    ]
                  },
                  {
                    "text": "Clinical manifestations result from accumulation of macrophages in tissues/organs and resultant inflammatory response in surrounding tissues"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Autosomal recessive inheritanceMore prevalent in Ashkenazi Jewish population",
                    "sub_points": [
                      "More prevalent in Ashkenazi Jewish population"
                    ]
                  },
                  {
                    "text": "Gaucher disease involves visceral organs, bone marrow, and bone in all affected patients"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Bone marrow reveals histiocytes with characteristic \"wrinkled paper appearance,\" known as Gaucher cells"
                  },
                  {
                    "text": "Stains positively with periodic acid-Schiff (PAS) and tartrate-resistant acid phosphatase (TRAP)"
                  },
                  {
                    "text": "Gaucher cells also show diffuse staining with iron stains"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Pseudo-Gaucher CellsCaused by rapid bone marrow turnover and are frequently associated with chronic myelogenous leukemia (CML)",
                    "sub_points": [
                      "Caused by rapid bone marrow turnover and are frequently associated with chronic myelogenous leukemia (CML)"
                    ]
                  },
                  {
                    "text": "Reactive conditions, other storage disorders, hemophagocytic lymphohistiocytosis (HLH), and Langerhans cell histiocytosis"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Gaucher disease: Autosomal recessive lysosomal storage disorder caused by mutation inGABgene"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Molecular Pathogenesis": [
                  {
                    "text": "(For more in-depth discussion, see PATHPrimer topic \"Gaucher Disease\" in Molecular section)"
                  },
                  {
                    "text": "Autosomal recessive inheritance of mutation inGABgeneLocated on chromosome 1q21More than 200 mutationsN370S, L444P, and 84GG mutations are most frequent",
                    "sub_points": [
                      "Located on chromosome 1q21",
                      "More than 200 mutations",
                      "N370S, L444P, and 84GG mutations are most frequent"
                    ]
                  },
                  {
                    "text": "Mutations inGABgene result in deficiency of lysosomal enzyme β-glucocerebrosidaseβ-glucocerebrosidase normally functions to break down glucocerebroside → glucose and ceramide",
                    "sub_points": [
                      "β-glucocerebrosidase normally functions to break down glucocerebroside → glucose and ceramide"
                    ]
                  },
                  {
                    "text": "Deficiency results in accumulation of glucocerebrosides in lysosomes of macrophages"
                  },
                  {
                    "text": "Glucocerebrosides may be 20-100 times that of normal tissues"
                  },
                  {
                    "text": "Clinical manifestations result from accumulation of macrophages in spleen, liver, bone marrow, bone, and other tissues/organs and resultant inflammatory response in surrounding tissues"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Incidence: 1 per 75,000 live births"
                  },
                  {
                    "text": "Type I is most common: ~ 90% of patientsMore prevalent in Ashkenazi Jewish population",
                    "sub_points": [
                      "More prevalent in Ashkenazi Jewish population"
                    ]
                  },
                  {
                    "text": "Type II/III are less common: Occur in all ethnicities"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Early identification is crucial because early treatment can prevent development of irreversible complications"
                  },
                  {
                    "text": "Gaucher disease involves visceral organs, bone marrow, and bone in all affected patients"
                  },
                  {
                    "text": "Disease severity is highly variable and can range from lethal to asymptomatic"
                  },
                  {
                    "text": "Three clinical subtypes have been designatedType I (non-neuronopathic)Lacks CNS manifestationsBony abnormalities: Osteopenia, bone pain, pathologic fractures, osteonecrosisHepatosplenomegalyCytopenias (anemia and thrombocytopenia are common)Lung diseaseType II (neuronopathic)Acute presentationEarly onset, typically in first yearPresentation same as type I, but with CNS manifestationsCNS manifestations include oculomotor dysfunction, severe hypotonia or rigidity, swallowing impairment, seizuresMay present clinically with congenital ichthyosisType III (neuronopathic)Subacute or chronicOnset later than type IICNS symptoms include those described in type II, and dementia, ataxia, and myoclonus",
                    "sub_points": [
                      "Type I (non-neuronopathic)Lacks CNS manifestationsBony abnormalities: Osteopenia, bone pain, pathologic fractures, osteonecrosisHepatosplenomegalyCytopenias (anemia and thrombocytopenia are common)Lung disease",
                      "Lacks CNS manifestations",
                      "Bony abnormalities: Osteopenia, bone pain, pathologic fractures, osteonecrosis",
                      "Hepatosplenomegaly",
                      "Cytopenias (anemia and thrombocytopenia are common)",
                      "Lung disease",
                      "Type II (neuronopathic)Acute presentationEarly onset, typically in first yearPresentation same as type I, but with CNS manifestationsCNS manifestations include oculomotor dysfunction, severe hypotonia or rigidity, swallowing impairment, seizuresMay present clinically with congenital ichthyosis",
                      "Acute presentation",
                      "Early onset, typically in first year",
                      "Presentation same as type I, but with CNS manifestationsCNS manifestations include oculomotor dysfunction, severe hypotonia or rigidity, swallowing impairment, seizures",
                      "CNS manifestations include oculomotor dysfunction, severe hypotonia or rigidity, swallowing impairment, seizures",
                      "May present clinically with congenital ichthyosis",
                      "Type III (neuronopathic)Subacute or chronicOnset later than type IICNS symptoms include those described in type II, and dementia, ataxia, and myoclonus",
                      "Subacute or chronic",
                      "Onset later than type II",
                      "CNS symptoms include those described in type II, and dementia, ataxia, and myoclonus"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Enzyme-replacement therapy (ERT)Imiglucerase: Recombinant glucosylceramidase is indicated in symptomatic patientsIndicated for patients with type I, and with type III with visceral symptomsEfficacy of ERT in patients with neuronopathic symptoms is less well-establishedImiglucerase does not cross blood-brain barrier and has limited impact on CNS disease",
                    "sub_points": [
                      "Imiglucerase: Recombinant glucosylceramidase is indicated in symptomatic patientsIndicated for patients with type I, and with type III with visceral symptoms",
                      "Indicated for patients with type I, and with type III with visceral symptoms",
                      "Efficacy of ERT in patients with neuronopathic symptoms is less well-establishedImiglucerase does not cross blood-brain barrier and has limited impact on CNS disease",
                      "Imiglucerase does not cross blood-brain barrier and has limited impact on CNS disease"
                    ]
                  },
                  {
                    "text": "Substrate-reduction therapy (SRT)Therapies directed at reducing glycolipid accumulation by decreasing synthesis of glucocerebroside (glucocerebroside inhibitors)",
                    "sub_points": [
                      "Therapies directed at reducing glycolipid accumulation by decreasing synthesis of glucocerebroside (glucocerebroside inhibitors)"
                    ]
                  },
                  {
                    "text": "Bone marrow transplant is curative, but associated with high morbidity and mortalityReserved for patients with neuronopathic forms",
                    "sub_points": [
                      "Reserved for patients with neuronopathic forms"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Bone marrow reveals histiocytes with characteristic \"wrinkled paper appearance,\" known as Gaucher cells"
                  },
                  {
                    "text": "Accumulated glucocerebrosides often displace cell nucleus eccentrically"
                  },
                  {
                    "text": "Stains positively with the followingPASTRAP",
                    "sub_points": [
                      "PAS",
                      "TRAP"
                    ]
                  },
                  {
                    "text": "Gaucher cells also show diffuse staining with iron stains"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Laboratory Assays": [
                  {
                    "text": "β-glucosylceramidase enzyme activityPerformed on peripheral blood leukocytesPatients with Gaucher disease have decreased enzymatic activity: < 15% of normal",
                    "sub_points": [
                      "Performed on peripheral blood leukocytes",
                      "Patients with Gaucher disease have decreased enzymatic activity: < 15% of normal"
                    ]
                  },
                  {
                    "text": "Targeted mutation analysis is available (also see PATHPrimer topic \"Gaucher Disease\" in Molecular section for more details)Most frequently used for carrier screening in high-risk populations",
                    "sub_points": [
                      "Most frequently used for carrier screening in high-risk populations"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Pseudo-Gaucher Cells": [
                  {
                    "text": "Caused by rapid bone marrow turnover, and are frequently associated with CMLCML will have other morphologic features (basophilia, granulocytic hyperplasia, hypolobated megakaryocytes) and will have classic t(9;22) orBCR/ABL1gene rearrangement",
                    "sub_points": [
                      "CML will have other morphologic features (basophilia, granulocytic hyperplasia, hypolobated megakaryocytes) and will have classic t(9;22) orBCR/ABL1gene rearrangement"
                    ]
                  }
                ],
                "Reactive Conditions": [
                  {
                    "text": "Histiocytic proliferations secondary to reactive conditions may resemble Gaucher cellsInfectionCollagen vascular diseaseFollowing myeloablative therapy",
                    "sub_points": [
                      "Infection",
                      "Collagen vascular disease",
                      "Following myeloablative therapy"
                    ]
                  }
                ],
                "Other Storage Disorders": [
                  {
                    "text": "Niemann-Pick diseaseDoes not have classic Gaucher cellsWill have decreased sphingomyelinase activity",
                    "sub_points": [
                      "Does not have classic Gaucher cells",
                      "Will have decreased sphingomyelinase activity"
                    ]
                  },
                  {
                    "text": "Many others, including mucolipidosis I, GM1 gangliosidosis, mannosidosis, fucosidosis, acid lipase deficiency, and sialic acid storage disease"
                  }
                ],
                "Hemophagocytic Lymphohistiocytosis (HLH)": [
                  {
                    "text": "Histiocytes will have ingested cellular elements (not a feature of Gaucher disease)"
                  },
                  {
                    "text": "Familial HLH will have associated mutations (e.g.,PFR1, MUNC13D, STX11)"
                  }
                ],
                "Langerhans Cell Histiocytosis": [
                  {
                    "text": "Histiocytes will be CD1a and S100 positive, and negative for PAS and TRAP"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Niemann-Pick Disease": {
            "name": "Niemann-Pick Disease",
            "url": "https://app.pathprimer.com/document/c06ec809-7eda-4da5-9c24-b63170374f0c/lesson/6e5627b8-d0a0-4739-ae70-d53f34f8cfcd",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Heterogeneous group of autosomal recessive lipid storage disorders secondary to lysosomal defects"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Types A and B:SMPD1mutations → acid sphingomyelinase deficiency → sphingomyelin accumulation"
                  },
                  {
                    "text": "Types C1 and C2:NPC1andNPC2mutations → cholesterol transport deficiency → cholesterol accumulation"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Hepatosplenomegaly with variable neurologic deficits"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Niemann-Pick cells (enlarged macrophages with foamy cytoplasm) in liver and other organs"
                  },
                  {
                    "text": "May have \"sea-blue\" histiocytes (granular and dark blue cytoplasm)"
                  },
                  {
                    "text": "Vacuolated lymphocytes also present in some subtypes"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Niemann-Pick disease (NPD)"
                  },
                  {
                    "text": "Central nervous system (CNS)"
                  },
                  {
                    "text": "High-density lipoprotein (HDL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Sphingomyelin-cholesterol lipidosis"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Group of autosomal recessive lipid storage disorders associated with splenomegaly and neurologic deficitsCharacterized by accumulation of sphingomyelin or cholesterol in lysosomes of monocytic cells",
                    "sub_points": [
                      "Characterized by accumulation of sphingomyelin or cholesterol in lysosomes of monocytic cells"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Pathogenesis": [
                  {
                    "text": "Types A and BMutations inSMPD1geneEncodes acid sphingomyelinase, which catalyzes conversion of sphingomyelin into ceramideSMPD1mutations result in reduced breakdown and accumulation of sphingomyelinResults in organ damage (brain, lungs, spleen, liver)",
                    "sub_points": [
                      "Mutations inSMPD1gene",
                      "Encodes acid sphingomyelinase, which catalyzes conversion of sphingomyelin into ceramide",
                      "SMPD1mutations result in reduced breakdown and accumulation of sphingomyelinResults in organ damage (brain, lungs, spleen, liver)",
                      "Results in organ damage (brain, lungs, spleen, liver)"
                    ]
                  },
                  {
                    "text": "Types C1 and C2Mutations inNPC1andNPC2genesMutations result in impaired intracellular trafficking of cholesterol and accumulation of cholesterolResults in organ damage (CNS)",
                    "sub_points": [
                      "Mutations inNPC1andNPC2genes",
                      "Mutations result in impaired intracellular trafficking of cholesterol and accumulation of cholesterolResults in organ damage (CNS)",
                      "Results in organ damage (CNS)"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Types A and B1 in 250,000 individuals",
                    "sub_points": [
                      "1 in 250,000 individuals"
                    ]
                  },
                  {
                    "text": "Types C1 and C21 in 150,000 individuals",
                    "sub_points": [
                      "1 in 150,000 individuals"
                    ]
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "Types A and B occur more frequently in Ashkenazi Jews"
                  },
                  {
                    "text": "Types C1 and C2 occur more frequently in French-Acadian descendants from Nova Scotia"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Type AHepatosplenomegaly by age 3 months, failure to thrive, psychomotor regressionCherry-red macular spot on routine eye examinationInterstitial lung diseaseHydrops fetalis can be seen",
                    "sub_points": [
                      "Hepatosplenomegaly by age 3 months, failure to thrive, psychomotor regression",
                      "Cherry-red macular spot on routine eye examination",
                      "Interstitial lung disease",
                      "Hydrops fetalis can be seen"
                    ]
                  },
                  {
                    "text": "Type BSymptoms begin mid-childhood to adolescenceSimilar but less severe presentation than type A",
                    "sub_points": [
                      "Symptoms begin mid-childhood to adolescence",
                      "Similar but less severe presentation than type A"
                    ]
                  },
                  {
                    "text": "Types C1 and C2Similar presentation that can occur at any ageAtaxia, vertical supranuclear gaze palsy, dystonia, speech difficulty, seizuresMild liver disease and interstitial lung diseaseSlow progression into adulthood",
                    "sub_points": [
                      "Similar presentation that can occur at any age",
                      "Ataxia, vertical supranuclear gaze palsy, dystonia, speech difficulty, seizures",
                      "Mild liver disease and interstitial lung disease",
                      "Slow progression into adulthood"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "NoncurativeType ANo specific treatmentType BBone marrow transplantTypes C1 and C2Miglustat for CNS symptoms",
                    "sub_points": [
                      "Type ANo specific treatment",
                      "No specific treatment",
                      "Type BBone marrow transplant",
                      "Bone marrow transplant",
                      "Types C1 and C2Miglustat for CNS symptoms",
                      "Miglustat for CNS symptoms"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Type AFatal by 3 yr of age",
                    "sub_points": [
                      "Fatal by 3 yr of age"
                    ]
                  },
                  {
                    "text": "Type BPossible survival into adulthood",
                    "sub_points": [
                      "Possible survival into adulthood"
                    ]
                  },
                  {
                    "text": "Types C1 and C2Possible survival into adulthood",
                    "sub_points": [
                      "Possible survival into adulthood"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Enlarged spleen with uniformly pale and homogeneous cut surface"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Niemann-Pick cellsEnlarged macrophages with foamy cytoplasm containing numerous vacuoles composed of sphingomyelin or cholesterol in portal tracts, hepatic lobules, other organs",
                    "sub_points": [
                      "Enlarged macrophages with foamy cytoplasm containing numerous vacuoles composed of sphingomyelin or cholesterol in portal tracts, hepatic lobules, other organs"
                    ]
                  },
                  {
                    "text": "May have \"sea-blue\" histiocytes (granular and dark blue cytoplasm)"
                  },
                  {
                    "text": "Vacuolated lymphocytes also present in some subtypes"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Genetic Testing": [
                  {
                    "text": "Molecular analysis ofSMPD1orNPC1/NPC2mutations"
                  }
                ],
                "Electron Microscopy": [
                  {
                    "text": "Concentric laminated inclusions in cytoplasm of histiocytes"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Gaucher Disease": [
                  {
                    "text": "Histiocytes with delicately \"wrinkled paper\" pale blue cytoplasm"
                  }
                ],
                "Cholesterol Ester Storage Disease": [
                  {
                    "text": "Histiocytes with birefringent droplets"
                  }
                ],
                "Tangier Disease": [
                  {
                    "text": "Lipid-laden macrophages, very low to absent HDL levels, andABCA1mutation"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Hepatosplenomegaly"
                  },
                  {
                    "text": "Variable neurologic presentation"
                  },
                  {
                    "text": "Reduced sphingomyelinase activity"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Niemann-Pick cells with foamy, vacuolated histiocytes in liver and other organs"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hemophagocytic Lymphohistiocytosis": {
            "name": "Hemophagocytic Lymphohistiocytosis",
            "url": "https://app.pathprimer.com/document/d8316d90-b56e-490d-96ac-3a9800573348/lesson/6e5627b8-d0a0-4739-ae70-d53f34f8cfcd",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "Defects in NK or cytotoxic T cellsInherited/primary causesAcquired/secondary causesInfections, cancer-associated",
                    "sub_points": [
                      "Inherited/primary causes",
                      "Acquired/secondary causesInfections, cancer-associated",
                      "Infections, cancer-associated"
                    ]
                  },
                  {
                    "text": "End result is cytokine stormOveractivation of macrophages and T cells",
                    "sub_points": [
                      "Overactivation of macrophages and T cells"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "SymptomsFever, central nervous system symptomsEasy bruisability and pallor",
                    "sub_points": [
                      "Fever, central nervous system symptoms",
                      "Easy bruisability and pallor"
                    ]
                  },
                  {
                    "text": "Physical findingsPallor &/or skin rashLymphadenopathy, splenomegaly, hepatomegalyPleural effusions, ascites",
                    "sub_points": [
                      "Pallor &/or skin rash",
                      "Lymphadenopathy, splenomegaly, hepatomegaly",
                      "Pleural effusions, ascites"
                    ]
                  },
                  {
                    "text": "Laboratory findingsCytopenia(s), often pancytopeniaElevated serum ferritinAbnormal liver function testsHypofibrinogenemia, hypertriglyceridemia",
                    "sub_points": [
                      "Cytopenia(s), often pancytopenia",
                      "Elevated serum ferritin",
                      "Abnormal liver function tests",
                      "Hypofibrinogenemia, hypertriglyceridemia"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Bland histiocytes show phagocytic activity"
                  },
                  {
                    "text": "Lymph nodes, spleen, liver, bone marrow"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Rosai-Dorfman Disease"
                  },
                  {
                    "text": "Histiocytic Sarcoma"
                  },
                  {
                    "text": "Langerhans Cell Histiocytosis"
                  },
                  {
                    "text": "Sinus Histiocytosis in Lymph Node"
                  }
                ],
                "Diagnostic Checklist": [
                  {
                    "text": "5 of 8 clinical and laboratory criteria required for diagnosisFeverSplenomegalyCytopeniasHypertriglyceridemia &/or hypofibrinogenemiaSerum ferritin > 500 µg/LHemophagocytosisLow or absent NK-cell activitySoluble CD25 (sIL-2 receptor) > 2,400 U/mL",
                    "sub_points": [
                      "Fever",
                      "Splenomegaly",
                      "Cytopenias",
                      "Hypertriglyceridemia &/or hypofibrinogenemia",
                      "Serum ferritin > 500 µg/L",
                      "Hemophagocytosis",
                      "Low or absent NK-cell activity",
                      "Soluble CD25 (sIL-2 receptor) > 2,400 U/mL"
                    ]
                  },
                  {
                    "text": "HLH also diagnosed by molecular testing"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Hemophagocytic lymphohistiocytosis (HLH)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Hemophagocytic syndrome"
                  },
                  {
                    "text": "Erythrophagocytic lymphohistiocytosis"
                  },
                  {
                    "text": "Viral-associated hemophagocytic syndrome"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Cytokine dysregulation, either due to inherited or secondary causesResults in overactivation of macrophages and T lymphocytesLeads to systemic symptoms and organ damage",
                    "sub_points": [
                      "Results in overactivation of macrophages and T lymphocytesLeads to systemic symptoms and organ damage",
                      "Leads to systemic symptoms and organ damage"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Inherited/Primary Defects": [
                  {
                    "text": "Result in depressed natural killer (NK) and cytotoxic T-cell activityPerforin (PRF1) mutationLocalized at chromosome 10q21-22Results in decrease or absence of perforin in NK or CD8(+) T cellsGriscelli syndromeMUNC13-4defectLack of protein rab27a, which controls secretion of lytic granules in NK and cytotoxic T cellsChediak-Higashi syndromeLYSTgene defectDefects in cytotoxic T-lymphocyte-associated antigen 4Syntaxin gene mutationsNK cells fail to degranulate when encountering susceptible targetsX-linked lymphoproliferative disease (XLP)SH2D1Agene mutationDefective T-cell signal transductionTriggers vigorous cytotoxic cellular responsesT-cell lytic defect against EBV-infected B lymphocytesDefect in apoptosis-caspase 3; T-cell accumulation",
                    "sub_points": [
                      "Perforin (PRF1) mutationLocalized at chromosome 10q21-22Results in decrease or absence of perforin in NK or CD8(+) T cells",
                      "Localized at chromosome 10q21-22",
                      "Results in decrease or absence of perforin in NK or CD8(+) T cells",
                      "Griscelli syndromeMUNC13-4defectLack of protein rab27a, which controls secretion of lytic granules in NK and cytotoxic T cells",
                      "Lack of protein rab27a, which controls secretion of lytic granules in NK and cytotoxic T cells",
                      "Chediak-Higashi syndromeLYSTgene defectDefects in cytotoxic T-lymphocyte-associated antigen 4",
                      "Defects in cytotoxic T-lymphocyte-associated antigen 4",
                      "Syntaxin gene mutationsNK cells fail to degranulate when encountering susceptible targets",
                      "NK cells fail to degranulate when encountering susceptible targets",
                      "X-linked lymphoproliferative disease (XLP)SH2D1Agene mutationDefective T-cell signal transductionTriggers vigorous cytotoxic cellular responsesT-cell lytic defect against EBV-infected B lymphocytes",
                      "SH2D1Agene mutation",
                      "Defective T-cell signal transduction",
                      "Triggers vigorous cytotoxic cellular responses",
                      "T-cell lytic defect against EBV-infected B lymphocytes",
                      "Defect in apoptosis-caspase 3; T-cell accumulation"
                    ]
                  }
                ],
                "Acquired/Secondary Defects": [
                  {
                    "text": "Infectious agents can be associated with HLH; mechanism(s) unclearVirusesEBV (most common), CMV, parvovirus B19, herpes simplexHerpes varicella-zoster, measles, HHV-8, HIVAdenovirus, respiratory syncytial virus, parainfluenza virus, enterovirusesBacteriaPseudomonas aeruginosa,Staphylococcus,StreptococcusEscherichia coliandBrucella abortusMycobacteria:Mycobacterium tuberculosisParasitesLeishmania donovani;PlasmodiumspeciesFungiHistoplasma capsulatum,Penicillium marneffei;AspergillusCryptococcusmeningitis, histoplasmosis, disseminatedTrichosporon beigeliiinfections",
                    "sub_points": [
                      "VirusesEBV (most common), CMV, parvovirus B19, herpes simplexHerpes varicella-zoster, measles, HHV-8, HIVAdenovirus, respiratory syncytial virus, parainfluenza virus, enteroviruses",
                      "EBV (most common), CMV, parvovirus B19, herpes simplex",
                      "Herpes varicella-zoster, measles, HHV-8, HIV",
                      "Adenovirus, respiratory syncytial virus, parainfluenza virus, enteroviruses",
                      "BacteriaPseudomonas aeruginosa,Staphylococcus,StreptococcusEscherichia coliandBrucella abortusMycobacteria:Mycobacterium tuberculosis",
                      "Pseudomonas aeruginosa,Staphylococcus,Streptococcus",
                      "Escherichia coliandBrucella abortus",
                      "Mycobacteria:Mycobacterium tuberculosis",
                      "ParasitesLeishmania donovani;Plasmodiumspecies",
                      "Leishmania donovani;Plasmodiumspecies",
                      "FungiHistoplasma capsulatum,Penicillium marneffei;AspergillusCryptococcusmeningitis, histoplasmosis, disseminatedTrichosporon beigeliiinfections",
                      "Histoplasma capsulatum,Penicillium marneffei;Aspergillus",
                      "Cryptococcusmeningitis, histoplasmosis, disseminatedTrichosporon beigeliiinfections"
                    ]
                  },
                  {
                    "text": "Autoimmune disorders can be associated with HLHSystemic lupus erythematosus, rheumatoid arthritisStill disease, polyarteritis nodosa, sarcoidosisMixed connective tissue disease, systemic sclerosis, Sjögren syndrome",
                    "sub_points": [
                      "Systemic lupus erythematosus, rheumatoid arthritis",
                      "Still disease, polyarteritis nodosa, sarcoidosis",
                      "Mixed connective tissue disease, systemic sclerosis, Sjögren syndrome"
                    ]
                  },
                  {
                    "text": "Malignancies can be associated with HLHT- and NK-cell lymphomasAcute myeloid leukemias and myelodysplastic syndromesAcute lymphoblastic leukemia/lymphoma (B or T lineage)B-cell lymphomas, carcinomase.g., Asian variant of intravascular diffuse large B-cell lymphoma",
                    "sub_points": [
                      "T- and NK-cell lymphomas",
                      "Acute myeloid leukemias and myelodysplastic syndromes",
                      "Acute lymphoblastic leukemia/lymphoma (B or T lineage)",
                      "B-cell lymphomas, carcinomase.g., Asian variant of intravascular diffuse large B-cell lymphoma",
                      "e.g., Asian variant of intravascular diffuse large B-cell lymphoma"
                    ]
                  },
                  {
                    "text": "Posttransplantation"
                  }
                ],
                "Common Etiologies of Inherited andAcquired HLH": [
                  {
                    "text": "Inappropriate immune reaction caused byOverproduction of cytokines (\"cytokine storm\")Interferon-γ, TNF-α, and granulocyte-macrophage colony-stimulating factorInterleukin-1 (IL-1) and interleukin-6 (IL-6)Associated with macrophage activationInadequate apoptosis of immunogenic cellsProliferation &/or activation of T cells either due to genetic defects or secondary causesLead to tissue damage and injury",
                    "sub_points": [
                      "Overproduction of cytokines (\"cytokine storm\")Interferon-γ, TNF-α, and granulocyte-macrophage colony-stimulating factorInterleukin-1 (IL-1) and interleukin-6 (IL-6)Associated with macrophage activationInadequate apoptosis of immunogenic cells",
                      "Interferon-γ, TNF-α, and granulocyte-macrophage colony-stimulating factor",
                      "Interleukin-1 (IL-1) and interleukin-6 (IL-6)",
                      "Associated with macrophage activation",
                      "Inadequate apoptosis of immunogenic cells",
                      "Proliferation &/or activation of T cells either due to genetic defects or secondary causes",
                      "Lead to tissue damage and injury"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "1.2 children per million per year1 case per every 50,000 births",
                    "sub_points": [
                      "1 case per every 50,000 births"
                    ]
                  },
                  {
                    "text": "Incidence in adults is unknown"
                  }
                ],
                "Age": [
                  {
                    "text": "Familial form frequently affects infantsBirth to age 18 months most common (70-80%)Rare familial cases can affect adolescents and adults",
                    "sub_points": [
                      "Birth to age 18 months most common (70-80%)",
                      "Rare familial cases can affect adolescents and adults"
                    ]
                  },
                  {
                    "text": "Acquired form can occur at any age"
                  }
                ],
                "Sex": [
                  {
                    "text": "M = F"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "No predilection for any race"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Fever≥ 7 days of fever as high as 38.5°C (101.3°F)",
                    "sub_points": [
                      "≥ 7 days of fever as high as 38.5°C (101.3°F)"
                    ]
                  },
                  {
                    "text": "Easy bruisability and pallor related to cytopenia(s) or coagulopathy"
                  },
                  {
                    "text": "SplenomegalySpleen palpable > 3 cm below costal margin",
                    "sub_points": [
                      "Spleen palpable > 3 cm below costal margin"
                    ]
                  },
                  {
                    "text": "Central nervous system (CNS) symptomsSeizures, ataxia, hemiplegia, mental status changes, irritability",
                    "sub_points": [
                      "Seizures, ataxia, hemiplegia, mental status changes, irritability"
                    ]
                  },
                  {
                    "text": "Skin rashScaly and waxy lesions; rashes on scalp and behind ear",
                    "sub_points": [
                      "Scaly and waxy lesions; rashes on scalp and behind ear"
                    ]
                  },
                  {
                    "text": "Lymphadenopathy"
                  },
                  {
                    "text": "Hepatomegaly, jaundice"
                  },
                  {
                    "text": "Pleural effusion"
                  },
                  {
                    "text": "Ascites"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Cytopenia(s), often pancytopeniaHemoglobin < 9.0 g/dLPlatelets < 100 x 10⁹/LAbsolute neutrophil count < 1 x 10⁹/L",
                    "sub_points": [
                      "Hemoglobin < 9.0 g/dL",
                      "Platelets < 100 x 10⁹/L",
                      "Absolute neutrophil count < 1 x 10⁹/L"
                    ]
                  },
                  {
                    "text": "Increased ferritin> 500 µg/LGlycosylated ferritin < 20% of total ferritinLevels parallel to course of diseaseCan use to monitor disease activity80% specific for diagnosis of HLH",
                    "sub_points": [
                      "> 500 µg/L",
                      "Glycosylated ferritin < 20% of total ferritin",
                      "Levels parallel to course of diseaseCan use to monitor disease activity",
                      "Can use to monitor disease activity",
                      "80% specific for diagnosis of HLH"
                    ]
                  },
                  {
                    "text": "HypofibrinogenemiaFibrinogen < 1.5 g/L, or > 3 standard deviations (SD) below normal value for age",
                    "sub_points": [
                      "Fibrinogen < 1.5 g/L, or > 3 standard deviations (SD) below normal value for age"
                    ]
                  },
                  {
                    "text": "HypertriglyceridemiaFasting triglycerides ≥ 2.0 mmol/L, or > 3 SD above normal value for age",
                    "sub_points": [
                      "Fasting triglycerides ≥ 2.0 mmol/L, or > 3 SD above normal value for age"
                    ]
                  },
                  {
                    "text": "Abnormal liver functionHyperbilirubinemia, hypoalbuminemiaIncreased aspartate aminotransferase (AST) and alanine aminotransferase (ALT)",
                    "sub_points": [
                      "Hyperbilirubinemia, hypoalbuminemia",
                      "Increased aspartate aminotransferase (AST) and alanine aminotransferase (ALT)"
                    ]
                  },
                  {
                    "text": "Serum lactate dehydrogenase (LDH) increased"
                  },
                  {
                    "text": "Defect in NK-cell activity; adequate NK-cell numberDecreased cytotoxic activityUsing peripheral blood mononuclear cells as effector cells and fluorescein isothiocyanate-labeled K562 cells as target cellsMeasure by flow cytometryCan differentiate between HLH subtypes",
                    "sub_points": [
                      "Decreased cytotoxic activityUsing peripheral blood mononuclear cells as effector cells and fluorescein isothiocyanate-labeled K562 cells as target cellsMeasure by flow cytometry",
                      "Using peripheral blood mononuclear cells as effector cells and fluorescein isothiocyanate-labeled K562 cells as target cells",
                      "Measure by flow cytometry",
                      "Can differentiate between HLH subtypes"
                    ]
                  },
                  {
                    "text": "Increased circulating soluble interleukin 2 receptor (sIL-2R)"
                  },
                  {
                    "text": "Molecular diagnosisGene mutation analysis",
                    "sub_points": [
                      "Gene mutation analysis"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "HLH-2004 protocol recommended by the Histiocytosis Association of America8-week period with dexamethasone, etoposide, and cyclosporineResolved nonfamilial HLH does not require continuation of therapeutic regimenChildren with persistent nonfamilial disease or familial disease continue therapy with cyclosporine, plus etoposide and dexamethasone pulses, until stem cell transplantIntrathecal methotrexate for persistently abnormal CSF or progressive CNS symptoms",
                    "sub_points": [
                      "8-week period with dexamethasone, etoposide, and cyclosporineResolved nonfamilial HLH does not require continuation of therapeutic regimenChildren with persistent nonfamilial disease or familial disease continue therapy with cyclosporine, plus etoposide and dexamethasone pulses, until stem cell transplant",
                      "Resolved nonfamilial HLH does not require continuation of therapeutic regimen",
                      "Children with persistent nonfamilial disease or familial disease continue therapy with cyclosporine, plus etoposide and dexamethasone pulses, until stem cell transplant",
                      "Intrathecal methotrexate for persistently abnormal CSF or progressive CNS symptoms"
                    ]
                  },
                  {
                    "text": "Stem cell transplantation for patients withFamilial HLHChildren and adults with persistent nonfamilial disease",
                    "sub_points": [
                      "Familial HLH",
                      "Children and adults with persistent nonfamilial disease"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "With HLH-2004 protocol3-year probability of survival was 51% for verified familial cases55% for entire group of HLH patients",
                    "sub_points": [
                      "3-year probability of survival was 51% for verified familial cases",
                      "55% for entire group of HLH patients"
                    ]
                  },
                  {
                    "text": "Stem cell transplantMatched transplant: Long-term disease-free rate ~ 70%",
                    "sub_points": [
                      "Matched transplant: Long-term disease-free rate ~ 70%"
                    ]
                  }
                ],
                "Special Form of HLH-Macrophage Activation Syndrome": [
                  {
                    "text": "Occurs in association with autoimmune diseases, especiallySystemic onset juvenile rheumatoid arthritisAdult-onset Still diseaseSystemic lupus erythematosus",
                    "sub_points": [
                      "Systemic onset juvenile rheumatoid arthritis",
                      "Adult-onset Still disease",
                      "Systemic lupus erythematosus"
                    ]
                  },
                  {
                    "text": "Clinical and laboratory featuresShare many characteristics with HLHDefective NK-cell function and low perforin expressionClinical signs and symptoms similar to HLHHemophagocytosis is present in bone marrow, spleen, lymph nodeHigh ferritin levelsFeatures that differ from HLHLess severe cytopeniasMore severe cardiac impairmentMore pronounced coagulopathyVery high C-reactive protein level",
                    "sub_points": [
                      "Share many characteristics with HLHDefective NK-cell function and low perforin expressionClinical signs and symptoms similar to HLHHemophagocytosis is present in bone marrow, spleen, lymph nodeHigh ferritin levels",
                      "Defective NK-cell function and low perforin expression",
                      "Clinical signs and symptoms similar to HLH",
                      "Hemophagocytosis is present in bone marrow, spleen, lymph node",
                      "High ferritin levels",
                      "Features that differ from HLHLess severe cytopeniasMore severe cardiac impairmentMore pronounced coagulopathyVery high C-reactive protein level",
                      "Less severe cytopenias",
                      "More severe cardiac impairment",
                      "More pronounced coagulopathy",
                      "Very high C-reactive protein level"
                    ]
                  },
                  {
                    "text": "TherapyCyclosporine and steroids firstIf no response, use HLH-2004 protocol",
                    "sub_points": [
                      "Cyclosporine and steroids first",
                      "If no response, use HLH-2004 protocol"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "General Features": [
                  {
                    "text": "No specific imaging patterns are diagnostic of HLH"
                  },
                  {
                    "text": "CT or ultrasonography findingsAscites, pleural effusionGallbladder wall thickeningLymphadenopathy",
                    "sub_points": [
                      "Ascites, pleural effusion",
                      "Gallbladder wall thickening",
                      "Lymphadenopathy"
                    ]
                  },
                  {
                    "text": "MR for CNS involvement"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Lymph nodes, liver, spleen, bone marrow"
                  },
                  {
                    "text": "Proliferation of small mature histiocytesHistiocytes show phagocytic activityIncreased lymphocytes; mostly T cellsTissue infiltrate and cellular injury",
                    "sub_points": [
                      "Histiocytes show phagocytic activity",
                      "Increased lymphocytes; mostly T cells",
                      "Tissue infiltrate and cellular injury"
                    ]
                  },
                  {
                    "text": "Underlying etiology of HLH may be presentLymphomaInfectious agentsHLH associated with EBV or CMV; lymph node may show changes of infectious mononucleosisHLH in HIV; changes of HIV lymphadenopathy may occurMycobacterial infection may show chronic granulomatous inflammation",
                    "sub_points": [
                      "Lymphoma",
                      "Infectious agentsHLH associated with EBV or CMV; lymph node may show changes of infectious mononucleosisHLH in HIV; changes of HIV lymphadenopathy may occurMycobacterial infection may show chronic granulomatous inflammation",
                      "HLH associated with EBV or CMV; lymph node may show changes of infectious mononucleosis",
                      "HLH in HIV; changes of HIV lymphadenopathy may occur",
                      "Mycobacterial infection may show chronic granulomatous inflammation"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Histiocytes are mature and cytologically benignVesicular nuclei and abundant cytoplasm",
                    "sub_points": [
                      "Vesicular nuclei and abundant cytoplasm"
                    ]
                  },
                  {
                    "text": "Histiocytes engulfErythrocytes (nucleated and anucleated)Platelets, ± lymphocytes and neutrophils",
                    "sub_points": [
                      "Erythrocytes (nucleated and anucleated)",
                      "Platelets, ± lymphocytes and neutrophils"
                    ]
                  }
                ],
                "Lymph Nodes": [
                  {
                    "text": "Overall architecture is maintainedFoci of hemorrhage commonFocal necrosis may be present",
                    "sub_points": [
                      "Foci of hemorrhage common",
                      "Focal necrosis may be present"
                    ]
                  },
                  {
                    "text": "Bland histiocytes in sinuses showing phagocytosis"
                  },
                  {
                    "text": "ImmunohistochemistryHistiocytes are CD68(+), S100(+/-), and CD1a(-)Lymphocytes mostly T cells",
                    "sub_points": [
                      "Histiocytes are CD68(+), S100(+/-), and CD1a(-)",
                      "Lymphocytes mostly T cells"
                    ]
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "Increased histiocytesPhagocytes often better appreciated on aspirate smears or touch imprintsEngulfing anucleated red cells, platelets, neutrophilsIn some cases, histiocytes can exhibit slightly immature morphology and increased Ki-67 activity",
                    "sub_points": [
                      "Phagocytes often better appreciated on aspirate smears or touch imprintsEngulfing anucleated red cells, platelets, neutrophils",
                      "Engulfing anucleated red cells, platelets, neutrophils",
                      "In some cases, histiocytes can exhibit slightly immature morphology and increased Ki-67 activity"
                    ]
                  },
                  {
                    "text": "Increased T cells"
                  },
                  {
                    "text": "Hematopoietic cells, especially erythrocytes, can show dysplastic featuresAssociated with acute bone marrow injuryDo not misinterpret as myelodysplasia",
                    "sub_points": [
                      "Associated with acute bone marrow injury",
                      "Do not misinterpret as myelodysplasia"
                    ]
                  }
                ],
                "Spleen": [
                  {
                    "text": "Splenomegaly"
                  },
                  {
                    "text": "Expanded red pulp, filled with histiocytes; white pulp usually sparedMany are phagocytes",
                    "sub_points": [
                      "Many are phagocytes"
                    ]
                  },
                  {
                    "text": "Focal necrosis can be present"
                  },
                  {
                    "text": "Extramedullary hematopoiesis can be present"
                  },
                  {
                    "text": "Underlying etiology of HLH can be present in spleen"
                  }
                ],
                "Liver": [
                  {
                    "text": "Portal lymphohistiocytic infiltrates"
                  },
                  {
                    "text": "Hyperplasia of Kupffer cells with hemophagocytosis"
                  },
                  {
                    "text": "± hepatocyte injury"
                  }
                ],
                "Skin Involvement": [
                  {
                    "text": "Occurs in ~ 10-60% of patients"
                  },
                  {
                    "text": "Erythematous macules and plaques"
                  },
                  {
                    "text": "Increased T cells and histiocytes"
                  },
                  {
                    "text": "Often nondiagnostic and only rarely shows hemophagocytosis"
                  },
                  {
                    "text": "Rule out subcutaneous panniculitis-like T-cell lymphoma, which may be associated with HLH"
                  }
                ],
                "Brain": [
                  {
                    "text": "Meningeal lymphohistiocytic infiltration"
                  },
                  {
                    "text": "Focal subarachnoid hemorrhage"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Genetic Testing": [
                  {
                    "text": "Essential to determine etiology of primary causes of HLH"
                  }
                ],
                "Testing for Acquired Causes": [
                  {
                    "text": "Special stains for identifying bacteria or fungiCultures needed",
                    "sub_points": [
                      "Cultures needed"
                    ]
                  },
                  {
                    "text": "Immunohistochemistry or in situ hybridization for viruses"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Rosai-Dorfman Disease": [
                  {
                    "text": "Lymph nodes or extranodal sites"
                  },
                  {
                    "text": "Patients can present withFever, leukocytosis, anemiaElevated sedimentation rate, polyclonal hypergammaglobulinemia",
                    "sub_points": [
                      "Fever, leukocytosis, anemia",
                      "Elevated sedimentation rate, polyclonal hypergammaglobulinemia"
                    ]
                  },
                  {
                    "text": "Histiocytes are S100(+), CD68(+), CD1a(-)"
                  },
                  {
                    "text": "Lymph nodesMarked dilation of sinuses filled with large histiocytesHistiocytes have abundant cytoplasm and round, vesicular nuclei with prominent central nucleoliHistiocytes contain intact lymphocytes (emperipolesis, lymphocytophagocytosis)Plasmacytosis usually present; often Russell bodies seen",
                    "sub_points": [
                      "Marked dilation of sinuses filled with large histiocytes",
                      "Histiocytes have abundant cytoplasm and round, vesicular nuclei with prominent central nucleoli",
                      "Histiocytes contain intact lymphocytes (emperipolesis, lymphocytophagocytosis)",
                      "Plasmacytosis usually present; often Russell bodies seen"
                    ]
                  },
                  {
                    "text": "Extranodal sitesEmperipolesis often focal or absentFibrosis commonly superimposed on process",
                    "sub_points": [
                      "Emperipolesis often focal or absent",
                      "Fibrosis commonly superimposed on process"
                    ]
                  }
                ],
                "Histiocytic Sarcoma": [
                  {
                    "text": "Systemic symptoms common, can be confused with HLH"
                  },
                  {
                    "text": "In lymph node, can diffusely replace architecture or involve sinuses"
                  },
                  {
                    "text": "Histiocytes cytologically malignantLarge and pleomorphicOften have abundant and eosinophilic cytoplasmVesicular chromatin, increased N:C ratioMitotic figures are often presentCan show hemophagocytosisProliferation rate (Ki-67) is increased",
                    "sub_points": [
                      "Large and pleomorphic",
                      "Often have abundant and eosinophilic cytoplasm",
                      "Vesicular chromatin, increased N:C ratio",
                      "Mitotic figures are often present",
                      "Can show hemophagocytosis",
                      "Proliferation rate (Ki-67) is increased"
                    ]
                  },
                  {
                    "text": "ImmunohistochemistryCD68(+), CD4(+), S100(+/-)CD1a(-), B-cell and T-cell antigens (-)",
                    "sub_points": [
                      "CD68(+), CD4(+), S100(+/-)",
                      "CD1a(-), B-cell and T-cell antigens (-)"
                    ]
                  }
                ],
                "Langerhans Cell Histiocytosis": [
                  {
                    "text": "Langerhans cells have abundant, pale eosinophilic cytoplasm"
                  },
                  {
                    "text": "Irregular and elongated nuclei with prominent nuclear grooves and folds"
                  },
                  {
                    "text": "Increased eosinophils in background; necrosis common"
                  },
                  {
                    "text": "Early lesions are often sinusoidal, but extensive disease replaces lymph node"
                  },
                  {
                    "text": "Langerhans cells do not exhibit phagocytosis"
                  },
                  {
                    "text": "ImmunohistochemistryLangerin/CD207(+), CD1a(+), S100(+), CD68(+/-)CD4(-), B-cell and T-cell antigens (-)",
                    "sub_points": [
                      "Langerin/CD207(+), CD1a(+), S100(+), CD68(+/-)",
                      "CD4(-), B-cell and T-cell antigens (-)"
                    ]
                  }
                ],
                "Sinus Histiocytosis in Lymph Node": [
                  {
                    "text": "Very common nonspecific histologic finding"
                  },
                  {
                    "text": "No clinical significance"
                  },
                  {
                    "text": "Often no systemic symptoms"
                  },
                  {
                    "text": "Associated with various etiologies (benign or malignant)"
                  },
                  {
                    "text": "Histologic findingsDilated and prominent sinuses; contain increased macrophagesOften absence of phagocytesHistiocytes and macrophages are CD68(+); can be S100(+ focal)",
                    "sub_points": [
                      "Dilated and prominent sinuses; contain increased macrophages",
                      "Often absence of phagocytes",
                      "Histiocytes and macrophages are CD68(+); can be S100(+ focal)"
                    ]
                  }
                ],
                "Lymph Nodes and Other Organs Post Blood Transfusion": [
                  {
                    "text": "Can show erythrophagocytosisCommon in lymph nodes and bone marrow",
                    "sub_points": [
                      "Common in lymph nodes and bone marrow"
                    ]
                  },
                  {
                    "text": "Patients often exhibit lack of other criteria for HLH"
                  }
                ],
                "Histiocytosis in Lymph Nodes Draining Prosthesis": [
                  {
                    "text": "Increased benign histiocytes filling sinuses and parenchyma"
                  },
                  {
                    "text": "Histiocyte cytoplasm may exhibit granular quality attributable to foreign material"
                  },
                  {
                    "text": "Polarized light may show polarizable foreign material"
                  }
                ],
                "Mycobacterial Infections": [
                  {
                    "text": "Most common in immunocompromised patients"
                  },
                  {
                    "text": "Mycobacterium avium intracellulare,M. tuberculosis(MTB), orM. lepraeGranulomas often are ill defined, irregular, or serpiginousLanghans-type giant cells are often presentNecrosis is common in MTB; often caseatingVariable plasma cells and neutrophilsAcid-fast stain reveals organisms",
                    "sub_points": [
                      "Granulomas often are ill defined, irregular, or serpiginous",
                      "Langhans-type giant cells are often present",
                      "Necrosis is common in MTB; often caseating",
                      "Variable plasma cells and neutrophils",
                      "Acid-fast stain reveals organisms"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Diagnosis of HLH can be based onMolecular testingClinicopathologic assessment5 of 8 diagnostic criteria need to be met for HLH",
                    "sub_points": [
                      "Molecular testing",
                      "Clinicopathologic assessment5 of 8 diagnostic criteria need to be met for HLH",
                      "5 of 8 diagnostic criteria need to be met for HLH"
                    ]
                  },
                  {
                    "text": "HLH usually found in lymph nodes, liver, spleen, bone marrowHistiocytes usually cytologically blandLymphocytes often increased, mainly small T cellsIn bone marrowPhagocytosis of nucleated cells more specific for macrophage activationHematopoietic cells may show dysplastic featuresDo not misinterpret as myelodysplasia",
                    "sub_points": [
                      "Histiocytes usually cytologically bland",
                      "Lymphocytes often increased, mainly small T cells",
                      "In bone marrowPhagocytosis of nucleated cells more specific for macrophage activationHematopoietic cells may show dysplastic featuresDo not misinterpret as myelodysplasia",
                      "Phagocytosis of nucleated cells more specific for macrophage activation",
                      "Hematopoietic cells may show dysplastic featuresDo not misinterpret as myelodysplasia",
                      "Do not misinterpret as myelodysplasia"
                    ]
                  },
                  {
                    "text": "Pathologists must be vigilant about diagnosisInability to demonstrate hemophagocytosis in initial specimen does not exclude diagnosis of HLHOther clinical criteria must be fulfilledPresence of phagocytosis not specific for diagnosis of HLH",
                    "sub_points": [
                      "Inability to demonstrate hemophagocytosis in initial specimen does not exclude diagnosis of HLHOther clinical criteria must be fulfilled",
                      "Other clinical criteria must be fulfilled",
                      "Presence of phagocytosis not specific for diagnosis of HLH"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Quantitative White Blood Cell Abnormalities": {
        "name": "Quantitative White Blood Cell Abnormalities",
        "url": "https://app.pathprimer.com/lesson/ee882547-8989-432d-aea3-f4fc0df1ba42",
        "topics": {
          "Neutrophilia": {
            "name": "Neutrophilia",
            "url": "https://app.pathprimer.com/document/45c3e647-09d3-40b7-a5be-a41ff82e5d28/lesson/ee882547-8989-432d-aea3-f4fc0df1ba42",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Absolute neutrophil count (ANC) that exceeds age-related normal rangesNewborn > 28.0 x 10⁹/LInfant > 10.0 x 10⁹/LChild > 8.0 x 10⁹/LAdult > 7.0 x 10⁹/L",
                    "sub_points": [
                      "Newborn > 28.0 x 10⁹/L",
                      "Infant > 10.0 x 10⁹/L",
                      "Child > 8.0 x 10⁹/L",
                      "Adult > 7.0 x 10⁹/L"
                    ]
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Many causes of secondary neutrophiliasInfections most commonOther causes: Inflammation, metabolic disorders, medicationsRare constitutional neutrophilias",
                    "sub_points": [
                      "Infections most common",
                      "Other causes: Inflammation, metabolic disorders, medications",
                      "Rare constitutional neutrophilias"
                    ]
                  },
                  {
                    "text": "PathogenesisDemarginationRelease of bone marrow reserve compartmentIncreased neutrophil production in bone marrow",
                    "sub_points": [
                      "Demargination",
                      "Release of bone marrow reserve compartment",
                      "Increased neutrophil production in bone marrow"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Absolute neutrophilia"
                  },
                  {
                    "text": "Variable degree of left shift of neutrophil lineage"
                  },
                  {
                    "text": "Toxic changes usually presentOther lineages generally unremarkable",
                    "sub_points": [
                      "Other lineages generally unremarkable"
                    ]
                  }
                ],
                "Diagnostic Checklist": [
                  {
                    "text": "Careful history for possible cytokine therapy"
                  },
                  {
                    "text": "Significant splenomegaly or basophilia is more suggestive of chronic myeloproliferative neoplasm"
                  },
                  {
                    "text": "Left shift doesnotgenerally include blasts in adultsexceptpatients receiving recombinant CSF"
                  },
                  {
                    "text": "Left shift may include blasts in septic neonates/young infants"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Synonyms": [
                  {
                    "text": "Granulocytosis"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Absolute neutrophil count (ANC) that exceeds age-related normal rangesNewborn > 28.0 x 10⁹/LInfant > 10.0 x 10⁹/LChild > 8.0 x 10⁹/LAdult > 7.0 x 10⁹/L",
                    "sub_points": [
                      "Newborn > 28.0 x 10⁹/L",
                      "Infant > 10.0 x 10⁹/L",
                      "Child > 8.0 x 10⁹/L",
                      "Adult > 7.0 x 10⁹/L"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Diverse Etiologies for 2° Neutrophilias": [
                  {
                    "text": "Infections (usually bacteria)"
                  },
                  {
                    "text": "Occasional viral infections (SARS, Hantavirus)"
                  },
                  {
                    "text": "Medications/hormones/endogenous overproductionColony-stimulating factorsChemokinesCSF/chemokine-producing neoplasmsEpinephrineCorticosteroidsLithium",
                    "sub_points": [
                      "Colony-stimulating factors",
                      "Chemokines",
                      "CSF/chemokine-producing neoplasms",
                      "Epinephrine",
                      "Corticosteroids",
                      "Lithium"
                    ]
                  },
                  {
                    "text": "Inflammatory and metabolic disordersBurns, traumaInfarction, goutCollagen vascular diseaseKetoacidosisEclampsia",
                    "sub_points": [
                      "Burns, trauma",
                      "Infarction, gout",
                      "Collagen vascular disease",
                      "Ketoacidosis",
                      "Eclampsia"
                    ]
                  },
                  {
                    "text": "OtherStressAsphyxiaPregnancySmokingToxinsVenoms",
                    "sub_points": [
                      "Stress",
                      "Asphyxia",
                      "Pregnancy",
                      "Smoking",
                      "Toxins",
                      "Venoms"
                    ]
                  }
                ],
                "Constitutional Neutrophilic Disorders": [
                  {
                    "text": "Leukocyte adhesion deficiency (LAD)Neutrophil production increasedMarked neutrophilia in bloodNeutrophils unable to migrate to sites of infectionMultiple genetic types",
                    "sub_points": [
                      "Neutrophil production increased",
                      "Marked neutrophilia in blood",
                      "Neutrophils unable to migrate to sites of infection",
                      "Multiple genetic types"
                    ]
                  },
                  {
                    "text": "Hereditary neutrophilia"
                  },
                  {
                    "text": "Familial cold urticaria"
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "Astronomical daily production rates of neutrophils in bone marrow"
                  },
                  {
                    "text": "Large reserve of neutrophils, bands, and neutrophilic myelocytes is present in central medullary regions of bone marrow"
                  },
                  {
                    "text": "Reserve pool can be released into blood"
                  },
                  {
                    "text": "Neutrophils circulate for only a few hours before migrating to tissue"
                  },
                  {
                    "text": "Neutrophils migrate by attaching to endothelium and passing through vessel wall"
                  },
                  {
                    "text": "ANC highest normal range at birthShould decline rapidly after birthLymphocytes outnumber neutrophils by 1 week of age",
                    "sub_points": [
                      "Should decline rapidly after birth",
                      "Lymphocytes outnumber neutrophils by 1 week of age"
                    ]
                  },
                  {
                    "text": "Neutrophil homeostasis maintained largely via steady bone marrow production"
                  }
                ],
                "Mechanisms of Neutrophilia": [
                  {
                    "text": "DemarginationNeutrophils attached to endothelium are released back into circulationCaused by epinephrineRapid processDoubles ANC within a few minutes",
                    "sub_points": [
                      "Neutrophils attached to endothelium are released back into circulation",
                      "Caused by epinephrine",
                      "Rapid process",
                      "Doubles ANC within a few minutes"
                    ]
                  },
                  {
                    "text": "Release of bone marrow reserve compartmentCaused by corticosteroids and G-CSFTakes several hoursLeft shift in blood",
                    "sub_points": [
                      "Caused by corticosteroids and G-CSF",
                      "Takes several hours",
                      "Left shift in blood"
                    ]
                  },
                  {
                    "text": "Increased productionCaused by sustained stimulusG-CSF-mediatedIncreased granulopoiesis in bone marrowRequires days to several weeksPrimary mechanism in sustained neutrophilias",
                    "sub_points": [
                      "Caused by sustained stimulus",
                      "G-CSF-mediated",
                      "Increased granulopoiesis in bone marrow",
                      "Requires days to several weeks",
                      "Primary mechanism in sustained neutrophilias"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "AdultsMore frequent in inpatient hospital settingLinked to numerous acute stressful events",
                    "sub_points": [
                      "More frequent in inpatient hospital setting",
                      "Linked to numerous acute stressful events"
                    ]
                  },
                  {
                    "text": "ChildrenNeutrophilia linked to acute infections, other acute stressful events",
                    "sub_points": [
                      "Neutrophilia linked to acute infections, other acute stressful events"
                    ]
                  },
                  {
                    "text": "NeonatesLinked to infection, acute stress (many causes), congenital anomalies, and rare constitutional neutrophilias",
                    "sub_points": [
                      "Linked to infection, acute stress (many causes), congenital anomalies, and rare constitutional neutrophilias"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Abnormal CBC"
                  },
                  {
                    "text": "Neutrophilia"
                  },
                  {
                    "text": "Clinical features highly variable due to many diverse causes of neutrophilia"
                  },
                  {
                    "text": "Many patients present with symptoms of acute or chronic infection"
                  },
                  {
                    "text": "Paradox of severe recurrent infections in setting of striking blood neutrophilia in rare patients with neutrophil migratory defect LAD"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "BloodIncreased ANCVariable toxic features of neutrophilsToxic granulationDohle bodiesVacuolizationVariable degree of left shift of neutrophil lineageLimited left shift in adults with infectionsMay see circulating blasts in infected neonates, infantsMonocytes may show toxic changes in infection, GM-CSF therapyOther lineages generally unremarkable",
                    "sub_points": [
                      "Increased ANC",
                      "Variable toxic features of neutrophilsToxic granulationDohle bodiesVacuolization",
                      "Toxic granulation",
                      "Dohle bodies",
                      "Vacuolization",
                      "Variable degree of left shift of neutrophil lineageLimited left shift in adults with infectionsMay see circulating blasts in infected neonates, infants",
                      "Limited left shift in adults with infections",
                      "May see circulating blasts in infected neonates, infants",
                      "Monocytes may show toxic changes in infection, GM-CSF therapy",
                      "Other lineages generally unremarkable"
                    ]
                  },
                  {
                    "text": "Bone marrowIncreased granulocytic lineage with intact maturation (if neutrophilia sustained)May see mild left shift if neutrophils released rapidly due to demandOther lineages and bone generally unremarkable",
                    "sub_points": [
                      "Increased granulocytic lineage with intact maturation (if neutrophilia sustained)",
                      "May see mild left shift if neutrophils released rapidly due to demand",
                      "Other lineages and bone generally unremarkable"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "PCR/Cytogenetics": [
                  {
                    "text": "Rule out chronic myelogenous leukemia"
                  },
                  {
                    "text": "Rule out other myeloproliferative neoplasms"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Cytokine-Mediated Neutrophilia": [
                  {
                    "text": "Recombinant G-CSF or GM-CSF therapy"
                  },
                  {
                    "text": "Used to induce rapid neutrophil recovery after profound myelosuppressive therapy"
                  },
                  {
                    "text": "May see increased blasts in blood and bone marrow during early response"
                  },
                  {
                    "text": "Marked toxic changes"
                  },
                  {
                    "text": "Rare binucleated neutrophils/neutrophil precursors"
                  }
                ],
                "Chronic Myelogenous Leukemia (CML)": [
                  {
                    "text": "WBC often > 100 x 10⁹/L"
                  },
                  {
                    "text": "Absence of toxic changes"
                  },
                  {
                    "text": "Left shift includes blasts"
                  },
                  {
                    "text": "Basophilia"
                  },
                  {
                    "text": "Splenomegaly"
                  },
                  {
                    "text": "BCR-ABL1by cytogenetics/molecular"
                  },
                  {
                    "text": "Hypercellular bone marrow"
                  },
                  {
                    "text": "Abnormal, hypolobated megakaryocytes"
                  }
                ],
                "Other Myeloproliferative Neoplasm (MPN)": [
                  {
                    "text": "WBC variable but may exhibit nontoxic neutrophilia"
                  },
                  {
                    "text": "Left shift may include blasts"
                  },
                  {
                    "text": "Basophilia variable"
                  },
                  {
                    "text": "Splenomegaly present"
                  },
                  {
                    "text": "JAK2mutations in many cases"
                  },
                  {
                    "text": "Hypercellular bone marrow"
                  },
                  {
                    "text": "Abnormal megakaryocytes with hyperlobation and clustering"
                  },
                  {
                    "text": "Variable fibrosis and osteosclerosis"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Cause of 2° neutrophilia usually clinically apparent"
                  },
                  {
                    "text": "Careful history for possible cytokine therapy"
                  },
                  {
                    "text": "Elevation of WBC and ANC usually ≤ 30 x 10⁹/L"
                  },
                  {
                    "text": "Left shift doesnotgenerally include blasts in adultsexceptpatients receiving recombinant CSF"
                  },
                  {
                    "text": "Left shift may include blasts in septic neonates/young infants"
                  },
                  {
                    "text": "Assess for toxic changes in neutrophils"
                  },
                  {
                    "text": "If blasts, basophilia, marked leukocytosis, &/or normoblasts present, consider chronic myeloproliferative neoplasm"
                  },
                  {
                    "text": "Significant splenomegaly more suggestive of chronic myeloproliferative neoplasm"
                  },
                  {
                    "text": "Genetic testing may be warranted to exclude some of the neoplastic neutrophilias"
                  },
                  {
                    "text": "In rare cases, sustained neutrophilia may be a consequence of CSF or chemokine-producing neoplasmsMyelomas, sarcomas, carcinomas, and mesotheliomas may aberrantly produce neutrophilia-inducing chemokines or cytokines",
                    "sub_points": [
                      "Myelomas, sarcomas, carcinomas, and mesotheliomas may aberrantly produce neutrophilia-inducing chemokines or cytokines"
                    ]
                  },
                  {
                    "text": "Constitutional neutrophilias restricted to rare family kindreds"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Lymphocytosis": {
            "name": "Lymphocytosis",
            "url": "https://app.pathprimer.com/document/d8c3f129-e2ad-4e65-a5b5-27f813a75c0f/lesson/ee882547-8989-432d-aea3-f4fc0df1ba42",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "Lymphocytosis in children most likely benign"
                  },
                  {
                    "text": "Persistent lymphocytosis in adults warrants diligent work-up to exclude neoplastic process"
                  },
                  {
                    "text": "More than 90% of humans are infected by Epstein-Barr virus (EBV)EBV infects B lymphocytes and becomes latent; individual becomes lifelong EBV carrier",
                    "sub_points": [
                      "EBV infects B lymphocytes and becomes latent; individual becomes lifelong EBV carrier"
                    ]
                  },
                  {
                    "text": "Persistent polyclonal B-cell lymphocytosis may show underlying genetic abnormalityPredominantly in women, usually cigarette smokers",
                    "sub_points": [
                      "Predominantly in women, usually cigarette smokers"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Flow cytometric studies should be performed on all persistent lymphocytosis in adults"
                  },
                  {
                    "text": "Assessment of T-cell receptor gene rearrangement by polymerase chain reaction (PCR) or Southern blot is helpful to assess clonality"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Peripheral blood (PB) of infectious mononucleosis reveals Downey type II or III lymphocytes"
                  },
                  {
                    "text": "Persistent polyclonal B-cell lymphocytosis shows mature nonreactive lymphocytes with frequent bilobed nuclei"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Elevated blood lymphocyte count above age-defined normal range"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Etiology": [
                  {
                    "text": "Lymphocytosis with reactive morphologyViral infections, such as Epstein-Barr virus (EBV), cytomegalovirus (CMV), or other",
                    "sub_points": [
                      "Viral infections, such as Epstein-Barr virus (EBV), cytomegalovirus (CMV), or other"
                    ]
                  },
                  {
                    "text": "Lymphocytosis with nonreactive morphologyWhooping cough (pertussis)Transient stress lymphocytosis (TSL)",
                    "sub_points": [
                      "Whooping cough (pertussis)",
                      "Transient stress lymphocytosis (TSL)"
                    ]
                  },
                  {
                    "text": "Large granular lymphocytosisT-cell large granular or chronic NK-cell lymphocytosis",
                    "sub_points": [
                      "T-cell large granular or chronic NK-cell lymphocytosis"
                    ]
                  },
                  {
                    "text": "Other causes of lymphocytosisNeoplasia, postsplenectomy, or hypersensitive reactions",
                    "sub_points": [
                      "Neoplasia, postsplenectomy, or hypersensitive reactions"
                    ]
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "Infectious mononucleosis (IM)EBV is DNA virus: Member ofHerpesviridaefamilyEBV infects B lymphocytes and becomes latent; individual becomes lifelong EBV carrierAcute infection induces cytotoxic T-cell response that eventually curbs viral proliferation and restrains immune responseIn fatal IM, lymphocytes invade vital organs, and cause hepatosplenomegaly, massive marrow necrosis, and severe pancytopeniaFatal IM patients are usually immunocompromisedMonoclonal or biclonal EBV and immunoglobulin heavy chain (IgH) or T-cell receptor (TCR) gene rearrangements are common in fatal IM",
                    "sub_points": [
                      "EBV is DNA virus: Member ofHerpesviridaefamily",
                      "EBV infects B lymphocytes and becomes latent; individual becomes lifelong EBV carrier",
                      "Acute infection induces cytotoxic T-cell response that eventually curbs viral proliferation and restrains immune response",
                      "In fatal IM, lymphocytes invade vital organs, and cause hepatosplenomegaly, massive marrow necrosis, and severe pancytopenia",
                      "Fatal IM patients are usually immunocompromised",
                      "Monoclonal or biclonal EBV and immunoglobulin heavy chain (IgH) or T-cell receptor (TCR) gene rearrangements are common in fatal IM"
                    ]
                  },
                  {
                    "text": "Transient stress lymphocytosis (TSL)Associated with acute stressor, such as trauma, myocardial infarct, obstetric emergencies, sickle cell crisis, septic shock, status epilepticusLikely induced by epinephrine released by body or administered iatrogenically",
                    "sub_points": [
                      "Associated with acute stressor, such as trauma, myocardial infarct, obstetric emergencies, sickle cell crisis, septic shock, status epilepticus",
                      "Likely induced by epinephrine released by body or administered iatrogenically"
                    ]
                  },
                  {
                    "text": "Large granular lymphocytosisT-cell large granular lymphocytosisAssociated with solid tumor, lymphomas, viral infections, immune-mediated thrombocytopenia, or hemophagocytosisPathogenesis unclear; expansion in response to antigen stimulation possible",
                    "sub_points": [
                      "T-cell large granular lymphocytosisAssociated with solid tumor, lymphomas, viral infections, immune-mediated thrombocytopenia, or hemophagocytosisPathogenesis unclear; expansion in response to antigen stimulation possible",
                      "Associated with solid tumor, lymphomas, viral infections, immune-mediated thrombocytopenia, or hemophagocytosis",
                      "Pathogenesis unclear; expansion in response to antigen stimulation possible"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology and Clinical Presentation": [
                  {
                    "text": "Infectious mononucleosis (IM)More than 90% of humans are infectedMost common pattern of EBV infection is clinically silent, childhood infectionIM results when primary infection occurs during adolescence or adulthoodIM presents with acute illness, such as fever, pharyngitis, fatigue, headache, cervical lymphadenopathy, and splenomegaly",
                    "sub_points": [
                      "More than 90% of humans are infected",
                      "Most common pattern of EBV infection is clinically silent, childhood infection",
                      "IM results when primary infection occurs during adolescence or adulthood",
                      "IM presents with acute illness, such as fever, pharyngitis, fatigue, headache, cervical lymphadenopathy, and splenomegaly"
                    ]
                  },
                  {
                    "text": "Persistent polyclonal B-cell lymphocytosis (PPBL)Predominantly in women, usually cigarette smokersPersists for many years",
                    "sub_points": [
                      "Predominantly in women, usually cigarette smokers",
                      "Persists for many years"
                    ]
                  },
                  {
                    "text": "Transient stress lymphocytosis (TSL)Rapid increase of all lymphocyte subsets",
                    "sub_points": [
                      "Rapid increase of all lymphocyte subsets"
                    ]
                  },
                  {
                    "text": "Large granular lymphocytosisAsymptomatic in many patientsMay present with anemia, neutropenia; needs extensive work-up to exclude neoplastic process",
                    "sub_points": [
                      "Asymptomatic in many patients",
                      "May present with anemia, neutropenia; needs extensive work-up to exclude neoplastic process"
                    ]
                  }
                ],
                "Laboratory Test": [
                  {
                    "text": "Flow cytometry studyPerformed on all persistent lymphocytosis of adults to assess cell lineage and to exclude clonal process",
                    "sub_points": [
                      "Performed on all persistent lymphocytosis of adults to assess cell lineage and to exclude clonal process"
                    ]
                  },
                  {
                    "text": "Infectious mononucleosis (IM)Lymphocytosis (usually over 4,000/μL) with reactive morphology; Downey type II or III lymphocytesPositive heterophile antibody test in older children and adultsHeterophile antibody is usually negative in young childrenPositive EBV-specific antibodies",
                    "sub_points": [
                      "Lymphocytosis (usually over 4,000/μL) with reactive morphology; Downey type II or III lymphocytes",
                      "Positive heterophile antibody test in older children and adults",
                      "Heterophile antibody is usually negative in young children",
                      "Positive EBV-specific antibodies"
                    ]
                  },
                  {
                    "text": "Persistent polyclonal B-cell lymphocytosis (PPBL)Immunophenotype: CD19(+), CD5(-), IgM(+), normal κ:λ ratioElevated polyclonal serum IgMDR7 phenotype in subset by HLA typing",
                    "sub_points": [
                      "Immunophenotype: CD19(+), CD5(-), IgM(+), normal κ:λ ratio",
                      "Elevated polyclonal serum IgM",
                      "DR7 phenotype in subset by HLA typing"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Follow-up is required in all cases"
                  },
                  {
                    "text": "No need for treatment in majority of cases"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Lymphocytosis in children is most likely benign"
                  },
                  {
                    "text": "Lymphocytosis in adults warrants diligent work-up to exclude neoplastic process"
                  },
                  {
                    "text": "Infectious mononucleosis (IM)Typically benign, self-limitedFatal in rare patients, especially immunocompromised patients",
                    "sub_points": [
                      "Typically benign, self-limited",
                      "Fatal in rare patients, especially immunocompromised patients"
                    ]
                  },
                  {
                    "text": "Persistent polyclonal B-cell lymphocytosis (PPBL)Stable, may persist for many yearsNo definitive malignant transformation potential",
                    "sub_points": [
                      "Stable, may persist for many years",
                      "No definitive malignant transformation potential"
                    ]
                  },
                  {
                    "text": "Transient stress lymphocytosis (TSL)Typically resolves within 24 to 48 hours",
                    "sub_points": [
                      "Typically resolves within 24 to 48 hours"
                    ]
                  },
                  {
                    "text": "Large granular lymphocytosisMay persist in some cases",
                    "sub_points": [
                      "May persist in some cases"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Cytologic Features": [
                  {
                    "text": "Lymphocytosis with reactive morphologyLarge cells with abundant clear to deep-blue cytoplasm, mature chromatin, and variable nucleoli",
                    "sub_points": [
                      "Large cells with abundant clear to deep-blue cytoplasm, mature chromatin, and variable nucleoli"
                    ]
                  },
                  {
                    "text": "Lymphocytosis with nonreactive morphologySmall cells with scant cytoplasm, condensed chromatin, and inconspicuous nucleoli",
                    "sub_points": [
                      "Small cells with scant cytoplasm, condensed chromatin, and inconspicuous nucleoli"
                    ]
                  },
                  {
                    "text": "Infectious mononucleosis (IM)Lymphocytosis with mostly Downey type II or III lymphocytesDowney type II cells are large with copious cytoplasm containing radial striationsDowney type I lymphocytes are usually associated with childhood EBV infectionThese are small cells with lobed nucleus and scant compact cytoplasm",
                    "sub_points": [
                      "Lymphocytosis with mostly Downey type II or III lymphocytes",
                      "Downey type II cells are large with copious cytoplasm containing radial striations",
                      "Downey type I lymphocytes are usually associated with childhood EBV infectionThese are small cells with lobed nucleus and scant compact cytoplasm",
                      "These are small cells with lobed nucleus and scant compact cytoplasm"
                    ]
                  },
                  {
                    "text": "Persistent polyclonal B-cell lymphocytosis (PPBL)Mature nonreactive lymphocytes with frequent bilobed nuclei",
                    "sub_points": [
                      "Mature nonreactive lymphocytes with frequent bilobed nuclei"
                    ]
                  },
                  {
                    "text": "Transient stress lymphocytosis (TSL)Mature nonreactive or reactive lymphocytes",
                    "sub_points": [
                      "Mature nonreactive or reactive lymphocytes"
                    ]
                  },
                  {
                    "text": "Large granular lymphocytosisLarge lymphocytes with abundant cytoplasm and sparse azurophilic granules",
                    "sub_points": [
                      "Large lymphocytes with abundant cytoplasm and sparse azurophilic granules"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Malignant Leukemia/Lymphoma in Peripheral Blood": [
                  {
                    "text": "Monotonous morphology"
                  },
                  {
                    "text": "Monoclonal B- or T-cell population by flow cytometry study (e.g., CLL or ALL)"
                  }
                ],
                "Whooping Cough (Pertussis)": [
                  {
                    "text": "Caused byBordetella pertussisinfection"
                  },
                  {
                    "text": "Infants or small children present with severe paroxysmal coughing"
                  },
                  {
                    "text": "Toxin causes striking lymphocytosis; usually up to 10,000/μL with nonreactive morphology, but cleaved lymphocytes are present"
                  }
                ],
                "T-cell Large Granular Lymphocytic Leukemia": [
                  {
                    "text": "Morphology indistinguishable from reactive large granular lymphocytes"
                  },
                  {
                    "text": "Flow cytometry study helpful to detect aberrant antigen expression and clonality"
                  },
                  {
                    "text": "Molecular study by PCR is clonal for T-cell receptor gene rearrangement in majority of cases"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Positive serology tests diagnostic of specific infection"
                  },
                  {
                    "text": "Paramount to rule out neoplastic lymphocytosis"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Monocytosis": {
            "name": "Monocytosis",
            "url": "https://app.pathprimer.com/document/12362f58-ea72-41e7-95f1-5f550dcf915a/lesson/ee882547-8989-432d-aea3-f4fc0df1ba42",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Absolute blood monocyte count > 0.8 x 10⁹/L in adults and > 3.5 x 10⁹/L in neonates"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Monocytes differentiate into tissue macrophages/histiocytes and dendritic cells"
                  },
                  {
                    "text": "Common causes of monocytosis are inflammation, immune-mediated disorders, infections, neoplasms"
                  },
                  {
                    "text": "Seen during interruption in neutrophil production"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "IHC: CD68(+), CD68R(+), CD163(+)"
                  },
                  {
                    "text": "Flow cytometric analysis: CD4, CD14, CD11b, CD36, CD38, CD64, CD13, CD15, CD33, HLA-DR, & CD45 positive"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Monocytes average 12-20 μm in diameterOften indented nucleus with reniform or folded appearanceAbundant gray to blue-gray cytoplasm with fine azurophilic granulesReactive features include ↑ cytoplasmic vacuolation",
                    "sub_points": [
                      "Often indented nucleus with reniform or folded appearance",
                      "Abundant gray to blue-gray cytoplasm with fine azurophilic granules",
                      "Reactive features include ↑ cytoplasmic vacuolation"
                    ]
                  },
                  {
                    "text": "Monoblasts and promonocytes are rare in normal bone marrows"
                  },
                  {
                    "text": "Increased immature monocytes may be seen during regeneration"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Absolute blood monocyte count > 0.8 x 10⁹/L in adults and > 3.5 x 10⁹/L in neonates"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Environmental Exposure": [
                  {
                    "text": "Alcoholic liver disease"
                  },
                  {
                    "text": "Therapy relatedColony stimulating factor (CSF) therapyGlucocorticoid administrationDrug-induced neutropenia or hemolytic anemiaExogenous cytokine therapyPostsplenectomy",
                    "sub_points": [
                      "Colony stimulating factor (CSF) therapy",
                      "Glucocorticoid administration",
                      "Drug-induced neutropenia or hemolytic anemia",
                      "Exogenous cytokine therapy",
                      "Postsplenectomy"
                    ]
                  },
                  {
                    "text": "Injury: Thermal injury, marathon running"
                  }
                ],
                "Infectious Agents": [
                  {
                    "text": "BacteriaTuberculosis, brucellosis, subacute bacterial endocarditis, syphilis, Rocky mountain spotted fever",
                    "sub_points": [
                      "Tuberculosis, brucellosis, subacute bacterial endocarditis, syphilis, Rocky mountain spotted fever"
                    ]
                  },
                  {
                    "text": "VirusCytomegalovirus, Epstein-Barr virus, varicella-zoster virus, parvovirus B19",
                    "sub_points": [
                      "Cytomegalovirus, Epstein-Barr virus, varicella-zoster virus, parvovirus B19"
                    ]
                  },
                  {
                    "text": "ParasiteMalaria, visceral leishmaniasis",
                    "sub_points": [
                      "Malaria, visceral leishmaniasis"
                    ]
                  }
                ],
                "Inflammatory/Immune-mediated Disorders": [
                  {
                    "text": "Collagen vascular diseasesSystemic lupus erythematosus, rheumatoid arthritis, polyarteritis nodosa, temporal arteritis, myositis",
                    "sub_points": [
                      "Systemic lupus erythematosus, rheumatoid arthritis, polyarteritis nodosa, temporal arteritis, myositis"
                    ]
                  },
                  {
                    "text": "Gastrointestinal disordersRegional enteritis, ulcerative colitis, sprue",
                    "sub_points": [
                      "Regional enteritis, ulcerative colitis, sprue"
                    ]
                  },
                  {
                    "text": "Liver diseases with increased bone marrow monocytesAutoimmune hepatitis, primary biliary cirrhosis, non-immune-mediated cirrhosis",
                    "sub_points": [
                      "Autoimmune hepatitis, primary biliary cirrhosis, non-immune-mediated cirrhosis"
                    ]
                  },
                  {
                    "text": "Sarcoidosis"
                  },
                  {
                    "text": "CytopeniasImmune-mediated hemolytic anemiaImmune-mediated thrombocytopenia",
                    "sub_points": [
                      "Immune-mediated hemolytic anemia",
                      "Immune-mediated thrombocytopenia"
                    ]
                  }
                ],
                "Neoplasms": [
                  {
                    "text": "Hematopoietic disordersLymphoma (Hodgkin and non-Hodgkin), plasma cell myeloma, myelodysplastic syndrome",
                    "sub_points": [
                      "Lymphoma (Hodgkin and non-Hodgkin), plasma cell myeloma, myelodysplastic syndrome"
                    ]
                  },
                  {
                    "text": "Nonhematopoietic tumorsCarcinomas and sarcomasCommon finding at diagnosisProminent monocytosis if M-CSF secreting tumor",
                    "sub_points": [
                      "Carcinomas and sarcomasCommon finding at diagnosis",
                      "Common finding at diagnosis",
                      "Prominent monocytosis if M-CSF secreting tumor"
                    ]
                  }
                ],
                "Other": [
                  {
                    "text": "CytopeniasHemolytic anemiaChronic or congenital neutropeniasWiskott-Aldrich syndrome",
                    "sub_points": [
                      "Hemolytic anemia",
                      "Chronic or congenital neutropeniasWiskott-Aldrich syndrome",
                      "Wiskott-Aldrich syndrome"
                    ]
                  },
                  {
                    "text": "Myocardial infarction"
                  }
                ],
                "General": [
                  {
                    "text": "DevelopmentDerived from common myeloid progenitor (CMP) → granulocyte/macrophage progenitor (GMP)GMP differentiates into both monocyte and granulocyte progenyMonocytes mature in bone marrowStages of maturation include monoblast, promonocyte, monocytePeripheral blood and bone marrow monocytes differentiate into resident phagocytesMacrophages/histiocytes in tissuesDendritic cells: Important for antigen presentation during T-cell activation",
                    "sub_points": [
                      "Derived from common myeloid progenitor (CMP) → granulocyte/macrophage progenitor (GMP)GMP differentiates into both monocyte and granulocyte progeny",
                      "GMP differentiates into both monocyte and granulocyte progeny",
                      "Monocytes mature in bone marrowStages of maturation include monoblast, promonocyte, monocyte",
                      "Stages of maturation include monoblast, promonocyte, monocyte",
                      "Peripheral blood and bone marrow monocytes differentiate into resident phagocytesMacrophages/histiocytes in tissuesDendritic cells: Important for antigen presentation during T-cell activation",
                      "Macrophages/histiocytes in tissues",
                      "Dendritic cells: Important for antigen presentation during T-cell activation"
                    ]
                  },
                  {
                    "text": "FunctionsPresentation of antigen, phagocytosis, immunomodulationWhen compared to neutrophils, monocytesProduce a variety of cytokines through new granule protein synthesisAccumulate more slowly at sites of acute inflammation but persist longerHave less powerful metabolic burst but can kill a greater diversity of microbial organisms",
                    "sub_points": [
                      "Presentation of antigen, phagocytosis, immunomodulation",
                      "When compared to neutrophils, monocytesProduce a variety of cytokines through new granule protein synthesisAccumulate more slowly at sites of acute inflammation but persist longerHave less powerful metabolic burst but can kill a greater diversity of microbial organisms",
                      "Produce a variety of cytokines through new granule protein synthesis",
                      "Accumulate more slowly at sites of acute inflammation but persist longer",
                      "Have less powerful metabolic burst but can kill a greater diversity of microbial organisms"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Age": [
                  {
                    "text": "Mean normal monocyte count changes with ageHigh in first few weeks of life (1 x 10⁹/L)Decreases rapidly to level of adults (0.4 x 10⁹/L)",
                    "sub_points": [
                      "High in first few weeks of life (1 x 10⁹/L)",
                      "Decreases rapidly to level of adults (0.4 x 10⁹/L)"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Transient monocytosisOccurs during interruption in neutrophil productionCancer chemotherapyIdiosyncratic drug reactionsStem cell transplantCyclic neutropenia, recovery phaseAcute infection or tissue injury",
                    "sub_points": [
                      "Occurs during interruption in neutrophil productionCancer chemotherapyIdiosyncratic drug reactionsStem cell transplantCyclic neutropenia, recovery phase",
                      "Cancer chemotherapy",
                      "Idiosyncratic drug reactions",
                      "Stem cell transplant",
                      "Cyclic neutropenia, recovery phase",
                      "Acute infection or tissue injury"
                    ]
                  },
                  {
                    "text": "Chronic monocytosisChronic inflammatory disordersChronic infectionsNeoplasms",
                    "sub_points": [
                      "Chronic inflammatory disorders",
                      "Chronic infections",
                      "Neoplasms"
                    ]
                  },
                  {
                    "text": "Symptoms depend on underlying etiology"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Complete blood count with differential cell countPeripheral blood smear reviewConfirm monocyte countEvaluate for blasts, promonocytes, abnormal monocytesEvaluate other lineages for dysplasia, toxic features, hemolysis",
                    "sub_points": [
                      "Peripheral blood smear reviewConfirm monocyte countEvaluate for blasts, promonocytes, abnormal monocytesEvaluate other lineages for dysplasia, toxic features, hemolysis",
                      "Confirm monocyte count",
                      "Evaluate for blasts, promonocytes, abnormal monocytes",
                      "Evaluate other lineages for dysplasia, toxic features, hemolysis"
                    ]
                  },
                  {
                    "text": "Possible bone marrow aspirate and biopsyPerform if unexplained abnormal peripheral blood smear findingsMorphologic evaluation of bone marrow for neoplastic process, infection, immune-mediated disorderSpecial stains for neoplasm or infectionImmunohistochemistry for monocytes/macrophages: CD68(+), CD163(+), CD68R(+)Cytogenetic &/or molecular evaluation for possible myeloid neoplasmCultures for virus, bacteria, fungus as clinically indicated",
                    "sub_points": [
                      "Perform if unexplained abnormal peripheral blood smear findingsMorphologic evaluation of bone marrow for neoplastic process, infection, immune-mediated disorderSpecial stains for neoplasm or infectionImmunohistochemistry for monocytes/macrophages: CD68(+), CD163(+), CD68R(+)Cytogenetic &/or molecular evaluation for possible myeloid neoplasmCultures for virus, bacteria, fungus as clinically indicated",
                      "Morphologic evaluation of bone marrow for neoplastic process, infection, immune-mediated disorder",
                      "Special stains for neoplasm or infection",
                      "Immunohistochemistry for monocytes/macrophages: CD68(+), CD163(+), CD68R(+)",
                      "Cytogenetic &/or molecular evaluation for possible myeloid neoplasm",
                      "Cultures for virus, bacteria, fungus as clinically indicated"
                    ]
                  },
                  {
                    "text": "Flow cytometric analysisMonocyte immunophenotypeCD4, CD14, ↑ CD11b, CD36, CD38, CD64, CD13, CD15, CD33, HLA-DR, and CD45 positiveBone marrow monocytes show variable expression of CD11b, CD14, and CD16 during maturation and activationReactive monocytesAberrant antigen expression usually isolated to 1 antigenCommon aberrancies include CD56(+), ↓ HLA-DR, ↓ CD13",
                    "sub_points": [
                      "Monocyte immunophenotypeCD4, CD14, ↑ CD11b, CD36, CD38, CD64, CD13, CD15, CD33, HLA-DR, and CD45 positiveBone marrow monocytes show variable expression of CD11b, CD14, and CD16 during maturation and activation",
                      "CD4, CD14, ↑ CD11b, CD36, CD38, CD64, CD13, CD15, CD33, HLA-DR, and CD45 positive",
                      "Bone marrow monocytes show variable expression of CD11b, CD14, and CD16 during maturation and activation",
                      "Reactive monocytesAberrant antigen expression usually isolated to 1 antigenCommon aberrancies include CD56(+), ↓ HLA-DR, ↓ CD13",
                      "Aberrant antigen expression usually isolated to 1 antigen",
                      "Common aberrancies include CD56(+), ↓ HLA-DR, ↓ CD13"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Monocytes average 12-20 μm in diameterOften indented nucleus with reniform or folded appearanceChromatin less condensed than neutrophil or lymphocyteUsually no nucleolus but may be small and subtleAbundant gray to blue-gray cytoplasmEvenly distributed fine azurophilic granulesReactive features include increased vacuolationNuclear cytoplasmic ratio is 4:1 to 2:1",
                    "sub_points": [
                      "Often indented nucleus with reniform or folded appearanceChromatin less condensed than neutrophil or lymphocyteUsually no nucleolus but may be small and subtle",
                      "Chromatin less condensed than neutrophil or lymphocyte",
                      "Usually no nucleolus but may be small and subtle",
                      "Abundant gray to blue-gray cytoplasmEvenly distributed fine azurophilic granulesReactive features include increased vacuolation",
                      "Evenly distributed fine azurophilic granules",
                      "Reactive features include increased vacuolation",
                      "Nuclear cytoplasmic ratio is 4:1 to 2:1"
                    ]
                  },
                  {
                    "text": "Monocytic precursors are rare in normal bone marrowMonoblastRound to oval nucleus, fine blastic chromatin, variably prominent nucleoliModerate cytoplasm with possible fine azurophilic granulationPromonocyteDelicately folded or creased nucleus, stippled nuclear chromatin, variably prominent nucleoliAbundant light gray or blue cytoplasm, scattered fine lilac-colored or azurophilic granulesIncreased immature monocytes may be seen during regeneration",
                    "sub_points": [
                      "MonoblastRound to oval nucleus, fine blastic chromatin, variably prominent nucleoliModerate cytoplasm with possible fine azurophilic granulation",
                      "Round to oval nucleus, fine blastic chromatin, variably prominent nucleoli",
                      "Moderate cytoplasm with possible fine azurophilic granulation",
                      "PromonocyteDelicately folded or creased nucleus, stippled nuclear chromatin, variably prominent nucleoliAbundant light gray or blue cytoplasm, scattered fine lilac-colored or azurophilic granules",
                      "Delicately folded or creased nucleus, stippled nuclear chromatin, variably prominent nucleoli",
                      "Abundant light gray or blue cytoplasm, scattered fine lilac-colored or azurophilic granules",
                      "Increased immature monocytes may be seen during regeneration"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Myeloid Neoplasms": [
                  {
                    "text": "Chronic myelomonocytic leukemia (CMML)Usually older adults (median age is 65-75 years)Persistent blood monocytosis > 1 x 10⁹/LDysplasia in ≥ 1 myeloid lineage, often dysgranulopoiesisBlasts ₊ promonocytes < 20% of cellsAbnormal monocytesAbnormal nuclear lobation or chromatin patternAbnormal cytoplasmic granulation",
                    "sub_points": [
                      "Usually older adults (median age is 65-75 years)",
                      "Persistent blood monocytosis > 1 x 10⁹/L",
                      "Dysplasia in ≥ 1 myeloid lineage, often dysgranulopoiesis",
                      "Blasts ₊ promonocytes < 20% of cells",
                      "Abnormal monocytesAbnormal nuclear lobation or chromatin patternAbnormal cytoplasmic granulation",
                      "Abnormal nuclear lobation or chromatin pattern",
                      "Abnormal cytoplasmic granulation"
                    ]
                  },
                  {
                    "text": "Juvenile myelomonocytic leukemiaChildren; 75% are < 3 years of ageGenerally marked hepatosplenomegalyOften increased hemoglobin F for ageLeukocytosis with left-shifted granulocytesPeripheral blood monocytosis > 1 x 10⁹/LClonal cytogenetic abnormalitiesMonosomy 7 (25%), other (10%)",
                    "sub_points": [
                      "Children; 75% are < 3 years of ageGenerally marked hepatosplenomegalyOften increased hemoglobin F for age",
                      "Generally marked hepatosplenomegaly",
                      "Often increased hemoglobin F for age",
                      "Leukocytosis with left-shifted granulocytesPeripheral blood monocytosis > 1 x 10⁹/L",
                      "Peripheral blood monocytosis > 1 x 10⁹/L",
                      "Clonal cytogenetic abnormalitiesMonosomy 7 (25%), other (10%)",
                      "Monosomy 7 (25%), other (10%)"
                    ]
                  },
                  {
                    "text": "Myelodysplastic/myeloproliferative neoplasm, unclassifiable"
                  },
                  {
                    "text": "Myeloid neoplasms withPDGFRBrearrangementHematologic features of CMML with eosinophilia",
                    "sub_points": [
                      "Hematologic features of CMML with eosinophilia"
                    ]
                  },
                  {
                    "text": "Acute myeloid leukemia (AML) with monocytic differentiationRecurrent cytogenetic abnormalitiesAML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11AML with t(9;11)(p22;q23);MLLT3-MLLAML with t(6;9)(p23;q34);DEK-NUP214Acute myelomonocytic leukemiaAcute monoblastic and monocytic leukemia (> 20% blasts & promonocytes)",
                    "sub_points": [
                      "Recurrent cytogenetic abnormalitiesAML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11AML with t(9;11)(p22;q23);MLLT3-MLLAML with t(6;9)(p23;q34);DEK-NUP214",
                      "AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11",
                      "AML with t(9;11)(p22;q23);MLLT3-MLL",
                      "AML with t(6;9)(p23;q34);DEK-NUP214",
                      "Acute myelomonocytic leukemia",
                      "Acute monoblastic and monocytic leukemia (> 20% blasts & promonocytes)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Eosinophilia": {
            "name": "Eosinophilia",
            "url": "https://app.pathprimer.com/document/ebbe27d2-5c81-4d6a-8f91-0fda4310cbcd/lesson/ee882547-8989-432d-aea3-f4fc0df1ba42",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Absolute eosinophil count > 0.5 x 10⁹/L, independent of age"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Reactive eosinophilia is usually caused by eosinopoietic cytokines, primarily IL-5 and GM-CSF"
                  },
                  {
                    "text": "In industrialized countries allergens are most common cause of eosinophilia"
                  },
                  {
                    "text": "In hospitalized patients medications are most common cause"
                  },
                  {
                    "text": "In nonindustrialized countries parasites are most common cause"
                  },
                  {
                    "text": "Activated eosinophils release proinflammatory mediators that cause tissue damage"
                  },
                  {
                    "text": "Intravascular degranulation of eosinophils causesGeneralized endothelial damageEndomyocardial fibrosisMarked propensity for thrombus formation",
                    "sub_points": [
                      "Generalized endothelial damage",
                      "Endomyocardial fibrosis",
                      "Marked propensity for thrombus formation"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Eosinophil atypia may be seen in both reactive and neoplastic disorders"
                  },
                  {
                    "text": "Bone marrow is often normocellular unless associated with an autoimmune or neoplastic disorder"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Absolute eosinophil count > 0.5 x 10⁹/L, independent of age"
                  },
                  {
                    "text": "Arbitrary ranges includeMild (0.6–1.5 x 10⁹/L)Moderate (1.6-5.0 x 10⁹/L)Severe (> 5 x 10⁹/L)",
                    "sub_points": [
                      "Mild (0.6–1.5 x 10⁹/L)",
                      "Moderate (1.6-5.0 x 10⁹/L)",
                      "Severe (> 5 x 10⁹/L)"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Environmental Exposure": [
                  {
                    "text": "Allergies"
                  },
                  {
                    "text": "Drug hypersensitivityNumerous drugsRecombinant cytokine therapy",
                    "sub_points": [
                      "Numerous drugs",
                      "Recombinant cytokine therapy"
                    ]
                  }
                ],
                "Infectious Agents": [
                  {
                    "text": "Parasites: HelminthsAscariasisFilariasisSchistosomiasisTrichinosisStrongyloidiasisCysticercosisEchinococcosisToxocariasisVisceral larva migrans",
                    "sub_points": [
                      "Ascariasis",
                      "Filariasis",
                      "Schistosomiasis",
                      "Trichinosis",
                      "Strongyloidiasis",
                      "Cysticercosis",
                      "Echinococcosis",
                      "Toxocariasis",
                      "Visceral larva migrans"
                    ]
                  },
                  {
                    "text": "FungalCryptococcosisAspergillosisCoccidioidomycosisHistoplasmosisBlastomycosis",
                    "sub_points": [
                      "Cryptococcosis",
                      "Aspergillosis",
                      "Coccidioidomycosis",
                      "Histoplasmosis",
                      "Blastomycosis"
                    ]
                  },
                  {
                    "text": "Protozoal"
                  },
                  {
                    "text": "Bacterial"
                  },
                  {
                    "text": "ViralHuman T-cell lymphotrophic virusWest Nile virus",
                    "sub_points": [
                      "Human T-cell lymphotrophic virus",
                      "West Nile virus"
                    ]
                  }
                ],
                "Underlying Illness": [
                  {
                    "text": "Pulmonary disordersLoeffler syndromeHypersensitivity pneumonitisBronchiectasisChurg-Strauss syndrome",
                    "sub_points": [
                      "Loeffler syndrome",
                      "Hypersensitivity pneumonitis",
                      "Bronchiectasis",
                      "Churg-Strauss syndrome"
                    ]
                  },
                  {
                    "text": "Skin lesions (atopic dermatitis, irticaria, pemphigus, bullous pemphigoid, eosinophilic panniculitis)"
                  },
                  {
                    "text": "Gastrointestinal diseaseCeliac diseaseInflammatory bowel diseaseEosinophilic gastroenteritisChronic pancreatitis",
                    "sub_points": [
                      "Celiac disease",
                      "Inflammatory bowel disease",
                      "Eosinophilic gastroenteritis",
                      "Chronic pancreatitis"
                    ]
                  }
                ],
                "Immunologic Disorders": [
                  {
                    "text": "Polyarteritis nodosa"
                  },
                  {
                    "text": "Kimura disease"
                  },
                  {
                    "text": "Churg-Strauss syndrome"
                  },
                  {
                    "text": "Sarcoidosis"
                  },
                  {
                    "text": "Collagen vascular diseases (scleroderma, systemic lupus erythematosus)"
                  },
                  {
                    "text": "Severe combined immunodeficiency"
                  }
                ],
                "Neoplastic Processes; Eosinophils Nonneoplastic": [
                  {
                    "text": "Classical Hodgkin lymphoma"
                  },
                  {
                    "text": "T-cell lymphoproliferative disorders"
                  },
                  {
                    "text": "B-lymphoblastic leukemia with t(5;14)(q31;q32)IL3-IGH@"
                  },
                  {
                    "text": "Langerhans cell histiocytosis"
                  },
                  {
                    "text": "Myelodysplastic syndromes"
                  },
                  {
                    "text": "Aberrant T-cell population (T cells may or may not be clonal)"
                  },
                  {
                    "text": "Natural killer (NK) cell neoplasms"
                  },
                  {
                    "text": "Carcinoma (paraneoplastic syndrome associated)"
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "Cytokine-producing constituents in secondary (reactive) eosinophiliaActivated T-cells (Th2)Mast cellsStromal cellsVarious neoplastic cells (e.g., lymphoma cells)",
                    "sub_points": [
                      "Activated T-cells (Th2)",
                      "Mast cells",
                      "Stromal cells",
                      "Various neoplastic cells (e.g., lymphoma cells)"
                    ]
                  },
                  {
                    "text": "Cytokines that stimulate eosinophil production in bone marrowIL-5IL-3IL-2GM-CSF",
                    "sub_points": [
                      "IL-5",
                      "IL-3",
                      "IL-2",
                      "GM-CSF"
                    ]
                  },
                  {
                    "text": "Sustained cytokine production linked to chronic eosinophiliaConstitutive IL-3 activation in B-lymphoblastic leukemia with t(5;14)IL3-IGH@",
                    "sub_points": [
                      "Constitutive IL-3 activation in B-lymphoblastic leukemia with t(5;14)IL3-IGH@"
                    ]
                  },
                  {
                    "text": "Eosinophil maturation takes approximately 5 days"
                  },
                  {
                    "text": "Eosinophils circulate 18-24 hours before migrating into tissues"
                  },
                  {
                    "text": "Chemotactic factors recruit eosinophils from blood into tissueEotaxinIL-5",
                    "sub_points": [
                      "Eotaxin",
                      "IL-5"
                    ]
                  },
                  {
                    "text": "Majority of eosinophils are in tissues"
                  },
                  {
                    "text": "Activated eosinophils release proinflammatory mediators that cause tissue damage"
                  },
                  {
                    "text": "Intravascular degranulation of eosinophils results inGeneralized endothelial damageEndomyocardial fibrosisMarked propensity for thrombus formation",
                    "sub_points": [
                      "Generalized endothelial damage",
                      "Endomyocardial fibrosis",
                      "Marked propensity for thrombus formation"
                    ]
                  },
                  {
                    "text": "In industrialized countries allergens are most common cause"
                  },
                  {
                    "text": "In hospitalized patients medications are most common cause"
                  },
                  {
                    "text": "In nonindustrialized countries parasites most common cause"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "Transient eosinophilia: Acute reactive processes infectionsAllergic or drug reactions, acute infections, nonspecific inflammationSymptoms related to underlying disorders",
                    "sub_points": [
                      "Allergic or drug reactions, acute infections, nonspecific inflammation",
                      "Symptoms related to underlying disorders"
                    ]
                  },
                  {
                    "text": "Chronic reactive eosinophiliaPersistent chronic infection (often parasitic in developing countries)Autoimmune and other immunologic disordersAtopic diseaseSymptoms related to underlying disorders",
                    "sub_points": [
                      "Persistent chronic infection (often parasitic in developing countries)",
                      "Autoimmune and other immunologic disorders",
                      "Atopic disease",
                      "Symptoms related to underlying disorders"
                    ]
                  },
                  {
                    "text": "Organ-restricted symptomsCardiovascularEosinophil granule release damages endocardiumProlonged endocardial damage leads to endomyocardial fibrosisDamaged endocardium site for thrombus formationThromboemboli may result in strokes/other sites of vascular occlusionPulmonarySkinEosinophil-associated gastrointestinal disorders (EGIDs)",
                    "sub_points": [
                      "CardiovascularEosinophil granule release damages endocardiumProlonged endocardial damage leads to endomyocardial fibrosisDamaged endocardium site for thrombus formationThromboemboli may result in strokes/other sites of vascular occlusion",
                      "Eosinophil granule release damages endocardium",
                      "Prolonged endocardial damage leads to endomyocardial fibrosis",
                      "Damaged endocardium site for thrombus formation",
                      "Thromboemboli may result in strokes/other sites of vascular occlusion",
                      "Pulmonary",
                      "Skin",
                      "Eosinophil-associated gastrointestinal disorders (EGIDs)"
                    ]
                  },
                  {
                    "text": "Systemic manifestationsKimura diseaseChurg-Strauss syndrome (ANCA[+] and ANCA[-] variants)Drug rash with eosinophilia and systemic symptoms (DRESS syndrome)Severe combined immunodeficiency (Omenn syndrome, hyper IgE syndromes)Neoplastic disorders with secondary eosinophiliaDiverse disease manifestations",
                    "sub_points": [
                      "Kimura disease",
                      "Churg-Strauss syndrome (ANCA[+] and ANCA[-] variants)",
                      "Drug rash with eosinophilia and systemic symptoms (DRESS syndrome)",
                      "Severe combined immunodeficiency (Omenn syndrome, hyper IgE syndromes)",
                      "Neoplastic disorders with secondary eosinophiliaDiverse disease manifestations",
                      "Diverse disease manifestations"
                    ]
                  },
                  {
                    "text": "DRESS syndromeSyndrome presents from 2-6 weeks after receiving an offending drugCharacterized by drug rash, eosinophilia, possible atypical lymphocytosis, systemic symptoms",
                    "sub_points": [
                      "Syndrome presents from 2-6 weeks after receiving an offending drug",
                      "Characterized by drug rash, eosinophilia, possible atypical lymphocytosis, systemic symptoms"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Depends on clinical history and physical examination findings"
                  },
                  {
                    "text": "Possible testing includesSerologic tests and stool exam for ova and parasitesBiopsies of skin, gastrointestinal tract, or bone marrowSerum tryptase levelCytogenetic, FISH, or molecular analysisImmunophenotypic &/or molecular analysis for abnormal T-cell populationAntineutrophil cytoplasmic antibodies (ANCA)",
                    "sub_points": [
                      "Serologic tests and stool exam for ova and parasites",
                      "Biopsies of skin, gastrointestinal tract, or bone marrow",
                      "Serum tryptase level",
                      "Cytogenetic, FISH, or molecular analysis",
                      "Immunophenotypic &/or molecular analysis for abnormal T-cell population",
                      "Antineutrophil cytoplasmic antibodies (ANCA)"
                    ]
                  }
                ],
                "Treatment": [],
                "Adjuvant therapy": [
                  {
                    "text": "Monoclonal antibody to IL-5 (mepolizumab, reslizumab)"
                  }
                ],
                "Drugs": [
                  {
                    "text": "Glucocorticosteroids"
                  },
                  {
                    "text": "Treatment of underlying disease"
                  },
                  {
                    "text": "Cytoreductive agents"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Excellent if transient eosinophilia and no significant organ involvement/damage"
                  },
                  {
                    "text": "Variable prognosis depending on treatment of causative disorder and extent of organ injury"
                  },
                  {
                    "text": "Eosinophil-induced inflammation leads to tissue damage with fibrosis &/or thrombosis"
                  },
                  {
                    "text": "Sites of irreversible damageEndocardium/myocardiumLungsCentral nervous systemDamage to other tissues often irreversible",
                    "sub_points": [
                      "Endocardium/myocardium",
                      "Lungs",
                      "Central nervous system",
                      "Damage to other tissues often irreversible"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Predominant Pattern/Injury Type": [
                  {
                    "text": "Bone marrow is often normocellular unless associated with autoimmune or neoplastic disorder"
                  }
                ],
                "Predominant Cell/Compartment Type": [
                  {
                    "text": "Eosinophil precursors increased"
                  }
                ],
                "Histologic Features": [
                  {
                    "text": "Approximately 80% of circulating eosinophils have 2 equally sized nuclear lobes"
                  },
                  {
                    "text": "Eosinophil cytoplasm contains 2 types of granulesLarge, electron-dense, crystalloid granules composed of cationic proteinsSmaller amorphous granules containing arylsulfatase and acid phosphatase",
                    "sub_points": [
                      "Large, electron-dense, crystalloid granules composed of cationic proteins",
                      "Smaller amorphous granules containing arylsulfatase and acid phosphatase"
                    ]
                  },
                  {
                    "text": "Activated eosinophils can show nuclear and cytoplasmic abnormalitiesIncreased or decreased nuclear lobesCytoplasmic degranulation or vacuolizationDysplasia in nonneoplastic eosinophils especially prominent in B-lymphoblastic leukemia with t(5;14)",
                    "sub_points": [
                      "Increased or decreased nuclear lobes",
                      "Cytoplasmic degranulation or vacuolization",
                      "Dysplasia in nonneoplastic eosinophils especially prominent in B-lymphoblastic leukemia with t(5;14)"
                    ]
                  },
                  {
                    "text": "Eosinophil precursors in bone marrow haveCytoplasm containing orange-red, refractile granulesNuclear features similar to neutrophilic myeloid precursors (starting at myelocyte stage)",
                    "sub_points": [
                      "Cytoplasm containing orange-red, refractile granules",
                      "Nuclear features similar to neutrophilic myeloid precursors (starting at myelocyte stage)"
                    ]
                  },
                  {
                    "text": "Charcot-Leyden crystals infrequently form in bone marrows with marked eosinophilic hyperplasia"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Clonal Disorders With Eosinophil Component": [
                  {
                    "text": "Myeloproliferative neoplasms (MPNs)Chronic eosinophilic leukemia, not otherwise specifiedEosinophil count > 1.5 x 10⁹/LClonal cytogenetic or molecular genetic abnormality that is not specific for one of the other MPNs> 2% blasts in peripheral blood or > 5% blasts in bone marrowChronic myelogenous leukemia,BCR-ABL1(+)Neutrophilic leukocytosisBCR-ABL1fusion gene located on Philadelphia chromosome t(9;22)(q34;q11.2)Systemic mastocytosisMyeloid and lymphoid neoplasms with eosinophilia and abnormalities ofPDGFRAMyeloproliferative neoplasm featuresAcute myeloid leukemia (AML) featuresPrecursor T-lymphoblastic leukemia/lymphoma with prominent eosinophilia andPDGFRArearrangement, i.e.,FIP1L1-PDGFRAfusion geneResponsive to imatinib therapyMyeloid and lymphoid neoplasms with eosinophilia and abnormalities ofPDGFRBincluding t(5;12)(q31-q33;p13)Chronic myelomonocytic leukemia featuresAtypical chronic myeloid leukemia featuresPh(-) chronic myeloid leukemia featuresJuvenile myelomonocytic leukemia featuresChronic eosinophilic leukemia featuresMyeloid and lymphoid neoplasms with eosinophilia and abnormalities ofFGFR1including t(8;13)(p11;q12) rearrangementsMyeloproliferative neoplasm featuresPrecursor B- or T-cell lymphoblastic leukemia/lymphoma featuresNot imatinib responsiveAcute myeloid leukemiaAML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11Other AMLs: Eosinophils are either part of clonal disorder or are reactive",
                    "sub_points": [
                      "Chronic eosinophilic leukemia, not otherwise specifiedEosinophil count > 1.5 x 10⁹/LClonal cytogenetic or molecular genetic abnormality that is not specific for one of the other MPNs> 2% blasts in peripheral blood or > 5% blasts in bone marrow",
                      "Eosinophil count > 1.5 x 10⁹/L",
                      "Clonal cytogenetic or molecular genetic abnormality that is not specific for one of the other MPNs",
                      "> 2% blasts in peripheral blood or > 5% blasts in bone marrow",
                      "Chronic myelogenous leukemia,BCR-ABL1(+)Neutrophilic leukocytosisBCR-ABL1fusion gene located on Philadelphia chromosome t(9;22)(q34;q11.2)",
                      "Neutrophilic leukocytosis",
                      "BCR-ABL1fusion gene located on Philadelphia chromosome t(9;22)(q34;q11.2)",
                      "Systemic mastocytosis",
                      "Myeloid and lymphoid neoplasms with eosinophilia and abnormalities ofPDGFRAMyeloproliferative neoplasm featuresAcute myeloid leukemia (AML) featuresPrecursor T-lymphoblastic leukemia/lymphoma with prominent eosinophilia andPDGFRArearrangement, i.e.,FIP1L1-PDGFRAfusion geneResponsive to imatinib therapy",
                      "Myeloproliferative neoplasm features",
                      "Acute myeloid leukemia (AML) features",
                      "Precursor T-lymphoblastic leukemia/lymphoma with prominent eosinophilia andPDGFRArearrangement, i.e.,FIP1L1-PDGFRAfusion gene",
                      "Responsive to imatinib therapy",
                      "Myeloid and lymphoid neoplasms with eosinophilia and abnormalities ofPDGFRBincluding t(5;12)(q31-q33;p13)Chronic myelomonocytic leukemia featuresAtypical chronic myeloid leukemia featuresPh(-) chronic myeloid leukemia featuresJuvenile myelomonocytic leukemia featuresChronic eosinophilic leukemia features",
                      "Chronic myelomonocytic leukemia features",
                      "Atypical chronic myeloid leukemia features",
                      "Ph(-) chronic myeloid leukemia features",
                      "Juvenile myelomonocytic leukemia features",
                      "Chronic eosinophilic leukemia features",
                      "Myeloid and lymphoid neoplasms with eosinophilia and abnormalities ofFGFR1including t(8;13)(p11;q12) rearrangementsMyeloproliferative neoplasm featuresPrecursor B- or T-cell lymphoblastic leukemia/lymphoma featuresNot imatinib responsive",
                      "Myeloproliferative neoplasm features",
                      "Precursor B- or T-cell lymphoblastic leukemia/lymphoma features",
                      "Not imatinib responsive",
                      "Acute myeloid leukemiaAML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11Other AMLs: Eosinophils are either part of clonal disorder or are reactive",
                      "AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11",
                      "Other AMLs: Eosinophils are either part of clonal disorder or are reactive"
                    ]
                  }
                ],
                "Nonclonal Chronic Eosinophilias": [
                  {
                    "text": "Idiopathic hypereosinophilic syndrome (HES)Eosinophil count > 1.5 x 10⁹/L for > 6 monthsAll reactive and neoplastic etiologies excluded by appropriate investigationsNo tissue damageNegative cytogenetic and molecular studies",
                    "sub_points": [
                      "Eosinophil count > 1.5 x 10⁹/L for > 6 months",
                      "All reactive and neoplastic etiologies excluded by appropriate investigations",
                      "No tissue damage",
                      "Negative cytogenetic and molecular studies"
                    ]
                  },
                  {
                    "text": "Familial eosinophiliaRare autosomal dominant disorder sometimes secondary to 5q31-33 abnormality",
                    "sub_points": [
                      "Rare autosomal dominant disorder sometimes secondary to 5q31-33 abnormality"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Neutropenia": {
            "name": "Neutropenia",
            "url": "https://app.pathprimer.com/document/f5c2ad9e-5c25-44ae-9bfb-3e531037c88f/lesson/ee882547-8989-432d-aea3-f4fc0df1ba42",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Absolute neutrophil count (ANC) in blood ﻿below﻿age-related normal range"
                  },
                  {
                    "text": "Grading of neutropeniaMild neutropenia: 1.0-1.5 x 10⁹/LModerate neutropenia: 0.5-1.0 x 10⁹/LSevere neutropenia: < 0.5 x 10⁹/L",
                    "sub_points": [
                      "Mild neutropenia: 1.0-1.5 x 10⁹/L",
                      "Moderate neutropenia: 0.5-1.0 x 10⁹/L",
                      "Severe neutropenia: < 0.5 x 10⁹/L"
                    ]
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Production defects"
                  },
                  {
                    "text": "Maturation defects"
                  },
                  {
                    "text": "Survival defects"
                  },
                  {
                    "text": "Distribution defects"
                  },
                  {
                    "text": "Age-related top considerationsNeutropenia at birth and ﻿early infancy﻿Neonatal infectionMaternal factors (autoimmune disease, medications, alloantibody formation)Neutropenia in ﻿childhood﻿InfectionNeutropenia in ﻿adults﻿Medications/toxins/homeopathic remedies",
                    "sub_points": [
                      "Neutropenia at birth and ﻿early infancy﻿Neonatal infectionMaternal factors (autoimmune disease, medications, alloantibody formation)",
                      "Neonatal infection",
                      "Maternal factors (autoimmune disease, medications, alloantibody formation)",
                      "Neutropenia in ﻿childhood﻿Infection",
                      "Infection",
                      "Neutropenia in ﻿adults﻿Medications/toxins/homeopathic remedies",
                      "Medications/toxins/homeopathic remedies"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Transient neutropenia is common in childrenLikely consequence of childhood infectionsSpontaneous remissions common",
                    "sub_points": [
                      "Likely consequence of childhood infections",
                      "Spontaneous remissions common"
                    ]
                  },
                  {
                    "text": "Neutropenia common in adultsSide effect of many medications",
                    "sub_points": [
                      "Side effect of many medications"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Absolute neutrophil count in blood ﻿below﻿lower limit of age-related normal rangeAdults: ≤ 1.5 x 10⁹/LChildren: ≤ 1.5 x 10⁹/LNeonates: ≤ 2.5 x 10⁹/L",
                    "sub_points": [
                      "Adults: ≤ 1.5 x 10⁹/L",
                      "Children: ≤ 1.5 x 10⁹/L",
                      "Neonates: ≤ 2.5 x 10⁹/L"
                    ]
                  },
                  {
                    "text": "Race-related variations in normal range for ANCOne-fourth of healthy children and adults of African ancestry have ANC 1.0-1.5 x 10⁹/LMay be linked to Duffy antigen chemokine receptor gene polymorphisms",
                    "sub_points": [
                      "One-fourth of healthy children and adults of African ancestry have ANC 1.0-1.5 x 10⁹/L",
                      "May be linked to Duffy antigen chemokine receptor gene polymorphisms"
                    ]
                  },
                  {
                    "text": "Degree of neutropeniaMild neutropenia: 1.0-1.5 x 10⁹/LModerate neutropenia: 0.5-1.0 x 10⁹/LSevere neutropenia: < 0.5 x 10⁹/L",
                    "sub_points": [
                      "Mild neutropenia: 1.0-1.5 x 10⁹/L",
                      "Moderate neutropenia: 0.5-1.0 x 10⁹/L",
                      "Severe neutropenia: < 0.5 x 10⁹/L"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Pathogenesis": [
                  {
                    "text": "Production defectsSevere attenuation of granulocytic lineage in bone marrowCan be constitutional or acquiredMay be transient or sustainedSustained in constitutional disorders and in chronic disease-associated neutropeniaTransient following myeloablative therapies, and medication-associated agranulocytosis",
                    "sub_points": [
                      "Severe attenuation of granulocytic lineage in bone marrow",
                      "Can be constitutional or acquired",
                      "May be transient or sustainedSustained in constitutional disorders and in chronic disease-associated neutropeniaTransient following myeloablative therapies, and medication-associated agranulocytosis",
                      "Sustained in constitutional disorders and in chronic disease-associated neutropenia",
                      "Transient following myeloablative therapies, and medication-associated agranulocytosis"
                    ]
                  },
                  {
                    "text": "Maturation defectsPathologic destruction of developing granulocytic cells within bone marrow due to enhanced apoptosis or other mechanismsGranulocytic lineage increased, maturation intactCan be constitutional or acquired",
                    "sub_points": [
                      "Pathologic destruction of developing granulocytic cells within bone marrow due to enhanced apoptosis or other mechanisms",
                      "Granulocytic lineage increased, maturation intact",
                      "Can be constitutional or acquired"
                    ]
                  },
                  {
                    "text": "Survival defectsEnhanced destruction of mature neutrophilsImmune mechanismsIncreased utilizationGranulocytic lineage increased, maturation intactUsually acquired",
                    "sub_points": [
                      "Enhanced destruction of mature neutrophilsImmune mechanismsIncreased utilization",
                      "Immune mechanisms",
                      "Increased utilization",
                      "Granulocytic lineage increased, maturation intact",
                      "Usually acquired"
                    ]
                  },
                  {
                    "text": "Distribution defectsPooling of neutrophils in sites such as spleenUsually acquiredSeldom primary cause of neutropenia",
                    "sub_points": [
                      "Pooling of neutrophils in sites such as spleen",
                      "Usually acquired",
                      "Seldom primary cause of neutropenia"
                    ]
                  }
                ],
                "Age-Related Etiologies": [
                  {
                    "text": "Neutropenia at birth and ﻿early infancy﻿Neonatal infection, acquired or vertically transmittedMaternal factors (autoimmune disease, medications, alloantibody formation)Antibody crosses placenta and affects fetusAutoimmune neutropenia of infancyUsual onset: 1-3 yearsSpontaneous remissionNot generally linked to serious infectious complicationsMetabolic disordersMedicationsConstitutional disorders, onset at birth or shortly afterSevere congenital neutropenia (Kostmann syndrome)Shwachman-Diamond syndromeCyclic neutropeniaDyskeratosis congenitaFanconi anemiaMyelokathexis (abnormal morphology)Chédiak-Higashi syndrome (abnormal morphology)",
                    "sub_points": [
                      "Neonatal infection, acquired or vertically transmitted",
                      "Maternal factors (autoimmune disease, medications, alloantibody formation)Antibody crosses placenta and affects fetus",
                      "Antibody crosses placenta and affects fetus",
                      "Autoimmune neutropenia of infancyUsual onset: 1-3 yearsSpontaneous remissionNot generally linked to serious infectious complications",
                      "Usual onset: 1-3 years",
                      "Spontaneous remission",
                      "Not generally linked to serious infectious complications",
                      "Metabolic disorders",
                      "Medications",
                      "Constitutional disorders, onset at birth or shortly afterSevere congenital neutropenia (Kostmann syndrome)Shwachman-Diamond syndromeCyclic neutropeniaDyskeratosis congenitaFanconi anemiaMyelokathexis (abnormal morphology)Chédiak-Higashi syndrome (abnormal morphology)",
                      "Severe congenital neutropenia (Kostmann syndrome)",
                      "Shwachman-Diamond syndrome",
                      "Cyclic neutropenia",
                      "Dyskeratosis congenita",
                      "Fanconi anemia",
                      "Myelokathexis (abnormal morphology)",
                      "Chédiak-Higashi syndrome (abnormal morphology)"
                    ]
                  },
                  {
                    "text": "Neutropenia in ﻿childhood﻿Infection, often viralAutoimmune neutropeniaImmunodeficiencyNeoplasmsMyeloablative therapiesMegaloblastic anemiaCopper deficiencyAplastic anemiaConstitutional disorders",
                    "sub_points": [
                      "Infection, often viral",
                      "Autoimmune neutropenia",
                      "Immunodeficiency",
                      "Neoplasms",
                      "Myeloablative therapies",
                      "Megaloblastic anemia",
                      "Copper deficiency",
                      "Aplastic anemia",
                      "Constitutional disorders"
                    ]
                  },
                  {
                    "text": "Neutropenia in ﻿adults﻿Medications/toxins/homeopathic remediesInfectionsChronic illnesses (collagen vascular disease, endocrine disorders)T-cell large granular lymphocytic leukemiaHypersplenismImmunodeficiencyNeoplasmsMyeloablative therapiesMegaloblastic anemiaCopper deficiency (may be zinc-induced)Aplastic anemiaCocaine contaminated with levamisole",
                    "sub_points": [
                      "Medications/toxins/homeopathic remedies",
                      "Infections",
                      "Chronic illnesses (collagen vascular disease, endocrine disorders)",
                      "T-cell large granular lymphocytic leukemia",
                      "Hypersplenism",
                      "Immunodeficiency",
                      "Neoplasms",
                      "Myeloablative therapies",
                      "Megaloblastic anemia",
                      "Copper deficiency (may be zinc-induced)",
                      "Aplastic anemia",
                      "Cocaine contaminated with levamisole"
                    ]
                  }
                ],
                "Neutrophil Homeostasis": [
                  {
                    "text": "Neutrophil production is exquisitely regulated in bone marrow"
                  },
                  {
                    "text": "Granulocyte-colony stimulating factor (G-CSF) is major cytokine driving neutrophil productionProduced by macrophages/T cells",
                    "sub_points": [
                      "Produced by macrophages/T cells"
                    ]
                  },
                  {
                    "text": "G-CSF binds to its receptor on progenitor cellsResults in proliferation of progenitor cells",
                    "sub_points": [
                      "Results in proliferation of progenitor cells"
                    ]
                  },
                  {
                    "text": "Maturation from myeloblast to neutrophil regulated by modulating gene expressionMaturation characterized by progressive nuclear condensation with ultimate segmentationMaturation characterized by progressive acquisition of first primary granules, and then secondary and tertiary granules",
                    "sub_points": [
                      "Maturation characterized by progressive nuclear condensation with ultimate segmentation",
                      "Maturation characterized by progressive acquisition of first primary granules, and then secondary and tertiary granules"
                    ]
                  },
                  {
                    "text": "Regulatory defects may be constitutional or acquired"
                  },
                  {
                    "text": "Large reserve compartment in bone marrow of neutrophils, neutrophilic metamyelocytes, and neutrophilic myelocytes"
                  },
                  {
                    "text": "Reserve compartment located in central medullary region for ease of release of cells into sinuses"
                  },
                  {
                    "text": "Sinuses coalesce into veins"
                  },
                  {
                    "text": "Neutrophil production requires about 5-7 days in bone marrow"
                  },
                  {
                    "text": "Neutrophils circulate for a few hours, and then migrate to tissueNeutrophils do not recirculate",
                    "sub_points": [
                      "Neutrophils do not recirculate"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Transient neutropenia is common in childrenLikely consequence of childhood infectionsSpontaneous remission in several months",
                    "sub_points": [
                      "Likely consequence of childhood infections",
                      "Spontaneous remission in several months"
                    ]
                  },
                  {
                    "text": "Other causes of neutropenia in children are much less common"
                  },
                  {
                    "text": "Neutropenia is common in adultsSide effect of many medications and homeopathic remediesLinked to numerous chronic illnessesMany other causes",
                    "sub_points": [
                      "Side effect of many medications and homeopathic remedies",
                      "Linked to numerous chronic illnesses",
                      "Many other causes"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Neutropenia detected by complete blood count (CBC)"
                  },
                  {
                    "text": "Patients with significant neutropenia may present with secondary infectionsUsually bacterial, endogenous organisms",
                    "sub_points": [
                      "Usually bacterial, endogenous organisms"
                    ]
                  },
                  {
                    "text": "Patients with constitutional neutropenias manifest with recurrent bacterial infectionsMay have other stigmata of constitutional genetic defectOnset in early infancyPositive family history",
                    "sub_points": [
                      "May have other stigmata of constitutional genetic defect",
                      "Onset in early infancy",
                      "Positive family history"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Variable, depending on underlying cause"
                  },
                  {
                    "text": "Recombinant G-CSF for selected patientsSome constitutional neutropeniasIn conjunction with myeloablative therapies for some patients",
                    "sub_points": [
                      "Some constitutional neutropenias",
                      "In conjunction with myeloablative therapies for some patients"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Peripheral Blood": [
                  {
                    "text": "Decreased ANC"
                  },
                  {
                    "text": "Neutrophil morphology generally normal; may show toxic features in secondary infections"
                  },
                  {
                    "text": "Distinctive neutrophil morphology in rare constitutional neutropeniasLarge coarse granules in neutrophils, other granulated cells in Chédiak-Higashi syndromeNeutrophils show excessively long, thin filamentous nuclear strands in myelokathexis",
                    "sub_points": [
                      "Large coarse granules in neutrophils, other granulated cells in Chédiak-Higashi syndrome",
                      "Neutrophils show excessively long, thin filamentous nuclear strands in myelokathexis"
                    ]
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "Highly variable"
                  },
                  {
                    "text": "Neutrophil lineage may be greatly attenuated and left-shifted"
                  },
                  {
                    "text": "Neutrophil lineage cells generally show normal morphology (exception Chédiak-Higashi, myelokathexis)Vacuolated granulocytic and erythroid precursors in copper deficiency",
                    "sub_points": [
                      "Vacuolated granulocytic and erythroid precursors in copper deficiency"
                    ]
                  },
                  {
                    "text": "Other lineages variable but often preserved"
                  },
                  {
                    "text": "In maturation and survival defect disordersMay see increased histiocytesMay see granulocytic hyperplasia at all stages",
                    "sub_points": [
                      "May see increased histiocytes",
                      "May see granulocytic hyperplasia at all stages"
                    ]
                  },
                  {
                    "text": "In production defect disorders myeloblasts and promyelocytes are seen only rarely"
                  },
                  {
                    "text": "Histiocytes may contain ingested neutrophils in the followingAutoimmune neutropenia of infancyMyelokathexisOther neutropenic disorders with increased cell turnover and apoptosis",
                    "sub_points": [
                      "Autoimmune neutropenia of infancy",
                      "Myelokathexis",
                      "Other neutropenic disorders with increased cell turnover and apoptosis"
                    ]
                  },
                  {
                    "text": "May see increased hematogones in specimens from infants and children"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Sustained Neutropenia from Birth/Early Infancy": [
                  {
                    "text": "Vertically transmitted infection, including HIV"
                  },
                  {
                    "text": "Distinguish single-lineage from multilineage disorder"
                  },
                  {
                    "text": "Evaluate for constitutional neutropenia"
                  },
                  {
                    "text": "Sequential CBCs to assess for possible cyclical pattern"
                  },
                  {
                    "text": "Family history of neutropenia"
                  },
                  {
                    "text": "Physical stigmata of constitutional disorder"
                  },
                  {
                    "text": "Appropriate genetic testing"
                  }
                ],
                "Isolated Acquired Neutropenia": [
                  {
                    "text": "Age-based considerations are importantInfection is most likely cause of neutropenia in infants and young childrenMedication is most likely cause of acquired neutropenia in adult outpatient setting",
                    "sub_points": [
                      "Infection is most likely cause of neutropenia in infants and young children",
                      "Medication is most likely cause of acquired neutropenia in adult outpatient setting"
                    ]
                  },
                  {
                    "text": "Consider T-cell large granular lymphocytic leukemia in patient with collagen vascular disease (Felty syndrome)"
                  }
                ],
                "Myelodysplasia": [
                  {
                    "text": "CBC often shows multiple cytopenias"
                  },
                  {
                    "text": "Left-shift, circulating blasts may be present"
                  },
                  {
                    "text": "Enlarged, hypogranular platelets may be present"
                  },
                  {
                    "text": "Bone marrow typically hypercellularSingle/multilineage dysplasiaVariably increased myeloblasts (< 20%)",
                    "sub_points": [
                      "Single/multilineage dysplasia",
                      "Variably increased myeloblasts (< 20%)"
                    ]
                  },
                  {
                    "text": "Clonal cytogenetic abnormalities common"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Lymphopenia": {
            "name": "Lymphopenia",
            "url": "https://app.pathprimer.com/document/bf06ed5e-1d61-4f03-8425-99a9f9311035/lesson/ee882547-8989-432d-aea3-f4fc0df1ba42",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Lymphopenia is defined as absolute lymphocyte count < 1,000/μL in adults or < 2,000/μL in children"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "SCID is immunodeficiency with defects in both humoral and cell-mediated immunity"
                  },
                  {
                    "text": "DiGeorge syndrome results from malformation of 3rd and 4th pharyngeal pouches"
                  },
                  {
                    "text": "HIV/AIDS infections cause lymphopenia by several mechanisms"
                  },
                  {
                    "text": "Other common causes include infection (other viral and bacterial), autoimmune disorders, malignancy, chemotherapy, and radiation"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "SCID is associated with excessive number of severe infections from infancyBone marrow transplantation cures SCID",
                    "sub_points": [
                      "Bone marrow transplantation cures SCID"
                    ]
                  },
                  {
                    "text": "DGS is associated with T-cell immunodeficiencyThymus transplantation in patient with complete DiGeorge anomaly corrects severe immunodeficiency",
                    "sub_points": [
                      "Thymus transplantation in patient with complete DiGeorge anomaly corrects severe immunodeficiency"
                    ]
                  },
                  {
                    "text": "HIV infection is most common cause of lymphopeniaAntiretroviral drugs target various stages of viral life cycle and result in lifelong viral suppression",
                    "sub_points": [
                      "Antiretroviral drugs target various stages of viral life cycle and result in lifelong viral suppression"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Complete blood count (CBC)"
                  },
                  {
                    "text": "DiGeorge syndrome (DGS)"
                  },
                  {
                    "text": "Severe combined immunodeficiency disease (SCID)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Lymphocytopenia"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Absolute lymphocyte count < 1,000/μL in adults or < 2,000/μL in children"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Congenital Immunodeficiency Disorders": [
                  {
                    "text": "SCIDImmunodeficiency with defects in both humoral and cell-mediated immunity",
                    "sub_points": [
                      "Immunodeficiency with defects in both humoral and cell-mediated immunity"
                    ]
                  },
                  {
                    "text": "DGSResults from deletion of chromosome 22q11.2Malformation of 3rd and 4th pharyngeal pouches, which give rise to thymus, parathyroid glands, part of aortic arch and face22q11.2 deletion may also give rise to velocardiofacial syndrome, with congenital heart diseases as major manifestations",
                    "sub_points": [
                      "Results from deletion of chromosome 22q11.2",
                      "Malformation of 3rd and 4th pharyngeal pouches, which give rise to thymus, parathyroid glands, part of aortic arch and face",
                      "22q11.2 deletion may also give rise to velocardiofacial syndrome, with congenital heart diseases as major manifestations"
                    ]
                  }
                ],
                "Acquired Immunodeficiency Disorders": [
                  {
                    "text": "HIV infection/AIDS causes lymphopenia by several mechanismsTransmitted through sexual or parental exposure to HIV-containing fluids or maternal-fetal transmissionHIV viruses cause destruction of CD4(+) lymphocytesDamage of thymus and other lymphoid tissues",
                    "sub_points": [
                      "Transmitted through sexual or parental exposure to HIV-containing fluids or maternal-fetal transmission",
                      "HIV viruses cause destruction of CD4(+) lymphocytes",
                      "Damage of thymus and other lymphoid tissues"
                    ]
                  },
                  {
                    "text": "Other viral infections"
                  },
                  {
                    "text": "Bacterial infections"
                  },
                  {
                    "text": "Systemic disordersNutritional deficienciesBurnsMalignancyAutoimmuneProtein-losing disease",
                    "sub_points": [
                      "Nutritional deficiencies",
                      "Burns",
                      "Malignancy",
                      "Autoimmune",
                      "Protein-losing disease"
                    ]
                  },
                  {
                    "text": "Iatrogenic causes of lymphocyte destructionRadiationChemotherapy",
                    "sub_points": [
                      "Radiation",
                      "Chemotherapy"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "HIV infection is most common cause of sustained lymphopenia"
                  },
                  {
                    "text": "DGS affects 1 in 2000-4000 live births"
                  },
                  {
                    "text": "SCID is rare; X-linked or autosomal recessive inheritance"
                  }
                ],
                "Presentation": [
                  {
                    "text": "SCIDExcessive number of severe infections from infancyHigh susceptibility to uncommon pathogensFungalAttenuated virus vaccineCytomegalovirus infectionsPersistent diarrhea results in failure to thrive, malnutrition, and weight loss",
                    "sub_points": [
                      "Excessive number of severe infections from infancy",
                      "High susceptibility to uncommon pathogensFungalAttenuated virus vaccineCytomegalovirus infections",
                      "Fungal",
                      "Attenuated virus vaccine",
                      "Cytomegalovirus infections",
                      "Persistent diarrhea results in failure to thrive, malnutrition, and weight loss"
                    ]
                  },
                  {
                    "text": "DGST-cell immunodeficiency; predisposes to infectionsMay have facial dysmorphia and palatal dysfunctionResult in feeding difficulties in infantsMay have cardiac anomaly, affecting outflow tractsDevelopmental delayIncreased chance of autoimmune diseases, especially juvenile rheumatoid arthritis and hematologic autoimmune disease",
                    "sub_points": [
                      "T-cell immunodeficiency; predisposes to infections",
                      "May have facial dysmorphia and palatal dysfunctionResult in feeding difficulties in infants",
                      "Result in feeding difficulties in infants",
                      "May have cardiac anomaly, affecting outflow tracts",
                      "Developmental delay",
                      "Increased chance of autoimmune diseases, especially juvenile rheumatoid arthritis and hematologic autoimmune disease"
                    ]
                  },
                  {
                    "text": "HIV/AIDSInitial infection with HIV presents with certain symptomsFeverMalaisePharyngitisDiarrheaRashGeneralized lymphadenopathySymptomatic disease appears when CD4 cell count falls below 350 cells/μLMay take yearsAIDS-defining diseases are common when CD4 cell count is below 200 cells/μLCommon in late stagePneumocystis jiroveciipneumoniaKaposi sarcomaCentral nervous system lymphoma",
                    "sub_points": [
                      "Initial infection with HIV presents with certain symptomsFeverMalaisePharyngitisDiarrheaRashGeneralized lymphadenopathy",
                      "Fever",
                      "Malaise",
                      "Pharyngitis",
                      "Diarrhea",
                      "Rash",
                      "Generalized lymphadenopathy",
                      "Symptomatic disease appears when CD4 cell count falls below 350 cells/μLMay take years",
                      "May take years",
                      "AIDS-defining diseases are common when CD4 cell count is below 200 cells/μL",
                      "Common in late stagePneumocystis jiroveciipneumoniaKaposi sarcomaCentral nervous system lymphoma",
                      "Pneumocystis jiroveciipneumonia",
                      "Kaposi sarcoma",
                      "Central nervous system lymphoma"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "SCIDLow absolute lymphocyte count on CBCDecreased T-cell subsets by flow cytometric analysisDecreased or lack of reaction to stimuli on T-cell function testDecreased serum immunoglobulin levels in some",
                    "sub_points": [
                      "Low absolute lymphocyte count on CBC",
                      "Decreased T-cell subsets by flow cytometric analysis",
                      "Decreased or lack of reaction to stimuli on T-cell function test",
                      "Decreased serum immunoglobulin levels in some"
                    ]
                  },
                  {
                    "text": "DGSDecreased CD3(+) T cells and CD4(+) helper cellsMany show decreased mitogen-induced proliferative response of T cellsHypocalcemiaFluorescence in situ hybridization is diagnostic; reveals hemizygous deletion of 22q11.2",
                    "sub_points": [
                      "Decreased CD3(+) T cells and CD4(+) helper cells",
                      "Many show decreased mitogen-induced proliferative response of T cells",
                      "Hypocalcemia",
                      "Fluorescence in situ hybridization is diagnostic; reveals hemizygous deletion of 22q11.2"
                    ]
                  },
                  {
                    "text": "HIV/AIDSFlow cytometric analysis of blood or histologic study of tissue reveal depletion of CD4(+) lymphocytesIncrease in reactive CD8(+) lymphocytes in response to HIV infectionDetection of anti-HIV antibody by immunologic assaysFlow cytometric analysis to monitor CD4 countQuantitative viral load by PCR or related methods to monitor treatment response",
                    "sub_points": [
                      "Flow cytometric analysis of blood or histologic study of tissue reveal depletion of CD4(+) lymphocytes",
                      "Increase in reactive CD8(+) lymphocytes in response to HIV infection",
                      "Detection of anti-HIV antibody by immunologic assays",
                      "Flow cytometric analysis to monitor CD4 count",
                      "Quantitative viral load by PCR or related methods to monitor treatment response"
                    ]
                  }
                ],
                "Treatment and Prognosis": [
                  {
                    "text": "SCIDImmunoglobulin replacementBone marrow transplantation cures SCIDPersistent risk of severe or fatal infection without bone marrow transplantation or gene therapyBone marrow transplantation success rate over 95% if performed within 3 months of birthOverall success rate is 60-70%Gene therapy can be potential cure; however, specific molecular abnormality needs to be determined",
                    "sub_points": [
                      "Immunoglobulin replacement",
                      "Bone marrow transplantation cures SCIDPersistent risk of severe or fatal infection without bone marrow transplantation or gene therapyBone marrow transplantation success rate over 95% if performed within 3 months of birthOverall success rate is 60-70%",
                      "Persistent risk of severe or fatal infection without bone marrow transplantation or gene therapy",
                      "Bone marrow transplantation success rate over 95% if performed within 3 months of birthOverall success rate is 60-70%",
                      "Overall success rate is 60-70%",
                      "Gene therapy can be potential cure; however, specific molecular abnormality needs to be determined"
                    ]
                  },
                  {
                    "text": "DGSThymus transplantation in patients with complete DiGeorge anomaly to correct severe immunodeficiencyGenerally well tolerated and results in stable immunoreconstitutionIrradiated blood products to prevent potential fatal graft-vs.-host disease in athymic patientsIn patients with partial DiGeorge syndrome, immunodeficiency may be mild and immunity may improve with age",
                    "sub_points": [
                      "Thymus transplantation in patients with complete DiGeorge anomaly to correct severe immunodeficiencyGenerally well tolerated and results in stable immunoreconstitution",
                      "Generally well tolerated and results in stable immunoreconstitution",
                      "Irradiated blood products to prevent potential fatal graft-vs.-host disease in athymic patients",
                      "In patients with partial DiGeorge syndrome, immunodeficiency may be mild and immunity may improve with age"
                    ]
                  },
                  {
                    "text": "HIV/AIDSAntiretroviral drugs, such as reverse transcriptase inhibitors, protease inhibitors, CCR5 inhibitors, and fusion inhibitors, target various stages of life cycleAntiretroviral therapy well tolerated and safe; results in lifelong suppression of HIV replicationIf left untreated, most die from disease",
                    "sub_points": [
                      "Antiretroviral drugs, such as reverse transcriptase inhibitors, protease inhibitors, CCR5 inhibitors, and fusion inhibitors, target various stages of life cycleAntiretroviral therapy well tolerated and safe; results in lifelong suppression of HIV replicationIf left untreated, most die from disease",
                      "Antiretroviral therapy well tolerated and safe; results in lifelong suppression of HIV replication",
                      "If left untreated, most die from disease"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Peripheral Blood": [
                  {
                    "text": "Lymphocytes are decreased in number but have normal morphology"
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "SCIDHypocellular marrow for ageNo dysplasia",
                    "sub_points": [
                      "Hypocellular marrow for age",
                      "No dysplasia"
                    ]
                  },
                  {
                    "text": "HIV/AIDSIncreased megakaryocytes with \"naked\" megakaryocytic nuclei, and atypical megakaryocytesLymphoid aggregates; may have germinal centersCommonly have granulomasIncreased polyclonal plasma cellsEarly stages of infection are often hypercellularLate stages of infection more frequently have marrow hypoplasia and foci of serous atrophy (gelatinous transformation)",
                    "sub_points": [
                      "Increased megakaryocytes with \"naked\" megakaryocytic nuclei, and atypical megakaryocytes",
                      "Lymphoid aggregates; may have germinal centers",
                      "Commonly have granulomas",
                      "Increased polyclonal plasma cells",
                      "Early stages of infection are often hypercellular",
                      "Late stages of infection more frequently have marrow hypoplasia and foci of serous atrophy (gelatinous transformation)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Constitutional Disorders": {
        "name": "Constitutional Disorders",
        "url": "https://app.pathprimer.com/lesson/28d45929-b064-4962-881e-aef087c2e426",
        "topics": {
          "Aplastic Anemia": {
            "name": "Aplastic Anemia",
            "url": "https://app.pathprimer.com/document/c19ed432-d733-4444-8ff0-bb92aa4ce17d/lesson/28d45929-b064-4962-881e-aef087c2e426",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Aplastic anemia: Pancytopenia secondary to marrow hypoplasia"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Acquired primary/idiopathic aplastic anemia is most common; thought to be due autoimmune etiology"
                  },
                  {
                    "text": "Acquired secondary aplastic anemia is caused by infectious agents, drugs/toxins, or radiation therapy"
                  },
                  {
                    "text": "Congenital aplastic anemia is caused by Faconi anemia or other inherited bone marrow failure syndromes"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Bimodal age distribution: Children/young adults, and adults older than 60 years"
                  },
                  {
                    "text": "Common presentation includes symptoms related to cytopeniasFatigue, infection, mucocutaneous bleeding, or bruising",
                    "sub_points": [
                      "Fatigue, infection, mucocutaneous bleeding, or bruising"
                    ]
                  },
                  {
                    "text": "Fatal in 1-2 years in severe cases without treatment"
                  },
                  {
                    "text": "May progress to MDS or AML"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Peripheral blood and bone marrow show pancytopenia with no overt dysplasia"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Flow cytometry and cytogenetics/molecular testing are used to exclude hypocellular MDS and PNH"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Aplastic anemia (AA)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Acquired primary/idiopathic aplastic anemia"
                  },
                  {
                    "text": "Acquired secondary aplastic anemia"
                  },
                  {
                    "text": "Congenital aplastic anemiae.g., Fanconi anemia, dyskeratosis congenita, Diamond-Blackfan anemia",
                    "sub_points": [
                      "e.g., Fanconi anemia, dyskeratosis congenita, Diamond-Blackfan anemia"
                    ]
                  }
                ],
                "Definitions": [
                  {
                    "text": "Aplastic anemia: Pancytopenia due to marrow hypoplasia"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Acquired Primary/Idiopathic Aplastic Anemia": [
                  {
                    "text": "Represents 70-80% of cases"
                  },
                  {
                    "text": "Autoimmune process that results in apoptosis of CD34+ hematopoietic stem cells induced by aberrantly activated cytotoxic T lymphocytes"
                  },
                  {
                    "text": "~ 30% of cases with telomere shorteningMutations inTERC,TERT, SBDS,TERF1/2",
                    "sub_points": [
                      "Mutations inTERC,TERT, SBDS,TERF1/2"
                    ]
                  }
                ],
                "Acquired Secondary Aplastic Anemia": [
                  {
                    "text": "Secondary causesInfectious agentsEpstein-Barr virusViral hepatitisInfluenzaParvovirusHIVDrugsChloramphenicolNSAIDsChemotherapyAnticonvulsantsAllopurinolToxinsGoldBenzeneInsecticidesSolventsRadiation therapy",
                    "sub_points": [
                      "Infectious agentsEpstein-Barr virusViral hepatitisInfluenzaParvovirusHIV",
                      "Epstein-Barr virus",
                      "Viral hepatitis",
                      "Influenza",
                      "Parvovirus",
                      "HIV",
                      "DrugsChloramphenicolNSAIDsChemotherapyAnticonvulsantsAllopurinol",
                      "Chloramphenicol",
                      "NSAIDs",
                      "Chemotherapy",
                      "Anticonvulsants",
                      "Allopurinol",
                      "ToxinsGoldBenzeneInsecticidesSolvents",
                      "Gold",
                      "Benzene",
                      "Insecticides",
                      "Solvents",
                      "Radiation therapy"
                    ]
                  }
                ],
                "Congenital Aplastic Anemia": [
                  {
                    "text": "Fanconi anemia"
                  },
                  {
                    "text": "Dyskeratosis congenita"
                  },
                  {
                    "text": "Diamond-Blackfan anemia"
                  },
                  {
                    "text": "Other inherited bone marrow failure syndromes"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "2-6 per 1,000,000 persons"
                  }
                ],
                "Age": [
                  {
                    "text": "BimodalChildren/young adultsOlder adults (> 60 years)",
                    "sub_points": [
                      "Children/young adults",
                      "Older adults (> 60 years)"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "No gender predilection"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "More common in Asians"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Secondary to cytopeniasFatigue, infection, &/or mucocutaneous bleeding/bruising",
                    "sub_points": [
                      "Fatigue, infection, &/or mucocutaneous bleeding/bruising"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "Severe cases can be fatal in 1-2 years without proper treatment"
                  },
                  {
                    "text": "May have flow cytometric +/- clinical findings of paroxysmal nocturnal hemoglobinuria (PNH)"
                  },
                  {
                    "text": "Progression to myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in up to 15% of cases"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Based on disease severity and comorbiditiesTransfusionsImmunosuppressive agentsAntithymocyte globulin (ATG)CyclosporineEltrombopag (rINN; Promacta)Small molecule thrombopoietin (TPO) receptor agonistUseful for refractory/relapsed casesHematopoietic stem cell transplantation (HSCT)",
                    "sub_points": [
                      "Transfusions",
                      "Immunosuppressive agentsAntithymocyte globulin (ATG)Cyclosporine",
                      "Antithymocyte globulin (ATG)",
                      "Cyclosporine",
                      "Eltrombopag (rINN; Promacta)Small molecule thrombopoietin (TPO) receptor agonistUseful for refractory/relapsed cases",
                      "Small molecule thrombopoietin (TPO) receptor agonist",
                      "Useful for refractory/relapsed cases",
                      "Hematopoietic stem cell transplantation (HSCT)"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Correlates with severity of cytopenias"
                  },
                  {
                    "text": "Up to 40% mortality within 2 years"
                  },
                  {
                    "text": "Better outcome with high-dose cyclophosphamide and matched related donor HSCT"
                  },
                  {
                    "text": "Worse outcome in older patients"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Peripheral bloodPancytopenia with no overt dysplasiaNonsevere AA (at least 2 of the following)Hemoglobin < 10 g/dLPlatelets < 50 x 10⁹/LAbsolute neutrophil count (ANC) < 1.5 × 109/L but > 0.5 x 10⁹/LSevere AA (at least 2 of the following)ANC 0.2-0.5 x 10⁹/LPlatelets < 20 x 10⁹/LCorrected reticulocyte count 0.2-0.5 x 10⁹/LVery severe AAANC < 0.2 x 10⁹/L",
                    "sub_points": [
                      "Pancytopenia with no overt dysplasiaNonsevere AA (at least 2 of the following)Hemoglobin < 10 g/dLPlatelets < 50 x 10⁹/LAbsolute neutrophil count (ANC) < 1.5 × 109/L but > 0.5 x 10⁹/LSevere AA (at least 2 of the following)ANC 0.2-0.5 x 10⁹/LPlatelets < 20 x 10⁹/LCorrected reticulocyte count 0.2-0.5 x 10⁹/LVery severe AAANC < 0.2 x 10⁹/L",
                      "Nonsevere AA (at least 2 of the following)Hemoglobin < 10 g/dLPlatelets < 50 x 10⁹/LAbsolute neutrophil count (ANC) < 1.5 × 109/L but > 0.5 x 10⁹/L",
                      "Hemoglobin < 10 g/dL",
                      "Platelets < 50 x 10⁹/L",
                      "Absolute neutrophil count (ANC) < 1.5 × 109/L but > 0.5 x 10⁹/L",
                      "Severe AA (at least 2 of the following)ANC 0.2-0.5 x 10⁹/LPlatelets < 20 x 10⁹/LCorrected reticulocyte count 0.2-0.5 x 10⁹/L",
                      "ANC 0.2-0.5 x 10⁹/L",
                      "Platelets < 20 x 10⁹/L",
                      "Corrected reticulocyte count 0.2-0.5 x 10⁹/L",
                      "Very severe AAANC < 0.2 x 10⁹/L",
                      "ANC < 0.2 x 10⁹/L"
                    ]
                  },
                  {
                    "text": "Bone marrowHypocellularity with trilineage hypoplasiaSevere AAMarrow cellularity < 25% of normal for ageIslands of residual hematopoiesis may be identifiedNo overt dysplasiaNonspecific megaloblastic changes in erythroid lineage may be seen",
                    "sub_points": [
                      "Hypocellularity with trilineage hypoplasiaSevere AAMarrow cellularity < 25% of normal for ageIslands of residual hematopoiesis may be identified",
                      "Severe AAMarrow cellularity < 25% of normal for ageIslands of residual hematopoiesis may be identified",
                      "Marrow cellularity < 25% of normal for age",
                      "Islands of residual hematopoiesis may be identified",
                      "No overt dysplasiaNonspecific megaloblastic changes in erythroid lineage may be seen",
                      "Nonspecific megaloblastic changes in erythroid lineage may be seen"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Absent to rare CD34+ blasts"
                  },
                  {
                    "text": "Helps rule out hematologic malignancy"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Normal phenotypeHelps exclude abnormal myeloid population (e.g., hypocellular MDS)",
                    "sub_points": [
                      "Helps exclude abnormal myeloid population (e.g., hypocellular MDS)"
                    ]
                  },
                  {
                    "text": "May show PNH clones in ~ 50-60% of cases"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Normal karyotype in ~ 90% of casesdel(5q), trisomy 6, trisomy 8, and monosomy 7 in ~ 10% of cases",
                    "sub_points": [
                      "del(5q), trisomy 6, trisomy 8, and monosomy 7 in ~ 10% of cases"
                    ]
                  },
                  {
                    "text": "Clonal hematopoiesis seen in > 40% of casesDNMT3AandASXL1associated with worse outcomes",
                    "sub_points": [
                      "DNMT3AandASXL1associated with worse outcomes"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Hypocellular Myelodysplastic Syndrome": [
                  {
                    "text": "MDS: Morphologic dysplasia, abnormal immunophenotype, and cytogenetic abnormalities"
                  }
                ],
                "Congenital Bone Marrow Failure Syndrome": [
                  {
                    "text": "e.g., Fanconi anemia, dyskeratosis congenita, Diamond-Blackfan anemia, Schwachman-Diamond syndromeMay have dysmorphic features, congenital abnormalities, growth retardation",
                    "sub_points": [
                      "May have dysmorphic features, congenital abnormalities, growth retardation"
                    ]
                  }
                ],
                "Paroxysmal Nocturnal Hemoglobinuria and PNH-AA Overlap Syndrome": [
                  {
                    "text": "Flow cytometry useful for identification of glycosylphosphatidylinositol (GPI)-linked proteins (CD55 and CD59) seen in PNH"
                  },
                  {
                    "text": "Pure PNH lacks cytopenias and hypocellular bone marrow"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Important to rule out inherited bone marrow failure syndrome in younger patients with idiopathic aplastic anemiaFanconi anemia, dyskeratosis congenita, Diamond-Blackfan anemia, Schwachman-Diamond syndrome",
                    "sub_points": [
                      "Fanconi anemia, dyskeratosis congenita, Diamond-Blackfan anemia, Schwachman-Diamond syndrome"
                    ]
                  },
                  {
                    "text": "Long-term risk of progression to MDS or AML"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Fanconi Anemia": {
            "name": "Fanconi Anemia",
            "url": "https://app.pathprimer.com/document/bb455b70-ff86-4e35-a6fe-57e776da3284/lesson/28d45929-b064-4962-881e-aef087c2e426",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Autosomal or X-linked recessive disorder of bone marrow failure, cancer susceptibility, and congenital abnormalities"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Caused by biallelic mutation in any of 13 separate genes comprising \"Fanconi anemia pathway\""
                  },
                  {
                    "text": "Collectively, proteins encoded by these genes serve to sense DNA damage and initiate DNA repair"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Congenital abnormalities present in 2/3 of cases (classically, hypoplastic/absent thumbs and radii)"
                  },
                  {
                    "text": "Bone marrow failure takes form of pancytopenia with marrow aplasia, generally in 1st decade"
                  },
                  {
                    "text": "Increased susceptibility to acute myeloid leukemia, myelodysplastic syndrome, solid tumors"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Increased chromosomal breakage with diepoxybutane or mitomycin C is gold standard test for diagnosis of FA"
                  },
                  {
                    "text": "FA patients may acquire cytogenetic abnormalities that wax and waneThus, morphology assumes dominant role in diagnosis of myelodysplasia in this setting",
                    "sub_points": [
                      "Thus, morphology assumes dominant role in diagnosis of myelodysplasia in this setting"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Dyskeratosis congenita"
                  },
                  {
                    "text": "Acquired aplastic anemia"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Fanconi anemia (FA)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Autosomal or X-linked recessive disorder characterized byBone marrow failureDefective DNA repairCancer susceptibilityCongenital abnormalities",
                    "sub_points": [
                      "Bone marrow failure",
                      "Defective DNA repair",
                      "Cancer susceptibility",
                      "Congenital abnormalities"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Molecular Pathogenesis": [
                  {
                    "text": "FA is caused by biallelic mutation in any of (at least) 13 separate genes comprising the \"Fanconi anemia pathway\""
                  },
                  {
                    "text": "Collectively, proteins encoded by these genes serve to sense DNA damage and initiate DNA repair"
                  },
                  {
                    "text": "FA pathway proteins fall into 3 separate groups, encoded by the following genesFanconi anemia core complexFANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCMFANCAis the most frequently mutated gene in Fanconi anemia\"ID complex\"FANCI, FANCD2Downstream effectorsFANCJ, FANCN(a.k.a.BRIP1andPALB2,respectively; heterozygous mutations confer breast cancer susceptibility)FANCD1(a.k.a.BRCA2; heterozygous mutations confer breast cancer susceptibility)",
                    "sub_points": [
                      "Fanconi anemia core complexFANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCMFANCAis the most frequently mutated gene in Fanconi anemia",
                      "FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCM",
                      "FANCAis the most frequently mutated gene in Fanconi anemia",
                      "\"ID complex\"FANCI, FANCD2",
                      "FANCI, FANCD2",
                      "Downstream effectorsFANCJ, FANCN(a.k.a.BRIP1andPALB2,respectively; heterozygous mutations confer breast cancer susceptibility)FANCD1(a.k.a.BRCA2; heterozygous mutations confer breast cancer susceptibility)",
                      "FANCJ, FANCN(a.k.a.BRIP1andPALB2,respectively; heterozygous mutations confer breast cancer susceptibility)",
                      "FANCD1(a.k.a.BRCA2; heterozygous mutations confer breast cancer susceptibility)"
                    ]
                  },
                  {
                    "text": "Functional interactions of FA proteinsCore complex detects DNA damage and ubiquitinates the ID complex proteinsID complex colocalizes at site of DNA damage with FA downstream effectors and other DNA repair proteins, includingRAD51 protein, which binds and promotes accurate DNA repair via homologous recombinationBRCA1 protein, which binds to facilitate repair and mediate cell cycle checkpoint control",
                    "sub_points": [
                      "Core complex detects DNA damage and ubiquitinates the ID complex proteins",
                      "ID complex colocalizes at site of DNA damage with FA downstream effectors and other DNA repair proteins, includingRAD51 protein, which binds and promotes accurate DNA repair via homologous recombinationBRCA1 protein, which binds to facilitate repair and mediate cell cycle checkpoint control",
                      "RAD51 protein, which binds and promotes accurate DNA repair via homologous recombination",
                      "BRCA1 protein, which binds to facilitate repair and mediate cell cycle checkpoint control"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "Congenital abnormalitiesPresent in 2/3 of casesHypoplastic or absent thumbs &/or radii\"Classic\" FA findingChanges range from severe hypoplasia to subtle anomalies of clefting between thumb & forefingerPigmentation abnormalities, including café au lait spotsRenal malformations, including horseshoe kidneyDuodenal atresia or other gastrointestinal malformationsMicrocephaly &/or microphthalmiaHeart defectsCryptorchidism or abnormal genitalia",
                    "sub_points": [
                      "Present in 2/3 of cases",
                      "Hypoplastic or absent thumbs &/or radii\"Classic\" FA findingChanges range from severe hypoplasia to subtle anomalies of clefting between thumb & forefinger",
                      "\"Classic\" FA finding",
                      "Changes range from severe hypoplasia to subtle anomalies of clefting between thumb & forefinger",
                      "Pigmentation abnormalities, including café au lait spots",
                      "Renal malformations, including horseshoe kidney",
                      "Duodenal atresia or other gastrointestinal malformations",
                      "Microcephaly &/or microphthalmia",
                      "Heart defects",
                      "Cryptorchidism or abnormal genitalia"
                    ]
                  },
                  {
                    "text": "Bone marrow failureGenerally presents in 1st decade of lifeLate presentations into early adulthood have also been describedPancytopenia with marrow aplasiaThrombocytopenia and neutropenia may precede anemia",
                    "sub_points": [
                      "Generally presents in 1st decade of lifeLate presentations into early adulthood have also been described",
                      "Late presentations into early adulthood have also been described",
                      "Pancytopenia with marrow aplasia",
                      "Thrombocytopenia and neutropenia may precede anemia"
                    ]
                  },
                  {
                    "text": "Family historyMost cases are autosomal recessive in inheritanceMutations affectingFANCBare the exception (X-linked recessive)Thus, risk to siblings of proband is 25% for disease, 50% for carrier statusSpecificFANCCmutation (IVS4+4A > T) occurs in Ashkenazi Jews, leading to increased incidence of FA in this population",
                    "sub_points": [
                      "Most cases are autosomal recessive in inheritanceMutations affectingFANCBare the exception (X-linked recessive)",
                      "Mutations affectingFANCBare the exception (X-linked recessive)",
                      "Thus, risk to siblings of proband is 25% for disease, 50% for carrier status",
                      "SpecificFANCCmutation (IVS4+4A > T) occurs in Ashkenazi Jews, leading to increased incidence of FA in this population"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Transfusion support as necessary"
                  },
                  {
                    "text": "Stem cell transplantationComplicated by inherent susceptibility of FA patients to DNA-damaging irradiation and drug therapyReduced intensity conditioning regimens may be used",
                    "sub_points": [
                      "Complicated by inherent susceptibility of FA patients to DNA-damaging irradiation and drug therapyReduced intensity conditioning regimens may be used",
                      "Reduced intensity conditioning regimens may be used"
                    ]
                  }
                ],
                "Drugs": [
                  {
                    "text": "Androgen therapy (e.g., oxymetholone)Improves peripheral counts in ~ 50% of FA patientsResistance often develops",
                    "sub_points": [
                      "Improves peripheral counts in ~ 50% of FA patients",
                      "Resistance often develops"
                    ]
                  },
                  {
                    "text": "Hematopoietic growth factors"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Bone marrow failureBy 5th decade, cumulative incidence is 90%Aplasia is often progressive",
                    "sub_points": [
                      "By 5th decade, cumulative incidence is 90%",
                      "Aplasia is often progressive"
                    ]
                  },
                  {
                    "text": "Acute myeloid leukemia/myelodysplastic syndromeRisk of AML in FA is increased ~ 800x above normalBy 5th decade, cumulative incidence of hematologic malignancy is 10-33%Although bone marrow failure usually precedes AML, in some cases AML will be the presenting manifestationTreatment complicated by inherent susceptibility of FA patients to DNA-damaging alkylating drug therapy",
                    "sub_points": [
                      "Risk of AML in FA is increased ~ 800x above normal",
                      "By 5th decade, cumulative incidence of hematologic malignancy is 10-33%",
                      "Although bone marrow failure usually precedes AML, in some cases AML will be the presenting manifestation",
                      "Treatment complicated by inherent susceptibility of FA patients to DNA-damaging alkylating drug therapy"
                    ]
                  },
                  {
                    "text": "Solid tumorsBy 5th decade, cumulative incidence is ~ 30%Head and neck tumors are especially common",
                    "sub_points": [
                      "By 5th decade, cumulative incidence is ~ 30%",
                      "Head and neck tumors are especially common"
                    ]
                  },
                  {
                    "text": "Genotype-phenotype correlationsSomeFANCCmutations predispose to early-onset bone marrow failureIncidence of AML and severe cytopenia is higher in patients with someFANCGandFANCAmutationsPatients withFANCD1mutations are at particular risk for early-onset AML and may benefit from early stem cell transplantation",
                    "sub_points": [
                      "SomeFANCCmutations predispose to early-onset bone marrow failure",
                      "Incidence of AML and severe cytopenia is higher in patients with someFANCGandFANCAmutations",
                      "Patients withFANCD1mutations are at particular risk for early-onset AML and may benefit from early stem cell transplantation"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Predominant Pattern/Injury Type": [
                  {
                    "text": "Aplasia"
                  }
                ],
                "Key Microscopic Findings": [
                  {
                    "text": "BloodPancytopeniaRed blood cells often show nonspecific changesMacrocytosisIncreased Hgb F in heterocellular distribution",
                    "sub_points": [
                      "Pancytopenia",
                      "Red blood cells often show nonspecific changesMacrocytosisIncreased Hgb F in heterocellular distribution",
                      "Macrocytosis",
                      "Increased Hgb F in heterocellular distribution"
                    ]
                  },
                  {
                    "text": "Bone marrow is hypocellularDegree of hypocellularity depends upon timing of biopsyLymphocytes and plasma cells may be relatively (though not absolutely) increased",
                    "sub_points": [
                      "Degree of hypocellularity depends upon timing of biopsy",
                      "Lymphocytes and plasma cells may be relatively (though not absolutely) increased"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Chromosomal Breakage Analysis": [
                  {
                    "text": "Gold standard test for diagnosis of FA"
                  },
                  {
                    "text": "Patient lymphocytes are stimulated and exposed to diepoxybutane &/or mitomycin C"
                  },
                  {
                    "text": "Cells arrested at mitosis and dropped onto slides, as for traditional chromosomal preparation"
                  },
                  {
                    "text": "Number of chromosomal breaks and \"radial\" formations are counted"
                  },
                  {
                    "text": "FA is diagnosed if breaks and radials significantly exceed those seen in normal controls"
                  },
                  {
                    "text": "Rarely, clinically or molecularly diagnosed FA patients show borderline or even negative resultsIn such case, reversion mutation may have occurred in hematopoietic compartmentReversion mutation corrects original mutation (e.g., frameshift mutation is shifted back into reading frame)Baseline DNA instability in FA contributes to this unusual phenomenon by increasing mutation rateIf reversion mutation is suspected, chromosomal breakage should be performed on cultured fibroblasts from skin biopsyIf skin biopsy study is negative, FA is ruled out",
                    "sub_points": [
                      "In such case, reversion mutation may have occurred in hematopoietic compartment",
                      "Reversion mutation corrects original mutation (e.g., frameshift mutation is shifted back into reading frame)",
                      "Baseline DNA instability in FA contributes to this unusual phenomenon by increasing mutation rate",
                      "If reversion mutation is suspected, chromosomal breakage should be performed on cultured fibroblasts from skin biopsy",
                      "If skin biopsy study is negative, FA is ruled out"
                    ]
                  },
                  {
                    "text": "FA carriers cannot be detected with chromosomal breakage studies"
                  }
                ],
                "Cytogenetics": [
                  {
                    "text": "FA patients may acquire cytogenetic abnormalities that wax and wane"
                  },
                  {
                    "text": "Thus, morphology assumes dominant role in diagnosis of myelodysplasia in this setting"
                  },
                  {
                    "text": "Abnormalities of chromosomes 1 and 7 are common"
                  },
                  {
                    "text": "Clonal amplification of chromosome 3q26-q29 often precedes progression to MDS/AMLAppears to upregulate expression ofEVI13q26 andEVI1abnormalities are rare in childhood AML, and if detected in an apparent de novo case may prompt consideration of underlying FA",
                    "sub_points": [
                      "Appears to upregulate expression ofEVI1",
                      "3q26 andEVI1abnormalities are rare in childhood AML, and if detected in an apparent de novo case may prompt consideration of underlying FA"
                    ]
                  }
                ],
                "Molecular Testing": [
                  {
                    "text": "Sequence analysis and targeted mutation analysis are clinically available to detect mutation in some FA genes"
                  },
                  {
                    "text": "FANCAis most commonly affected gene (~ 66%)However, since any of the 13 large genes may be affected, comprehensive molecular testing is currently impractical",
                    "sub_points": [
                      "However, since any of the 13 large genes may be affected, comprehensive molecular testing is currently impractical"
                    ]
                  },
                  {
                    "text": "Carrier and prenatal testing are facilitated if specific familial mutation is known"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Acquired Aplastic Anemia": [
                  {
                    "text": "While more often diagnosed in adults, acquired aplastic anemia may occur in children and mimic FA"
                  },
                  {
                    "text": "Increased susceptibility to chromosomal breakage is not a feature of acquired aplastic anemia"
                  }
                ],
                "Other Constitutional Disorders of Trilineage Bone Marrow Failure": [
                  {
                    "text": "Dyskeratosis congenita (DKC)Often later onset of bone marrow failure (adolescence), though may overlap with FAPatients typically show mucocutaneous abnormalities, but this finding is variableDiagnosis of DKC is often pursued after negative chromosomal breakage study",
                    "sub_points": [
                      "Often later onset of bone marrow failure (adolescence), though may overlap with FA",
                      "Patients typically show mucocutaneous abnormalities, but this finding is variable",
                      "Diagnosis of DKC is often pursued after negative chromosomal breakage study"
                    ]
                  }
                ],
                "Other Congenital Syndromes with Radial Abnormalities without Bone Marrow Failure": [
                  {
                    "text": "Especially relevant if diagnosis is attempted before onset of bone marrow failure (e.g., infant with hypoplastic thumbs)"
                  },
                  {
                    "text": "Additional specific anomalies should prompt consideration of these disorders"
                  },
                  {
                    "text": "Specific disorders includeHolt-Oram syndrome (TBX5mutations)SALL4-related disordersDuane-radial ray syndrome (Okihiro syndrome)Acro-renal-ocular syndromeVACTERL association",
                    "sub_points": [
                      "Holt-Oram syndrome (TBX5mutations)",
                      "SALL4-related disordersDuane-radial ray syndrome (Okihiro syndrome)Acro-renal-ocular syndrome",
                      "Duane-radial ray syndrome (Okihiro syndrome)",
                      "Acro-renal-ocular syndrome",
                      "VACTERL association"
                    ]
                  }
                ],
                "Other Congenital Syndromes with Radial Abnormalities and Bone Marrow Failure": [
                  {
                    "text": "Thrombocytopenia absent radius (TAR)"
                  },
                  {
                    "text": "Diamond-Blackfan anemia (DBA)TAR and DBA cause predominant thrombocytopenia and anemia, respectivelyEspecially relevant if diagnosis is attempted before onset of bone marrow failure (e.g., infant with hypoplastic thumbs)",
                    "sub_points": [
                      "TAR and DBA cause predominant thrombocytopenia and anemia, respectively",
                      "Especially relevant if diagnosis is attempted before onset of bone marrow failure (e.g., infant with hypoplastic thumbs)"
                    ]
                  }
                ],
                "Childhood Acute Myeloid Leukemia/Myelodysplastic Syndrome/Solid Tumors": [
                  {
                    "text": "While bone marrow failure usually precedes malignancy, cancer may be the presenting manifestation of FA"
                  }
                ],
                "Other Congenital Syndromes with Increased Chromosomal Breakage": [
                  {
                    "text": "Ataxia-telangiectasia and Bloom syndromeIncreased spontaneous chromosomal breakage, but only FA cells show increased breaks in response to diepoxybutane",
                    "sub_points": [
                      "Increased spontaneous chromosomal breakage, but only FA cells show increased breaks in response to diepoxybutane"
                    ]
                  },
                  {
                    "text": "Nijmegen breakage syndrome (NBS)May show increased breakage in response to mitomycin CNBS is distinguished from FA by presence ofNBS1mutations and specific congenital anomalies",
                    "sub_points": [
                      "May show increased breakage in response to mitomycin C",
                      "NBS is distinguished from FA by presence ofNBS1mutations and specific congenital anomalies"
                    ]
                  },
                  {
                    "text": "Seckel syndromeMolecular and phenotypic overlap with FAMay show increased breakage in response tobothdiepoxybutane and mitomycin CSome cases caused by mutation toATR, impairing DNA repairBone marrow failure and AML have been reported in Seckel syndromeBut characteristic \"bird-headed\" appearance of Seckel syndrome is not a feature of FA",
                    "sub_points": [
                      "Molecular and phenotypic overlap with FAMay show increased breakage in response tobothdiepoxybutane and mitomycin CSome cases caused by mutation toATR, impairing DNA repairBone marrow failure and AML have been reported in Seckel syndromeBut characteristic \"bird-headed\" appearance of Seckel syndrome is not a feature of FA",
                      "May show increased breakage in response tobothdiepoxybutane and mitomycin C",
                      "Some cases caused by mutation toATR, impairing DNA repair",
                      "Bone marrow failure and AML have been reported in Seckel syndrome",
                      "But characteristic \"bird-headed\" appearance of Seckel syndrome is not a feature of FA"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Diamond-Blackfan Anemia": {
            "name": "Diamond-Blackfan Anemia",
            "url": "https://app.pathprimer.com/document/a6fd6b8f-b567-48fc-88dd-c7e8162b0264/lesson/28d45929-b064-4962-881e-aef087c2e426",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Inherited bone marrow failure disorder"
                  },
                  {
                    "text": "Severe hematologic consequences essentially limited to red cell lineage"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "DBA is caused by mutations in genes coding for one of several ribosomal subunit proteins, most frequentlyRPS19"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Almost always presents in infancy (average age of onset is 8 weeks of age)"
                  },
                  {
                    "text": "Congenital anomalies are present in many cases of DBA"
                  },
                  {
                    "text": "Most DBA patients respond to corticosteroids at least initiallyTransfusion support may be preferred in 1st year of life to permit initial normal development",
                    "sub_points": [
                      "Transfusion support may be preferred in 1st year of life to permit initial normal development"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Macrocytic anemia with erythroblastopenia"
                  },
                  {
                    "text": "Normal bone marrow cellularity and well-preserved granulocytic and megakaryocytic series"
                  },
                  {
                    "text": "Decreased erythroid precursors, usually limited to scattered erythroblasts"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "It iscrucialthat TEC be considered and ruled out before making diagnosis of DBAMCV, fetal hemoglobin, RBC adenosine deaminase activity assist in differentiating TEC from DBA",
                    "sub_points": [
                      "MCV, fetal hemoglobin, RBC adenosine deaminase activity assist in differentiating TEC from DBA"
                    ]
                  },
                  {
                    "text": "Increased hematogones sometimes seen in DBA may raise possibility of ALL"
                  },
                  {
                    "text": "Serologic studies or immunohistochemical stains for parvovirus should be performed in all cases of erythroblastopenia"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Diamond-Blackfan anemia (DBA)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Congenital pure red cell aplasia"
                  },
                  {
                    "text": "Congenital pure red cell hypoplastic anemia"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Inherited bone marrow failure disorder, almost always presents in infancy"
                  },
                  {
                    "text": "Severe hematologic consequences primarily limited to red cell lineage"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Molecular Genetics": [
                  {
                    "text": "DBA is caused by mutations in genes encoding several ribosomal subunit proteinsConsidered to be a \"ribosomopathy\"Mutation ofRPS19in 25% of casesOther genes includeRPS17,RPS24,RPL5,RPL11,RPL35A,RPS7,RPS10,RPS26Account for over 60% of casesHigh throughput sequencing detects mutations in 90%Sequence variants inRPL36,RPS15, andRPS27Adetected in rare individuals with DBA and may represent causative mutations",
                    "sub_points": [
                      "Considered to be a \"ribosomopathy\"",
                      "Mutation ofRPS19in 25% of cases",
                      "Other genes includeRPS17,RPS24,RPL5,RPL11,RPL35A,RPS7,RPS10,RPS26Account for over 60% of cases",
                      "Account for over 60% of cases",
                      "High throughput sequencing detects mutations in 90%Sequence variants inRPL36,RPS15, andRPS27Adetected in rare individuals with DBA and may represent causative mutations",
                      "Sequence variants inRPL36,RPS15, andRPS27Adetected in rare individuals with DBA and may represent causative mutations"
                    ]
                  }
                ],
                "Ribosomal Stress Hypothesis": [
                  {
                    "text": "Numerous ribosomal proteins associate with RNA in precise and complex manner to form functional ribosomes"
                  },
                  {
                    "text": "DBA mutations prevent ribosomal proteins from becoming incorporated into complete ribosomes"
                  },
                  {
                    "text": "Free ribosomal proteins bind MDM2, an ubiquitin ligase that otherwise targets p53 for degradationThus, unbound ribosomal proteins occupy MDM2, thereby increasing concentration of p53 and favoring apoptosis",
                    "sub_points": [
                      "Thus, unbound ribosomal proteins occupy MDM2, thereby increasing concentration of p53 and favoring apoptosis"
                    ]
                  },
                  {
                    "text": "Developing erythroid cells may be especially sensitive to \"ribosomal stress\" because of enormous demand for hemoglobin synthesisErythroid precursor apoptosis in bone marrow is mechanism underlying erythroblastopenia in DBA",
                    "sub_points": [
                      "Erythroid precursor apoptosis in bone marrow is mechanism underlying erythroblastopenia in DBA"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "AnemiaClassical DBA presents within 1st year of lifeAverage onset is at 8 weeks of ageMay coincide with increased demand for erythropoiesis following \"physiologic nadir\"",
                    "sub_points": [
                      "Classical DBA presents within 1st year of lifeAverage onset is at 8 weeks of ageMay coincide with increased demand for erythropoiesis following \"physiologic nadir\"",
                      "Average onset is at 8 weeks of age",
                      "May coincide with increased demand for erythropoiesis following \"physiologic nadir\""
                    ]
                  },
                  {
                    "text": "May present as autosomal dominant familial disorderBut family history is not sensitive for diagnosis of DBAPenetrance of DBA mutations is highly variableAffected family members may show only mild macrocytosis &/or anemia and be clinically undiagnosedMutations may also arise de novo",
                    "sub_points": [
                      "But family history is not sensitive for diagnosis of DBAPenetrance of DBA mutations is highly variableAffected family members may show only mild macrocytosis &/or anemia and be clinically undiagnosedMutations may also arise de novo",
                      "Penetrance of DBA mutations is highly variable",
                      "Affected family members may show only mild macrocytosis &/or anemia and be clinically undiagnosed",
                      "Mutations may also arise de novo"
                    ]
                  },
                  {
                    "text": "Congenital anomalies are present in many cases of DBA (30-47% in various series)Craniofacial abnormalities may includeFlat or snub noseMicrocephalyHypertelorismCleft or high-arched palateMicroretrognathiaMicrotia or low-set earsThumb abnormalities may includeTriphalangeal thumbAbsent thumbShort statureVarious urogenital and cardiac abnormalities",
                    "sub_points": [
                      "Craniofacial abnormalities may includeFlat or snub noseMicrocephalyHypertelorismCleft or high-arched palateMicroretrognathiaMicrotia or low-set ears",
                      "Flat or snub nose",
                      "Microcephaly",
                      "Hypertelorism",
                      "Cleft or high-arched palate",
                      "Microretrognathia",
                      "Microtia or low-set ears",
                      "Thumb abnormalities may includeTriphalangeal thumbAbsent thumb",
                      "Triphalangeal thumb",
                      "Absent thumb",
                      "Short stature",
                      "Various urogenital and cardiac abnormalities"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Transfusion support"
                  },
                  {
                    "text": "Stem cell transplantation"
                  }
                ],
                "Drugs": [
                  {
                    "text": "CorticosteroidsMost DBA patients are at least initially steroid-responsiveHowever, transfusion support may be preferred in 1st year of life to permit initial normal growth and development",
                    "sub_points": [
                      "Most DBA patients are at least initially steroid-responsive",
                      "However, transfusion support may be preferred in 1st year of life to permit initial normal growth and development"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Remission20% of DBA patients achieve independent adequate erythropoiesisMost remissions occur by 10 years of ageEtiology of remission is unclear",
                    "sub_points": [
                      "20% of DBA patients achieve independent adequate erythropoiesis",
                      "Most remissions occur by 10 years of age",
                      "Etiology of remission is unclear"
                    ]
                  },
                  {
                    "text": "Cancer susceptibilityIncreased incidence of neoplasmsHematologic malignancies: MDS and AML most common",
                    "sub_points": [
                      "Increased incidence of neoplasmsHematologic malignancies: MDS and AML most common",
                      "Hematologic malignancies: MDS and AML most common"
                    ]
                  },
                  {
                    "text": "Median survival of DBA patients is ~ age 40Survival of steroid-responsive patients is better than that of transfusion-dependent patients",
                    "sub_points": [
                      "Survival of steroid-responsive patients is better than that of transfusion-dependent patients"
                    ]
                  },
                  {
                    "text": "Multilineage bone marrow failureWhile risk of aplasia is quite low, progression of DBA to multiple lineage failure or aplastic anemia has been described",
                    "sub_points": [
                      "While risk of aplasia is quite low, progression of DBA to multiple lineage failure or aplastic anemia has been described"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Macrocytic anemia with reticulocytopenia"
                  },
                  {
                    "text": "Normal bone marrow cellularity and well-preserved granulocytic and megakaryocytic series"
                  },
                  {
                    "text": "Decreased erythroid precursors, usually limited to scattered erythroblastsAbsence of erythroid lineage in bone marrow biopsy is often striking at low powerViral inclusions absent",
                    "sub_points": [
                      "Absence of erythroid lineage in bone marrow biopsy is often striking at low power",
                      "Viral inclusions absent"
                    ]
                  },
                  {
                    "text": "Significant dysplasia is not present"
                  },
                  {
                    "text": "Hematogones may be markedly increased in number"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Transient Erythroblastopenia of Childhood": [
                  {
                    "text": "It iscrucialthat transient erythroblastopenia of childhood (TEC) be considered and ruled out before making diagnosis of DBA"
                  },
                  {
                    "text": "TEC is characterized byFailure of red blood cell production that remits spontaneously after 1-2 monthsMay represent post-viral, transient autoimmune response",
                    "sub_points": [
                      "Failure of red blood cell production that remits spontaneously after 1-2 months",
                      "May represent post-viral, transient autoimmune response"
                    ]
                  },
                  {
                    "text": "Typical age of onset, mean corpuscular volume, fetal hemoglobin, and erythrocyte deaminase activity are useful in differentiating TEC from DBA"
                  },
                  {
                    "text": "Molecular analysis for common, known DBA mutations may be useful in definitive diagnosisHowever, mutations for a substantial portion of DBA cases remain uncharacterized, limiting sensitivity of this analysis",
                    "sub_points": [
                      "However, mutations for a substantial portion of DBA cases remain uncharacterized, limiting sensitivity of this analysis"
                    ]
                  }
                ],
                "Other Inherited Bone Marrow Failure Syndromes": [
                  {
                    "text": "Although red cell maturation is predominantly affected, rare DBA patients develop or present with neutropenia or more generalized bone marrow failureMolecular analysis for DBA mutations may assist in distinction from other bone marrow failure syndromes",
                    "sub_points": [
                      "Molecular analysis for DBA mutations may assist in distinction from other bone marrow failure syndromes"
                    ]
                  },
                  {
                    "text": "Fanconi anemia and thrombocytopenia with absent radii (TAR), in particular, may enter differential diagnosis if abnormal thumbs are presentIncreased chromosomal breakage in presence of clastogenic agents is a feature of Fanconi anemia, but not DBARadii are normal in DBA but absent in TARRadial findings in FA are variableMegakaryopoiesis in DBA is well preserved in comparison to TAR",
                    "sub_points": [
                      "Increased chromosomal breakage in presence of clastogenic agents is a feature of Fanconi anemia, but not DBA",
                      "Radii are normal in DBA but absent in TARRadial findings in FA are variable",
                      "Radial findings in FA are variable",
                      "Megakaryopoiesis in DBA is well preserved in comparison to TAR"
                    ]
                  }
                ],
                "Infection": [
                  {
                    "text": "ParvovirusDBA lacks characteristic nuclear inclusions seen in parvovirus infectionImmunohistochemical stains for parvovirus antigens should be performed in all cases of anemia with erythroblastopeniaSerologic or molecular analysis of peripheral blood for evidence of parvovirus infection may also be warranted",
                    "sub_points": [
                      "DBA lacks characteristic nuclear inclusions seen in parvovirus infection",
                      "Immunohistochemical stains for parvovirus antigens should be performed in all cases of anemia with erythroblastopenia",
                      "Serologic or molecular analysis of peripheral blood for evidence of parvovirus infection may also be warranted"
                    ]
                  },
                  {
                    "text": "Other viral infection (especially HIV)"
                  }
                ],
                "Treacher Collins Syndrome (TCS)": [
                  {
                    "text": "Phenotypic overlap between DBA and TCS facial features, especially involving cleft palate"
                  },
                  {
                    "text": "Some apparent DBA patients are initially diagnosed with TCS, and some apparent TCS patients have subtle macrocytic anemia suggestive of DBA"
                  },
                  {
                    "text": "DBA patients withRPL5mutations are especially noted to show TCS-like phenotype"
                  },
                  {
                    "text": "Both DBA and TCS are characterized by mutations of genes involved in ribosomal biogenesis, providing molecular explanation for this phenotypic overlap"
                  },
                  {
                    "text": "TCOF1is mutated in 90% of TCS patientsPatients suspected of TCS but with no identifiableTCOF1mutation may benefit from analysis for DBA-associated mutations",
                    "sub_points": [
                      "Patients suspected of TCS but with no identifiableTCOF1mutation may benefit from analysis for DBA-associated mutations"
                    ]
                  }
                ],
                "Thymoma": [
                  {
                    "text": "\"Textbook\" cause of pure red cell aplasia, but rarely encountered in clinical practice"
                  }
                ],
                "Miscellaneous Agents of Suppression of Hematopoiesis": [
                  {
                    "text": "Drugs"
                  },
                  {
                    "text": "Autoimmune disease"
                  },
                  {
                    "text": "Nutritional deficiencies"
                  }
                ],
                "Antibodies Directed Against Erythropoietin": [
                  {
                    "text": "May be acquired post treatment with recombinant erythropoietin"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Congenital Dyserythropoietic Anemia": {
            "name": "Congenital Dyserythropoietic Anemia",
            "url": "https://app.pathprimer.com/document/2013ad1d-bf75-452d-a4cf-538822b7f6ad/lesson/28d45929-b064-4962-881e-aef087c2e426",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Hereditary erythrocyte maturation disorder"
                  },
                  {
                    "text": "Bone marrow required for diagnosis"
                  },
                  {
                    "text": "Distinctive morphologic abnormalities of erythroid cells, including internuclear bridging and multinucleation"
                  },
                  {
                    "text": "3 major subtypes (CDAI-III)"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Autosomal recessive or autosomal dominant inheritance"
                  },
                  {
                    "text": "Genetic defect in mitosis"
                  },
                  {
                    "text": "Ineffective erythropoiesisReticulocyte count low for degree of anemia",
                    "sub_points": [
                      "Reticulocyte count low for degree of anemia"
                    ]
                  },
                  {
                    "text": "Most cases diagnosed by early adulthood"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "RBC agglutination by anti-i & anti-I positive in CDA II"
                  },
                  {
                    "text": "Acidified serum test positive in CDA II"
                  },
                  {
                    "text": "SDS-PAGE (polyacrylamide gel electrophoresis)Abnormal in CDA II and CDA III",
                    "sub_points": [
                      "Abnormal in CDA II and CDA III"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "BloodVariable degree of anemiaVariably prominent anisopoikilocytosis",
                    "sub_points": [
                      "Variable degree of anemia",
                      "Variably prominent anisopoikilocytosis"
                    ]
                  },
                  {
                    "text": "Bone marrowProminent erythroid hyperplasiaVariable megaloblastic changes, multinucleation, nuclear budding, karyorrhexis, and internuclear bridgingOther bone marrow lineages are unremarkable",
                    "sub_points": [
                      "Prominent erythroid hyperplasia",
                      "Variable megaloblastic changes, multinucleation, nuclear budding, karyorrhexis, and internuclear bridging",
                      "Other bone marrow lineages are unremarkable"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Congenital dyserythropoietic anemia (CDA) I-III"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Hereditary erythroblast multinuclearity with positive acidified serum (HEMPAS) (for CDA II)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Hereditary erythrocyte maturation disorderVariably severe anemiaAnisopoikilocytosis of red blood cells (RBC)",
                    "sub_points": [
                      "Variably severe anemia",
                      "Anisopoikilocytosis of red blood cells (RBC)"
                    ]
                  },
                  {
                    "text": "Distinctive morphologic abnormalities of erythroid lineage cells within bone marrowInternuclear bridgingMultinucleationNuclear budding, karyorrhexis",
                    "sub_points": [
                      "Internuclear bridging",
                      "Multinucleation",
                      "Nuclear budding, karyorrhexis"
                    ]
                  },
                  {
                    "text": "3 major subtypes (CDAI, II, III)"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Genetic Features": [
                  {
                    "text": "Autosomal recessive or autosomal dominant inheritance"
                  },
                  {
                    "text": "Genetic defect primarily involving mitosis"
                  },
                  {
                    "text": "Genetic localization for CDA I, II, III describedCDAN1mutation in CDA I results in abnormal codanin-1 protein",
                    "sub_points": [
                      "CDAN1mutation in CDA I results in abnormal codanin-1 protein"
                    ]
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "Ineffective erythropoiesis"
                  },
                  {
                    "text": "Increased erythroid lineage in bone marrow with inadequate erythrocyte production"
                  },
                  {
                    "text": "Reduced reticulocyte count for degree of anemia"
                  }
                ],
                "Incidence/Ethnicity": [
                  {
                    "text": "Rare; generally limited to family kindreds or geographic regionsItaly, Sweden, Israeli Bedouins, Lebanon, India, Japan, China",
                    "sub_points": [
                      "Italy, Sweden, Israeli Bedouins, Lebanon, India, Japan, China"
                    ]
                  },
                  {
                    "text": "~ 400 family kindreds in Europe"
                  },
                  {
                    "text": "Very rare sporadic cases"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "AgeBlood & bone marrow abnormalities present at birthAge at disease presentation highly variableMay manifest at birth or early infancyManifestation may be as late as middle ageMost cases diagnosed by early adulthood",
                    "sub_points": [
                      "Blood & bone marrow abnormalities present at birth",
                      "Age at disease presentation highly variableMay manifest at birth or early infancyManifestation may be as late as middle age",
                      "May manifest at birth or early infancy",
                      "Manifestation may be as late as middle age",
                      "Most cases diagnosed by early adulthood"
                    ]
                  },
                  {
                    "text": "Symptoms of chronic moderate to severe anemia"
                  },
                  {
                    "text": "Some patients may be jaundiced"
                  },
                  {
                    "text": "Splenomegaly with variable hepatomegaly by adulthood in CDA I, CDA II"
                  },
                  {
                    "text": "Some patients have skeletal abnormalities"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Reticulocyte count suboptimal for degree of anemia"
                  },
                  {
                    "text": "LDH (lactic dehydrogenase) elevated"
                  },
                  {
                    "text": "Indirect bilirubin elevated in CDA I, CDA II"
                  },
                  {
                    "text": "Acidified serum test positive in CDA II"
                  },
                  {
                    "text": "RBC agglutination by anti-i & anti-I positive in CDA IIVariable in CDA I and CDA III",
                    "sub_points": [
                      "Variable in CDA I and CDA III"
                    ]
                  },
                  {
                    "text": "SDS-PAGE (polyacrylamide gel electrophoresis)Abnormal in CDA II and CDA III",
                    "sub_points": [
                      "Abnormal in CDA II and CDA III"
                    ]
                  },
                  {
                    "text": "Genetic testing for codanin and other mutations may be positive"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Transfusions may be required during infancy/early childhood"
                  },
                  {
                    "text": "Other patients require lifelong transfusionsMay require chelation therapy for iron overload",
                    "sub_points": [
                      "May require chelation therapy for iron overload"
                    ]
                  },
                  {
                    "text": "Interferon-α (CDA I)"
                  },
                  {
                    "text": "Hematopoietic stem cell transplant (CDA I, CDA II)"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Generally excellent"
                  },
                  {
                    "text": "Iron overload adverse impact"
                  }
                ]
              },
              "IMAGING": {
                "Radiographic Findings": [
                  {
                    "text": "Skull and other bone lesions due to increased hematopoiesis"
                  },
                  {
                    "text": "Mediastinal and paravertebral masses due to extramedullary hematopoiesis"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "BloodSeverity of anemia ranges from mild to severeErythrocytes often macrocytic, but sometimes normocytic (depending on subtype)Variable, usually prominent anisopoikilocytosisWBC and platelet lineages generally unremarkable",
                    "sub_points": [
                      "Severity of anemia ranges from mild to severe",
                      "Erythrocytes often macrocytic, but sometimes normocytic (depending on subtype)",
                      "Variable, usually prominent anisopoikilocytosis",
                      "WBC and platelet lineages generally unremarkable"
                    ]
                  },
                  {
                    "text": "Bone marrowBone marrow required for diagnosisProminent erythroid hyperplasiaSpectrum of morphologic featuresMegaloblastic changesVariable bi-/multinucleationNuclear buddingNuclear karyorrhexisVariable internuclear bridgingOther bone marrow lineages generally unremarkableHistiocytes may show ingestion of abnormal erythroid precursors",
                    "sub_points": [
                      "Bone marrow required for diagnosis",
                      "Prominent erythroid hyperplasia",
                      "Spectrum of morphologic featuresMegaloblastic changesVariable bi-/multinucleationNuclear buddingNuclear karyorrhexisVariable internuclear bridging",
                      "Megaloblastic changes",
                      "Variable bi-/multinucleation",
                      "Nuclear budding",
                      "Nuclear karyorrhexis",
                      "Variable internuclear bridging",
                      "Other bone marrow lineages generally unremarkable",
                      "Histiocytes may show ingestion of abnormal erythroid precursors"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Electron Microscopy": [
                  {
                    "text": "Defects in nuclear membrane prevalent"
                  },
                  {
                    "text": "Cytoplasmic contents may spill through nuclear membrane defects into nucleus"
                  },
                  {
                    "text": "Electron-lucent areas within heterochromatin create a \"Swiss cheese\" appearance in CDA I"
                  },
                  {
                    "text": "Double cytoplasmic membrane in CDA II"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Erythrocyte Disorders With Dyserythropoiesis": [
                  {
                    "text": "Dyserythropoiesis in many conditionsConstitutional disordersAcquired nonneoplastic disordersAcquired clonal myeloid neoplasms",
                    "sub_points": [
                      "Constitutional disorders",
                      "Acquired nonneoplastic disorders",
                      "Acquired clonal myeloid neoplasms"
                    ]
                  },
                  {
                    "text": "Many drugs/supplements/toxins can cause dyserythropoiesis"
                  },
                  {
                    "text": "Multinucleation of erythroid precursors can be seen in myeloid neoplasms"
                  }
                ],
                "Thalassemias": [
                  {
                    "text": "Lifelong anemia and positive family history"
                  },
                  {
                    "text": "Variably severe anemia"
                  },
                  {
                    "text": "Distinctive features in hemoglobin electrophoresis"
                  },
                  {
                    "text": "Prominent anisopoikilocytosis in severe forms"
                  },
                  {
                    "text": "Erythroid hyperplasia in bone marrow"
                  },
                  {
                    "text": "Lacksmultinuclearity, nuclear bridging, nuclear karyorrhexis"
                  }
                ],
                "Hemoglobinopathies": [
                  {
                    "text": "Lifelong history and positive family history"
                  },
                  {
                    "text": "Variably severe anemia, variable anisopoikilocytosis"
                  },
                  {
                    "text": "Positive hemoglobin electrophoresis"
                  }
                ],
                "Hereditary Sideroblastic Anemia": [
                  {
                    "text": "Distinctive ring sideroblasts in bone marrow"
                  }
                ],
                "Congenital Megaloblastic Anemia": [
                  {
                    "text": "Striking megaloblastic changes"
                  },
                  {
                    "text": "Lacksmultinucleation, nuclear bridging"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Anisopoikilocytosis relatively nonspecific"
                  },
                  {
                    "text": "CDA is rare cause of anisopoikilocytosis"
                  },
                  {
                    "text": "Combination of anisopoikilocytosis and ineffective erythropoiesis is the key"
                  },
                  {
                    "text": "Bone marrow essential for diagnosis and classification"
                  },
                  {
                    "text": "Family history is essential"
                  },
                  {
                    "text": "Presentation at any age, but most cases are diagnosed by early adulthood"
                  },
                  {
                    "text": "Isolated red blood cell disorder; other lineages unremarkable"
                  },
                  {
                    "text": "Additional tests include molecular screening, SDS-PAGE, and Ham test"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Severe Congenital Neutropenia (Kostmann Syndrome)": {
            "name": "Severe Congenital Neutropenia (Kostmann Syndrome)",
            "url": "https://app.pathprimer.com/document/b2842ed3-39e4-4520-938a-c547d3548d88/lesson/28d45929-b064-4962-881e-aef087c2e426",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Heterogeneous group of disorders manifesting as profound neutropenia with maturation arrest in myeloid maturation"
                  },
                  {
                    "text": "Congenital abnormalities absent"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Inherited gene mutations; most caused byELANEmutationsELANE/ELA2encodes neutrophil elastaseProtease found in primary azurophilic granules of granulocytic cellsAccumulation of misfolded proteins in endoplasmic reticulum leads to \"unfolded protein response\" and induces apoptosis",
                    "sub_points": [
                      "ELANE/ELA2encodes neutrophil elastase",
                      "Protease found in primary azurophilic granules of granulocytic cells",
                      "Accumulation of misfolded proteins in endoplasmic reticulum leads to \"unfolded protein response\" and induces apoptosis"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Recurrent severe life-threatening pyogenic infections with high mortality and significant risk for progression to MDS or AML"
                  },
                  {
                    "text": "Manifests in infancy"
                  },
                  {
                    "text": "Profound neutropenia (ANC 0-0.2 x 10⁹/L)"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Severe neutropenia with myeloid maturation arrest seen in bone marrow (reduced or absent mature granulocytes)"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Cyclic neutropenia; secondary/reactive neutropenia due to infection, drugs, toxins, autoimmune causes; Shwachman-Diamond syndrome; Fanconi anemia"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Severe congenital neutropenia (SCN)"
                  },
                  {
                    "text": "Absolute neutrophil count (ANC)"
                  },
                  {
                    "text": "Granulocyte colony-stimulating factor (G-CSF)"
                  },
                  {
                    "text": "Myelodysplastic syndrome (MDS)"
                  },
                  {
                    "text": "Acute myeloid leukemia (AML)"
                  },
                  {
                    "text": "Hematopoietic stem cell transplantation (HSCT)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Severe and persistent neutropenia with maturation arrest in myeloid maturation"
                  },
                  {
                    "text": "Heterogeneous disorders due to inherited gene mutations"
                  },
                  {
                    "text": "Congenital abnormalities absent"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Inherited Mutations": [
                  {
                    "text": "Approximately 60% of cases caused byELANEmutations"
                  }
                ],
                "ELANE/ELA2Mutations": [
                  {
                    "text": "ELANE/ELA2encodes neutrophil elastaseProtease found in primary azurophilic granules of granulocytic cellsAccumulation of misfolded proteins in endoplasmic reticulum leads to \"unfolded protein response\" and induces apoptosis",
                    "sub_points": [
                      "Protease found in primary azurophilic granules of granulocytic cells",
                      "Accumulation of misfolded proteins in endoplasmic reticulum leads to \"unfolded protein response\" and induces apoptosis"
                    ]
                  }
                ],
                "HAX1Mutations": [
                  {
                    "text": "Kostmann syndromeAutosomal recessive form described in 1956",
                    "sub_points": [
                      "Autosomal recessive form described in 1956"
                    ]
                  },
                  {
                    "text": "HAX1encodes antiapoptotic mitochondrial protein"
                  },
                  {
                    "text": "HAX1mutations trigger uncontrolled mitochondrion-dependent apoptosis"
                  },
                  {
                    "text": "Tend to have chronic, marked neutropenia (ANC < 0.2 × 10⁹/L)"
                  }
                ],
                "GFI1Dominant Negative Mutations (Rare Cases)": [
                  {
                    "text": "GFI1encodes transcriptional repressor ofELANE"
                  }
                ],
                "WASMutations": [
                  {
                    "text": "WASgain-of-function mutations cause X-linked form of disease"
                  },
                  {
                    "text": "Loss of autoinhibition leads to enhanced WAS protein activity"
                  }
                ],
                "CSF3RMutations": [
                  {
                    "text": "CSF3Rencodes G-CSF receptor"
                  },
                  {
                    "text": "Not responsive to G-CSF therapy"
                  }
                ],
                "G6PC3Mutations": [
                  {
                    "text": "G6PC3encodes for glucose-6-phosphatase catalytic subunit 3"
                  },
                  {
                    "text": "Not responsive to G-CSF therapy"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "Manifests in infancy"
                  },
                  {
                    "text": "Recurrent severe life-threatening pyogenic infectionsCellulitis, abscesses, oropharyngeal infections",
                    "sub_points": [
                      "Cellulitis, abscesses, oropharyngeal infections"
                    ]
                  },
                  {
                    "text": "Congenital physical anomalies are not present"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Profound neutropenia (ANC 0-0.2 x 10⁹/L)"
                  },
                  {
                    "text": "Concomitant monocytosis and eosinophilia common"
                  }
                ],
                "Natural History": [
                  {
                    "text": "Significant risk for progression to MDS or AMLCumulative risk 20%-25%Risk may be additionally increased with G-CSF therapy",
                    "sub_points": [
                      "Cumulative risk 20%-25%",
                      "Risk may be additionally increased with G-CSF therapy"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "G-CSFIncreases ANCReduces infections",
                    "sub_points": [
                      "Increases ANC",
                      "Reduces infections"
                    ]
                  },
                  {
                    "text": "HSCTFor G-CSF refractory cases or cases with progressive myeloid neoplasm",
                    "sub_points": [
                      "For G-CSF refractory cases or cases with progressive myeloid neoplasm"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Increased risk for infection and sepsis"
                  },
                  {
                    "text": "Often die before 3 yr of age without HSCT"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Peripheral bloodSevere neutropeniaANC < 0.5 x 10⁹/LGranulocytic hypoplasia or aplasiaMonocytosis and eosinophilia are often presentThought to be compensatory for neutropeniaMild anemia or thrombocytopenia in some patients",
                    "sub_points": [
                      "Severe neutropeniaANC < 0.5 x 10⁹/LGranulocytic hypoplasia or aplasia",
                      "ANC < 0.5 x 10⁹/L",
                      "Granulocytic hypoplasia or aplasia",
                      "Monocytosis and eosinophilia are often presentThought to be compensatory for neutropenia",
                      "Thought to be compensatory for neutropenia",
                      "Mild anemia or thrombocytopenia in some patients"
                    ]
                  },
                  {
                    "text": "Bone marrowMaturation arrestRare or absent mature granulocytesIncreased number of enlarged and multinucleated promyelocytes with cytoplasmic vacuolesIncreased monocytes, eosinophils, macrophages, plasma cells",
                    "sub_points": [
                      "Maturation arrestRare or absent mature granulocytesIncreased number of enlarged and multinucleated promyelocytes with cytoplasmic vacuoles",
                      "Rare or absent mature granulocytes",
                      "Increased number of enlarged and multinucleated promyelocytes with cytoplasmic vacuoles",
                      "Increased monocytes, eosinophils, macrophages, plasma cells"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Cyclic Neutropenia": [
                  {
                    "text": "Similar clinical presentation"
                  },
                  {
                    "text": "Also hasELANEgene mutation"
                  },
                  {
                    "text": "Distinguished by 21-day periodicity of cyclic ANC"
                  }
                ],
                "Noninherited Causes of Neutropenia": [
                  {
                    "text": "Secondary/reactive neutropeniaInfection, drugs, or toxins",
                    "sub_points": [
                      "Infection, drugs, or toxins"
                    ]
                  }
                ],
                "Autoimmune Neutropenia of Infancy/Primary Autoimmune Neutropenia": [
                  {
                    "text": "Neutropenia in infancy due to autoimmunity"
                  },
                  {
                    "text": "Spontaneous remission"
                  },
                  {
                    "text": "Distinguished by presence of antineutrophil antibodies"
                  }
                ],
                "Shwachman-Diamond Syndrome": [
                  {
                    "text": "Neutropenia with pancreatic insufficiencyMalabsorption, steatorrhea, failure to thrive",
                    "sub_points": [
                      "Malabsorption, steatorrhea, failure to thrive"
                    ]
                  },
                  {
                    "text": "Autosomal recessive, increased hemoglobin F"
                  },
                  {
                    "text": "Distinguished by presence ofSBDSmutations and pancreatic insufficiency"
                  }
                ],
                "Fanconi Anemia": [
                  {
                    "text": "Tends to have multilineage hypoplasia or cytopenia"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Cyclic Neutropenia": {
            "name": "Cyclic Neutropenia",
            "url": "https://app.pathprimer.com/document/1e11813a-3edf-4132-a8be-a07f6c5a9599/lesson/28d45929-b064-4962-881e-aef087c2e426",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Disorder characterized by episodes of severe neutropenia with recurrence in approximately 21-day cycles; no congenital physical abnormalities"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "ELANEmutations in ≥ 80% of cases, leading to \"unfolded protein response\" and apoptosis of neutrophils"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Recurrent oral ulcers and bacterial infection that may progress to pneumonia, abscess, gangrene, bacteremia, septic shock"
                  },
                  {
                    "text": "In contrast to SCN, symptoms in CN tend to decrease with age and do not progress to MDS or AML"
                  },
                  {
                    "text": "Treatment with G-CSF"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Myeloid lineage with \"maturation arrest\" with reduced or absent mature granulocytes when ANC is low"
                  },
                  {
                    "text": "Near-normal to normal marrow when ANC recovers"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Severe congenital neutropenia; secondary/reactive neutropenia due to infection, drugs, toxins; autoimmune causes; Shwachman-Diamond syndrome; Fanconi anemia"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Cyclic neutropenia (CN)"
                  },
                  {
                    "text": "Severe congenital neutropenia (SCN)"
                  },
                  {
                    "text": "Granulocyte colony-stimulating factor (G-CSF)"
                  },
                  {
                    "text": "Myelodysplastic syndrome (MDS)"
                  },
                  {
                    "text": "Acute myelogenous leukemia (AML)"
                  },
                  {
                    "text": "Absolute neutrophil count (ANC)"
                  },
                  {
                    "text": "Hematopoietic stem cell transplantation (HSCT)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Autosomal dominant cyclic hematopoiesis"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Disorder characterized by episodes of severe neutropenia with recurrence in approximately 21-day cyclesCycles 14-36 days",
                    "sub_points": [
                      "Cycles 14-36 days"
                    ]
                  },
                  {
                    "text": "Congenital physical abnormalities absent"
                  },
                  {
                    "text": "ELANE/ELA2mutations the cause in ≥ 80% of cases"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "General Pathogenesis": [
                  {
                    "text": "The 21-day cycle is thought to represent time for neutrophil progenitors to pass through bone marrow and be removed from peripheral tissue"
                  },
                  {
                    "text": "ELANE/ELA2mutationsAccount for ≥ 80% of casesELANE/ELA2encodes neutrophil elastaseProtease found in primary azurophilic granules of granulocytic cellsAccumulation of misfolded form in endoplasmic reticulum leads to \"unfolded protein response\" and induces apoptosisHampers survival of neutrophil progenitors and suppresses neutrophil productionAlso seen with SCNTermELANE-related neutropenia refers to both CN and SCN",
                    "sub_points": [
                      "Account for ≥ 80% of cases",
                      "ELANE/ELA2encodes neutrophil elastaseProtease found in primary azurophilic granules of granulocytic cellsAccumulation of misfolded form in endoplasmic reticulum leads to \"unfolded protein response\" and induces apoptosisHampers survival of neutrophil progenitors and suppresses neutrophil production",
                      "Protease found in primary azurophilic granules of granulocytic cells",
                      "Accumulation of misfolded form in endoplasmic reticulum leads to \"unfolded protein response\" and induces apoptosisHampers survival of neutrophil progenitors and suppresses neutrophil production",
                      "Hampers survival of neutrophil progenitors and suppresses neutrophil production",
                      "Also seen with SCNTermELANE-related neutropenia refers to both CN and SCN",
                      "TermELANE-related neutropenia refers to both CN and SCN"
                    ]
                  },
                  {
                    "text": "AcquiredCSF3RmutationsCSF3Rencodes G-CSF receptorAcquired activatingCSF3Rmutations reported in at least 2 cases of CN",
                    "sub_points": [
                      "CSF3Rencodes G-CSF receptor",
                      "Acquired activatingCSF3Rmutations reported in at least 2 cases of CN"
                    ]
                  },
                  {
                    "text": "Dominant de novoGFI1mutationsGFI1encodes transcriptional repressor ofELANE",
                    "sub_points": [
                      "GFI1encodes transcriptional repressor ofELANE"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Incidence approximately 1 in 1 million persons"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Usually in first few years of life"
                  },
                  {
                    "text": "Recurrent, painful mouth ulcersHelpful first clue",
                    "sub_points": [
                      "Helpful first clue"
                    ]
                  },
                  {
                    "text": "Fevers"
                  },
                  {
                    "text": "Bacterial infectionPharyngitis, sinusitis, otitis",
                    "sub_points": [
                      "Pharyngitis, sinusitis, otitis"
                    ]
                  },
                  {
                    "text": "More severe but less frequent consequencesPneumonia, abscess, cellulitis, gangrene, bacteremia, septic shock",
                    "sub_points": [
                      "Pneumonia, abscess, cellulitis, gangrene, bacteremia, septic shock"
                    ]
                  },
                  {
                    "text": "Symptoms usually decrease with age"
                  },
                  {
                    "text": "In contrast to SCN, CN does not progress to MDS or AML"
                  }
                ],
                "Treatment": [
                  {
                    "text": "G-CSFBoosts ANC and shortens cycle lengthIn contrast to SCN, HSCT not indicated",
                    "sub_points": [
                      "Boosts ANC and shortens cycle length",
                      "In contrast to SCN, HSCT not indicated"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Related to disease severityApproximately 10% fatal infections",
                    "sub_points": [
                      "Approximately 10% fatal infections"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Peripheral bloodOscillation of blood neutrophil counts approximately every 21 daysANC at nadir of cycle (< 0.2 × 10⁹/L) for 3-5 daysFollowed by rise to lower limit of normal level near end of cycle (\"recovery\" stage)Oscillations in monocyte, reticulocyte, and platelet counts also observed",
                    "sub_points": [
                      "Oscillation of blood neutrophil counts approximately every 21 daysANC at nadir of cycle (< 0.2 × 10⁹/L) for 3-5 daysFollowed by rise to lower limit of normal level near end of cycle (\"recovery\" stage)",
                      "ANC at nadir of cycle (< 0.2 × 10⁹/L) for 3-5 daysFollowed by rise to lower limit of normal level near end of cycle (\"recovery\" stage)",
                      "Followed by rise to lower limit of normal level near end of cycle (\"recovery\" stage)",
                      "Oscillations in monocyte, reticulocyte, and platelet counts also observed"
                    ]
                  },
                  {
                    "text": "Bone marrowWhen ANC is lowAccelerated apoptosis of bone marrow progenitor cells found in all stages of cycle\"Maturation arrest\" appearance to myeloid lineageReduced or absent mature granulocytesWhen ANC is relatively normalMarrow looks near normal to normal",
                    "sub_points": [
                      "When ANC is lowAccelerated apoptosis of bone marrow progenitor cells found in all stages of cycle",
                      "Accelerated apoptosis of bone marrow progenitor cells found in all stages of cycle",
                      "\"Maturation arrest\" appearance to myeloid lineageReduced or absent mature granulocytes",
                      "Reduced or absent mature granulocytes",
                      "When ANC is relatively normalMarrow looks near normal to normal",
                      "Marrow looks near normal to normal"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Genetic Testing": [
                  {
                    "text": "25% autosomal dominant"
                  },
                  {
                    "text": "ELANE/ELA2mutations confined to exons 4/5 and introns 4/5"
                  },
                  {
                    "text": "ELANE/ELA2sequencing is not helpful to distinguish from severe congenital neutropenia because both can have gene mutation"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Severe Congenital Neutropenia": [
                  {
                    "text": "Similar clinical presentation"
                  },
                  {
                    "text": "Often has sameELANEgene mutation"
                  },
                  {
                    "text": "CN distinguished by 21-day periodicity of cyclic ANC change"
                  }
                ],
                "Reactive or Secondary Neutropenia": [
                  {
                    "text": "Infection, drugs, toxins"
                  },
                  {
                    "text": "Spontaneous remission"
                  },
                  {
                    "text": "Absence of 21-day cycle of neutropenic periodicity"
                  }
                ],
                "Autoimmune Neutropenia of Infancy/Primary Autoimmune Neutropenia": [
                  {
                    "text": "Neutropenia in infancy due to autoimmunity"
                  },
                  {
                    "text": "Spontaneous remission"
                  },
                  {
                    "text": "Presence of antineutrophil antibodies"
                  },
                  {
                    "text": "Absence of 21-day cycle of neutropenic periodicity"
                  },
                  {
                    "text": "Bone marrow may show hemophagocytosis"
                  }
                ],
                "Shwachman-Diamond Syndrome": [
                  {
                    "text": "Neutropenia with pancreatic insufficiencyMalabsorption, steatorrhea, failure to thrive",
                    "sub_points": [
                      "Malabsorption, steatorrhea, failure to thrive"
                    ]
                  },
                  {
                    "text": "Autosomal recessive, increased hemoglobin F"
                  },
                  {
                    "text": "Distinguished byPresence ofSBDSmutations and pancreatic insufficiencyAbsence of 21-day cycle of neutropenic periodicity",
                    "sub_points": [
                      "Presence ofSBDSmutations and pancreatic insufficiency",
                      "Absence of 21-day cycle of neutropenic periodicity"
                    ]
                  }
                ],
                "Fanconi Anemia": [
                  {
                    "text": "Tends to have multilineage hypoplasia or other cytopenias"
                  },
                  {
                    "text": "Absence of 21-day cycle of neutropenic periodicity"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Serial ANC 2-3 times/week for 6-8 weeks may be necessary for establishing periodicity"
                  },
                  {
                    "text": "In contrast to SCN, CN does not appear to have significantly increased risk of progression to MDS or AML"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Shwachman-Diamond Syndrome": {
            "name": "Shwachman-Diamond Syndrome",
            "url": "https://app.pathprimer.com/document/f77bc9f3-3fa5-4f19-b347-ae5808052e50/lesson/28d45929-b064-4962-881e-aef087c2e426",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Autosomal recessive bone marrow failure disorder characterized byPredominant intermittent or persistent neutropeniaPancreatic insufficiency",
                    "sub_points": [
                      "Predominant intermittent or persistent neutropenia",
                      "Pancreatic insufficiency"
                    ]
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "SBDSmutations, usually derived from gene conversion events"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Identification of exocrine pancreatic insufficiency, especially by serum levels of pancreatic enzymes, is key to diagnosis of SDS"
                  },
                  {
                    "text": "While neutropenia is predominant hematologic manifestation, other cytopenias are not uncommon in SDS"
                  },
                  {
                    "text": "SDS is disease of leukemia predisposition"
                  },
                  {
                    "text": "Skeletal abnormalities are common in SDS"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Myelopoiesis is typically hypoplastic and left shifted"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Pearson syndromeLike SDS, characterized by bone marrow failure and pancreatic insufficiency",
                    "sub_points": [
                      "Like SDS, characterized by bone marrow failure and pancreatic insufficiency"
                    ]
                  },
                  {
                    "text": "Other neoplastic, constitutional, and reactive causes of neutropenia must be excluded"
                  }
                ],
                "Diagnostic Checklist": [
                  {
                    "text": "Given high incidence of MDS and AML in SDS patients, lifelong periodic bone marrow assessment is critical component of patient management"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Shwachman-Diamond syndrome (SDS)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Autosomal recessive bone marrow failure disorder characterized byPredominant neutropeniaPancreatic insufficiencyBiallelicSBDSmutations",
                    "sub_points": [
                      "Predominant neutropenia",
                      "Pancreatic insufficiency",
                      "BiallelicSBDSmutations"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Overview of Pseudogenes": [
                  {
                    "text": "Similar to protein-coding genes but harbor differences that prevent transcription or translation into functional protein"
                  },
                  {
                    "text": "Arise through several mechanisms, includingRandom duplication of gene, often via unequal crossing overAccumulation of mutations in resulting 2nd copy of geneSince original copy of gene remains intact, there is little evolutionary pressure against these mutations",
                    "sub_points": [
                      "Random duplication of gene, often via unequal crossing over",
                      "Accumulation of mutations in resulting 2nd copy of geneSince original copy of gene remains intact, there is little evolutionary pressure against these mutations",
                      "Since original copy of gene remains intact, there is little evolutionary pressure against these mutations"
                    ]
                  },
                  {
                    "text": "Results in duplicate version of original gene, very similar in overall sequence but carrying crippling mutations"
                  }
                ],
                "Overview of Gene Conversion": [
                  {
                    "text": "Nonreciprocal relocation of sequence from 1 gene to another of very similar, but not identical, overall sequence"
                  },
                  {
                    "text": "Most often occurs by unequal crossing over during meiosis"
                  },
                  {
                    "text": "Can also occur when cellular machinery repairs DNA break using homologous sequence as template\"Template\" sequence may be located in several placesOn sister chromatid, following DNA replicationOn homologous chromosomeOn same chromosome as break, if copy exists",
                    "sub_points": [
                      "\"Template\" sequence may be located in several placesOn sister chromatid, following DNA replicationOn homologous chromosomeOn same chromosome as break, if copy exists",
                      "On sister chromatid, following DNA replication",
                      "On homologous chromosome",
                      "On same chromosome as break, if copy exists"
                    ]
                  },
                  {
                    "text": "Process may lead to replacement of portion of gene by pseudogeneAllows introduction of pseudogene mutations into original, functional copy of gene",
                    "sub_points": [
                      "Allows introduction of pseudogene mutations into original, functional copy of gene"
                    ]
                  }
                ],
                "Normal Function ofSBDSGene": [
                  {
                    "text": "Codes for very highly conserved protein of 250 amino acids"
                  },
                  {
                    "text": "Normal SBDS protein function is incompletely understood"
                  },
                  {
                    "text": "SBDS may play multiple rolesRibosomal biogenesisStabilization of mitotic spindle",
                    "sub_points": [
                      "Ribosomal biogenesis",
                      "Stabilization of mitotic spindle"
                    ]
                  }
                ],
                "SBDSGene Conversion and Mutations": [
                  {
                    "text": "SBDSat 7q11 lies adjacent to pseudogene,SBDSP"
                  },
                  {
                    "text": "SBDSPhas 97% sequence homology withSBDSAmong those 3% divergent bases are some that prevent production of functional SBDS protein",
                    "sub_points": [
                      "Among those 3% divergent bases are some that prevent production of functional SBDS protein"
                    ]
                  },
                  {
                    "text": "SBDSmutations most often arise through gene conversionCorrupted, nonfunctional sequences fromSBDSPreplace regions of normalSBDS",
                    "sub_points": [
                      "Corrupted, nonfunctional sequences fromSBDSPreplace regions of normalSBDS"
                    ]
                  },
                  {
                    "text": "90% of SDS patients carry at least 1SBDSmutation derived from gene conversionSBDSmutations unrelated to gene conversion also persist at lower allele frequency",
                    "sub_points": [
                      "SBDSmutations unrelated to gene conversion also persist at lower allele frequency"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "CytopeniasThough neutropenia is predominant hematologic manifestation, other cytopenias are not uncommon in SDSEither thrombocytopenia or anemia are described in a significant proportion of casesBetween 10% and 65% of SDS patients present with or develop pancytopeniaNeutropenia may be either intermittent or persistentIntermittent neutropenia is more common",
                    "sub_points": [
                      "Though neutropenia is predominant hematologic manifestation, other cytopenias are not uncommon in SDSEither thrombocytopenia or anemia are described in a significant proportion of casesBetween 10% and 65% of SDS patients present with or develop pancytopenia",
                      "Either thrombocytopenia or anemia are described in a significant proportion of cases",
                      "Between 10% and 65% of SDS patients present with or develop pancytopenia",
                      "Neutropenia may be either intermittent or persistentIntermittent neutropenia is more common",
                      "Intermittent neutropenia is more common"
                    ]
                  },
                  {
                    "text": "Identification of exocrine pancreatic insufficiency is key clue to diagnosis of SDS in children with unexplained neutropenia &/or other cytopeniasClinical presentations of this includeFailure to thriveMalabsorptionSteatorrheaDeficiency of fat-soluble vitamins",
                    "sub_points": [
                      "Clinical presentations of this includeFailure to thriveMalabsorptionSteatorrheaDeficiency of fat-soluble vitamins",
                      "Failure to thrive",
                      "Malabsorption",
                      "Steatorrhea",
                      "Deficiency of fat-soluble vitamins"
                    ]
                  },
                  {
                    "text": "Skeletal abnormalitiesCommon in SDS, though variable in type and locationShort stature is present in ~ 50% of SDS patients",
                    "sub_points": [
                      "Common in SDS, though variable in type and location",
                      "Short stature is present in ~ 50% of SDS patients"
                    ]
                  },
                  {
                    "text": "Since SDS is leukemia predisposition syndrome, some clinically mild or occult cases may present initially as MDS or AML"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Serum isoamylase and trypsinogenLow concentrations of these pancreas-derived digestive enzymes may be seen in SDSHowever, these tests must be interpreted with cautionSerum pancreatic isoamylase normally does not reach adult levels until approximately age 3Trypsinogen level increases with age in some cases of SDSThus, trypsinogen is preferred marker for patients under age 3 and isoamylase for those over age 3",
                    "sub_points": [
                      "Low concentrations of these pancreas-derived digestive enzymes may be seen in SDS",
                      "However, these tests must be interpreted with cautionSerum pancreatic isoamylase normally does not reach adult levels until approximately age 3Trypsinogen level increases with age in some cases of SDSThus, trypsinogen is preferred marker for patients under age 3 and isoamylase for those over age 3",
                      "Serum pancreatic isoamylase normally does not reach adult levels until approximately age 3",
                      "Trypsinogen level increases with age in some cases of SDS",
                      "Thus, trypsinogen is preferred marker for patients under age 3 and isoamylase for those over age 3"
                    ]
                  },
                  {
                    "text": "72-hour stool collectionAbnormal fecal fat indicates pancreatic insufficiency",
                    "sub_points": [
                      "Abnormal fecal fat indicates pancreatic insufficiency"
                    ]
                  },
                  {
                    "text": "Pancreatic imagingIn SDS, gross pancreatic abnormalities includeSmall sizeFatty infiltration",
                    "sub_points": [
                      "In SDS, gross pancreatic abnormalities includeSmall sizeFatty infiltration",
                      "Small size",
                      "Fatty infiltration"
                    ]
                  },
                  {
                    "text": "Direct stimulation of pancreatic enzyme secretionIntravenous administration of secretin or cholecystokinin with direct aspiration of duodenal contentsMost sensitive method for documenting exocrine pancreatic insufficiencyLogistically complex and often available only at referral centers",
                    "sub_points": [
                      "Intravenous administration of secretin or cholecystokinin with direct aspiration of duodenal contents",
                      "Most sensitive method for documenting exocrine pancreatic insufficiency",
                      "Logistically complex and often available only at referral centers"
                    ]
                  },
                  {
                    "text": "Tests to rule out cystic fibrosisCFTRmutation analysisSweat chloride quantification",
                    "sub_points": [
                      "CFTRmutation analysis",
                      "Sweat chloride quantification"
                    ]
                  },
                  {
                    "text": "SBDSmutation analysisAt least 1 mutation will be detected in most cases using targeted analysis for 2 common mutationsSDS is autosomal recessive diseaseThus, pathogenic mutations are expected on both alleles for molecular diagnostic confirmation2 common mutations may be present intrans(1 mutation on each of 2 chromosomes) or incis(both present on same chromosome)If both common mutations are present,cisortransconfiguration can be resolved bySBDSmutation analysis of parentsIftransconfiguration is proven, pathogenic mutations are present in both alleles, and SDS diagnosis is genetically confirmedIf necessary, other mutations may be sought using more extensive sequencing or mutation scanning techniquesSome patients with clinical SDS lack demonstrableSBDSmutationsThus, negative mutation analysis does not rule out diagnosisAs-yet unidentified gene may harbor causative mutations in these patients",
                    "sub_points": [
                      "At least 1 mutation will be detected in most cases using targeted analysis for 2 common mutations",
                      "SDS is autosomal recessive diseaseThus, pathogenic mutations are expected on both alleles for molecular diagnostic confirmation",
                      "Thus, pathogenic mutations are expected on both alleles for molecular diagnostic confirmation",
                      "2 common mutations may be present intrans(1 mutation on each of 2 chromosomes) or incis(both present on same chromosome)If both common mutations are present,cisortransconfiguration can be resolved bySBDSmutation analysis of parentsIftransconfiguration is proven, pathogenic mutations are present in both alleles, and SDS diagnosis is genetically confirmed",
                      "If both common mutations are present,cisortransconfiguration can be resolved bySBDSmutation analysis of parents",
                      "Iftransconfiguration is proven, pathogenic mutations are present in both alleles, and SDS diagnosis is genetically confirmed",
                      "If necessary, other mutations may be sought using more extensive sequencing or mutation scanning techniques",
                      "Some patients with clinical SDS lack demonstrableSBDSmutationsThus, negative mutation analysis does not rule out diagnosisAs-yet unidentified gene may harbor causative mutations in these patients",
                      "Thus, negative mutation analysis does not rule out diagnosis",
                      "As-yet unidentified gene may harbor causative mutations in these patients"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "Cytogenetic abnormalitiesOften arise during disease courseFrequently involve chromosome 7Isochromosome 7qMonosomy 7Clinical and prognostic significance of these changes is not completely understood though iso(7q) may be relatively benignGiven role of SBDS in mitotic spindle stability, some have proposed thatSBDSmutations directly promote genetic instability and chromosomal abnormalities",
                    "sub_points": [
                      "Often arise during disease course",
                      "Frequently involve chromosome 7Isochromosome 7qMonosomy 7",
                      "Isochromosome 7q",
                      "Monosomy 7",
                      "Clinical and prognostic significance of these changes is not completely understood though iso(7q) may be relatively benign",
                      "Given role of SBDS in mitotic spindle stability, some have proposed thatSBDSmutations directly promote genetic instability and chromosomal abnormalities"
                    ]
                  },
                  {
                    "text": "Disease progressionRisk of MDS or AML is ~ 36% at 30 years",
                    "sub_points": [
                      "Risk of MDS or AML is ~ 36% at 30 years"
                    ]
                  },
                  {
                    "text": "ImmunodeficiencySDS patients show increased susceptibility to infectionsLikely a consequence of neutropenia, though other immune abnormalities have been demonstrated",
                    "sub_points": [
                      "SDS patients show increased susceptibility to infections",
                      "Likely a consequence of neutropenia, though other immune abnormalities have been demonstrated"
                    ]
                  },
                  {
                    "text": "Pancreatic functionExocrine pancreatic function spontaneously improves, for unknown reasons, in ~ 50% of SDS patients",
                    "sub_points": [
                      "Exocrine pancreatic function spontaneously improves, for unknown reasons, in ~ 50% of SDS patients"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Granulocyte-colony-stimulating factor (G-CSF)May be considered in patients with severe infections secondary to neutropeniaHas not been proven to increase risk of MDS or AML",
                    "sub_points": [
                      "May be considered in patients with severe infections secondary to neutropenia",
                      "Has not been proven to increase risk of MDS or AML"
                    ]
                  },
                  {
                    "text": "Bone marrow transplantTiming of transplant is controversialSDS patients have increased risk of transplant-related mortality using standard conditioning regimensReduced intensity conditioning regimens have been reported to be effective",
                    "sub_points": [
                      "Timing of transplant is controversial",
                      "SDS patients have increased risk of transplant-related mortality using standard conditioning regimens",
                      "Reduced intensity conditioning regimens have been reported to be effective"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Overall bone marrow cellularity is variableHypocellular, normocellular, and even hypercellular presentations of SDS are described though most cases are hypocellular",
                    "sub_points": [
                      "Hypocellular, normocellular, and even hypercellular presentations of SDS are described though most cases are hypocellular"
                    ]
                  },
                  {
                    "text": "Myelopoiesis may beHypoplasticLeft shifted",
                    "sub_points": [
                      "Hypoplastic",
                      "Left shifted"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Pearson Syndrome": [
                  {
                    "text": "Characterized by bone marrow failure and pancreatic insufficiencyThus, can be close mimic of SDS",
                    "sub_points": [
                      "Thus, can be close mimic of SDS"
                    ]
                  },
                  {
                    "text": "Ring sideroblasts and vacuolated precursors are seen in Pearson syndrome, but not in SDS"
                  },
                  {
                    "text": "Mitochondrial deletions are characteristic of Pearson syndrome, but not of SDS"
                  }
                ],
                "Other Constitutional Bone Marrow Failure Syndromes": [
                  {
                    "text": "Specific considerations includeFanconi anemiaDyskeratosis congenitaSevere congenital neutropenia",
                    "sub_points": [
                      "Fanconi anemia",
                      "Dyskeratosis congenita",
                      "Severe congenital neutropenia"
                    ]
                  },
                  {
                    "text": "Pancreatic insufficiency is not characteristic of these syndromes"
                  },
                  {
                    "text": "Chromosomal breakage analysis, flow-FISH for measuring telomere length, andELANEmutation analysis should be considered to further explore these syndromes"
                  }
                ],
                "Other Causes of Neutropenia": [
                  {
                    "text": "NeoplasticAcute lymphoblastic leukemia is particularly crucial to rule out in this pediatric age group",
                    "sub_points": [
                      "Acute lymphoblastic leukemia is particularly crucial to rule out in this pediatric age group"
                    ]
                  },
                  {
                    "text": "Acquired or reactiveAutoimmune neutropenia of infancy/primary autoimmune neutropeniaPresence of antineutrophil antibodies may support diagnosis of autoimmune neutropenia of infancy",
                    "sub_points": [
                      "Autoimmune neutropenia of infancy/primary autoimmune neutropeniaPresence of antineutrophil antibodies may support diagnosis of autoimmune neutropenia of infancy",
                      "Presence of antineutrophil antibodies may support diagnosis of autoimmune neutropenia of infancy"
                    ]
                  }
                ],
                "Other Disorders of Exocrine Pancreatic Insufficiency": [
                  {
                    "text": "Cystic fibrosis (CF) can be differentiated from SDS in multiple waysLack of significant hematologic abnormalities in CFSweat chloride andCFTRmutation analysis, both of which are normal in SDS",
                    "sub_points": [
                      "Lack of significant hematologic abnormalities in CF",
                      "Sweat chloride andCFTRmutation analysis, both of which are normal in SDS"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Chediak-Higashi Syndrome": {
            "name": "Chediak-Higashi Syndrome",
            "url": "https://app.pathprimer.com/document/8b9489ac-b9f7-4321-97ba-2a0e19de8433/lesson/28d45929-b064-4962-881e-aef087c2e426",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Autosomal recessive inherited syndrome characterized byLYSTmutations and abnormalities of lysosome-related organelle morphology and function"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Partial oculocutaneous albinism—specialized ophthalmologic examination may be necessary to detect this change"
                  },
                  {
                    "text": "Immunodeficiency"
                  },
                  {
                    "text": "Mild bleeding tendency"
                  },
                  {
                    "text": "Some mildly affected individuals may show only subtle oculocutaneous albinism, slight propensity to infection, and no significant bleeding tendency"
                  },
                  {
                    "text": "Neurologic complications develop as later manifestation of disease"
                  },
                  {
                    "text": "Most patients progress to accelerated phaseCan resemble lymphoma in some cases but is better classified as hemophagocytic lymphohistiocytosisIndiscriminate histiocytic activation appears to be related to underlying NK cell hypofunctionMajor contributor to morbidity in CHS patients",
                    "sub_points": [
                      "Can resemble lymphoma in some cases but is better classified as hemophagocytic lymphohistiocytosis",
                      "Indiscriminate histiocytic activation appears to be related to underlying NK cell hypofunction",
                      "Major contributor to morbidity in CHS patients"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Prominent in granulocytes but also typically present in large granular lymphocytes"
                  },
                  {
                    "text": "Precursors in bone marrow show abnormal granules, as do megakaryocytes"
                  },
                  {
                    "text": "Usually myeloperoxidase positive in cells of granulocytic lineage"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Ehrlichiosis is a particularly noteworthy mimic of Chédiak-Higashi granules"
                  }
                ],
                "Diagnostic Checklist": [
                  {
                    "text": "If Chédiak-Higashi-type granules are detected in undiagnosed patient, additional steps in work-up may includeFormal ophthalmologic examination to uncover subtle oculocutaneous albinismPlatelet function testing to demonstrate absent or reduced second wave of aggregationMolecular confirmation ofLYSTmutation as necessary",
                    "sub_points": [
                      "Formal ophthalmologic examination to uncover subtle oculocutaneous albinism",
                      "Platelet function testing to demonstrate absent or reduced second wave of aggregation",
                      "Molecular confirmation ofLYSTmutation as necessary"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Chédiak-Higashi syndrome (CHS)"
                  },
                  {
                    "text": "Natural killer (NK)"
                  },
                  {
                    "text": "Acute myeloid leukemia (AML)"
                  },
                  {
                    "text": "Large granular lymphocyte (LGL)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Autosomal recessive inherited syndrome characterized byLYSTmutations and abnormalities of lysosome-related organelle morphology and functionSpecific findingsOculocutaneous albinismImmunodeficiencyMild bleeding tendency",
                    "sub_points": [
                      "Specific findingsOculocutaneous albinismImmunodeficiencyMild bleeding tendency",
                      "Oculocutaneous albinism",
                      "Immunodeficiency",
                      "Mild bleeding tendency"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Normal Function ofLYST": [
                  {
                    "text": "LYSTencodes regulator of lysosome size and traffickingPrecise role in process is not entirely understoodLikely controls some aspects of membrane fusion, recycling, or maturation",
                    "sub_points": [
                      "Precise role in process is not entirely understood",
                      "Likely controls some aspects of membrane fusion, recycling, or maturation"
                    ]
                  },
                  {
                    "text": "LYSTis occasionally referred to asCHSorCHS1, although this is not standard nomenclature"
                  }
                ],
                "LYSTMutations and CHS": [
                  {
                    "text": "In CHS, all cells of body show abnormal, enlarged lysosomes on ultrastructural analysisEnlarged lysosomes are thought to form via improper fusion of smaller lysosomes",
                    "sub_points": [
                      "Enlarged lysosomes are thought to form via improper fusion of smaller lysosomes"
                    ]
                  },
                  {
                    "text": "Clinical manifestations of CHS all can be traced to improper cellular handling of lysosomesMelanosomes cannot be used for proper pigmentation, leading to oculocutaneous albinismIn lymphocytes, cytolytic granules are not available for cell-mediated cytotoxic activities, leading to immunodeficiencyPlatelet-dense bodies are lysosomally derived, and in their absence, platelet function abnormalities lead to mild bleeding tendencyGiant granules form in neutrophils and other lineages, representing abnormal lysosomes",
                    "sub_points": [
                      "Melanosomes cannot be used for proper pigmentation, leading to oculocutaneous albinism",
                      "In lymphocytes, cytolytic granules are not available for cell-mediated cytotoxic activities, leading to immunodeficiency",
                      "Platelet-dense bodies are lysosomally derived, and in their absence, platelet function abnormalities lead to mild bleeding tendency",
                      "Giant granules form in neutrophils and other lineages, representing abnormal lysosomes"
                    ]
                  },
                  {
                    "text": "Proteomic analysis of CHS lysosomes reveals abnormal content of various membrane proteins"
                  },
                  {
                    "text": "General plasma membrane repair has also been shown to be adversely affected"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "Partial oculocutaneous albinismDegree of pigmentation abnormality is highly variableHair may be partially white or gray in color, sometimes with metallic sheenDecreased iris pigmentationAssociated with decreased visual acuity, photosensitivity, nystagmus, and abnormal retinal pigmentationSpecialized ophthalmologic examination may be necessary to detect subtle evidence of oculocutaneous albinism",
                    "sub_points": [
                      "Degree of pigmentation abnormality is highly variable",
                      "Hair may be partially white or gray in color, sometimes with metallic sheen",
                      "Decreased iris pigmentationAssociated with decreased visual acuity, photosensitivity, nystagmus, and abnormal retinal pigmentation",
                      "Associated with decreased visual acuity, photosensitivity, nystagmus, and abnormal retinal pigmentation",
                      "Specialized ophthalmologic examination may be necessary to detect subtle evidence of oculocutaneous albinism"
                    ]
                  },
                  {
                    "text": "Recurrent infectionsUsually bacterial or pyogenic in naturePeriodontitis is increasingly well-recognized manifestation of CHS",
                    "sub_points": [
                      "Usually bacterial or pyogenic in nature",
                      "Periodontitis is increasingly well-recognized manifestation of CHS"
                    ]
                  },
                  {
                    "text": "Mild bleeding tendencyEasy bruisabilityMucosal bleedingEpistaxis",
                    "sub_points": [
                      "Easy bruisability",
                      "Mucosal bleeding",
                      "Epistaxis"
                    ]
                  },
                  {
                    "text": "Atypical presentationsMildly affected individuals may show only subtle oculocutaneous albinism, slight propensity to infection, and no significant bleeding tendencySome come to clinical attention only when late-onset neurologic symptoms beginIndividuals with these atypical presentations may not be recognized as having CHS, which is consequently thought to be underdiagnosed",
                    "sub_points": [
                      "Mildly affected individuals may show only subtle oculocutaneous albinism, slight propensity to infection, and no significant bleeding tendencySome come to clinical attention only when late-onset neurologic symptoms begin",
                      "Some come to clinical attention only when late-onset neurologic symptoms begin",
                      "Individuals with these atypical presentations may not be recognized as having CHS, which is consequently thought to be underdiagnosed"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Platelet aggregation studiesAbsent or reduced second wave of aggregation due to absence of dense bodies is seen in CHSDeficiency of dense bodies is also detectable by electron microscopic examination of platelets",
                    "sub_points": [
                      "Absent or reduced second wave of aggregation due to absence of dense bodies is seen in CHSDeficiency of dense bodies is also detectable by electron microscopic examination of platelets",
                      "Deficiency of dense bodies is also detectable by electron microscopic examination of platelets"
                    ]
                  },
                  {
                    "text": "Molecular analysis ofLYSTFull sequencing ofLYSTcan identify mutations in approximately 70% of CHS patients",
                    "sub_points": [
                      "Full sequencing ofLYSTcan identify mutations in approximately 70% of CHS patients"
                    ]
                  },
                  {
                    "text": "Leukocyte functional assaysNK cell function is decreasedNeutrophil chemotaxis and bactericidal activity are decreased",
                    "sub_points": [
                      "NK cell function is decreased",
                      "Neutrophil chemotaxis and bactericidal activity are decreased"
                    ]
                  },
                  {
                    "text": "Microscopic examination of hairPigment clumping can be identified in hair of CHS patients by light microscopy",
                    "sub_points": [
                      "Pigment clumping can be identified in hair of CHS patients by light microscopy"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Hematopoietic stem cell transplantationDefinitively addresses most disease manifestations except for neurologic symptoms, which develop even in successfully transplanted patientsOutcome is worse for patients transplanted during accelerated phase of CHS",
                    "sub_points": [
                      "Definitively addresses most disease manifestations except for neurologic symptoms, which develop even in successfully transplanted patients",
                      "Outcome is worse for patients transplanted during accelerated phase of CHS"
                    ]
                  },
                  {
                    "text": "Platelet transfusionsAs needed for bleeding or invasive procedures",
                    "sub_points": [
                      "As needed for bleeding or invasive procedures"
                    ]
                  }
                ],
                "Drugs": [
                  {
                    "text": "Prophylactic antibioticsHelp to control infections",
                    "sub_points": [
                      "Help to control infections"
                    ]
                  },
                  {
                    "text": "DDAVPAs needed for bleeding or invasive procedures",
                    "sub_points": [
                      "As needed for bleeding or invasive procedures"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Neurologic complicationsDevelop as later manifestation of diseaseOnset is typically in young adulthood if patients survive to this ageImpaired cognitive abilitiesAtaxiaProgressive neurodegenerationCan occasionally be subtle, manifesting only as peripheral neuropathyBone marrow transplantation does not prevent development of neurologic symptoms",
                    "sub_points": [
                      "Develop as later manifestation of diseaseOnset is typically in young adulthood if patients survive to this age",
                      "Onset is typically in young adulthood if patients survive to this age",
                      "Impaired cognitive abilities",
                      "Ataxia",
                      "Progressive neurodegeneration",
                      "Can occasionally be subtle, manifesting only as peripheral neuropathy",
                      "Bone marrow transplantation does not prevent development of neurologic symptoms"
                    ]
                  },
                  {
                    "text": "Accelerated phaseDevelops in approximately 85% of patientsLymphohistiocytic infiltration of multiple organsCan resemble lymphoma in some cases but is better classified as hemophagocytic lymphohistiocytosisAs inherited syndrome, CHS is considered to be cause of familial hemophagocytic lymphohistiocytosis (a.k.a. hemophagocytic syndrome)Indiscriminate histiocytic activation appears to be related to underlying NK cell hypofunctionMajor contributor to mortality in CHS patients",
                    "sub_points": [
                      "Develops in approximately 85% of patients",
                      "Lymphohistiocytic infiltration of multiple organs",
                      "Can resemble lymphoma in some cases but is better classified as hemophagocytic lymphohistiocytosisAs inherited syndrome, CHS is considered to be cause of familial hemophagocytic lymphohistiocytosis (a.k.a. hemophagocytic syndrome)",
                      "As inherited syndrome, CHS is considered to be cause of familial hemophagocytic lymphohistiocytosis (a.k.a. hemophagocytic syndrome)",
                      "Indiscriminate histiocytic activation appears to be related to underlying NK cell hypofunction",
                      "Major contributor to mortality in CHS patients"
                    ]
                  },
                  {
                    "text": "Genotype/phenotype correlationPrecise nature ofLYSTmutation may affect clinical courseMissense mutations, with some preservation of protein function, may be associated with milder course or late-onset neurodegeneration onlyMore disruptive truncating mutations are associated with severe early onset of disease and quick progression to accelerated phase",
                    "sub_points": [
                      "Precise nature ofLYSTmutation may affect clinical courseMissense mutations, with some preservation of protein function, may be associated with milder course or late-onset neurodegeneration onlyMore disruptive truncating mutations are associated with severe early onset of disease and quick progression to accelerated phase",
                      "Missense mutations, with some preservation of protein function, may be associated with milder course or late-onset neurodegeneration only",
                      "More disruptive truncating mutations are associated with severe early onset of disease and quick progression to accelerated phase"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Giant Inclusions": [
                  {
                    "text": "Prominent in granulocytes but also typically present in large granular lymphocytes"
                  },
                  {
                    "text": "Platelet granules may be larger than normal"
                  },
                  {
                    "text": "Precursors in bone marrow show abnormal granules, as do megakaryocytes"
                  },
                  {
                    "text": "Usually myeloperoxidase positive in cells of granulocytic lineage"
                  }
                ],
                "Neutropenia": [
                  {
                    "text": "Basis for neutropenia is not certain though neutrophil function is altered in CHS"
                  },
                  {
                    "text": "Neutropenia may be transient in CHS"
                  },
                  {
                    "text": "Complete myeloid maturation is present regardless of absolute neutrophil count"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Potential Morphologic Mimics": [
                  {
                    "text": "AML with pseudo-Chédiak-Higashi granulesAbnormally large Chédiak-Higashi-like granules are seen in rare cases of AMLThese cases are readily distinguished from CHS by overall features of malignancy",
                    "sub_points": [
                      "Abnormally large Chédiak-Higashi-like granules are seen in rare cases of AML",
                      "These cases are readily distinguished from CHS by overall features of malignancy"
                    ]
                  },
                  {
                    "text": "Lysosomal storage diseaseAbnormal granulation patterns, particularly in lymphocytes, are seen in diverse lysosomal storage diseasesGranules are generally not as large as those seen in CHSCytoplasmic vacuoles are present in some forms of lysosomal storage disease but are not present in CHSWhile mild phenotypes are always possible, in general, lysosomal storage diseases are associated with relatively prominent and characteristic clinical findings",
                    "sub_points": [
                      "Abnormal granulation patterns, particularly in lymphocytes, are seen in diverse lysosomal storage diseases",
                      "Granules are generally not as large as those seen in CHS",
                      "Cytoplasmic vacuoles are present in some forms of lysosomal storage disease but are not present in CHS",
                      "While mild phenotypes are always possible, in general, lysosomal storage diseases are associated with relatively prominent and characteristic clinical findings"
                    ]
                  },
                  {
                    "text": "Atypical granulation of LGLsGranules in normal LGLs are much smaller than Chédiak-Higashi granulesLarger granules can be seen in rare cases of LGL leukemia or reactive large granular lymphocytosisPatients should not show evidence of oculocutaneous albinism or platelet dysfunction, and large granules will not be present in granulocytes",
                    "sub_points": [
                      "Granules in normal LGLs are much smaller than Chédiak-Higashi granules",
                      "Larger granules can be seen in rare cases of LGL leukemia or reactive large granular lymphocytosis",
                      "Patients should not show evidence of oculocutaneous albinism or platelet dysfunction, and large granules will not be present in granulocytes"
                    ]
                  },
                  {
                    "text": "Intracellular organismsEhrlichiosis is a particularly noteworthy mimic of Chédiak-Higashi granulesIn such infections, absence of abnormal granules in eosinophils or large granular lymphocytes can assist in distinction from CHS",
                    "sub_points": [
                      "Ehrlichiosis is a particularly noteworthy mimic of Chédiak-Higashi granules",
                      "In such infections, absence of abnormal granules in eosinophils or large granular lymphocytes can assist in distinction from CHS"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Review of peripheral smear for Chédiak-Higashi granules should be performed in all patients withUnexplained recurrent infections &/or neutropeniaBleeding tendencyAlbinismNeurologic complications",
                    "sub_points": [
                      "Unexplained recurrent infections &/or neutropenia",
                      "Bleeding tendency",
                      "Albinism",
                      "Neurologic complications"
                    ]
                  },
                  {
                    "text": "If Chédiak-Higashi-type granules are detected in undiagnosed patient, additional steps in work-up may includeFormal ophthalmologic examination to uncover subtle oculocutaneous albinismPlatelet function testing to demonstrate absent or reduced second wave of aggregationMolecular confirmation ofLYSTmutation as necessary",
                    "sub_points": [
                      "Formal ophthalmologic examination to uncover subtle oculocutaneous albinism",
                      "Platelet function testing to demonstrate absent or reduced second wave of aggregation",
                      "Molecular confirmation ofLYSTmutation as necessary"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Myelokathexis in WHIM Syndrome": {
            "name": "Myelokathexis in WHIM Syndrome",
            "url": "https://app.pathprimer.com/document/520b3537-4fec-4d8a-b890-63f837227261/lesson/28d45929-b064-4962-881e-aef087c2e426",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Warts, hypogammaglobulinemia, infections, myelokathexis (WHIM)"
                  },
                  {
                    "text": "Autosomal dominant disorder characterized byProfound neutropeniaAccelerated apoptosisDefective granulocyte and lymphocyte trafficking",
                    "sub_points": [
                      "Profound neutropenia",
                      "Accelerated apoptosis",
                      "Defective granulocyte and lymphocyte trafficking"
                    ]
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Heterozygous truncating mutations in chemokine receptorCXCR4gene at 2q21"
                  },
                  {
                    "text": "Prolonged retention of neutrophils in bone marrow reserve compartment"
                  },
                  {
                    "text": "Defective release of mature neutrophils from bone marrow"
                  },
                  {
                    "text": "Accelerated apoptosis of neutrophils"
                  },
                  {
                    "text": "Defective homing and proliferation of B cells linked to hypogammaglobulinemia"
                  },
                  {
                    "text": "Lymphocyte/natural killer cell homing defects linked to susceptibility to viral infectionsPapilloma virusEBV",
                    "sub_points": [
                      "Papilloma virus",
                      "EBV"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Profound neutropenia"
                  },
                  {
                    "text": "Neutrophils show aberrant segmentation"
                  },
                  {
                    "text": "Long, thin, filamentous strands connecting pyknotic nuclear lobes"
                  },
                  {
                    "text": "Hypercellular bone marrow with increased centrally located reserve compartmentNeutrophilsMetamyelocytes",
                    "sub_points": [
                      "Neutrophils",
                      "Metamyelocytes"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Warts, hypogammaglobulinemia, infections, myelokathexis (WHIM)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "WHIM syndrome"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Autosomal dominant disorder characterized byProfound neutropeniaAccelerated apoptosisDefective granulocyte and lymphocyte trafficking",
                    "sub_points": [
                      "Profound neutropenia",
                      "Accelerated apoptosis",
                      "Defective granulocyte and lymphocyte trafficking"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Constitutional Disorder": [
                  {
                    "text": "Autosomal dominant"
                  },
                  {
                    "text": "Heterozygous truncating mutations in chemokine receptorCXCR4gene at 2q21"
                  },
                  {
                    "text": "Defective regulation ofCXCR4signaling or expression"
                  },
                  {
                    "text": "Chemokine-chemokine receptor interactions critical for neutrophil migration/trafficking"
                  },
                  {
                    "text": "CXCR4 is receptor for CXC-chemokine L 12 (CXCL12)"
                  },
                  {
                    "text": "CXCL12 constitutively produced by stromal and endothelial cells"
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "Truncating mutations inCXCR4causeProlonged retention of neutrophils in bone marrow (BM) reserve compartmentDefective release of mature neutrophils from BMAccelerated apoptosis of neutrophils within BMDefective homing and proliferation of B cells linked to hypogammaglobulinemia",
                    "sub_points": [
                      "Prolonged retention of neutrophils in bone marrow (BM) reserve compartment",
                      "Defective release of mature neutrophils from BM",
                      "Accelerated apoptosis of neutrophils within BM",
                      "Defective homing and proliferation of B cells linked to hypogammaglobulinemia"
                    ]
                  },
                  {
                    "text": "Lymphocyte/natural killer cell homing defects linked to susceptibility to viral infectionsPapilloma virus and EBV",
                    "sub_points": [
                      "Papilloma virus and EBV"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Very rare"
                  }
                ],
                "Age": [
                  {
                    "text": "Onset in childhood"
                  }
                ],
                "Sex": [
                  {
                    "text": "Female predominance (unexplained)"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Recurrent bacterial infections from common pathogens during early childhoodPneumoniaOtitis mediaSinusitis",
                    "sub_points": [
                      "Pneumonia",
                      "Otitis media",
                      "Sinusitis"
                    ]
                  },
                  {
                    "text": "Skeletal abnormalities"
                  },
                  {
                    "text": "Abnormal susceptibility to warts"
                  },
                  {
                    "text": "Increased morbidity from papilloma virus and Epstein-Barr virus"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "CBC with differential countConfirm neutropenia/reduced absolute neutrophil count (ANC)",
                    "sub_points": [
                      "Confirm neutropenia/reduced absolute neutrophil count (ANC)"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "Growth and development generally normal"
                  },
                  {
                    "text": "Bronchiectasis and hearing loss may result from chronic infections"
                  },
                  {
                    "text": "Warts develop in 2nd decade of life"
                  }
                ],
                "Treatment": [],
                "Drugs": [
                  {
                    "text": "Pharmacologic agents that modulateCXCR4expression/function and reduce complications"
                  },
                  {
                    "text": "G-CSF or GM-CSF therapy may produce clinical improvement during bacterial infectious episodes"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Generally, milder overall disease course than other constitutional neutropenias"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Predominant Pattern/Injury Type": [
                  {
                    "text": "Apoptosis, ineffective granulopoiesis"
                  }
                ],
                "Histologic Features": [
                  {
                    "text": "BloodLeukopenia, WBC ≤ 1.2 x 10⁹/LProfound neutropenia, < 0.5 x 10⁹/L ANCNeutrophils show aberrant segmentationLong, thin, filamentous strands connecting pyknotic nuclear lobesHypersegmentation commonErythrocytes and platelets generally normal",
                    "sub_points": [
                      "Leukopenia, WBC ≤ 1.2 x 10⁹/L",
                      "Profound neutropenia, < 0.5 x 10⁹/L ANC",
                      "Neutrophils show aberrant segmentationLong, thin, filamentous strands connecting pyknotic nuclear lobesHypersegmentation common",
                      "Long, thin, filamentous strands connecting pyknotic nuclear lobes",
                      "Hypersegmentation common",
                      "Erythrocytes and platelets generally normal"
                    ]
                  },
                  {
                    "text": "Bone marrowHypercellularIncreased mature neutrophils within central medullary regions (reserve compartment)Aberrant segmentation of neutrophilsMacrophages may contain ingested neutrophilsUnremarkable erythroid and megakaryocytic lineages and bone",
                    "sub_points": [
                      "Hypercellular",
                      "Increased mature neutrophils within central medullary regions (reserve compartment)",
                      "Aberrant segmentation of neutrophils",
                      "Macrophages may contain ingested neutrophils",
                      "Unremarkable erythroid and megakaryocytic lineages and bone"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "PCR": [
                  {
                    "text": "DNA sequencing ofCXCR4gene to detect mutations"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Other Constitutional Neutropenias": [
                  {
                    "text": "Severe congenital neutropenia (Kostmann)"
                  },
                  {
                    "text": "Dyskeratosis congenita"
                  },
                  {
                    "text": "Shwachman-Diamond syndrome"
                  },
                  {
                    "text": "Reduction in granulocytic lineage in bone marrow characteristic in these disorders"
                  },
                  {
                    "text": "No morphologic abnormalities in neutrophils"
                  },
                  {
                    "text": "Severity and frequency of recurrent bacterial infections more prominent in these constitutional neutropenias"
                  }
                ],
                "Acquired Neutropenic Disorders": [
                  {
                    "text": "Megaloblastic anemiaMacrocytosis, oval macrocytes, hypersegmented neutrophilsHypercellular bone marrow, florid megaloblastic changes",
                    "sub_points": [
                      "Macrocytosis, oval macrocytes, hypersegmented neutrophils",
                      "Hypercellular bone marrow, florid megaloblastic changes"
                    ]
                  },
                  {
                    "text": "Acquired agranulocytosis (many causes)"
                  },
                  {
                    "text": "MyelodysplasiaDysplastic morphology",
                    "sub_points": [
                      "Dysplastic morphology"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Pelger-Huët Anomaly": {
            "name": "Pelger-Huët Anomaly",
            "url": "https://app.pathprimer.com/document/15a900b6-fb37-4b1b-9839-b8f66f7c9cda/lesson/28d45929-b064-4962-881e-aef087c2e426",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Nuclear hyposegmentation of neutrophils and other granulocytic cells producingBilobed (pince-nez) nucleiMononuclear (Stodtmeister) nuclei",
                    "sub_points": [
                      "Bilobed (pince-nez) nuclei",
                      "Mononuclear (Stodtmeister) nuclei"
                    ]
                  },
                  {
                    "text": "Familial and acquired forms"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Autosomal dominant familial PHAMutations in lamin β-receptor (LBR) gene at 1q41-43Results in defects in scaffolding proteins that control shape of nuclear membraneNuclear hypolobation results from reduced levels of LBR proteinAll granulocytic lineages affectedNeutrophil function normal",
                    "sub_points": [
                      "Mutations in lamin β-receptor (LBR) gene at 1q41-43",
                      "Results in defects in scaffolding proteins that control shape of nuclear membrane",
                      "Nuclear hypolobation results from reduced levels of LBR protein",
                      "All granulocytic lineages affected",
                      "Neutrophil function normal"
                    ]
                  },
                  {
                    "text": "Numerous medications linked to acquired, nonneoplastic PHA"
                  },
                  {
                    "text": "Chronic infections can cause acquired PHA"
                  },
                  {
                    "text": "Clonal myeloid neoplasms linked to acquired PHA"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "1 per 5,000 population for familial PHA"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Bilobed or monolobated nuclei of neutrophils, eosinophils, and basophils≥ 70% of neutrophils are hyposegmented with increased nuclear clumpingNeutrophils show normal cytoplasmic granularityOther lineages usually normal in familial PHA",
                    "sub_points": [
                      "≥ 70% of neutrophils are hyposegmented with increased nuclear clumping",
                      "Neutrophils show normal cytoplasmic granularity",
                      "Other lineages usually normal in familial PHA"
                    ]
                  },
                  {
                    "text": "Multilineage abnormalities common in acquired, clonal PHA"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Pelger-Huët anomaly (PHA)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Nuclear hyposegmentation of neutrophils and other granulocytic cells resulting in either bilobed (pince-nez) or mononuclear (Stodtmeister) morphology"
                  },
                  {
                    "text": "Familial and acquired forms"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Multifactorial Causes": [
                  {
                    "text": "Autosomal dominant familial PHA"
                  },
                  {
                    "text": "Numerous medications linked to acquired, nonneoplastic PHASulfisoxazoleSulfonamidesMycophenolate mofetilMyelosuppressive agentsColchicineGanciclovirValproic acidPaclitaxelOther medications",
                    "sub_points": [
                      "Sulfisoxazole",
                      "Sulfonamides",
                      "Mycophenolate mofetil",
                      "Myelosuppressive agents",
                      "Colchicine",
                      "Ganciclovir",
                      "Valproic acid",
                      "Paclitaxel",
                      "Other medications"
                    ]
                  },
                  {
                    "text": "Chronic infections can cause acquired PHAHIVTuberculosisMycoplasma pneumoniaInfluenzaMalaria",
                    "sub_points": [
                      "HIV",
                      "Tuberculosis",
                      "Mycoplasma pneumonia",
                      "Influenza",
                      "Malaria"
                    ]
                  },
                  {
                    "text": "Clonal myeloid neoplasms linked to acquired PHAMyelodysplasia (MDS)Acute myeloid leukemia (AML)Myelodysplastic/myeloproliferative neoplasmsNeutrophils are component of neoplastic clone",
                    "sub_points": [
                      "Myelodysplasia (MDS)",
                      "Acute myeloid leukemia (AML)",
                      "Myelodysplastic/myeloproliferative neoplasms",
                      "Neutrophils are component of neoplastic clone"
                    ]
                  }
                ],
                "Pathogenesis of Familial PHA": [
                  {
                    "text": "Autosomal dominantMutations in lamin β-receptor (LBR) gene at 1q41-43Results in defects in scaffolding proteins that control shape of nuclear membraneNuclear hypolobation results from reduced levels of LBR proteinAll granulocytic lineages affectedNeutrophil function normal",
                    "sub_points": [
                      "Mutations in lamin β-receptor (LBR) gene at 1q41-43",
                      "Results in defects in scaffolding proteins that control shape of nuclear membrane",
                      "Nuclear hypolobation results from reduced levels of LBR protein",
                      "All granulocytic lineages affected",
                      "Neutrophil function normal"
                    ]
                  },
                  {
                    "text": "Neutrophil migratory defect linked to soft tissue infections"
                  }
                ],
                "Pathogenesis of Acquired Secondary, Nonneoplastic PHA": [
                  {
                    "text": "Unknown"
                  }
                ],
                "Pathogenesis of Acquired, Clonal PHA in Myeloid Neoplasms": [
                  {
                    "text": "Possible acquired mutations inLBR"
                  },
                  {
                    "text": "Possible apoptotic defect with resulting dense, nonsegmented nuclei"
                  },
                  {
                    "text": "Possible acquired clonal 17p deletion linked to prominent PHA"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "1 per 5,000 population for familial PHA"
                  },
                  {
                    "text": "Highly variable for acquired PHA dependent upon cause"
                  }
                ],
                "Age": [
                  {
                    "text": "Present at birth in familial PHA"
                  },
                  {
                    "text": "Wide age range for acquired PHA dependent upon cause"
                  }
                ],
                "Sex": [
                  {
                    "text": "No gender predilection except for HIV-associated acquired PHA, which is more common in males"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "No ethnic predilection"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Incidental finding in familial PHA"
                  },
                  {
                    "text": "Clinical findings variable in acquired PHA dependent on underlying cause"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Complete blood count (CBC) with differentialNormal hematopoietic parameters in familial PHAAbnormal granulocyte morphology",
                    "sub_points": [
                      "Normal hematopoietic parameters in familial PHA",
                      "Abnormal granulocyte morphology"
                    ]
                  },
                  {
                    "text": "Many potential laboratory tests for underlyingInfectionsNeoplasms",
                    "sub_points": [
                      "Infections",
                      "Neoplasms"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "Normal lifespan for familial PHAUsually no propensity to life-threatening infectionsMay develop soft tissue infections due to neutrophil migratory defect (usually mild)",
                    "sub_points": [
                      "Usually no propensity to life-threatening infections",
                      "May develop soft tissue infections due to neutrophil migratory defect (usually mild)"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "None for familial PHA"
                  },
                  {
                    "text": "Dependent on underlying cause of acquired PHA"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Predominant Pattern/Injury Type": [
                  {
                    "text": "Nuclear segmentation defect"
                  }
                ],
                "Predominant Cell/Compartment Type": [
                  {
                    "text": "Granulocytic lineage cells"
                  }
                ],
                "Histologic Features": [
                  {
                    "text": "Blood in familial PHABilobed or monolobated nuclei of neutrophils, eosinophils, and basophils≥ 70% of neutrophils are hyposegmented with increased nuclear clumpingNeutrophils show normal cytoplasmic granularityOther lineages unremarkableNormal CBC",
                    "sub_points": [
                      "Bilobed or monolobated nuclei of neutrophils, eosinophils, and basophils",
                      "≥ 70% of neutrophils are hyposegmented with increased nuclear clumping",
                      "Neutrophils show normal cytoplasmic granularity",
                      "Other lineages unremarkable",
                      "Normal CBC"
                    ]
                  },
                  {
                    "text": "Bone marrow findings in familial PHANormocellular, normal maturationHyposegmentation with increased nuclear clumping of neutrophils, eosinophils, and basophilsMay see increased nuclear clumping of other hematopoietic cells",
                    "sub_points": [
                      "Normocellular, normal maturation",
                      "Hyposegmentation with increased nuclear clumping of neutrophils, eosinophils, and basophils",
                      "May see increased nuclear clumping of other hematopoietic cells"
                    ]
                  },
                  {
                    "text": "Blood findings in acquired, clonal PHA associated with myeloid neoplasmsSpectrum of cytopeniasWBC highly variableFrequent single, multilineage dysplasiaCirculating blasts may be presentHyposegmented neutrophils may show hypogranular cytoplasmProportion of hyposegmented neutrophils variable, usually < 40%",
                    "sub_points": [
                      "Spectrum of cytopenias",
                      "WBC highly variable",
                      "Frequent single, multilineage dysplasia",
                      "Circulating blasts may be present",
                      "Hyposegmented neutrophils may show hypogranular cytoplasm",
                      "Proportion of hyposegmented neutrophils variable, usually < 40%"
                    ]
                  },
                  {
                    "text": "Bone marrow findings in acquired, clonal PHA associated with myeloid neoplasmsFrequent hypercellularityVariable percent blasts, often increasedSingle or multilineage dysplasiaHyposegmentation of granulocytic cells is component of dysplastic profileOther findings dependent upon type of myeloid neoplasm",
                    "sub_points": [
                      "Frequent hypercellularity",
                      "Variable percent blasts, often increased",
                      "Single or multilineage dysplasia",
                      "Hyposegmentation of granulocytic cells is component of dysplastic profile",
                      "Other findings dependent upon type of myeloid neoplasm"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Familial PHA must be distinguished from acquired PHACBC in conjunction with morphologic review of blood smear essentialIsolated PHA in otherwise normal CBC favors familial PHAHigh proportion of hyposegmented neutrophils favors familial PHAClinical information and family history criticalDetection of PHA in 1st-degree relatives confirms familial PHA",
                    "sub_points": [
                      "CBC in conjunction with morphologic review of blood smear essential",
                      "Isolated PHA in otherwise normal CBC favors familial PHA",
                      "High proportion of hyposegmented neutrophils favors familial PHA",
                      "Clinical information and family history critical",
                      "Detection of PHA in 1st-degree relatives confirms familial PHA"
                    ]
                  },
                  {
                    "text": "Acquired PHA must be subcategorized into nonneoplastic and neoplastic groupsClinical information essentialCareful history of medication useEvaluate for underlying infectionsReview of CBC, blood smear, & possibly bone marrow for clues to HIV infection or myeloid neoplasmAppreciate that PHA is 1 morphologic component of dysplastic profile in myeloid neoplasmsIf medication, infection, and myeloid neoplasm excluded, consider rare causes of secondary PHABone marrow transplantationNon-hematopoietic neoplasmBenzene exposure",
                    "sub_points": [
                      "Clinical information essential",
                      "Careful history of medication use",
                      "Evaluate for underlying infections",
                      "Review of CBC, blood smear, & possibly bone marrow for clues to HIV infection or myeloid neoplasm",
                      "Appreciate that PHA is 1 morphologic component of dysplastic profile in myeloid neoplasms",
                      "If medication, infection, and myeloid neoplasm excluded, consider rare causes of secondary PHABone marrow transplantationNon-hematopoietic neoplasmBenzene exposure",
                      "Bone marrow transplantation",
                      "Non-hematopoietic neoplasm",
                      "Benzene exposure"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Alder-Reilly Anomaly": {
            "name": "Alder-Reilly Anomaly",
            "url": "https://app.pathprimer.com/document/83a0face-5c7b-4015-823c-65b0e1597029/lesson/28d45929-b064-4962-881e-aef087c2e426",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Morphologic finding of WBCs with prominent metachromatic granulation, seen most commonly in MPS"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Lysosomal enzymatic deficiency results in accumulation of undegraded or partially degraded GAG complexes"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Coarse facies, cardiac abnormalities, skeletal abnormalities, developmental delay, hepatosplenomegaly, joint stiffness, corneal clouding"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Mucopolysaccharidosis (MPS)"
                  },
                  {
                    "text": "Glycosaminoglycan (GAG)"
                  },
                  {
                    "text": "White blood cell (WBC)"
                  },
                  {
                    "text": "Chédiak-Higashi syndrome (CHS)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Alder-Reilly phenomenon"
                  },
                  {
                    "text": "Reilly bodies"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Autosomal recessive disorder characterized by prominent metachromatic granules in granulocytes and lymphocytesAssociated with MPS but is also seen in healthy individuals",
                    "sub_points": [
                      "Associated with MPS but is also seen in healthy individuals"
                    ]
                  },
                  {
                    "text": "Described by Alder in 1939 and Reilly in 1941"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Pathogenesis of Mucopolysaccharidosis": [
                  {
                    "text": "Accumulation of undegraded or partially degraded GAG complexes within lysosomes due to deficiencies of lysosomal enzymes and related proteins"
                  },
                  {
                    "text": "Function of WBCs not affected"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Affects 1:25,000 people"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Variable clinical findings based on storage disease subtypesCoarse faciesCardiac abnormalitiesSkeletal abnormalitiesDevelopmental delayHepatosplenomegalyJoint stiffnessCorneal cloudingObstructive airway disease",
                    "sub_points": [
                      "Coarse facies",
                      "Cardiac abnormalities",
                      "Skeletal abnormalities",
                      "Developmental delay",
                      "Hepatosplenomegaly",
                      "Joint stiffness",
                      "Corneal clouding",
                      "Obstructive airway disease"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Disease specificDirect enzyme replacementStem cell transplantation",
                    "sub_points": [
                      "Direct enzyme replacement",
                      "Stem cell transplantation"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Variable"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Peripheral blood and bone marrowCytopenia may be presentWBCs with dark purple and azurophilic granules (metachromatic) in cytoplasmGranules resemble primary granules of promyelocytesGranules often surrounded by clear vacuolesAbnormally granulated cells may be more prominent in bone marrow than in peripheral blood",
                    "sub_points": [
                      "Cytopenia may be present",
                      "WBCs with dark purple and azurophilic granules (metachromatic) in cytoplasm",
                      "Granules resemble primary granules of promyelocytes",
                      "Granules often surrounded by clear vacuoles",
                      "Abnormally granulated cells may be more prominent in bone marrow than in peripheral blood"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Morphology and cytoplasmic distribution of granules variable among subtypes of storage disease"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Analysis of Accumulated Storage Products": [],
                "Enzymatic Activity": [],
                "Molecular Mutational Study": []
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Reactive Toxic Granulation": [
                  {
                    "text": "Toxic granules are finer in texture"
                  }
                ],
                "Chédiak-Higashi Syndrome": [
                  {
                    "text": "CHS has larger granules"
                  },
                  {
                    "text": "Characteristic recurrent pyogenic infection (secondary to neutropenia), neuropathy, and partial albinism"
                  }
                ],
                "Large Granular Lymphocytes": [
                  {
                    "text": "Granules are smaller and present only in lymphocytes"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Alder-Reilly anomaly provides clues for investigation of lysosome storage diseases"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Alder-Reilly anomaly is defined based on morphology and is not disease specific"
                  },
                  {
                    "text": "Normal urinary test for GAG does not rule out MPS"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      }
    }
  }
}